DK3767_FM.qxd
9/14/05
10:58 AM
Page A
Neurogenetics: Scientific and Clinical Advances
Copyright 2006 by Taylor & Fr...
300 downloads
3067 Views
5MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
DK3767_FM.qxd
9/14/05
10:58 AM
Page A
Neurogenetics: Scientific and Clinical Advances
Copyright 2006 by Taylor & Francis Group, LLC
DK3767_FM.qxd
9/14/05
10:58 AM
Page B
NEUROLOGICAL DISEASE AND THERAPY Advisory Board Louis R. Caplan, M.D. Professor of Neurology Harvard University School of Medicine Beth Israel Deaconess Medical Center Boston, Massachusetts
William C. Koller, M.D. Mount Sinai School of Medicine New York, New York
John C. Morris, M.D. Friedman Professor of Neurology Co-Director, Alzheimer’s Disease Research Center Washington University School of Medicine St. Louis, Missouri
Bruce Ransom, M.D., Ph.D. Warren Magnuson Professor Chair, Department of Neurology University of Washington School of Medicine Seattle, Washington
Kapil Sethi, M.D. Professor of Neurology Director, Movement Disorders Program Medical College of Georgia Augusta, Georgia
Mark Tuszynski, M.D., Ph.D. Associate Professor of Neurosciences Director, Center for Neural Repair University of California–San Diego La Jolla, California
Copyright 2006 by Taylor & Francis Group, LLC
DK3767_FM.qxd
9/14/05
10:58 AM
Page C
1. Handbook of Parkinson’s Disease, edited by William C. Koller 2. Medical Therapy of Acute Stroke, edited by Mark Fisher 3. Familial Alzheimer’s Disease: Molecular Genetics and Clinical Perspectives, edited by Gary D. Miner, Ralph W. Richter, John P. Blass,
Jimmie L. Valentine, and Linda A. Winters-Miner 4. Alzheimer’s Disease: Treatment and Long-Term Management,
edited by Jeffrey L. Cummings and Bruce L. Miller 5. Therapy of Parkinson’s Disease, edited by William C. Koller
and George Paulson 6. Handbook of Sleep Disorders, edited by Michael J. Thorpy 7. Epilepsy and Sudden Death, edited by Claire M. Lathers
and Paul L. Schraeder 8. Handbook of Multiple Sclerosis, edited by Stuart D. Cook 9. Memory Disorders: Research and Clinical Practice,
edited by Takehiko Yanagihara and Ronald C. Petersen 10. The Medical Treatment of Epilepsy, edited by Stanley R. Resor, Jr.,
and Henn Kutt 11. Cognitive Disorders: Pathophysiology and Treatment,
edited by Leon J. Thal, Walter H. Moos, and Elkan R. Gamzu 12. Handbook of Amyotrophic Lateral Sclerosis, edited by Richard Alan Smith 13. Handbook of Parkinson’s Disease: Second Edition, Revised and Expanded,
edited by William C. Koller 14. Handbook of Pediatric Epilepsy, edited by Jerome V. Murphy
and Fereydoun Dehkharghani 15. Handbook of Tourette’s Syndrome and Related Tic and Behavioral Disorders, edited by Roger Kurlan 16. Handbook of Cerebellar Diseases, edited by Richard Lechtenberg 17. Handbook of Cerebrovascular Diseases, edited by Harold P. Adams, Jr. 18. Parkinsonian Syndromes, edited by Matthew B. Stern
and William C. Koller 19. Handbook of Head and Spine Trauma, edited by Jonathan Greenberg 20. Brain Tumors: A Comprehensive Text, edited by Robert A. Morantz
and John W. Walsh 21. Monoamine Oxidase Inhibitors in Neurological Diseases,
edited by Abraham Lieberman, C. Warren Olanow, Moussa B. H. Youdim, and Keith Tipton 22. Handbook of Dementing Illnesses, edited by John C. Morris 23. Handbook of Myasthenia Gravis and Myasthenic Syndromes,
edited by Robert P. Lisak 24. Handbook of Neurorehabilitation, edited by David C. Good
and James R. Couch, Jr. 25. Therapy with Botulinum Toxin, edited by Joseph Jankovic
and Mark Hallett 26. Principles of Neurotoxicology, edited by Louis W. Chang 27. Handbook of Neurovirology, edited by Robert R. McKendall
and William G. Stroop 28. Handbook of Neuro-Urology, edited by David N. Rushton 29. Handbook of Neuroepidemiology, edited by Philip B. Gorelick
and Milton Alter
Copyright 2006 by Taylor & Francis Group, LLC
DK3767_FM.qxd
9/14/05
10:58 AM
Page D
30. Handbook of Tremor Disorders, edited by Leslie J. Findley
and William C. Koller 31. Neuro-Ophthalmological Disorders: Diagnostic Work-Up and Management, edited by Ronald J. Tusa and Steven A. Newman 32. Handbook of Olfaction and Gustation, edited by Richard L. Doty 33. Handbook of Neurological Speech and Language Disorders,
edited by Howard S. Kirshner 34. Therapy of Parkinson’s Disease: Second Edition, Revised and Expanded,
edited by William C. Koller and George Paulson 35. Evaluation and Management of Gait Disorders, edited by
Barney S. Spivack 36. Handbook of Neurotoxicology, edited by Louis W. Chang
and Robert S. Dyer 37. Neurological Complications of Cancer, edited by Ronald G. Wiley 38. Handbook of Autonomic Nervous System Dysfunction,
edited by Amos D. Korczyn 39. Handbook of Dystonia, edited by Joseph King Ching Tsui
and Donald B. Calne 40. Etiology of Parkinson’s Disease, edited by Jonas H. Ellenberg,
William C. Koller and J. William Langston 41. Practical Neurology of the Elderly, edited by Jacob I. Sage
and Margery H. Mark 42. Handbook of Muscle Disease, edited by Russell J. M. Lane 43. Handbook of Multiple Sclerosis: Second Edition, Revised and Expanded,
edited by Stuart D. Cook 44. Central Nervous System Infectious Diseases and Therapy,
edited by Karen L. Roos 45. Subarachnoid Hemorrhage: Clinical Management, edited by
Takehiko Yanagihara, David G. Piepgras, and John L. D. Atkinson 46. Neurology Practice Guidelines, edited by Richard Lechtenberg
and Henry S. Schutta 47. Spinal Cord Diseases: Diagnosis and Treatment, edited by
Gordon L. Engler, Jonathan Cole, and W. Louis Merton 48. Management of Acute Stroke, edited by Ashfaq Shuaib
and Larry B. Goldstein 49. Sleep Disorders and Neurological Disease, edited by Antonio Culebras 50. Handbook of Ataxia Disorders, edited by Thomas Klockgether 51. The Autonomic Nervous System in Health and Disease,
David S. Goldstein 52. Axonal Regeneration in the Central Nervous System, edited by
Nicholas A. Ingoglia and Marion Murray 53. Handbook of Multiple Sclerosis: Third Edition, edited by Stuart D. Cook 54. Long-Term Effects of Stroke, edited by Julien Bogousslavsky 55. Handbook of the Autonomic Nervous System in Health and Disease,
edited by C. Liana Bolis, Julio Licinio, and Stefano Govoni 56. Dopamine Receptors and Transporters: Function, Imaging, and Clinical Implication, Second Edition, edited by Anita Sidhu,
Marc Laruelle, and Philippe Vernier 57. Handbook of Olfaction and Gustation: Second Edition, Revised and Expanded, edited by Richard L. Doty
Copyright 2006 by Taylor & Francis Group, LLC
DK3767_FM.qxd
9/14/05
10:58 AM
Page E
58. Handbook of Stereotactic and Functional Neurosurgery, edited by
Michael Schulder 59. Handbook of Parkinson’s Disease: Third Edition, edited by Rajesh Pahwa,
Kelly E. Lyons, and William C. Koller 60. Clinical Neurovirology, edited by Avindra Nath and Joseph R. Berger 61. Neuromuscular Junction Disorders: Diagnosis and Treatment, Matthew N. Meriggioli, James F. Howard, Jr., and C. Michel Harper 62. Drug-Induced Movement Disorders, edited by Kapil D. Sethi 63. Therapy of Parkinson’s Disease: Third Edition, Revised and Expanded, edited by Rajesh Pahwa, Kelly E. Lyons, and William C. Koller 64. Epilepsy: Scientific Foundations of Clinical Practice, edited by Jong M. Rho, Raman Sankar, and José E. Cavazos 65. Handbook of Tourette’s Syndrome and Related Tic and Behavioral Disorders: Second Edition, edited by Roger Kurlan 66. Handbook of Cerebrovascular Diseases: Second Edition, Revised and Expanded, edited by Harold P. Adams, Jr. 67. Emerging Neurological Infections, edited by Christopher Power and Richard T. Johnson 68. Treatment of Pediatric Neurologic Disorders, edited by Harvey S. Singer, Eric H. Kossoff, Adam L. Hartman, and Thomas O. Crawford 69. Synaptic Plasticity : Basic Mechanisms to Clinical Applications, edited by Michel Baudry, Xiaoning Bi, and Steven S. Schreiber 70. Handbook of Essential Tremor and Other Tremor Disorders, edited by Kelly E. Lyons and Rajesh Pahwa 71. Handbook of Peripheral Neuropathy, edited by Mark B. Bromberg and A. Gordon Smith 72. Carotid Artery Stenosis: Current and Emerging Treatments, edited by Seemant Chaturvedi and Peter M. Rothwell 73. Gait Disorders: Evaluation and Management, edited by Jeffrey M. Hausdorff and Neil B. Alexander 74. Surgical Management of Movement Disorders (HBK), edited by Gordon H. Baltuch and Matthew B. Stern 75. Neurogenetics: Scientific and Clinical Advances, edited by David R. Lynch 76. Epilepsy Surgery: Principles and Controversies, edited by John W. Miller and Daniel L. Silbergeld 77. Clinician's Guide To Sleep Disorders, edited by Nathaniel F. Watson and Bradley Vaughn 78. Amyotrophic Lateral Sclerosis, edited by Hiroshi Mitsumoto, Serge Przedborski and Paul H. Gordon
Copyright 2006 by Taylor & Francis Group, LLC
DK3767_FM.qxd
9/14/05
10:58 AM
Page i
Neurogenetics: Scientific and Clinical Advances Edited by
David R. Lynch, M.D., Ph.D. Children’s Hospital Philadelphia, Pennsylvania, U.S.A.
Associate Editor
Jennifer M. Farmer, M.S., C.G.C. Genetic Counselor, Department of Pathology and Laboratory Medicine University of Pennsylvania School of Medicine Philadelphia, Pennsylvania, U.S.A.
New York London
Copyright 2006 by Taylor & Francis Group, LLC
DK3767_Discl.fm Page 1 Monday, September 19, 2005 11:17 AM
Published in 2006 by Taylor & Francis Group 270 Madison Avenue New York, NY 10016 © 2006 by Taylor & Francis Group, LLC No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-10: 0-8247-2942-0 (Hardcover) International Standard Book Number-13: 978-0-8247-2942-4 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reprinted material is quoted with permission, and sources are indicated. A wide variety of references are listed. Reasonable efforts have been made to publish reliable data and information, but the author and the publisher cannot assume responsibility for the validity of all materials or for the consequences of their use. No part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC) 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data Catalog record is available from the Library of Congress
Taylor & Francis Group is the Academic Division of Informa plc.
Copyright 2006 by Taylor & Francis Group, LLC
Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com
Foreword Those working in the field of neurogenetics view the advances of the last decade as a fantastic explosion of knowledge. But to others, particularly the practicing neurologist, it may seem less than fantastic. It can seem, well, downright daunting. Take Charcot-Marie-Tooth disease, for example. What once was broadly classified into two clinically distinguishable forms of neuropathy now represents more than 20 genetic conditions. Or take the hereditary ataxias: over 25 genetic causes already identified—and that’s just the dominant forms of disease! Diseases that, clinically, we thought we knew so well sometimes seem to change once the underlying genes are discovered. Friedreich’s ataxia, for example, was originally defined as a childhood disorder, but the gene now tells us otherwise: it is a disease of adults, too, and can look altogether different in adults. In short, while the onslaught of advances in neurogenetics has helped to clarify disease mechanisms and improve diagnosis, it sometimes leaves non-geneticists wanting to throw in the towel. My advice to you: don’t throw in that towel just yet. First, read this book. David Lynch has assembled a remarkable group of experts who have written a wide-ranging collection of chapters on neurogenetics principles. These authors clearly and succinctly explain neurogenetics—both its general, underlying principles and specific heritable diseases—as we understand them in 2006. When I say read this book, I don’t mean read only the chapter about your favorite disease, then place it on the shelf. I mean sit down and read this book from page one. The opening chapters on neurogenetics in the clinic, genetic testing, genetic counseling, and ethical issues are a beautiful foray into the practical nuts and bolts of neurogenetics that physicians, including neurologists, increasingly must deal with. These introductions to fundamental aspects of neurogenetics are written in a compelling and straightforward manner that will leave readers, whether they are training scientists, resident physicians or even seasoned professors, with a clearer
Copyright 2006 by Taylor & Francis Group, LLC
understanding of what it means for a disease to ‘‘look genetic’’ and how best to pursue the underlying genetic cause. If, on top of that, you finish your reading also knowing how to draw a pedigree (well described in Bennett’s genetic counseling chapter), that’s icing on the cake. Once these general principles are introduced in the first few chapters, they are then applied by disease experts to a wide range of inherited neurological diseases. The 28 chapters comprising this book cover nearly all of the major areas of neurogenetics that an adult neurologist will see in the clinic, as well as a good many pediatric disorders. Neuromuscular and neurodegenerative disease are particularly well covered. This comes as no surprise since they have led the way in neurogenetics. But areas in which genetics are just beginning to make their full presence known—epilepsy and paroxysmal disorders, to name a few—are also well represented. Even someone who studies molecular mechanisms of genetic diseases for a living (like I do) will learn quite a bit of cutting edge information about a wide range of important diseases. A major strength of this book is that most chapters ground their discussion where it matters most—in the clinical realm. The disease experts typically begin by describing the clinical features of disease followed by a discussion of the underlying genetic basis and, when known, the molecular mechanism. This often then leads to a discussion of where treatment stands today and how recent insights from the underlying neurogenetics are leading to novel treatments. This last point is emphasized in certain chapters that are dedicated to describing such advancements, such as Pierson and Wolfe’s chapter on gene therapy. But even chapters that concentrate on particular diseases, for example, Leavitt’s and Raymond’s chapter on Huntington’s disease, compellingly describe how modern science is leading to novel therapies. Finally, perhaps we can stop lamenting the complexity of neurogenetic disorders. In many cases, knowing the genes and the underlying genetic mechanisms has actually simplified the view of the class of diseases. When experts write about these diseases in a clear and compelling manner, as they do here, classification schemes that formerly seemed vexing begin to make sense. Provided you read the book, of course. Henry L. Paulson, MD, PhD University of Iowa Carver College of Medicine
Copyright 2006 by Taylor & Francis Group, LLC
Preface In the past decade, no field of neurology has changed more than that of neurogenetics. Once limited to the clinical description of rare, inherited neurologic disease, the introduction of molecular technologies and genomic medicine approaches have allowed for more precise diagnosis, better scientific understanding of the pathophysiology, and introduction of novel therapies for neurogenetic disease. Molecular technology has also broadened the field to recognize genetic contributions and significance in complex diseases, such as Parkinson’s disease, epilepsy, and Alzheimer’s disease, leading to advances in the understanding and treatment of these disorders as well. These advances demand greater knowledge of basic genetic principles, the ability to translate the utility of genetic advances into clinical practice, appreciation for ethical issues raised by genetic testing, and recognition of a growing group of conditions in neurogenetic disease, from clinical neurology practitioners, academic neurologists, and neuroscience researchers. The huge volume of information on neurogenetic disease now allows the clinician to answer more clinical and diagnostic questions than previously and potentially allows researchers to ask new questions directed at disease mechanisms. However, understanding the utility of these advances is not easy, and the limitations of genetic approaches are frequently misunderstood. In addition, new ethical dilemmas arise in situations such as predictive genetic testing, in which a genetic test can be used to inform individuals of whether they will eventually acquire a disease years before they may feel any symptoms. Paradigms for application of such testing to patients are frequently unfamiliar to even some of the best-informed clinicians. The present book should allow clinicians and researchers to be familiar with modern neurogenetic approaches and information, and apply that information to the questions that arise in practice and research. In this volume, we seek to present the most current perspectives on neurogenetic disease from both clinical and scientific perspectives. There
Copyright 2006 by Taylor & Francis Group, LLC
are three sections of this book. In the first, authors present overviews of modern approaches to genetic testing and counseling, and the dilemmas that arise with molecular technologies and genomic medicine. These chapters illustrate the type of information now available, how it can be used, and how it can be confounded in general ways using specific practical examples. In the second section of the book, each chapter reviews a classical genetic neurological disorder (or group of disorders) with an application of modern knowledge to clinical evaluation, management and treatment, and basic pathophysiology. In the final section of the book, each chapter examines traditionally non-genetic neurological illness, and demonstrates the significance and utility of genetic approaches and technology in the pathophysiological understanding and clinical management of these disorders. This approach should provide clinical neurologists, academicians, and researchers with the tools and the knowledge to answer modern questions in neurogenetic illnesses. David R. Lynch Jennifer M. Farmer
Copyright 2006 by Taylor & Francis Group, LLC
Contents
Foreword Preface Contributors 1. Neurogenetics in the Clinic Thomas D. Bird Factors Suggesting a Neurogenetic Disorder Neurogenetic Diseases ‘‘Hiding’’ in Nonspecific Categories Importance of Family History Assessment of Sporadic Cases Genetic Counseling Genetic Testing Neurogenetics Information Resources An Integrated Clinical Neurogenetics Strategy References 2. Genetic Testing for Neurological Disorders Martha A. Nance Introduction Principles of Genetic Inheritance Genotype Changes and Their Significance in Phenotypic Appearance Gene Mutations and Assays to Detect Them Clinical Use of Gene Tests
Copyright 2006 by Taylor & Francis Group, LLC
Resources for the Clinician References 3. Genetic Counseling Robin L. Bennett Introduction Are Genetic Disorders Unique? Who Are Genetic Counselors? The Process of Genetic Counseling Genetic Family History—The Pedigree Pedigree Analysis and Risk Perception Summary References 4. Gene Therapy for Inherited Diseases of the Central Nervous System Tyler Mark Pierson and John H. Wolfe Introduction General Properties of CNS Gene Therapy Candidate Diseases for Gene Therapy in the CNS Animal Models of Genetic CNS Disorders Lysosomal Storage Disease: Animal Models as a Paradigm for CNS Gene Therapy Gene Delivery Vehicles Summary References 5. Ethical Dilemmas in Neurogenetics Wendy R. Uhlmann Testing Minors Testing a Child for Adoption Testing an Adult Child When the At-Risk Parent Refuses Testing Is There a ‘‘Duty to Warn’’ and Share Test Results with Other At-Risk Family Members? Testing Identical Twins Non-Disclosure of Test Results Testing Siblings Simultaneously Copyright 2006 by Taylor & Francis Group, LLC
Testing Individuals Who Work in Professions Where Neurological Deficits Can Jeopardize the Safety of Others Testing Symptomatic Individuals Who Think They Are Asymptomatic Testing ‘‘Asymptomatic’’ Individuals Who have Recently Attempted Suicide Testing a Blood Sample from Someone Who Has Just Committed Suicide Testing a Pregnancy Giving Informed Consent for Individuals with Cognitive/Psychiatric Impairment Insurance Issues Anonymous Testing Legal Cases Resources Summary Recommended Reading References 6. Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders Craig L. Bennett Scope of This Chapter CMT: Background and General Clinical Features Electrophysiological Classification of CMT Major Forms of Demyelinating CMT1 Major Forms of Demyelinating CMT2 Prognosis in CMT Summary Electronic Databases References 7. Duchenne and Becker Muscular Dystrophies Leta S. Steffen and Louis M. Kunkel Introduction Clinical Symptoms Clinical Diagnosis Clinical Treatment History of the Dystrophin Discovery Dystrophin—Molecular Characterization Copyright 2006 by Taylor & Francis Group, LLC
Animal Models of DMD Current Research for DMD/BMD Therapies Conclusion References 8. The Congenital and Limb-Girdle Muscular Dystrophies Janbernd Kirschner and Carsten G. Bo¨nnemann Introduction Congenital Muscular Dystrophies Limb-Girdle Muscular Dystrophies References 9. Non-dystrophic Myotonias and Periodic Paralyses Arie Struyk and Stephen Cannon Introduction Chloride Channel Myotonias (Myotonia Congenita) Sodium Channel Myotonia and Periodic Paralysis Hypokalemic Periodic Paralysis Andersen’s Syndrome Conclusions References 10. The Myotonic Dystrophies—Effects of an RNA Mutation John W. Day and Laura P. W. Ranum Introduction Clinical Features of the Myotonic Dystrophies Genetics of the Myotonic Dystrophies Molecular Pathogenesis of the Myotonic Dystrophies Reports of a Third Form of Myotonic Dystrophy Summary References 11. Spinal Muscular Atrophy Stephen J. Kolb and J. Paul Taylor Introduction Clinical Features of Autosomal Recessive SMA Copyright 2006 by Taylor & Francis Group, LLC
Molecular Genetics of Autosomal Recessive SMA SMA Unrelated to Mutations in SMN1 Basic Research on Autosomal Recessive SMA: The SMN Complex Model Systems Therapeutics References 12. Hereditary Spastic Paraplegia Kleopas A. Kleopa Introduction Clinical and Pathological Features of HSP Genetics and Neurobiology of HSP Diagnostic Approach and Treatment in HSP Conclusion References 13. Mitochondrial Disorders Clotilde Lagier-Tourenne and Michio Hirano Introduction Principles of Mitochondrial Genetics Primary Mitochondrial DNA Mutations Nuclear DNA Mutations General Features of Mitochondrial Diseases Specific Mitochondrial Diseases MELAS References 14. Friedreich Ataxia Martin B. Delatycki, Michael C. Fahey, Louise Corben, and Andrew Churchyard Introduction Clinical Features Pathology Molecular Genetics Pathogenesis Management of Patients with FRDA Potential Pharmacological Therapies for FRDA Conclusion References Copyright 2006 by Taylor & Francis Group, LLC
15. Autosomal Dominant Ataxias Susan L. Perlman Introduction The Typical Dominant Ataxias SCA1 SCA2 SCA3 SCA4 SCA5 SCA6 SCA7 SCA8 SCA9 SCA10 SCA11 SCA12 SCA13 SCA14 SCA15 SCA16 SCA17 SCA18 SCA19 SCA20 SCA21 SCA22 SCA23 SCA24 SCA25 SCA26 SCA Due to FGF14 Conclusion References 16. Huntington’s Disease: Mechanisms of Pathogenesis and Development of New Therapies Blair R. Leavitt and Lynn A. Raymond Clinical, Pathologic, and Genetic Features of Huntington’s Disease Animal Models of HD Copyright 2006 by Taylor & Francis Group, LLC
Pathogenesis of HD Preclinical Trials in Mouse Models of HD Clinical Trials in HD Conclusions References 17. Wilson’s Disease George J. Brewer Introduction and Historical Overview Pathophysiology Genetics and Epidemiology Clinical Presentations Recognition, Screening, and Diagnosis Treatment with Anticopper Drugs Prognosis References 18. Neurogenetics of Dystonia and Paroxysmal Dyskinesias Jennifer Friedman and David G. Standaert Dystonia Genetics of Primary Dystonias Genetics of Dystonia Plus Syndromes Genetics of Paroxysmal Dystonias and Dyskinesias References 19. Inherited Epilepsies Yr Sigurdardottir and Annapurna Poduri Introduction Channelopathies Myoclonic Epilepsies Generalized Epilepsy Syndromes Localization-Related Epilepsy Syndromes Conclusion References 20. Leukodystrophies James Y. Garbern Introduction Disorders of Myelin Lipid Metabolism Copyright 2006 by Taylor & Francis Group, LLC
Closing Thoughts Resources References 21. Lysosomal Storage Disorders David A. Wenger and Stephanie Coppola Introduction General Concepts Clinical Features that Suggest a LSD Diagnosis of LSDS Treatment of LSDS References 22. The Tuberous Sclerosis Complex: Clinical Manifestations and Molecular Genetics John R. Pollard and Peter B. Crino Clinical Features of TSC Neurological Manifestations Neuropathology Genetics Signaling Pathway and Cell Biology Conclusion References 23. Neurofibromatosis Amit Malhotra, James Dowling, and David H. Gutmann Introduction Neurofibromatosis 1 Clinical Features of Neurofibromatosis 2 References 24. Genetics of Parkinson’s Disease Sathya R. Sriram, Valina L. Dawson, and Ted M. Dawson Introduction Genes Linked to Familial PD Clinical Testing for Genetic Forms of PD Conclusion References
Copyright 2006 by Taylor & Francis Group, LLC
25. Alzheimer’s Disease R. Scott Turner Introduction Epidemiology Clinical Criteria Pathologic Criteria Risk Factors Genetics of Familial AD Genetics of Sporadic (Late-Onset) Alzheimer’s Disease The Amyloid Hypothesis Genetic Testing Current Treatment Strategies Future Treatment Strategies Perspectives References 26. Tauopathies John C. van Swieten Introduction Tau Gene—Tau Protein Frontotemporal Dementia FTDP-17 Pathology of FTDP-17 Conclusions References 27. Amyotrophic Lateral Sclerosis Teepu Siddique and Lisa Dellefave ALS Background Approaches to Mendelian Inherited ALS Understanding ALS Pathophysiology Through Mendelian Inherited ALS Approaches to SALS as a Genetically Complex or Multifactorial Disorder Clinical Management Remaining Questions to Be Answered References
Copyright 2006 by Taylor & Francis Group, LLC
28. Prion Diseases William S. Baek and James A. Mastrianni Introduction Historical Background Prion Protein (PrP) and the Prion Concept Pathogenesis of Prions Transmissible Properties of Prions Epidemiology Mutations of PRNP Cause Familial PrD PRNP Polymorphisms Prion-Like Protein Gene (Prnd ) The Phenotypes of PrD Diagnosis of Prion Disease Diagnostic Studies Treatment References About the Editor
Copyright 2006 by Taylor & Francis Group, LLC
Contributors
William S. Baek Department of Neurology, University of Chicago Hospitals, Chicago, Illinois, U.S.A. Craig L. Bennett Division of Genetics and Developmental Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, U.S.A. Robin L. Bennett University of Washington, Medical Genetics, Seattle, Washington, U.S.A. Thomas D. Bird Department of Neurology, University of Washington Geriatric Research Center, VA Medical Center, Seattle, Washington, U.S.A. Carsten G. Bo¨nnemann Division of Neurology, The Children’s Hospital of Philadelphia, Abramson Research Center, Philadelphia, Pennsylvania, U.S.A. George J. Brewer Department of Human Genetics and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, U.S.A. Stephen Cannon Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A. Andrew Churchyard Monash Institute for Neurological Disease, Southern Health, Monash Medical Centre, Victoria, Australia
Copyright 2006 by Taylor & Francis Group, LLC
Stephanie Coppola Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania, U.S.A. Louise Corben Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Victoria, Australia Peter B. Crino Department of Neurology and Epilepsy Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, U.S.A. Ted M. Dawson Departments of Neurology and Neuroscience and Program in Cellular and Molecular Medicine, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. Valina L. Dawson Departments of Neurology, Neuroscience, and Physiology and Program in Cellular and Molecular Medicine, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. John W. Day Department of Neurology, Institute of Human Genetics, University of Minnesota School of Medicine, Minneapolis, Minnesota, U.S.A. Martin B. Delatycki Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Victoria, Australia Lisa Dellefave Davee Department of Neurology and Clinical Neuroscience, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, U.S.A. James Dowling The Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A. Michael C. Fahey Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Victoria, Australia Jennifer Friedman Department of Neurology, Children’s Hospital and Health Center, San Diego, California, U.S.A. James Y. Garbern Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
Copyright 2006 by Taylor & Francis Group, LLC
David H. Gutmann Department of Neurology, Washington University School of Medicine and St. Louis Children’s Hospital, St. Louis, Missouri, U.S.A. Michio Hirano Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, U.S.A. Janbernd Kirschner Division of Neuropediatrics and Muscle Disorders, University Children’s Hospital, Freiburg, Germany Kleopas A. Kleopa Nicosia, Cyprus
The Cyprus Institute of Neurology and Genetics,
Stephen J. Kolb Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A. Louis M. Kunkel Program in Genomics, Children’s Hospital Boston, Department of Genetics, Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts, U.S.A. Clotilde Lagier-Tourenne Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, U.S.A. Blair R. Leavitt Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, and Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada Amit Malhotra Department of Neurology, Washington University School of Medicine and St. Louis Children’s Hospital, St. Louis, Missouri, U.S.A. James A. Mastrianni Department of Neurology, University of Chicago Hospitals, Chicago, Illinois, U.S.A. Martha A. Nance Department of Neurology, University of Minnesota, Minneapolis, Minnesota, U.S.A. Susan L. Perlman Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A. Tyler Mark Pierson Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.
Copyright 2006 by Taylor & Francis Group, LLC
Annapurna Poduri Division of Epilepsy and Neurophysiology, Children’s Hospital Boston, Boston, Massachusetts, U.S.A. John R. Pollard Department of Neurology and Epilepsy Center, University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, U.S.A. Laura P. W. Ranum Department of Genetics, Cell Biology and Development, Institute of Human Genetics, University of Minnesota School of Medicine, Minneapolis, Minnesota, U.S.A. Lynn A. Raymond Department of Psychiatry, Division of Neurology, Department of Medicine, and Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada Teepu Siddique Davee Department of Neurology and Clinical Neurosciences and Department of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, U.S.A. Yr Sigurdardottir Department of Pediatrics, University Hospital Iceland, Reykjavik, Iceland Sathya R. Sriram Institute for Cell Engineering and Program in Cellular and Molecular Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, U.S.A. David G. Standaert MassGeneral Institute for Neurodegenerative Disorders, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, U.S.A. Leta S. Steffen Program in Genomics, Children’s Hospital Boston, and Department of Genetics, Harvard Medical School, Boston, Massachusetts, U.S.A. Arie Struyk Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A. J. Paul Taylor Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A. R. Scott Turner Department of Neurology and Neurology Service and Neuroscience Program and VA Geriatric Research Education and Clinical Center, Institute of Gerontology, University of Michigan, Ann Arbor, Michigan, U.S.A.
Copyright 2006 by Taylor & Francis Group, LLC
Wendy R. Uhlmann Department of Internal Medicine, Division of Molecular Medicine and Genetics, and Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, U.S.A. John C. van Swieten Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands David A. Wenger Department of Neurology, Jefferson Medical College, Philadelphia, Pennsylvania, U.S.A. John H. Wolfe Division of Neurology, Children’s Hospital of Philadelphia and W. F. Goodman Center for Comparative Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
Copyright 2006 by Taylor & Francis Group, LLC
About the Editor DAVID R. LYNCH is Associate Professor of Neurology and Pediatrics and Director of the Integrated Friedreich’s Ataxia Clinic, University of Pennsylvania, Philadelphia. Dr. Lynch received the B.S. degree from Yale University, New Haven, Connecticut, and the M.D. and Ph.D. degrees from The Johns Hopkins University School of Medicine, Baltimore, Maryland. He completed residency and fellowship training at the University of Pennsylvania, Philadelphia.
Copyright 2006 by Taylor & Francis Group, LLC
1 Neurogenetics in the Clinic Thomas D. Bird Department of Neurology, University of Washington, Geriatric Research Center, VA Medical Center, Seattle, Washington, U.S.A.
The clinical practice of neurogenetics is complex, challenging, and rewarding. Several guidelines will be helpful. This chapter will briefly focus on eight aspects of clinical neurogenetics, namely, (i) Factors suggesting the presence of a genetic disease, (ii) Neurogenetic diseases that may be ‘‘hiding’’ in nonspecific categories, (iii) The importance of family history, (iv) The assessment of sporadic cases, (v) Genetic counseling, (vi) Genetic testing, (vii) Available information resources, and (viii) An integrated clinical neurogenetic strategy. [A discussion of this approach has appeared previously in Ref. (1).]
FACTORS SUGGESTING A NEUROGENETIC DISORDER Table 1 highlights several of the clues indicating an increased probability that a patient may have a neurogenetic disorder. First and foremost is the presence of a positive family history. By nature, genetic diseases are usually inherited (although there are exceptions), and thus it is common to identify other affected family members. This is true of all patterns of inheritance including autosomal dominant, autosomal recessive, X-linked, and mitochondrial. Therefore, a positive family history of at least two similarly affected individuals is a compelling sign of a genetic disorder. However, there are two major exceptions to finding a positive family history. The first is that isolated or sporadic cases without a positive family history can still be genetic. The various explanations for sporadic cases are discussed later in
Copyright 2006 by Taylor & Francis Group, LLC
2
Bird
Table 1 Clues to the Presence of a Neurogenetic Disease Positive family history Similarity to a known genetic syndrome Chronic, progressive clinical course Consanguinity Increased frequency in a specific ethnic group
this chapter. The second exception is that not all familial disorders are genetic. In other words, family members sharing the same environment may be affected with the same nongenetic acquired disease. For example, common exposure to infectious or toxic agents may produce a positive family history of a disorder (such as neuropathy or ataxia), which is not genetic. Thus, although a positive family history is a strong sign of a genetic disease, all familial disorders are not always genetic and all genetic disorders are not always familial. Probably the next most important clue suggesting a genetic disorder is a constellation of signs and symptoms suggesting a known genetic syndrome. This is common sense, but often requires a detailed knowledge of, and memory for syndromic identification. For example, atypical facial ‘‘acne’’ and a seizure disorder suggest tuberous sclerosis, progressive ataxia with loss of reflexes suggests Friedreich ataxia, white matter disease with hyperactive tendon reflexes in a male suggests adrenoleukodystrophy or Pelizaeus-Merzbacher disease, and weakness with cataracts suggests myotonic dystrophy. Other factors can be helpful in identifying a genetic disease but are less specific. For example, most (but not all) genetic diseases have a slow, subtle onset, and prolonged, chronic course. Many have onset in childhood, although it is not uncommon to have a later onset (especially in autosomal dominant triplet repeat conditions). Consanguinity (matings between blood relatives) is a clue to autosomal recessive disorders. In addition, certain diseases are more common in specific ethnic groups. Examples include Tay-Sachs disease in Eastern European Jews, Unverricht-Lundborg myoclonic epilepsy in Finns, dentatorubral-pallidoluysian atrophy (DRPLA) in Japanese, spinocerebellar ataxia (SCA) 3 in Portuguese and cerebral cavernous malformations or SCA10 in Mexicans.
NEUROGENETIC DISEASES ‘‘HIDING’’ IN NONSPECIFIC CATEGORIES Certain nonspecific diagnostic categories often harbor patients with neurogenetic diseases and can be viewed as ‘‘reservoirs’’ where neurogenetic patients may be ‘‘hiding.’’ Several of these categories are listed in Table 2. These categories are quite general and such diagnoses, when applied to
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics in the Clinic
3
Table 2 Diagnostic Reservoirs of Neurogenetic Diseases Cerebral palsy Mental retardation Epilepsy Movement disorders Ataxias Dementias Atypical multiple sclerosis Peripheral neuropathy
individual patients, often warrant additional investigation. This is particularly true of cerebral palsy, epilepsy, mental retardation, and multiple sclerosis (MS). Certainly, any patient with one of these diagnoses and with a positive family history of a similarly affected individual should initiate a further search for a more specific genetic cause. Patients referred to our clinic with a diagnosis of cerebral palsy actually have been discovered to have familial spastic paraplegia, ataxia telangiectasia, or Pelizaeus-Merzbacher disease. Patients with dementia, not otherwise specified, have been found to have genetic forms of Alzheimer’s disease, Creutzfeldt-Jakob disease, and frontotemporal dementia. MS has been an initial diagnosis for individuals later re-diagnosed as cerebral autosomal dominant arteriopathy with subcortal infarcts and leukoencephalopathy (CADASIL) and a variety of genetic leukodystrophies. Persons with movement disorders of uncertain cause have been found to have Huntington’s disease, hereditary ataxias, and genetic forms of dystonia. More detailed evaluation of patients with unexplained epilepsy has uncovered cases of myoclonus epilepsy associated with ragged-red fibers (MERRF) and autosomal recessive myoclonic epilepsy. Many patients with Charcot-Marie-Tooth (CMT) disease have a diagnosis of peripheral neuropathy without recognition of its genetic nature. IMPORTANCE OF FAMILY HISTORY Because a positive family history is such an important element in the diagnosis of neurogenetic disorders, it is critical to pay careful attention to the family medical history and to record it appropriately for future reference (2). The physician should always inquire about the health of siblings, parents, and children. If clues begin to accumulate that a genetic disease may be present, then one inquires about more distant relatives such as grandparents, aunts, uncles, and cousins. Not only is it important to inquire about numerous family members, but the types of questions also need to be carefully tailored to the differential diagnosis. For example, if one is considering myotonic muscular dystrophy, you would ask about other family
Copyright 2006 by Taylor & Francis Group, LLC
4
Bird
members with baldness, diabetes, developmental delay, or cataract. If considering (CMT) neuropathy, the questions would include difficulty in walking, high arched feet, braces, or foot surgery. Possible neurofibromatosis would initiate questions about skin spots and skin lumps, and possible tuberous sclerosis would trigger questions about mental retardation, seizures, and kidney disease. A broad knowledge of the various possible syndromes is critical because nonobvious questions may become important; for example, the association of berry aneurysm with autosomal dominant polycystic kidney disease; diabetes and gall bladder disease with myotonic dystrophy; and schizophrenia with Huntington’s disease. Furthermore, general questions about other family members may add diagnostic support to the potential diagnosis. Figure 1 shows the pedigree of an index case with epilepsy. The occurrence of mental retardation, seizures, and renal tumors in other family members greatly increases the likelihood that the index case has tuberous sclerosis. There are standard protocols for
Figure 1 The index case (proband) in this family is a 16-year-old man with epilepsy. There has been no previous specific diagnosis of a genetic disease in his family. However, his family history reveals instances of seizures, mental retardation, renal tumor, developmental delay, and learning disability. This constellation of findings strongly suggests the possibility of tuberous sclerosis occurring in this family. This is an example of a careful family history contributing important diagnostic information regarding the physical complaints of the proband. The diagnosis of tuberous sclerosis is not trivial because it includes implications for the entire family regarding genetic risk, genetic testing, and the use of important medical procedures such as MRI, CT, and renal ultrasound.
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics in the Clinic
5
drawing and recording family pedigrees. The important elements are shown in the figure and more detailed information can be found in chapter 3 (2). ASSESSMENT OF SPORADIC CASES A sporadic or isolated case means a single occurrence of a disease without a positive family history. Table 3 lists most of the possible explanations for the sporadic occurrence of an apparent genetic disease. The most important possibility to consider is that the disease is not genetic but actually acquired (a so-called phenocopy). There are many nongenetic causes of chronic neuropathy, cerebellar ataxia, movement disorders, and spasticity that may mimic CMT disease, hereditary ataxias, Huntington’s disease, or familial spastic paraplegia, respectively. Our clinic has seen a dramatic case of lead poisoning masquerading as acute intermittent porphyria (3). On the other hand, sporadic or index cases may certainly have a genetic cause. Persons with autosomal recessive diseases are expected to have normal, heterozygous, carrier parents. In a small sibship, there may be only a single individual affected with an autosomal recessive disease. A sporadic case of an autosomal dominant disease may represent a new mutation (de novo). This is not uncommon in conditions such as neurofibromatosis and tuberous sclerosis. In addition, many autosomal dominant and mitochondrial disorders have reduced penetrance, meaning a parent may carry the disease mutation but demonstrate no signs of the disease or may have very mild expression; carriers of the mutation may not be noticed by family or physicians. This is true of mutations in mitochondrial genes as well as diseases showing mendelian inheritance. A lack of biological family history information is a common situation for adopted persons, and some persons do not know the true identity of their biologic father (false paternity). Diseases caused by chromosomal aberrations are genetic in that they represent abnormalities of DNA, but they often occur only once in a family, such as typical trisomy 21 Down’s syndrome.
Table 3 Causes of a Sporadic Case Having an Apparent Genetic Phenotype Not genetic Autosomal recessive New mutation Decreased penetrance in family Mild expression in family Adoption False paternity Mitochondrial inheritance Chromosomal abnormality
Copyright 2006 by Taylor & Francis Group, LLC
6
Bird
GENETIC COUNSELING Genetic counseling is an important aspect of the management of every patient with a neurogenetic disorder (4). It is discussed in detail in chapter 3 but will be briefly reviewed here in the context of several specific neurogenetic disease categories. Genetic counseling may sometimes be relatively uncomplicated. For example, a patient with sporadic, well-documented multiple sclerosis (MS) may inquire about the risk for MS in his or her children. A brief discussion of multifactorial inheritance and reference to an empiric table of risks for MS (indicating that the risk is about 2–3%) is usually satisfactory. However, many families with neurogenetic diseases raise complex issues that require detailed and time-consuming counseling by an experienced professional with knowledge of both the disease process and the genetic factors. The various aspects of genetic counseling are outlined in Table 4. Accurate diagnosis is essential for genetic counseling. The wrong diagnosis will lead to inaccurate and inappropriate genetic counseling. Establishing the correct diagnosis is often a difficult and sometimes incomplete process. It is better to state that the diagnosis is unclear and provide nonspecific counseling rather than assume an erroneous diagnosis and provide inaccurate counseling. It is important to recognize that genetic counseling is quite different for Duchenne muscular dystrophy versus limb girdle muscular dystrophy (X-linked vs. autosomal recessive or dominant), or CMT type 1A (autosomal
Table 4 Genetic Counseling Diagnosis Education Recurrence risks Expression Penetrance Natural history Prognosis Need for further testing DNA-based tests Other tests Other family members Genetic options Prenatal testing Adoption Artificial insemination Pre-implantation diagnosis Treatment options Referral to consultants Support groups Follow-up
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics in the Clinic
7
dominant) versus X-linked CMT, or MS (multifactorial) versus an autosomal recessive leukodystrophy. The diagnosis should be as specific as possible. For example, it is not enough to know that a patient has lower motor neuron disease. For genetic counseling, it is critical to know if the diagnosis is ALS or spinal muscular atrophy or Kennedy’s spinobulbar muscular atrophy. Given a correct diagnosis, an important part of genetic counseling becomes determination of recurrence risk, i.e., identifying who else in the family is at risk for inheriting the disease and the magnitude of that risk. Pattern of inheritance is the most important factor in determining risk and this is covered in detail in chapter 3. The most important part of this determination is the inheritance pattern associated with the accurate diagnosis. Single gene mendelian diseases have the recurrence risks associated with autosomal dominant, autosomal recessive and X-linked inheritance patterns. These risks are carefully explained and enumerated in several basic texts (5). These risks must also take into consideration the known penetrance of the relevant disease gene. Some disorders have a significantly reduced penetrance, such that many persons inheriting the mutation never show signs of the disease. For example, the penetrance of the most common form of autosomal dominant dystonia (DYT1) is only about 40%. Also, penetrance depends on patient’s age and comprehensiveness of testing. Thus, the penetrance of the Huntington’s disease gene at age 20 is only about 10%, whereas it is greater than 90% by age 70. Similarly, many people with cerebral cavernous malformations seen on MRI will not have any clinical symptoms and appear not to have the disease. The family should also receive a discussion of prognosis and natural history of the specific neurogenetic disease. It is especially important to convey information of variable expression, that is, the range of both severity and types of clinical signs in individuals who have the disease gene. It is often helpful to describe a very mild case, an average or typical case, and a severe case. This requires that the counselor know the pertinent literature and have experience with families having the disease. The counselor also needs to determine the need for additional testing. It is frequently valuable to examine or test other family members to help arrive at the correct diagnosis or to determine who else is affected. Potential additional tests will be tailored to the disease entity, and might include EMG, EEG, MRI, or biochemical tests. DNA-based diagnostic tests are playing an increasingly important role in arriving at highly specific diagnoses in index family members and their relatives (see below). However, genetic or other diagnostic testing may not always be appropriate in asymptomatic at-risk relatives, especially when no treatment is available. Genetic counseling should also answer specific questions that families have. Many families ask for information regarding genetic options related to family planning. These options may include the availability of prenatal testing, adoption, artifical insemination, and pre-implantation diagnosis.
Copyright 2006 by Taylor & Francis Group, LLC
8
Bird
Table 5 Genetic Testing Risks Depression Hypervigilance to symptoms Altered relationships Trouble with insurance Trouble with employment Social isolation
Benefits Specific diagnosis Family planning Financial planning Decreased anxiety Eligible for treatment or prevention trials
The availability and relevance of such genetic options depends on the specific disease and an ever-changing technology. Family members will also want the latest information regarding treatment options. Traditionally, neurogenetic diseases have been considered ‘‘untreatable.’’ However, that perspective is changing and an expanding number of neurogenetic disorders will soon have available treatments. PKU and pyridoxine dependent seizures are models of neurogenetic diseases for which there have long been recognized treatments. New treatment options are appearing for an increasing number of neurogenetic diseases (one recent example being the Fabry disease) (6). Therefore, it is important to gather timely information on relevant clinical trails for patients. Finally, complete genetic counseling includes any appropriate referrals to diagnostic or therapeutic consultants, identification of disease specific patient and caregiver support groups, and arrangement for long-term clinical follow-up. GENETIC TESTING Genetic testing is an ever-expanding component of the evaluation of families with neurogenetic diseases. The number and variety of DNA-based diagnostic tests is rapidly increasing. Table 5 lists many of the risks and benefits of genetic testing. It is important to recall that there are several different kinds of genetic tests including chromosome karyotypes, biologic assays, DNAbased tests and linkage analysis. Genetic testing is reviewed in more detail in the chapter by Dr. Nance in this book (7). NEUROGENETICS INFORMATION RESOURCES No neurologist can possibly have a detailed knowledge of all neurogenetic diseases. It is impossible to remain up to date on all aspects of differential diagnosis, gene identification, genetic testing, and available support groups. Table 6 lists additional resources providing specific and detailed information about neurogenetic diseases. The table also lists four websites.
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics in the Clinic
9
Table 6 Neurogenetic Information Resources www.geneclinics.org www.genetests.org www.ncbi.nlm.nih.gov/Omim/ www.neuro.wustl.edu/neuromuscular/ Pulst S. Neurogenetics. New York: Oxford Press, 2000. Rosenberg RN, Prusiner SB, DiMarco S, Bardin RL. The Molecular and Genetic Basis of Neurological Disease. 3rd ed. Boston: Butterworth–Heinemann, 2003. Lynch DR, Farmer JM, eds. Neurologic Clinics: Neurogenetics. Vol. 20:3. Philadelphia: W.B. Saunders Co Elsevier Science, 2002. This text
Geneclinics (www.geneclinics.org) has expert authored and peer reviewed profiles on more than 300 of the most important genetic diseases including many neurogenetic disorders. The profiles are organized in a user-friendly way that includes diagnostic criteria, differential diagnosis, genetic testing, genetic counseling, molecular background, support groups, and literature references. A valuable resource for genetic testing information is the website www.genetests.org. This site is an annotated index of hundreds of genetic diseases, the availability of genetic testing for each disease, and a listing of associated testing laboratories with contact information. The site helpfully divides laboratories into those doing commercial/clinical or research testing and the information is constantly updated. Online Mendelian Inheritance in Man (OMIM) is an extensive listing of all known human genetic diseases with a selected bibliography for each entry. The Washington University website (http://www.neuro.wustl.edu) is specifically designed for neuromuscular diseases. Rosenberg et al. and Pulst are text books that contain an overview of neurogenetics. Finally, this present text now provides another up-to-date resource regarding neurogenetic diseases.
AN INTEGRATED CLINICAL NEUROGENETICS STRATEGY The comprehensive evaluation and management of patients with neurogenetic diseases has four main components (Table 7). The first is primarily neurological. This relates to taking a history, examining the patient, formulating a differential diagnosis, establishing a correct diagnosis, understanding the natural history and potential complications of the disease, and treatment and management. The second is primarily genetic. This relates to obtaining a detailed pedigree, establishing the correct pattern of inheritance, determining genetic risks, identifying the importance of the diagnosis to other family members, understanding issues of penetrance and variable expression, interpreting genetic test results, and giving advice about genetic
Copyright 2006 by Taylor & Francis Group, LLC
10
Bird
Table 7 Integrated Strategy for Clinical Neurogenetics Neurological Genetic Psychosocial Whole family perspective
options. The third is psychosocial counseling. This refers to the frequent necessity for helping patients and their families deal with the often complex mental, emotional, and social implications of their diseases. The fourth aspect is having a family perspective. This means recognizing that genetic diseases have important implications for more than just the initial index case. When a genetic diagnosis is made, other family members are quickly drawn into the cascade of events that flow from the initial diagnosis out into the larger family. Other family members often require evaluation and counseling. Practioners of medical genetics clearly practice ‘‘family medicine.’’ No individual can provide all of these services. A core neurogenetics clinical unit would include a neurologist, genetics counselor, social worker, and psychologist or psychiatrist. Consultations to nurses, rehabilitation medicine specialists, radiologists, and relevant subspecialties of internal medicine are common. This team approach will provide the best long term care for patients with neurogenetic diseases and form an integrated evaluation and management strategy.
REFERENCES 1. Bird TD. Approaches to the patient with neurogenetic disease. In: Lynch DR, Farmer JM, eds. Neurologic Clinics: Neurogenetics. Vol. 20. Philadelphia, PA: W.B. Saunders, 2002:619–626. 2. Bennett R. The Practical Guide to the Genetic Family History. Wiley-Liss, 1999. 3. Bird TD, Wallace DM, Labbe RF. The porphria, plumbism, pottery puzzle. JAMA 1982; 247(6):813–814. 4. Pagon RA. Genetic diagnosis and counseling. In: Dale DC, Federman DD, eds. Sci Am Med. Vol. 2. Sect 9: Subsect VIII. New York, NY: Scientific American, Inc., 2001. 5. Nussbaum R, McInnes R, Willard H. Genetics in Medicine. 6th ed. Philadelphia: W.B. Saunders, 2001. 6. Eng C, Guffon N, Wilcox W, Germain D. Safety and efficacy of recombinant human a-galactosidase a replacement therapy in Fabry’s disease. N Engl J Med 2001; 345:9–16. 7. Bird T. Risks and benefits of DNA testing for neurogenetic disorders. Seminars in Neurology 1999; 19:253–259.
Copyright 2006 by Taylor & Francis Group, LLC
2 Genetic Testing for Neurological Disorders Martha A. Nance Department of Neurology, University of Minnesota, Minneapolis, Minnesota, U.S.A.
INTRODUCTION Historically, the most important legacy of the Human Genome Project in the field of neuroscience will be the era of experimental human neurogenetics: the ability to create experimental animal models of otherwise exclusively human neurologic disorders, and to perform experimental research using those animal models. However, while neurologists and their patients and families await the improved treatments that experimental neuroscience promises, a direct and immediate consequence of the discovery of disease genes, genetic testing is already available in clinical practice. We review below the role of genetic testing in neurology, and the role of the neurologist in ensuring that genetic tests are used and interpreted properly. PRINCIPLES OF GENETIC INHERITANCE A full discussion on the principles of genetics is beyond the scope of this chapter, but a few points are important to consider. We will assume that the concepts of autosomal dominant, autosomal recessive, and X-linked inheritance are known to the reader, and will briefly discuss other concepts that are important to the appropriate use and interpretation of gene tests.
Copyright 2006 by Taylor & Francis Group, LLC
12
Nance
Reduced Penetrance, Variable Expressivity, Manifesting Carriers The concepts of reduced penetrance and variable expressivity are relevant to dominantly inherited genetic conditions, for which a single copy of a mutation-bearing gene is sufficient to cause the disease. Individuals carrying mutations known to cause diseases such as Huntington’s disease occasionally remain symptom free throughout a long lifetime; in these individuals, the gene mutation is said to be nonpenetrant. Apparent nonpenetrance may be seen in a young patient carrying a gene mutation for tuberous sclerosis or neurofibromatosis type 1 (NF1) (1,2); complete penetrance for NF1 by age five, however, has been documented (2). The terms ‘‘reduced’’ and ‘‘incomplete’’ penetrance refer to the behavior of a gene mutation in a population, while ‘‘nonpenetrance’’ applies to a single individual or group of individuals who have no disease symptoms despite carrying the gene mutation. A related concept is that of variable expressivity. A parent with five cafe´-au-lait spots who is otherwise normal in every way can have a child with severe manifestations of neurofibromatosis; a clinically asymptomatic sibling of a child who has many manifestations of tuberous sclerosis may show periventricular heterotopias on brain magnetic resonance imaging (MRI) (3,4). Striking genotypic and phenotypic heterogeneity has been reported for the myotonic dystrophies (5,6), hereditary spastic paraplegias (7), hereditary neuropathies (8), and many other dominantly inherited conditions. Variable expression of disease symptoms in patients carrying the same gene mutation is related to other specific genes, environmental influences, and genetic (ethnic) background, among other factors. For the polyglutamine disorders, a group of neurodegenerative disorders caused by expansion of the trinucleotide cytosine–adenine–guanine (CAG) within the coding portion of the causative genes, variable expression takes the form of an inverse correlation between the size of the repeat expansion and the age of symptom onset—including the possibility of nonpenetrance for individuals with borderline expansions of the trinucleotide repeat sequence (9,10). As noted above, reduced penetrance and variable expressivity occur because of other genetic and environmental factors that modify the effects of the disease gene mutation. Identifying these modifiers is one of the goals of current research for many neurogenetic diseases, but clinically important successes have yet to be reported. As clinicians provide genetic testing for patients with single-gene disorders, they must help the patients understand to what extent the presence of a disease gene does or does not explain or predict the onset age, severity, or nature of disease symptoms, as well as the potential psychosocial implications of the results (11,12). Manifestation of disease symptoms is sometimes reported in female carriers of genes responsible for X-linked disorders. Carriers of mutations in the CMTX gene, for example, can have symptoms of neuropathy, and
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
13
carriers of ABCD1 (adrenoleukodystrophy) or proteolipid protein gene (spastic paraplegia/Pelizeaus-Merzbacher disease) mutations have been reported to have white matter changes on brain MRI, and sometimes to have disease symptoms (13,14). Depending on the gene and disease, the classic teaching that ‘‘females are carriers for X-linked disorders but only males can develop the disease’’ may oversimplify the relationship between the gene and the disease, and is likely to be inaccurate. In most situations, female carriers will have milder disease symptoms than males, presumably because of the presence of a second X chromosome bearing a normal copy of the gene. The severity of disease manifestations in a female relates at least in part to the vagaries of X chromosome inactivation (a mechanism by which one of the X chromosomes is ‘‘turned off ’’ in each cell), a phenomenon that cannot be measured currently in clinical laboratories (15). A new example of the complex relationship between genes and diseases is the recently described Fragile X Tremor-Ataxia Syndrome (FXTAS). In this syndrome, premutations in the FMR1 gene—a gene in which full mutations are associated with male mental retardation—have been associated with the development of tremor and gait disturbance in later life, in both men and women (16,17). Splitting Identification of disease genes often leads to ‘‘splitting’’ of clinically defined neurologic entities into genetically defined, often clinically indistinguishable subgroups. What was once Charcot-Marie-Tooth disease (CMT) is now a group of over 25 genetically defined entities (8). At least 20 different genes responsible for autosomal recessive and dominant and X-linked forms of hereditary spastic paraplegia have been localized; gene tests are clinically available for at least seven of these genes (7). Identification of disease genes and the development of clinically useful tests remains a work in progress. For example, although spinocerebellar ataxia types 1–3,6,7, and 8 account for about 50% to 70% of autosomal dominant hereditary ataxias, a significant proportion of patients who undergo testing for all of these genes will remain without a specific diagnosis, as a number of ataxia genes remain to be localized, and others that have been localized remain to be identified (18,19). Although a specific genetic diagnosis may not lead to changes in therapy, there are three important clinical benefits to a specific genetic diagnosis (e.g., spinocerebellar ataxia type 2) in comparison to a general clinical diagnosis (e.g., hereditary ataxia): (i) an end to the search for a ‘‘correct’’ diagnosis allows patients to focus on disease management or treatment, (ii) accurate prognosis often depends on the specific diagnosis, and (iii) accurate genetic risk assessment and counseling, as well as the availability of predictive, prenatal, or carrier testing for the patient or relatives, critically depends on a specific diagnosis.
Copyright 2006 by Taylor & Francis Group, LLC
14
Nance
In addition to the possibility of multiple genocopies, for some neurogenetic conditions, apparently nongenetic phenocopies also exist. For example, the vast majority of Parkinson’s disease and about 90% of Alzheimer’s disease are sporadic, or (apparently) nongenetic, in nature. Although a higher proportion of ataxia is genetic, sporadic phenocopies are also very common. This heterogeneity complicates the diagnostic evaluation for many neurogenetic disorders. GENOTYPE CHANGES AND THEIR SIGNIFICANCE IN PHENOTYPIC APPEARANCE The relationship between gene mutations and the diseases they are associated with can be more or less straightforward. About 70–80% of Charcot-MarieTooth I is caused by duplications of the PMP22 gene (CMT 1A), but about 1% to 2% of cases—often with more severe symptoms—are caused by point mutations in the same gene. Furthermore, a clinically distinct condition, hereditary neuropathy with liability to pressure palsies, is caused by deletions in the same gene. CMT types 1B, C, and D may be genetically distinguished from CMT 1A by the presence of mutations in the MPZ, EGR2, and LITAF genes, respectively (20). Larger trinucleotide repeat expansions in the DM1 and FRDA genes have been associated, in general, with more severe myotonic dystrophy and Friedreich’s ataxia phenotypes, respectively, than are smaller expansions (21,22). Trinucleotide repeat expansions in the SCA6 gene cause a neurodegenerative ataxia, while point mutations cause episodic ataxia type 2 or familial hemiplegic migraine (23,24). Even more remarkably, trinucleotide repeat expansions in the gene encoding the androgen receptor cause Kennedy syndrome (spinobulbar muscular atrophy), while point mutations cause an androgen insensitivity syndrome (25,26). On the other hand, mutations in the gene coding for dystrophin are of many types, leading to a continuum of phenotypes ranging from the classic Duchenne to Becker muscular dystrophy to isolated dilated cardiomyopathy (27). Similarly, attempts to correlate disease symptoms or severity with the location or type of mutation in the neurofibromatosis gene NFI have not been successful (3). For some genes, the relationship between gene mutation and the development of a disease is clear: 100% of Huntington’s disease (HD) is caused by CAG repeat expansions in the gene encoding huntingtin, for example, and all CAG repeat expansions in this gene beyond a certain size cause HD (there is reduced penetrance for small CAG expansions). The relationship between mutations in parkin and Parkinson’s disease, however, is less clear. Homozygous parkin mutations (mutations in both copies of the gene) cause autosomal recessive juvenile onset Parkinson’s disease. Heterozygous parkin mutations are also seen in about 20% of patients with young-adult onset Parkinson’s disease, and 2% of those with later onset disease, and may
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
15
be associated with evidence of dopaminergic dysfunction in asymptomatic carriers, but are neither necessary nor sufficient to cause Parkinson’s disease (28,29). The Apo E4 allele, likewise, is neither necessary nor sufficient to cause a disease, but has clearly been associated with the presence of Alzheimer’s disease, and may serve as a determinant of onset age for both Alzheimer’s and Parkinson’s diseases (30,31).
GENE MUTATIONS AND ASSAYS TO DETECT THEM There is a tendency to refer to genetic testing as though it is a single entity, when, of course, each gene and test is unique. Different kinds of gene mutations require different detection techniques in the laboratory. Table 1 lists some types of gene mutations, with examples for each. Barriers to the transition from gene identification in the research laboratory to clinical assay in a service laboratory have been discussed recently (32). Mutation detection methods used in molecular diagnostic laboratories have also been reviewed (33). The most straightforward situation is when a single mutation is always responsible for the disease, allowing the laboratory to create a specific assay for that mutation. This might be the case for a common point mutation, a gene duplication (as in the PMP22 gene in CMT), or for the CAG repeat expansion in a trinucleotide repeat disorder. Techniques used for mutation analysis depend on the specifics of the particular gene and mutation. Duplications of the PMP22 gene are large enough to be detected using the molecular cytogenetic technique of fluorescence in situ hybridization (FISH). Most gene tests currently performed in molecular diagnostic laboratories, however, use the polymerase chain reaction (PCR) to selectively increase
Table 1 Types of Gene Mutations Mutation type Point mutations Single base pair or small deletions, insertions Large deletions Gene duplications Trinucleotide repeat CAG repeat Other repeats Abbreviation: CAG, cytosine–adenine–guanine.
Copyright 2006 by Taylor & Francis Group, LLC
Example Many recessively inherited neurogenetic disorders Many neurogenetic disorders Duchenne muscular dystrophy Charcot-Marie-Tooth 1A Fragile X syndrome, myotonic dystrophy 1 Huntington’s disease, spinocerebellar ataxias 1–3 Myotonic dystrophy 2; spinocerebellar ataxia 10
16
Nance
the abundance of the DNA segment of interest among all the other DNA sequences in the sample, followed by various gel electrophoresis techniques to separate DNA sequences by size, and the use of specific probes, stains, or fluorescent markers to detect the mutation or size variation of interest. Different methods are required when there are many known or possible point mutations or small deletions within a gene. In order to detect ‘‘private’’ (family specific) mutations, laboratories may have to sequence the gene, a laborious and expensive task. More often, techniques such as single-strand conformation polymorphism (SSCP) or denaturing gradient gel electrophoresis (DGGE) are first used to screen for differences between the patient DNA sequence and a normal gene sequence. In some laboratories or for some genes, the testing process may stop after the screening SSCP analysis, with a report stating that a variation was found between the patient DNA and a normal sequence, but without specifying what that difference is and whether it is pathogenic or simply a polymorphism (normal variation). At other times, or in some laboratories, additional efforts may be undertaken after SSCP to sequence the relevant part of the gene to identify the specific mutation. In some clinical and laboratory situations, once a novel gene mutation is identified in a patient, an allele-specific oligonucleotide (ASO) can be developed to test for the mutation in other family members. Communication between the clinician and the laboratory may be necessary to ensure that both parties understand what test has been done, the detection rate for the specific method, what its clinical implications are, and whether further testing is possible either in that laboratory or elsewhere if there is a negative or informative result. There are certain technique-imposed limitations to the resolution of some gene tests. An assay designed to be sensitive to CAG repeat expansions in the range of 20 to 80 repeats could miss a very large repeat expansion, and an assay designed to detect repeat expansions will not detect point mutations (34). Undetected variations in the DNA sequence at the primer site used in the PCR reaction to ‘‘cut out’’ the DNA region to be assayed could reduce or prevent amplification of that region, and loss of detection of that gene (35). Alleles carrying large trinucleotide repeat expansions or gene insertions may also amplify poorly in the PCR reaction, ultimately resulting in the detection of only the normal allele. In the laboratory, detection of a single band on the gel may mean either that only a single allele was identified or that both alleles were of the same size. If genetic test results are discordant with the clinical situation or diagnosis, the laboratory may be able to utilize special techniques to resolve the discrepancy. Not all genes responsible for neurogenetic disorders have been identified. For genes that have been localized but not yet identified, or for genes in which the specific mutation is uncertain, analysis using markers genetically linked to the gene of interest may be possible in a family. Genetic linkage testing is not widely used for clinical purposes, as it is time consuming, expensive,
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
17
and requires the cooperation of multiple family members. Identification of families and genetic linkage analysis, however, remains an important research tool for the identification of new disease genes. The gene encoding dystrophin provides an interesting example of the varying methodologies used in molecular diagnostic testing. About 65% of patients with Duchenne muscular dystrophy (DMD) have large deletions in the DMD gene, which can often be detected by FISH analysis or by electrophoretic techniques that can resolve large DNA fragments (Southern blotting) (36). About 30% of patients have small deletions, point mutations, or insertions that can be detected by mutation screening or scanning techniques. About 6% of patients have duplications of a portion of the gene. Novel or combined strategies can help increase the yield of diagnostic testing (37). If Duchenne muscular dystrophy is strongly suspected but a gene mutation has not been confirmed by molecular genetic analysis, then a muscle biopsy specimen can be examined for dystrophin protein content. Identification of a gene mutation is not the only way to diagnose a genetic condition. For any number of inborn errors of metabolism or other enzymopathies, measuring the blood or tissue level of the enzyme encoded by the gene, or the metabolite that builds up in the absence of the enzyme, may be a more efficient and informative path to diagnosis than a gene assay. For example, the diagnosis of adrenoleukodystrophy in males is usually secured by measurement of plasma very long chain fatty acid levels, with mutation analysis of the ABCD1 gene providing a diagnostic backup procedure (13). CLINICAL USE OF GENE TESTS Genetic testing is used in four different clinical situations: (i) as part of a diagnostic evaluation, (ii) predictive testing for an adult-onset disease in an asymptomatic person, (iii) prenatal or preimplantation testing for an at-risk couple, and (iv) carrier testing for an X-linked or autosomal recessive condition. The neurologist is most often involved in the evaluation of a patient who has neurologic symptoms, and thus is most likely to order gene tests for diagnostic purposes. However, it is important for the physician who diagnoses or treats a genetic condition to be aware of the direct implications of the patient’s diagnosis for other relatives, and to offer or refer the patient and/or these relatives for further genetic counseling or testing as appropriate. Diagnostic Genetic Testing In the appropriate clinical situation, a gene test affords a rapid, efficient, and precise diagnosis. Whether or not the precise diagnosis leads to any change
Copyright 2006 by Taylor & Francis Group, LLC
18
Nance
in treatment, it allows the physician to better define the patient’s prognosis and provide specific information about the disease, as well as allowing the patient and family to focus on symptom management. From the physician’s perspective, it is difficult to escape the view that more information is better, although some patients (and importantly, some health insurers), noting that gene test results may not alter the patient’s treatment, are reluctant to bear the cost of such tests. Patients should always be informed about and consent to genetic testing, and should ideally have genetic counseling prior to undergoing the test. Genetic counseling typically includes a review and documentation of the family history, a discussion of relevant aspects of basic genetics, including a description of how the gene test is done and how accurate it is, what genetic condition(s) is being tested for, as well as a discussion of the potential emotional impact of a genetic diagnosis on the patient and family (see chap. 3). Gene test results should be provided in the context of supportive counseling, as for the diagnosis of any chronic condition, with the added recognition that other family members may have concerns about their own genetic risks and testing possibilities. Some neurogenetic conditions are common enough that one or more molecular diagnostic laboratories offer diagnostic testing, while others are so uncommon or difficult to test for that clinical service laboratories do not perform the test. Tables 2–4 list some of the trinucleotide repeat disorders, hereditary neuropathies, and spastic paraplegias for which genetic testing is clinically available. These tables provide a perspective on the relative availability and completeness of a clinical testing. For uncommon diseases, diagnostic testing can sometimes be arranged through a research laboratory. Many research laboratories in the United States are no longer making research test results available to patients because of patient privacy and ethical concerns, as well as legal liability concerns regarding the release of research data to subjects by a non-Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (38). Before sending a patient sample to a research laboratory, the physician and patient should be clear whether the sample is to be used for research purposes, whether any ‘‘results’’ are expected to return to the physician or patient, and what the expected time frame is for receipt of results. The physician who orders a gene test also bears the burden of interpreting the test results for the patient and family (39). While a laboratory report often includes an interpretation, standardized reports may not reflect the most recent findings in this rapidly evolving area, or may use terminology that is confusing or vague. For example, a laboratory report might describe a result of 37 CAG repeats within the HD gene as being within an ‘‘intermediate range’’ or ‘‘indeterminate,’’ implying that the clinical relevance of the result is entirely uncertain. A more appropriate term might be ‘‘incomplete penetrance,’’ meaning that a result in this range in a symptomatic person confirms the diagnosis, while a result in this range in an asymptomatic person
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
19
Table 2 Repeat Expansion Diseases Disease CAG repeat (polyglutamine) disorders Huntington’s disease Spinocerebellar ataxia type 1 (SCA1) Spinocerebellar ataxia type 2 (SCA2) Machado Joseph Disease (SCA3) Spinocerebellar ataxia type 6 (SCA6) Spinocerebellar ataxia type 7 (SCA7) Spinocerebellar ataxia type 12 (SCA12) Spinocerebellar ataxia type 17 (SCA17) Dentatorubral-pallidoluysian atrophy (DRPLA) Spinobulbar muscular atrophy (Kennedy disease) Others Fragile X (FRAXA) Myotonic dystrophy type 1 (DM1) Myotonic dystrophy type 2 (DM2) Friedreich’s ataxia Progressive myoclonic epilepsy type 1 (EPM1) Spinocerebellar ataxia type 8 (SCA8) Spinocerebellar ataxia type 10 (SCA10) Oculopharyngeal muscular dystrophy
Repeat CAG CAG CAG CAG CAG CAG CAG CAG CAG
Inheritance Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal
dominant dominant dominant dominant dominant dominant dominant dominant dominant
CAG
X-linked
CGG CTG CCTG GAA Dodecamer
X-linked Autosomal dominant Autosomal dominant Autosomal recessive Autosomal recessive
CTG ATTCT GCG
Autosomal dominant Autosomal dominant Dominant/recessive
neither rules out nor makes certain the later clinical development of HD. For clinical entities for which there are multiple causative genes, the challenge may be in helping the patient understand that a normal gene test result does not prove that the condition is nongenetic, simply that the condition was not caused by a mutation in that particular gene. For genetic disorders for which there are multiple causative mutations within the same gene, the physician must understand and explain whether normal test results ruled out all possible mutations within the gene, or just one or some of them. The first genes identified were those for single-gene disorders, for which there was a clear relationship between the presence of the gene and the development of the disease, according to well-understood genetic inheritance patterns (autosomal dominant, recessive, and X-linked). The genetic waters grow ever murkier, however, as clinicians develop the tools to test for genetic mutations or polymorphisms that confer an increased risk of disease without directly causing the disease (e.g., the Apo E4 allele in Alzheimer’s disease), or whose relationship to the disease is uncertain (e.g., the gene encoding parkin in juvenile, earlyonset, and late-onset Parkinson’s disease). Detailed and careful counseling
Copyright 2006 by Taylor & Francis Group, LLC
20
Nance
Table 3 Clinically Testable Hereditary Neuropathies Disease
Protein
Mutation type
CMT1A
Peripheral myelin protein 22
HNPP
Peripheral myelin protein 22
CMT1B CMT1D CMT2E CMT4A
Myelin protein zero Early growth response protein 2 Neurofilament triple L protein Ganglioside-induced differentiation protein 1 Early growth response protein 2 Periaxin Connexin-32
CMT 4E CMT4F CMTX
Duplication (98%), pt mutation (2%) Deletion (80%), pt mutation/ small del (20%) pt mutation pt mutation pt mutation pt mutation pt mutation pt mutation pt mutation, small del
Abbreviations: CMT, Charcot-Marie-Tooth disease; pt, point; del, deletion; HNPP, hereditary neuropathy with liability to pressure palsies.
is required to explain to the patient the clinical relevance of these types of tests (40). Predictive Testing Predictive testing refers to the use of a gene test in a patient at risk for a genetic disease (typically an adult-onset disease) of which the patient does Table 4 Clinically Testable Spastic Paraplegias Locus
Protein
Inheritance
SPG1
L1CAM
X-linked
SPG2
PLP2
X-linked
SPG3A SPG4 SPG6 SPG7 SPG10 SPG13 SPG17 SPG20 SPG21
Atlastin Spastin NIPA1 Paraplegin KIF5A HSPD1 Seipin Spartin Maspardin
Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal Autosomal
dominant dominant dominant recessive recessive dominant dominant dominant dominant
Condition SP with MR, aqueductal stenosis/ hydrocephalus SP, Pelizaeus-Merzbacher disease Pure SP Pure SP SP SP Pure SP Pure SP Silver syndrome Troyer syndrome Mast syndrome
Abbreviations: SPG, spastic paraplegia locus; L1CAM, L1 cell-adhesion molecule; SP, spastic paraplegia; MR, mental retardation; PLP2, proteolipid protein 2.
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
21
not currently have symptoms. Until treatments are found to forestall or prevent such conditions, which are usually dominantly inherited neurodegenerative disorders, the only purpose of predictive testing is the psychosocial benefit perceived by the patient. For this reason, the principles underlying predictive testing are somewhat different than those guiding the use of gene tests for diagnostic purposes. Detailed genetic counseling is necessary to ensure that the patient understands clearly what the gene test means and what it does not mean (the presence of the abnormal gene, for instance, does not determine that a person is symptomatic, nor does it determine at what age the person will become symptomatic), as well as the potential adverse psychological and social outcomes of the test. The decision to undergo predictive testing should be voluntary and informed, meaning that parents should not request predictive testing for their underage children, adoptive agencies should not require predictive testing duplicates prior to adoption, and other third parties—spouses, employers, insurance agencies, or courts—should not require or perform predictive testing without the consent of the person being tested. Protocols have been established for predictive testing in HD, the first condition for which predictive testing was performed with any frequency; these protocols are associated with a low risk of adverse outcomes in those at risk for HD, and can easily be applied to other neurogenetic conditions (41,42). The main points within HD predictive testing protocols include (i) the provision of genetic counseling prior to the test, (ii) pretest psychological assessment and counseling, (iii) the availability of a neurological examination if a patient requesting predictive testing is concerned about possible symptoms of the disease, (iv) freely given consent for the predictive test, (v) the opportunity to opt out of having the test or being informed of the results, even after consent is given, and (vi) results to be given in person in a supportive counseling environment. Many patients choose to selfpay for most or all of the procedures and visits related to predictive testing, to provide an additional layer of protection against the possibility of insurance discrimination. Some patients request anonymous or pseudonymous testing to provide additional privacy protection; providers and their institutions vary in the degree of anonymity they are able or willing to provide (in some medical centers, patients cannot register to be seen without providing a social security number, for example, and some physicians and genetic counselors are uncomfortable providing predictive testing to a person who is unwilling to provide a name, family history information, or some amount of personal information) (43). A more detailed discussion of the ethical issues raised by predictive testing can be found in chapter 5. Predictive testing has been reported for an increasing number of diseases, including hereditary ataxias, neuropathies, muscular dystrophies, hereditary Alzheimer’s disease, CADASIL, spastic paraplegias but by far the greatest experience has accrued with its use in HD (44–47).
Copyright 2006 by Taylor & Francis Group, LLC
22
Nance
Prenatal and Preimplantation Testing Prenatal testing refers to the use of a gene test by a parent on behalf of an at-risk fetus, while preimplantation testing involves the combination of in vitro fertilization techniques with single-cell DNA assays, with implantation into the uterus of an embryo proven to be free of the abnormal gene in question. Prenatal testing has focused in the past on life threatening or disabling conditions of infantile or childhood onset, but can also now be applied to adult-onset neurogenetic conditions (48–50). Prenatal or preimplantation testing could be requested by a patient who currently suffers from a neurogenetic condition, by a patient who is known to carry a gene mutation that causes a disease but who is not currently symptomatic, by a couple both known to be carriers of a recessive disease gene, or by a patient who is at risk for carrying an abnormal gene but unaware of his or her genetic status. Preimplantation testing could also be requested by a patient who is known to have an abnormal disease-causing gene, or by a patient who is at risk but who does not wish to know his or her own gene status (51). Prenatal and preimplantation testing both require detailed counseling about the risks of the procedures used to obtain fetal tissue, the potential outcomes of the testing process, and the medical choices to be made based on those outcomes. In general, the only ‘‘therapeutic’’ procedure to be offered if a prenatal test shows the presence of a disease-causing gene mutation is termination of the pregnancy. If this is not a permissible alternative for the patient or physician, then it may not be appropriate to perform the prenatal test. Preimplantation testing avoids the issue of abortion, but requires intensive testing, medications, and procedures which are usually not covered by insurance, and thus requires a firm commitment from the patient or couple. It should be noted that genetic counseling for at-risk couples includes a discussion not only of options that include gene tests, but other reproductive options such as childbearing without testing, artificial insemination, surrogate mother, adoption, or sterilization procedures to permanently prevent the possibility of pregnancy. Carrier Testing The term ‘‘carrier’’ refers to an individual who carries a single copy of an abnormal gene that alone does not cause disease symptoms in the presence of a second, normal copy of the gene. The term is relevant for genetic disorders inherited in an autosomal recessive fashion, and for X-linked disorders. Both biological parents of a child who is affected with an autosomal recessive disorder are obligate carriers of a single copy of the abnormal gene, barring rare and unusual genetic events, and the mother of a boy with an X-linked disease is also likely to be a carrier of the abnormal, disease-causing gene. Others at risk for being carriers in either of these
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
23
scenarios include clinically normal siblings of the affected person, as well as aunts (and uncles for autosomal disorders) and grandparents. Genetic testing of individuals who do not have a disease diagnosis or any neurological symptoms must be thought out carefully, with discussion of the implication of the carrier state to their own health and that of their descendants, as well as the possibility that others will misunderstand or misinterpret the significance of the carrier state. RESOURCES FOR THE CLINICIAN The clinician must identify appropriate candidates for genetic testing, select the correct test, ensure that the patient is properly counseled about the test and its potential outcomes, understand the significance of the results for the patient, and recognize the potential importance of the results for other relatives. It is very difficult for any physician to remain current in this rapidly moving field, and the use of on-line resources is encouraged. Online Mendelian Inheritance in Man (OMIM) (www.ncbi.nlm.nih.gov), and GeneTests (www.genetests.org) both provide descriptions of neurologic disorders and the gene mutations associated with them. GeneTests also provides detailed information about laboratories that perform clinical or research tests for many conditions, including contact information for the laboratories, and summarizes both the clinical and the genetic aspects of diseases and groups of diseases in a clinically useful fashion. Disease-specific lay organizations often provide accurate and up-to-date information about the genetic aspects of a disease. Finally, genetic counselors and genetics physician specialists can be an invaluable resource to the neurologist, as they can provide both the genetic education and the supportive counseling that patients and families undergoing genetic testing require, as well as assisting with referrals for prenatal, preimplantation, or carrier testing. REFERENCES 1. Kwiatkowski J, Jozwiak S, et al. Comprehensive mutational analysis of the TSC1 gene: observations on frequency of mutation, associated features, and nonpenetrance. Ann Hum Genet 1998; 62:277–285. 2. Huson SM, Compston DA, et al. A genetic study of von Recklinghausen neurofibromatosis in south east Wales: I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet 1989; 26:704–711. 3. Carey JC, Viskochil DH. Neurofibromatosis type 1: a model condition for the study of the molecular basis of variable expressivity in human disorders. Am J Med Genet 1999; 89:7–13. 4. Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. J Child Neurol 2002; 17:562–570. 5. Day JW, Ricker K, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurology 2003; 60:657–664.
Copyright 2006 by Taylor & Francis Group, LLC
24
Nance
6. Mankodi A, Thornton CA. Myotonic syndromes. Curr Opin Neurol 2002; 15:545–552. 7. Fink JK. Hereditary spastic paraplegia. Neurol Clin 2002; 20:711–726. 8. Berciano J, Combarros O. Hereditary neuropathies. Curr Opin Neurol 2003; 16:613–622. 9. Langbehn DR, Brinkman RR, et al. A new model for prediction of the age of onset and penetrance for Huntington’s disease based on CAG length. Clin Genet 2004; 65:267–277. 10. Brinkman RR, Mezei MM, et al. The likelihood of being affected with Huntington’s disease by a particular age, for a specific CAG size. Am J Hum Genet 1997; 60:1202–1210. 11. Origone P, Bonioli E, et al. The Genoa experience of prenatal diagnosis in NF1. Prenat Diagn 2000; 20:719–724. 12. Bird TD. Risks and benefits of DNA testing for neurogenetic disorders. Semin Neurol 1999; 19:253–259. 13. Moser H, Dubey P, Fatemi A. Progress in X–linked adrenoleukodystrophy. Curr Opin Neurol 2004; 17:263–269. 14. Battini R, Bianchi MC, et al. Unusual clinical and magnetic resonance imaging findings in a family with proteolipd gene mutation. Arch Neurol 2003; 60:268–272. 15. Heard E. Recent advances in X-chromosome inactivation. Curr Opin Cell Biol 2004; 16:247–255. 16. Hagerman RJ, Leavitt BR, et al. Fragile X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74:1051–1056. 17. Hagerman PJ, Hagerman RJ. Fragile X-associated tremor ataxia syndrome (FXTAS). Ment Retard Dev Disabil Rev 2004; 10:25–30. 18. Schols L, Bauer P, et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3:291–304. 19. Taroni F, DiDonato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 2004; 5:641–655. 20. Bird TD. Charcot-Marie-Tooth Type 1 in Gene Reviews. www.genetests.org, accessed February 6, 2005. 21. Ranum LP, Day JW. Myotonic dystrophy: RNA pathogenesis comes into focus. Am J Hum Genet 2004; 74:793–804. 22. Mateo I, Llorca J, et al. Expanded GAA repeats and clinical variation in Friedreich’s ataxia. Acta Neurol Scand 2004; 109:75–78. 23. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62:17–22. 24. Mantuano E, Veneziano L, et al. Spinocerebellar ataxia type 6 and episodic ataxia type 2: differences and similarities between the two allelic disorders. Cytogenet Genome Res 2003; 100:147–153. 25. Greenland KJ, Zajac JD. Kennedy’s disease: pathogenesis and clinical approaches. Intern Med J 2004; 34:279–286. 26. Zitzmann M, Nieschlag E. The CAG repeat polymorphism within the androgen receptor gene and maleness. Int J Androl 2003; 26:76–83. 27. Muntoni F, Torelli S, Ferlini A. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. Lancet Neurol 2003; 2:731–740.
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Testing for Neurological Disorders
25
28. Khan NL, Scherfler C, et al. Dopaminergic dysfunction in unrelated asymptomatic carriers of a single parkin mutation. Neurology 2005; 64:134–136. 29. Poorkaj P, Nutt JG, et al. Parkin mutation analysis in clinic patients with earlyonset Parkinson’s disease. Am J Med Genet A 2004; 15:44–50. 30. Zareparsi S, Camicioli R, et al. Age at onset of Parkinson disease and apolipoprotein E genotypes. Am J Med Genet 2002; 15:156–161. 31. Kamboh MI. Molecular genetics of late-onset Alzheimer’s disease. Ann Hum Genet 2004; 68:381–404. 32. Amos J, Grody W. Development and integration of molecular genetic tests into clinical practice: the US experience. Exp Rev Mol Diagn 2004; 4:465–477. 33. Taylor CF, Taylor GR. Current and emerging techniques for diagnostic mutation detection: an overview of methods for mutation detection. Methods Mol Med 2004; 92:9–44. 34. Mao R, Aylsworth AS, et al. Childhood-onset ataxia: testing for large CAG repeats in SCA2 and SCA7. Am J Med Genet 2002; 110:338–345. 35. Wong LJ, Chen TJ, et al. Novel SNP at the common primer site of exon IIIa of FGFR2 gene causes error in molecular diagnosis of craniosynostosis syndrome. Am J Med Genet 2001; 102:282–285. 36. Korf BR, Darras BT, Urion DK. Dystrophinopathies. In GeneTests, www. genetests.org, accessed February 6, 2005. 37. Schwartz M, Duno M. Improved molecular diagnosis of dystrophin gene mutations using the multiplex ligation-dependent probe amplification method. Genet Test 2004; 8:361–367. 38. Schwartz MK. Genetic testing and the clinical laboratory improvement amendments of 1988: present and future. Clin Chem 1999; 45:739–745. 39. McInerney-Leo A, Hadley DW, et al. Genetic testing in Parkinson’s disease. Mov Disord 2005; 20:1–10. 40. Bird TD. Apolipoprotein E genotyping in the diagnosis of Alzheimer’s disease: a cautionary view. Ann Neurol 1995; 38:2–4. 41. Anonymous. Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology 1994; 44:1533–1536. 42. Nance MA, Myers R, et al. Genetic guidelines for Huntington’s Disease: Its Relevance and Implications (Revised). New York: Huntington’s Disease Society of America, 2003. 43. Visintainer CL, Matthias–Hagen V, et al. Anonymous predictive testing for Huntington’s disease in the United States. Genet Test, 2001; 5:213–218. 44. Prevost C, Veillette S, et al. Psychosocial impact of predictive testing for myotonic dystrophy type 1. Am J Med Genet 2004; 126:68–77. 45. Yoshida K, Tamai M, et al. Analysis of 14 individuals who requested predictive genetic testing for hereditary neuromuscular disorders. Rinsho Shinkeigaku 2002; 42:113–117. 46. Lesca G, Goizet C, Durr A. Predictive testing in the context of pregnancy: experience in Huntington’s disease and autosomal dominant cerebellar ataxia. J Med Genet 2002; 39:522–525. 47. Creighton S, Almqvist EW, et al. Predictive, prenatal, and diagnostic genetic testing for Huntington’s disease: the experience in Canada from 1987 to 2000. Clin Genet 2003; 63:462–475.
Copyright 2006 by Taylor & Francis Group, LLC
26
Nance
48. Dean NL, Tan SL, Ao A. The development of preimplantation genetic diagnosis for myotonic dystrophy using multiplex fluorescent polymerase chain reaction and its clinical application. Mol Hum Reprod 2001; 7:895–901. 49. de Die Smulders CE, Land JA, et al. Results from 10 years of preimplantationgenetic diagnostics in The Netherlands. Ned Tijdschr Geneeskd 2004; 148: 2491–2496. 50. Piyangmonkol W, Harper JC, et al. A successful strategy for preimplantation genetic diagnosis of myotonic dystrophy using multiplex fluorescent PCR. Prenat Diagn 2001; 21:223–232. 51. Schulman JD, Black SH, et al. Preimplantation genetic testing for Huntington disease and certain other dominantly inherited disorders. Clin Genet 1996; 49:57–58.
Copyright 2006 by Taylor & Francis Group, LLC
3 Genetic Counseling Robin L. Bennett University of Washington, Medical Genetics, Seattle, Washington, U.S.A.
INTRODUCTION No matter what a person’s age, the diagnosis of a neurodegenerative disorder can be devastating. When such a disorder is inherited, effects can ripple through the family and often through many generations. The child or adult, their spouse or partner, their friends and family will have a plethora of questions: What is this condition? How rare is it? Will it get worse? Is there a cure? Is there a decreased life expectancy? Will my children or other relatives be affected? Is there any prenatal testing? Is there a test to diagnose this condition before a person has symptoms? Will I or my family face discrimination in social situations, in seeking insurance coverage, or in employment? Genetic counseling can make a difference in how individuals and their families cope with the diagnosis, make decisions about genetic testing (particularly presymptomatic or predictive testing), and make reproductive choices and other important life decisions. Genetic counseling may be a one-time meeting or occur over several sessions, even over many years (1). ARE GENETIC DISORDERS UNIQUE? Health professionals are accustomed to giving ‘‘bad news;’’ so what, if anything, makes providing care and information to individuals with genetic disorders unique? All diseases probably have a genetic component, and it is essential that all health professionals develop genetic competency (2). Although an aura of ‘‘genetics exceptionalism’’ is counter-productive to incorporating
Copyright 2006 by Taylor & Francis Group, LLC
28
Bennett
genomic medicine into primary and specialty health care, there are several aspects of genetic disorders that carry important distinctions from disorders without a strong genetic component because of their personal, family, and social consequences (3–5). The most obvious characteristic of genetic disorders is that they are familial—a diagnosis in one person has implications for the rest of the family, offspring, parents, siblings, and extended relatives. When a person has a herniated disk or back pain, no other relatives are involved; this is a private conversation between that individual and the health care provider(s) regarding diagnostic evaluation and management. In contrast, if a person has a neurogenetic disorder, the whole family may become ‘‘the patient.’’ This brings challenges in communicating medical and risk information to relatives, which may have accompanying emotional consequences, as well as raising unique issues of confidentiality and privacy of health and personal information. A complicating factor is that often genetic testing entails first testing a person who is known to have the condition before testing unaffected relatives. For example, there are many different forms of autosomal dominant ataxia (chap. 15), and a mutation must first be identified in an affected family member before presymptomatic testing can be offered to unaffected relatives. Families often reflect back on their ancestors with pride, as evidenced by the millions of people worldwide that are involved in genealogy research. Genealogist David Hey notes, ‘‘Knowing one’s ancestors is not a matter of mild curiosity; it is often part of an attempt to explain life and to understand how we have come to be what we are, not just physically through inherited genes, but how we have come to believe in certain principles or to have acquired the attitudes, prejudices, and characteristics that mould our personality. For many people, tracing a family tree and discovering the lives of their ancestors is not a task that is undertaken lightly’’ (6). The identification of a genetic disorder in a family may be perceived as ‘‘a blemish’’ in the family lineage. Over 100 years ago, Francis Galton observed that ‘‘There are some disorders of which we barely wish to speak, as if timidity of utterance could hush thoughts’’ (7). Unfortunately, many genetic disorders continue to be stigmatizing, particularly if the condition (such as Huntington’s Disease) is associated with mental illness or dementia. Individuals and their relatives may worry about genetic discrimination. Fears of labeling, stigma, and genetic discrimination may hinder communication in the family in relation to a genetic diagnosis or make relatives wary about participating in research studies. These worries may be so profound that an individual may be dissuaded from disclosing important health information to health-care providers. Providing patients with information about current federal and state laws protecting against discrimination of individuals with disabilities and in some states, protection for individuals with genetic disorders, can be reassuring (8–10).
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Counseling
29
The familial nature of genetic disorders can also be associated with feelings of guilt. This may take the forms of both parental and survivor guilt. A parent may feel guilty for having passed a condition on to their offspring, even though a parent has no control over which gene alterations are passed to one’s children. A couple often experiences conflicting emotions about knowingly ‘‘passing’’ a condition to future offspring instead of making the choice not to have biological children, or choosing prenatal diagnosis to identify an affected fetus. A person or couple may feel that the genetic disorder is punishment by God or a higher power for some past deed. Feelings of guilt can be exacerbated by casting blame. For example, a child may bluntly query a parent, ‘‘Will I be like you?’’ Survivor guilt may be experienced by a person who is unaffected by the genetic condition but feels guilty for having ‘‘escaped’’ the condition, whereas other relatives have been less fortunate. One client at risk for Huntington’s disease described her experience of survivor guilt as feeling like the client was standing outside of a burning house with the rest of her family inside. The ‘‘survivor’’ may feel on the outskirts of the ‘‘family team’’ despite knowing it is irrational to desire ill health (11). The diagnosis of a genetic condition can alter reproductive plans for not just the initial person diagnosed with the condition, but many other relatives. Often, the perceived parental role is threatened by finding out genetic carrier status (12). The religious and ethical belief systems of couples and their extended families may be challenged, particularly as couples wrestle with core values on how they regard life and health and their relationship to their own and their family’s views on biological parenting. Couples at risk to have an offspring with a neurogenetic disorder face difficult decisions about adoption, assistive reproductive technologies (including use of donor egg or sperm, and preimplantation diagnosis), prenatal diagnosis and possible abortion of an affected fetus, or taking their spin at genetic roulette. Despite advances in management of genetic disorders, currently no cures exist for most genetic diseases. The permanent nature of genetic disease may bring a sense of fatalism or hopelessness accompanying the diagnosis or the results of genetic testing. As genetic disorders are chronic diseases, there may be a continual array of new health and physical challenges over a person’s lifetime. The individual and the family may experience ‘‘chronic sorrow’’ for the ‘‘healthy person who will never be.’’ Results of genetic testing may alter the person’s perception of health, self-concept and self-esteem, as well as their perceived genetic or social identity (12–14). Genetic counselors are specifically trained to deal with the spectrum of scientific and psychosocial issues that are involved with genetic diagnosis and testing for individuals and their families who wrestle with neurological disorders having a genetic etiology.
Copyright 2006 by Taylor & Francis Group, LLC
30
Bennett
WHO ARE GENETIC COUNSELORS? Genetic counseling is a distinct medical specialty with the role of providing clinical health care, education and emotional support to individuals and families challenged by congenital and inherited diseases. The focus is on how genetic conditions affect the psychological, medical, financial and social aspects of the lives of individuals and their families diagnosed with, or at risk for, disorders with a genetic component. The term ‘‘genetic counselor’’ is generally reserved for masters-level health professionals with extensive training in human genetics and counseling skills. The field began with the first group of 10 genetic counselors who graduated from Sarah Lawrence College in 1971. Currently, there are 30 programs in the United States and Canada accredited by the American Board of Genetic Counseling (15), with similar programs in place in the United Kingdom, South Africa, and Australia (8). As of 2004, there are over 2400 members of the professional society of genetic counselors, the National Society of Genetic Counselors. Other health professionals who are trained specifically to provide genetic counseling services include physician geneticists (medical geneticists) and clinical nurse specialists in genetics. Medical geneticists attend a fellowship or residency program accredited by the American Board of Medical Genetics (16) or the Canadian College of Medical Genetics. Advance Practice Genetic Nurses and Genetics Clinical Nurses meet genetic competencies through a portfolio process established by the Genetic Nursing Credentialing Commission (17). Table 1 includes a list of resources for locating health professionals with expertise in genetic counseling. Given the complexity of neurogenetic disorders, a multi-disciplinary team approach is ideal. Many advocacy organizations for various genetic disorders are recognizing ‘‘Centers of Excellence,’’ where such teams have assembled to provide comprehensive care for individuals with genetic disorders. The Genetic Alliance is a network of genetic advocacy organizations with a listing of disease-specific support groups whose websites note the growing number of disease focused centers of excellence (18).
Table 1 Resources for Locating a Clinical Genetics Professional American Board of Genetic Counseling http://www.abgc.org American College of Medical Genetics http://www.acmg.net Canadian College of Medical Genetics http://ccmg.medical.org International Society of Nurses in Genetics http://www.isong.org National Society of Genetic Counselors http://www.nsgc.org GeneClinics http://www.geneclinics.org
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Counseling
31
THE PROCESS OF GENETIC COUNSELING Genetic counseling is important across the lifespan—from preconception counseling and prenatal diagnosis, to the diagnosis of inherited disorders in newborns and children, and the diagnosis of adults with inherited predisposition to a variety of neurodegenerative disorders. The approach to genetic counseling involves assessing family and environmental history (e.g., occupational exposures and embryonic teratogens) to determine disease risk; assisting in genetic testing, diagnosis, and disease prevention and management; and offering psychosocial support and ethical guidance to help patients make informed, autonomous health decisions and reproductive choices. The process of genetic counseling is outlined in Table 2. Genetic counseling has a tradition of not directing patient decisionmaking (nondirective counseling) particularly with regard to reproductive choices, and demonstrating respect for patient autonomy. There has been a clear effort to distance genetic counseling from the eugenics movement of the 1930s and 40s. The current approach to genetic counseling favors a psychosocial approach that emphasizes shared deliberation and decisionmaking between the counselor and the client (1,19–21). GENETIC FAMILY HISTORY—THE PEDIGREE A primary component of genetic counseling is obtaining and interpreting a medical family history that is usually recorded in the form of a pedigree (3).
Table 2 The Process of Genetic Counseling Obtaining and assessing family history (3–4 generation pedigree) Assessing environmental exposures (e.g., occupational, embryonic teratogens) Psychosocial assessment Interpretation of medical and family history Confirmation of diagnosis of disease in the family [may necessitate obtaining family medical records, death certificates, and/or genetic testing of a patient’s relative(s)] Assessment of chance of disease occurrence or recurrence Education about pattern(s) of inheritance Discussion of options of genetic testing (including costs, specificity, and sensitivity) Discussion of possible emotional consequences of genetic diagnosis and/or testing Review of management options and prevention Review and discussion of reproductive options Discussion of key ethical issues (e.g., testing minor children for adult onset conditions, testing individual at 25% risk for autosomal dominant condition) Education about resources (e.g., disease specific support groups) Referral to specialists as needed Referral to research as appropriate Counseling to promote informed choices and adaptation to the condition
Copyright 2006 by Taylor & Francis Group, LLC
32
Bennett
Figure 1 Pedigree symbols of relationships. Source: Adapted from Ref. 3.
Standard pedigree symbols (Figs. 1–3) are used to record relationships of relatives and to track diseases and demographic characteristics (22). The square or circle representing an affected relative can be shaded to document a disease, and more than one condition can be shown by partitioning the symbol into more than one sector and using different fill patterns. The age of onset of the condition should be noted on the pedigree as well as the age and cause of death of relatives. Ideally, confirmation of a clinical
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Counseling
Figure 2 Common pedigree symbols. Source: Adapted from Ref. 3.
Copyright 2006 by Taylor & Francis Group, LLC
33
34
Bennett
Figure 3 Pedigree symbols of pregnancy and pregnancies not carried to term. Source: Adapted from Ref. 3.
diagnosis with medical records or death certificates provides the most accurate information from which to base pedigree analysis and genetic risk assessment (3). A pedigree key or legend is used to identify the medical conditions that are traced in the pedigree, and to explain unusual abbreviations or less commonly used symbols. Typically, a pedigree includes two generations of ascent from the consultand (the person requesting the medical or genetic information) or proband (the affected individual who brings the family to medical attention), and two generations of descent. Information is usually collected on firstdegree relatives (children, siblings, and parents), second-degree relatives (half-siblings, aunts, uncles, nieces, nephews, grandparents, and grandchildren), and sometimes third-degree relatives (e.g., first cousins). For example, pedigree assessment of a 50-year-old male with a hereditary neuropathy may include information about the man’s children and grandchildren, parents and grandparents, siblings, nieces and nephews, aunts and uncles, and cousins; whereas the pedigree assessment of a 10-year-old girl with ataxia would likely only include information about her siblings, parents, aunts and uncles, cousins, and grandparents. Certain genetic disorders are more common in various ancestral groups; for example, Canavan disease or Tay-Sachs disease are found in individuals of Ashkenazi Jewish ancestry. The ancestral origins of both sets of grandparents should be noted on the pedigree (e.g., German, Vietnamese, Italian, Amish, Czekoviz, African American). The offspring of consanguineous
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Counseling
35
unions (relationships between individuals with a closely related common ancestor, e.g., first cousins) are more likely to share a deleterious recessive gene in common; therefore, noting if consanguinity is present in the family is important for genetic risk assessment (23). A pedigree provides complicated and comprehensive medical information about a family in a simple-to-obtain format. A pedigree can be the key to making a genetic diagnosis and can help identify other relatives at risk for the genetic disease who may benefit from genetic counseling and genetic testing. However, a pedigree is more than a diagnostic tool (3,24). The process of obtaining a pedigree can help develop client rapport. It can be used as a teaching tool to demonstrate to a patient the evidence of reduced penetrance, variable expression of the disease phenotype (phenotype is the physical characteristics of a disease), and varied age of onset of the disease symptoms. A pedigree can also be used to clarify patient misconceptions or family myths. For example, a patient may believe that only men have the condition in the family or that only the first person in every generation is affected, and the pedigree is often a graphic means of teaching the pattern of inheritance. PEDIGREE ANALYSIS AND RISK PERCEPTION One of the major purposes of drawing a pedigree is to recognize patterns of inheritance that may aid in clinical diagnosis (e.g., distinguishing recessive ataxias such as Friedreich ataxia, from dominant ataxias such as the many spinocerebellar ataxias). The common patterns of inheritance as well as the variables that can mask recognition of these patterns are reviewed in Table 3. Communicating the concept of risk to patients is a challenge in genetic counseling. Explaining the meaning of risk in multiple ways is the most effective approach; for example, distinguishing an absolute risk from a relative risk (e.g., a 5% absolute risk but a two-fold increased risk), and using percentages to frame the magnitude of risks from different perspectives. For example, a couple at risk to have a child with an autosomal recessive condition would be counseled that the risk is 25% chance or a one in four chance for an affected child, but a 75% chance, or a three in four chance of having a child who is unaffected. Comparing individual risk to population risks can help clients put their personal risk in perspective. When presenting risk figures, the clinician should be careful not to relay any personal bias as to whether a risk is high or low. Usually, it is best to give a result as a fact, rather than prefacing the result with ‘‘I have good news’’ or ‘‘I have bad news’’ (25). Understanding the patient’s perception of risk is more important than the actual number. Patients may have trouble accepting risks that are different from their preconceived notion of whether the ‘‘chances’’ were high or low. Each patient will have different notions on what is an acceptable chance or risk. The interpretation of risk will be influenced by patients’ prior experience with the disease, and with their social, religious, and ethnocultural views of
Copyright 2006 by Taylor & Francis Group, LLC
36
Table 3 Examples of Clues for Recognizing Patterns of Inheritance and Variables That Can Mask Recognition of These Patterns Inheritance pattern
Mode of transmission
Pedigree clues
Confounding factors
Disease examples
50% risk of disease to each son/daughter
Condition in consecutive generations Males/females affected Observe male–maletransmission Often variability in disease severity Homozygotes may be affected more severely Homozygous state may be lethal
Reduced penetrance Can miss diagnosis in relatives if mild expression for disease New mutations may be mistaken for sporadic if small family size
Charcot-Marie-Tooth 1 Huntington’s disease Neurofibromatosis 1 Myotonic muscular dystrophy Tuberous sclerosis complex Frontotemporal dementia (FTDP-17) CADASIL Spinocerebellar ataxias
AR
25% risk of disease to each son/daughter 50% risk of passing on carrier state to each son/daughter Parents are carriers (healthy—no symptoms)
Usually one generation Males/females affected Often seen in newborn, infancy, childhood Often inborn errors of metabolism May be more common in certain ethnic groups (e.g. Tay-Sachs disease and Ashekenazism) Sometimes parental consanguinity
May be mistaken as sporadic if small family size If carrier frequency high, can look autosomal dominant (e.g., hemochromatosis)
Friedreich ataxia Metachromatic leukodystrophy Niemann Pick disease Spinal muscular atrophy Wilson disease
Copyright 2006 by Taylor & Francis Group, LLC
Bennett
AD
Heterozygous women are affected and their daughters have a 50% chance of being affected/sons have a 50% chance of being affected (lethal)
XLR
Sons of female carriers have a 50% chance of being affected Daughters of female carriers have a 50% chance of being carriers
Chromosomal
Increased risk for trisomy seen with advanced maternal age
No-male-to-male transmission Often lethal in males so see paucity of males in pedigree May see multiple miscarriages (due to male fetal lethality) Females usually express condition but have milder symptoms than males No male-to-male transmission Males affected Females may be affected, but often milder and/ or with later onset than males Suspect if individuals has 2þ major birth defects or 3þ minor birth
Small family size
Rett syndrome
May be missed if paucity of females in pedigree. Symptoms in female carriers is thought to be caused by lyonization (imbalance of X-inactivation)
Duchenne/Becker muscular dystrophy Fabry disease Fragile X syndrome Spinal bulbar muscular atrophy Adrenoleukodystrophy Trisomy 21 (Down’s syndrome) Trisomy 18
Genetic Counseling
XLD
(Continued)
Copyright 2006 by Taylor & Francis Group, LLC
37
38
Table 3 Examples of Clues for Recognizing Patterns of Inheritance and Variables That Can Mask Recognition of These Patterns (Continued ) Inheritance pattern
Pedigree clues
Risk for affected fetus depends on specific chromosomal rearrangement (ranges from 1% to 15% or higher)
defects Fetus with structural anomalies Unexplained MR (static) especially with dysmorphic features Unexplained psychomotor retardation Amgibuous genitalia Lymphedema or cystic hygroma in newborn Couples with 3 or more pregnancy losses Individuals with multiple congenital anomalies and family history of MR Unexplained infertility
Copyright 2006 by Taylor & Francis Group, LLC
Confounding factors
Disease examples Turner syndrome (45,X) Robertsonian translocations Reciprocal translocations Subtelomeric defects
Bennett
Mode of transmission
0–100%
No male transmission to offspring, only maternal transmission Highly variable clinical expression Often central nervous disorders Males and females affected, often in multiple generations
Generally considered rare
Multifactorial
Based on empiric risk tables
Males and females affected No clear pattern Skips generations Few affected family members
May actually be single gene
Mitochondrial encephalopathy with ragged-red fibers (MERRF) Mitochondrial encephalopathy, lactic acidosis, strokes (MELAS) Neropathy with ataxia and retinitis pigmentosa (NARP) Schizophrenia Bipolar disorder Epilepsy
Genetic Counseling
Mitochondrial
Abbreivations: AD, autosomal dominant; AR, autosomal recessive; MR, mental retardation; XLD, X-linked dominant; XL, X-linked recerssive Source: Adapted from Ref. 24.
Copyright 2006 by Taylor & Francis Group, LLC
39
40
Bennett
the disease. Providing information in several ways to accommodate various learning styles (e.g., audiovisual, verbal, and written) is helpful. Providing a summary letter after the clinic visit is a useful resource for the patient and family and can facilitate coordination of the patient’s care if it is sent to relevant health professionals (13,26).
SUMMARY Genetic counseling provides more than estimates of disease occurrence or recurrence. Genetic counseling is the process of helping people understand and adapt to the medical, psychological, and familial implications of genetic contributions to disease. It is multifaceted in that genetic counseling includes assessing personal, social, religious, and ethnocultural views on how a genetic diagnosis, genetic testing, and genetic test results potentially influence a person’s life. Pre- and post-test genetic counseling is important for individuals who undergo genetic testing. Interpretation of genetic testing must be placed in the context of the patient’s and the family’s medical history. Genetic counseling involves obtaining and interpreting a medical family history, and education about inheritance, testing, management, disease prevention, reproductive options, ethical issues, resources, and research. It is particularly important that individuals who are considering presymptomatic or prenatal genetic testing receive genetic counseling before genetic testing, and not only after a positive test result. The ultimate goals of genetic counseling are to facilitate patient decision-making to promote informed choices and adaptation to the condition. Patient decisions are supported in the context of individual values, beliefs, and goals. Genetic counselors and other clinical genetic specialists are specifically trained to serve as a resource to health professionals and their patients with regard to genetic diagnosis and management, and to provide psychological support for individuals and their families who are faced with the many issues surrounding a neurogenetic diagnosis. REFERENCES 1. Bennett RL, Hampel HL, Mandell JB, Marks JH. Genetic counselors: translating genomic science into clinical practice. J Clin Invest 2003; 112:1274–1279. 2. National Coalition of Health Care Professionals in Genetics, Genetic Core Competencies (http://www.nchpeg.org accessed January 2005). 3. Bennett RL. The Practical Guide to the Genetic Family History. New York: John Wiley and Sons, Inc., 1999. 4. Plumridge D, Bennett R, Dinno N, Branson C. The Student with a Genetic Disorder: Educational Implications for Special Education Teachers and For Physical Therapists, Occupational Therapists and Speech Pathologists. Springfield: Charles C Thomas, 1973. 5. Schild S, Black RB. Social Work and Genetics. A Guide for Practice. New York: The Hawthorth Press, 1984.
Copyright 2006 by Taylor & Francis Group, LLC
Genetic Counseling
41
6. Hey D. The Oxford Guide to Family History. Oxford and New York: Oxford University Press, 1993. 7. Galton F. Natural Inheritance. London: MacMillan, 1889. 8. National Society of Genetic Counselors (http://www.nsgc.org, accessed January 2005). 9. National Human Genome Research Institute (http://www.nhgri.nih.gov/ 11510227 accessed January 2005). 10. National Conference of State Legislatures (http://www.ncsl.org/programs/ health/genetics/charts.etm.asp accessed January 2005). 11. Williams JK, Schutte DL, Evers C, Holkup PA. Redefinition: coping with normal results from predictive gene testing for neurodegenerative disorders. Res Nurs Health 2000; 23:260–269. 12. McConkie-Rosell A, Devellis BM. Threat to parental role: a possible mechanism of altered self-consept related to carrier knowledge. J Genet Couns 2000; 9:285–302. 13. Baker DL, Schuette JL, Uhlmann WR, eds. A Guide to Genetic Counseling. New York: Wiley-Liss, 1998. 14. Weil J. Psychosocial Genetic Counseling. Oxford: Oxford University Press, 2000. 15. American Board of Genetic Counseling (http://www.abgc.net accessed January 2005). 16. American Board of Medical Genetics (http://www.abmg.org accessed January 2005). 17. Genetic Nursing Credentialing Commission, Inc (http://geneticnurse.org accessed January 2005). 18. Genetic Alliance (http://www.geneticalliance.org accessed January 2005). 19. Wiel J. Psychosocial genetic counseling in the post-nondirective era: a point of view. J Genet Couns 2003; 12:199–211. 20. Biesecker BB. Back to the future of genetic counseling: commentary on psychosocial genetic counseling in the post-nondirective era. J Genet Couns 2003; 12:213–217. 21. Biesecker B, Peter K. Genetic counseling: ready for a new definition? J Genet Couns 2003; 11:536–537. 22. Bennett RL, Steinhaus KA, Uhrich SB, O’Sullivan CK, Resta RG, Doyle DL, Markel DS, Vincent V, Haminishi J. Recommendations for standardized human pedigree nomenclature. Am J Hum Genet 1994; 56:745–752. 23. Bennett RL, Motulsky AG, Bittles A, Hudgins L, Uhrich S, Lochner Doyle D, Silvey K, Scott CR, Cheng E, McGillivray B, Steiner RD, Olson D. Genetic counseling and screening of consanguineous couples and their offspring: Recommendations of the National Society of Genetic Counselors. J Genet Couns 2002; 11:97–119. 24. Bennett RL. The family medical history. Prim Care Clin Office Pract 2004; 31:479–495. 25. Bennett RL, Bird TD, Teri L. Offering predictive testing for Huntington’s disease in a medical genetics clinic: practical applications. J Genet Couns 1993; 2:123–137. 26. Hallowell N, Murton F. The value of written summaries of genetic consultations. Patient Educ Couns 1998; 35:27–34.
Copyright 2006 by Taylor & Francis Group, LLC
4 Gene Therapy for Inherited Diseases of the Central Nervous System Tyler Mark Pierson Division of Neurology, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.
John H. Wolfe Division of Neurology, Children’s Hospital of Philadelphia and W. F. Goodman Center for Comparative Medical Genetics, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, U.S.A.
INTRODUCTION Gene therapy is a potential treatment regimen where exogenous genes or genetically engineered cells are introduced into individuals to relieve a disease phenotype. A number of methods for the delivery of DNA or RNA are under active investigation. The goal of therapy is to produce therapeutic proteins or alter gene expression in the host to stabilize or correct a potential disease state by providing appropriate intracellular homeostasis or by reducing the concentration of extracellular toxins. Difficulties with the cellspecific targeting of vectors, cell-specific transgene expression and regulation, the toxicity of delivery vehicles, and host immune responses have all hampered the achievement of these goals. To date, there has been limited success with human gene therapy for genetic disease and no successful therapy involving the central nervous system (CNS) (see http://www4.od.nih. gov/oba/rdna/htm for past and current gene therapy trials).
Copyright 2006 by Taylor & Francis Group, LLC
44
Pierson and Wolfe
The CNS is an especially difficult target because of the need to circumvent the blood–brain barrier (BBB) to access the brain parenchyma, as well as the complex characteristics of its anatomy and cellular makeup. Most clinical trials for gene therapy in the CNS have been directed to neoplastic disease and adult neurodegenerative disorders, including Parkinson’s disease, amyotrophic lateral sclerosis; and Huntington’s disease (1–11). The only attempts to treat childhood-onset inherited disease have been in the Canavan and Batten diseases (12,13). This review will evaluate the potential application of gene therapy for the correction of genetic disease in the CNS. The major problem with genetic diseases affecting the brain is that the lesions are typically globally distributed, necessitating widespread delivery of either the gene or the protein. The discussion will focus on strategies for correcting different types of neurogenetic diseases based on their molecular and genetic pathology. Examples are provided for several types of disorders, including the effects of specific features associated with the diseases that affect gene therapy strategies and the various delivery vehicles. GENERAL PROPERTIES OF CNS GENE THERAPY Gene therapy involving the CNS must overcome a number of potential problems. Finding ways to circumvent the restricted entry of any compound into the CNS by the BBB is of primary importance. Once past the BBB, the delivery vehicle must reach the target cells via the complex microscopic and macroscopic structures of the brain. Another problem associated with CNS-based gene therapy strategies is the restriction on the volume of gene transfer vector preparation that can be injected. The BBB is especially problematic for the introduction of therapeutic genes or cells into the CNS. While many gene therapy protocols outside the CNS use intravenous delivery, the BBB effectively removes this option by restricting the movement of most substrates from the vasculature into the brain parenchyma (14). One approach to circumvent this restriction utilizes intravenously administered liposomal compounds to access the brain by active and passive transport across the intact BBB (15–17). Early data have shown some promise with this technique; however, cell-specific targeting of gene therapy may be difficult to achieve with these methods. Liposomes have been used to deliver drugs in humans with some efficacy (18). However, safety concerns regarding their use for gene delivery have not been determined (discussed in the section ‘‘Liposomal Delivery Systems’’). Another strategy is to temporarily open the BBB by using osmotic agents. These methods have not generally been very successful, and there is a significant concern about the adverse side effects of the procedure. Viral vectors may enter the brain if they are administered intravenously to an individual prior to the complete maturation of the BBB (19).
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
45
However, this method requires the diagnosis to be made in the prenatal or neonatal period, which can be difficult even in individuals with a high suspicion of having a neurogenetic disease (20,21). Because of these obstacles, most protocols use a direct transcranial approach to deliver therapeutic agents to the parenchyma or ventricles. This may significantly increase health risks in comparison to an intravenous injection, as neurosurgery can lead to serious complications, such as intracranial hemorrhage or fatal meningoencephalitis. Once the transgenic vehicle is injected into the parenchyma, diffusion may be inadequate for effective dispersion of the vehicle throughout the brain. Dispersion often is not uniform as viral vectors injected into specific parts of the brain may travel more easily along different neuroanatomical pathways than into some structures that are just millimeters away (22). Hyperosmolar solutions have been used to increase diffusion of delivery vehicles as they shift fluid out of parenchymal cells, increasing the relative volume of the extracellular space (23). Another means of increasing the area exposed to the therapeutic vehicle includes the use of multiple injection sites; however, the additional areas of local injury may increase the risk of local damage or infection, making surgery even more risky and less attractive. Other difficulties include targeting specific cell types within the brain, the risk of direct injury to cells by the delivery vehicle, and the potential of organ-wide damage or inflammation leading to increased intracranial pressure and herniation. These problems have been addressed in several ways. Some vehicles (viruses in particular) have specific tropisms toward different cell types and so may allow for cell-specific targeting (24). In cases where delivery is unable to target specific cell types, cell-specific expression can be regulated by cell-specific promoters. The nestin promoter can be used to target neural stem cells (25,26), the glial fibrillary acidic protein (GFAP) promoter can be used for astrocytes (27,28), and the neuron-specific enolase promoter can be used for neurons (29,30). Importantly, the vectors must not cause significant toxicity as this may result in forming an epileptogenic focus or provoke a large inflammatory response that could increase intracranial pressure (31,32). Tumorigenesis of transplanted cells could also hinder progress. These examples emphasize that therapeutic complications in the brain may result in extremely deleterious effects. CANDIDATE DISEASES FOR GENE THERAPY IN THE CNS There are numerous genetic disorders of the CNS that are potential targets for correction by gene therapy. These disorders can be classified into two general categories: (i) diseases where only a subset of cells will need to express the therapeutic protein or RNA, with subsequent correction of nearby cells; and (ii) diseases in which most of the affected cells will need to express the therapeutic protein or RNA for amelioration of disease. The
Copyright 2006 by Taylor & Francis Group, LLC
46
Pierson and Wolfe
first category includes disorders in which the therapeutic protein can be provided to other cells by secretion and endocytosis (33) or the toxic compound can diffuse into the cells expressing the therapeutic protein (34). In the first type of correction, the therapeutic effect is supplied to affected cells by other cells and will be described as being ‘‘in trans’’ or via ‘‘trans-correction.’’ Cells capable of providing trans-correction could be targeted by a delivery vehicle in vivo or in vitro with subsequent transplantation into the CNS (also known as ex vivo therapy). In contrast, the second category consists of disorders with a need to express the therapeutic protein or RNA in a cellular compartment that is inaccessible from outside the cell. In these cases, the affected cells are required to possess the transgene and express the therapeutic protein or RNA themselves. In this type of correction, the therapeutic intervention will be described as being supplied ‘‘in cis’’ or via ‘‘cis-correction.’’ The diseases that can be corrected in trans have more flexibility in their application than those requiring cis-correction because of less-specific targeting requirements and a lower number of transduction events. The following discussion of neurogenetic disease further categorizes disorders amenable to gene therapy by their genetic mechanisms and then hypothesizes whether they require cis- or trans-correction. Autosomal Recessive Mutations of Cytoplasmic or Nuclear Proteins Autosomal recessive (AR) mutations of cytoplasmic or nuclear proteins result in disease through the absence or diminished activity of a specific protein. Expression of the deficient wild-type protein corrects the cellular pathology; however, the cytoplasmic or nuclear location of these proteins requires transduction of these cells with the therapeutic gene, as there are no other ways to traffic proteins or RNA interference (RNAi) to these compartments. Because of the need to correct every affected cell, diseases like Pelizaeus-Merzbacher disease (35), vanishing white matter disease (36), or MNGIE (37) would be difficult to correct as affected cells are located throughout the brain. In contrast, disorders with a more limited cohort of affected cells may be more amenable to correction. Pantothenate kinaseassociated neurodegeneration (one of numerous subtypes of a disorder formerly known as Hallavorden–Spatz disease) is an example of this type of disorder. An AR disease characterized by dystonia, pigmentary retinopathy, and psychiatric symptoms is caused by mutations in the gene encoding pantothenate kinase 2. Pantothenate kinase 2 is essential for coenzyme A biosynthesis and deficiency of this enzyme causes tissue-specific accumulation of cysteine-containing enzyme substrates that lead to iron accumulation in the basal ganglia and retina resulting in cell dysfunction (38). Correction
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
47
of this disease would require transduction of the deficient gene into the affected cells in the basal ganglia or retina in order to return coenzyme A concentrations to sufficient levels. Because the affected cells are located in well-defined areas of the brain, the delivery of genes to the affected areas may be less difficult and yet still have a significant impact on the disease pathology. In contrast, targeting AR disorders of cytoplasmic proteins with more widespread pathology may have a lesser impact on the disease state as widespread transduction may be more difficult and correction less efficient on the whole. Dominant Negative Mutations Dominant negative mutations cause pathology in the presence of wild-type proteins by disrupting their normal function. Correction of these disorders could involve the use of RNA interference (RNAi) technology by specifically blocking the translation of the dominant negative protein (39,40). This technology relies on the therapeutic transgene expressing small interfering RNAs (siRNAs) consisting of sequences specific to the mutations of the dominant negative alleles. The siRNAs then cause degradation of the mutant mRNA, while having little or no effect on the translation of the wild-type mRNA (41). This mechanism for degrading the mutant RNA must be present in the cytoplasm of every affected cell and so would require the siRNA-encoding transgene to be provided in cis for correction. Dominant negative disorders with focal pathology would have a greater chance of correction than those with more diffuse lesions. An example of a dominant negative disorder with focal pathology is idiopathic earlyonset torsional dystonia. The disorder is characterized by paroxysmal sustained muscle contractions in the legs or arms that can be unsettling and painful to the patient. The disease is due to mutations in the DYT1 gene, which encodes torsinA, an AAAþ ATPase that resides within the endoplasmic reticulum and nuclear membrane. The mutant gene product accumulates in the nuclear envelope leading to neuronal dysfunction (42,43). The pathology of this disorder is felt to be localized to the basal ganglia, and thus cis-correction of the affected cells may be able to ameliorate the phenotype. Other possible targets of this type of technology are the trinucleotide repeat (CAG) disorders that encode a polyglutamine tract. These are autosomal dominant diseases [spinocerebellar atrophies, Huntington’s disease, and Kennedy disease (44)] with pathology secondary to the expression of a toxic protein that accumulates in the nucleus of affected neurons. Targeting these proteins would be challenging for this technology secondary to the common presence of CAG repeats in many normal transcripts, but other methods or abnormalities could allow for successful interference (40,41).
Copyright 2006 by Taylor & Francis Group, LLC
48
Pierson and Wolfe
Autosomal Recessive Mutations Causing Accumulation of Diffusible Toxins There are a number of AR neurogenetic disorders affecting the function of cytoplasmic proteins that catabolize diffusible cellular toxins, including amino acidopathies, organic acidopathies, and peroxisomal diseases. Current treatment options include limiting the ingestion of foods that are rich in the toxin’s precursors (45), or removing circulating toxins from the bloodstream by liver or other organ transplantation (46). Unfortunately, in many cases these options are inadequate or too toxic to protect the brain from further injury. However, if the deficient enzymes were present in the microenvironment of the brain, accumulation of the toxin might be limited, reducing the risk of further neurologic injury. Studies utilizing bone marrow transplantation (BMT) for many of these disorders indicate that removal of the circulating toxins by a cohort of cells expressing the deficient protein may be a better method of correction (47). Unfortunately, BMT is associated with significant morbidity and mortality and may require at least a year to show any benefit while the disease continues to progress (47,48). Because of these disadvantages, the use of trans-corrective gene therapy may be a more attractive alternative. A cohort of cells would be engineered in vivo or ex vivo to express the deficient protein and metabolize the accumulating toxins, allowing for immediate expression in the CNS and avoiding any need for immuno-ablation. Adrenoleukodystrophy is an example of a peroxisomal disorder where the accumulation of toxic fatty acids causes disease, and removal of toxins has relieved the disease phenotype (47,48). Due to mutations of lignoceroyl-CoA synthetase, the disease is the result of the defective transport of very long chain fatty acids (VLCFAs) into the peroxisome. It presents insidiously with diminished attentiveness and cognition and these symptoms are associated with significant white matter changes. As the disease progresses, the patient becomes severely incapacitated and death occurs within 10–20 years of diagnosis (or even more rapidly in some patients) (49,50). Refsum disease is another peroxisomal disease caused by the accumulation of phytanic acid leading to ataxia and polyneuropathies (51). Relief of the disease phenotype is also associated with decreased circulating toxin. Maple syrup urine disease is an amino-acidopathy due to the accumulation of branched chain amino acids in the brain. Dietary restrictions are the primary means of therapy; however, removal of circulating toxins has also been shown to ameliorate disease and decrease progression of neurologic symptoms (46). Type I glutaric aciduria is an example of an organic acidemia, due to a deficiency in glutaryl-CoA dehydrogenase that leads to the accumulation of glutaric acid. Experience indicates that removal of these compounds by trans-correction may protect against any further CNS damage with metabolic exacerbations (52,53). These examples represent a few of the different types of amino acidopathies, organic
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
49
acidemias, or peroxisomal disorders that may be amenable to a transcorrective gene therapy approach. All are attractive targets because in each case the corrected cells may be able to break down the toxins for the rest of the brain. Questions that need to be answered with this strategy include: (i) How many cells expressing the deficient proteins are required to relieve CNS pathology? (ii) Do these cells need to be scattered throughout the CNS or will a concentrated group be enough to remove the toxins? (iii) Will the removal of the circulating toxins be enough to correct pathology or would significant metabolic deficiencies still be present causing other types of pathology? Lysosomal Storage Disease Lysosomal diseases are the result of AR mutations in genes encoding lysosomal acid hydrolases (Hunter disease is an X-linked exception) and other proteins that affect lysosome function. The acid hydrolases are posttranslationally modified with the addition of a mannose-6-phosphate residue, which binds specific mannose-6-phosphate receptors, enabling the enzyme to be sorted to the lysosome during its passage through the vesicular system. Modest quantities of these enzymes are secreted into the extracellular space as well, where they can bind to mannose-6-phosphate receptors located on the extracellular surface of the plasma membrane of neighboring cells, allowing the enzymes to be endocytosed and translocated to their lysosomes. Intravenous enzyme replacement therapy (ERT) has used this feature to correct Fabry and the non-neuronopathic subtype of Gaucher disease in humans (although the enzyme used in correcting Gaucher disease is mannose-terminated) (54–58). However, the intravenous delivery of the deficient enzyme does not allow transport into the brain due to the restriction of the BBB (19). Direct infusion of protein into the brain via indwelling intracranial catheters carries a high risk of infection and makes this strategy an unattractive option. BMT has been used as well, with some success (47,48), but the CNS disease is not improved in many engrafted patients. These data have led to numerous studies of CNS trans-correction in animal models of lysosomal disease, many of which have shown promising results (59). Lysosomal disease is subcategorized into mucopolysaccharidoses, lipidoses, mucolipidoses, and neuronal ceroid lipofucsinoses by the type of substrate that accumulates in lysosomes. Though each disease is rare, cumulatively these disorders are present in approximately 1 of 8000 live births (60–62). Examples of the mucopolysaccharidoses are Hurler disease, Hunter disease, San Filippo disease, and Sly disease. These disorders accumulate glycosaminoglycans (previously known as mucopolysaccharides) in their lysosomes with associated alterations in cell size and physiology. The resulting phenotypes include coarse facies, bony malformations, mental retardation, and hydrocephalus (63). Examples of the sphingolipidoses are
Copyright 2006 by Taylor & Francis Group, LLC
50
Pierson and Wolfe
metachromatic leukodystrophy, Krabbe disease, and Tay-Sachs disease. Patients with these disorders accumulate toxic lipids in their cellular membranes resulting in myelin dysfunction. Individuals are not dysmorphic, but experience relentless progression of spasticity and cognitive decline (49,64). Mucolipidoses are due to errors in the post-translational modification of lysosomal enzymes. Lysosomal enzymes in these disorders lack a mannose-6-phosphate residue and are trafficked through the secretory pathway and not to the lysosome. Examples of these disorders include I-cell and pseudo-Hurler diseases that have characteristics of both the mucopolysaccharidoses and sphingolipidoses (65). Neuronal ceroid lipofuscinoses are a diverse group of neurodegenerative diseases associated with intractable epilepsy, dementia, and brain atrophy (66,67). Disease Severity, Diagnosis, and Age of Treatment Initiation Genetic diseases affecting the CNS generally follow a progressive degenerative course, making it important to diagnose and treat patients prior to the onset of debilitating symptoms (47,48). Individuals with infantile-onset disorders often carry mutant alleles that encode little or no enzyme activity, while later-onset disorders usually have partial enzyme activity. Infantileonset disorders are more difficult to treat because the lack of enzyme activity leads to rapid progression of the disease with significant disabilities being present by the time a definitive diagnosis is made. These patients may be immunologically na€ve to the transgenic protein, thus immune responses may complicate therapy. Alternatively, juvenile- and adult-onset disease may be more capable of responding to therapy because of the expression of mutant enzymes with partial activity. These mutant enzymes allow for a slower accumulation of the toxic substrate and a less aggressive progression of symptomatology. They may also expose the immune system to a variant of the wild-type protein making it less likely to elicit an immune response to the therapeutic protein.
ANIMAL MODELS OF GENETIC CNS DISORDERS Animal models of neurogenetic disease that accurately reflect the human phenotype are very important in evaluating the efficacy and safety of any gene therapy prior to its use in humans. Many animal models have been discovered as naturally occurring mutations in domestic stocks. Germ-line gene mutation technology (knockout mice) has made many more mouse models available. Animal models with naturally occurring mutations can be very accurate in their phenotypic representation of human disease, mostly because their phenotype is what brought them to attention. However, with molecular genetic analysis, some of these models had mutations that were inconsistent
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
51
with their representative human disease. For example, one of the most common human mutations of Krabbe disease (I546T) is inconsistent with the galactocerebrosidase mutation (W339X) found in the twitcher mouse, a model of Krabbe disease (68–70). Dog and monkey models of the disease were also inconsistent with this common human mutation (69,70). In contrast, knockout animals have been very successful at reproducing human gene mutations, but may have different phenotypic characteristics than the human or other animal models (70). Both the naturally occurring mutants and knockout animals provide investigators with a large amount of information and means by which to study gene therapy. The majority of these illnesses use mouse models; However, large animal models, however are much closer in brain size to humans and will be important translational models. Mice are the most utilized species since they can be generated rapidly and have well-characterized genetic backgrounds. Examples of naturally occurring mouse models of human neurogenetic disease include the jimpy and rumpshaker mice, which have different mutations in the myelin proteolipid protein gene. Human genotypic and phenotypic variants are PelizeausMerzbacher disease and X-linked Paraplegia type 2, respectively (71,72). Other examples of naturally occurring mouse models of human disease include the sulfamidase-deficient mouse (San Filippo disease) (73) and beta-glucuronidase-deficient mouse (Sly disease) (74). The model of Sly disease [mucopolysaccharidosis type (MPS) VII] has become widely used in the field of gene therapy in the CNS because of the number of experimental assays that are available to both localize and quantify the transferred gene and enzyme (discussed further) (59). Rats have many of the same advantages as mice in regard to breeding and genetic background, but may be more useful for certain behavioral studies. Rat models involving deficiencies in proteolipid protein (75), N-acetylgalactosamine-4-sulfatase (MPS VI) (76) and acid lipase (Wolman disease) (77) have been characterized; however, rat models are not as numerous as the naturally occurring mouse models. The disruption of genes by inserting intervening sequence into their coding regions (the knockout mouse) is a valuable tool for the generation of animal models of human neurogenetic disease. Examples of this technology include mice deficient in arylsulfatase A (metachromatic leukodystrophy) (78), the hexosaminidase a-subunit (Tay-Sachs disease) (79), the hexosaminidase b-subunit (Sandhoff disease) (80,81), superoxide dismutase (familial amyotrophic lateral sclerosis) (82), a-mannosidase (83), and a-L-iduronidase (Hurler disease) (84). The technology has also enabled researchers to produce exact genotypic models by replacing wild-type genes with genes carrying specific human mutations. These mice are termed ‘‘knock-in’’ mice and examples include models for superoxide dismutase and the Gaucher disease (85,86). Many of the knockout or knock-in mice have been shown to accurately mimic the phenotype of their homologous human disease. For example,
Copyright 2006 by Taylor & Francis Group, LLC
52
Pierson and Wolfe
the arylsulfatase A deficient mouse has increased urine sulfatides, gait abnormalities, and white matter signal changes that are similar to lateinfantile onset metachromatic leukodystrophy (78). Other examples include the Sandhoff and Hurler mice having very similar clinical, pathological, and biochemical characteristics when compared to the human disease (80,81,84). Knockout mice do not generate protein products from the disrupted locus and this may be significant in how the immune systems of these animals react to the presence of a previously unseen therapeutic protein. In comparison, knock-in models may produce near full length proteins, which are non-functional but may decrease the immunogenicity of the therapeutic protein (59). In addition, the presence of mutant proteins identical to those found in human disease may be valuable in modeling the subtle aspects of the disease or in revealing interactions between the mutant and normal proteins when they are co-expressed. Knockout or knock-in mice do not always accurately depict the human phenotype. For example, disruption of the gene encoding the b-hexosaminidase a subunit, which is defective in Tay-Sachs disease, had no affect on the neurologic development or life span in mice. This occurred because mice accumulate toxic gangliosides at much lower levels than their human counterparts, as a result of degradation via an alternative biochemical pathway not present in humans (81,87). Similar results occur in hypoxanthine-guanine phosphoribosyltransferase (HPRT)-deficient mice, the gene involved in Lesch–Nyhan disease, due to higher flux through a salvage pathway in mice (88). Knockout mice may also be inaccurate models for disease correction when the loss of the protein is not the pathophysiologic cause of the disease, as experienced with the Cu/Zn superoxide dismutase in SOD1 null mice (82). These animals were created to model familial amyotrophic lateral sclerosis (ALS), but did not develop motor neuron disease. Subsequent generation of knock-in mice with the human G37R or G85R or G93A mutations exhibited the appropriate phenotype. The greater accuracy of the knock-in was due to a ‘‘gain of toxicity’’ mechanism specific to the mutant allele (85,89–91); thus, reproducing the specific human mutation was crucial in generating an accurate model. Even this method may be inadequate. Specific point mutations of the b-glucocerebrosidase gene associated with the less severe forms of Gaucher disease were generated in knock-in mice, but were found to express a phenotype consistent with the more devastating forms of the disease (86). However, while many knockout or knock-in mice can be very useful in modeling some human diseases for gene therapy, each genetic change must be evaluated for its similarities to the human disease. Transgenic and knock-in technology has also been used to generate animal models of dominant negative disease. These models are valuable in evaluating strategies to disrupt the production of the dominant negative
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
53
protein, such as interfering RNA (RNAi). Numerous animal models of trinucleotide repeat disorders have been generated expressing transgenes containing pathologic amounts of the CAG repeats. Functional models of human disease include the Machado-Joseph disease (spinocerebellar ataxia type 3) (MJD) and Huntington’s disease mice. MJD mice express transgenes possessing 79 CAG repeats in the open reading frame (ORF) of the MJD1 protein. Expression of this mutation in Purkinje cells resulted in the development of severe ataxia, wide-based hind-limb postures, and cerebellar atrophy (92). Huntington’s disease mice were engineered to contain the 50 upstream region and exon 1 of the huntingtin gene containing CAG expansions of 115–150 repeats. These mice have progressive neurodegeneration and limb dyskinesias consistent with the human disease (93). However, other trinucleotide repeat studies have been less successful. A model of spinobulbar muscular atrophy expressing the testosterone receptor gene containing 45 CAG repeats exhibited no pathology and was inadequate for study because of locus stability, as well as the low expression of the transgenic mRNA (94). Expression of the mutant genes from their natural promoter or locus may be a remedy to this problem, as the natural loci may favor more accurate tissue-specific levels of gene expression, which would provide a more physiologic target for testing RNAi-based gene therapies. A major drawback of using rodents to model human neurogenetic disease is the relatively small and simple structure of their brains. This simplicity may not allow gene therapy protocols to function more effectively in brains of animals with significantly larger volume and physical complexity (59). Cats and dogs possess brains that are more similar in physical characteristics to human brains than rodents. They have longer life spans and their relatively large size allows them to be manipulated more easily with surgical and non-invasive imaging modalities. Animal models of neurogenetic disease in larger mammalian species are exclusively naturally occurring, as knockout technology is not yet available for these species. Naturally occurring models exist for a number of LSDs, for example, both cat and dog models have been discovered for MPS I [Hurler disease (95,96)], GM1 gangliosidosis (97,98), and MPS VII [Sly disease (99,100)]. In addition, cat models exist for a-mannosidosis (101), MPS VI (102), and Tay-Sachs disease (103), while dog models exist for MPS IIIa (104), Krabbe disease (105), and one of the subtypes of neuronal ceroid lipofuscinosis (Batten disease) (106,107). Other types of genetic disease affecting the CNS include dog models of narcolepsy (108) and juvenile-onset epilepsy (Lafora disease), which was recently shown to be due to a triplet repeat (109). These models are important for studies to scale up gene therapy for human neurogenetic disease. However, the slow generation times, increased cost of medical management, and other difficulties usually restrict their use to translational studies after proof-of-principle experiments in mice.
Copyright 2006 by Taylor & Francis Group, LLC
54
Pierson and Wolfe
LYSOSOMAL STORAGE DISEASE: ANIMAL MODELS AS A PARADIGM FOR CNS GENE THERAPY Animal models of lysosomal storage disease have been the most abundant and widely used genetic disease models for the CNS. Lysosomal diseases have been identified in numerous species, including the mouse, rat, cat, dog, guinea pig, quail, cattle, goat, pig, sheep, and even the emu (59). These naturally occurring mutations are rare, as in humans, and were discovered in domestic stocks because the phenotypic abnormalities are stereotypical and dramatic. Some of these mutants were identified many years ago, and are some of the most well-understood illnesses in animals. They have played a major role in evaluating the natural diversity of these diseases. Many of these mutations were among the first disease genes to be characterized in neurogenetic disease. Lysosomal diseases possess many features that make them attractive candidates for gene therapy (discussed in the section ‘‘Lysosomal Storage Disease’’). Most of them are caused by deficiencies in enzymes with similar traits, including the requirement for the acidic environment of the lysosome to function, intravesicular trafficking via mannose-6-phosphate residues, and secretion and uptake by neighboring cells. In principle, therefore, vectors and strategies developed to treat one lysosomal disease should be applicable to others by changing only the transferred gene, although there are important differences in the physical characteristics among the enzymes, such as stability. This will be important in human disease because of the rarity of each disorder and the limited therapeutic options for the CNS pathology in these disorders. A type of trans-correction strategy for the CNS is to use secretion of the therapeutic enzyme from endogenous cells transduced in vivo or exogenous cells transduced in vitro and subsequently transplanted into the CNS. Trans-correction has been utilized with some success outside the CNS utilizing enzyme replacement therapy (ERT) in individuals with nonneuronopathic Gaucher (57,58) or Fabry disease (54,56). This method uses the intravenous delivery of the deficient enzymes to trans-correct affected cells. Data from these studies indicated the therapeutic enzyme activity does not need to be restored to wild-type levels, as 10% to 20% of this amount can be adequate for correction. Although ERT usually does not work for CNS disease due to the BBB, these results suggest that enzyme expression within the brain by gene transfer has a reasonable chance of success in humans. Animal studies support this. One disorder that has been used extensively as a model system for gene therapy is MPS VII (Sly disease), which is caused by a deficiency of b-glucuronidase (GUSB). MPS VII is a multisystemic disorder affecting the liver, spleen, bones and joints, heart, eye, and CNS. It is a rare case of neurologic diseases in humans (110) and animals, but breeding colonies
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
55
have been established from carriers in the mouse, cat, and dog for study. The animal models have very similar clinical presentations to affected children. Early studies on the biochemical genetics of GUSB in the mouse led to the relatively early isolation and use of the GUSB cDNA in some transfer studies (99,111,112). The GUSB enzyme has a number of features that enhance its usefulness for gene therapy experiments. Most importantly, the enzymatic activity can be localized within the brain by using a simple histochemical staining reaction for direct visualization. In combination with in situ hybridization, the enzyme-positive cells expressing the GUSB mRNA can be distinguished from cells that have taken up the enzyme (113–116). Correction of pathology can be monitored histologically by evaluating lysosomal distension and cellular size. Species differences in heat stability of the enzyme have been used to measure the human GUSB expressed from a vector, as opposed to the endogenous mouse or cat forms (113,114,117). This permits many studies to be done in normal animals prior to evaluating their diseased counterparts, which are more difficult to produce and maintain. Cells can express GUSB at super-physiologic levels without obvious toxic side effects, thus engineering cells to overexpress enzyme may result in better delivery to the surrounding tissues (118,119). Finally, the animal models of MPS VII have significant pathology with involvement of numerous organ systems on the macro- and microscopic level. This pathology accurately models the human disease in the CNS and non-CNS tissues. The technical advantages of this model system have allowed a number of principles of gene therapy to be demonstrated first in MPS VII, which are applicable in principle to this whole class of disorders: (i) It is only necessary to transfer the gene to a small number of cells because the normal enzyme can be secreted in three dimensions to correct the surrounding diseased cells, with less than 5% of normal activity needed to fully reverse the metabolic defect in some cases (120). (ii) Lysosomal storage can be reversed after the disease is advanced, including in large animals (120,121). (iii) The brain with advanced lesions can respond, but needs to have the enzyme present within the brain matter (122). (iv) Behavioral abnormalities can be corrected after the disease is advanced (123). (v) Despite the global distribution of storage lesions, selective neurodegeneration occurs in brain areas (hippocampus and cerebral cortex) that are important for mentation and can be reversed by gene transfer, thus it may not be necessary to correct all of the brain disease to have a positive effect in a clinical setting (124). (vi) More extensive distribution of enzyme can occur by neuronal transport in certain pathways to distal sites (22), which may be clinically important due to the limited number of injection sites that can be used. Many of these findings were subsequently extended to other experiments in models of MPS VII models and other LSDs (125,126). When applying these principles to other diseases, there will be variations in specific
Copyright 2006 by Taylor & Francis Group, LLC
56
Pierson and Wolfe
responses due to inherent differences in the specific enzymes. For example, the percentage of normal levels that will be needed for correction may vary, since there are significant differences in the stability among the different enzymes. Another example is that dogs mount a vigorous immune response to alpha-L-iduronidase (defective in Hurler disease, MPS I) (127), whereas they respond only with humoral immunity to foreign GUSB and the response does not appear to interfere with graft survival, vector gene expression, or enzyme transfer to diseased cells (121,128). GENE DELIVERY VEHICLES Gene delivery vehicles can be divided into four general categories: naked DNA, liposomes, viral vectors, and transplanted engineered cells. Naked DNA transfer has been used mostly in muscle and has not been very effective in the brain. The other three methods have specific advantages and disadvantages as delivery methods in the CNS. The viral and liposomal methods of delivering genes involve introducing an exogenous nucleic acid to the subject’s own CNS cells, which express the gene to supply a therapeutic protein or inhibitory RNA in cis or trans. Transplanted cells deliver the therapeutic activity via inactivating diffusible toxins or supplying the therapeutic protein in trans. All three of these methods can be combined to increase the flexibility and complexity of delivering transgenes to their targets. Liposomal Delivery Systems Liposomal delivery systems were first developed by using cationic polyplexes that formed complexes with anionic DNA, but the compounds are much more stable in water than in saline, thus they accumulated in the lungs in vivo (129–131). When naked DNA was encapsulated in a very small liposome (<85 nm) and conjugated with polyethyleneglycol (PEG) strands, the new complex was stable in the blood for extended periods of time (17). These ‘‘PEGylated’’ liposomes can traverse the BBB if they are conjugated to a monoclonal antibody (mAb) targeting plasma membrane receptors and are termed PEGylated immuno-liposomes (PILs) (15,16). The mAbs can potentially be directed at various target molecules involved with the BBB. Neuron-specific enzyme activity was seen in Rhesus monkeys intravenously administered PILs with a mAb against the human insulin receptor and containing a plasmid expressing b-galactosidase from a neuron-specific promoter (132). Studies with the transferrin receptor have produced similar brain-specific expression patterns (133). This evidence indicates liposomal delivery using promoters driving expression within specific cells in the brain that can provide unique expression patterns to genes even when gene delivery is non-specific. This technology has been used to express
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
57
the gene for tyrosine hydroxylase (134,135) and siRNAs in protocols for cancer gene therapy (136). Although these systems possess great potential for widespread gene delivery in the CNS, gene expression is very short-lived (only a few days). Viral Delivery Systems Viral vectors for gene delivery consist of a genetically engineered viral particle that contains a gene or cDNA in the viral genome encoding the therapeutic protein orsi RNA. The vectors are rendered incapable of replication by the removal of sequences required for viral replication from the vector. Most of these deleted sequences encode viral replication proteins that must be supplied in trans from ‘‘packaging’’ cells or plasmids transiently transfected into cells, which allows the therapeutic nucleic acid to be encapsulated into a viral particle. The resulting product is a replication-defective virus particle containing the desired transgene. When these vectors infect CNS cells, the modified viral genome either integrates into the endogenous DNA or is maintained as episomal DNA, depending on the type of virus. This characteristic is important because of the potential for the integrated viral genome to disrupt tumor suppressor genes or activate oncogenes that may lead to tumorgenesis (137–140). Episomal DNA vectors can also integrate, but do so at a much lower frequency. There are numerous characteristics that a viral vector must possess to be ideal for gene transfer. The most important is that it should not be toxic to the cells it infects. Toxicity can be in the form of viral-mediated effects or the induction of an immune response, which is especially dangerous in the brain (31,32). Both have caused numerous problems with gene therapy protocols and trials in the past. Another attractive feature is cell-specific tropism. This characteristic is governed by the surface proteins (capsid or envelope) of the virus, which bind to receptors on the cell surface. The ability of the virus to infect postmitotic cells is also a desirable quality, since many cells in the CNS are postmitotic. Finally, the ease of genetic manipulation due to a large transgene packaging capacity permits the inclusion of various gene regulatory elements and/or multiple target proteins. No single viral vector possesses all of these characteristics; hence, the investigator needs to determine which vector is most attractive to address the experimental requirements. Most viral vectors have had extensive modifications of their genomes for use in gene therapy (141). Most of the endogenous viral sequences are removed to make room for the target transgene and regulatory elements, including those responsible for replication or other pathogenic traits. Some of the other viral proteins are required for the production of viral particles or expression of the viral genome in the infected cells (e.g., reverse transcriptase in retroviruses). Because of the need to remove these from the target
Copyright 2006 by Taylor & Francis Group, LLC
58
Pierson and Wolfe
cell, most of these proteins are supplied in trans by a packaging cell line or helper virus that encodes the needed sequences in their DNA. There are also cis-acting viral sequences that are required in the viral vector for packaging of the nucleic acid or integration into the host genome. Much of the research involving the production of viral vectors for gene therapy has involved the delineation of which sequences are required in cis and which can be supplied in trans for each specific viral vector systems. Whether the viral genome integrates into the host genome or is maintained as an extra-chromosomal constituent of the nucleus is an important characteristic when deciding which viral vector to use. The two most important types of viral vectors that integrate into the nuclear genome are the retro- and the adeno-associated viruses, while adenovirus and herpesvirus genomes are mostly present in episomal forms. The following discussion highlights advantages and disadvantages of the various viral vector systems and their use in animal models of CNS gene therapy. Retrovirus Delivery Systems Retroviruses are single-stranded RNA viruses that require reverse transcriptase for the viral genome to be transcribed into DNA and incorporated into the host cell’s genome. This group includes oncoviruses and lentiviruses, consisting of the viral genome, reverse transcriptase, a protein core, and a phospholipid membrane envelope containing surface glycoproteins. Wild-type virus requires 50 and 30 long terminal repeats (LTRs) containing promoter/enhancer elements and sequences needed for reverse transcription and integration. Self-inactivating (SIN) retroviral vectors have functioning 50 promoter elements but their 30 LTRs have had the transcriptional regulatory sequences deleted. As a result of the reverse transcription mechanism, these alterations are duplicated in the 50 LTR in the double-stranded DNA provirus that integrates into the cellular genome, eliminating all promoters except those engineered with the transgene (142,143). The capacity for foreign genes in retroviral vectors is approximately 6–7 kb, which is an intermediate size when compared to other viral delivery vehicles. This capacity provides adequate space for several ORFs as well as additional regulatory elements. An attractive feature of the retroviral family is that certain envelope glycoproteins (env) from other viruses can be incorporated into the viral membrane. Different envelope proteins bind different receptors, giving each virus its particular tropism, thus exchanging the glycoproteins can alter the host cell range of the vector. Envelope proteins from Ebola, Marburg, LCMV, Mokola lyssavirus, vesicular stomatitis virus, and others been used in retroviral delivery systems (144–147). The vesicular stomatitis virus-G surface glycoprotein (VSV-G) is a particularly important envelope protein as it binds plasma membrane lipids instead of protein receptors, giving it a wide tropism in the brain (148). VSV-G also increases the stability of viral
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
59
particles enough to allow ultracentrifugation, providing higher viral concentrations (149). One disadvantage of using retroviruses for gene therapy is their potential for integration site dependent mutagenesis, where insertion into oncogenes could transform the cell. This has occurred in a clinical trial for the X-linked form of severe combined immune deficiency (X-SCID) (138,150). Hematopoietic stem cells were infected with oncoretroviral vectors in cell culture in order to express the deficient protein, the interleukin Z receptor gamma chain (IL-2Rg). Nine of ten patients had reconstitution of their immune systems by the genetically engineered cells, but regrettably, three of the patients developed T-cell leukemia after transplantation. The leukemia cells of two of the patients had a copy of the intact vector inserted in the vicinity of the LMO2 gene locus, a known oncogene (137). Subsequent study demonstrated the neoplasias were secondary to the transgenic promoter activating expression of LMO2, which kept some cells in a more undifferentiated state and increased their leukemic potential (138–140). However, these trials used retroviral vectors containing intact LTRs, which are powerful promoters and can be eliminated by using SIN configurations. Further transcriptional regulation of the integrated transgene’s promoter by utilizing insulators to block promoter effects of or by adjacent loci, may limit this possibility in the future (151–153). Retroviral vectors were some of the first viral vectors used in protocols for gene therapy (154), and can be divided into two main subtypes based on their ability to infect nondividing cells. Oncoretroviruses cannot infect nondividing cells, while the lentiviruses can infect both dividing and nondividing cells. Lentiviral systems are the more widely used vector in gene therapy of neurogenetic disease. The Maloney murine leukemia virus (MLV) is the prototypic subtype of the oncoretroviral vectors, and was one of the first vectors used in human trials of gene therapy for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA–SCID) (154–157). All other oncoretroviral vectors are derived from this basic prototype and have similar means of function, but with enhanced capabilities. One of the biggest drawbacks of using oncoretroviral vectors is their inability to infect nondividing cells (158). Because of the relative paucity of mitotic cells in the CNS, most oncoretroviruses are not very useful for CNS gene therapy. However, they are used for ex vivo manipulation of cells (fibroblasts, hematopoietic, and neural stem cells) (122). Lentiviruses can infect postmitotic cells but have more viral elements that must be supplied in trans than the oncoretroviruses (114). HIV-1 is the prototypical lentivirus, but FIV, HIV-2, EIAV, and SIV viruses are also being used in gene therapy studies (123,159–162). Lentiviruses have been pseudotyped with a number of different envelope glycoproteins to expand their tropism in the brain (146,163). Vectors containing the envelope proteins of the rabies-related Mokola virus, lymphocytic choriomeningitis
Copyright 2006 by Taylor & Francis Group, LLC
60
Pierson and Wolfe
virus (LCMV), and VSV transduce similar patterns of cells in the striatum, thalamus, and white matter of the rodent brain. In contrast, the MuLVpseudotyped vectors had a less extensive transduction pattern, but had selective expression in the striatum and hippocampal dentate gyrus. Ebola-pseudotyped vectors had no recognizable pattern of transduction in the CNS (163). In the rat, lentivirus vectors pseudotyped with the VSV Indiana strain, wild-type ERA, and CVS strains had strong transduction in the striatum, while Mokola- and LCMV-pseudotyped vectors were less effective (164). The use of cell-type specific promoters in the CNS showed that even if lentiviruses infected a wide variety of cell-types, the promoters could limit expression of the transgene to the expected target cells (165). This study compared neuronal and glial specific promoters [neuron-specific enolase (rNSE) and the glial fibrillary acidic protein (hGFAP)] with the more ubiquitously expressed human cytomegalovirus promoter (hCMV), a hybrid CMV/beta-actin promoter (CAG) and human elongation factor 1a (EF1a) promoters from VSV-G pseudotyped lentiviruses. The GFAP promoter was expressed only in astrocytes and the NSE promoter was expressed only in neurons, while the hCMV, CAG, and EF1a were ubiquitously expressed. These results indicated that pairing pseudotypes with low cell-type specificity to various promoters can confer cell-specific expression of the transgene in the brain. The most extensive use of lentivirus vectors in the CNS has been in Parkinson disease models. For neurogenetic diseases, the widest application has been in mouse models of lysosomal storage diseases. Multiple injections result in spread of the secreted enzyme and have been demonstrated to correct storage lesions in MPS VII and an metachromatic leukodystrophy model (arylsulfatase-A deficiency), and can mediate improvements in some behavioral tasks (125,166). Cognitive improvement in the MPS VII model was associated with alteration in expression of genes associated with neuronal plasticity (123). Other studies have used lentivirus vectors to deliver trophic factors to rescue genetically diseased neurons, for example, in the mouse model of ALS (167). These data suggest that it may be feasible to use lentivirus vectors in human gene therapy trials for neurogenetic diseases. Adeno-associated Virus Delivery Systems Adeno-associated virus (AAV) is a single-stranded DNA virus of the parvovirus family. It can be maintained as an episome or be integrated into the nuclear DNA. AAV is classified as a dependovirus because it requires a helper virus (adenovirus or herpesvirus) for active replication in infected cells. The required helper functions can be supplied in trans by packaging plasmids to make vector virus. AAV is particularly attractive for gene transfer because the wild-type virus has no known pathology in humans. The major limitation of AAV vectors is that they have a cloning capacity for foreign genetic
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
61
sequences of only 4.5 kb. This relatively small size can accommodate many cDNAs, but limits the choice of promoters, introns, and other regulatory elements in the vector genome (168). This limitation can be overcome by dual infection of the same cell with multiple vectors containing different but overlapping sequences because the vector genome forms head-to-tail concatemers in the cell, which is maintained in an episomal state (169,170). However, the efficiency of this type of vector is generally low. The outer coat of AAV viruses is formed from the capsid protein. The capsids are grouped by serotype, and 11 different serotypes have been identified. A vector genome only requires the inverted terminal repeat (ITR) elements (approximately 150 nucleotides at each end of the vector) from the viral genome. The AAV2-derived ITRs are the most commonly used for vector construction in gene therapy protocols (24). The vector genome can be packaged with any of the capsid serotypes, and AAV serotypes have a wide range of tropisms in the CNS. In mice, AAV-2 and AAV-3 predominately infect neuronal cells, AAV-4 infects ependymal cells, and AAV5 effectively transduces neuronal and glial cells (171,172). Intraventricular injections of neonatal mice with AAV1 or AAV2 vectors result in very widespread gene delivery that is maintained in the adult for at least one year (173,174). AAV5 transduces very efficiently when injected into the adult mouse brain (175), but is very limited when injected into the ventricles of neonates (176). These characteristics make AAV vectors very promising tools in any potential gene therapy in the CNS and they have been used successfully in a number of animal studies of CNS gene therapy (168,177). AAV-2 vectors have been used in many experiments in the MPS VII mouse brain, showing long-term expression and reversal of storage (178–181). AAV vectors containing the alpha-N-acetylglucosaminidase gene driven by a CMV or neuron-specific enolase promoters were used to treat the brains of adult MPSIIIB mice using similar procedures (182). These mice have their cellular pathology corrected in regions up to 1.5 mm from the injection site. Knockout mice that model ALS have been improved by intramuscular injection with AAV vectors expressing IGF-1. They had reduced disease progression after retrograde delivery of the transgenes to the motor neurons in the spinal cord (183). N-acetylaspartylase (ASPA) knockout mice (Canavan disease) had an AAV vector expressing genes for both ASPA and green fluorescent protein (GFP) injected into their striatum and thalamus (184). Three to five months after the injection, ASPA activity and GFP expression were elevated. MRI of injected animals showed a remarkable lack of spongiform degeneration in the thalamus, while magnetic resonance spectroscopy showed decreased N-acetoaspartate levels near the injection site. In parallel to these studies, a protocol for human gene therapy of the Canavan disease utilized the neurosurgical administration of AAV vectors containing the ASPA gene into 21 patients. These patients are currently
Copyright 2006 by Taylor & Francis Group, LLC
62
Pierson and Wolfe
being evaluated with a variety of biochemical, radiological, and neurological tests and the final results are still pending. These gene transfer studies represent the first clinical use of AAV in the human brain (12). Studies of children with Batten disease have been initiated (13). Both of these studies use AAV2 vectors, but other serotypes may be better for clinical use if they are safe. In studies on the cat brain, AAV-1 transduced a greater number of gray matter cells than AAV-2, and AAV-5 was ineffective even though it works well in the rodent brain (117,185). AAV-1 was the only serotype that also transduced white matter cells (117,185). Subsequently, cats with the lysosomal storage disease a-mannosidosis were injected with AAV-1 vectors expressing feline a-mannosidase (185). Significant improvements were noted in the animal’s neurologic signs. MRI revealed improvement in myelination and postmortem evaluation revealed reduction of storage lesions throughout the brain, even in areas relatively distant from the injection sites (185). The experiments in mammals with brains more similar in size to humans may suggest more effective strategies for clinical trials. Adenovirus Delivery Systems Adenovirus is a double-stranded DNA virus with a protein capsid that confers a specific serotype to the individual viruses. Most of the adenoviral vectors used in gene delivery are based on serotype 5 (Ad5), but Ad2, Ad4, and Ad7 are also used. Ad5 affords a greater capacity for retrograde transport in the brain than other serotypes. Adenoviral vectors are generally episomal and thus most result in fewer integration dependent alterations in cellular homeostasis or oncogenesis than vectors requiring integration for function (186,187). Adenovirus also has a large number of serotypes (>50, primarily on the basis of neutralization assays) that can infect a very diverse set of cell types (188). It has no requirement for helper virus or complex post-infectious processing (i.e., reverse transcription, etc.) (189). The first adenoviral systems had transgene capacities of 6 kb to 8 kb, but newer adenoviral vector systems (discussed further) have an increased transgene capacity of up to 25 kb to 40 kb, which is one of the largest of the viral vectors. Although these traits make adenovirus useful for experiments, adenovirus has been linked to a fatality in a human gene therapy trial. This death resulted from the patient’s aggressive immunologic response to the adenoviral vector (190–192). Because adenovirus is a common human pathogen, it is not surprising that over 55% of subjects tested express antibodies to Ad5 serotype (193,194). Ways of reducing the immunogenicity of adenovirus include the removal of most of the endogenous viral sequences from the vector. The viral proteins must then be expressed in trans by packaging cells. Capsid proteins may also be engineered to decrease their cross-reactivity with wild-type adenoviruses. A variation of adenoviral vectors called high capacity (HC) or ‘‘gutless vectors’’ can be derived in which a substantial portion of the endogenous
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
63
adenovirus genome has been deleted, with the vector only containing some small cis-acting sequences and the transgene (195). The optimal size of these vectors for stable packaging into the capsid is within 27 kb to 42 kb in length. Smaller genomes experience significant gene rearrangements. This range produces a large transgene capacity for genetic manipulation, which can accommodate additional regulatory elements within the vector genome, such as insulators or regulable promoters or multiple transgenes. If the vector is less than 27 kb, ‘‘stuffer’’ sequences of non-coding DNA sequence may be added to ensure it is large enough for packaging. Adenoviral vectors have been studied in a number of animal models (196,197). In utero intravenous injection of rats with adenovirus expressing LacZ led to widespread expression of the reporter gene (198). Transduction occurred primarily in the telencephalon and hypophysis, with expression persisting for at least one week after birth. In another study, neonatal mice with GM1 gangliosidosis were given a single intravenous injection of adenoviral vector encoding murine beta-galactosidase. After 30 days, the treatment attenuated GM1 ganglioside accumulation, and corrected mice reported 10% to 20% of normal enzyme activity in the brain (199). Intracerebral injections of adenovirus encoding the b-subunit of hexosaminidase into Sandhoff mice resulted in expression of near normal levels of hexosaminidase A and B (23). Studies with adenoviral vectors expressing GUSB in MPS VII mice have also been performed. Intravenous and intraventricular delivery of adenovirus encoding GUSB in fetal, neonatal, adult mice has led to correction of storage lesions throughout the brain (200–202). HC-adenoviral vectors have also been successfully used in the CNS to express transgenes (196,203–207). Adenoviral vectors will continue to play a significant role in future CNS gene therapy experiments, especially when large cloning capacity is required (196,205–207). Herpesvirus Delivery Systems Type I herpes simplex virus (HSV-1) is a common human pathogen with a strong tropism for neurons (208). It is a double-stranded enveloped DNA virus that exists in latent and replicating states, which have unique subsets of gene expression from latency- or replication dependent promoters. Many of these genes must be expressed for viral replication and maintenance, but are toxic to cells. These genes must be expressed from regulable promoters for vector production in packaging cell lines. The only gene actively transcribed during latency is the latency associated transcript (LAT) gene from the LAT promoter (209,210). This promoter has shown expression of transgene in vivo for extended periods of time (211). One variant of HSV-1 that is used in gene therapy experiments has a deletion in a gene associated with pathogenicity, allowing it to be injected directly into the brain at titers that would be lethal with a wild-type vector (212). Another herpesvirus vector
Copyright 2006 by Taylor & Francis Group, LLC
64
Pierson and Wolfe
system is the amplicon vector, in which many of the viral-encoded genes are removed except for cis-acting sequences required for packaging the capsid. Once these sequences are removed, vectors have a transgene capacity of 15 kb to 20 kb and form concatemers up to the 150 kb genome length of wild-type HSV-1 (213,214). This large transgene capacity is desirable when complex regulatory systems and/or multiple ORFs are needed. Another favorable quality of herpesviruses is their extensive ability to infect neurons via the axon and be transported back to the nucleus along the axonal microtubules. This makes it an attractive method for delivery of transgenes to spinal cord neurons in models of neuropathy and motor neuron disease. Examples of its use in animals include studies where HSV vectors were injected into the gastrocnemi of rats with a latencyassociated promoter upstream of b-galactosidase (215). Subsequently, b-galactosidase was expressed in anterior horn cells of the spinal cord bilaterally, with 90% of the anterior horn motor neurons having enzyme activity for up to 182 days after the injection. Other related studies used herpesviral vectors indirect intracranial injections of mice with a transgene expressing GUSB from a latency-associated promoter (216). The herpesvirus has a great deal of potential for gene delivery, but much more research is required to more fully understand the regulation of its gene expression and its infectivity. Poliovirus Delivery Systems Poliovirus is an example of a vector system that can infect neural cells, but which has limited applications due to its basic biology. Poliovirus is a nonenveloped single-stranded RNA virus and does not have a DNA form in the cell. The hallmark feature of poliovirus is its tropism for anterior horn cells (217). However, poliovirus may be a very difficult vector system to use in studies of gene therapy for several reasons. A major obstacle in using the system in humans is the almost worldwide immunity to the virus. Indeed, poliovirus may be the one virus in which the successful efforts of world health organizations for global vaccinations makes it a safety risk for use in human gene therapy. Another difficulty with poliovirus is the limited ability to use the virus in modeling studies as many animals lack the poliovirus receptor and cannot be infected. Transgenic mice expressing the poliovirus receptor are available and can be infected with the live virus (218). One of the biggest disadvantages of using poliovirus is its lack of a DNA form. This means the genome is relatively short-lived in infected cells and possible longterm correction of disease may be difficult to achieve. This may be advantageous for use in gene therapy where short-term expression may be desirable, such as tumor therapy. Replication-competent poliovirus containing RNA encoding brainderived neurotrophic factor (BDNF) were injected in intramuscularly transgenic mice expressing the human poliovirus receptor (219). At three days
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
65
post-infection, antigens of poliovirus and BDNF were detected in the motor neurons of the spinal cord; however, these antigens were no longer detectable four days later. Other studies focused on the use of poliovirus-capsid encapsulated RNA replicons in anterior horn cells or intarsia inoculation. GFP, luciferase, and murine tumor necrosis factor alpha have been expressed in the spinal cord with some success (217,220). These studies suggest that poliovirus can be used as a vector for the delivery of neurotrophic factors or deficient enzymes to motor neurons. However, the significant difficulties involved with the immunogenicity, the short-lived expression of transgenes, and a need for transgenic mouse models for infection will need to be overcome. Ex Vivo Methods in Gene Therapy Another means of delivering therapeutic enzyme to the brain is by transplanting cells genetically engineered in vitro to express or overexpress proteins capable of trans-correcting pathologic cells. This ex vivo method would provide the therapeutic proteins via secretion, as with lysosomal enzymes (122), or as cytoplasmic proteins capable of detoxifying diffusible substrates or trophic factors to maintain cells. It could also allow for endogenous neuronal cells deficient in cytoplasmic proteins to be genetically engineered to express the protein with subsequent repopulation of pathologic sites. Hematopoietic cell transplantation (HCT) uses a similar trans-corrective approach to treat patients with lysosomal or peroxisomal disorders affecting the CNS (48,221). Utilizing the migration of hematopoietic cells into the brain and subsequent differentiation of these cells into microglia as the enzyme donors has had some success alleviating these disorders (48,221). However, HCT is often not effective because too few of the cells cross the BBB and so inadequate amounts of protein reach the brain. HCT is also associated with the potentially fatal risks of graft versus host disease or infection during periods of immunocompromise. In addition, the use of relatives as donors often means that the grafts are heterozygous for the gene of interest and do not produce optimal amounts of the therapeutic protein. The goal of ex vivo gene therapy is to use stem cells derived from the affected individual and genetically engineer them to express the deficient enzyme in order to avoid many of these transplantation barriers. The use of NSCs in ex vivo protocols has the potential of being used in the treatment of neurodegenerative disease. However, this will require removing cells from the patient’s brain, engineering them in culture, and expanding them to large numbers enough for transplantation back into the brain. The most likely regions to obtain NSCs postnatally with the lowest level of surgical risk will be the cerebellum (up to two years of age) and the olfactory bulbs.
Copyright 2006 by Taylor & Francis Group, LLC
66
Pierson and Wolfe
In animal models, ex vivo manipulated neural stem cells (NSCs), neuronal progenitors, astrocytes, fibroblasts, and bone marrow stromal cells have been transplanted into the CNS and successful provided therapeutic enzymes to endogenous cells (122,222–224). A detailed discussion of neural stem cells is beyond the scope of this review, but several excellent reviews have been written discussing their properties in detail (225–230). Neural stem cells are undifferentiated cells that exist in developing and adult nervous systems that are self-renewable, while also having the potential to differentiate into many of the cell types of the CNS (227–230). When NSCs are transplanted into the CNS, they are capable of becoming integrated into the local milieu, where they can differentiate into glia or neurons depending on the site of engraftment and the local microenvironment (229). NSCs elaborate neurotrophic factors, which can aid in alleviating or repairing disease pathology (231). They can be expanded in vitro to provide significant numbers of cells for ex vivo genetic manipulation (232) and possibly large scale transplantation into large animal brains. NSCs preferentially migrate to regions of pathology and damage, which may be valuable in correcting neurogenetic diseases with focal pathology (e.g., type I glutaric aciduria) (229). They can also replace CNS cells lost in the pathogenesis of the disease with cells expressing the deficient protein, making them more resistant to the disease process (233). An important factor regulating the ability of NSCs to migrate from the graft site and disperse throughout the brain is the developmental stage of the brain at the time of transplantation. In mouse models, fetal and neonatal brains have been shown to be more amenable to widespread dispersion of NSCs than adult brains. For example, NSCs overexpressing GUSB were injected into the ventricles of newborn MPS VII mice and were subsequently found throughout the brain (225). These cells corrected disease pathology and were a source of therapeutic enzyme throughout the life of these mice. NSCs capable of expressing the a-subunit of b-hexosaminidase were also injected into the ventricles of fetal mice with similar results (234). NSCs were also used to replace lost oligodendroglia in the shiverer mouse, which has mutations in myelin basic protein that cause widespread oligodendroglia loss (235). Neonatal injections of wild-type NSCs into the ventricles of these mice resulted in widespread engraftment and a predisposition toward forming oligodendroglia, which led to a significant decrease in clinical symptomatology (233). In the adult mouse brain, the migrational properties of NSCs are much more limited. NSCs injected into the ventricles of adult mice follow a less widespread migratory pattern than in neonates with a large number of NSCs accumulating in the olfactory bulbs (236,237). NSCs expressing b-galactosidase were injected into the subventricular zone, striatum, cortex, and olfactory bulb of adult mice. Several weeks after transplantation, the cells were found near the transplant sites, but extensive migration of grafted cells was observed in the olfactory bulb only (229,238–241). The dispersion
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
67
of NSCs in the adult brain is less widespread than in the fetal and the neonatal brain and is likely to be inadequate for correction of the diffuse pathogenesis of most neurogenetic diseases in the adult brain. Mechanisms to increase the migratory potential of these cells may allow them to be more capable of widespread correction of pathogenesis in human neurogenetic disease (242,243). The studies suggest that ex vivo methods of gene therapy may be more readily used in the CNS of neonates affected by neurogenetic disease than at later ages. The predisposition of NSCs to migrate to areas of injury or tumors may make them more useful in adult brains with focal lesions. The neurogenetic disorders typically have diffuse CNS pathology, thus transplants of NSCs into the developing neonatal brain may result in better dispersion of cells for trans-correction than in adults. SUMMARY Inherited diseases of the CNS produce a wide variety of metabolic and structural lesions. Each type of disease has unique characteristics that can be exploited, or are barriers to genetic correction. There have been significant improvements in vector design over the past several years, which have been applied successfully to a number of animal models. However, human gene therapy trials have shown that there are a number of significant obstacles still to be overcome. Safety is a major concern: insertional mutagenesis by a retrovirus vector, with subsequent malignant transformation of the targeted cells, has occurred in three children receiving therapy for X-linked severe combined immunodeficiency, with one death; and a young adult patient with ornathine transcarbamylase deficiency died from an aggressive immune response to the adenovirus delivery vector. Thus, much of the current research is aimed at developing more effective means to safeguard against these and other complications of gene delivery. The safety of vector systems has been significantly improved, such as the self-inactivating retroviruses that remove viral promoter elements from the integrated provirus. However, the insertion of foreign DNA into cells still carries a risk of altering genes to deregulate normal cellular controls on growth. The use of targeted insertion of foreign DNA is commonplace in transgenic technology, but is currently too inefficient for somatic gene therapy applications. Further refinement of transgene expression driven by cell-specific promoters or inducible systems associated with transcriptional insulators may more precisely regulate production of the transferred gene and avoid inappropriate expression from mistargeted tissues. Temporary immunosuppression to block the host’s immune response until the gene transfer process is completed has been demonstrated, which may improve safety (224). Gene delivery in the brain presents additional difficulties. Although techniques to deliver genes across the BBB would obviate the need for
Copyright 2006 by Taylor & Francis Group, LLC
68
Pierson and Wolfe
surgery, the methods developed so far are either inefficient or have only resulted in transient gene delivery. For the inherited diseases, the goal is permanent correction. Many genes associated with inherited CNS disease have been discovered, isolated, and characterized, and there is increasing understanding of the mechanisms of pathogenesis at the cellular and biochemical levels. The development of accurate genotypic and phenotypic animal models has led to the development of trans-corrective strategies for certain categories of disease, which may significantly decrease the total number of cells to which the gene must be transferred to correct the disease process. The size of the human brain compared to rodents makes translation much more difficult than in other organ systems and is particularly important in genetic diseases due to the global distribution of the lesions. The first study demonstrating that gene transfer into the brain could be effective in ameliorating clinical neurological signs in a large animal model of a human genetic CNS disease was published only recently (185). The potential for transferring normal copies of genes into defective cells to effect permanent correction was recognized when the first gene was cloned. Much like the ideas of organ or tissue transplantation, gene therapy will develop over time to deliver on its promise. This development must occur with caution to better predict potential obstacles, but gene therapy is likely to be at least partially effective in the CNS for some diseases. This will require special approaches and methods because of the inherent complexity of the brain, as well as its relative isolation from the rest of the body, but advances in animal models have demonstrated in principle that this goal in all likelihood will be accomplished.
ACKNOWLEDGMENTS We thank Drs. M. Romanko and R. Walton for excellent review of the manuscript. The work in J.H.W.’s laboratory is supported by NIH grants DK42707, DK46637, DK47757, DK63973, NS29390, and NS38690; T.M.P. is supported by a training grant from the National Institute of Child Health and Development (HD43021). REFERENCES 1. Trask TW, Trask RP, Aguilar-Cordova E, Shine HD, Wyde PR, Goodman JC, Hamilton WJ, Rojas-Martinez A, Chen SH, Woo SL, Grossman RG. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. Mol Ther 2000; 1:195–203. 2. Eck SL, Alavi JB, Alavi A, Davis A, Hackney D, Judy K, Mollman J, Phillips PC, Wheeldon EB, Wilson JM. Treatment of advanced CNS malignancies
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
69
with the recombinant adenovirus H5.010RSVTK: a phase I trial. Hum Gene Ther 1996; 7:1465–1482. Eck SL, Alavi JB, Judy K, Phillips P, Alavi A, Hackney D, Cross P, Hughes J, Gao G, Wilson JM, Propert K. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. Hum Gene Ther 2001; 12:97–113. Harsh GR, Deisboeck TS, Louis DN, Hilton J, Colvin M, Silver JS, Qureshi NH, Kracher J, Finkelstein D, Chiocca EA, Hochberg FH. Thymidine kinase activation of ganciclovir in recurrent malignant gliomas: a gene-marking and neuropathological study. J Neurosurg 2000; 92:804–811. Kim JH, Kim SH, Kolozsvary A, Brown SL, Kim OB, Freytag SO. Selective enhancement of radiation response of herpes simplex virus thymidine kinase transduced 9L gliosarcoma cells in vitro and in vivo by antiviral agents. Int J Radiat Oncol Biol Phys 1995; 33:861–868. Okada H, Pollack IF, Lotze MT, Lunsford LD, Kondziolka D, Lieberman F, Schiff D, Attanucci J, Edington H, Chambers W, Robbins P, Baar J, Kinzler D, Whiteside T, Elder E. Gene therapy of malignant gliomas: a phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response. Hum Gene Ther 2000; 11:637–653. Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 2000; 7:867–874. Ridet JL, Deglon N, Aebischer P. Gene transfer techniques for the delivery of GDNF in Parkinson’s disease. Novartis Found Symp 2000; 231:202–215; Discussion 215–209, 302–206. Aebischer P, Pochon NA, Heyd B, Deglon N, Joseph JM, Zurn AD, Baetge EE, Hammang JP, Goddard M, Lysaght M, Kaplan F, Kato AC, Schluep M, Hirt L, Regli F, Porchet F, De Tribolet N. Gene therapy for amyotrophic lateral sclerosis (ALS) using a polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum Gene Ther 1996; 7:851–860. Aebischer P, Schluep M, Deglon N, Joseph JM, Hirt L, Heyd B, Goddard M, Hammang JP, Zurn AD, Kato AC, Regli F, Baetge EE. Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996; 2:696–699. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, Remy P, Goddard M, Lefaucheur JP, Brugieres P, Baudic S, Cesaro P, Peschanski M, Aebischer P. Neuroprotective gene therapy for Huntington’s disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000; 11:1723–1729. Janson C, McPhee S, Bilaniuk L, Haselgrove J, Testaiuti M, Freese A, Wang DJ, Shera D, Hurh P, Rupin J, Saslow E, Goldfarb O, Goldberg M, Larijani G, Sharrar W, Liouterman L, Camp A, Kolodny E, Samulski J, Leone P. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002; 13:1391–1412.
Copyright 2006 by Taylor & Francis Group, LLC
70
Pierson and Wolfe
13. Crystal RG, Sondhi D, Hackett NR, Kaminsky SM, Worgall S, Stieg P, Souweidane M, Hosain S, Heier L, Ballon D, Dinner M, Wisniewski K, Kaplitt M, Greenwald BM, Howell JD, Strybing K, Dyke J, Voss H. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis. Hum Gene Ther 2004; 15:1131–1154. 14. Schlachetzki F, Zhang Y, Boado RJ, Pardridge WM. Gene therapy of the brain: the trans-vascular approach. Neurology 2004; 62:1275–1281. 15. Huwyler J, Drewe J, Klusemann C, Fricker G. Evidence for P-glycoproteinmodulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br J Pharmacol 1996; 118:1879–1885. 16. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93:14,164–14,169. 17. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci USA 2000; 97:7567–7572. 18. Alberts DS, Muggia FM, Carmichael J, Winer EP, Jahanzeb M, Venook AP, Skubitz KM, Rivera E, Sparano JA, Dibella NJ, Stewart SJ, Kavanagh JJ, Gabizon AA. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials. Semin Oncol 2004; 31:53–90. 19. Saunders NR, Habgood MD, Dziegielewska KM. Barrier mechanisms in the brain, II. Immature brain. Clin Exp Pharmacol Physiol 1999; 26:85–91. 20. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD, Fuller M, Christensen E, Skovby F, Hopwood JJ. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics 2004; 114:909–916. 21. Meikle PJ, Fietz MJ, Hopwood JJ. Diagnosis of lysosomal storage disorders: current techniques and future directions. Expert Rev Mol Diagn 2004; 4:677–691. 22. Passini MA, Lee EB, Heuer GG, Wolfe JH. Distribution of a lysosomal enzyme in the adult brain by axonal transport and by cells of the rostral migratory stream. J Neurosci 2002; 22:6437–6446. 23. Bourgoin C, Emiliani C, Kremer EJ, Gelot A, Tancini B, Gravel RA, Drugan C, Orlacchio A, Poenaru L, Caillaud C. Widespread distribution of betahexosaminidase activity in the brain of a Sandhoff mouse model after coinjection of adenoviral vector and mannitol. Gene Ther 2003; 10:1841–1849. 24. Tenenbaum L, Chtarto A, Lehtonen E, Velu T, Brotchi J, Levivier M. Recombinant AAV-mediated gene delivery to the central nervous system. J Gene Med 2004; 6(Suppl 1):S212–222. 25. Dahlstrand J, Lardelli M, Lendahl U. Nestin mRNA expression correlates with the central nervous system progenitor cell state in many, but not all, regions of developing central nervous system. Brain Res Dev Brain Res 1995; 84:109–129. 26. Cheng L, Jin Z, Liu L, Yan Y, Li T, Zhu X, Jing N. Characterization and promoter analysis of the mouse nestin gene. FEBS Lett 2004; 565:195–202. 27. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 1985; 8: 203– 214.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
71
28. Zhuo L, Sun B, Zhang CL, Fine A, Chiu SY, Messing A. Live astrocytes visualized by green fluorescent protein in transgenic mice. Dev Biol 1997; 187:36–42. 29. Klein RL, Meyer EM, Peel AL, Zolotukhin S, Meyers C, Muzyczka N, King MA. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998; 150:183–194. 30. Deloulme JC, Lucas M, Gaber C, Bouillon P, Keller A, Eclancher F, Sensenbrenner M. Expression of the neuron-specific enolase gene by rat oligodendroglial cells during their differentiation. J Neurochem 1996; 66:936–945. 31. Lohler J. Immunopathological reactions in viral infections of the central nervous system. J Neuroimmunol 1988; 20:181–188. 32. Evans CF, Redwine JM, Patterson CE, Askovic S, Rall GF. LCMV and the central nervous system: uncovering basic principles of CNS physiology and virus-induced disease. Curr Top Microbiol Immunol 2002; 263:177–195. 33. Taylor RM, Wolfe JH. Cross-correction of beta-glucuronidase deficiency by retroviral vector-mediated gene transfer. Exp Cell Res 1994; 214:606–613. 34. Cartier N. Gene therapy strategies for X-linked adrenoleukodystrophy. Curr Opin Mol Ther 2001; 3:357–361. 35. Inoue K. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics 2005; 6:1–16. 36. van der Knaap MS, Leegwater PA, Konst AA, Visser A, Naidu S, Oudejans CB, Schutgens RB, Pronk JC. Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. Ann Neurol 2002; 51:264–270. 37. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283:689–692. 38. Ponka P. Hereditary causes of disturbed iron homeostasis in the central nervous system. Ann NY Acad Sci 2004; 1012:267–281. 39. Ding H, Schwarz DS, Keene A, Affar el B, Fenton L, Xia X, Shi Y, Zamore PD, Xu Z. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis. Aging Cell 2003; 2:209–217. 40. Davidson BL, Paulson HL. Molecular medicine for the brain: silencing of disease genes with RNA interference. Lancet Neurol 2004; 3:145–149. 41. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431:371–378. 42. Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci USA 2004; 101:847–852. 43. Naismith TV, Heuser JE, Breakefield XO, Hanson PI. TorsinA in the nuclear envelope. Proc Natl Acad Sci USA 2004; 101:7612–7617. 44. Cummings CJ, Zoghbi HY. Fourteen and counting: unraveling trinucleotide repeat diseases. Hum Mol Genet 2000; 9:909–916. 45. Schonberger S, Schweiger B, Schwahn B, Schwarz M, Wendel U. Dysmyelination in the brain of adolescents and young adults with maple syrup urine disease. Mol Genet Metab 2004; 82:69–75. 46. Wendel U, Saudubray JM, Bodner A, Schadewaldt P. Liver transplantation in maple syrup urine disease. Eur J Pediatr 1999; 158(Suppl 2):S60–64.
Copyright 2006 by Taylor & Francis Group, LLC
72
Pierson and Wolfe
47. Shapiro E, Krivit W, Lockman L, Jambaque I, Peters C, Cowan M, Harris R, Blanche S, Bordigoni P, Loes D, Ziegler R, Crittenden M, Ris D, Berg B, Cox C, Moser H, Fischer A, Aubourg P. Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. Lancet 2000; 356:713–718. 48. Peters C, Steward CG. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant 2003; 31:229–239. 49. Moser HW. Neurometabolic disease. Curr Opin Neurol 1998; 11:91–95. 50. Schiffmann R, van der Knaap MS. The latest on leukodystrophies. Curr Opin Neurol 2004; 17:187–192. 51. Wills AJ, Manning NJ, Reilly MM. Refsum’s disease. Qjm 2001; 94:403–406. 52. Hoffmann GF, Zschocke J. Glutaric aciduria type I: from clinical, biochemical and molecular diversity to successful therapy. J Inherit Metab Dis 1999; 22:381–391. 53. Kolker S, Hoffmann GF. Adult onset glutaric aciduria type I presenting with a leukoencephalopathy. Neurology 2003; 60:1399(author reply 1399). 54. Beck M, Ricci R, Widmer U, Dehout F, de Lorenzo AG, Kampmann C, Linhart A, Sunder-Plassmann G, Houge G, Ramaswami U, Gal A, Mehta A. Fabry disease:overall effects of agalsidase alfa treatment. Eur J Clin Invest 2004; 34:838–844. 55. Desnick RJ. Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 2004; 27:385–410. 56. Hilz MJ, Brys M, Marthol H, Stemper B, Dutsch M. Enzyme replacement therapy improves function of C-, Adelta-, Abeta-nerve fibers in Fabry neuropathy. Neurology 2004; 62:1066–1072. 57. Barton NW, Brady RO, et al. Replacement therapy for inherited enzyme deficiency—macrophage-targeted glucocerebrosidase for Gaucher’s disease. N Engl J Med 1991; 324:1464–1470. 58. MacKenzie JJ, Amato D, Clarke JT. Enzyme replacement therapy for Gaucher’s disease: the early Canadian experience. Cmaj 1998; 159:1273–1278. 59. Ellinwood NM, Vite CH, Haskins ME. Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 2004; 6:481–506. 60. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA 1999; 281:249–254. 61. Dionisi-Vici C, Rizzo C, Burlina AB, Caruso U, Sabetta G, Uziel G, Abeni D. Inborn errors of metabolism in the Italian pediatric population: a national retrospective survey. J Pediatr 2002; 140:321–327. 62. Devereux G, Stellitano L, Verity CM, Nicoll A, Will RG, Rogers P. Variations in neurodegenerative disease across the UK: findings from the national study of Progressive Intellectual and Neurological Deterioration (PIND). Arch Dis Child 2004; 89:8–12. 63. Bosch A, Heard JM. Gene therapy for mucopolysaccharidosis. Int Rev Neurobiol 2003; 55:271–296. 64. Ozkara HA. Recent advances in the biochemistry and genetics of sphingolipidoses. Brain Dev 2004; 26:497–505.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
73
65. Mach L. Biosynthesis of lysosomal proteinases in health and disease. Biol Chem 2002; 383:751–756. 66. Santavuori P, Lauronen L, Kirveskari K, Aberg L, Sainio K. Neuronal ceroid lipofuscinoses in childhood. Suppl Clin Neurophysiol 2000; 53:443–451. 67. Mole SE. The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol 2004; 14:70–76. 68. Suzuki K. The twitcher mouse: a model for Krabbe disease and for experimental therapies. Brain Pathol 1995; 5:249–258. 69. Wenger DA, Rafi MA, Luzi P. Molecular genetics of Krabbe disease (globoid cell leukodystrophy): diagnostic and clinical implications. Hum Mutat 1997; 10:268–279. 70. Luzi P, Rafi MA, Zaka M, Curtis M, Vanier MT, Wenger DA. Generation of a mouse with low galactocerebrosidase activity by gene targeting: a new model of globoid cell leukodystrophy (Krabbe disease). Mol Genet Metab 2001; 73:211–223. 71. Yamamoto T, Nanba E, Zhang H, Sasaki M, Komaki H, Takeshita K. Jimpy(msd) mouse mutation and connatal Pelizaeus-Merzbacher disease. Am J Med Genet 1998; 75:439–440. 72. Karthigasan J, Evans EL, Vouyiouklis DA, Inouye H, Borenshteyn N, Ramamurthy GV, Kirschner DA. Effects of rumpshaker mutation on CNS myelin composition and structure. J Neurochem 1996; 66:338–345. 73. Bhaumik M, Muller VJ, Rozaklis T, Johnson L, Dobrenis K, Bhattacharyya R, Wurzelmann S, Finamore P, Hopwood JJ, Walkley SU, Stanley P. A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology 1999; 9:1389–1396. 74. Birkenmeier EH, Davisson MT, Beamer WG, Ganschow RE, Vogler CA, Gwynn B, Lyford KA, Maltais LM, Wawrzyniak CJ. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989; 83:1258–1266. 75. Boison D, Stoffel W. Myelin-deficient rat: a point mutation in exon III (A—C, Thr75—Pro) of the myelin proteolipid protein causes dysmyelination and oligodendrocyte death. EMBO J 1989; 8:3295–3302. 76. Kunieda T, Simonaro CM, Yoshida M, Ikadai H, Levan G, Desnick RJ, Schuchman EH. Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, identification of the mutation. Genomics 1995; 29:582–587. 77. Nakagawa H, Matsubara S, Kuriyama M, Yoshidome H, Fujiyama J, Yoshida H, Osame M. Cloning of rat lysosomal acid lipase cDNA and identification of the mutation in the rat model of Wolman’s disease. J Lipid Res 1995; 36:2212–2218. 78. Hess B, Saftig P, Hartmann D, Coenen R, Lullmann-Rauch R, Goebel HH, Evers M, von Figura K, D’Hooge R, Nagels G, De Deyn P, Peters C, Gieselmann V. Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc Natl Acad Sci USA 1996; 93: 14821–14826. 79. Yamanaka S, Johnson MD, Grinberg A, Westphal H, Crawley JN, Taniike M, Suzuki K, Proia RL. Targeted disruption of the Hexa gene results in mice
Copyright 2006 by Taylor & Francis Group, LLC
74
80.
81.
82.
83.
84.
85.
86. 87.
88.
89. 90. 91. 92.
93.
Pierson and Wolfe with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci USA 1994; 91:9975–9979. Sango K, Yamanaka S, et al. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat Genet 1995; 11:170–176. Phaneuf D, Wakamatsu N, Huang JQ, Borowski A, Peterson AC, Fortunato SR, Ritter G, Igdoura SA, Morales CR, Benoit G, Akerman BR, Leclerc D, Hanai N, Marth JD, Trasler JM, Gravel RA. Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases. Hum Mol Genet 1996; 5: 1–14. Reaume AG, Elliott JL, Hoffman EK, Kowall NW, Ferrante RJ, Siwek DF, Wilcox HM, Flood DG, Beal MF, Brown RH, Jr. Scott, RW Snider, WD. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13:43–47. Stinchi S, Lullmann-Rauch R, Hartmann D, Coenen R, Beccari T, Orlacchio A, von Figura K, Saftig P. Targeted disruption of the lysosomal alpha-mannosidase gene results in mice resembling a mild form of human alpha-mannosidosis. Hum Mol Genet 1999; 8:1365–1372. Clarke LA, Russell CS, Pownall S, Warrington CL, Borowski A, Dimmick JE, Toone J, Jirik FR. Murine mucopolysaccharidosis type I: targeted disruption of the murine alpha-L-iduronidase gene. Hum Mol Genet 1997; 6:503–511. Ripps ME, Huntley GW, Hof PR, Morrison JH, Gordon JW. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 1995; 92: 689–693. Sidransky E, Ginns EI. Gaucher’s disease: the best laid schemes of mice and men. Baillieres Clin Haematol 1997; 10:725–737. Cohen-Tannoudji M, Marchand P, et al. Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mamm Genome 1995; 6:844–849. Wu CL, Melton DW. Production of a model for Lesch-Nyhan syndrome in hypoxanthine phosphoribosyltransferase-deficient mice. Nat Genet 1993; 3:235–240. Wong PC, Borchelt DR. Motor neuron disease caused by mutations in superoxide dismutase 1. Curr Opin Neurol 1995; 8:294–301. Gurney ME, Pu H, et al. Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994; 264:1772–1775. Gurney ME. Transgenic-mouse model of amyotrophic lateral sclerosis. N Engl J Med 1994; 331:1721–1722. Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, Kakizuka A. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 1996; 13:196–202. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87:493–506.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
75
94. Bingham PM, Scott MO, Wang S, McPhaul MJ, Wilson EM, Garbern JY, Merry DE, Fischbeck KH. Stability of an expanded trinucleotide repeat in the androgen receptor gene in transgenic mice. Nat Genet 1995; 9:191–196. 95. Haskins ME, Aguirre GD, Jezyk PF, Desnick RJ, Patterson DF. The pathology of the feline model of mucopolysaccharidosis I. Am J Pathol 1983; 112:27–36. 96. Shull RM, Helman RG, Spellacy E, Constantopoulos G, Munger RJ, Neufeld EF. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am J Pathol 1984; 114:487–495. 97. Baker HJ Jr, Lindsey JR McKhann GM, Farrell DF. Neuronal GM1 gangliosidosis in a Siamese cat with beta-galactosidase deficiency. Science 1971; 174:838–839. 98. Yamato O, Masuoka Y, Yonemura M, Hatakeyama A, Satoh H, Kobayashi A, Nakayama M, Asano T, Shoda T, Yamasaki M, Ochiai K, Umemura T, Maede Y. Clinical and clinico-pathologic characteristics of Shiba dogs with a deficiency of lysosomal acid beta-galactosidase: a canine model of human GM1 gangliosidosis. J Vet Med Sci 2003; 65:213–217. 99. Fyfe JC, Kurzhals RL, Lassaline ME, Henthorn PS, Alur PR, Wang P, Wolfe JH, Giger U, Haskins ME, Patterson DF, Sun H, Jain S, Yuhki N. Molecular basis of feline beta-glucuronidase deficiency: an animal model of mucopolysaccharidosis VII. Genomics 1999; 58:121–128. 100. Haskins ME, Desnick RJ, DiFerrante N, Jezyk PF, Patterson DF. Betaglucuronidase deficiency in a dog: a model of human mucopolysaccharidosis VII. Pediatr Res 1984; 18:980–984. 101. Jezyk PF, Haskins ME, Newman LR. Alpha-mannosidosis in a Persian cat. J Am Vet Med Assoc 1986; 189:1483–1485. 102. Vine DT, McGovern MM, Haskins ME, Desnick RJ. Feline mucopolysaccharidosis VI: purification and characterization of the resident arylsulfatase B activity. Am J Hum Genet 1981; 33:916–927. 103. Rattazzi MC, Lanse SB, McCullough RA, Nester JA, Jacobs EA. Towards enzyme replacement in GM2 gangliosidosis: organ disposition and induced central nervous system uptake of human beta-hexosaminidase in the cat. Birth Defects Orig Artic Ser 1980; 16:179–193. 104. Yogalingam G, Pollard T, Gliddon B, Jolly RD, Hopwood JJ. Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs. Genomics 2002; 79:150–153. 105. Victoria T, Rafi MA, Wenger DA. Cloning of the canine GALC cDNA and identification of the mutation causing globoid cell leukodystrophy in West Highland White and Cairn terriers. Genomics 1996; 33:457–462. 106. Koppang N. English setter model and juvenile ceroid-lipofuscinosis in man. Am J Med Genet 1992; 42:599–604. 107. Lingaas F, Aarskaug T, Sletten M, Bjerkas I, Grimholt U, Moe L, Juneja RK, Wilton AN, Galibert F, Holmes NG, Dolf G. Genetic markers linked to neuronal ceroid lipofuscinosis in English setter dogs. Anim Genet 1998; 29: 371–376. 108. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98:365–376.
Copyright 2006 by Taylor & Francis Group, LLC
76
Pierson and Wolfe
109. Lohi H, Young EJ, Fitzmaurice SN, Rusbridge C, Chan EM, Vervoort M, Turnbull J, Zhao XC, Ianzano L, Paterson AD, Sutter NB, Ostrander EA, Andre C, Shelton GD, Ackerley CA, Scherer SW, Minassian BA. Expanded repeat in canine epilepsy. Science 2005; 307:81. 110. Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, biochemical features of a new mucopolysaccharidosis. J Pediatr 1973; 82:249–257. 111. Wolfe JH, Schuchman EH, Stramm LE, Concaugh EA, Haskins ME, Aguirre GD, Patterson DF, Desnick RJ, Gilboa E. Restoration of normal lysosomal function in mucopolysaccharidosis type VII cells by retroviral vector-mediated gene transfer. Proc Natl Acad Sci USA 1990; 87:2877–2881. 112. Stramm LE, Wolfe JH, Schuchman EH, Haskins ME, Patterson DF, Aguirre GD. Beta-glucuronidase mediated pathway essential for retinal pigment epithelial degradation of glycosaminoglycans. Disease expression and in vitro disease correction using retroviral mediated cDNA transfer. Exp Eye Res 1990; 50:521–532. 113. Sands MS, Wolfe JH, Birkenmeier EH, Barker JE, Vogler C, Sly WS, Okuyama T, Freeman B, Nicholes A, Muzyczka N, Chang PL, Axelrod HR. Gene therapy for murine mucopolysaccharidosis type VII. Neuromuscul Disord 1997; 7:352–360. 114. Watson DJ, Wolfe JH. Lentiviral vectors for gene transfer to the central nervous system. Applications in lysosomal storage disease animal models. Meth Mol Med 2003; 76:383–403. 115. Vogler C, Barker J, Sands MS, Levy B, Galvin N, Sly WS. Murine mucopolysaccharidosis VIL: impact of therapies on the phenotype, clinical course, pathology in a model of a lysosomal storage disease. Pediatr Dev Pathol 2001; 4:421–433. 116. Cheng SH, Smith AE. Gene therapy progress and prospects: gene therapy of lysosomal storage disorders. Gene Ther 2003; 10:1275–1281. 117. Vite CH, Passini MA, Haskins ME, Wolfe JH. Adeno-associated virus vectormediated transduction in the cat brain. Gene Ther 2003; 10:1874–1881. 118. Casal ML, Wolfe JH. In utero transplantation of fetal liver cells in the mucopolysaccharidosis type VII mouse results in low-level chimerism, but overexpression of beta-glucuronidase can delay onset of clinical signs. Blood 2001; 97:1625–1634. 119. Vogler C, Galvin N, Levy B, Grubb J, Jiang J, Zhou XY, Sly WS. Transgene produces massive overexpression of human beta -glucuronidase in mice, lysosomal storage of enzyme, strain-dependent tumors. Proc Natl Acad Sci USA 2003; 100:2669–2673. 120. Wolfe JH, Sands MS, Barker JE, Gwynn B, Rowe LB, Vogler CA, Birkenmeier EH. Reversal of pathology in murine mucopolysaccharidosis type VII by somatic cell gene transfer. Nature 1992; 360:749–753. 121. Wolfe JH, Sands MS, Harel N, Weil MA, Parente MK, Polesky AC, Reilly JJ, Hasson C, Weimelt S, Haskins ME. Gene transfer of low levels of betaglucuronidase corrects hepatic lysosomal storage in a large animal model of mucopolysaccharidosis VII. Mol Ther 2000; 2:552–561.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
77
122. Taylor RM, Wolfe JH. Decreased lysosomal storage in the adult MPS VII mouse brain in the vicinity of grafts of retroviral vector-corrected fibroblasts secreting high levels of beta-glucuronidase. Nat Med 1997; 3:771–774. 123. Brooks AI, Stein CS, Hughes SM Heth, J McCray PM Jr, Sauter SL, Johnston JC, Cory-Slechta DA, Federoff HJ, Davidson BL. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci USA 2002; 99:6216–6221. 124. Heuer GG, Passini MA, Jiang K, Parente MK, Lee VM, Trojanowski JQ, Wolfe JH. Selective neurodegeneration in murine mucopolysaccharidosis VII is progressive and reversible. Ann Neurol 2002; 52:762–770. 125. Consiglio A, Quattrini A, Martino S, Bensadoun JC, Dolcetta D, Trojani A, Benaglia G, Marchesini S, Cestari V, Oliverio A, Bordignon C, Naldini L. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat Med 2001; 7:310–316. 126. Hennig AK, Levy B, Ogilvie JM, Vogler CA, Galvin N, Bassnett S, Sands MS. Intravitreal gene therapy reduces lysosomal storage in specific areas of the CNS in mucopolysaccharidosis VII mice. J Neurosci 2003; 23:3302–3307. 127. Lutzko C, Kruth S, Abrams-Ogg AC, Lau K, Li L, Clark BR, Ruedy C, Nanji S, Foster R, Kohn D, Shull R, Dube ID. Genetically corrected autologous stem cells engraft, but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 1999; 93:1895–1905. 128. Moullier P, Bohl D, Cardoso J, Heard JM, Danos O. Long-term delivery of a lysosomal enzyme by genetically modified fibroblasts in dogs. Nat Med 1995; 1:353–357. 129. Hofland HE, Shephard L, Sullivan SM. Formation of stable cationic lipid/ DNA complexes for gene transfer. Proc Natl Acad Sci USA 1996; 93: 7305–7309. 130. Hong K, Zheng W, Baker A, Papahadjopoulos D. Stabilization of cationic liposome-plasmid DNA complexes by polyamines and poly(ethylene glycol)phospholipid conjugates for efficient in vivo gene delivery. FEBS Lett 1997; 400:233–237. 131. Song YK, Liu F, Chu S, Liu D. Characterization of cationic liposomemediated gene transfer in vivo by intravenous administration. Hum Gene Ther 1997; 8:1585–1594. 132. Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003; 7:11–18. 133. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci USA 2001; 98:12754–12759. 134. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003; 14:1–12.
Copyright 2006 by Taylor & Francis Group, LLC
78
Pierson and Wolfe
135. Zhang YF, Boado RJ, Pardridge WM. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 2003; 20:1779–1785. 136. Zhang Y, Zhu C, Pardridge WM. Antisense gene therapy of brain cancer with an artificial virus gene delivery system. Mol Ther 2002; 6:67–72. 137. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302:415–419. 138. Dave UP, Jenkins NA, Copeland NG. Gene therapy insertional mutagenesis insights. Science 2004; 303:333. 139. McCormack MP, Rabbitts TH. Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. N Engl J Med 2004; 350:913–922. 140. Mikkers H, Berns A. Retroviral insertional mutagenesis: tagging cancer pathways. Adv Cancer Res 2003; 88:53–99. 141. Deglon N, Hantraye P. Viral vectors as tools to model and treat neurodegenerative disorders. J Gene Med. 2005; 7:530–539. 142. Yu SF, von Ruden T, Kantoff PW, Garber C, Seiberg M, Ruther U, Anderson WF, Wagner EF, Gilboa E. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83:3194–3198. 143. Iwakuma T, Cui Y, Chang LJ. Self-inactivating lentiviral vectors with U3 and U5 modifications. Virology 1999; 261:120–132. 144. Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J Virol 2000; 74:4933–4937. 145. Beyer WR, Westphal M, Ostertag W, von Laer D. Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, broad host range. J Virol 2002; 76:1488–1495. 146. Desmaris N, Bosch A, Salaun C, Petit C, Prevost MC, Tordo N, Perrin P, Schwartz O, de Rocquigny H, Heard JM. Production and neurotropism of lentivirus vectors pseudotyped with lyssavirus envelope glycoproteins. Mol Ther 2001; 4:149–156. 147. Watson DJ, Longhi L, Lee EB, Fulp CT, Fujimoto S, Royo NC, Passini MA, Trojanowski JQ, Lee VM, McIntosh TK, Wolfe JH. Genetically modified NT2N human neuronal cells mediate long-term gene expression as CNS grafts in vivo and improve functional cognitive outcome following experimental traumatic brain injury. J Neuropathol Exp Neurol 2003; 62:368–380. 148. Schlegel R, Tralka TS, Willingham MC, Pastan I. Inhibition of VSV binding and infectivity by phosphatidylserine: is phosphatidylserine a VSV-binding site? Cell 1983; 32:639–646.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
79
149. Burns JC, Friedmann T, Driever W, Burrascano M, Yee JK. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 1993; 90:8033–8037. 150. Hacein-Bey-Abina S, Le Deist F, Carlier F, Bouneaud C, Hue C, De Villartay JP, Thrasher AJ, Wulffraat N, Sorensen R, Dupuis-Girod S, Fischer A, Davies EG, Kuis W, Leiva L, Cavazzana-Calvo M. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med 2002; 346:1185–1193. 151. Pluta K, Luce MJ, Bao L, Agha-Mohammadi S, Reiser J. Tight control of transgene expression by lentivirus vectors containing second-generation tetracycline-responsive promoters. J Gene Med 2005; 7:803–817. 152. Rivella S, Callegari JA, May C, Tan CW, Sadelain M. The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol 2000; 74:4679–4687. 153. Jakobsson J, Rosenqvist N, Thompson L, Barraud P, Lundberg C. Dynamics of transgene expression in a neural stem cell line transduced with lentiviral vectors incorporating the cHS4 insulator. Exp Cell Res 2004; 298:611–623. 154. Hock RA, Miller AD, Osborne WR. Expression of human adenosine deaminase from various strong promoters after gene transfer into human hematopoietic cell lines. Blood 1989; 74:876–881. 155. Blaese RM, Culver KW, et al. T lymphocyte-directed gene therapy for ADASCID: initial trial results after 4 years. Science 1995; 270:475–480. 156. Mullen CA, Snitzer K, Culver KW, Morgan RA, Anderson WF, Blaese RM. Molecular analysis of T lymphocyte-directed gene therapy for adenosine deaminase deficiency: long-term expression in vivo of genes introduced with a retroviral vector. Hum Gene Ther 1996; 7:1123–1129. 157. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Alleyne M, Brown M, Bernstein W, Schurman SH, Fleisher TA, Leitman SF, Dunbar CE, Blaese RM, Candotti F. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. Blood 2003; 101:2563–2569. 158. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990; 10:4239–4242. 159. D’Costa J, Harvey-White J, Qasba P, Limaye A, Kaneski CR, Davis-Warren A, Brady RO, Bankiewicz KS, Major EO, Arya SK. HIV-2 derived lentiviral vectors: gene transfer in Parkinson’s and Fabry disease models in vitro. J Med Virol 2003; 71:173–182. 160. Haskell RE, Hughes SM, Chiorini JA, Alisky JM, Davidson BL. Viralmediated delivery of the late-infantile neuronal ceroid lipofuscinosis gene, TPP-I to the mouse central nervous system. Gene Ther 2003; 10:34–42. 161. Waddington SN, Mitrophanous KA, Ellard FM, Buckley SM, Nivsarkar M, Lawrence L, Cook HT, Al-Allaf F, Bigger B, Kingsman SM, Coutelle C, Themis M. Long-term transgene expression by administration of a lentivirus-
Copyright 2006 by Taylor & Francis Group, LLC
80
162.
163.
164.
165.
166.
167.
168. 169.
170.
171.
172.
173.
174.
Pierson and Wolfe based vector to the fetal circulation of immuno-competent mice. Gene Ther 2003; 10:1234–1240. Stitz J, Muhlebach MD, Blomer U, Scherr M, Selbert M, Wehner P, Steidl S, Schmitt I, Konig R, Schweizer M, Cichutek K. A novel lentivirus vector derived from apathogenic simian immunodeficiency virus. Virology 2001; 291:191–197. Watson DJ, Kobinger GP, Passini MA, Wilson JM, Wolfe JH. Targeted transduction patterns in the mouse brain by lentivirus vectors pseudotyped with VSV, Ebola, Mokola, LCMV, or MuLV envelope proteins. Mol Ther 2002; 5:528–537. Wong LF, Azzouz M, Walmsley LE, Askham Z, Wilkes FJ, Mitrophanous KA, Kingsman SM, Mazarakis ND. Transduction patterns of pseudotyped lentiviral vectors in the nervous system. Mol Ther 2004; 9:101–111. Jakobsson J, Ericson C, Jansson M, Bjork E, Lundberg C. Targeted transgene expression in rat brain using lentiviral vectors. J Neurosci Res 2003; 73: 876–885. Bosch A, Perret E, Desmaris N, Trono D, Heard JM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirusmediated gene transfer. Hum Gene Ther 2000; 11:1139–1150. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, Kingsman SM, Carmeliet P, Mazarakis ND. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004; 429:413–417. Haberman RP, McCown TJ. Regulation of gene expression in adenoassociated virus vectors in the brain. Methods 2002; 28:219–226. Duan D, Sharma P, Dudus L, Zhang Y, Sanlioglu S, Yan Z, Yue Y, Ye Y, Lester R, Yang J, Fisher KJ, Engelhardt JF. Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J Virol 1999; 73:161–169. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73:9468–9477. Burger C, Gorbatyuk OS, Velardo MJ, Peden CS, Williams P, Zolotukhin S, Reier PJ, Mandel RJ, Muzyczka N. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004; 10:302–317. Shevtsova Z, Malik JM, Michel U, Bahr M, Kugler S. Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo. Exp Physiol 2005; 90:53–59. Passini MA, Wolfe JH. Widespread gene delivery and structure-specific patterns of expression in the brain after intraventricular injections of neonatal mice with an adeno-associated virus vector. J Virol 2001; 75:12382–12392. Passini MA, Watson DJ, Vite CH, Landsburg DJ, Feigenbaum AL, Wolfe JH. Intraventricular brain injection of adeno-associated virus type 1 (AAV1) in neonatal mice results in complementary patterns of neuronal transduction to AAV2 and total long-term correction of storage lesions in the brains of beta-glucuronidase-deficient mice. J Virol 2003; 77:7034–7040.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
81
175. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA. Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000; 97:3428–3432. 176. Watson DJ, Passini MA, Wolfe JH. Transduction of the choroid plexus and ependyma in neonatal mouse brain by vesicular stomatitis virus glycoprotein-pseudotyped lentivirus and adeno-associated virus type 5 vectors. Hum Gene Ther 2005; 16:49–56. 177. Okada T, Nomoto T, Shimazaki K, Lijun W, Lu Y, Matsushita T, Mizukami H, Urabe M, Hanazono Y, Kume A, Muramatsu S, Nakano I, Ozawa K. Adenoassociated virus vectors for gene transfer to the brain. Methods 2002; 28:237–247. 178. Skorupa AF, Fisher KJ, Wilson JM, Parente MK, Wolfe JH. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 1999; 160:17–27. 179. Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000; 1:63–70. 180. Sferra TJ, Qu G, McNeely D, Rennard R, Clark KR, Lo WD, Johnson PR. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther 2000; 11:507–519. 181. Elliger SS, Elliger CA, Lang C, Watson GL. Enhanced secretion and uptake of beta-glucuronidase improves adeno-associated viral-mediated gene therapy of mucopolysaccharidosis type VII mice. Mol Ther 2002; 5:617–626. 182. Fu H, Samulski RJ, McCown TJ, Picornell YJ, Fletcher D, Muenzer J. Neurological correction of lysosomal storage in a mucopolysaccharidosis IIIB mouse model by adeno-associated virus-mediated gene delivery. Mol Ther 2002; 5:42–49. 183. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003; 301:839–842. 184. Matalon R, Surendran S, Rady PL, Quast MJ, Campbell GA, Matalon KM, Tyring SK, Wei J, Peden CS, Ezell EL, Muzyczka N, Mandel RJ. Adenoassociated virus-mediated aspartoacylase gene transfer to the brain of knockout mouse for canavan disease. Mol Ther 2003; 7:580–587. 185. Vite CH, McGowan JC, Niogi SN, Passini MA, Drobatz KJ, Haskins ME, Wolfe JH. Effective gene therapy for an inherited CNS disease in a large animal model. Ann Neurol 2005; 57:355–364. 186. Volpers C, Kochanek S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004; 6(suppl 1):S164–171. 187. Imperiale MJ, Kochanek S. Adenovirus vectors: biology, design, and production. Curr Top Microbiol Immunol 2004; 273:335–357. 188. Barnett BG, Crews CJ, Douglas JT. Targeted adenoviral vectors. Biochem Biophys Acta 2002; 1575:1–14.
Copyright 2006 by Taylor & Francis Group, LLC
82
Pierson and Wolfe
189. Douglas JT. Adenovirus-mediated gene delivery: an overview. Meth Mol Biol 2004; 246:3–14. 190. Jenks S. Gene therapy death—‘‘everyone has to share in the guilt.’’ J Natl Cancer Inst 2000; 92:98–100. 191. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, Furth EE, Propert KJ, Robinson MB, Magosin S, Simoes H, Speicher L, Hughes J, Tazelaar J, Wivel NA, Wilson JM, Batshaw ML. A pilot study of in vivo liver-directed gene transfer with an adenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13:163–175. 192. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, Wilson JM, Batshaw ML. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80:148–158. 193. Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999; 6:1574–1583. 194. Jooss K, Chirmule N. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther 2003; 10:955–963. 195. Schiedner G, Morral N, Parks RJ, Wu Y, Koopmans SC, Langston C, Graham FL, Beaudet AL, Kochanek S. Genomic DNA transfer with a highcapacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet 1998; 18:180–183. 196. Barkats M, Bilang-Bleuel A, Buc-Caron MH, Castel-Barthe MN, Corti O, Finiels F, Horellou P, Revah F, Sabate O, Mallet J. Adenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases. Prog Neurobiol 1998; 55:333–341. 197. Eto Y, Shen JS, Meng XL, Ohashi T. Treatment of lysosomal storage disorders: cell therapy and gene therapy. J Inherit Metab Dis 2004; 27:411–415. 198. Shen JS, Meng XL, Ohashi T, Eto Y. Adenovirus-mediated prenatal gene transfer to murine central nervous system. Gene Ther 2002; 9:819–823. 199. Takaura N, Yagi T, Maeda M, Nanba E, Oshima A, Suzuki Y, Yamano T, Tanaka A. Attenuation of ganglioside GM1 accumulation in the brain of GM1 gangliosidosis mice by neonatal intravenous gene transfer. Gene Ther 2003; 10:1487–1493. 200. Kamata Y, Tanabe A, Kanaji A, Kosuga M, Fukuhara Y, Li XK, Suzuki S, Yamada M, Azuma N, Okuyama T. Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adenovirus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther 2003; 10:406–414. 201. Ghodsi A, Stein C, Derksen T, Yang G, Anderson RD, Davidson BL. Extensive beta-glucuronidase activity in murine central nervous system after adenovirusmediated gene transfer to brain. Hum Gene Ther 1998; 9:2331–2340. 202. Shen JS, Meng XL, Maeda H, Ohashi T, Eto Y. Widespread gene transduction to the central nervous system by adenovirus in utero: implication for prenatal gene therapy to brain involvement of lysosomal storage disease. J Gene Med 2004; 6:1206–1215.
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
83
203. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Preexisting antiadenoviral immunity is not a barrier to efficient and stable transduction of the brain, mediated by novel high-capacity adenovirus vectors. Hum Gene Ther 2001; 12:839–846. 204. Thomas CE, Schiedner G, Kochanek S, Castro MG, Lowenstein PR. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with highcapacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000; 97:7482–7487. 205. Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet 1993; 3:224–228. 206. Davidson BL, Allen ED, Kozarsky KF, Wilson JM, Roessler BJ. A model system for in vivo gene transfer into the central nervous system using an adenoviral vector. Nat Genet 1993; 3:219–223. 207. Bajocchi G, Feldman SH, Crystal RG, Mastrangeli A. Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat Genet 1993; 3:229–234. 208. Jacobs A, Breakefield XO, Fraefel C. HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications. Neoplasia 1999; 1:402–416. 209. Mitchell WJ, Steiner I, Brown SM, MacLean AR, Subak-Sharpe JH, Fraser NW. A herpes simplex virus type 1 variant, deleted in the promoter region of the latency-associated transcripts, does not produce any detectable minor RNA species during latency in the mouse trigeminal ganglion. J Gen Virol 1990; 71(Pt 4):953–957. 210. Naito J, Mukerjee R, Mott KR, Kang W, Osorio N, Fraser NW, Perng GC. Identification of a protein encoded in the herpes simplex virus type 1 latency associated transcript promoter region. Virus Res 2005; 108:101–110. 211. Wolfe JH, Deshmane SL, Fraser NW. Herpesvirus vector gene transfer and expression of beta-glucuronidase in the central nervous system of MPS VII mice. Nat Genet 1992; 1:379–384. 212. Wolfe JH, Martin CE, Deshmane SL, Reilly JJ, Kesari S, Fraser NW. Increased susceptibility to the pathogenic effects of wild-type and recombinant herpesviruses in MPS VII mice compared to normal siblings. J Neurovirol 1996; 2:417–422. 213. Wade-Martins R, Smith ER, Tyminski E, Chiocca EA, Saeki Y. An infectious transfer and expression system for genomic DNA loci in human and mouse cells. Nat Biotechnol 2001; 19:1067–1070. 214. Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001; 3:591–601. 215. Yamamura J, Kageyama S, Uwano T, Kurokawa M, Imakita M, Shiraki K. Long-term gene expression in the anterior horn motor neurons after intramuscular inoculation of a live herpes simplex virus vector. Gene Ther 2000; 7:934–941.
Copyright 2006 by Taylor & Francis Group, LLC
84
Pierson and Wolfe
216. Zhu J, Kang W, Wolfe JH, Fraser NW. Significantly increased expression of beta-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector. Mol Ther 2000; 2:82–94. 217. Bledsoe AW, Jackson CA, McPherson S, Morrow CD. Cytokine production in motor neurons by poliovirus replicon vector gene delivery. Nat Biotechnol 2000; 18:964–969. 218. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H, Nomoto A. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA 1991; 88:951–955. 219. Jia Q, Liang F, Ohka S, Nomoto A, Hashikawa T. Expression of brainderived neurotrophic factor in the central nervous system of mice using a poliovirus-based vector. J Neurovirol 2002; 8:14–23. 220. Jackson CA, Messinger J, Palmer MT, Peduzzi JD, Morrow CD. Gene expression in the muscle and central nervous system following intramuscular inoculation of encapsidated or naked poliovirus replicons. Virology 2003; 314: 45–61. 221. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr 2002; 49:359–378. 222. Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 1995; 374:367–370. 223. Ridet JL, Sarkis C, Serguera C, Zennou V, Charneau P, Mallet J. Transplantation of human adult astrocytes: efficiency and safety requirements for an autologous gene therapy. J Neurosci Res 2003; 72:704–708. 224. Jin HK, Schuchman EH. Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol Ther 2003; 8:876–885. 225. Snyder EY, Macklis JD. Multipotent neural progenitor or stem-like cells may be uniquely suited for therapy for some neurodegenerative conditions. Clin Neurosci 1995; 3:310–316. 226. Snyder EY, Wolfe JH. Central nervous system cell transplantation: a novel therapy for storage diseases? Curr Opin Neurol 1996; 9:126–136. 227. Fischer A. Primary immunodeficiency diseases: natural mutant models for the study of the immune system. Scand J Immunol 2002; 55:238–241. 228. Vescovi AL, Snyder EY. Establishment and properties of neural stem cell clones: plasticity in vitro and in vivo. Brain Pathol 1999; 9:569–598. 229. Gage FH. Mammalian neural stem cells. Science 2000; 287:1433–1438. 230. Park KI, Ourednik J, Ourednik V, Taylor RM, Aboody KS, Auguste KI, Lachyankar MB, Redmond DE, Snyder EY. Global gene and cell replacement strategies via stem cells. Gene Ther 2002; 9:613–624. 231. Niles LP, Armstrong KJ, Rincon Castro LM, Dao CV, Sharma R, McMillan CR, Doering LC, Kirkham DL. Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci 2004; 5:41. 232. Heuer GG, Skorupa AF, Prasad Alur RK, Jiang K, Wolfe JH. Accumulation of abnormal amounts of glycosaminoglycans in murine mucopolysaccharido-
Copyright 2006 by Taylor & Francis Group, LLC
Gene Therapy for Inherited Diseases of CNS
233.
234.
235.
236. 237.
238.
239.
240.
241.
242.
243.
85
sis type VII neural progenitor cells does not alter the growth rate or efficiency of differentiation into neurons. Mol Cell Neurosci 2001; 17:167–178. Yandava BD, Billinghurst LL, Snyder EY. ‘‘Global’’ cell replacement is feasible via neural stem cell transplantation: evidence from the dysmyelinated shiverer mouse brain. Proc Natl Acad Sci USA 1999; 96:7029–7034. Lacorazza HD, Flax JD, Snyder EY, Jendoubi M. Expression of human betahexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells. Nat Med 1996; 2:424–429. Roach A, Takahashi N, Pravtcheva D, Ruddle F, Hood L. Chromosomal mapping of mouse myelin basic protein gene and structure and transcription of the partially deleted gene in shiverer mutant mice. Cell 1985; 42:149–155. Lois C, Alvarez-Buylla A. Long-distance neuronal migration in the adult mammalian brain. Science 1994; 264:1145–1148. Flax JD, Aurora S, Yang C, Simonin C, Wills AM, Billinghurst LL, Jendoubi M, Sidman RL, Wolfe JH, Kim SU, Snyder EY. Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes. Nat Biotechnol 1998; 16:1033–1039. Rousselot P, Lois C, Alvarez-Buylla A. Embryonic (PSA) N-CAM reveals chains of migrating neuroblasts between the lateral ventricle and the olfactory bulb of adult mice. J Comp Neurol 1995; 351:51–61. Doetsch F, Alvarez-Buylla A. Network of tangential pathways for neuronal migration in adult mammalian brain. Proc Natl Acad Sci USA 1996; 93:14895–14900. Herrera DG, Garcia-Verdugo JM, Alvarez-Buylla A. Adult-derived neural precursors transplanted into multiple regions in the adult brain. Ann Neurol 1999; 46:867–877. Zhang RL, Zhang L, Zhang ZG, Morris D, Jiang Q, Wang L, Zhang LJ, Chopp M. Migration and differentiation of adult rat subventricular zone progenitor cells transplanted into the adult rat striatum. Neuroscience 2003; 116:373–382. Boockvar JA, Kapitonov D, Kapoor G, Schouten J, Counelis GJ, Bogler O, Snyder EY, McIntosh TK, O’Rourke DM. Constitutive EGFR signaling confers a motile phenotype to neural stem cells. Mol Cell Neurosci 2003; 24:1116– 1130. Pedersen MW, Tkach V, Pedersen N, Berezin V, Poulsen HS. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. Int J Cancer 2004; 108: 643–653.
Copyright 2006 by Taylor & Francis Group, LLC
5 Ethical Dilemmas in Neurogenetics Wendy R. Uhlmann Department of Internal Medicine, Division of Molecular Medicine and Genetics, and Department of Human Genetics, University of Michigan, Ann Arbor, Michigan, U.S.A.
This chapter will discuss ethical dilemmas that arise from neurogenetic conditions and genetic testing for these conditions, with a focus on Huntington disease, as it has been a paradigm for such issues. The guidelines for predictive genetic testing for Huntington disease, initially published in 1989 (1–3) and revised in 1994 (4–6) after the cloning of the HD gene, set the global standard for this type of testing. These guidelines set a high bar for patient autonomy in testing decisions and in the comprehensiveness of information provided prior to testing. In recent years, these guidelines have served as a template for predictive testing for other neurogenetic conditions and hereditary cancers (7,8). While ordering a genetic test to make a diagnosis in a symptomatic patient is within a neurologist’s scope of practice, neurologists should only order predictive genetic testing on an asymptomatic patient if they are working on a team that includes a genetics specialist (e.g., genetic counselor, geneticist, genetics nurse). Otherwise, these patients should be referred to a genetics clinic. The counseling, decision making, and potential ethical issues involved in predictive genetic testing are complex and these are time-consuming cases. Generally, the initial counseling session is longer than one hour, not including the time spent prior to the appointment obtaining family history information, constructing a three-generation pedigree, reviewing medical records, and ascertaining pertinent information about genetic testing and support groups (9). Central to predictive genetic testing is the pretest and post-test counseling
Copyright 2006 by Taylor & Francis Group, LLC
88
Uhlmann
that is needed, which is described in the testing guidelines for Huntington disease (4–6), in a position paper by the National Society of Genetic Counselors (10) and in Chapters 1–3 of this book. While genetic testing can determine whether a gene mutation has been inherited, it generally cannot predict age of onset, type of symptoms, severity, or disease course. Predictive genetic testing for neurogenetic conditions usually does not change medical therapy because there currently is no treatment to delay the onset of symptoms. The decision to undergo predictive genetic testing must be made with great care as one is looking into a crystal ball to predict the future. Therefore, patient autonomy in deciding about predictive testing is paramount. It must be left up to the patient to determine whether this information will be helpful to know in living their life and making decisions about finances, marriage, children, and employment. It is important that patients understand the benefits, risks, and limitations of genetic testing and have thought about the potential personal and familial impact that results will have in order to arrive at an informed decision. When a parent has been diagnosed or had a positive predictive test result for an autosomal dominant neurogenetic condition, each child is at 50% risk and the risk to other family members is significantly increased as well. Given the potential familial implications of test results, family dynamics, and communication issues with relatives, there have been several ethical issues raised by predictive genetic testing for neurogenetic conditions including: 1. 2. 3. 4. 5. 6. 7. 8.
Patients’ rights versus relatives’ rights Right to confidentiality versus right to information Right to know versus right not to know Communication of genetic information to at-risk relatives Duty of confidentiality versus duty to warn Coercion of family members to be tested Childhood and prenatal testing for adult-onset conditions Potential use of results by insurers and employers.
Some of these ethical issues are either addressed or can be extrapolated from the predictive testing guidelines for Huntington disease while others have been handled on a case-by-case basis. Resolving these ethical issues requires consideration of core ethical principles and practice guidelines, evaluation of the locus of decision making, a careful determination of risks and benefits, and establishing whose rights take precedence when there is a conflict. The case scenarios and approaches used to resolve the ethical issues that are presented in this chapter are based on actual Huntington disease cases. However, similar ethical dilemmas could arise with testing for other neurogenetic conditions including early-onset Alzheimer’s disease, frontotemporal dementia, spinocerebellar ataxias, dentatorubral-pallidoluysian atrophy (DRPLA), cerebral autosomal dominant arteriopathy with subcortical
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
89
infarcts and leukoencephalopathy (CADASIL), amyotrophic lateral sclerosis (ALS) and others. The approaches used to resolve the Huntington disease cases described below could similarly be applied in such cases. TESTING MINORS Denise is 42 years old. She recently underwent predictive genetic testing for Huntington disease and her results were positive. Now she would like her teen-age children tested. Denise feels that knowing the results will be helpful in planning her children’s future and would be particularly helpful in their financial planning and allocation of their limited financial resources. Above all, Denise wants relief from the anxiety of not knowing whether or not her children are at risk for Huntington disease. Should children be tested for neurogenetic conditions that will not arise until adulthood? A parent may feel that it is their parental right to know this information and that it is needed both to prepare the child and plan for the child’s future. However, there is also the risk that positive test results could result in changes in family dynamics, differential treatment, stigmatization and adversely affect psychological well-being and perceptions of self (11). The potential benefits and harms of genetic testing in children are summarized in the American Society of Human Genetics/American College of Medical Genetics 1995 report (11). Given that there currently is no medical benefit to determining carrier status for adult-onset neurogenetic conditions in childhood, the consensus is that such testing should be deferred until the child reaches the age of majority and can decide whether to learn this information (Table 1). This applies whether the adult-onset neurogenetic condition follows an autosomal dominant, autosomal recessive, or other pattern of inheritance irrespective of whether the child is at risk to be affected or simply a carrier. What if a child has behavioral issues, learning disabilities, nonspecific neurological findings, or problems with the law? These findings are not characteristic symptoms of adult-onset neurogenetic conditions and are commonly seen in children in the general population. The development of symptoms in childhood for adult-onset neurogenetic conditions is rare. Children should only have genetic testing if a neurologist/physician familiar with the juvenile form of the condition thinks a child is truly symptomatic. While children should not be tested unless there is a medical indication, the guidelines clearly state that ‘‘the child be informed of his or her at-risk status upon reaching the age of reason’’ (comment 2.1, page 1533) (5). TESTING A CHILD FOR ADOPTION The woman on the phone was anxious and insistent. She shared that she wanted to adopt a 2-year-old girl but had just learned that the girl’s biological
Copyright 2006 by Taylor & Francis Group, LLC
90
Uhlmann
Table 1 Pertinent Guidelines Regarding Genetic Testing of Minors American Society of Human Genetics, American College of Medical Genetics (1995). Points to consider: ethical, legal and psychosocial implications of genetic testing in children and adolescents, page 1233. (11) ‘‘Timely medical benefit to the child should be the primary justification for genetic testing in children and adolescents.’’ ‘‘If the medical or psychosocial benefits of a genetic test will not accrue until adulthood, as in the case of carrier status or adult-onset diseases, genetic testing generally should be deferred.’’ Huntington Disease Society of America (1994): Guidelines for Genetic Testing for Huntington’s Disease, page 10. (4) ‘‘Minors should not be tested unless there is a medically compelling reason for doing so, i.e., an at-risk child is believed to be showing symptoms. However, under no circumstances is testing a substitute for a thorough neurological and neuropsychological workup . . . Parental anxiety concerning a child’s risk does not constitute a medically compelling reason.’’ International Huntington’s Association and the World Federation of Neurology Research Group on Huntington’s Chorea (1994): Guidelines for the Molecular Genetics Predictive Test in Huntington’s Disease, page 1533. (5) ‘‘The decision to take the test is solely the choice of the individual concerned. No requests from third parties—family members or otherwise—shall be considered.’’ (Recommendation 2) ‘‘The test is available only to individuals who have reached the age of majority (according to the laws of the respective country).’’ (Recommendation 2.1)
mother had Huntington disease. Could we arrange for genetic testing on the child as soon as possible? The guidelines for testing children for adult-onset genetic conditions described above equally apply for children who are being considered for adoption. The American College of Medical Genetics and the American Society of Human Genetics jointly issued a position statement in 2000 (12), adopted by the National Society of Genetic Counselors in 2002 (13), which states: ‘‘Because the primary justification for genetic testing of any child is a timely medical benefit to the child, genetic testing of newborns and children in the adoption process should be limited to testing for conditions which manifest themselves during childhood or for which preventive measures or therapies may be undertaken during childhood’’ (page 761) (12). Only genetic testing that would be ordered on all children of a similar age should be performed on children in the adoption process (12). Performing genetic tests on children to be adopted outside of those that are considered standard could potentially lessen their opportunities for adoption. ‘‘Although a result indicating that the child does not carry the HD gene may facilitate an adoption (albeit one in which the adoptive parents have
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
91
demonstrated less than wholehearted acceptance), a positive result may consign a child to permanent foster care’’ (page 11) (4).
TESTING AN ADULT CHILD WHEN THE AT-RISK PARENT REFUSES TESTING Adam, age 24, requested predictive genetic testing for Huntington disease. His maternal grandmother, two maternal aunts, a maternal uncle, and two cousins have all been diagnosed with Huntington disease. Adam’s 45-year-old mother has no symptoms and reportedly does not want to be tested. Newly married, Adam wants to know whether he is at risk for Huntington disease for family planning and career decisions. Can Adam proceed with genetic testing? If Adam tests positive for the Huntington disease gene mutation, then his mother’s positive status would also be known, even though she does not want her status ascertained. In essence, proceeding with the adult-child’s request to be tested could be viewed as coercing the at-risk parent to be tested. Given the laws of patient confidentiality, the genetic counselor or physician cannot just contact Adam’s mother about his request to be tested. Even if Adam contacted his mother and she granted permission to be contacted, she may remain steadfast in not wanting her carrier status for Huntington disease determined. Whose rights then take precedence—the adult-child’s right to know or the at-risk parent’s right not to know? The predictive testing guidelines (Table 2) support proceeding with the adult
Table 2 Pertinent Guidelines Regarding Testing an Adult Child at 25% Risk for Huntington Disease Recommendation
Comment
2.4 ‘‘This issue will arise when a child at 25% risk 2.4 ‘‘Extreme care should requests testing with full knowledge that his or her be exercised when testing parent does not want to know his or her own status. would provide Every effort should be made by the counselors and information about the individuals concerned to arrive at a satisfactory another person who has resolution of this conflict. A considerable majority not requested the test.’’ of representatives from lay organizations feel that if no consensus can be reached, the right of the adult child to know should have priority over the right of the parent not to know.’’ International Huntington’s Association and the World Federation of Neurology Research Group on Huntington’s Chorea (1994): Guidelines for the Molecular Genetics Predictive Test in Huntington’s Disease, pages 1533–1534. Source: From Ref. 5.
Copyright 2006 by Taylor & Francis Group, LLC
92
Uhlmann
child’s request. What is unclear is how much effort should or can be extended by the health care professional ‘‘to arrive at a satisfactory resolution of this conflict’’ (pages 1533–1534) (5). The approach our clinic has taken has been to discuss all of these testing implications with the patient, to encourage the patient to discuss the desire for testing with the at-risk parent, to provide the patient with contact information for genetics clinics and supportive resources for the at-risk parent. We also document our counseling in a detailed letter, which is sent to the patient and can be shared with family members. Some patients are unaware of the implications and will subsequently decide to approach their at-risk parent and communicate their desire for testing. Other patients will either refuse to discuss testing with their at-risk parent or will be unsuccessful in their attempts (14,15). In some of our cases and other studies (14,15), when the child has subsequently discussed these issues with the at-risk parent, the at-risk parent has decided to proceed with genetic testing. The rights and obligations of the parent and at-risk child, conflicts of interests, and approaches to resolving these ethical issues are discussed in an article by Lindblad (16). Maat-Kievit et al. have proposed guidelines for predictive testing of 25% at-risk applicants, which address different testing strategies and communication issues and emphasize finding a balance between involvement of the parent with the child’s autonomy in the decision-making process (14).
IS THERE A ‘‘DUTY TO WARN’’ AND SHARE TEST RESULTS WITH OTHER AT-RISK FAMILY MEMBERS? In the case above, Adam proceeds with predictive genetic testing for Huntington disease and his results are positive. Adam indicates that he has no plans to share his test results with his mother or his siblings even though he knows that his mother will have Huntington disease and his siblings are at 50% risk. Are you obligated to share this information with Adam’s mother and his siblings? It is not unusual for a physician to care for multiple family members. When a physician is caring for a family member and knows health status information that has significant implications for other family members who are also under their care or seen in their practice, how should this be handled? Regardless of whether or not other family members are under the physician’s care, is there an obligation to contact them when the patient has been diagnosed or had a positive predictive genetic test result for Huntington disease? According to the American Society of Human Genetics (ASHG) Statement on Professional Disclosure of Familial Genetic Information (17): ‘‘Genetic information, like all medical information, should be protected by the legal and ethical principle of confidentiality’’ (page 474) (17).
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
93
The ASHG statement provides stipulations for the professional disclosure of genetic information: ‘‘Disclosure should be permissible where: 1. Attempts to encourage disclosure on the part of the patient have failed. 2. The harm is highly likely to occur and is serious, imminent, and foreseeable. 3. The at-risk relative(s) is identifiable. 4. The disease is preventable, treatable or medically accepted standards indicate that early monitoring will reduce the genetic risk.’’ (page 474) (17). While in cases like the one above, the at-risk relatives are identifiable and attempts to encourage disclosure have failed, Huntington disease does not meet the other criteria for professional disclosure of genetic information. Huntington disease is highly likely to occur in individuals who inherit the gene mutation; however, the onset of symptoms is gradual, and currently there are no preventative measures or treatment that will reduce the risk. ‘‘At a minimum, the health care professional should be obliged to inform the patient of the implications of his/her genetic test results and potential risks to family members’’ (page 474) (17). The health care professional should document in the medical record and send a letter to the patient about the familial implications of these genetic test results and the fact that the patient was encouraged to share this information with relatives. Hakimian further examines the ethical and legal issues faced by physicians in disclosing or withholding information about Huntington disease from known but unknowing family members (18). The consideration of whether there is a duty to warn will become more of an issue when there are preventative measures or treatment for neurogenetic conditions. Even today, this might pose an issue for a physician caring for a patient with myotonic dystrophy. Individuals with myotonic dystrophy can have cardiac conduction defects and cardiomyopathy which can result in early mortality. In addition, there is also an increased risk for congenital myotonic dystrophy, with significant morbidity and mortality, when this condition is inherited from a female parent. The duty to warn would need to be carefully considered if there were identifiable relatives who would significantly benefit from cardiac surveillance or knowing their reproductive risks. However, it should be emphasized that the duty to warn remains a challenging, controversial issue, and one that needs to be carefully assessed and decided. The issue of nondisclosure of test results to an identifiable at-risk relative also applies in the identical twin case discussed below. TESTING IDENTICAL TWINS Eric, age 25 and newly married, requested predictive genetic testing for Huntington disease. His father and several paternal relatives had Huntington
Copyright 2006 by Taylor & Francis Group, LLC
94
Uhlmann
disease. Eric has an identical twin, Daniel, who lives in a different state. Eric reported that he talked with Daniel and Daniel had no interest in finding out whether he was at risk for Huntington disease. In fact, he was angry at Eric for wanting to be tested. Should you proceed with Eric’s testing request? In such cases, it is important to inquire how it was determined that they are identical twins since twins can look alike and not be identical. There are no specific guidelines regarding predictive testing of identical twins. Heimler and Zanko published a report of a case where a twin requested predictive genetic testing for Huntington disease (19). The approach taken by Heimler and Zanko was to first determine zygosity of the twins. Once monozygosity was established, arrangements for genetic counseling were made for the second twin with the understanding that both twins would have to make a voluntary decision and be in agreement about proceeding with genetic testing. The twins underwent predictive genetic testing simultaneously and great effort was extended by the genetic counselors to time appointments and results disclosure, a logistical challenge given that one twin resided on the East Coast and the other on the West Coast. Other genetic counselors challenged the approach of Heimler and Zanko and would have allowed the twin to be tested, even if the co-twin was not in agreement (20,21). The guidelines make it clear that an individual should independently make the decision to be tested and not be coerced. In essence, proceeding with an identical twin’s request to be tested could be viewed as coercing the other twin to be tested. Similar to cases where an adult child at 25% risk wants to be tested, there is the issue of a patient requesting testing where information could be learned about a family member who does not want this information known. By extension of the guidelines for individuals at 25% risk, this means that the identical twin should be made aware of the implications of the results for the co-twin. Efforts should be extended to try to resolve the conflict, but ultimately the right to know would take precedence over the co-twin’s desire not to learn the carrier status. This has been the approach taken by our clinic. We also provide the patient with contact information for genetics clinics and supportive resources for the twin and document our counseling in a detailed letter to the patient. NON-DISCLOSURE OF TEST RESULTS Paul, age 39, underwent predictive genetic testing for Huntington disease. Hours before his clinic appointment to receive his test results, he called to cancel, indicating that he was not sure when or if he would reschedule. In preparation for his clinic visit, the genetic counselor had opened his test results and knew that he had tested negative. Should she share this information with Paul?
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
95
The guidelines make it clear that results should only be disclosed in person and that the tested patient has the right to decide not to receive these results: 1. ‘‘The participant has the right to decide, prior to the date fixed for the delivery of the results, that these results shall not be revealed to him or her’’ (Recommendation 8.4, page 1536) (5). 2. ‘‘The results of the test should be revealed in person by the counselor to the individual and his or her companion. No result should ever be revealed by telephone or by mail. The counselor must have time to discuss any questions with the individual’’ (Recommendation 8.5, page 1536) (5). Even patients who receive the ‘‘good news’’ that they are negative for Huntington disease can experience adverse reactions to the results, potentially having misgivings about life decisions made based on thinking they would be affected or experiencing ‘‘survivor’’ guilt from having escaped the fate of other affected family members (22,23). What if the test results are positive for Huntington disease—is there an obligation to make sure the patient knows the results? Communicating test results when the patient has indicated the desire not to know the results would be contrary to the guidelines. Result disclosure would likewise not be supported by the ASHG Statement on Professional Disclosure of Familial Genetic Information (17) since there is no imminent harm, preventative measures, or treatment. TESTING SIBLINGS SIMULTANEOUSLY Two sisters, Lisa and Anne, called and asked to be seen together for predictive genetic testing for Huntington disease. Both in their mid 30s and married, they had watched their affected father’s symptoms progress to the point where he now resided in a nursing home and no longer recognized them. The sisters wanted to be tested together, without their husbands’ involvement. They felt strongly that this was an experience that they shared with each other, one which only they could fully understand. Should their request for simultaneous testing be honored? It is recommended in the guidelines that a support person accompany the patient throughout the testing process but it is stipulated that ‘‘It may not be appropriate for the companion to be another at-risk individual’’ (Comment 3, page 1534) (5). The concern is whether an at-risk individual would be able to fully provide support given the shared risk for the same condition. If a sibling or at-risk family member is serving as a support person, learning their relative’s results could have a significant emotional impact. For siblings who request testing together, there is the added concern that siblings could receive discordant results. When we have to deliver discordant results, our approach is to disclose the negative result first and then the positive result. Delivering test results simultaneously to siblings and
Copyright 2006 by Taylor & Francis Group, LLC
96
Uhlmann
providing appropriate counseling and support is challenging. At our clinic, we feel that siblings should be apprised of these issues but ultimately, the patient’s decision to be tested, either alone or with a specific support person present, related or unrelated, should be respected. TESTING INDIVIDUALS WHO WORK IN PROFESSIONS WHERE NEUROLOGICAL DEFICITS CAN JEOPARDIZE THE SAFETY OF OTHERS David, age 45, had a father and several paternal relatives with Huntington disease. His 43-year-old sister was recently diagnosed with Huntington disease. David is an airplane pilot and is asymptomatic. He proceeds with predictive genetic testing and his results are positive for Huntington disease. For patients who are airplane pilots, truck drivers, construction workers, heavy equipment operators, and work in other similar professions, receiving a positive test result will have significant implications for the safe performance of their jobs. Close neurological follow-up is paramount and the frequency of evaluations should be determined by the neurologist. Patients should be informed that as long as they are asymptomatic, they can continue in their line of work but should be thinking of alternatives for their job responsibilities in anticipation that they will eventually become symptomatic.
TESTING SYMPTOMATIC INDIVIDUALS WHO THINK THEY ARE ASYMPTOMATIC Nancy, age 46, was interested in genetic testing because of her family history of Huntington disease. During the clinic visit, the genetic counselor noted that Nancy had involuntary movements. When she asked Nancy directly whether she had any symptoms of Huntington disease, she denied having symptoms. In a 2002 study, Goizet et al. found that of patients who requested predictive genetic testing, approximately 10% had subtle neurological or behavioral symptoms of Huntington disease (24). Of note, this study also found that a number of patients who had subtle symptoms actually tested negative for Huntington disease. This emphasizes the importance of being conservative in assessing patients and cautious in interpreting and communicating findings. In the guidelines it states that ‘‘Particular care should be taken with participants who are believed to be showing early symptoms of HD; however, individuals with established, unacknowledged symptoms should not automatically be excluded from the test and should receive additional counseling’’ (comment 5.2.5, page 1535) (5). A neurology evaluation is recommended in the guidelines for predictive testing for Huntington
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
97
disease, although a patient can be tested without this evaluation. If a patient is symptomatic but not aware of symptoms, it is important to inform the patient that a diagnosis could potentially be made with the neurology exam so that there is advance preparation for this possibility. In addition, it is important for the patient to understand that a diagnosis will have significant implications for other family members whose risk could be as high as 50%. A patient who undergoes diagnostic testing for Huntington disease is not required to meet with a therapist. Therefore, if symptomatic patients request predictive testing, thinking that they are asymptomatic, the requirement to meet with a therapist as part of the predictive testing protocol could be beneficial and a helpful resource as they later adjust to this diagnosis. TESTING ‘‘ASYMPTOMATIC’’ INDIVIDUALS WHO HAVE RECENTLY ATTEMPTED SUICIDE The call came from the inpatient psychiatric unit. The 38-year-old female patient had a strong family history of Huntington disease and was just hospitalized following a suicide attempt with an overdose of medications. Could we see the patient and order genetic testing? Individuals with Huntington disease have an increased risk for suicide. Psychiatric symptoms can precede or occur simultaneously with neurological symptoms of this disease. The suicide attempt could in fact be indicative that the patient has symptoms of Huntington disease. Alternatively, the patient could have underlying depression or significant anxiety from being at risk that resulted in the suicide attempt. In cases like the one above, the line becomes blurred between genetic testing for Huntington disease being diagnostic or predictive. A neurology consult can be helpful in determining whether the patient additionally has any neurological symptoms consistent with Huntington disease, which would increase suspicions that the suicide attempt is a manifestation of the disease. Testing should be performed at a time of low stress (4) and therefore, testing at the time of a suicide attempt is not optimal. A history of depression or suicide attempts, however, is not a contraindication for testing. It is stipulated in the guidelines that ‘‘For applicants with evidence of a serious psychiatric condition, it may be advisable that testing be delayed and support services put into place’’ (Recommendation 2.5, page 1534) (5). It is important to ensure that the patient is not being coerced into testing, is in a position to give informed consent, and understands the significance and implications of the test results. The bottom line is that the patient’s suicide attempt needs to be medically addressed and that knowing whether or not the patient has Huntington disease will not significantly impact this treatment. The results of genetic testing often are not available for two to three weeks. The patient may be released from the psychiatric unit well before genetic test results are known, so it is important to make sure
Copyright 2006 by Taylor & Francis Group, LLC
98
Uhlmann
that the patient has appropriate ongoing psychiatric support in place and that there are plans to disclose the Huntington disease test results in person. TESTING A BLOOD SAMPLE FROM SOMEONE WHO HAS JUST COMMITTED SUICIDE The caller was using her cell phone from a funeral home. Her 43-year-old husband had just committed suicide. His father had died of Huntington disease. A couple months prior to his death, her husband had become abusive and erratic in his behavior. The woman wanted answers: Did he have Huntington disease and was her daughter now at risk? The legal next-of-kin has the right to make such testing decisions. This can become challenging when family members differ strongly about proceeding with testing and no consensus can be reached. Sometimes, it is not technically possible to test a sample from a recently deceased individual if the sample was obtained in the wrong type of tube, has not been stored at the proper temperature, or kept too long before processing. The Huntington disease genetic test is highly sensitive so even if an affected individual is not tested, testing still remains an option for at-risk relatives. When positive test results for Huntington disease are obtained for an individual who has committed suicide, it can be of benefit to family members’ grief process and help bring some closure by providing an explanation for the suicide. In addition, test results can provide useful information for determining whether relatives are at increased risk for Huntington disease. One can imagine similar test requests from family members of individuals with other neurogenetic conditions. If testing is not available, DNA banking can be offered; labs offering this service can be accessed at GeneTests (www.genetests.org). TESTING A PREGNANCY Sara, age 38, recently underwent predictive genetic testing for Huntington disease and received positive test results. Now 10 weeks pregnant, she wished to have her pregnancy tested. Sara knew that the pregnancy was at 50% risk for Huntington disease and wanted the pregnancy tested but was unsure what she would do if the results were positive. It is controversial whether prenatal testing should be offered for adult-onset genetic conditions. It raises the issue of the value of a life given that an individual can often live 30þ years before the onset of symptoms of Huntington disease and approximately 25% of individuals first become symptomatic after age 50 (25). Even if a child is prenatally diagnosed today as having the HD gene mutation, it is anticipated that there may be more effective treatment options and possibly a cure before that child becomes symptomatic. Given the neurological deterioration that occurs in affected individuals and the familial impact of this disease, individuals may feel strongly about not wanting to
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
99
Table 3 Pertinent Guidelines Regarding Prenatal Testing for Huntington Disease Recommendation 7.1 ‘‘It is essential that antenatal testing for the HD mutation be performed only if the parent has already been tested.’’
Comment 7.1 ‘‘It is highly desirable that both parents agree to an antenatal test. If there is a conflict, every effort should be made by the counselors and the couple to reach an agreement. Exceptional circumstances (e.g. rape or incest) may justify deviating from this recommendation.’’
7.2 ‘‘The couple requesting antenatal testing must be clearly informed that if they intend to complete the pregnancy if the fetus is a carrier of the gene defect, there is no valid reason for performing the test. Furthermore, this situation is contrary to recommendation 2.1, since a child thus born with the gene defect cannot elect not to take the test upon reaching majority’’ International Huntington’s Association and the World Federation of Neurology Research Group on Huntington’s Chorea (1994): Guidelines for the Molecular Genetics Predictive Test in Huntington’s Disease, page 1535. Source: From Ref. 5.
have children at risk for Huntington disease. Prenatal testing for Huntington disease is an option though the guidelines make it clear (Table 3) that such testing should only be performed if positive test results will impact the decision to continue the pregnancy; pregnancy continuation with known positive results would be tantamount to testing a minor, which is contrary to the guidelines. For some neurogenetic conditions (e.g., some of the spinocerebellar ataxias, myotonic dystrophy) where there are genotype–phenotype correlations, these prenatal decisions will be even more complex. A parent may wish to terminate a pregnancy when testing indicates a high number of trinucleotide repeats, consistent with the neonatal form, but continue a pregnancy when the repeat number is in the range for adult onset of symptoms. For the continued pregnancies, this means that there would be parental knowledge of the future child’s affected status in adulthood (depending on disease penetrance) which would deprive the child of autonomy in deciding whether to ascertain this information. What about testing a pregnancy when the at-risk parent has not already been tested? Some patients who we have seen have requested to rule out Huntington disease in the pregnancy but do not want to be tested themselves. They understand that they could learn of their positive carrier status
Copyright 2006 by Taylor & Francis Group, LLC
100
Uhlmann
through testing the pregnancy. Some of these patients have also said that a benefit of learning their positive status this way is that the results would be in the pregnancy records, not in their personal records, which would limit insurers’ access to this information. In these cases and at other centers (26–28), if both parents have consented to testing and understand that positive results could be revealed simultaneously for the pregnancy and the atrisk parent, we have proceeded with their requests. Maat-Kievit et al. also advocate that the guidelines include the option of direct testing of the pregnancy given that it is simpler, faster and has just a 25% chance of revealing the status of the at-risk parent (26,29). What if the father of the pregnancy is at risk and does not want his carrier status determined but his pregnant partner wants the pregnancy, which is at 25% risk, tested? Does the woman’s right to independently make decisions about a pregnancy take priority over the father’s wishes not to have his status determined? Both our group (30,31) and Tassicker et al. (32) feel that efforts should be extended to try to resolve the conflict but generally, the at-risk father’s decision not to have his carrier status determined should be respected. GIVING INFORMED CONSENT FOR INDIVIDUALS WITH COGNITIVE/PSYCHIATRIC IMPAIRMENT Brandon, age 45, came to clinic with his wife and 24-year-old daughter to discuss genetic testing for Huntington disease. The genetic counselor noted that Brandon had some involuntary movements, was slow to respond to questions and seemed depressed. She was unsure as to whether his symptoms were due to anxiety and depression or in fact were early symptoms of Huntington disease. Brandon would not allow the neurologist to examine him. Brandon’s wife and daughter provided most of the family and medical history information. Newly engaged, Brandon’s daughter was particularly interested in finding out whether her father had Huntington disease. Brandon’s wife was concerned about some of the changes she was seeing in her husband and was looking for answers. Brandon was noncommittal when asked about whether he wanted to be tested for Huntington disease. A central issue is whether patients who have cognitive impairment yet still act as their own guardians can actually provide informed consent. The healthcare provider needs to assess whether the patient has the decision-making capacity that includes the abilities to understand, appreciate, communicate a choice, and reason. Recognition that a patient has cognitive impairment will likely be apparent from the health care provider’s interactions with the patient. Cognitive functioning can also be more formally assessed through the Mini-Mental State Examination (MMSE) (33), a standard component of most neurological evaluations, the Aid to Capacity Evaluation (ACE) (34), the MacArthur Competence Assessment Tool—Treatment (MacCAT-T) (35), or use of other similar instruments.
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
101
There are guidelines from the American Medical Association (36,37) and American Psychiatric Association (38) regarding obtaining informed consent when there is impairment of the patient’s decision-making capacity. In these cases, it is important to work with the family, keeping in mind state laws of working with a proxy and who can serve in this role. Even in cases where there is impaired decision-making capacity, one should strive to obtain the assent of the patient and act in accordance with core ethical principles. While one should strive to maintain the autonomy of patients, this needs to be balanced with the fact that patients may no longer have the capacity to make decisions that are in their best interest. If the patient is truly suspected to have symptoms of Huntington disease or other neurogenetic condition, this information may be important for health care and safety issues (e.g., driving), and has implications for other family members. INSURANCE ISSUES Patients requesting predictive testing often have concerns about whether their insurance will cover the costs and what the implications will be for their insurance coverage if results are positive. Patients need to be informed about the costs of testing, evaluations (therapist, neurologist), and clinic fees, which often total several hundred dollars, and that some insurance companies may not cover testing unless it is ordered to make a diagnosis of a symptomatic individual. Prior to proceeding with predictive genetic testing, it is advisable that patients have in place their desired coverage for health, life, long-term disability, and long-term care insurance. It should be emphasized with patients that they need to acknowledge their family history of a neurological condition if this information is requested and that denying this history could be treated as insurance fraud. Some states have laws prohibiting insurance and employment discrimination based on genetic information, and there are bills being considered at a federal level (see Resources section). ANONYMOUS TESTING The man on the phone was hesitant and would not identify himself. His request: ‘‘I want to be tested anonymously for Huntington disease.’’ Should you facilitate this patient having anonymous testing for Huntington disease or other neurogenetic conditions? There are no specific guidelines regarding anonymous testing for Huntington disease. The limited experience with anonymous testing for Huntington disease has been addressed in articles by Burgess et al. (39) and Visintainer et al. (40). Our policy has been to not offer anonymous testing (41) though others feel this should be an option (42). Given the fact that neurogenetic conditions can have similar symptoms, it is important to confirm the diagnosis in the family prior to proceeding with genetic testing for a specific condition. Anonymity can be a
Copyright 2006 by Taylor & Francis Group, LLC
102
Uhlmann
barrier in establishing rapport, providing accurate risk assessments, and appropriate genetic counseling. While most HD testing centers do not offer anonymous genetic testing (40), at our center and others, there have been patients who have had anonymous genetic testing by virtue of the fact that they only provided limited nonidentifying family history information with no medical record documentation of their family history of Huntington disease, used a post-office box for all communication, and paid cash for their clinic appointments. LEGAL CASES There have been anecdotal reports of at-risk individuals being forced to have predictive testing for Huntington disease in divorce, child custody, criminal, and other legal cases. Genetic testing of individuals under these circumstances could be viewed as coercion. The guidelines clearly stipulate that ‘‘The individual must choose freely whether to be tested and must not be coerced by family, friends, partners or potential partners, physicians, insurance companies, employers, governments or others’’ (comment 2.1, page 1533) (5). In such cases, it is important to consult with your hospital’s attorney prior to agreeing to see patients involved in legal cases. Given that the results may or may not be in the best interest of the patient, ‘‘testing should only be performed with the consent of the patient and his/her understanding of the likely social and legal results of a positive test’’ (page 258) (43). RESOURCES It is recommended in the guidelines that predictive genetic testing be performed by a team that includes genetics specialists. To locate genetics specialists in your area, the National Society of Genetic Counselors (www.nsgc.org), GeneTests (www.genetests.org), and the American College of Medical Genetics (www.acmg.net) have searchable on-line directories of genetics providers and clinics. To locate support groups for your patients, the Genetic Alliance (www.geneticalliance.org) and National Organization for Rare Disorders (NORD) (www.rarediseases.org) have on-line directories. The National Human Genome Research Institute (www.genome.gov) and the National Conference of State Legislatures (www.ncsl.org/programs/ health/Genetics/charts.htm) have on-line access to information on state and federal laws regarding use of genetic information by insurers and employers. SUMMARY This chapter focused on the ethical issues encountered in predictive genetic testing for Huntington disease, which are also applicable to other adult-onset autosomal dominant neurogenetic conditions for which there currently is no
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
103
cure. Genetics expertise is essential for providing the pretest and post-test counseling, addressing the complex counseling issues, and resolving the challenging ethical dilemmas. These cases demonstrate that the patient may not just be the person seated in front of you and that results may reveal carrier status and have significant implications for other family members. Predictive genetic testing for neurogenetic conditions raises several core issues including autonomy, coercion, locus of decision making, weighing the right to know versus the right not to know, and a careful determination of whose rights take precedence when there is a conflict. To resolve ethical dilemmas, it is important to use testing guidelines, position statements from professional societies, and take into account basic ethical principles. Sometimes giving patients copies of the testing guidelines and position statements can be helpful in resolving ethical dilemmas by showing them that there are global standards and that their request is not being questioned or denied without basis. Consulting with the hospital’s ethics committee and attorney may also be helpful, particularly for legal cases. Advances in genetics will result in an increase in the number of genetic tests. As effective treatment options become available, some of the ethical issues associated with predictive testing will become less significant and easier to resolve.
RECOMMENDED READING Smith DH, Quaid KA, Dworkin RB, Gramelspacher GP, Granbois JA, Vance GH. Early Warning: Cases and Ethical Guidance for Presymptomatic Testing in Genetic Diseases. Bloomington: Indiana University Press, 1998. REFERENCES 1. Huntington’s Disease Society of America. Guidelines for predictive testing for Huntington’s disease. New York, 1989. 2. World Federation of Neurology: Research Committee. Research Group on Huntington’s chorea. Ethical issues policy statement on Huntington’s disease molecular genetics predictive test. J Neurol Sci 1989; 94:327–332. 3. Went L. Ethical issues policy statement on Huntington’s disease molecular genetics predictive test. International Huntington Association. World Federation of Neurology. J Med Genet 1990; 27:34–38. 4. Huntington’s Disease Society of America Inc. Guidelines for genetic testing for Huntington’s disease. New York: Huntington’s Disease Society of America, Inc., 1994. 5. International Huntington Association and World Federation of Neurology Research Group on Huntington’s Chorea. Guidelines for the molecular genetics predictive test in Huntington’s disease. Neurology 1994; 44:1533–1536. 6. International Huntington Association and the World Federation of Neurology Research Group on Huntington’s Chorea. Guidelines for the molecular genetics predictive test in Huntington’s disease. J Med Genet 1994; 31:555–559.
Copyright 2006 by Taylor & Francis Group, LLC
104
Uhlmann
7. Burson CM, Markey KR. Genetic counseling issues in predictive genetic testing for familial adult-onset neurologic diseases. Semin Pediatr Neurol 2001; 8: 177–186. 8. Hayden MR. Predictive testing for Huntington’s disease: a universal model? Lancet 2003; 2:141–142. 9. Uhlmann WR. A guide to case management. In: Baker DL, Schuette JL, Uhlmann WR, eds. A Guide to Genetic Counseling. New York: Wiley, 1998:199–229. 10. McKinnon WC, Baty BJ, Bennett RL, Magee M, Neufeld-Kaiser WA, Peters KF, Sawyer JC, Schneider KA. Predisposition genetic testing for late-onset disorders in adults: a position paper of the National Society of Genetic Counselors. JAMA 1997; 278:1217–1220. 11. American Society of Human Genetics, American College of Medical Genetics. Points to consider: Ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995; 57:1233–1241. http:// www.acmg.net/resources/policies/pol-018.asp; http://www.ashg.org/genetics/ ashg/policy/pol-13.htm. 12. American Society of Human Genetics Social Issues Committee, American College of Medical Genetics Social, Ethical and Legal Issues Committee. ASHG/ACMG statement: Genetic testing in adoption. Am J Hum Genet 2000; 66:761–767. http://www.acmg.net/resources/policies/pol-017.asp;http://www.ashg.org/genetics/ashg/policy/pol-36.htm. 13. National Society of Genetic Counselors, Inc. Genetic testing and adoption position statement. 2002. http://www.nsgc.org/about/position.asp#testandadoption. 14. Maat-Kievit A, Vegter-van der Vlis M, Zoeteweij M, Losekoot M, van Haeringen A, Roos RAC. Predictive testing of 25 percent at-risk individuals for Huntington disease (1987–1997). Am J Med Genet (Neuropsych Genet) 1999; 88:662–668. 15. Benjamin CM, Lashwood A. United Kingdom experience with presymptomatic testing of individuals at 25% risk for Huntington’s disease. Clin Genet 2000; 58: 41–49. 16. Lindblad AN. To test or not to test: an ethical conflict with presymptomatic testing of individuals at 25% risk for Huntington’s disorder. Clin Genet 2001; 60:442–446. 17. American Society of Human Genetics Social Issues Committee on Familial Disclosure. Professional disclosure of familial genetic information. Am J Hum Genet 1998; 62:474–483. http://www.ashg.org/genetics/ashg/policy/pol-29.htm. 18. Hakimian R. Disclosure of Huntington’s disease to family members: the dilemma of known but unknowing parties. Genet Test 2000; 4:359–364. 19. Heimler A, Zanko A. Huntington disease: a case study describing the complexities and nuances of predictive testing of monozygotic twins. J Genet Counsel 1995; 4:125–137. 20. Hodge SE. Paternalistic and protective? Genet Counsel 1995; 4:351–352. 21. Reich E. Testing for HD in twins. J Genet Counsel 1996; 5:47–49. 22. Huggins M, Block M, Wiggins S, Adams S, Sucherowsky O, Trew M, Klimek ML, Greenberg CR, Eleff M, Thompson LP, Knight J, MacLeod P, Girard K, Theilmann J, Hayden MR. Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving decreased risk. Am J Hum Genet 1992; 42:509–515.
Copyright 2006 by Taylor & Francis Group, LLC
Ethical Dilemmas in Neurogenetics
105
23. Meiser B, Dunn S. Psychological impact of genetic testing for Huntington disease: an update of the literature. J Neurol Neurosurg Psychiatry 2000; 69: 574–578. 24. Goizet C, Lesca G, Durr A, French Group for Presymptomatic Testing in Neurogenetic Disorders. Presymptomatic testing in Huntington’s disease and autosomal dominant cerebellar ataxias. Neurology 2002; 59:1330–1336. 25. Myers RH, Sax DS, Schoenfeld M, Bird ED, Wolf PA, Vonsattel JP, White RF, Martin JB. Late onset of Huntington’s disease. J Neurol Neurosurg Psychiatry 1985; 48:530–534. 26. Maat-Kievit A, Vegter-van der Vlis M, Zoeteweij M, Losekoot M, van Haeringen A, Roos R. Paradox of a better test for Huntington’s disease. J Neurol Neurosurg Psychiatry 2000; 69:579–583. 27. Simpson SA, Harper PS, United Kingdom Huntington’s Disease Prediction Consortium. Prenatal testing for Huntington’s disease: experience within the UK 1994–1998. J Med Genet 2001; 38:333–335. 28. Simpson SA, Zoeteweij MW, Nys K, Harper P, Durr A, Jacopini G, Yapijakis C, Evers-Kiebooms G. Prenatal testing for Huntington’s disease: a European collaborative study. Eur J Hum Genet 2002; 10:689–693. 29. Maat-Kievit A, Vegter-van der Vlis M, Zoeteweij M, Losekoot M, van Haeringen A, Kanhai H, Roos R. Experience in prenatal testing for Huntington’s disease in the Netherlands: procedures, results and guidelines (1987–1997). Prenat Diagn 1999; 19:450–457. 30. Uhlmann W, Markel D, Petty E. Prenatal testing for adult-onset conditions: A Huntington disease testing dilemma [abstr]. J Genet Counsel 1996; 5:229–230. 31. Uhlmann WR, Markel DS, Goldman EB, Petty EM. Prenatal testing for Huntington disease: Whose decision is it? Report of a testing dilemma and analysis of ethical and legal issues. Submitted for publication. 32. Tassicker R, Savulescu J, Skene L, Marshall P, Fitzgerald L, Delatycki MB. Prenatal diagnosis requests for Huntington’s disease when the father is at risk and does not want to know his genetic status: clinical, legal and ethical viewpoints. BMJ 2003; 326:331–333. 33. Mini-Mental State Examination (MMSE) http://www.minimental.com. 34. Aid to Capacity Evaluation. http://www.utoronto.ca/jcb/disclaimers/ace_main. htm. 35. MacArthur Competence Assessment Tool—Treatment (MacCAT-T) http:// www.prpress.com/books/mactfr.html. 36. American Medical Association. H-140.989 Informed consent and decisionmaking in health care. http://www.amaassn.org/apps/pf_new/pf_online?f_n¼ resultLink&doc¼policyfiles/HnE/H140.989.HTM&s_t¼%22H140.989%22& catg¼AMA/HnE&catg¼AMA/BnGnC&catg¼AMA/DIR&&nth¼1&&st_p¼ 0&nth¼1&. 37. American Medical Association. E-8.081 Surrogate decision making. 2001. http://www.ama-assn.org/ama/pub/category/8489.html. 38. American Psychiatric Association. Principles of informed consent in psychiatry resource document. APA Document Reference No. 960001: 1996. http://www. psych.org/edu/other_res/lib_archives/archives/199601.pdf.
Copyright 2006 by Taylor & Francis Group, LLC
106
Uhlmann
39. Burgess MM, Adam S, Bloch M, Hayden MR. Dilemmas of anonymous predictive testing for Huntington disease: privacy vs. optimal care. Am J Med Genet 1997; 71:197–201. 40. Visintainer CL, Matthias-Hagen V, Nance MA, US Huntington Disease Genetic Testing Group. Anonymous predictive testing for Huntington’s disease in the United States. Genet Test 2001; 5:213–218. 41. Uhlmann WR, Ginsburg D, Gelehrter TD, Nicholson J, Petty EM. Questioning the need for anonymous genetic counseling and testing. Am J Hum Genet 1996; 59:968–970. 42. Mehlman MJ, Kodish ED, Whitehouse P, Zinn AB, Sollitto S, Berger J, Chiao EJ, Dosick MS, Cassidy SB. The need for anonymous genetic counseling and testing. Am J Hum Genet 1996; 58:393–397. 43. Bird TD. Risks and benefits of DNA testing for neurogenetic disorders. Semin Neurol 1999; 19:253–259.
Copyright 2006 by Taylor & Francis Group, LLC
6 Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders Craig L. Bennett Division of Genetics and Developmental Medicine, Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, U.S.A.
SCOPE OF THIS CHAPTER At present, over 20 genes have been identified that through mutation cause various forms of Charcot-Marie-tooth (CMT) disease. The major division of CMT into type 1 (CMT1) and type 2 (CMT2) has been accepted for many years now, and this division still seems to be helpful in delineating the various types of CMT despite the ever increasing identification of CMT genes and genetic loci. In this chapter, I will focus predominantly on the autosomal dominant (AD) forms of CMT1 (demyelinating) and CMT2 (axonal). The autosomal recessive (AR) forms of CMT are less common and will not be reviewed in this chapter for space constraints (discussed in Ref. 1). I will describe the basic clinical and genetic features of the major forms of AD CMT1 and CMT2, along with a discussion of the possible underlying pathogenetic mechanism for each CMT form, if it is known. CMT: BACKGROUND AND GENERAL CLINICAL FEATURES CMT neuropathy or hereditary motor and sensory neuropathy (HMSN) is a group of heterogeneous inherited diseases of peripheral nerves (2–4). CMT
Copyright 2006 by Taylor & Francis Group, LLC
108
Bennett
is a common disorder affecting both children and adults, causing significant neuromuscular impairment. With an estimated 1 in 2500 persons affected, CMT is a major contributing category within all neurogenetic diseases (5). CMT contributes to significant morbidity, and in one or two rare forms, CMT also contributes to mortality. A major diagnostic criterion of CMT is that both motor and sensory nerve functions are affected, which leads to clinical features that include distal muscle weakness and atrophy, impaired sensation, and absent or hypoactive deep tendon reflexes. The onset of CMT is typically within the first or second decade of life, although it may be detected by neurophysiological methods in infancy. The spectrum of CMT clinical presentation is wide, ranging from individuals with clinical findings of pes cavus with minimal or no distal muscle weakness to patients with severe distal atrophy and marked hand and foot deformity. CMT patients most commonly present with signs and symptoms of muscle loss and weakness of the lower legs and feet. Later the disorder progresses to affect the hands and forearms. For many patients, a history of abnormal gait with frequent tripping is reported. Patients may also present with complaints related to foot deformities resulting from loss of intrinsic muscles (pes cavus). Less often a patient’s initial complaint may be a sensory-related problem. Patients will frequently benefit from physical therapy where indicated and ankle-foot orthotics (AFOs) are often used to alleviate foot drop in some patients. Surgery should only be considered when pain or difficult walking results from severe foot deformity, or cannot be managed by more conservative (less invasive) means. Recent data suggest that foot deformities need to be aggressively managed, particularly when the disease manifests early in adolescence. Prevention of deformities before they become fixed can make it possible for a plantigrade foot that is capable of bearing normal body loads to fit better into shoes, allowing for more comfortable ambulation which prevents future problems (6).
ELECTROPHYSIOLOGICAL CLASSIFICATION OF CMT The current CMT classification system divides the disorder into two broad categories. The first is demyelinating CMT (CMT type 1 or ‘‘CMT1’’) that likely results from Schwann cell (SC) dysfunction, leading to loss of peripheral nervous system (PNS) myelin. The second category are those forms of CMT resulting from putative axonal degeneration (axonal CMT, CMT type 2 or ‘‘CMT2’’) (7). Individuals with CMT1 show hypertrophic demyelinating neuropathy (‘‘onion bulbs’’) on pathological examination. Patients have reduced motor and sensory nerve conduction velocities (NCVs) (<38–40 m/sec) and prolonged distal latencies. The reduction of NCVs seen
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
109
in CMT1 are uniform and symmetric, a feature that contrasts with the acquired demyelinating neuropathies. In contrast, CMT2 patients possess a relatively preserved myelin sheath and generate normal or near normal NCVs. More diagnostic of axonal CMT2 is that patients show very low motor compound muscle action potentials (CMAPs) and sensory nerve action potentials (SNAPs) that are either reduced in amplitude or absent. Other subdivisions of CMT classification include the more severe forms of CMT such as Dejerine-Sottas disease and congenital hypomyelination. CMT4 is used to designate AR forms of demyelinating CMT. There is also the relatively new category of dominant intermediate CMT (DI-CMT) with features of both demyelinating and axonal CMT. Mutation of the Dynamin 2 gene (DNM2) has recently been identified as the molecular basis of DI-CMTB (8). The mechanism by which mutations in the DMN2 gene, which encodes a protein of the large GTPase family, lead to an intermediate form of CMT is not known. The various chromosomal locations and genetic mechanisms underlying the various forms of CMT and related disorders are given in Table 1.
MAJOR FORMS OF DEMYELINATING CMT1 Genetics of CMT1 The mode of inheritance in CMT1 is AD. The majority of CMT1 pedigrees are linked to chromosome 17p11.2-12 and are designated as CMT1A (9). Genetic linkage studies have indicated that some CMT1 pedigrees demonstrate linkage to the long arm of chromosome 1 and have been designated CMT1B (10). Rare AD CMT1 pedigrees that map to chromosome 16p13 have been designated CMT1C (11). Additional pedigrees have been identified that link to chromosome 10q21-q22 and have been assigned the designation CMT1D (12). The X-linked form of demyelinating CMT1 maps to chromosome Xq13.1 and is now termed CMT1X (13). The causal genes for each form of CMT1 will be described in detail further. CMT1: Etiology and Pathogenesis Much of what is known of the etiology and pathogenesis of CMT1 comes from early studies on CMT1A or CMT1B. More recently, the genes that cause other forms of CMT1 have been discovered. This chapter will focus on the genes that through mutation cause the major forms of AD CMT1 and CMT2. Particular attention will be given to those genes that have yielded new understanding of pathogenetic mechanisms leading to disease, and to the genes that account for a high percentage of total CMT disease.
Copyright 2006 by Taylor & Francis Group, LLC
110
Bennett
Table 1 Charcot-Marie-Tooth Genes, Genetic Loci and Mode of Inheritance Inheritance
Locus
Gene
Mechanism
17p11-p12
PMP22
AD AD AD AD
1q22-q23 16p12-p13 10q21-q22 1q22-q23
MPZ SIMPLE EGR2 MPZ
Duplication/ Point mutation Point mutation Point mutation Point mutation Point mutation
AD X-linked
8p21 Xq13
NF-L Cx32
Point mutation Point mutation
17p11-p12 1q22-q23 10q21-q22 8q23-q24 19q13
PMP22 MPZ EGR2 ? PRX
Point Point Point ? Point
17p11-p12 1q22-q23 10q21-q22
PMP22 MPZ EGR2
Point mutation Point mutation Point mutation
Hereditary neuropathy with pressure palsies HNPP A AD 17p11-p12
PMP22
Deletion/ point mutation
1p35-p36 1p35-p36 3q13-q22
KIF1Bb MFN2 Rab7
Point mutation Point mutation Point mutation
12q23-q24
?
?
7p14 8p21 1q22-q23 Xq13 3q13
GARS NF-L MPZ Cx32 ?
Point Point Point Point ?
Xq24-q26 Xq26
? ?
? ?
Charcot-Marie-Tooth Type 1 CMT1A AD CMT1B CMT1C CMT1D CMT1E (deafness) CMT1F CMT1E Dejerine-Sottas (HMSNIII) DSDA DSD B DSD C DSD D DSD E
disease AD(AR) AD(AR) AD AD AR
Congenital hypomyelination (CMT4E) CHN A AD CHN B AD CHN C AD (AR)
Charcot-Marie-Tooth Type 2 (HMSNII) CMT2A AD CMT2A AD CMT2B AD (ulcers) CMT2C (vocal AD cord) CMT2D AD CMT2E AD (CMT1B) AD (CMTX) X-linked CMT2G AD (HMSNP) CMT2XA X-linked CMT2XB X-linked
mutation mutation mutation mutation
mutation mutation mutation mutation
(Continued)
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
111
Table 1 Charcot-Marie-Tooth Genes, Genetic Loci and Mode of Inheritance (Continued ) Inheritance
Gene
Mechanism
1q21
LMNA ?
Point mutation ?
8q13-q21 11q22 11p15 ? 5q23-q33 8q24
GDAP1 MTMR2 SBF2 ? KIAA1985 NDRG1
Point Point Point ? Point Point
19q13
PRX
Point mutation
Charcot-Marie-Tooth ‘‘dominant intermediate’’ DI-CMTA AD 10q24 DI-CMTB AD 19p12
? DNM2
DI-CMTC
?
? Deletion/ point mutation ?
CMT2 AR A CMT2 AR B (CMT4C)
AR AR
Charcot-Marie-Tooth Type 4 CMT4A AR CMT4B1 AR CMT4B2 AR CMT4B3 AR CMT1 AR C AR CMT1 AR D AR (HMSNLom) CMT1 AR F AR (CMT4F)
AD
Locus
1p34
mutation mutation mutation mutation mutation
Abbreviations: AD, autosomal dominant; AR, autosomal recessive.
CMT1A: The Peripheral Myelin Protein-22 Gene CMT1A is associated with a 1.5 megabase (Mb) tandem DNA duplication on chromosome 17p11.2-p12 (14,15), and has been detected in many ethnic groups (16). The duplication in most pedigrees is inherited as a stable Mendelian trait; however, in some instances, it may arise as a de novo event. Features consistent with CMT1A have also been detected in patients with either partial or complete trisomy 17p, providing further support for the hypothesis that the duplication in CMT1A results from a gene dosage mechanism (17,18). Further understanding of the disease mechanism in CMT1A was provided by studies of murine disease models. The trembler (Tr) mouse suffers a dominantly inherited hypomyelinating neuropathy and has subsequently been found to represent a murine model for CMT1A (19). The gene for the Tr locus was identified when a point mutation was found in the peripheral myelin protein-22 (PMP22) gene (20). These findings in the Tr mouse suggested that the human PMP22 gene might map within the CMT1A gene duplication region, which was subsequently proven (21). While rarer in comparison to the duplication mutation, point mutations of the PMP22 gene in CMT1A patients were subsequently identified (22,23).
Copyright 2006 by Taylor & Francis Group, LLC
112
Bennett
The PMP22 gene encodes a membrane-associated protein of 18 kD that is increased to 22 kD by glycosylation. PMP22 localizes to the compact portions of peripheral nerve myelin (Fig. 1, reproduced from Ref. 24), and contains four putative transmembrane domains (25–27). Chance et al. suggested that the neuropathy in patients with the 17p11.2–12 duplication may result from the additional copy of PMP22 gene leading to a 50% increase in expression at this locus (17). This was subsequently confirmed by examining patients’ sural nerve biopsy for PMP22 message and protein levels (28–30). It should be noted that the meiotic events that lead to the duplication in CMT1A can also cause the reciprocal chromosome deletion. When this occurs, a 50% reduction in the copy number of the PMP22 gene results. Patients receiving the deletion chromosome suffer a disorder known as hereditary neuropathy with liability to pressure palsies (HNPP), a disorder characterized by painless episodic, recurrent, and focal demyelinating nerve palsies (31). The fact that duplication or deletion of PMP22 gene can lead to either CMT1A or HNPP highlights the dosage sensitivity of PMP22. A greater level of effort has gone into understanding the disease pathology of CMT1A and the biology of the PMP22 protein than for any other CMT gene to date. PMP22 proteins carrying missense mutations associated with CMT1A are retained intracellularly (32–35) and appear to belong to a growing class of mutations termed ‘‘endoplasmic reticulum (ER) retention mutations’’ (36). These are mutations that are recognized by ER-resident-folding proteins, molecular chaperones, and/or other enzymes that serve to monitor the fidelity of protein synthesis and macromolecular assembly (37,38). In wild-type sciatic nerves, PMP22 associates in a specific, transient (t1/2 11 min), and oligosaccharide processing-dependent manner with the lectin chaperone calnexin (CNX). In sciatic nerves of Trembler-J mice (point mutation), prolonged association of mutant PMP22 with CNX is found (t1/2 > 60 min) (36). Regulation of myelination not only requires timely synthesis of sufficient quantities of myelin constituents, but also their coordinated trafficking and assembly. In SC, 80% of newly synthesized PMP22 is known to be rapidly degraded (39). This likely serves as a major burden on the cellular machinery responsible for clearing misfolded proteins and, if this balance is perturbed due to overexpression of PMP22, CMT1A results (40). This phenomenon of misfolded protein is also seen with the cystic fibrosis membrane protein CTFR, where up to 75% of newly synthesized protein is rapidly degraded (41). Trembler mice, in which one PMP22 allele is mutated (G150D), are much more severely affected than PMP22þ/ heterozygous mice carrying a single PMP22 allele (42). They have less myelin than PMP22þ/ animals, and the steady state levels of their myelin-specific mRNAs are dramatically reduced (43). It has been suggested that PMP22 protein interactions with chaperone proteins within the ER may account for the observed decrease
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
113
Figure 1 The organization of a myelinated axon. Panel (A) depicts an ‘‘unrolled’’ myelinating Schwann cell, revealing the regions that form compact and non-compact myelin. Tight junctions are depicted as two continuous (faint grey) lines; these form a circumferential belt and are also found in incisures. Gap junctions are depicted as grey ovals; these are found between the rows of tight junctions, and are more numerous in the inner aspects of incisures and paranodes. Adherens junctions are depicted as dark ovals; these are more numerous in the outer aspects of incisures and paranodes. The nodal, paranodal, and juxtaparanodal regions of the axonal membrane are all indicated by labeled arrows, respectively. Panel (B) depicts the proteins of compact and non-compact myelin. Compact myelin contains P0, PMP22, and MBP; non-compact myelin contains E-cadherin, MAG, DM20, Cx32, and an unknown claudin. Source: Adapted from Ref. 24.
Copyright 2006 by Taylor & Francis Group, LLC
114
Bennett
in myelin protein insertion of PMP22 protein. Misfolded proteins in the ER subsequently activate transcription of the gene encoding GRP78 (BiP), and other ER-resident proteins through the transcription factor, HAC1 (44,45). Mutant PMP22 is sequestered in the ER after transfection into Cos-7 cells, and the protein mislocalized to the ER in Trembler sciatic nerve (33). Therefore, PMP22 is a peripheral nerve protein that is highly dependent on the cellular machinery for detecting and degrading misfolded proteins. One hypothesis is that if the SC burden to remove misfolded proteins is increased through point mutations or through overexpression, a disease state can result. It is known that PMP22 has three major transcript lengths that all encode the same protein. One PMP22 transcript is expressed from a nerve-specific promoter by using an alternate untranslated exon, 1A (46). It has been suggested that this nerve-specific transcript could be the target for specific knock-down as a therapeutic strategy for CMT1A in future studies (47). CMT1B: The Myelin Protein Zero Gene The clinical presentation in CMT1B is virtually identical to that seen in CMT1A (48). Mutations in the human myelin protein zero (MPZ ) gene, which was mapped to chromosome 1q22-q23, are the molecular basis of CMT1B (49). The protein encoded by MPZ is the major structural component of PNS myelin (approximately 50% of total protein mass) and represents approximately 7% of total SC mRNA (50). MPZ is a member of the immunoglobulin super-family of cell adhesive molecules and localizes to the compact portion of peripheral nerve myelin (Fig. 1). MPZ is a 28-kD protein with a single transmembrane spanning domain. Analysis of MPZ as a candidate gene for CMT1B revealed point mutations in affected individuals from pedigrees with this disorder (49). Numerous additional mutations in MPZ associated with CMT1B pedigrees have been described [96 different MPZ mutations (HGMD)], firmly establishing mutations in this crucial component of peripheral nerve myelin as the molecular basis of CMT1B. The MPZ gene, like PMP22, may also be dosage-sensitive. With either murine models of MPZ overexpression or MPZ-null mice, myelination defects of varying degrees occur. For example, Wrabetz et al. (51) demonstrated that transgenic mice containing extra copies of MPZ manifested a dose-dependent, dysmyelinating neuropathy, ranging from transient perinatal hypomyelination to arrested myelination. Normal myelination could be restored by breeding the transgene into an MPZ-null background. Interestingly, while MPZ mRNA overexpression ranged between 30–700%, increased MPZ protein was only detected in nerves of low-copy-number animals and dysmyelination only occurred when MPZ overexpression was increased between 30% and 80%. It is well established that mice either homo- or heterozygous null for the MPZ gene, share pathological features
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
115
with human patients suffering from MPZ-related Dejerine-Sottas syndrome (DSS) or CMT1B, respectively (52). CMT1C: The Small Integral Membrane Protein of the Lysosome/Late Endosome The CMT1C designation was originally assigned when two families with AD CMT1 did not link with either of the major CMT1 loci on chromosome 1 or chromosome 17 (7). A subsequent genome-wide linkage study mapped the locus for CMT1C to chromosome 16p13.1-p12.3 (11). Affected individuals in these families manifest characteristic CMT1 symptoms including high-arched feet, distal muscle weakness and atrophy, depressed deep tendon reflexes, sensory impairment, slow NCVs, and nerve demyelination. Point mutations in the small integral membrane protein of the lysosome/late endosome (SIMPLE) gene were found to be the cause of CMT1C (53). In the three families originally described, and in additional pedigrees subsequently identified, the CMT1C phenotype could not be distinguished from either CMT1A or CMT1B (53,54). SIMPLE protein localization has been examined in several studies, and interestingly, SIMPLE does not locate to the myelin membrane like PMP22 and MPZ. Using recombinant protein, Moriwaki et al. found that SIMPLE localized to the lysosome/early-endosome in several cells lines (55). Bennett et al. examined human sciatic nerve samples by immunohistochemistry (IHC) and found that SIMPLE was present in most types of cells of the nerve and that SIMPLE did not localize to the myelin sheath of SC, but rather showed a cytoplasmic localization (54). Another finding for SIMPLE that can be contrasted with other genes that cause CMT1 is that the SIMPLE message does not undergo characteristic changes in expression following Wallerian degeneration (53). Further, northern blot analysis has shown that SIMPLE mRNA is present in all tissues examined which contrasts with limited expression of other CMT1 genes (53). It has been proposed that altered lysosomal function and protein degradation may have an impact on myelin development and maintenance based on the up regulation of this pathway in the Tr-J mouse (56). Lysosomal involvement may prove to be a common feature of both CMT1A and CMT1C. Mutated SIMPLE may exert its effects through a loss-of-function or dominant-negative mechanism leading to defects in lysosomal degradation, a pathway in which SIMPLE protein is proposed to operate (53). Currently, DNA testing is available for SIMPLE mutations on a research basis only; however, testing will soon be available commercially. CMT1D: The Early Growth Response 2 Protein Gene CMT1D is a rare but severe form of CMT1. Mutations of the early growth response 2 (ERG2) protein gene have been found in patients with severe
Copyright 2006 by Taylor & Francis Group, LLC
116
Bennett
forms of demyelinating CMT (CMT1D) and Dejerine-Sottas neuropathy (DSN; OMIM:145900) (12,57). To date, only six different point mutations of the EGR2 gene have been identified (HGMD). The EGR2 protein is a transcription factor with three tandem C2H2type zinc fingers, and plays a crucial role in the regulation of PNS myelination (58). Mice deficient in the murine orthologue of EGR2 (Krox20) show a total lack of myelin (amyelination) (59). Overexpression of EGR2 in SC leads to increased expression of MPZ, PMP22, GJB1/Cx32, periaxin (PRX) and other myelin-related genes (58). The fact that ERG2 is involved in controlling expression of so many critical myelin proteins may explain why mutation of this protein often leads to severe forms of CMT1. DNA testing for EGR2 mutations is commercially available. CMT1X: The Connexin 32 (Cx32/GJB1) It may be that CMT1X would more appropriately be placed within a unique category of its own, as it possibly represents both a demyelinating and an axonal form of CMT. When CMT1X is included within the CMT1 category, it represents a major proportion, accounting for approximately 10% of all demyelinating CMT patients. CMT1X has features of a demyelinating CMT1 neuropathy, as well as an absence of male-to-male transmission, an earlier age of onset, and a faster rate of progression in males than in females. The electrodiagnostic (EDX) findings in CMT1X are complicated, with significant gender differences. Motor NCVs in male CMT1X patients often fall in the intermediate range 30–40 m/sec in the upper extremities. Females may have normal NCVs or mild slowing only (60). CMAP amplitudes are often low in median, ulnar, and peroneal nerves with intermediate slowing. SNAPs are abnormal in most patients, especially in the lower extremities. EMG examination shows rare active denervation (fibrillation potentials and, positive sharp waves) with chronic reinnervation (reduced recruitment of large motor unit action potentials) in distal muscles. It remains to be determined whether CMT1X is primarily an axonal loss or a demyelinating disorder. Some have reported pathologic findings consistent with axonal loss (60,61), whereas others have reported findings consistent with a primary demyelinating neuropathy (62,63). Associated central nervous system (CNS) findings have been reported in some patients, including transient and reversible neurologic deficits (weakness, numbness, abnormalities of cranial nerves, dysarthria, and aphasia) associated with reversible, confluent white matter lesions seen on MRI of the brain (64–66). CMT1X maps to chromosome Xq13-q21 and results from point mutations in the connexin-32 (Cx32) gene also known as the gap junction beta-1 gene (GJB1) (67). Cx32 encodes a protein of 284 amino acids and is a major component of gap junctions. Cx32 is structurally similar to the PMP22
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
117
protein, both proteins containing four putative transmembrane domains in similar orientation. To date, 244 different mutations of the Cx32 protein have been described in CMT1X patients. Cx32 has a pattern of expression in peripheral nerve similar to that of other structural myelin genes which are immediately down regulated following crush or transection nerve injury experiments. IHC studies show that the Cx32 protein localizes to the uncompacted folds of SC cytoplasm around the nodes of Ranvier and at Schmidt–Lanterman incisures, unlike PMP22 and MPZ which are present in compact myelin (67) (Fig. 1). This localization suggests a role for gap junctions composed of Cx32 in providing a pathway for the transfer of ions and nutrients across the folds of the myelin sheath. DNA testing is clinically available for GJB1/Cx32 mutations causing CMT1X.
MAJOR FORMS OF DEMYELINATING CMT2 Genetics of CMT2 CMT2 is less common than CMT1, accounting for approximately 30% of all forms of CMT (68). Many loci have now been identified that cause rare forms of CMT2 in different families, with both AD (CMT2) and AR inheritance (AR-CMT2 or CMT4C). The fact that several of the genes that cause CMT have now been shown to cause either CMT1 or CMT2 through rare mutations, complicates these clinical designations. It was originally unclear if mutations in any single gene would prove to be a common cause of CMT2. It has recently become apparent that mutations in the Mitofusin 2 (MFN2) gene is the major cause of CMT2A and may ultimately prove to be the most common cause of CMT2 (69). It is also possible that mutations of the ganglioside-induced differentiationassociated protein 1 (GDAP1) gene may emerge as a relatively frequent cause of CMT4C or AR-CMT2 (not described in detail in this chapter). CMT2: Etiology and Pathogenesis In general, CMT2 has a later age-of-onset than CMT1, produces less involvement of the intrinsic muscles of the hands, and lacks palpably enlarged nerves. Extensive demyelination with ‘‘onion bulb’’ formation is not present in CMT2. Axonal pathological changes consist of a loss of large myelinated axons and signs of regeneration with abundant small thinlymyelinated axons (70). Clinical DNA testing is not widely available for most forms of CMT2, but a few reference laboratories will sequence the NEFL gene that causes CMT2E. Also, sequencing of the GDAP1 gene is available for recessive forms of CMT that span the range of phenotypes: severe
Copyright 2006 by Taylor & Francis Group, LLC
118
Bennett
demyelinating CMT4A, severe axonal CMT4C4 with vocal cord paresis, and severe axonal or intermediate CMT4C5 without accessory features. CMT2A: The Mitofusin 2 Gene CMT2A was first mapped to chromosome 1p35-p36 in three CMT2 families (71). A mutation in the KIF1B gene, which encodes an axonal motor protein, was found in one Japanese pedigree (72,73). Subsequent analysis of additional pedigrees mapping within the original 9.6-cM interval have shown that CMT2A more commonly results from mutations of the MFN2 (69). All pedigrees with CMT2A are defined by distal muscle weakness and atrophy, depressed deep tendon reflexes, pes cavus, and abnormal EDX exams compatible with CMT2. Like most CMT2 pedigrees, CMT2A is characterized with variable disease expression, variable age-of-onset, and NCVs that are normal or only slightly diminished. A total of 13 mutations have now been reported in the MFN2 gene (69). In fact, it may be that MFN2 mutations will prove to be the most common cause of CMT2. A small study of 36 families with axonal CMT, each too small for linkage analysis, uncovered seven additional individuals (19%) with MFN2 mutations as part of the initial study reporting the MFN2 gene as the cause of CMT2A. MFN2 is expressed predominantly in skeletal muscle and heart, with lower expression in brain, kidney, and liver (74). Message has also been detected in spinal cord and peripheral nerve by northern blot (69). MFN2 protein localizes to the outer mitochondrial membrane and regulates the mitochondrial network architecture by fusion of mitochondria. Six of seven MFN2 mutations were identified within or immediately upstream of the GTPase domain of MFN2. It has been shown that an intact GTPase domain is essential for the function of mitofusins (75–77). Mitochondria undergo a dynamically regulated balance between fusion and fission reactions and have a tubular and branched membrane network (78). An efficient mitochondrial network is required for fundamental cell functions, such as equilibrating mitochondrial gene products to overcome acquired somatic mutations of mitochondrial DNA (79), and establishing a uniform membrane potential for energy supply (80). These essential functions of mitochondria may be perturbed by mutations of MFN2. Zuchner et al. (69) suggest that MFN2 may also be involved in the process of apoptosis as MFN2 protein colocalizes with the proapoptotic protein, Bax (81). Homozygous Mfn2 knockout mice die in mid-gestation owing to placental defects (75). Although heterozygous Mfn2þ/ mice were reported to have a normal phenotype, murine embryonic fibroblast cultures from Mfn2þ/ mice had markedly lower mitochondrial mobility (75). To date, it is not known if Mfn2þ/ mice will develop a CMT2A-like phenotype with
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
119
age. Zuchner et al. hypothesize that mobility and transport of mitochondria, which are key elements to the functional health of the extended neuronal axons, may be affected by MFN2 mutations and lead to CMT2A (69). Looking toward a future therapy for CMT2A, a virally transported MFN2 construct in a Mfn2þ/ murine cell line was shown to rescue mitochondrial fusion–fission imbalances (75), raising the intriguing possibility that CMT2A may be amenable to future intervention. Currently, DNA testing for MFN2 is available on a research basis only. CMT2B: Ras-Associated Protein CMT2B is one form of CMT where limb ulceration is a prominent feature (OMIM: 600882) and onset is in the second or third decade of life. The degree of neuropathy ranges from mild to severe, with distal muscle weakness and wasting often preceding the onset of sensory loss, foot ulceration, infections, and amputations of the toes. It has been argued that CMT2B could be classified as a hereditary sensory and autonomic neuropathy, but motor features are also common to the families with Ras-associated protein (RAB7) missense mutations. CMT2B was mapped to chromosome 3q13q22 (82) and results from mutations in the RAB7 gene (83). Mutations in RAB7 appear to be rare, and to date only the two missense mutations have been reported. The RAB7 protein is a member of the Rab family of ras-related GTPases. Members of this family are important regulators of vesicular transport and are located in specific intracellular compartments such as the late endosome and the late endocytic pathway. In addition, RAB7 has been shown to have a fundamental role in the cellular vacuolation induced by the cytotoxin VacA of Helicobacter pylori (84), and to be ubiquitously expressed (83). Interesting results have been produced with RAB7 knock-down models in various cell lines. Down regulation of RAB7 in HeLa cells by antisense RNA induces severe cell vacuolation that resembles the phenotype seen in fibroblasts of patients with Chediak–Higashi syndrome (OMIM: 214500) (85). In growth factor deprived cells, Edinger et al. found that blocking RAB7 function prevented the clearance of glucose and amino acid transporters from the cell surface (86). In the same growth factor deprived–RAB7 inhibited cells, mitochondrial membrane potential was maintained and cells displayed prolonged growth-factor-independent, nutrient-dependent cell survival. The authors concluded that RAB7 functions as a proapoptotic protein by limiting cell-autonomous nutrient uptake. Interestingly, some comparisons can be made between the CMT2B and CMT1C. Both RAB7 and SIMPLE: (i) localize to the late endosome or lysosome/late endosome, respectively, (ii) cause CMT disease through AD inheritance of missense mutations, and (iii) are ubiquitously expressed.
Copyright 2006 by Taylor & Francis Group, LLC
120
Bennett
Further understanding of how these two proteins, which may have some functional overlap, can lead to rare forms of demyelinating or axonal CMT will be of interest and the subject of future functional studies. CMT2C: Causal Gene Unknown Further genetic heterogeneity within CMT2 is evidenced by the identification of kindreds with the features of axonal neuropathy, weakness of the diaphragm, and vocal cord paralysis. Such pedigrees, which are rare, carry the designation CMT2C, and have been mapped to chromosome 12q23q24 (87). The onset of CMT2C is typically slow and insidious, with respiratory symptoms and alterations in voice. The muscles of the hand become weak and atrophic, but leg weakness may often be asymptomatic. EDX testing reveals an axonal sensorimotor peripheral neuropathy. NCVs are generally normal or only mildly slowed in patients. CMAP amplitudes are low or absent in the lower extremities and normal or low in the upper extremities. SNAPs are absent or low in the lower extremities. EMG testing shows mild active denervation (positive sharp waves and fibrillation potentials) with chronic reinnervation including reduced recruitment of large, prolonged, polyphasic motor unit action potentials (88). Phrenic nerve stimulation reveals low or absent CMAP amplitudes in the majority of patients (88). Laryngeal EMG examination of one patient with CMT2C revealed fibrillation potentials and reduced recruitment of large, polyphasic motor unit action potentials in some, but not all, laryngeal muscles (89). CMT2D: Glycyl-tRNA Synthetase CMT2D patients present with predominantly upper limb involvement. Onset has been documented in the second or third decade of life, with sensory deficits reaching the same prevalence as motor impairment and the degree of progression seems to be mild (OMIM: 601472). The CMT2D locus has been mapped to chromosome 7p14 (90), and mutations in the glycyl tRNA synthetase gene (GARS) have been associated with CMT2D (91). Four mutations in GARS have been reported, and some families show evidence of distal hereditary motor neuropathy 5/distal spinal muscular atrophy V (HMN V/dSMA-V), proving these are allelic disorders (91). Aminoacyl-tRNA synthetases perform the essential function in protein synthesis of catalyzing the esterification of an amino acid to its cognate tRNA. These enzymes are necessarily present in each cell. From their primary amino acid sequences, two classes of synthetases have been recognized, with similarity of certain structural features, amino acid attachment sites, and other properties between members of a class. The GARS gene seems to be another general housekeeping gene. Certain aminoacyl-tRNA synthetases are auto-antigens in patients with the idiopathic inflammatory myopathies, polymyositis, and dermatomyositis. On the surface, it may
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
121
seem surprising that mutations of such genes are the cause of peripheral neuropathies. Further analysis will be required to uncover the pathogenetic mechanism in this disorder. CMT2E: Neurofilament-Light Gene A large Russian pedigree segregating an AD CMT2 axonopathy was mapped to chromosome 8p21 and later designated CMT2E (92). A nonconservative missense mutation (A998C; Q333P) in the neurofilament light chain (NEFL) gene was found to cosegregate with the disease in all affected members of the family (93). The NEFL gene encodes a protein that is one of three major neurofilament (NF) protein constituents. The NEFL Q333P mutation is located within the coil domain 2B of the NEFL protein, the last and largest of four coil domains that form the rod region. Supporting evidence of the single-point mutation found within the Russian pedigree comes from murine studies. A L394P mutation in the same coil domain in the mouse orthologue resulted in a severe peripheral neuropathy. Interestingly, NEFL null mice do not have a CMT-like phenotype. A second Slovenian family has been identified with a slowly progressive CMT with onset in the first decade of life (94). Distal leg involvement precedes distal arm involvement, and all patients were ambulatory 20–30 years after disease onset. A P22S missense mutation was found to segregate with CMT2 disease. NEFL mutations have also been associated with CMT1F (not discussed in this review) with some patients in these pedigrees having near normal NCVs, suggesting that phenotypic overlap between CMT1 and CMT2 may occur with an identical mutation in a family (95,96). CMT2F: Heat-Shock 27-Kd Protein B1 A single Russian family was originally reported with typical CMT2 features. The age-of-onset in this large pedigree was the second or third decade of life. Initial lower limb involvement and slowly progressive disability, mild to moderate sensory deficits, including pain and temperature, occur in the feet and hands. Linkage analysis identified a locus at chromosome 7q11-q21 for this form of CMT designated CMT2F (97). On EDX testing, the findings were consistent with an axonal sensorimotor peripheral neuropathy. Subsequent analysis in the original Russian pedigree identified a missense mutation in the Heat-Shock 27-kD B1 protein (HSPB1) gene (98). Screening for mutations in HSPB1 in 301 individuals with CMT and 115 individuals with distal hereditary motor neuropathies (dHMNs) confirmed the previously observed mutation and identified four additional missense mutations. The additional HSPB1 mutations were found in four dHMN families and in one individual with CMT neuropathy (98).
Copyright 2006 by Taylor & Francis Group, LLC
122
Bennett
PROGNOSIS IN CMT The prognosis for many individuals with CMT is relatively favorable and it is very important to communicate this message to patients and to give them hope. Although occasional patients with CMT1 are confined to a wheelchair, most can anticipate remaining ambulatory with the use of simple bracing and having only a mild to moderate degree of impairment in functional strength. Patients with CMT2 generally also remain ambulatory throughout their lifetime. Patients with DSS are often wheelchair bound in childhood or by adolescence. Patients with CMT and HNPP have a normal life expectancy, with the important exception of patients with CMT2C, with diaphragmatic and vocal cord involvement, who may have a shortened lifespan from complications related to respiratory and bulbar insufficiency. The prognosis in HNPP is relatively benign, although rare patients develop a progressive peripheral neuropathy.
SUMMARY As was stated in the opening sentences of this chapter, a large number of genes have been recently discovered that cause CMT. More than half of these genes have been identified in the past four to five years. This has necessarily precipitated a burst of information regarding peripheral nerve biology and pathologic mechanisms in CMT. It is likely that the next five years will see more genes discovered but possibly at a slower rate as more emphasis is placed on uncovering the pathogenic mechanisms leading to peripheral nerve disease. It is hoped that the next major phase in CMT research will include improvements in molecular-based diagnostics, rational approaches to molecular therapeutics, and the development of targeted drug therapies.
ELECTRONIC DATABASES Human Gene Mutation Database (HGMD): http://archive.uwcm.ac.uk/ uwcm/mg/hgmd0.html REFERENCES 1. Vallat JM, Grid D, Magdelaine C, Sturtz F, Tazir M. Autosomal recessive forms of Charcot-Marie-Tooth disease. Curr Neurol Neurosci Rep 2004; 4:413–419. 2. Chance PF, Shapiro BE. Charcot-Marie-Tooth disease and related disorders. In: Katirji B, Kaminski HJ, Preston DC, Ruff RL, Shapiro BE, eds. Neuromuscular Disorders in Clinical Practice. Philadelphia: Butterworth-Heinemann, 2002.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
123
3. Dyck PJ, Chance PF, Lebo RV, Carney JA. Hereditary motor and sensory neuropathies. In: Dyck PJ, Thomas PJ, Griffin JW, Low PA, Poduslo JF, eds. Peripheral Neuropathy. Philadelphia: WB Saunders, 1993:1094–1136. 4. Scherer SS, Kleopa KA, Chance PF, Benson MD. Peripheral neuropathies. In: Rosenberg RN, Prusiner SB, DiMauro S, Barchi RL, Kunkel LM, eds. The Molecular and Genetic Basis of Neurological Disease. Oxford: ButterworthHeinemann, 2003:435–453. 5. Skre H. Genetic and clinical aspects of Charcot-Marie-Tooth’s disease. Clin Genet 1974; 6:98–118. 6. Hsu JD. Prevention of the development of foot and ankle deformaties in the adolescent Charcot-Marie-Tooth patient, First European and North American Charcot-Marie-Tooth Consortium Meeting, Antwerpen, July 8–10, 2004. 7. Chance PF, Bird TD, O’Connell P, Lipe H, Lalouel J-M, Leppert M. Genetic linkage and heterogeneity in type 1 Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy type 1). Am J Hum Genet 1990; 47:915–925. 8. Zuchner S, Noureddine M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005; 37:289–294. 9. Vance JM, Nicholson GA, et al. Linkage of Charcot-Marie-Tooth neuropathy type 1a to chromosome 17. Exp Neurol 1989; 104:186–189. 10. Bird TD, Ott J, Giblett ER. Evidence for linkage of Charcot-Marie-Tooth neuropathy to the Duffy locus on chromosome 1. Am J Hum Genet 1982; 34:388–394. 11. Street VA, Goldy JD, Golden AS, Tempel BL, Bird TD, Chance PF. Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies. Am J Hum Genet 2002; 70:244–250. 12. Warner LE, Mancias P, Butler IJ, McDonald CM, Keppen L, Gene Koob K, Lupski JR. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998; 18:382–384. 13. Omori Y, Mesnil M, Yamasaki H. Connexin 32 mutations from X-linked Charcot-Marie-Tooth disease patients: functional defects and dominant negative effects. Mol Biol Cell 1996; 7:907–916. 14. Lupski JR, Montes de Oca-Luna R, et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 1991; 66:219–232. 15. Raeymaekers P, Timmerman V, et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). Neuromusc Disord 1991; 1:93–97. 16. Raeymaekers P, Timmerman V, Nelis E, Van Hul W, De Jonghe P, Martin JJ, Van Broeckhoven C. Estimation of the size of the chromosome 17p11.2 duplication in Charcot-Marie-Tooth neuropathy type 1a (CMT1a). HMSN Collaborative Research Group. J Med Genet 1992; 29:5–11. 17. Chance PF, Matsunami N, Lensch W, Smith B, Bird TD. Analysis of the DNA duplication 17p11.2 in Charcot-Marie-Tooth neuropathy type 1 pedigrees: Additional evidence for a third autosomal CMT1 locus. Neurology 1992; 42:2037–2041. 18. Lupski JR, Wise CA, Kuwano A, Pentao L, Parke JT, Glaze DG, Ledbetter DH, Greenberg F, Patel PI. Gene dosage is a mechanism for Charcot-MarieTooth disease type 1A. Nat Genet 1992; 1:29–33.
Copyright 2006 by Taylor & Francis Group, LLC
124
Bennett
19. Falconer DS. Two new mutants, ‘‘Trembler’’ and ‘‘Reeler’’ with neurological actions in the mouse (Mus musculus L.). J Genet 1951; 50:192–201. 20. Suter U, Welcher AA, Ozcelik T, Snipes GJ, Kosaras B, Francke U, BillingsGagliardi S, Sidman RL, Shooter EM. Trembler mouse carries a point mutation in a myelin gene. Nature 1992; 356:241–244. 21. Matsunami N, Smith B, et al. Peripheral myelin protein-22 gene maps in the duplication in chromosome 17p11.2 associated with Charcot-Marie-Tooth 1A. Nat Genet 1992; 1:176–179. 22. Roa BB, Garcia CA, et al. Charcot-Marie-Tooth disease type 1A. Association with a spontaneous point mutation in the PMP22 gene. N Engl J Med 1993; 329:96–101. 23. Valentijn LJ, Baas F, Wolterman RA, Hoogendijk JE, van den Bosch NHA, Zorn I, Gabreels-Festen AAWM, de Visser M, Bolhuis PA. Identical point mutations of PMP-22 in Trembler-J mouse and Charcot-Marie-Tooth disease type 1A. Nat Genet 1992; 2:288–291. 24. Scherer SS, Arroyo EJ. Recent progress on the molecular organization of myelinated axons. J Peripher Nerv Syst 2002; 7:1–12. 25. Patel PI, Roa BB, et al. The gene for the peripheral myelin protein PMP-22 is a candidate for Charcot-Marie-Tooth disease type 1A. Nat Genet 1992; 1:159– 165. 26. Snipes GJ, Suter U. Molecular anatomy and genetics of myelin proteins in the peripheral nervous system. J Anat 1995; 186:483–494. 27. Snipes GJ, Suter U, Welcher AA, Shooter EM. Characterization of a novel peripheral nervous system myelin protein (PMP-22/SR13). J Cell Biol 1992; 117:225–238. 28. Gabriel JM, Erne B, Pareyson D, Sghirlanzoni A, Taroni F, Steck AJ. Gene dosage effects in hereditary peripheral neuropathy. Expression of peripheral myelin protein 22 in Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies nerve biopsies. Neurology 1997; 49: 1635–1640. 29. Schenone A, Nobbio L, et al. Correlation between PMP-22 messenger RNA expression and phenotype in hereditary neuropathy with liability to pressure palsies. Ann Neurol 1997; 42:866–872. 30. Yoshikawa H, Nishimura T, Nakatsuji Y, Fujimura H, Himoro M, Hayasaka K, Sakoda S, Yanagihara T. Elevated expression of messenger RNA for peripheral myelin protein 22 in biopsied peripheral nerves of patients with CharcotMarie-Tooth disease type 1A. Ann Neurol 1994; 35:445–450. 31. Windebank AJ. Inherited recurrent focal neuropathies. In: Dyck PJ, Thomas PJ, Griffin JW, Low PA, Poduslo JF, eds. Peripheral Neuropathy Vol. 144. Philadelphia: WB Saunders 1993:1137–1148. 32. D’Urso D, Prior R, Greiner-Petter R, Gabreels-Festen AA, Muller HW. Overloaded endoplasmic reticulum-Golgi compartments, a possible pathomechanism of peripheral neuropathies caused by mutations of the peripheral myelin protein PMP22. J Neurosci 1998; 18:731–740. 33. Naef R, Adlkofer K, Lescher B, Suter U. Aberrant protein trafficking in Trembler suggests a disease mechanism for hereditary human peripheral neuropathies. Mol Cell Neurosci 1997; 9:13–25.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
125
34. Naef R, Suter U. Impaired intracellular trafficking is a common disease mechanism of PMP22 point mutations in peripheral neuropathies. Neurobiol Dis 1999; 6:1–14. 35. Colby J, Nicholson R, Dickson KM, Orfali W, Naef R, Suter U, Snipes GJ. PMP22 carrying the trembler or trembler-J mutation is intracellularly retained in myelinating Schwann cells. Neurobiol Dis 2000; 7:561–573. 36. Dickson KM, Bergeron JJ, Shames I, Colby J, Nguyen DT, Chevet E, Thomas DY, Snipes GJ. Association of calnexin with mutant peripheral myelin protein22 ex vivo: a basis for ‘‘gain-of-function’’ ER diseases. Proc Natl Acad Sci USA 2002; 99:9852–9857. 37. Aridor M, Balch WE. Integration of endoplasmic reticulum signaling in health and disease. Nat Med 1999; 5:745–751. 38. Zapun A, Jakob CA, Thomas DY, Bergeron JJ. Protein folding in a specialized compartment: the endoplasmic reticulum. Structure Fold Des 1999; 7:R173–R182. 39. Pareek S, Notterpek L, et al. Neurons promote the translocation of peripheral myelin protein 22 into myelin. J Neurosci 1997; 17:7754–7762. 40. Roa BB, Garcia CA, Lupski JR. Charcot-Marie-Tooth disease type 1A: molecular mechanisms of gene dosage and point mutation underlying a common inherited peripheral neuropathy. Int J Neurol 1991; 25–26:97–107. 41. Ward CL, Kopito RR. Intracellular turnover of cystic fibrosis transmembrane conductance regulator. Inefficient processing and rapid degradation of wildtype and mutant proteins. J Biol Chem 1994; 269:25710–25718. 42. Adlkofer K, Naef R, Suter U. Analysis of compound heterozygous mice reveals that the Trembler mutation can behave as a gain-of-function allele. J Neurosci Res 1997; 49:671–680. 43. Garbay B, Domec C, Fournier M, Bonnet J. Developmental expression of the P0 glycoprotein and basic protein mRNAs in normal and Trembler mutant mice. J Neurochem 1989; 53:907–911. 44. Cox JS, Shamu CE, Walter P. Transcriptional induction of genes encoding endoplasmic reticulum resident proteins requires a transmembrane protein kinase. Cell 1993; 73:1197–1206. 45. Chapman R, Sidrauski C, Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus. Annu Rev Cell Dev Biol 1998; 14:459–485. 46. Nelis E, De Jonghe P, De Vriendt E, Patel PI, Martin JJ, Van Broeckhoven C. Mutation analysis of the nerve specific promoter of the peripheral myelin protein 22 gene in CMT1 disease and HNPP. J Med Genet 1998; 35:590–593. 47. Saifi GM, Szigeti K, Snipes GJ, Garcia CA, Lupski JR. Molecular mechanisms, diagnosis, and rational approaches to management of and therapy for CharcotMarie-Tooth disease and related peripheral neuropathies. J Invest Med 2003; 51:261–283. 48. Lewis RA, Sumner AJ, Shy ME. Electrophysiological features of inherited demyelinating neuropathies: a reappraisal in the era of molecular diagnosis. Muscle Nerve 2000; 23:1472–1487. 49. Hayasaka K, Himoro M, Sato W, Takada G, Uyemura K, Shimizu N, Bird TD, Conneally PM, Chance PF. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993; 5:31–34. 50. Lemke G. The molecular genetics of myelination: an update. Glia 1993; 7:263–271.
Copyright 2006 by Taylor & Francis Group, LLC
126
Bennett
51. Wrabetz L, Feltri ML, et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 2000; 148:1021–1034. 52. Martini R. P0-deficient knockout mice as tools to understand pathomechanisms in Charcot-Marie-Tooth 1B and P0-related Dejerine-Sottas syndrome. Ann NY Acad Sci 1999; 883:273–280. 53. Street VA, Bennett CL, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003; 60: 22–26. 54. Bennett CL, Shirk AJ, et al. SIMPLE mutation in demyelinating neuropathy and distribution in sciatic nerve. Ann Neurol 2004; 55:713–720. 55. Moriwaki Y, Begum NA, Kobayashi M, Matsumoto M, Toyoshima K, Seya T. Mycobacterium bovis Bacillus Calmette-Guerin and its cell wall complex induce a novel lysosomal membrane protein, SIMPLE, that bridges the missing link between lipopolysaccharide and p53-inducible gene, LITAF(PIG7), and estrogen-inducible gene, EET-1. J Biol Chem 2001; 276:23065–23076. 56. Notterpek L, Shooter EM, Snipes GJ. Upregulation of the endosomal-lysosomal pathway in the trembler-J neuropathy. J Neurosci 1997; 17:4190–4200. 57. Bellone E, Di Maria E, Soriani S, Varese A, Doria LL, Ajmar F, Mandich P. A novel mutation (D305V) in the early growth response 2 gene is associated with severe Charcot-Marie-Tooth type 1 disease. Hum Mutat 1999; 14:353–354. 58. Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J. EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron 2001; 30:355–368. 59. Tobler AR, Notterpek L, Naef R, Taylor V, Suter U, Shooter EM. Transport of Trembler-J mutant peripheral myelin protein 22 is blocked in the intermediate compartment and affects the transport of the wild-type protein by direct interaction. J Neurosci 1999; 19:2027–2036. 60. Birouk N, LeGuern E, et al. X-linked Charcot-Marie-Tooth disease with connexin 32 mutations: clinical and electrophysiologic study. Neurology 1998; 50: 1074–1082. 61. Hahn AF, Brown WF, Koopman WJ, Feasby TE. X-linked dominant hereditary motor and sensory neuropathy. Brain 1990; 113:1511–1525. 62. Bahr M, Andres F, Timmerman V, Nelis ME, Van Broeckhoven C, Dichgans J. Central visual, acoustic, and motor pathway involvement in a Charcot-MarieTooth family with an Asn205Ser mutation in the connexin 32 gene. J Neurol Neurosurg Psychiatry 1999; 66:202–206. 63. Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993; 43:2558–2564. 64. Hanemann CO, Bergmann C, Senderek J, Zerres K, Sperfeld AD. Transient, recurrent, white matter lesions in X-linked Charcot-Marie-Tooth disease with novel connexin 32 mutation. Arch Neurol 2003; 60:605–609. 65. Panas M, Karadimas C, Avramopoulos D, Vassilopoulos D. Central nervous system involvement in four patients with Charcot-Marie-Tooth disease with connexin 32 extracellular mutations. J Neurol Neurosurg Psychiatry 1998; 65:947–948. 66. Taylor RA, Simon EM, Marks HG, Scherer SS. The CNS phenotype of X-linked Charcot-Marie-Tooth disease: more than a peripheral problem. Neurology 2003; 61:1475–1478.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Charcot-Marie-Tooth Disease and Related Disorders
127
67. Bergoffen J, Scherer SS, et al. Connexin mutations in X-linked Charcot-MarieTooth disease. Science 1993; 262:2039–2042. 68. Harding AE, Thomas PK. The clinical features of hereditary motor and sensory neuropathy types I and II. Brain 1980; 103:259–280. 69. Zuchner S, Mersiyanova IV, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36:449–451. (Epub 2004 Apr 4). 70. Thomas PK, King RH, Small JR, Robertson AM. The pathology of CharcotMarie-Tooth disease and related disorders. Neuropathol Appl Neurobiol 1996; 22:269–284. 71. Ben Othmane K, Middleton LT, et al. Localization of a gene (CMT2A) for autosomal dominant Charcot-Marie-Tooth disease type 2 to chromosome 1p and evidence of genetic heterogeneity. Genomics 1993; 17:370–375. 72. Saito M, Hayashi Y, Suzuki T, Tanaka H, Hozumi I, Tsuji S. Linkage mapping of the gene for Charcot-Marie-Tooth disease type 2 to chromosome 1p (CMT2A) and the clinical features of CMT2A. Neurology 1997; 49:1630–1635. 73. Zhao C, Takita J, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001; 105:587–597. 74. Bach D, Pich S, et al. Mitofusin-2 determines mitochondrial network architecture and mitochondrial metabolism. A novel regulatory mechanism altered in obesity. J Biol Chem 2003; 278:17190–17197. (Epub 2003 Feb 21). 75. Chen H, Detmer SA, Ewald AJ, Griffin EE, Fraser SE, Chan DC. Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development. J Cell Biol 2003; 160:189–200. (Epub 2003 Jan 13). 76. Hales KG, Fuller MT. Developmentally regulated mitochondrial fusion mediated by a conserved, novel, predicted GTPase. Cell 1997; 90:121–129. 77. Santel A, Fuller MT. Control of mitochondrial morphology by a human mitofusin. J Cell Sci 2001; 114:867–874. 78. Nunnari J, Marshall WF, Straight A, Murray A, Sedat JW, Walter P. Mitochondrial transmission during mating in Saccharomyces cerevisiae is determined by mitochondrial fusion and fission and the intramitochondrial segregation of mitochondrial DNA. Mol Biol Cell 1997; 8:1233–1242. 79. Ono T, Isobe K, Nakada K, Hayashi JI. Human cells are protected from mitochondrial dysfunction by complementation of DNA products in fused mitochondria. Nat Genet 2001; 28:272–275. 80. Skulachev VP. Mitochondrial filaments and clusters as intracellular power-transmitting cables. Trends Biochem Sci 2001; 26:23–29. 81. Karbowski M, Lee YJ, et al. Spatial and temporal association of Bax with mitochondrial fission sites, Drp1, and Mfn2 during apoptosis. J Cell Biol 2002; 159:931–938. (Epub 2002 Dec 23). 82. Kwon JM, Elliott JL, Yee WC, Ivanovich J, Scavarda NJ, Moolsintong PJ, Goodfellow PJ. Assignment of a second Charcot-Marie-Tooth type II locus to chromosome 3q. Am J Hum Genet 1995; 57:853–858. 83. Verhoeven K, De Jonghe P, et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003; 72:722–727.
Copyright 2006 by Taylor & Francis Group, LLC
128
Bennett
84. Li Y, Wandinger-Ness A, Goldenring JR, Cover TL. Clustering and redistribution of late endocytic compartments in response to Helicobacter pylori vacuolating toxin. Mol Biol Cell 2004; 15:1946–1959. (Epub 2004 Jan 23). 85. Davies JP, Cotter PD, Ioannou YA. Cloning and mapping of human Rab7 and Rab9 cDNA sequences and identification of a Rab9 pseudogene. Genomics 1997; 41:131–134. 86. Edinger AL, Cinalli RM, Thompson CB. Rab7 prevents growth factor-independent survival by inhibiting cell-autonomous nutrient transporter expression. Dev Cell 2003; 5:571–582. 87. Klein CJ, Cunningham JM, et al. The gene for HMSN2C maps to 12q23–24: a region of neuromuscular disorders. Neurology 2003; 60:1151–1156. 88. Dyck PJ, Litchy WJ, Minnerath S, Bird TD, Chance PF, Schaid DJ, Aronson AE. Hereditary motor and sensory neuropathy with diaphragm and vocal cord paresis. Ann Neurol 1994; 35:608–615. 89. Dray TG, Robinson LR, Hillel AD. Laryngeal electromyographic findings in Charcot-Marie-Tooth disease type II. Arch Neurol 1999; 56:863–865. 90. Ionasescu VV, Kimura J, Searby CC, Smith WLJ, Ross MA, Ionasescu R. A Dejerine-Sottas neuropathy family with a gene mapped on chromosome 8. Muscle Nerve 1996; 19:319–323. 91. Antonellis A, Ellsworth RE, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72:1293–1299. (Epub 2003 Apr 10). 92. Mersiyanova IV, Perepelov AV, Polyakov AV, Sitnikov VF, Dadali EL, Oparin RB, Petrin AN, Evgrafov OV. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67:37–46. 93. Mersiyanova IV, Perepelov AV, Polyakov AV, Sitnikov VF, Dadali EL, Oparin RB, Petrin AN, Evgrafov OV. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67:37–46. 94. Georgiou DM, Zidar J, Korosec M, Middleton LT, Kyriakides T, Christodoulou K. A novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics 2002; 4:93–96. 95. De Jonghe P, Mersivanova I, Nelis E, Del Favero J, Martin JJ, Van Broeckhoven C, Evgrafov O, Timmerman V. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol 2001; 49:245–249. 96. Jordanova A, De Jonghe P, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126:590–597. 97. Ismailov SM, Fedotov VP, Dadali EL, Polyakov AV, Van Broeckhoven C, Ivanov VI, De Jonghe P, Timmerman V, Evgrafov OV. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J Hum Genet 2001; 9:646–650. 98. Evgrafov OV, Mersiyanova I, et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004; 36:602–606. (Epub 2004 May 02).
Copyright 2006 by Taylor & Francis Group, LLC
7 Duchenne and Becker Muscular Dystrophies Leta S. Steffen Program in Genomics, Children’s Hospital Boston, and Department of Genetics, Harvard Medical School, Boston, Massachusetts, U.S.A.
Louis M. Kunkel Program in Genomics, Children’s Hospital Boston, Department of Genetics, Harvard Medical School, and Howard Hughes Medical Institute, Boston, Massachusetts, U.S.A.
INTRODUCTION Muscular dystrophies are a heterogeneous group of muscle disorders characterized by progressive muscle weakening due to degeneration of muscle fibers and infiltration of connective and adipose tissue. To date, mutations in more than 20 genes have been identified in human muscular dystrophies (1,2). These genes encode structural proteins at the muscle fiber membrane and the contractile apparatus, as well as potential signaling and enzymatic molecules (see Fig. 1, reviewed in Refs. 2 and 3). Duchenne muscular dystrophy (DMD), a severe X-linked disease occurring in approximately 1 out of 3500 live male births, is the most common form of muscular dystrophy. Disease onset occurs in early childhood, causing bilateral weakness in the proximal muscles of the hip girdle and legs and progressing by age 11 to widespread weakening of the musculature and loss of ambulation. The average life expectancy of DMD patients is now in the third decade, with death most frequently resulting from respiratory failure
Copyright 2006 by Taylor & Francis Group, LLC
130
Steffen and Kunkel
Figure 1 The DAPC binds dystrophin at the muscle fiber sarcolemma, connecting the internal actin cytoskeleton to extracellular matrix components. The DAPC consists of the dystroglycans, the sarcospan–sarcoglycan complex, and dystrobrevin and syntrophin. Abbreviation: DAPC, dystrophin-associated protein complex.
or cardiac complications. Becker muscular dystrophy (BMD), affecting only 1 in 30,000 males, is a milder disease with onset after 5 years of age and a much broader variation in symptoms, rate of progression, and life expectancy. The gene mutated in both DMD and BMD was identified by Monaco et al. in 1986 using a revolutionary positional cloning method (4). Named dystrophin, the 2.4 Mb gene is the largest in the human genome, potentially explaining the high frequency of spontaneous disease-causing mutations (5). The 427 kDa dystrophin protein product was found to localize to the cytoplasmic face of the muscle membrane and co-purify with a large complex of proteins, called the dystrophin-associated protein complex (DAPC) (6–8). Subsequent research identified mutations in several genes encoding DAPC members that cause autosomal recessive limb girdle muscular dystrophies (2,3). Cloning of the dystrophin gene and subsequent protein studies have enabled significant diagnostic and therapeutic advances for Duchenne and Becker muscular dystrophies. Analysis of dystrophin protein in muscle biopsy specimens can distinguish DMD and BMD from many other muscular dystrophies. Current polymerase chain reaction (PCR) and sequencing
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
131
methods allow for the detection of most causative mutations, in many cases verifying diagnoses without invasive procedures and allowing accurate prenatal and carrier genetic testing. Most importantly, analysis of the genetic differences behind Duchenne and Becker muscular dystrophies has opened the door to several potential therapies, including cell and viral delivery of a functional truncated dystrophin gene and directed changes in dystrophin transcript splicing to alleviate the molecular and pathogenic characteristics of the disease. CLINICAL SYMPTOMS DMD affected boys are generally first seen by a physician for a variety of muscular and/or cognitive complaints between one and five years of age (reviewed extensively in Refs. 9 and 10). The most common complaints are motor delays, abnormalities in gait, frequent tripping or falling, and/or difficulty climbing stairs. Patients often walk with a characteristic waddling gait or on their toes because of weakening hip girdle and tibialis anterior muscles, respectively. Affected boys also experience difficulty rising from the floor and eventually exhibit Gower’s sign, using the hands to push off the floor and walk up the thighs into a standing position. Weakness is usually accompanied by muscle pseudohypertrophy—apparent enlargement, typically of the calf muscles, which is caused by infiltration of adipose and connective tissue into the degenerating muscle. Muscle weakness is bilateral and symmetrical, initiating in the proximal muscles and progressing to more distal muscles (9,10). Weakness is usually apparent in lower limbs before upper limbs and will eventually affect all voluntary muscles. By the age of 11, most DMD patients experience loss of ambulation. As a result of weakening trunk muscles and inactivity, patients develop pronounced scoliosis and secondarily, lung atelectasis. The combination of atelectasis and weakened intercostal and diaphragm muscles leads to decreased lung capacity and function in the later stages of the disease. Eventually, DMD patients become hypercapnic and may have difficulty clearing respiratory secretions, increasing the risk of pneumonia and respiratory failure. DMD patients may live into their mid to late twenties with respiratory insufficiency being a common cause of death. Some female carriers may exhibit mild dystrophic symptoms with later onset, including weakness, muscle fatigue, and calf pseudohypertrophy (9). BMD was first characterized as a distinct disease phenotype by Emil Becker in 1955 (11). Upon cloning of the dystrophin gene, it was found that BMD and DMD are allelic diseases. BMD exhibits many of the same symptoms as DMD, most strikingly the pattern of affected muscles. A subset of BMD patients also presents with symptoms of muscle pain and/or cramping (9). While DMD appears consistently severe and rapid in progression, BMD cases show later onset and slower progression but may vary in the severity of
Copyright 2006 by Taylor & Francis Group, LLC
132
Steffen and Kunkel
the clinical phenotype, making it difficult to distinguish from many other muscular dystrophies without diagnostic tests (9). Cardiac muscle tissue is also affected in DMD/BMD (reviewed in Ref. 12). DMD patients often have abnormal electrocardiograms and exhibit cardiomyopathy, usually after 10 years of age. Similar abnormalities have been observed in BMD patients, though often less severe, consistent with the overall milder phenotype. However, a subset of BMD patients exhibits severe cardiomyopathy, occasionally without accompanying skeletal muscle deficiencies (10,12). Female carriers may also exhibit late life cardiomyopathies and should be monitored regularly. Both DMD and BMD are characterized by a nonprogressive decrease in mean IQ by one standard deviation (average 85) such that one-third of DMD/BMD patients are mildly mentally retarded (13,14). A variety of specific verbal and language deficiencies has been suggested, possibly accounting for the overall low IQ (15–18). No direct genotype/phenotype correlation has been made, though mutations affecting the distal portion of dystrophin, particularly the brain-specific Dp140 transcript, have been reported to correlate with decreased IQ (19–22). CLINICAL DIAGNOSIS Approximately 70% of DMD/BMD cases have affected relatives, while the remaining 30% are considered de novo mutations (23). A preliminary diagnosis may often be made on the basis of the patient’s family history, pattern of muscle involvement, age of onset, and presence of any of the abovementioned clinical symptoms (Fig. 2). In almost all cases, a blood sample will be tested for increased serum levels of muscle enzymes to distinguish DMD and BMD from other neuromuscular disorders. Serum testing reveals dramatically increased levels of creatine kinase (CK) in DMD/BMD patients, usually 20–200 times that of an unaffected child, and similarly increased levels in most female carriers (9). Serum aldolase, alanine amino transferase (ALT), aspartate amino transferase (AST), and lactate dehydrogenase (LDH) levels will also be increased in DMD/BMD but are expressed in non-muscle tissues as well and are therefore less specific (9). In certain cases that do not clearly fit a dystrophic profile, electromyograms may be performed to exclude the possibility of a primary neurogenic disease. DMD is caused by mutations that change the reading frame of the transcript, resulting in a premature stop codon and transcript instability. Approximately 60% of these mutations are large deletions in the gene, 5% are duplications, and the remaining 35% are point mutations or small insertions/deletions (24–26). BMD results from mutations maintaining the reading frame of the transcript, and is associated with a higher incidence of deletions than DMD (25). To confirm a DMD/BMD diagnosis, multiplex PCR testing is performed across the deletional ‘‘hot spots’’ of the dystrophin
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
133
Figure 2 Current diagnostic procedure and a predicted future diagnostic procedure for Duchenne and Becker muscular dystrophies. The establishment of universal amplification techniques such as SCAIP for full, automated coverage of entire genes using single condition PCR may allow for identification of nearly all dystophin mutations. Abbreviation: SCAIP, single condition amplification/internal primers.
gene (Fig. 2). PCR across 18 exons (out of 79 total) detects 98% of deletional mutations (approximately 59% of total DMD/BMD) and can be used as an inexpensive primary diagnostic test for suspected DMD/BMD cases (27). If PCR screening does not identify an obvious mutation in dystrophin and there is no previous family history of the disease, a muscle biopsy is often performed to confirm the diagnosis. Histological examination of dystrophic muscle reveals variation in muscle fiber size, necrosis and phagocytosis, regenerating fibers, and connective and adipose tissue infiltration. Protein studies using antibodies against portions of the dystrophin protein may be used to distinguish DMD (and often BMD) from other muscular dystrophies. Immunohistochemistry on muscle biopsy sections shows nearly complete absence of dystrophin at the muscle fiber sarcolemma in DMD, muscle and often decreased dystrophin in BMD muscle. On western blot of muscle proteins, DMD samples exhibit little or no dystrophin protein (<3%) (28). BMD samples most commonly display decreased dystrophin size and/or abundance (28). Sequencing of the entire coding region of dystrophin may be needed to identify a mutation and confirm a diagnosis. Knowledge of the exact
Copyright 2006 by Taylor & Francis Group, LLC
134
Steffen and Kunkel
mutation also may be desired for entry into clinical trials, for prenatal testing or genetic testing of other family members, or for future tailoring of potential therapies. However, due to the enormous size of the dystrophin gene (79 exons over 2.4 kb), full sequencing to detect point mutations and small deletions/ duplications has been prohibitively costly and laborious until recently. Three main techniques are now employed by diagnostic laboratories to screen for non-deletional mutations not detected by multiplex PCR. Denaturing gradient gel electrophoresis (DDGE), denaturing high performance liquid chromatography (DHPLC), and ‘‘detection of virtually all mutations’’ single strand conformation polymorphism (DOVAM-SSCP) provide methods of screening dystrophin exons for deletions and small mutations, limiting the number of exons ultimately sequenced (29–31). If no deletional or point mutations are detected, duplications may be identified by multiplex amplifiable probe hybridization (MAPH), requiring a lengthy process of hybridizations and PCR amplifications for each patient (32). Recently, however, Flanagan et al. have established the technique SCAIP (single condition amplification/internal primers), allowing PCR amplification of the entire dystrophin gene and promoter regions under a single set of conditions to screen for large deletions (33). If no deletion is found, PCR products can be robotically purified and sequenced within a day, reducing the labor, time, and cost associated with traditional direct sequencing. Such universal techniques should eventually lead to accurate molecular diagnosis of all dystrophy mutations. Identification of dystrophin mutations in female carriers presents a unique problem: the technique must be sensitive enough to detect a mutation under heterozygous conditions. Southern blotting, FISH, and MAPH can be used to detect deletions and duplications, but are time consuming. Instead, a quantitative real-time PCR approach has recently been shown to reveal heterozygosity in female patients, allowing detection of deletions and duplications in carriers (34). This method can be theoretically extended to cover the entire dystrophin gene, allowing for PCR assessment of all carriers and duplications. CLINICAL TREATMENT Curative therapies do not yet exist for DMD/BMD, so current treatments are intended to maintain muscle flexibility and strength or provide mechanical or respiratory support (reviewed in Ref. 9). Early treatment involves physical therapy and orthotics while patients are still ambulatory. When joint contractures of the ankles, knees, and hips begin to interfere with walking, single or multiple surgical releases of the joints may be recommended (though no agreement has yet been reached about when and on whom such treatment should be used). At five to eight years of age, glucocorticoid steroids are often prescribed to boost muscle mass and forestall wheelchair
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
135
reliance. After loss of ambulation and onset of scoliosis, patients may undergo spinal surgery, inserting rods and hooks into the spine to straighten and support the trunk. The average lifespan of DMD patients has increased from 14.4 years in the 1960s to 25.3 years in ventilated patients in the 1990s, primarily due to advances in respiratory assistance and careful monitoring of respiratory function (35). As the respiratory muscles weaken and lung capacity diminishes, nocturnal breathing will decrease as well. The availability of portable nasal ventilators allows for assisted nighttime ventilation (and eventually daytime support) and is recommended to prevent nocturnal hypoventilation when respiratory function declines (36). The use of portable ventilators has greatly increased the quality and length of life. Vaccinations against influenza and pneumonia may also contribute to the lifespan extension by preventing acute respiratory infections leading to respiratory failure (35). Development of cardiomyopathy is frequent in DMD patients and to a lesser extent in BMD patients and female carriers. All affected individuals and carriers should have regular electrocardiograms, and angiotensin-converting enzyme (ACE) inhibitor treatment should be initiated at signs of cardomyopathic progression (37). Later stage DMD patients may also benefit from beta-blockers while a subset of BMD and female carrier patients ultimately require cardiac transplantation (37). Although the benefits of glucocorticoid steroid use in DMD have been well documented, there is only emerging consensus on the best dose, dosage regimen, and age at which treatment should be initiated. Prednisone is the most commonly prescribed in the United States, followed by its derivatives prednisolone and deflazacort (not available in the United States). All have been reported to improve muscular dystrophy symptoms in humans and animal models, potentially through immunosuppression, anti-inflammatory effects, stabilization of the sarcolemma, protection from Ca2þ influx, or utrophin protein upregulation (reviewed in Refs. 38–46). Significant side effects include weight gain, behavioral changes, cushingoid appearance, stunting of growth, loss of bone density, and cataracts (38). Clinical trials have recently demonstrated that alternative dosing regimens (e.g., weekend only or 10-days on/10-days off schedules) may offer all of the benefits of glucocorticoid use in DMD patients without many side effects (47,48). In addition, evidence suggests that glucocorticoid treatment of very young DMD patients may elicit an even greater response (49,50). In addition to traditional medical and surgical procedures, the potential of several nutritional supplements to affect muscle or muscular dystrophies has initiated a series of clinical trials. Creatine in particular has been most closely studied and, in a small DMD group, demonstrated mild increases in arm muscle strength and time until fatigue (51). Work in the mdx mouse, a model for DMD, also demonstrated decreased skeletal muscle necrosis in response to creatine (52). At the time of writing, clinical trials for
Copyright 2006 by Taylor & Francis Group, LLC
136
Steffen and Kunkel
creatine, glutamine, and CoenzymeQ for maintenance of muscle strength in DMD were underway. HISTORY OF THE DYSTROPHIN DISCOVERY Many genetic diseases have been described, but as of the mid-1980s, very few of the causative genes had been isolated. Identification of the dystrophin gene represented an innovative step forward, allowing researchers to isolate the causative mutation for a human disease. Since then, similar methods have been used to identify mutations causing over 2000 different human genetic disorders, including cystic fibrosis, familial breast cancer, and Huntington’s disease (53–55). Even as the dystrophin gene location was being mapped, knowledge of co-localizing markers allowed for early genetic diagnosis and prenatal screening (56). Since the 1900s, Duchenne and others had noticed that DMD was inherited as a sex-linked trait affecting almost solely male children. In the mid-1980s, restriction fragment length polymorphisms (RFLPs) of DMD patients and DNA from three key patients positioned the mutation on the short arm of the X chromosome: two rare female DMD patients exhibited X:autosome translocations with breakpoints in Xp21, and a male patient (B.B.) with DMD and three other X-linked diseases showed a macroscopic deletion in Xp21 (57–60). Ronald Worton’s group pursued the female X:autosome translocations, using one patient with an autosomal breakpoint in the 28S ribosomal RNA gene. Clones from the normal 28S rRNA gene were used to isolate an altered genomic restriction digest fragment of the patient’s DNA, presumably spanning the breakpoint region. A genomic phage library of the patient was scanned with the breakpoint clone to identify the corresponding phage that was then restriction enzyme mapped to locate the exact X chromosome breakpoint (61). Concurrently, our laboratory at Children’s Hospital, Boston was focusing on Xp21 using the male patient BB. Recognizing that BB’s DNA represented a void in the desired region, it was used in a subtractive cloning method with DNA from an XXXXY human cell line (62). An excess of sheared BB DNA was incubated with limited MboI-cleaved XXXXY DNA and allowed to hybridize to one another. The resulting fragments were ligated into a vector with MboI ends, thus cloning only XXXXY self-hybridizing fragments missing from the BB region. This library of Xp21 clones was used to scan other unrelated DMD patients identifying a single clone, pERT87, that was missing from 5 out of 57 affected boys (57). The pERT87 clone was used to initiate a series of chromosomal walks. Non-repetitive sequences isolated in the walk were subcloned and used to identify RFLPs for a large collaborative study (56). A 5% to 6% recombination frequency in several diagnostic RFLP sites plus mapping of patient’s
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
137
deletion breakpoints suggested that the DMD gene was very large (63). To locate coding exons, the subcloned fragments were hybridized to Southern blots of several mammalian species to identify conserved, potentially exon-coding stretches (4). Two putative exons were identified in humans and their counterparts cloned from a mouse phage library. One of the exons hybridized with an approximately 16 kb polyAþ mRNA from human fetal skeletal muscle and was used to screen a cDNA library, initiating a ‘‘walk’’ that identified cDNA clones covering the entire dystrophin transcript (4,5). The cloned cDNA fragments were hybridized with genomic DNA in a Southern blot, identifying approximately 60 exons with large intronic sequences (4,5). Later mapping and sequencing of the region demonstrated that the gene, now called dystrophin, consists of 79 exons and spans 2.4 Mb, constituting the largest gene in the human genome. DYSTROPHIN—MOLECULAR CHARACTERIZATION The longest transcript from the dystrophin locus is 14 kb, resulting in a 427 kDa protein (6). To date, seven tissue-specific promoter regions have been identified: three yield full-length transcripts differing only in the first exon (50 UTR plus the first few amino acids). Other promoters lie in intronic regions and share the C0 terminus (reviewed in Ref. 64). Function of the shorter transcripts (along with several identified splice variants) is not yet clear, but some, like the Dp140 transcript in neural tissues, may contribute to pathogenesis of the disease in non-muscle tissue (22). The dystrophin protein contains four discrete regions: an amino terminus actin-binding sequence, an extended rod domain of 24 spectrin-like repeats interrupted by four hinge regions, a cysteine-rich domain required for b-dystroglycan binding and dystrophin stability, and a unique carboxy terminus domain (6). Early studies using antibodies to dystrophin showed localization to the cytoplasmic face of the muscle fiber sarcolemma and co-immunoprecipitation with a group of proteins, called the DAPC (7,65,66). Localization of the DAPC to the sarcolemma requires dystrophin presence and is significantly decreased in DMD membranes. Thus, it has been hypothesized that one function of dystrophin is to direct localization of the DAPC. The DAPC is composed of three groups of proteins: the dystroglycans, the sarcoglycans and sarcospan, and dystrobrevins and syntrophins (Fig. 1, reviewed in Ref. 2). Dystrophin binds the integral membrane b-dystroglycan that associates with a-dystroglycan, a peripheral membrane protein binding extracellular matrix components (Fig. 1). Dystrophin’s primary function may thus be structural, connecting the actin cytoskeleton to the extracellular matrix and stabilizing the sarcolemma against repeated cycles of muscle contraction and relaxation. In support, sarcolemmal lesions and increased permeability to dyes have been observed in both DMD and mdx (the mouse
Copyright 2006 by Taylor & Francis Group, LLC
138
Steffen and Kunkel
model for DMD) muscle (67). Several lines of research have suggested that dystrophin may also have a role in signaling, as the molecules of the DAPC have been shown to interact with potential signaling molecules, such as nNOS, g-filamin, and the Grb2-Sos-Rac1 pathway (68–71). In muscle lacking dystrophin, localization of these molecules is altered and may contribute to the disease phenotype. Calcium concentrations in muscle are finely controlled and play an important role in the contractile signal. It has been hypothesized that improper calcium homeostasis, secondary to dystrophin absence and sarcolemmal instability, may account for the muscle fiber necrosis in DMD and mdx muscle. In support, cellular increases in calcium concentration have been reported in DMD patients and several animal models (72,73). An increase in calcium-leak channels has been seen in dystrophic muscle during normal membrane sealing, increasing the sub-sarcolemmal level of Ca2þ (73,74). In addition, several calcium sequestering and buffering proteins exhibit decreased expression and/or function, suggesting that calcium handling is improperly controlled in dystrophic muscle (75). ANIMAL MODELS OF DMD Several animal models of DMD have allowed significant research into dystrophin function and interactions, disease pathophysiology, and response to pharmacological and therapeutic agents (reviewed in Ref. 76). In particular, research on murine models may be performed on a scale available to most laboratories and allows experimentation not possible in humans. Five strains of mice with dystrophin mutations have been used to model DMD, the most common being the naturally occurring mdx mouse identified by its dramatically increased serum creatine kinase levels (77,78). Mdx carries a T to A point mutation in exon 23, resulting in a nonsense codon (79). Despite almost complete absence of the protein, the mdx phenotype is far milder than human DMD, showing very little functional deficiency, progressive muscle wasting, or connective tissue infiltration and only mild cardiac involvement. Many muscles, however, exhibit variation in fiber size, necrosis and phagocytosis, and centrally nucleated regenerating fibers. More recently, mdx mice also carrying a mutation in the dystrophin homolog, utrophin (mdx/; utr/) have demonstrated disease progression and pathology more similar to human DMD and may become a more suitable model for certain therapeutic studies (80). The canine X-linked muscular dystrophy (CXMD) golden retrievers are perhaps the best physiological model for DMD (81). Affected dogs show early onset of severe progressive muscle weakening and early death. Histology in these animals is very similar to humans, including fibrotic infiltration of degenerating muscles. However, size, litter-to-litter variation, and ethical considerations have limited the number of studies in these animals. A feline
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
139
DMD model also exists but exhibits muscle hypertrophy instead of muscle wasting and is not commonly used in DMD research (76,82). Two newer models of DMD may enable valuable research into pharmacological means of treating the disease. Deletion of the dystrophin-like gene (dys-1) coupled with a mild mutation in the muscle transcription factor MyoD results in a muscle degeneration/regeneration phenotype in the nematode C. elegans. This model has recently been used in a proof of principal drug screen that isolated the glucocorticoid prednisone, currently used in DMD patients (83). In zebrafish, an ENU mutagenesis screen has identified several potential dystrophic fish including sapje, a strain that has been mapped to a mutation in the dystrophin gene (84). While neither model precisely phenocopies human DMD, they represent similar genetic mutations that may be screened in large numbers for drug responsiveness in a whole organism approach. CURRENT RESEARCH FOR DMD/BMD THERAPIES Because the rate of spontaneous mutations is high, DMD and BMD will never be preventable. The diseases also present unique difficulties for therapeutic research, including the large size of the dystrophin gene, the variety of muscles affected, and the need for nearly systemic targeting. However, studies in mice suggest that achieving 20% to 30% of normal dystrophin expression is enough to correct the disease phenotype (85). Currently, cell-based and viral based therapies are being developed to deliver functional dystrophin to degenerating muscles. Pharmacological and antisense models are also being developed to induce translational or splicing infidelity, resulting in at least semifunctional dystrophin. Finally, a number of genes have been identified that ameliorate the dystrophic phenotype and may offer non-immune reactive targets. Cell-Based Therapy Introduction of cells bearing a functional dystrophin gene is an attractive method for muscular dystrophy therapies. Mature muscle is composed of syncytial fibers, created and maintained by proliferation and fusion of mononuclear myogenic precursors called satellite cells. Early studies in mice demonstrated that normal neonatal mouse or human myoblasts could fuse with mdx fibers in vitro and in vivo, generating expression of the normal dystrophin gene at the sarcolemma in a small percentage of muscle (86,87). Several clinical trials of intramuscular myoblast transfer in human DMD and BMD patients were initiated, but none were able to demonstrate functional strength improvements or more than low, transient dystrophin expression (reviewed in Ref. 88). Since then, research has focused on use of less differentiated myogenic populations delivered via intravenous or intramuscular injection. Side
Copyright 2006 by Taylor & Francis Group, LLC
140
Steffen and Kunkel
population (SP) cells, so-called because of their low staining with the vital dye Hoechst 33342 using a fluorescence-activated cell sorter (FACS), were first isolated from mouse bone marrow in 1996 and shown to have potent hematopoietic stem cell properties (89). Using a similar procedure, SP cells were isolated from adult mouse muscle and were shown to exhibit myogenic properties in vitro when co-cultured with muscle cell lines (90). Intravenous injection of muscle-derived SP cells in mdx mice demonstrated homing of donor cells to the damaged muscle and fusion into and dystrophin expression in host muscle fibers, albeit at low percentages. In addition, mononuclear donor cells were identified in the position of satellite cells, suggesting that cell transfer may provide a semipermanent progenitor population (90). Recent work has demonstrated the successful potential of autologous transplantation, isolating muscle SP from an mdx5cv mouse, transducing in vitro with a lentiviral vector carrying the human micro-dystrophin gene, and intravenously injecting corrected cells back into an mdx5cv mouse (91). Other muscle-derived cell types have shown some success in muscle engraftment, including non-adherent cell populations such as muscle-derived stem cells (MDSC) (92–95). Cells from bone marrow, liver, and skin have also demonstrated low efficiency integration into dystrophic muscle and delivery of normal gene products (90,95–98). In order to achieve successful systemic delivery of donor cells, more recent research has employed intraarterial delivery, potentially because cells are immediately delivered to the capillary bed of affected muscles. The highest level of engraftment to date has been reported using intraarterial injection of a fetal dorsal aorta-derived cell population, named mesangioblasts (99). These cells are capable of differentiating into several mesodermal cell types in vivo and could be expanded in vitro indefinitely. Intraarterial delivery of mouse wild type or autologous lentiviral-corrected mesangioblasts into a-sarcoglycan null mice (a model for LGMD 2D) resulted in expression of a-sarcoglycan and correct localization in wide swaths of all downstream muscles (100). Serial injection showed functional and histological improvements and in one muscle tested, it is reported that >50% of fibers were a-sarcoglycan positive. Intraarterial delivery has demonstrated the potential application of this method to the dystrophin-deficient mdx model as well. Sca-1/CD-34 double positive cells isolated from newborn mouse muscle and delivered intraarterially were able to localize to and express dystrophin in regenerating muscle (101). Preliminary experiments using intraarterial delivery of muscle SP cells have recently yielded better results, with engraftment of 5% to 8% after a single injection in the mdx mouse (Fig. 3) (E. Bachrach, unpublished data, 2004). These studies hold great therapeutic promise, identifying a replicating pool of cells that may deliver corrected genes as well as developing a technique for multimuscle engraftment with a single injection. Descriptions of
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
141
Figure 3 Intravenous and intraarterial delivery of muscle SP cells results in engraftment of SP cells into mdx muscle fibers and expression of dystrophin. Muscle SP cells isolated by FACS were transduced with a lentiviral vector carrying the human microdystrophin gene and injected either (A) intravenously or (B) intraarterially into mdx mice. Four to seven weeks later, the quadriceps muscles were sectioned transversely and immunohistochemistry was performed using a human-specific dystrophin antibody (positive fibers labeled with an asterisk). Preliminary studies demonstrate that 1% of fibers express human dystrophin at the muscle membrane upon intravenous injection (A) while 5% to 8% of fibers express human dystrophin upon intraarterial injection (B) (E. Bachrach, unpublished data). Abbreviations: FACS, flourescenceactivated cell sorter; SP, side population.
donor cell contributions to the in vivo satellite cell pool yields hope that cellbased correction may also be long lived (90,100). Current studies are focused on translating these results to humans and to comparison with more easily isolated cell populations (e.g., autologous skin, bone marrow, and muscle) delivered in the same method. The ultimate goal would be isolation of a
Copyright 2006 by Taylor & Francis Group, LLC
142
Steffen and Kunkel
progenitor cell population from the affected individual, in vitro expansion and correction of the mutated gene, and delivery and engraftment of the autologous cells for therapeutic amelioration of the disease. Viral Therapies Over the last decade, many studies have also introduced viral delivery of functional genes that can incorporate into the host DNA for permanent expression. The 14 kb size of the dystrophin transcript initially prevented its use in traditional vectors, but newer vector backbones and development of mini- and micro-dystrophin genes has enabled several promising avenues of experimentation. Retroviruses showed the first in vitro and in vivo delivery of a 6.3 kb mini-dystrophin gene carrying deletions in the rod domain, similar to a deletion mutation in very mild BMD (102,103). Intramuscular injection of the vector resulted in approximately 6% of fibers expressing dystrophin, and relocalized the DAPC to the sarcolemma in mouse models of DMD (103). However, retrovirus use is limited in humans due to their high immunogenicity and inability to infect nondividing cells. Newer lentiviral vectors have been employed for gene delivery and can encode up to 9 kb of sequence. These viruses have greatly decreased immunoreactivity and can transduce nondividing cells, making them ideal vectors for therapy (104). In vitro infection of primary myogenic cells has demonstrated highly efficient gene transduction, which is maintained upon cell injection and fusion into muscle in vivo (91). The adenovirus backbone has also been used to introduce the dystrophin gene. Early adenoviral vectors and adeno-associated viral vectors (AAV) have been used to introduce the dystrophin mini-gene and microgene (3.6–4.2 kb) (105–107). Later generation adenoviruses consist of an almost entirely gutted backbone and can hold the full-length dystrophin gene. Intramuscular injection of these viruses with dystrophin under a muscle-specific promoter resulted in 25% to 30% of fibers expressing the protein and improvement of contraction-induced injury to the sarcolemma one month after injection (108). A similar study using tandem dystrophin genes showed similar infection rates and retention of dystrophin expression for up to six months (109). Aminoglycoside Antibiotic Read-Through of Stop Codons It has long been known that aminoglycoside antibiotics can induce translational infidelity in bacteria and yeast (110,111). These antibiotics bind a site on the small subunit rRNA to allow improper tRNA-codon recognition and amino acid substitution for intra-exon stop codons (112), possibly also stabilizing transcripts against nonsense-mediated decay (NMD). In the mid-1990s, it was shown that treatment of mammalian cells with the aminoglycoside gentamicin partially restored expression of the gene involved in cystic fibrosis
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
143
from a gene with a premature stop codon mutation (113,114). It was therefore hypothesized that antibiotic treatment might also be of use in allowing translational read-through in the 5–10% of DMD patients with intra-exon stop codons, allowing expression of full length dystrophin (115). Barton-Davis et al. published the first demonstration both in vitro and in vivo of gentamicin-induced dystrophin restoration in the mdx mouse, showing that dystrophin was expressed and localized with the DAPC to the sarcolemma in 10% to 20% of muscle fibers (116). Gentamicin offers the benefit of already being approved for use in humans, but follow-up studies and clinical trials have returned mixed results for its efficacy in the treatment of DMD (117,118). Additional work in mdx mice also failed to reproduce the original results (119). Clinical trials are now underway to study gentamicin treatment in DMD patients with nonsense mutations on a broader scale. The variability of gentamicin effectiveness suggests that not all DMD patients with nonsense mutations may benefit from antibiotic treatment. Work in yeast demonstrated that certain stop codons are more stringent, and that surrounding sequences also affect translational fidelity, suggesting that only certain mutations may benefit from gentamicin (120–122). Therefore, future research may be directed toward the identification of other pharmacological means to target translational fidelity with wider sequence specificity. Induced Exon-Skipping to Yield a BMD Phenotype from a DMD Mutation While the great majority of DMD/BMD cases adhere to the ‘‘frame-shift hypothesis,’’ approximately 8% of patients exhibit mutations inconsistent with the expected reading frame of the clinical diagnosis (123). Recent research suggests that these outliers may result from mutations that alter the normal splicing pattern, causing occasional skipping of the mutated exon(s) and restoration of the transcript reading frame (124,125). Thus, induced exon-skipping to correct the transcript reading frame may offer an alternative to cell-based and viral-based therapies, specifically for the purposes of reducing immune response. Mann et al. first demonstrated in vivo induction of dystrophin exon skipping by using antisense oligoribonucleotides (AOs) directed against the splice site of the affected intron in mdx mice (126). Similar techniques have achieved 15% to 20% dystrophin positive fibers in the injected muscle and moderate strength improvement with detectable dystrophin remaining for up to three months (127). In addition to splice site targeting, success has been achieved with AOs directed against exon-recognition sequences (ERS) within the exons (128). Currently, AOs have been developed to target at least 20 exons, covering over 75% of known human DMD mutations (128–130). Work with other types of antisense molecules, including
Copyright 2006 by Taylor & Francis Group, LLC
144
Steffen and Kunkel
morpholinos and altered snRNAs, has also demonstrated the ability to alter dystrophin splicing (131,132). Current antisense methods only transiently affect dystrophin transcripts and would require repeated injection into all affected muscles. An alternative method, however, has recently shown some success achieving permanent induction of exon-skipped dystrophin species in vitro using chimeraplasts. These chimeric DNA/RNA oligomers use cellular mismatch repair mechanisms to induce base pair changes in the genome (133). Chimeraplast targeting of the mdx point mutation demonstrated gene correction in mdx cell culture while targeting to mask exon splice sites induced exonskipping to correct the transcript frame shift in vivo (133,134). Though currently highly inefficient, chimeraplast treatment may hold the potential to affect permanent dystrophin changes without the immune difficulties of cellular and viral treatments, nor the limitation of transient expression seen with antisense treatments. Regulation of Other Genes to Ameliorate the DMD/BMD Phenotype Human, mouse, and canine models of DMD have shown sarcolemmal upregulation of utrophin, a dystrophin homolog that is expressed at the sarcolemma during development and is maintained at the neuromuscular junction (NMJ) in the adult (135–137). At the NMJ, utrophin complexes with the DAPC and may provide a similar link between the cytoskeleton and extracellular matrix. Data from the mdx-utrophin murine mutant showing increased severity suggests that utrophin may be partially compensating for dystrophin loss in the mdx model (80). Transgenic mdx mice expressing a mini-utrophin gene showed disease amelioration while highexpressing full length utrophin transgenics demonstrated almost complete prevention of dystrophy (138,139). Transgenic mdx mice overexpressing ADAM12 (140) or calcineurin (141) also showed upregulation of endogenous utrophin and pathological improvement, suggesting that methods to increase endogenous levels or introduce exogenous utrophin may provide a therapy for DMD. Myostatin, a TGF-beta family member, has been shown to act as a negative regulator of muscle growth. Myostatin knockout mice exhibit increased muscle mass due to hyperplasia and some hypertrophy, a phenotype indicating a potential applicability to therapeutic targeting in DMD/ BMD (142). Weekly injection of anti-myostatin antibodies in mdx mice elicits highly effective strength and histological improvements, and nearly normal serum creatine kinase levels (143). Research has also demonstrated functional improvements following injection into adult mdx mice (144), suggesting that inhibition of myostatin may benefit patients at all stages of DMD/BMD.
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
145
CONCLUSION Advances in ventilation, surgical, and pharmacological methods for alleviating DMD/BMD symptoms have greatly increased patient lifespans in the last decade. New techniques in automated dystrophin amplification and sequencing have also established faster ways of mutation identification for the purposes of diagnosis, genetic testing, and in the future, therapeutic tailoring. Current research is now focused on understanding the function of dystrophin and methods of dystrophin replacement for long-term therapeutic treatment of Duchenne and Becker muscular dystrophies. Intraarterial delivery of cells carrying functional dystrophin offers a particularly exciting possibility for systemic replacement of muscle fiber dystrophin, while the identification of drugs and molecules that can induce frame-shifting, translational read-through, or alteration of compensating endogenous proteins may offer pharmacological methods of alleviating disease symptoms.
ACKNOWLEDGMENTS We would like to thank members of the Kunkel lab for critical reading of this manuscript, especially Kaliopi Liadaki and Richard Bennett. L.M.K is an investigator of the Howard Hughes Medical Institute. Funding support was provided by the Bernard F. and Alva B. Gimbel Foundation and the Muscular Dystrophy Association (L.M.K.). L.S.S. is supported by a Graduate Research Fellowship from the National Science Foundation.
REFERENCES 1. http://www.dmd.nl (accessed May 2004). 2. Dalkilic I, Kunkel LM. Muscular dystrophies: genes to pathogenesis. Curr Opin Genet Dev 2003; 13:231–238. 3. Mukherjee M, Mittal B. Muscular dystrophies. Ind J Pediatr 2004; 71:161–168. 4. Monaco AP, Neve RL, Colletti-Feener C, Bertelson CJ, Kurnit DM, Kunkel LM. Isolation of candidate cDNAs for portions of the Duchenne muscular dystrophy gene. Nature 1986; 323:646–650. 5. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, Kunkel LM. Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 1987; 50:509–517. 6. Koenig M, Monaco AP, Kunkel LM. The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 1988; 53:219–226. 7. Zubrzycka-Gaarn EE, Bulman DE, Karpati G, Burghes AH, Belfall B, Klamut HJ, Talbot J, Hodges RS, Ray PN, Worton RG. The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. Nature 1988; 333:466–469.
Copyright 2006 by Taylor & Francis Group, LLC
146
Steffen and Kunkel
8. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51:919–928. 9. Darris B, Menache C, Kunkel L. Dystrophinopathies. In: Jones H Jr, DeVivo D, Darras B, eds. Neuromuscular Disorders of Infancy, Childhood, and Adolscence: A Clinician’s Approach. Philadelphia, PA: Elsevier Science, Inc., 2003:649–699. 10. Emery A. Duchenne Muscular Dystrophy. 24 Second Oxford: Oxford University Press, 1993. 11. Becker P, Kerner F. Eine neue X-chromosomale Muskeldystrophie. Archiv fur Psychiatric und Nervenkrankheiten 1955; 193:427–448. 12. Finsterer J, Stollberger C. The heart in human dystrophinopathies. Cardiology 2003; 99:1–19. 13. Worden DK, Vignos PJ Jr. Intellectual function in childhood progressive muscular dystrophy. Pediatrics 1962; 29:968–977. 14. Dubowitz V, Lorber J, Zachary RB. Lipoma of the Cauda Equina. Arch Dis Child 1965; 40:207–213. 15. Whelan TB. Neuropsychological performance of children with Duchenne muscular dystrophy and spinal muscle atrophy. Dev Med Child Neurol 1987; 29:212–220. 16. Ogasawara A. Downward shift in IQ in persons with Duchenne muscular dystrophy compared to those with spinal muscular atrophy. Am J Ment Retard 1989; 93:544–547. 17. Billard C, Gillet P, Signoret JL, Uicaut E, Bertrand P, Fardeau M, BarthezCarpentier MA, Santini JJ. Cognitive functions in Duchenne muscular dystrophy: a reappraisal and comparison with spinal muscular atrophy. Neuromuscul Disord 1992; 2:371–378. 18. Blake DJ, Kroger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle? Trends Neurosci 2000; 23:92–99. 19. Nicholson LV, Johnson MA, et al. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis. J Med Genet 1993; 30:745–751. 20. Lenk U, Hanke R, Thiele H, Speer A. Point mutations at the carboxy terminus of the human dystrophin gene: implications for an association with mental retardation in DMD patients. Hum Mol Genet 1993; 2:1877–1881. 21. Hodgson SV, Abbs S, Clark S, Manzur A, Heckmatt JZ, Dubowitz V, Bobrow M. Correlation of clinical and deletion data in Duchenne and Becker muscular dystrophy, with special reference to mental ability. Neuromuscul Disord 1992; 2:269–276. 22. Felisari G, Martinelli Boneschi F, Bardoni A, Sironi M, Comi GP, Robotti M, Turconi AC, Lai M, Corrao G, Bresolin N. Loss of Dp140 dystrophin isoform and intellectual impairment in Duchenne dystrophy. Neurology 2000; 55: 559–564. 23. Matsuo M. Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. Brain Dev 1996; 18:167–172. 24. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM. Exploring the molecular basis for variability
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
25.
26.
27. 28.
29.
30.
31.
32.
33.
34.
35.
36.
147
among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am J Hum Genet 1991; 49:54–67. Den Dunnen JT, Grootscholten PM, Bakker E, Blonden LA, Ginjaar HB, Wapenaar MC, van Paassen HM, van Broeckhoven C, Pearson PL, van Ommen GJ. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989; 45:835–847. Hu XY, Ray PN, Murphy EG, Thompson MW, Worton RG. Duplicational mutation at the Duchenne muscular dystrophy locus: its frequency, distribution, origin, and phenotypegenotype correlation. Am J Hum Genet 1990; 46:682–695. Beggs AH, Koenig M, Boyce FM, Kunkel LM. Detection of 98% of DMD/ BMD gene deletions by polymerase chain reaction. Hum Genet 1990; 86:45–48. Hoffman EP, Fischbeck KH, et al. Characterization of dystrophin in musclebiopsy specimens from patients with Duchenne’s or Becker’s muscular dystrophy. N Engl J Med 1988; 318:1363–1368. Bennett RR, den Dunnen J, O’Brien KF, Darras BT, Kunkel LM. Detection of mutations in the dystrophin gene via automated DHPLC screening and direct sequencing. BMC Genet 2001; 2:17. Hofstra RM, Mulder IM, Vossen R, de Koning-Gans PA, Kraak M, Ginjaar IB, van der Hout AH, Bakker E, Buys CH, van Ommen GJ, van Essen AJ, den Dunnen JT. DGGE-based whole-gene mutation scanning of the dystrophin gene in Duchenne and Becker muscular dystrophy patients. Hum Mutat 2004; 23:57–66. Mendell JR, Buzin CH, Feng J, Yan J, Serrano C, Sangani DS, Wall C, Prior TW, Sommer SS. Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 2001; 57:645–650. White S, Kalf M, Liu Q, Villerius M, Engelsma D, Kriek M, Vollebregt E, Bakker B, van Ommen GJ, Breuning MH, den Dunnen JT. Comprehensive detection of genomic duplications and deletions in the DMD gene, by use of multiplex amplifiable probe hybridization. Am J Hum Genet 2002; 71:365–374. Flanigan KM, von Niederhausern A, Dunn DM, Alder J, Mendell JR, Weiss RB. Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 2003; 72:931–939. Joncourt F, Neuhaus B, Jostarndt-Foegen K, Kleinle S, Steiner B, Gallati S. Rapid identification of female carriers of DMD/BMD by quantitative real-time PCR. Hum Mutat 2004; 23:385–391. Eagle M, Baudouin SV, Chandler C, Giddings DR, Bullock R, Bushby K. Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation. Neuromuscul Disord 2002; 12:926–929. Wallgren-Pettersson C, Bushby K, Mellies U, Simonds A. 117th ENMC workshop: ventilatory support in congenital neuromuscular disorders—congenital myopathies, congenital muscular dystrophies, congenital myotonic dystrophy and SMA (II) 4–6 April 2003, Naarden, The Netherlands. Neuromuscul Disord 2004; 14:56–69.
Copyright 2006 by Taylor & Francis Group, LLC
148
Steffen and Kunkel
37. Bushby K, Muntoni F, Bourke JP. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th–9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 2003; 13:166–172. 38. Moxley R III. Corticosteroid and anabolic hormone treatment of Duchenne’s muscular dystrophy. In: Jones H Jr, DeVivo D, Darras B, eds. Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician’s Approach. Philadelphia, PA: Elsevier Science, Inc., 2003:1209–1225. 39. Gaud A, Simon JM, Witzel T, Carre-Pierrat M, Wermuth CG, Segalat L. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord 2004; 14:365–370. 40. Leijendekker WJ, Passaquin AC, Metzinger L, Ruegg UT. Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress. Br J Pharmacol 1996; 118:611–616. 41. Passaquin AC, Lhote P, Ruegg UT. Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells. Br J Pharmacol 1998; 124:1751–1759. 42. Courdier-Fruh I, Barman L, Briguet A, Meier T. Glucocorticoid-mediated regulation of utrophin levels in human muscle fibers. Neuromuscul Disord 2002; 12(suppl 1):S95–104. 43. Jacobs SC, Bootsma AL, Willems PW, Bar PR, Wokke JH. Prednisone can protect against exercise-induced muscle damage. J Neurol 1996; 243:410–416. 44. Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byrnes T, Wang JC, Hsiao JC. Strength and endurance in the therapeutic evaluation of prednisolone-treated MDX mice. Res Commun Chem Pathol Pharmacol 1993; 79:45–60. 45. Granchelli JA, Pollina C, Hudecki MS. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000; 10:235–239. 46. Muntoni F, Fisher I, Morgan JE, Abraham D. Steroids in Duchenne muscular dystrophy: from clinical trials to genomic research. Neuromuscul Disord 2002; 12(suppl 1):S162–165. 47. Connolly AM, Schierbecker J, Renna R, Florence J. High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12:917–925. 48. Kinali M, Mercuri E, Main M, Muntoni F, Dubowitz V. An effective, lowdosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy. Neuromuscul Disord 2002; 12(suppl 1): S169–174. 49. Dubowitz V, Kinali M, Main M, Mercuri E, Muntoni F. Remission of clinical signs in early Duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy. Eur J Paediatr Neurol 2002; 6:153–159. 50. Merlini L, Cicognani A, Malaspina E, Gennari M, Gnudi S, Talim B, Franzoni E. Early prednisone treatment in Duchenne muscular dystrophy. Muscle Nerve 2003; 27:222–227. 51. Louis M, Lebacq J, Poortmans JR, Belpaire-Dethiou MC, Devogelaer JP, Van Hecke P, Goubel F, Francaux M. Beneficial effects of creatine supplementation in dystrophic patients. Muscle Nerve 2003; 27:604–610. 52. Passaquin AC, Renard M, Kay L, Challet C, Mokhtarian A, Wallimann T, Ruegg UT. Creatine supplementation reduces skeletal muscle degeneration
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
53. 54. 55.
56.
57.
58.
59.
60.
61.
62.
63. 64. 65. 66. 67.
68.
149
and enhances mitochondrial function in mdx mice. Neuromuscul Disord 2002; 12:174–182. Riordan JR, Rommens JM, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 1989; 245:1066–1073. Miki Y, Swensen J, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66–71. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. The Huntington’s Disease Collaborative Research Group. Cell 1993; 72:971–983. Monaco AP, Bertelson CJ, Middlesworth W, Colletti CA, Aldridge J, Fischbeck KH, Bartlett R, Pericak-Vance MA, Roses AD, Kunkel LM. Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment. Nature 1985; 316:842–845. Jacobs PA, Hunt PA, Mayer M, Bart RD. Duchenne muscular dystrophy (DMD) in a female with an X/autosome translocation: further evidence that the DMD locus is at Xp21. Am J Hum Genet 1981; 33:513–518. Worton RG, Duff C, Sylvester JE, Schmickel RD, Willard HF. Duchenne muscular dystrophy involving translocation of the dmd gene next to ribosomal RNA genes. Science 1984; 224:1447–1449. Davies KE, Pearson PL, Harper PS, Murray JM, O’Brien T, Sarfarazi M, Williamson R. Linkage analysis of two cloned DNA sequences flanking the Duchenne muscular dystrophy locus on the short arm of the human X chromosome. Nucleic Acids Res 1983; 11:2303–2312. Francke U, Ochs HD, et al. Minor Xp21 chromosome deletion in a male associated with expression of Duchenne muscular dystrophy, chronic granulomatous disease, retinitis pigmentosa, and McLeod syndrome. Am J Hum Genet 1985; 37:250–267. Ray PN, Belfall B, Duff C, Logan C, Kean V, Thompson MW, Sylvester JE, Gorski JL, Schmickel RD, Worton RG. Cloning of the breakpoint of an X;21 translocation associated with Duchenne muscular dystrophy. Nature 1985; 318:672–675. Kunkel LM, Monaco AP, Middlesworth W, Ochs HD, Latt SA. Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. Proc Natl Acad Sci USA 1985; 82:4778–4782. Kunkel LM. Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy. Nature 1986; 322:73–77. Sadoulet-Puccio HM, Kunkel LM. Dystrophin and its isoforms. Brain Pathol 1996; 6:25–35. Yoshida M, Ozawa E. Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem (Tokyo) 1990; 108:748–752. Campbell KP, Kahl SD. Association of dystrophin and an integral membrane glycoprotein. Nature 1989; 338:259–262. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 1993; 90:3710–3714. Brenman JE, Chao DS, Gee SH, McGee AW, Craven SE, Santillano DR, Wu Z, Huang F, Xia H, Peters MF, Froehner SC, Bredt DS. Interaction of
Copyright 2006 by Taylor & Francis Group, LLC
150
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82. 83.
Steffen and Kunkel nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1syntrophin mediated by PDZ domains. Cell 1996; 84:757–767. Thompson TG, Chan YM, Hack AA, Brosius M, Rajala M, Lidov HG, McNally EM, Watkins S, Kunkel LM. Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. J Cell Biol 2000; 148:115–126. Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M, Shapiro SS. Filamins as integrators of cell mechanics and signalling. Nat Rev Mol Cell Biol 2001; 2:138–145. Oak SA, Zhou YW, Jarrett HW. Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Rac1. J Biol Chem 2003; 278: 39287–39295. Bodensteiner JB, Engel AG. Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies. Neurology 1978; 28:439–446. Bertorini TE, Bhattacharya SK, Palmieri GM, Chesney CM, Pifer D, Baker B. Muscle calcium and magnesium content in Duchenne muscular dystrophy. Neurology 1982; 32:1088–1092. Fong PY, Turner PR, Denetclaw WF, Steinhardt RA. Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. Science 1990; 250:673–676. Dowling P, Doran P, Ohlendieck K. Drastic reduction of sarcalumenin in Dp427 (dystrophin of 427 kDa)-deficient fibres indicates that abnormal calcium handling plays a key role in muscular dystrophy. Biochem J 2004; 379: 479–488. Collins CA, Morgan JE. Duchenne’s muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. Int J Exp Pathol 2003; 84:165–172. Chapman VM, Miller DR, Armstrong D, Caskey CT. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci U S A 1989; 86:1292–1296. Im WB, Phelps SF, Copen EH, Adams EG, Slightom JL, Chamberlain JS. Differential expression of dystrophin isoforms in strains of mdx mice with different mutations. Hum Mol Genet 1996; 5:1149–1153. Sicinski P, Geng Y, Ryder-Cook AS, Barnard EA, Darlison MG, Barnard PJ. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989; 244:1578–1580. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L, Watt DJ, Dickson JG, Tinsley JM, Davies KE. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90:717–727. Sharp NJ, Kornegay JN, et al. An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy. Genomics 1992; 13:115–121. Carpenter JL, Hoffman EP, et al. Feline muscular dystrophy with dystrophin deficiency. Am J Pathol 1989; 135:909–919. Gaud A, Simon JM, Witzel T, Carre-Pierrat M, Wermuth CG, Segalat L. Prednisone reduces muscle degeneration in dystrophin-deficient Caenorhabditis elegans. Neuromuscul Disord 2004; 14:365–370.
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
151
84. Bassett DI, Bryson-Richardson RJ, Daggett DF, Gautier P, Keenan DG, Currie PD. Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development 2003; 130:5851–5860. 85. Chamberlain J. Dystrophin levels required for genetic correction of Duchenne muscular dystrophy. Basic Appl Myol 1997; 7:251–255. 86. Karpati G, Pouliot Y, Zubrzycka-Gaarn E, Carpenter S, Ray PN, Worton RG, Holland P. Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am J Pathol 1989; 135:27–32. 87. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. Nature 1989; 337:176–179. 88. Partridge T. Myoblast transplantation. Neuromuscul Disord 2002; 12(suppl 1): S3–6. 89. Goodell MA, Brose K, Paradis G, Conner AS, Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996; 183:1797–1806. 90. Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, Kunkel LM, Mulligan RC. Dystrophin expression in the mdx mouse restored by stem cell transplantation. Nature 1999; 401:390–394. 91. Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, Flint A, Chamberlain J, Kunkel LM. Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proc Natl Acad Sci USA 2004; 101:3581–3586. 92. Qu Z, Balkir L, van Deutekom JC, Robbins PD, Pruchnic R, Huard J. Development of approaches to improve cell survival in myoblast transfer therapy. J Cell Biol 1998; 142:1257–1267. 93. Lee JY, Qu-Petersen Z, Cao B, Kimura S, Jankowski R, Cummins J, Usas A, Gates C, Robbins P, Wernig A, Huard J. Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. J Cell Biol 2000; 150:1085–1100. 94. Qu-Petersen Z, Deasy B, Jankowski R, Ikezawa M, Cummins J, Pruchnic R, Mytinger J, Cao B, Gates C, Wernig A, Huard J. Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J Cell Biol 2002; 157:851–864. 95. Cao B, Zheng B, Jankowski RJ, Kimura S, Ikezawa M, Deasy B, Cummins J, Epperly M, Qu-Petersen Z, Huard J. Muscle stem cells differentiate into haematopoietic lineages but retain myogenic potential. Nat Cell Biol 2003; 5:640–646. 96. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu G, Mavilio F. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279:1528–1530. 97. Fukada S, Miyagoe-Suzuki Y, Tsukihara H, Yuasa K, Higuchi S, Ono S, Tsujikawa K, Takeda S, Yamamoto H. Muscle regeneration by reconstitution with bone marrow or fetal liver cells from green fluorescent protein-gene transgenic mice. J Cell Sci 2002; 115:1285–1293. 98. Montanaro F, Liadaki K, Volinski J, Flint A, Kunkel LM. Skeletal muscle engraftment potential of adult mouse skin side population cells. Proc Natl Acad Sci USA 2003; 100:9336–9341.
Copyright 2006 by Taylor & Francis Group, LLC
152
Steffen and Kunkel
99. Minasi MG, Riminucci M, De Angelis L, Borello U, Berarducci B, Innocenzi A, Caprioli A, Sirabella D, Baiocchi M, De Maria R, Boratto R, Jaffredo T, Broccoli V, Bianco P, Cossu G. The meso-angioblast: a multipotent, selfrenewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development 2002; 129:2773–2783. 100. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D’Antona G, Pellegrino MA, Barresi R, Bresolin N, De Angelis MG, Campbell KP, Bottinelli R, Cossu G. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 2003; 301:487–492. 101. Torrente Y, Tremblay JP, Pisati F, Belicchi M, Rossi B, Sironi M, Fortunato F, El Fahime M, D’Angelo MG, Caron NJ, Constantin G, Paulin D, Scarlato G, Bresolin N. Intraarterial injection of muscle-derived CD34(þ)Sca-1(þ) stem cells restores dystrophin in mdx mice. J Cell Biol 2001; 152:335–348. 102. Dunckley MG, Love DR, Davies KE, Walsh FS, Morris GE, Dickson G. Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro. FEBS Lett 1992; 296:128–134. 103. Dunckley MG, Wells DJ, Walsh FS, Dickson G. Direct retroviral-mediated transfer of a dystrophin minigene into mdx mouse muscle in vivo. Hum Mol Genet 1993; 2:717–723. 104. Kafri T, Blomer U, Peterson DA, Gage FH, Verma IM. Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet 1997; 17:314–317. 105. Ragot T, Vincent N, Chafey P, Vigne E, Gilgenkrantz H, Couton D, Cartaud J, Briand P, kaplan J, Perricaudet M, Kahn A. Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeleted muscle of mdx mice. Nature 1993; 361:647–650. 106. Wang B, Li J, Xiao X. Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc Natl Acad Sci USA 2000; 97:13714–13719. 107. Fabb SA, Wells DJ, Serpente P, Dickson G. Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. Hum Mol Genet 2002; 11:733–741. 108. DelloRusso C, Scott JM, Hartigan-O’Connor D, Salvatori G, Barjot C, Robinson AS, Crawford RW, Brooks SV, Chamberlain JS. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc Natl Acad Sci USA 2002; 99:12979–12984. 109. Gilbert R, Dudley RW, Liu AB, Petrof BJ, Nalbantoglu J, Karpati G. Prolonged dystrophin expression and functional correction of mdx mouse muscle following gene transfer with a helper-dependent (gutted) adenovirus-encoding murine dystrophin. Hum Mol Genet 2003; 12:1287–1299. 110. Palmer E, Wilhelm JM, Sherman F. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 1979; 277:148–150. 111. Singh A, Ursic D, Davies J. Phenotypic suppression and misreading Saccharomyces cerevisiae. Nature 1979; 277:146–148.
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
153
112. Wimberly BT, Brodersen DE, Clemons WM Jr, Morgan-Warren RJ, Carter AP, Vonrhein C, Hartsch T, Ramakrishnan V. Structure of the 30S ribosomal subunit. Nature 2000; 407:327–339. 113. Howard M, Frizzell RA, Bedwell DM. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 1996; 2:467–469. 114. Bedwell DM, Kaenjak A, Benos DJ, Bebok Z, Bubien JK, Hong J, Tousson A, Clancy JP, Sorscher EJ. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 1997; 3:1280–1284. 115. Prior TW, Bartolo C, Pearl DK, Papp AC, Snyder PJ, Sedra MS, Burghes AH, Mendell JR. Spectrum of small mutations in the dystrophin coding region. Am J Hum Genet 1995; 57:22–33. 116. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 1999; 104:75–381. 117. Wagner KR, Hamed S, Hadley DW, Gropman AL, Burstein AH, Escolar DM, Hoffman EP, Fischbeck KH. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 2001; 49:706–711. 118. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, Paciello O, Comi LI. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 2003; 22:15–21. 119. Dunant P, Walter MC, Karpati G, Lochmuller H. Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 2003; 27:624–627. 120. Tate WP, Poole ES, Mannering SA. Hidden infidelities of the translational stop signal. Prog Nucleic Acid Res Mol Biol 1996; 52:293–335. 121. Bonetti B, Fu L, Moon J, Bedwell DM. The efficiency of translation termination is determined by a synergistic interplay between upstream and downstream sequences in Saccharomyces cerevisiae. J Mol Biol 1995; 251:334–345. 122. Namy O, Hatin I, Rousset JP. Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep 2001; 2:787–793. 123. Koenig M, Beggs AH, et al. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet 1989; 45:498–506. 124. Wilton SD, Dye DE, Laing NG. Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve 1997; 20:728–734. 125. Lu QL, Morris GE, Wilton SD, Ly T, Artem’yeva OV, Strong P, Partridge TA. Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 2000; 148:985–996. 126. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA, Wilton SD. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98:42–47. 127. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA, Wilton SD. Functional amounts of dystrophin produced by
Copyright 2006 by Taylor & Francis Group, LLC
154
128.
129.
130.
131.
132.
133. 134.
135.
136.
137.
138.
139.
140.
Steffen and Kunkel skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9:1009–1014. van Deutekom JC, Bremmer-Bout M, Janson AA, Ginjaar IB, Baas F, den Dunnen JT, van Ommen GJ. Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. Hum Mol Genet 2001; 10:1547–1554. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, Baas F, van Ommen GJ, van Deutekom JC. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum Mol Genet 2003; 12:907–914. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, van Ommen GJ, den Dunnen JT, van Deutekom JC. Antisense-induced multiexon skipping for Duchenne muscular dystrophy makes more sense. Am J Hum Genet 2004; 74:83–92. Gebski BL, Mann CJ, Fletcher S, Wilton SD. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003; 12:1801–1811. De Angelis FG, Sthandier O, Berarducci B, Toso S, Galluzzi G, Ricci E, Cossu G, Bozzoni I. Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48–50 DMD cells. Proc Natl Acad Sci USA 2002; 99:9456–9461. Rice MC, Czymmek K, Kmiec EB. The potential of nucleic acid repair in functional genomics. Nat Biotechnol 2001; 19:321–326. Bertoni C, Lau C, Rando TA. Restoration of dystrophin expression in mdx muscle cells by chimeraplast-mediated exon skipping. Hum Mol Genet 2003; 12:1087–1099. Pons F, Nicholson LV, Robert A, Voit T, Leger JJ. Dystrophin and dystrophinrelated protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. Neuromuscul Disord 1993; 3:507–514. Schatzberg SJ, Olby NJ, Breen M, Anderson LV, Langford CF, Dickens HF, Wilton SD, Zeiss CJ, Binns MM, Kornegay JN, Morris GE, Sharp NJ. Molecular analysis of a spontaneous dystrophin ‘knockout’ dog. Neuromuscul Disord 1999; 9:289–295. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP. Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 1992; 360:588–591. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, Gillis JM, Davies K. Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 1998; 4:1441–1444. Tinsley JM, Potter AC, Phelps SR, Fisher R, Trickett JI, Davies KE. Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 1996; 384:349–353. Moghadaszadeh B, Albrechtsen R, Guo LT, Zaik M, Kawaguchi N, Borup RH, Kronqvist P, Schroder HD, Davies KE, Voit T, Nielsen FC, Engvall E, Wewer UM. Compensation for dystrophin-deficiency: ADAM12
Copyright 2006 by Taylor & Francis Group, LLC
Duchenne and Becker Muscular Dystrophies
141.
142. 143.
144.
155
overexpression in skeletal muscle results in increased alpha 7 integrin, utrophin and associated glycoproteins. Hum Mol Genet 2003; 12:2467–2479. Chakkalakal JV, Harrison MA, Carbonetto S, Chin E, Michel RN, Jasmin BJ. Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum Mol Genet 2004; 13:379–388. McPherron AC, Lawler AM, Lee SJ. Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature 1997; 387:83–90. Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, Khurana TS. Functional improvement of dystrophic muscle by myostatin blockade. Nature 2002; 420:418–421. Whittemore LA, Song K, Li X, Aghajanian J, Davies M, Girgenrath S, Hill JJ, Jalenak M, Kelley P, Knight A, Maylor R, O’Hara D, Pearson A, Quazi A, Ryerson S, Tan XY, Tomkinson KN, Veldman GM, Widom A, Wright JF, Wudyka S, Zhao L, Wolfman NM. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 2003; 300:965–971.
Copyright 2006 by Taylor & Francis Group, LLC
8 The Congenital and Limb-Girdle Muscular Dystrophies Janbernd Kirschner Division of Neuropediatrics and Muscle Disorders, University Children’s Hospital, Freiburg, Germany
Carsten G. Bo¨nnemann Division of Neurology, The Children’s Hospital of Philadelphia, Abramson Research Center, Philadelphia, Pennsylvania, U.S.A.
INTRODUCTION Muscular dystrophies as a group are common but genetically very heterogeneous. As a clinical entity they were first recognized with the detailed description of the clinical presentation of Duchenne muscular dystrophy (DMD) in 1852 and thereafter (1,2). About 50 years later Batten (3) published the first cases of a congenital form of muscular dystrophy (CMD). In contrast to DMD and related conditions, patients with CMD typically have weakness and dystrophic changes in the muscle biopsy at birth, but the course is frequently less progressive compared to that of patients with the Duchenne form. During the following years other clinical groups of muscular dystrophy were delineated as distinct entities on a clinical basis. These now include Emery-Dreifuss muscular dystrophy (EDMD), fascioscapulohumeral dystrophy (FSHD), myotonic dystrophy, oculopharyngeal muscular dystrophy, distal muscular dystrophies, and limb-girdle muscular dystrophies.
Copyright 2006 by Taylor & Francis Group, LLC
158
Kirschner and Bo¨nnemann
The term limb-girdle muscular dystrophy (LGMD) was introduced in the middle of the 20th century when it became obvious that there was an additional major group of noncongenital muscular dystrophies in addition to DMD and FSHD (4). The term LGMD is now used for clinical phenotypes with progressive weakness, onset in the limb girdle muscles, and histological evidence for a dystrophic process in muscle. Other causes for a limb girdle distribution of weakness also must have been excluded on the basis of the muscle biopsy. The age of onset of LGMD as a group may range from early childhood to late adulthood (5). Even though possible on the basis of this definition, DMD and Becker muscular dystrophies (BMD) are not customarily subsumed under this group. During recent years exciting progress has been made in the fields of CMD and LGMD emphasizing differences as well as commonalities between the two groups. Careful clinical delineation of phenotypes within CMD and LGMD combined with advances in genetic and histochemical characterization has led to the identification of numerous molecularly defined subtypes of muscular dystrophy. This has brought individual clinical entities into sharper focus, but has also blurred the boundaries between the traditional categories of muscular dystrophy. For example, it has now been recognized that mutations in the same protein can give rise to very different phenotypes. Fukutin-related protein (FKRP) mutations can manifest with variable severity ranging from a severe CMD [MDC1C (6), including variants of muscle–eye–brain disease, or Walker–Warburg syndrome (7)] to juvenile and a milder adult onset LGMD (type 2I) (8–10). Dysferlinopathies can present either as a classical LGMD phenotype (type 2B), as a distal muscular dystrophy (Miyoshi type) or as mixed phenotypes (10,11). Mutations in lamin A/C have an even wider spectrum of phenotypes associated with them, extending even to include disorders such as lipodystrophy, progeria, and types of Charcot-Marie-Tooth neuropathy (12–18). Table 1 gives an overview of genetically recognized forms of CMD and LGMD organized according to the different groups of proteins involved in their pathogenesis. In this chapter, we will focus on entities within the scope of congenital and limb girdle muscular dystrophies. After some general comments on the approach in the differential diagnosis of patients with possible muscular dystrophies, we will give some more details on the clinical and genetic characteristics of the more common subtypes of congenital and limb girdle muscular dystrophies. CONGENITAL MUSCULAR DYSTROPHIES The congenital muscular dystrophies (CMDs) are a group of genetic disorders in which weakness and abnormal muscle histology typically are present at birth. Muscle weakness is variable but is usually stable, depending on the individual disease, whereas complications of the disease can become
Copyright 2006 by Taylor & Francis Group, LLC
Protein group Dystrophin associated and membrane based
Extracellular matrix
Contractile apparatus
Putative glycosyltransferases (posttranslational modification of a-dystroglycan)
Protein
Gene symbol
Associated muscular dystrophy
Dysferlin
SGCA, SGCB, SGCD, SGCG DYSF
LGMD2B
Calveolin-3
CAV3
LGMD1C
Laminin a2 (Merosin) Collagen VI
LAMA2 COL6A1, COL6A2, COL6A3 ITGA7 TCAP TTID TTN FLNC
MDC1A Ullrich CMD
a-, b-, g-, d-Sarcoglycan
Integrin a7 Telethonin, Titin-Cap Myotilin Titin Filamin C O-mannose beta-1, 2-N-acetylglucosaminyltransferase Protein O-mannosyltransferases
POMGNT1 POMT1, POMT2
Other allelic phenotypes
LGMD2C-F
CMD LGMD2G LGMD1A LGMD2J Limb gridle myopathy Muscle-eye-brain disease Walker–Warburg LGMD2K
Miyoshi myopathy, anterior distal myopathy Rippling muscle disease, hypertrophic cardiomyopathy Bethlem myopathy
Dilated cardiomyopathy Hypertrophic and dilated cardiomyopathy
159
(Continued)
Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
Table 1 Different Groups of Proteins Associated with Muscular Dystrophies and Selected Examples of Associated Allelic Variants
Protein group
Protein
Gene symbol
Associated muscular dystrophy
FCMD FKRP
Other enzymes
LARGE Selenoprotein 1
LARGE SEPN1
CAPN3 TRIM32
LGMD2A LGMD2H
Nuclear membrane
Calpain 3 Tripartite motif-containing protein 32 Lamin A/C
LMNA
LGMD1B, EmeryDreifuss muscular dystrophy
Copyright 2006 by Taylor & Francis Group, LLC
Fukuyama CMD LGMD2I, MDC1C MDC1D Rigid spine syndrome
Other allelic phenotypes
Multiminicore myopathy, Desminrelated myopathy with Mallory-like inclusions Sarcotubular myopathy Progerias, lipodystrophies, cardiomyopathies, mandibuloacral dysplasia, CharcotMarie-Tooth neuropathy
Kirschner and Bo¨nnemann
Fukutin Fukutin related protein
160
Table 1 Different Groups of Proteins Associated with Muscular Dystrophies and Selected Examples of Associated Allelic Variants (Continued )
The Congenital and Limb-Girdle Muscular Dystrophies
161
more prominent over the time. In order to establish a diagnosis of CMD, a muscle biopsy is required in addition to the clinical examination. Pathological findings include variation in fiber size, internal nuclei, and increased endomysial and fatty tissue (19). Signs of active degeneration and regeneration often are less prominent compared with later onset muscular dystrophies (e.g., DMD/BMD or sarcoglycanopathies). Elevations in serum creatine kinase concentrations are variable; they are elevated in forms affecting dystroglycan and merosin but can be normal in other forms. The mode of inheritance for most CMD is autosomal recessive with significant genetic heterogeneity. The worldwide incidence of CMDs is not known, but for northeast Italy it has been estimated at 4.7/100,000 (20). For a useful clinical approach CMD can be segregated in subgroups with normal mental development on the one hand and with mental retardation on the other hand. Magnetic resonance imaging (MRI) of the brain is an indispensable tool in the clinical approach to CMD as it may show abnormalities of brain formation and neuronal migration, changes of the white matter, or be completely normal even in the presence of mental retardation. Although this clinical approach does not completely coincide with a classification according to the involved proteins, most of the forms with abnormalities of brain formation that have been defined on a molecular level show abnormalities of posttranslational processing of a-dystroglycan, while mutations of laminin a2 (part of laminin-2/merosin) and other proteins of the extracellular matrix generally allow normal mental development, even though abnormalities of the white matter are seen in laminin a2 mutations. CMD with Normal Mental Development An important subgroup in this category consists of patients with a primary laminin-2 (merosin) deficiency due to mutations in the laminin-a2 chain (MDC1A) (21–24). These patients mostly present at birth or during the first month of life with muscular hypotonia, contractures, and respiratory and feeding problems. Facial weakness is often prominent and motor development is markedly delayed precluding independent ambulation in patients with complete deficiency. Most patients develop respiratory insufficiency requiring ventilatory support during the first decade of life. Although cognitive function is usually normal, T2 weighted magnetic resonance imaging of the brain by six months of age almost always shows abnormalities of the white matter. A small minority of patients shows structural brain changes in the form of occipital pachy- or agyria, which is associated with mental retardation and epilepsy. However, epilepsy is also found in about one-third of patients without such structural brain abnormalities (22). Most children will have a demyelinating or hypo-myelinating motor neuropathy since laminin-a2 normally is also expressed in Schwann cells. Partial deficiency of laminin-a2 can lead to milder phenotypes including an LGMD-like
Copyright 2006 by Taylor & Francis Group, LLC
162
Kirschner and Bo¨nnemann
presentation as well as contractures akin to EDMD. However, white matter abnormalities and a mild demyelinating or hypo-myelinating peripheral neuropathy are features even in mild cases of lamininopathy (25). A related phenotype is shared by some patients with severe mutations in the FKRP gene, encoding a putative glycosyltransferase involved in the posttranslational O-mannose linked glycosylation of a-dystroglycan, leading to a variable secondary deficiency of laminin-2/merosin (MDC1C) (6,10). Useful clinical features that are divergent from MDC1A include the presence of pseudohypertrophy of leg muscles and evidence of left ventricular dilative cardiomyopathy in many patients later in the course as well as the absence of the white matter abnormalities and the peripheral neuropathy seen in MDC1A (6,10). Very recently, the phenotypic spectrum of this entity has been widened with the identification of homozygous FKRP mutations in two patients with the severe phenotypes of Walker–Warburg syndrome and muscle–eye–brain disease (7). As described later, mutations in the FKRP gene more commonly give rise to a type of LGMD (LGMD2I). Ullrich muscular dystrophy (UCMD) defines a distinct group of CMD with normal brain development. Clinically, it is characterized by generalized muscle weakness and striking hypermobility of distal joints in conjunction with contractures of more proximal joints, which may be present early (torticollis) but may also develop over time (26). Additional findings may include kyphoscoliosis, protruded calcaneus, and early respiratory failure. Although in the classical presentation the disease is severe precluding or leading to early loss of ambulation, considerably milder presentations have now also been recognized (27). A number of patients with UCMD are deficient in collagen type VI on the basis of autosomal recessive mutations in one of the three a-chain genes (27–31). Autosomal dominant mutations of collagen VI are known to cause the milder phenotype of Bethlem myopathy (32). However, recently it has been shown that de novo dominant mutations are also a common cause of severe UCMD so that mutation detection becomes critical for accurate genetic counseling in this disorder (30,31,33). Mildly affected patients with UCMD have only mild muscle weakness with marked joint hypermobility, and there is ultrastructural evidence to suggest pathophysiological overlap with the hypermobility type of Ehlers–Danlos syndrome (34). Even though the majority of patients with phenotypic UCMD in Western countries will have mutations in the collagen VI genes, there is evidence of further genetic heterogeneity underlying the phenotype of UCMD as involvement of collagen VI was excluded by immunohistochemistry or linkage analysis in a number of patients with the clinical characteristics of UCMD (35). The group of CMD with rigid spine syndrome (RSS) is characterized by early rigidity of the spine and frequently associated with a restrictive respiratory syndrome. These signs are often preceded by hypotonia in the first months of life and predominantly axial muscle weakness. However,
Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
163
independent ambulation is normally achieved before 18 months of age. Many patients with this phenotype have mutations of selenoprotein N (SEPN1) (27). Selenoprotein N mutations have now also been described in patients with the classical form of multi-minicore disease (37), and with a desmin-related myopathy with Mallory body-like inclusions (38) indicating significant overlap with other congenital myopathies. Not surprisingly, corelike structures can sometimes also be seen in biopsies from patients with RSS CMD caused by mutations in SEPN1 (37). Overall the clinical phenotype in this group of disorders is more consistent than the morphology. CMD with Abnormal Brain Development and Mental Retardation The main phenotypes in this group have been delineated on clinical grounds and include Fukuyama CMD (39), muscle-eye-brain disease (40,41), and Walker–Warburg syndrome (42). All three of these syndromes can be caused by mutations in distinct glycosyltransferases or putative glycosyltransferases involved in the posttranslational modification of a-dystroglycan (Table 1). Common characteristics include severe muscular dystrophy, neuronal migration defects including lissencephaly type II (cobblestone complex), pachygyria, cerebellar dysplasia, and variable ocular anomalies. Fukuyama CMD is mainly found in the Japanese population and characterized by congenital weakness, profound delay of motor development (generally precluding independent ambulation), and severe mental retardation. Typical findings on cerebral imaging include abnormal gyral formation as outlined above, a flat brainstem, and cerebellar hypoplasia (39). The mutation in Japan is a retrotransposon insertion causing a hypomorphic allele (43); a homozygous null mutation has been described in a case of Walker–Walker syndrome (44). Isolated cases of Fukuyama CMD in non-Japanese have been reported in other countries (45). Muscle–eye–brain disease was first described in Finland, where it still remains most prevalent. In addition to severe CMD and brain malformations such as lissencephaly II/pachygyria and cerebello-pontine hypoplasia, this syndrome presents with more severe ocular abnormalities including severe congenital myopia, congenital glaucoma, pallor of the optic discs, and retinal hypoplasia (40,41). Walker–Warburg syndrome generally presents with the most severe brain involvement and frequently is lethal either prenatally or within the first years of life. The morphological features are altogether more severe than what is found in muscle–eye–brain disease; in addition to the features seen in that condition, affected children may have congenital cataracts, microophthalmia, hydrocephalus, occipital encephalocele, fusion of the hemispheres, and absence of the corpus callosum (42). However, with the identification of the genes involved in these three syndromes (Table 2) it has also been recognized that the phenotypic spectrum and the regional
Copyright 2006 by Taylor & Francis Group, LLC
Disease entity
Locus protein product
Helpful clinical features
164
Table 2 Congenital Muscular Dystrophies (CMD) with Identified Gene Defects CNS involvement
Copyright 2006 by Taylor & Francis Group, LLC
Mostly complete laminin-a2 deficiency on IH/WB, secondary reduction of integrin a7 possible, mutation analysisa a-DG with diminished MW on WB, or reduction of IH using antibodies against glycosylated isotopes, secondary reductions in laminin-a2 on IH/WB, mutation analysis IH/WB comparable to MDC1C, mutation analysisa
IH for collagen VI with severe to mild deficiency, mutation analysisa
Normal expression of laminin a2, mutation analysis
Kirschner and Bo¨nnemann
Sitting and standing with support as Abnormal white matter signal (T2 maximal motor ability if complete MRI), 5% occipital deficiency, neuropathy, epilepsy in pachy- or agyria about 30%, possible subclinical cardiomyopathy, generally normal mental development Often reminiscent of MDC 1A, but Generally normal, Fukutin related 19q13.3 Fukutin structural severity more variable, from severe proteinopathy related protein abnormalities with CMD to LGMD (see there), (MDC1C) (FKRP, putative cerebellar cysts generally normal mental phospholigand possible development, rare cases with transferase) structural brain involvement and mental retardation LARGE related 22q12.3 LARGE So far only one patient described. White matter changes, CMD (MDC1D) (putative Congenital muscular dystrophy hypoplastic glycosyltransferase) with profound mental retardation brainstem, mild pachygyria No Distal joint hyperextensibility, Ullrich CMD 21q22.3 and 2q37 proximal contractures, motor (UCMD) a1/2 and a3 abilities variable, precludes collagen VI independent ambulation in severe cases, soft palmar skin No CMD with early Delayed walking, predominantly 1p36–p35 spine rigidity axial weakness with early Selenoprotein Nb (RSMD) development of rigidity of the spine, restrictive respiratory syndrome 6q22–q23 CMD with Laminin-a2 primary laminin2 (merosin) deficiency (MDC1A)
Laboratory testing
Muscle-eye-brain disease (MEB)
Walker–Warburg syndrome (WWS)
Integrin a7 (1)
IH/WB comparable to 9q31 Fukutin Frequent in Japanese population, Lissencephaly type MDC1C, mutation analysis (putative never walk, mental retardation, II/pachygyria, phospholigand epilepsy common cerebellar transferase)b abnormalities IH/WB comparable to Lissencephaly type Severe weakness and mental 1q32–q34 ProteinMDC1C, mutation analysis II/pachygyria, eye retardation, large head, prominent O-linked mannose malformations, forehead, flat midface, walking b1, 2-N-acetylgluco brain stem and rarely achieved, ocular saminyltranferase 1 cerebellar involvement (e.g. severe myopia, (POMGnT1)c abnormalities retinal hypoplasia), deterioration because of spasticity Severe, lethal within first years of life Lissencephaly type II, IH/WB comparable to 9q34.1 and 14q24.3 MDC1C, same phenotype pachygyria, hydrobecause of severe CNS protein-O-mannocan also be caused by cephalus, involvement syltransferases Fukutin or FKRP encephalocele, eye (POMT1 and mutations, mutation malformations POMT2)d analysis 12q13 Integrin a7 Rare, delayed motor milestones, No Absence of integrin a7 on IH walking with 2–3 years (secondary reduction possible), mutation analysisa
The Congenital and Limb-Girdle Muscular Dystrophies
Fukuyama CMD (FCMD)
a
Currently not available as diagnostic testing, only performed on a research basis. Marked genetic heterogeneity for this phenotype. c Genetic heterogeneity for MEB includes FKRP. d Genetic heterogeneity for WWS includes FKRP and Fukutin. Abbreviations: CK, creatine kinase; DG, dystroglycan; IH, immunohistochemistry; MW, molecular weight; WB, Westernblot. Source: References for CMD entities not mentioned in the text: (1) Hayashi YK, et al. Nat Genet 1998; 19(1):94–97. b
165
Copyright 2006 by Taylor & Francis Group, LLC
Disease entity
Helpful clinical features
CMD with partial merosin deficiency (MDC1B) (1)
Rare, variety of severity, delayed onset possible, proximal girdle weakness, generalized muscle hypertrophy, early respiratory failure possible
CMD with microcephaly/calf hypertrophy (3) CMD with adducted thumbs (4)
Joint contractures associated, severe psychomotor retardation, no walking, striking enlargement of the calf and quadriceps muscles, CK grossly elevated Rare, adducted thumbs, toe contractures, generalized weakness, delayed walking, ptosis, external ophthalmoplegia, mild mental retardation Microcephaly, delayed psychomotor development, generalized muscular wasting and weakness with mild facial involvement, calf pseudohypertrophy, joint contractures, severe mental retardation Delayed motor milestones, mild intellectual impairment
CMD with mental retardation and microcephaly (5)
CMD with short stature, proximal contractures and distal laxitiy (7)
Generalized weakness, more proximal, no independent ambulation, short stature, rigidity of the spine, proximal contractures, distal laxity, early respiratory failure, mild to moderate mental retardation
Laboratory testing
Abnormal white matter and Partial deficiency of laminin-a2 on IH/ structural changes WB, a-DG signipossible ficantly reduced on IH, phenotype has been linked to 1q42 Megacisterna magna, Mild to moderate cerebellar hypoplasia, partial deficiency of white matter changes laminin a2 on IH Mild cerebellar hypoplasia Normal expression of laminin a2 and aDG on IH Pontocerebellar hypoplasia, Normal expression of laminin a2 focal cortical dysplasia, white matter changes, cerebellar cysts Normal expression of Moderate to severe laminin a2 cerebellar hypoplasia, no white matter abnormalities Normal MRI in most cases, Normal expression of collagen VI patchy dysmyelination in one case
Abbreviations: DG, dystroglycan; IH, immunohistochemistry; MW, molecular weight; WB, Westernblot. Source: References for CMD entities not mentioned in the text: (1) Brockington M, et al. Am J Hum Genet 2000; 66:428–435, (2) Hayashi YK, et al. Nat Genet 1998 May; 19(1):94–97, (3) Villanova M, et al. Neuromuscul Disord 2000; 10:541–547, (4) Voit T, et al. Neuromuscul Disord 2002; 12:623–630, (5) Ruggieri V, et al. Neuromuscul Disord 2001; 11: 570–578, (6) Echenne B, et al. Neurol 1998; 50:1477–1480, (7) Mercuri E, et al. Neuropediatrics 2004; 35:224–229. Copyright 2006 by Taylor & Francis Group, LLC
Kirschner and Bo¨nnemann
CMD with cerebellar atrophy (6)
CNS involvement
166
Table 3 Congenital Muscular Dystrophies (CMD) without Identified Gene Defects
The Congenital and Limb-Girdle Muscular Dystrophies
167
distribution for individual genetic defects is probably wider than previously assumed, thus blurring the boundaries between the clinically defined entities (46). LIMB-GIRDLE MUSCULAR DYSTROPHIES The term LGMD is used for all noncongenital muscular dystrophies with progressive proximal weakness and spared facial muscles that are not caused by the dystrophin-related muscular dystrophies DMD and BMD. Onset, progression, and distribution of weakness vary considerably among patients and genetic subtypes (5). As in CMD, most of the time a muscle biopsy will be necessary to confirm the presence of dystrophic changes including evidence for degeneration and regeneration and also to differentiate LGMD from other causes of progressive proximal weakness that do not qualify as muscular dystrophies. To keep track of an increasing number of distinct forms of LGMD, a purely genetic nomenclature was introduced (47). This nomenclature chronologically assigned LGMD 1A, 1B, 1C and so on to the autosomal dominant forms and 2A, 2B, 2C and so on to autosomal recessive forms. Autosomal recessive forms are about 10 times more common than dominant forms (48). Within autosomal recessive LGMD, calpainopathy, sarcoglycanopathies, dysferlinopathy, and FKRP mutations are the most important entities. In addition, a number of other disorders not strictly recognized as LGMD in this classification may present with LGMD-like phenotypes and therefore have to be considered in the differential diagnosis. Examples include FSHD, partial deficiency of laminin a2, and myofibrillar myopathies, X-linked EDMD, or Bethlem myopathy. In developing a clinical approach, careful evaluation of the family history, the age of onset and progression, and the pattern of weakness and contractures are important clues to narrow the differential diagnostic possibilities and to guide further histological and genetic workup. Even in the absence of other affected family members, a careful analysis of the family structure is important to see if haplotype analysis would be feasible within the family to narrow down diagnostic possibilities. Some characteristic clinical features can direct the clinician to individual disorders, though there is considerable clinical heterogeneity and overlap among these disorders. In characterization of large numbers of patients with LGMD, there seems to be a gradation according to the age of onset and clinical severity based on genotype. While early onset Duchenne-like phenotypes tend to be caused by either sarcoglycan or FKRP mutations, calpain mutations more commonly present with juvenile onset, and dysferlin mutations in early adulthood (49,50). The autosomal-dominant types often show milder phenotypes, with onset in the later teens or adulthood. However, late onset is also common in FKRP mutations and can indeed occur in any type of LGMD.
Copyright 2006 by Taylor & Francis Group, LLC
168
Kirschner and Bo¨nnemann
Calpainopathy (LGMD 2A) In this relatively frequent type of LGMD the age of onset is in childhood or adolescence for most patients, with a range from about 2 to 40 years, and a peak onset around 16–18 years. An initial scapular–humeral–pelvic distribution of muscle weakness and atrophy with preserved strength of the adductor muscles is characteristic and allows for its clinical recognition in perhaps two–thirds of the cases. In general, calpainopathy is a more atrophic muscular dystrophy with early development of contractures, so that toe walking can be one of the first symptoms. Contractures can be so extensive as to mimic EDMD. The course is progressive with loss of ambulation mostly in the second or third decade, or 20 years after onset (4–44 years) (51). Life expectancy, however, is close to normal (52). Muscle biopsies from patients with calpain-3 mutations often show so-called ‘‘lobulated’’ fibers, in particular on the histochemical type I stain. However, these fibers can occur later in the course of the disease and are not specific for this disorder. In addition, while a clear reduction of calpain-3 on immunoblot analysis is indicative of a calpainopathy, it is not specific (e.g., secondary reduction in dysferlinopathies) and a normal protein level does not exclude the diagnosis (51,53). Dysferlinopathy (LGMD 2B, Miyoshi Myopathy) Although the initial clinical presentation can be of various types, the time of onset in dysferlinopathies clusters around 20 years of age (54,55). Possible patterns of muscle involvement include a limb-girdle phenotype, a posterior distal presentation (gastrocnemius) as Miyoshi myopathy, an anterior distal presentation and mixed presentations even with identical mutations (56). Various forms of onset can be observed within the same family. In the LGMD phenotype, the periscapular muscles are relatively spared in the early course compared with other types of LGMD (e.g., sarcoglycanopathies). Even in the LGMD presentation there is often characteristic early involvement of the gastrocnemius and soleus muscle, which can lead to wasting and difficulties in walking on the toes, a diagnostically helpful feature (40,54). The weakness is slowly progressive and loss of ambulation may occur in the fourth decade. Serum levels of creatine kinase are very high, at least in early stages of the disease. Immunohistochemistry and immunoblot of muscle biopsy show absence of dysferlin in most patients and are very helpful in the diagnostic work up, as mutation analysis is very laborious due to the size of the dysferlin gene (44 exons). Sarcoglycanopathies This group comprises defects of g-, a-, b-, and d-sarcoglycan (LGMD2C, D, E, F) and is more frequently found in the severe forms of LGMD as opposed to milder or later onset presentations (41,57–62). The clinical picture
Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
169
(although variable) resembles that of DMD in many aspects. The course is invariably progressive with loss of ambulation often occurring during the second decade of life. However, especially in cases with later onset, ambulation may be preserved until adult life. Unlike DMD there is no cognitive involvement and overt cardiomyopathy is much less common. However, in about 30% of patients subclinical findings on ECG or echocardiography indicate dilative cardiomyopathy (63). Patients with b- and d-sarcoglycan mutations may be at higher risk for cardiac manifestations that are clinically relevant. Immunohistochemical analysis of the muscle biopsy may help to prioritize genetic analysis within the four sarcoglycan genes. Fukutin-Related Proteinopathy (LGMD2I) Mutations of the enzyme FKRP cause defects of the posttranslational glycosylation of a-dystroglycan with phenotypic presentations ranging from severe CMD with or without brain malformation to mild forms of LGMD in late adulthood (6,8,10,11). Characteristic features include early weakness of the upper arms, shoulders, and neck flexors. Muscle hypertrophy is relatively common and muscle MRI might be helpful to recognize a typical pattern of muscle involvement (64). There may be mild facial weakness especially in early onset cases. Intelligence and MRI of the brain are normal, but dilative cardiomyopathy and respiratory failure are common and occur in more than one-third of patients (8,10,11). The risk of respiratory failure increases in particular after loss of ambulation. In clinical appearance and because of the cardiac involvement, there are considerable clinical similarities to DMD and BMD. Immunohistochemistry can show a mild reduction of a-dystroglycan but can also be normal, so that mutation analysis of FKRP is often necessary to confirm or rule out the diagnosis of LGMD2I. Other Autosomal Recessive LGMD These rare disorders include telethoninopathy (LGMD2G) (65,66), TRIM32related dystrophy (LGMD2H) (67,68) and titinopathy (LGMD2J) (69,70) and have so far been confined to specific pedigrees or populations. Autosomal Dominant LGMD with Cardiac Involvement LGMD1B (laminopathy) is allelic with autosomal dominant EDMD caused by lamin A/C mutations (71). In addition, this gene has been associated with a striking number of clinical phenotypes including cardiomyopathies, progeria, lipodystrophies, and neuropathies (72). Recently, a number of combinations of these phenotypes have been described and some of these also include myopathy (73,74). The clinical spectrum of myopathies associated with lamin A/C mutations ranges from early onset myopathies with severe contractures (EDMD phenotype) to a late onset limb girdle phenotype
Copyright 2006 by Taylor & Francis Group, LLC
170
Table 4 The Limb-Girdle Muscular Dystrophies (LGMD) Locus protein product
Disease entity
15q15 Calpain-3
LGMD2B Dysferlinopathy
2p13 Dysferlin
LGMD2C g-SGpathy, LGMD2D a-SGpathy, LGMD2E b-SGpathy LGMD2F d-SGpathy LGMD2G Telethoninopathy
13q12 g-sarcoglycan 17q21 a-sarcoglycan 4q12 b-sarcoglycan 5q33–34 d-sarcoglycan 17q11–12 Telethonin (Titin-cap)
Copyright 2006 by Taylor & Francis Group, LLC
Laboratory testing
Onset around 10 years of age, but variable, early periscapular and humeral weakness, in the lower extremity, hip abductors relatively spared and posterior compartment of the thigh prominently affected Onset around 18 years of age with proximal, proximal-distal or distal (Miyoshi) weakness, periscapular muscles relatively spared, distal biceps involved, gastrocnemius involved early Onset around six to eight years of age, but great variability with much later onset, distribution of weakness reminiscent of DMD/BMD, but sometimes earlier scapular involvement, calf hypertrophy very common, mental development normal, significant cardiomyopathy possible in a subset Variable clinical picture, may have initial anterior tibial weakness with foot drop, but may also present as pure LGMD picture
Imaging to confirm selective posterior involvement, lobulated type I fibers, calpain-3 reduction only on WB, mutation analysis CK excessively elevated, deficiency of dysferlin in IH/WB, secondary reduction of calpain-3 on WB possible, mutation analysis possible but laborious (55 exons), dysferlin expression in lymphocytesa CK elevated to very high, IH pattern of primary and/or secondary reduction of all four SG antibodies helpful to direct mutation analysis, secondary reduction in IH of dystrophin possible but normal size on WB, mutation analysis mostly necessary for definitive diagnosis Rimmed vacuoles in some patients, reduction in IH/WB for telethonin, mutation analysis (2 exons)a
Kirschner and Bo¨nnemann
LGMD2A Calpainopathy
Helpful clinical features
LGMD2I FKRPpathy
LGMD2J Titinopathy LGMD2K(1)
LGMD1A Myotilinopathy
LGMD1B Laminopathy LGMD1C Caveolinopathy
9q33.2 TRIM32
Onset usually mid 20s, somewhat slower progression, back pain, some evidence for cardiac involvement on ECG, so far only in Hutterites 19q13.3 Fukutin Wide spectrum of possible age of onset and related protein severity, from Duchenne-like severity to (FKRP) mild late onset presentation, often reminiscent of dystrophinopathies, including muscle pseudohypertrophy and cardiomyopathy, more weakness in the upper extremity/shoulders relative to the lower extremities 2q24.3 Titin Heterozygous parents might present with tibial muscular dystrophy, proximal weakness before 10 years of age 9q34.1 POMT1 Onset during childhood, mild proximal weakness, mental retardation, elevated CK levels 5q22–q34 Onset in young adulthood, slowly progressive, Myotilin nasal quality of speech, mildly raised CK values, no cardiac involvement, only described in two families 1q21 Lamin A/C Onset in late teens or early adulthood, cardiac manifestation with conduction system disease, overlap with AD-EDMD 3p25 Caveolin-3 Onset in childhood, muscle cramping and calf hypertrophy possible, no cardiac involvement
CK levels 5- to 50-fold elevated, dystrophic picture on biopsy, mutation analysisa
a-dystroglycan with diminished MW on WB, or reduction of IH using antibodies against glycosylated isotopes, secondary reduction in laminin-a2 on IH/WB possible, mutation analysis
Possibly secondary deficiency of calpain-3 on WB, mutation analysisa Reduced glycosylation of L-dystroglycan
Biopsy with autophagic vacuoles and nemaline rod like structures, IH normal, mutation analysisa Antibody studies for lamin A/C normal in heterozygous mutations, mutation analysis Reduction in IH for caveolin 3, mutation analysis (2 exons)
171
(Continued) Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
LGMD2H
172
Table 4
The Limb-Girdle Muscular Dystrophies (LGMD) (Continued )
Disease entity
Locus protein product
LGMD1D (2)b
7q
LGMD1E (3)b
6q23
LGMD1F (4)
7q32 (distinct from LGMD1D locus) 4p21
LGMD1G (5)
Helpful clinical features
Laboratory testing
Onset in late adulthood, dysphagia possible, Only by linkage analysisa no cardiac involvement, 2 families Onset in early adulthood, slowly progressive, Only by linkage analysisa cardiomyopathy, 1 family Progressive weakness mainly affecting Only by linkage analysisa proximal muscle, age of onset ranging from less than 1 year to 58 years, 1 family One Brazilian family with adult onset weakness and progressive finger and toe flexion contractures
Only by linkage analysisa
a
Currently not available as diagnostic testing, research only. Confused terminology between these two disorders in the literature. Abbreviations: CK, creatine kinase; IH, immunohistochemistry; WB, Westernblot. Source: References for LGMD entities not mentioned in the text: Balci B, et al. Neuromuscul Disord 2005; 15:271–275, (2) Speer MC, et al. Am J Hum Genet 1999; 64:556–562, (3) Messina DN, et al. Am J Hum Genet 1997; 61:909–917, (4) Palenzuela L, et al. Neurology 2003; 61:404–406, (5) Starling A, et al. Europ J Hum Genet 2004; 12:1033–1040. b
Kirschner and Bo¨nnemann
Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
173
without contractures; there seems to be a continuum between these disorders. The possible cardiac involvement with various degrees of conduction block is comparable to the EDMD phenotype and necessitates early diagnoses and close follow up. LGMD1E is very similar to LGMD1B with respect to the nature of the cardiac involvement; however a gene has not yet been isolated for that type (75).
Autosomal Dominant LGMD Without Cardiac Involvement LGMD1A is a slowly progressive form of LGMD in which some affected members have characteristic nasal speech. Mutations in myotilin have been identified in two families. Mutations in myotilin are also a cause of myofibrillar myopathy, indicating overlap between these phenotypes (76). The spectrum of clinical phenotypes associated with caveolin-3 mutations has recently broadened considerably. In addition to the rare LGMD phenotype (1C), possible presentations include asymptomatic hyperCKemia (77), myalgias (78), an autosomal dominant and recessive form of rippling muscle disease (79,80), and distal myopathy (81). CK levels tend to be higher than in other autosomal dominant LGMDs and immunohistochemistry and immunoblot can show significant reduction of caveolin-3 in the muscle biopsy. REFERENCES 1. Meryon E. On granular and fatty degeneration of the voluntary muscles. Med Chir Trans 1852; 35:73–84. 2. Duchenne G. Recherches sur la paralysie musculaire pseudohypertrophique on paralysie myosclerosique. Arch Gen Med 1868; 11:5–25. 3. Batten F. Three cases of myopathy, infantile type. Brain 1903; 26:147–148. 4. Bell J. On pseudohypertrophic and allied types of progressive muscular dystrophy. In: Fischer RA, ed. The Treasury of Human Inheritance. London: Cambridge University Press, 1943:283–342. 5. Bushby KMD. Diagnostic criteria for the limb-girdle muscular dystrophies: Report of the ENMC consortium on limb-girdle dystrophies. Neuromuscul Disord 1995; 5:71–74. 6. Brockington M, Blake DJ, Prandini P, Brown SC, Torelli S, Benson MA. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. Am J Hum Genet 2001; 69(6):1198–1209. 7. Beltran-Valero DB, Voit T, Longman C, Steinbrecher A, Straub V, Yuva Y. Mutations in the FKRP gene can cause muscle-eye-brain disease and WalkerWarburg syndrome. J Med Genet 2004; 41(5):e61. 8. Brockington M, Yuva Y, Prandini P, Brown SC, Torelli S, Benson MA. Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. Hum Mol Genet 2001; 10(25):2851–2859.
Copyright 2006 by Taylor & Francis Group, LLC
174
Kirschner and Bo¨nnemann
9. Harel T, Goldberg Y, Shalev SA, Chervinski I, Ofir R, Birk OS. Limb-girdle muscular dystrophy 2I: phenotypic variability within a large consanguineous Bedouin family associated with a novel FKRP mutation. Eur J Hum Genet 2004; 12(1):38–43. 10. Mercuri E, Brockington M, Straub V, Quijano-Roy S, Yuva Y, Herrmann R, et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 2003; 53(4):537–542. 11. Poppe M, Cree L, Bourke J, Eagle M, Anderson LV, Birchall D, et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 2003; 60(8): 1246–1251. 12. Bonne G, Di Barletta MR, Varnous S, Becane HM, Hammouda EH, Merlini L, et al. Mutations in the gene encoding lamin A/C cause autosomal dominant Emery-Dreifuss muscular dystrophy. Nat Genet 1999; 21(3):285–288. 13. Chen L, Lee L, Kudlow BA, Dos Santos HG, Sletvold O, Shafeghati Y, et al. LMNA mutations in atypical Werner’s syndrome. Lancet 2003; 362(9382): 440–445. 14. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, et al. Lamin A Truncation in Hutchinson-Gilford Progeria. Science 2003; Published online 17 April 2003 (10.1126/science.1084125). 15. De Sandre-Giovannoli A, Chaouch M, Kozlov S, Vallat JM, Tazir M, Kassouri N, et al. Homozygous defects in LMNA, encoding lamin A/C nuclear-envelope proteins, cause autosomal recessive axonal neuropathy in human (CharcotMarie-Tooth disorder type 2) and mouse. Am J Hum Genet 2002; 70(3):726–736. 16. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, et al. Recurrent de novo point mutations in lamin A cause Hutchinson-Gilford progeria syndrome. Nature 2003; 423(6937):293–298. 17. Fatkin D, MacRae C, Sasaki T, Wolff MR, Porcu M, Frenneaux M, et al. Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. N Engl J Med 1999; 341(23): 1715–1724. 18. Novelli G, Muchir A, Sangiuolo F, Helbling-Leclerc A, D’Apice MR, Massart C, et al. Mandibuloacral dysplasia is caused by a mutation in LMNA-encoding lamin A/C. Am J Hum Genet 2002; 71(2):426–431. 19. Dubowitz V. The congenital myopathies. In: Muscle Disorders in Childhood. London: W.B. Saunders, 1995:134–176. 20. Mostacciuolo ML, Miorin M, Martinello F, Angelini C, Perini P, Trevisan CP. Genetic epidemiology of congenital muscular dystrophy in a sample from north-east Italy. Hum Genet 1996; 97(3):277–279. 21. Helbling-Leclerc A, Zhang X, Topaloglu H, Cruaud C, Tesson F, Weissenbach J, et al. Mutations in the laminin alpha 2-chain gene (LAMA2) cause merosindeficient congenital muscular dystrophy. Nat Genet 1995; 11(2):216–218. 22. Jones KJ, Morgan G, Johnston H, Tobias V, Ouvrier RA, Wilkinson I, et al. The expanding phenotype of laminin alpha2 chain (merosin) abnormalities: case series and review. J Med Genet 2001; 38(10):649–657. 23. Pegoraro E, Marks H, Garcia CA, Crawford T, Mancias P, Connolly AM, et al. Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology 1998; 51(1):101–110.
Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
175
24. Philpot J, Sewry C, Pennock J, Dubowitz V. Clinical phenotype in congenital muscular dystrophy: correlation with expression of merosin in skeletal muscle. Neuromuscul Disord 1995; 5(4):301–305. 25. Tan E, Topaloglu H, Sewry C, Zorlu Y, Naom I, Erdem S, et al. Late onset muscular dystrophy with cerebral white matter changes due to partial merosin deficiency. Neuromuscul Disord 1997; 7(2):85–89. 26. Ullrich O. Kongenitale atonisch-sklerotische Muskeldystrophie, ein weiterer Typus der heredodegenerativen Erkrankungen des neuromuskula¨ren Systems. Z Ges Neurol Psychiat 1930; 126:171–201. 27. Higuchi I, Shiraishi T, Hashiguchi T, Suehara M, Niiyama T, Nakagawa M, et al. Frameshift mutation in the collagen VI gene causes Ullrich’s disease. Ann Neurol 2001; 50(2):261–265. 28. Camacho Vanegas O, Bertini E, Zhang RZ, Petrini S, Minosse C, Sabatelli P, et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci USA 2001; 98(13):7516–7521. 29. Demir E, Sabatelli P, Allamand V, Ferreiro A, Moghadaszadeh B, Makrelouf M, et al. Mutations in COL6A3 cause severe and mild phenotypes of Ullrich congenital muscular dystrophy. Am J Hum Genet 2002; 70(6):1446–1458. 30. Lampe AK, Dunn DM, von Niederhausern AC, Hamil C, Aoyagi A, Laval SH, et al. Automated genomic sequence analysis of the three collagen VI genes: applications to Ullrich congenital muscular dystrophy and Bethlem myopathy. J Med Genet 2005; 42(2):108–120. 31. Pan TC, Zhang RZ, Sudano DG, Marie SK, Bonnemann CG, Chu ML. New molecular mechanism for Ullrich congenital muscular dystrophy: a heterozygous in-frame deletion in the COL6A1 gene causes a severe phenotype. Am J Hum Genet 2003; 73(2):355–369. 32. Jo¨bsis GJ, Keizers H, Vreijling JP, de Visser M, Speer MC, Woltermann RA, et al. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. Nature Genetics 1996; 14:113–115. 33. Baker NL, Morgelin M, Peat R, Goemans N, North KN, Bateman JF, et al. Dominant collagen VI mutations are a common cause of Ullrich congenital muscular dystrophy. Hum Mol Genet 2005; 14(2):279–293. 34. Kirschner J, Hausser I, Zou Y, Schreiber G, Christen HJ, Brown SC, et al. Ullrich congenital muscular dystrophy: connective tissue abnormalities in the skin support overlap with Ehlers-Danlos syndromes. Am J Med Genet A 2005; 132(3):296–301. 35. Mercuri E, Yuva Y, Brown SC, Brockington M, Kinali M, Jungbluth H, et al. Collagen VI involvement in Ullrich syndrome: a clinical, genetic, and immunohistochemical study. Neurology 2002; 58(9):1354–1359. 36. Moghadaszadeh B, Petit N, Jaillard C, Brockington M, Roy SQ, Merlini L, et al. Mutations in SEPN1 cause congenital muscular dystrophy with spinal rigidity and restrictive respiratory syndrome. Nat Genet 2001; 29(1):17–18. 37. Ferreiro A, Quijano-Roy S, Pichereau C, Moghadaszadeh B, Goemans N, Bonnemann C, et al. Mutations of the selenoprotein N gene, which is implicated in rigid spine muscular dystrophy, cause the classical phenotype of multiminicore disease: reassessing the nosology of early-onset myopathies. Am J Hum Genet 2002; 71(4):739–749.
Copyright 2006 by Taylor & Francis Group, LLC
176
Kirschner and Bo¨nnemann
38. Ferreiro A, Ceuterick-de Groote C, Marks JJ, Goemans N, Schreiber G, Hanefeld F, et al. Desmin-related myopathy with Mallory body-like inclusions is caused by mutations of the selenoprotein N gene. Ann Neurol 2004; 55(5):676–686. 39. Fukuyama Y, Osawa M, Suzuki H. Congenital progressive muscular dystrophy of the Fukuyama type-clinical, genetic and pathological considerations. Brain Dev 1981; 3(1):1–29. 40. Santavuori P, Leisti J, Kruus S. Muscle, eye and brain disease: a new syndrome. Neuropa¨diatrie 1977; 8(suppl):553. 41. Santavuori P, Somer H, Sainio K, Rapola J, Kruus S, Nikitin T, et al. Muscleeye-brain disease (MEB). Brain Dev 1989; 11(3):147–153. 42. Dobyns WB, Pagon RA, Armstrong D, Curry CJ, Greenberg F, Grix A, et al. Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet 1989; 32(2):195–210. 43. Kobayashi K, Nakahori Y, Miyake M, Matsumura K, Kondo-Iida E, Nomura Y, et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998; 394(6691):388–392. 44. Silan F, Yoshioka M, Kobayashi K, Simsek E, Tunc M, Alper M, et al. A new mutation of the fukutin gene in a non-Japanese patient. Ann Neurol 2003; 53(3):392–396. 45. de Bernabe DB, Van Bokhoven H, Van Beusekom E, Van den AW, Kant S, Dobyns WB, et al. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. J Med Genet 2003; 40(11):845–848. 46. Yoshida A, Kobayashi K, Manya H, Taniguchi K, Kano H, Mizuno M, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001; 1(5):717–724. 47. Beltran-Valero De Bernabe D, Currier S, Steinbrecher A, Celli J, Van Beusekom E, Van Der Zwaag B, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder WalkerWarburg syndrome. Am J Hum Genet 2002; 71(5):1033–1043. 48. Taniguchi K, Kobayashi K, Saito K, Yamanouchi H, Ohnuma A, Hayashi YK, et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet 2003; 12(5):527–534. 49. Topaloglu H, Brockington M, Yuva Y, Talim B, Haliloglu G, Blake D, et al. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 2003; 60(6):988–992. 50. Bushby KM, Beckmann JS. The limb girdle muscular dystrophies–proposal for a new nomenclature. Neuromuscul Disord 1995; 4:337–343. 51. van der Kooi AJ, Barth PG, Busch HFM, de Haan R, Ginjaar HB, van Essen AJ, et al. The clinical spectrum of limb girdle muscular dystrophy: A survey in the Netherlands. Brain 1996; 119:1471–1480. 52. Passos-Bueno MR, Vainzof M, Moreira ES, Zatz M. Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. Am J Med Genet 1999; 82(5):392–398. 53. Ginjaar HB, van der Kooi AJ, Ceelie H, Kneppers AL, van Meegen M, Barth PG, et al. Sarcoglycanopathies in Dutch patients with autosomal recessive limb girdle muscular dystrophy. J Neurol 2000; 247(7):524–529. 54. Richard I, Broux O, Allamand V, Fougerousse F, Chiannilkulchai N, Bourg N, et al. Mutations in the proteolytic enzyme calpain 3 cause limb-girdle muscular dystrophy type 2A. Cell 1995; 81:27–40.
Copyright 2006 by Taylor & Francis Group, LLC
The Congenital and Limb-Girdle Muscular Dystrophies
177
55. Saenz A, Leturcq F, Cobo AM, Poza JJ, Ferrer X, Otaegui D, et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 2005. 56. Fardeau M, Hillaire D, Mignard C, Feingold N, Feingold J, Mignard D, et al. Juvenile limb-girdle muscular dystrophy: Clinical, histopathological and genetic data from a small community living in the Reunion Island. Brain 1996; 119:295–308. 57. Fanin M, Fulizio L, Nascimbeni AC, Spinazzi M, Piluso G, Ventriglia VM, et al. Molecular diagnosis in LGMD2A: mutation analysis or protein testing? Hum Mutat 2004; 24(1):52–62. 58. Argov Z, Sadeh M, Mazor K, Soffer D, Kahana E, Eisenberg I, et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 2000; 123(Pt 6):1229–1237. 59. Linssen WH, Notermans NC, Van der Graaf Y, Wokke JH, Van Doorn PA, Howeler CJ, et al. Miyoshi-type distal muscular dystrophy: Clincal spectrum in 24 Dutch patients. Brain 1997; 120:1989–1996. 60. Weiler T, Bashir R, Anderson LV, Davison K, Moss JA, Britton S, et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 1999; 8(5):871–877. 61. Bo¨nnemann CG, Modi R, Noguchi S, Mizuno Y, Yoshida M, Gussoni E, et al. b-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. Nat Genet 1995; 11(3):266–273. 62. Fanin M, Duggan DJ, Mostacciuolo ML, Martinello F, Freda MP, Soraru G, et al. Genetic epidemiology of muscular dystrophies resulting from sarcoglycan gene mutations. J Med Genet 1997; 34(12):973–977. 63. Lim LE, Duclos F, Broux O, Bourg N, Sunada Y, Allamand V, et al. b-sarcoglycan (43 DAG): Characterization and involvement in a recessive form of limb-girdle muscular dystrophy linked to chromosome 4q12. Nat Genet 1995; 11:257–265. 64. Nigro V, de Sa Moriera E, Piluso G, Vainzof M, Belsito A, Politano L, et al. The 5q autosomal recessive limb-girdle muscular dystrophy (LGMD 2F) is caused by a mutation in the d-sarcoglycan gene. Nature Genetics 1996; 14(2):195–198. 65. Noguchi S, McNally EM, Ben Othmane K, Hagiwara Y, Mizuno Y, Yoshida M, et al. Mutations in the dystrophin-associated protein g sarcoglycan in chromosome 13 muscular dystrophy. Science 1995; 270:819–822. 66. Roberds SL, Leturcq F, Allamand V, Piccolo F, Jeanpierre M, Anderson RD, et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 1994; 78:625–633. 67. Melacini P, Fanin M, Duggan DJ, Freda MP, Berardinelli A, Danieli GA, et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations. Muscle Nerve 1999; 22(4):473–479. 68. Fischer D, Walter MC, Kesper K, Petersen JA, Aurino S, Nigro V, et al. Diagnostic value of muscle MRI in differentiating LGMD2I from other LGMDs. J Neurol 2005. 69. Moreira ES, Vainzof M, Marie SK, Sertie AL, Zatz M, Passos-Bueno MR. The seventh form of autosomal recessive limb-girdle muscular dystrophy is mapped to 17q11–12. Am J Hum Genet 1997; 61(1):151–159. 70. Moreira ES, Wiltshire TJ, Faulkner G, Nilforoushan A, Vainzof M, Suzuki OT, et al. Limb-girdle muscular dystrophy type 2G is caused by mutations in the gene encoding the sarcomeric protein telethonin. Nat Genet 2000; 24(2):163–166. Copyright 2006 by Taylor & Francis Group, LLC
178
Kirschner and Bo¨nnemann
71. Frosk P, Weiler T, Nylen E, Sudha T, Greenberg CR, Morgan K, et al. Limbgirdle muscular dystrophy type 2H associated with mutation in TRIM32, a Putative E3-Ubiquitin-Ligase Gene. Am J Hum Genet 2002; 70(3):663–672. 72. Weiler T, Greenberg CR, Zelinski T, Nylen E, Coghlan G, Crumley MJ, et al. A gene for autosomal recessive limb-girdle muscular dystrophy in manitoba hutterites maps to chromosome region 9q31-q33: evidence for another limbgirdle muscular dystrophy locus. Am J Hum Genet 1998; 63(1):140–147. 73. Hackman P, Vihola A, Haravuori H, Marchand S, Sarparanta J, De Seze J, et al. Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 2002; 71(3):492–500. 74. Udd B. Limb-girdle type muscular dystrophy in a large family with distal myopathy: homozygous manifestation of a dominant gene? J Med Genet ; 29(6):383–389. 75. van der Kooi AJ, Ledderhof TM, de Voogt WG, Res CJ, Bouwsma G, Troost D, et al. A newly recognized autosomal dominant limb girdle muscular dystrophy with cardiac involvement. Ann Neurol 1996; 39(5):636–642. 76. Maraldi NM, Squarzoni S, Sabatelli P, Capanni C, Mattioli E, Ognibene A, et al. Laminopathies: Involvement of structural nuclear proteins in the pathogenesis of an increasing number of human diseases. J Cell Physiol 2004. 77. Walter MC, Witt TN, Weigel BS, Reilich P, Richard P, Pongratz D, et al. Deletion of the LMNA initiator codon leading to a neurogenic variant of autosomal dominant Emery-Dreifuss muscular dystrophy. Neuromuscul Disord 2005; 15(1):40–44. 78. Kirschner J, Brune T, Wehnert M, Denecke J, Wasner C, Feuer A, et al. p.S143F mutation in lamin A/C: a new phenotype combining myopathy and progeria. Ann Neurol 2005; 57(1):148–151. 79. Messina DN, Speer MC, Pericak-Vance MA, McNally EM. Linkage of familial dilated cardiomyopathy with conduction defect and muscular dystrophy to chromosome 6q23. Am J Hum Genet 1997; 61(4):909–917. 80. Selcen D, Engel AG. Mutations in myotilin cause myofibrillar myopathy. Neurology 2004; 62(8):1363–1371. 81. Carbone I, Bruno C, Sotgia F, Bado M, Broda P, Masetti E, et al. Mutation in the CAV3 gene causes partial caveolin-3 deficiency and hyperCKemia. Neurology 2000; 54(6):1373–1376. 82. Herrmann R, Straub V, Blank M, Kutzick C, Franke N, Jacob EN, et al. Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. Hum Mol Genet 2000; 9(15):2335–2340. 83. Kubisch C, Ketelsen UP, Goebel I, Omran H. Autosomal recessive rippling muscle disease with homozygous CAV3 mutations. Ann Neurol 2005; 57(2): 303–304. 84. Betz RC, Schoser BG, Kasper D, Ricker K, Ramirez A, Stein V, et al. Mutations in CAV3 cause mechanical hyperirritability of skeletal muscle in rippling muscle disease. Nat Genet 2001; 28(3):218–219. 85. Tateyama M, Aoki M, Nishino I, Hayashi YK, Sekiguchi S, Shiga Y, et al. Mutation in the caveolin-3 gene causes a peculiar form of distal myopathy. Neurology 2002; 58(2):323–325.
Copyright 2006 by Taylor & Francis Group, LLC
9 Non-dystrophic Myotonias and Periodic Paralyses Arie Struyk and Stephen Cannon Department of Neurology, University of Texas Southwestern Medical Center, Dallas, Texas, U.S.A.
INTRODUCTION One of the intriguing developments in the biology of excitable membranes has been the discovery that several heritable disorders are due to mutations of ion channel genes. The integrated function of many ion channels is required for the generation and propagation of action potentials over the skeletal muscle sarcolemma and into the transverse tubules. Derangements in muscle electrical excitability cause myotonia or periodic paralysis. This chapter reviews the molecular genetic origins of these disorders and outlines the pathophysiological link between altered behavior of mutant channels and clinical phenotype. Disordered Sarcolemmal Excitability Is a Spectrum of Phenotypes The phenotypic manifestations of disordered sarcolemmal excitability cover a spectrum between transient loss of excitability (paralytic attacks) and enhanced excitability manifest as involuntary tonic muscle activity lasting several seconds, preventing muscle relaxation after voluntary contraction (myotonic stiffness). The electrophysiological basis of this delayed relaxation is a self-sustaining train of action potentials, which fluctuates in amplitude and frequency over several seconds (Fig. 1) and produces a characteristic
Copyright 2006 by Taylor & Francis Group, LLC
180
Struyk and Cannon
Figure 1 Sustained discharges recorded from a myotonia congenita patient. Myotonia waxes and wanes for several seconds in the top trace, while decay of a myotonic discharge is demonstrated in the lower trace. Voltage and time scales are noted for each trace. (Courtesy of Gil Wolfe, M.D., Department of Neurology UTSouthwestern Medical Center.
‘‘dive-bomber’’ sound on the audio monitor during needle ‘‘compound muscle action potential’’ (CMAP) (1). Attacks of weakness and periodic paralysis are characterized by loss of muscle contractility, often with reduced tendon reflexes and tone. The EMG during paralytic episodes shows a reduced interference pattern and reduced amplitude of the compound muscle action potential (CMAP). Remarkably, some affected individuals may have both myotonia and periodic paralysis. Physiological Basis of the Sarcolemmal Excitability The physiological underpinnings of muscle excitability have been an important guide in the identification of disease genes and conceptual understanding of disease mechanisms. Microelectrode studies of muscle biopsied from patients with myotonia or periodic paralysis revealed the alterations in specific ionic currents, which then implicated candidate disease genes in these disorders. Once the genetic basis of these disorders was identified, the identification of specific mutations has led to a consideration of genotype– phenotype correlations and to both theoretical and biological models of how functional alterations of mutant channels account for the spectrum of phenotypes in these disorders. A brief review of this physiology will help put descriptions of these disorders in context. Electrical excitability arises from two fundamental cellular properties: the concentration gradient of diffusible ions and the selective permeability of the membrane. Steep concentration gradients of Naþ and Kþ ions are
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
181
maintained across the sarcolemma through the continuous activity of ion pumps. The electrochemical gradients thus established define equilibrium potentials for each of these ions, denoted ENaþ and EKþ where the net inward movement balances the outward flux of these ions. In muscle, EKþ is about 95 mV and ENa is þ66 mV. The importance of these values lies in the fact that the membrane potential is determined by a weighted average of the equilibrium potentials, in proportion to their relative contribution to the total membrane conductance. At rest, the sarcolemmal permeability to Kþ, although small, nevertheless predominates, setting the resting membrane potential near EKþ of 95 mV. In response to the small local depolarization caused by acetylcholine released from the nerve terminal binding to its postsynaptic receptor, an action potential is initiated and propagated by the opening of Naþ channels, which depolarizes the membrane potential toward ENaþ. An unusual feature of skeletal muscle is the large number of chloride channels open at the resting membrane potential (2). The resting Cl conductance is 2.5 times larger than the potassium conductance that sets the resting membrane potential. In contrast to Naþ and Kþ, however, Cl ions are not distributed by an active pump mechanism, and the passive equilibration of the Cl across the membrane adjusts the intracellular concentration until ECl equals the resting potential. The importance of the Cl conductance is revealed whenever the membrane potential deviates from its resting value. In response to this shift, a large Cl current will flow that tends to return the membrane potential to its previously established resting value. In effect, the Cl conductance is an electrical buffer that stabilizes the resting membrane potential against small depolarizing currents. Current flow through the pore of an ion channel is regulated by conformational changes in the protein that open or close access to the pore in a process termed ‘‘gating.’’ The open or closed conformation of the gate is regulated by various stimuli for different channels, such as ligand binding, stretch, intracellular messengers, or voltage itself. The gating properties of ion channels are critically important for orchestrating the precisely timed sequence of events that produce an action potential. The action potential is a wave of membrane depolarization that rapidly propagates in an all-or-none fashion along the length of the muscle fiber. At the motor endplate, local depolarization is initiated by ligand activation of nicotinic acetylcholine receptors. This initial depolarization causes voltage-gated Naþ channels to open (‘‘activate’’), producing a sharp rise in sarcolemmal Naþ conductance and the rapid (within 1 msec) upstroke of an action potential toward ENaþ. Repolarization during the latter part of an action potential is dependent on three phenomena: First, Naþ channels inactivate in a slightly delayed, voltage-dependent process, effectively shutting off the Naþ current within milliseconds of its activation. Second, voltagegated Kþ channels activate with delayed kinetics as the membrane depolarizes, increasing the membrane permeability to Kþ and promoting the
Copyright 2006 by Taylor & Francis Group, LLC
182
Struyk and Cannon
return of the membrane potential toward EKþ. Finally, voltage-gated Cl channels open, further increasing the already large chloride conductance and accelerating the recovery of the resting membrane potential. The availability of Naþ channels, after having recovered from the inactive state to a closed, resting conformation, is a critical determinant of the capability of propagating another action potential. The recovery process is highly voltage dependent (faster and more complete at more negative potentials). Even modest shifts in the resting membrane potential may have a large effect on Naþ channel availability. A depolarization of 10 mV, for example, may inactivate enough Naþ channels to render the sarcolemma inexcitable.
CHLORIDE CHANNEL MYOTONIAS (MYOTONIA CONGENITA) Phenotypes Myotonia congenita is unique among the disorders of sarcolemmal excitability, in that it can be inherited as either a dominant or a recessive trait. The dominant form was first described by Asmus Julius Thomsen in 1876, who suffered from the disorder himself. Dominant myotonia congenita or Thomsen’s disease usually becomes clinically apparent during infancy. The more severe recessive myotonia (Becker’s generalized myotonia) typically presents later in the first decade, initially affecting the lower extremities then spreading to involve the rest of the skeletal musculature within a few years. Clinical examination readily elicits both grip myotonia (delayed relaxation after a voluntary grasp) and percussion myotonia (sustained contraction of a muscle elicited by percussion with a reflex hammer). Myotonic stiffness tends to lessen significantly after several repetitions, known as the ‘‘warm-up’’ phenomenon. Cooler ambient temperatures may increase the myotonic activity but does not affect contractile force. Skeletal muscle hypertrophy is often observed, due to chronically high muscular activity. Occasional transient episodes of weakness have been noted in the recessive form, but these last only seconds to a few minutes in contrast to the prolonged episodes in periodic paralysis. In general, symptom penetrance in males is greater than females. Mutation of the C1C-1 Chloride Channel Underlies Myotonia Congenita One of the first clues to the pathophysiology of human myotonia congenita arose from electrophysiological studies of goats afflicted with a dominant form of myotonia, in which microelectrode recordings revealed a marked reduction in membrane chloride conductance (3). Subsequent to this, a similarly reduced chloride conductance was found in biopsy fibers from
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
183
myotonia congenita patients (4). These electrophysiological insights led to a candidate gene approach to screen for mutations in CLCN1. This gene encodes the C1C-1 channel (5), a 988 amino acid protein that homodimerizes to form the major chloride conductance in skeletal muscle (6). To date, over 60 disease-causing mutations in CLCNl have been reported (for a detailed list, see Ref. 7). Of these, only a few are dominant mutations. The clinical delineation between dominant and recessive phenotypes is slightly blurred at the genotypic level, as a number of individual mutations show incomplete dominance or variable penetrance. Loss of Chloride Conductance in C1C-1 Mutants Causes Myotonia The physiological basis of myotonia in all variants of myotonia congenita is reduced chloride current carried by C1C-1. In addition to the loss of the repolarizing influence of the Cl current, this defect renders the sarcolemma more susceptible to the use-dependent depolarizing effect of potassium accumulation in the transverse tubules due to the egress of Kþ from the myoplasm with each action potential (8). This Kþ-induced depolarization is thought to elicit self-sustaining trains of action potentials (APs) in the absence of an endplate stimulus. Pharmacological studies indicate that block of up to 70% of the sarcolemmal chloride conductance is well tolerated; only in the setting of more severe decreases in chloride conductance do myotonic discharges appear (9). This phenomenon offers a context in which to differentiate the modes of inheritance of myotonia-inducing mutations. In general, mutations that render the protein incapable of dimer formation through premature truncation of the polypeptide (frameshift insertions or deletions, splice site defects, or nonsense codons), underlie the recessively inherited disease variant (10). In these cases, heterozygotic carriers with one wildtype allele retain 50% of C1C-1 activity, sufficient to prevent myotonic hyperexcitability. Patients with two recessive mutant alleles are unable to generate any C1C-1 channels, probably explaining the greater symptomatic severity in these patients. Given the large number of different recessively linked mutations distributed in the population, patients with the recessive variant are usually compound heterozygotes for two different peptide truncating mutations, rather than homozygotes for the same mutation. Heterozygous carriers are asymptomatic, but latent myotonia may be detected electromyographically in some individuals (11). In contrast, mutations linked to the dominantly inherited variant generally do not prevent dimer formation with subunits derived from the wildtype allele, but rather exert a dominant-negative effect such that the chloride conductance of the heteroallelic dimer pairs is severely impaired (12). Commonly, this dominant negative effect is a positive shift in the voltage dependence of channel activation, such that heteroallelic dimers are significantly less likely to be open when the membrane is between 40 mV and 80 mV.
Copyright 2006 by Taylor & Francis Group, LLC
184
Struyk and Cannon
Treatment Most patients with myotonia congenita manage their symptoms by avoiding maneuvers that provoke myotonic stiffness, and thus do not require pharmacological intervention. In cases of disabling myotonic stiffness, treatment with use-dependent Naþ channel blockers (e.g., mexiletine) is effective in reducing or often completely preventing myotonia.
SODIUM CHANNEL MYOTONIA AND PERIODIC PARALYSIS Phenotypes In contrast to chloride channel myotonia, the sodium channelopathies of skeletal muscle always result in autosomal dominant inheritance with high penetrance. Another unique feature of the Naþ channel disorders is that the phenotypic variability spans the entire spectrum from myotonia only (potassium-aggravated myotonia), to admixtures of myotonia and periodic paralysis (paramyotonia congenita and hyperkalemic periodic paralysis), to periodic paralysis without myotonia (hypokalemic periodic paralysis). The sodium channel disorders associated with myotonia are observed more frequently and share the common feature of underlying gain-of-function defects. Sodium channel mutations are an infrequent cause of hypokalemic periodic paralysis, as described in the next section. Potassium aggravated myotonia (PAM) bears a close phenotypic resemblance to dominantly inherited myotonia congenita. Only after genetic screening became available was it determined that a subset of patients clinically diagnosed with dominantly inherited congenital myotonia (Thomsen’s disease) were instead linked to the Naþ channel gene. In the wake of this revelation, subtle phenotypic differences between the two disorders, first noted by Thomsen in his early monographs, became clearer. Like the stiffness characteristic of myotonia congenita, the myotonic stiffness of PAM is the greatest upon initiation of movement, and declines after ‘‘warm-up’’ repetition. As reflected in the name, however, elevation of serum potassium tends to increase the frequency and duration of the myotonia in PAM. In addition, myotonic stiffness attributable to PAM is often variable day-today, and is often worsened after very prolonged periods of exercise, in contrast to myotonia congenita. Attacks of weakness usually do not occur and if they do are very infrequent, brief, and mild. Temperature changes do not alter the clinical symptoms. Paramyotonia congenita (PMC) is also a predominantly myotonic phenotype. However, the ‘‘paradoxical’’ myotonia of this disorder allows clinical differentiation from other myotonic disorders. In contrast to the ‘‘warm-up’’ phenomenon of PAM and myotonia congenita, the hallmark of PMC is the exacerbation of myotonia by repeated or continuous effort.
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
185
Myotonia worsens upon exposure to cold, and occasionally episodes of flaccid paralysis may also occur under cooling conditions. The classic presentation of hyperkalemic periodic paralysis (HyperPP) is episodic attacks of flaccid paralysis in association with elevated serum potassium. Myotonic stiffness is usually found between attacks and may be the more prominent complaint in a subset of patients. Paralytic episodes typically start during the first decade. Paralysis arises throughout the skeletal musculature within a few minutes, typically sparing bulbar and respiratory muscle function. In many cases, attacks of weakness can be predictably precipitated by exercise or exogenous administration of potassium, although other episodes may occur without obvious provocation. Episodes of paralysis frequently last for several minutes, but durations on the order of hours can occur and full strength may not return for days. The classic finding of serum hyperkalemia during an attack aids in establishing the diagnosis, but a normal serum potassium level does not rule it out. Cooling neither exacerbates the myotonia nor affects contractile force. A late onset permanent muscle weakness often affects the limb girdle musculature in HyperPP after the fourth decade and is associated with a vacuolar myopathy and accumulation of tubular aggregates. Point Mutations of the Voltage-Gated Na1 Channel Cause PAM PMC and HyperPP Early electrophysiological studies of skeletal muscle fibers derived from biopsies of patients with both PMC and HyperPP identified an aberrant, non-inactivating Naþ current in both populations (13,14). This discovery implicated SCN4A, the gene encoding the alpha subunit of the voltage-gated sodium channel of skeletal muscle (Nav1.4), as a candidate for linkage screening. The gene product of SCN4A is an 1851 amino acid protein (Navl.4) that forms the main pore-forming subunit of the skeletal muscle Naþ channel. Navl.4 is a member of a large family of voltage-gated Naþ channels distributed in other excitable tissues (15). In all voltage-gated Naþ channels, the a subunit contains four large homologous domains, each of which is composed of six transmembrane segments (S1–S6). The fourth transmembrane segment within each domain contains an evenly spaced series of positively charged residues (either arginine or lysine). Substantial evidence indicates that translocation of these segments in response to changes in the membrane potential confers voltage dependence to channel gating. In skeletal muscle, Nav1.4 is non-covalently co-assembled with an accessory b1 subunit (16). Other Naþ channels in brain and heart are also heteromeric assemblies of a and accessory b subunits. The b subunits appear to be important in the targeting and anchoring of sodium channel complexes and also modulate channel gating. Missense mutations in the b1 subunit
Copyright 2006 by Taylor & Francis Group, LLC
186
Struyk and Cannon
have been associated with a rare form of generalized epilepsy, but curiously these patients do not have cardiac or skeletal muscle defects (17). More than 30 mutations in SCN4A have been identified in kindreds with myotonia or periodic paralysis (Fig. 2). In all cases, the mutation results in a missense substitution in the open reading frame. No deletion, nonsense, or splice site defects have been reported. Mutations are clustered in three functional domains of NaVl.4. One group lies in the cytoplasmic loop linking the third and fourth homologous domains. Another cluster is at the cytoplasmic ends of S5 or S6 transmembrane segments, which line the inner mouth of the ion-conducting pore. These regions are thought to form the inactivation gate and its docking site, respectively, and explains why such a widely spread distribution of mutations in the primary sequence disrupt inactivation. The third cluster of mutations is in the S4 segment of the fourth domain, which is a voltage-sensing domain that couples membrane depolarization to inactivation. For the most part, individual missense mutations are consistently linked with PAM, PMC, or HyperPP. However, heterogeneity is often found
Figure 2 Diagrams depict the major structural features of NaV1.4 (A) and CaV1.1 (B) in relation to the plasma membrane. Amino and carboxyl termini for both proteins are oriented intracellularly. S4 membrane-spanning segments carrying positive charges (voltage sensors) are denoted by plus signs. Locations of mutations associated with PAM (gray squares), PMC (gray triangles), HyperPP (gray circles) and HypoPP (black circles) are overlaid.
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
187
in the phenotypic expression of identical mutations between individuals, sometimes within the same kindred. In some cases, incomplete penetrance has been reported, suggesting the existence of modifying factors important for full phenotypic expression (18). The bulk of PAM, HyperPP, and PMC cases are accounted for by a few mutations occurring more frequently in the population, whereas several mutations have been demonstrated in only one kindred or even single individuals. Haplotype analysis has not supported a common founder effect and suggests these more frequently occurring mutant alleles have arisen as independent events (19,20). The Physiological Basis of Myotonia and Paralysis: Na1 Channel Gain of Function Defects The electrical derangements of the sarcolemma in PAM, PMC, and HyperPP all share the common feature that the primary abnormality is a gain-of-function of mutant Naþ channels, usually due to an impairment of inactivation but also caused in some cases by enhanced activation. The mechanism by which both myotonia and periodic paralysis arise from this common defect (and can co-exist in many patients with these disorders) has been established by a combination of experimental and computational models. A toxin-based model has provided direct experimental evidence that even a partial disruption of inactivation is sufficient to produce myotonia. Application of micromolar concentrations of ATXII toxin from sea anemone to rat muscle in vitro prevents inactivation for about 2% of Naþ channels. A single shock elicits a burst of myotonic discharges and prolonged contraction in toxin-exposed fibers. In a computer simulation of the electrical properties of a muscle fiber, introduction of a persistent Naþ current due to a small fraction (2%) of inactivation-deficient Naþ channels is sufficient to generate self-sustaining myotonic discharges. A slight increase in the fraction of non-inactivating Naþ channels (3%) induces myotonic runs that dissipate into a persistent membrane depolarization at 40 mV, rendering the sarcolemma incapable of propagating further action potentials. This sustained aberrant depolarization is maintained by the persistent inward Naþ current through the inactivation-deficient fraction of channels. The simulation demonstrates that the critical parameter for determining paralytic and non-paralytic phenotypes is the degree to which inactivation is compromised by a missense mutation. Experimental support for this is found in the observation that those mutants associated with paralytic phenotypes tend to have more significant defects of inactivation than those linked to purely myotonic phenotypes (21). Additional features of Naþ channel gating influence the association between specific mutations and the clinical phenotype. For example, some mutations slow the rate of inactivation, which otherwise is eventually complete (22). This kinetic defect is sufficient to produce transient bursts of
Copyright 2006 by Taylor & Francis Group, LLC
188
Struyk and Cannon
myotonic discharges, but cannot cause sustained depolarization and flaccid paralysis. Sodium channels also undergo more than one type of inactivation. In response to prolonged depolarization lasting seconds, or to the more physiologically common scenario of sustained trains of discharges, sodium channels enter a more stable ‘‘slow inactivated’’ state. Slow inactivation is detected by the prolonged duration required for recovery of channel availability at the resting potential, which is in the order of several seconds as compared to the recovery from fast inactivation within a few milliseconds. Slow inactivation is mediated by different structural components in Navl.4 than those responsible for fast inactivation (23). This observation led to the prediction that mutations associated with paralytic phenotypes should also have defective slow inactivation (24). Otherwise, the slow inactivation mechanism would shut off the aberrant persistent Naþ current and allow the fiber to hyperpolarize. Indeed, functional testing of NaVl.4 mutants has shown that every mutation that impairs slow inactivation is associated with a paralytic phenotype (HyperPP). The converse is not always true, however, and has led to the notion that defective slow inactivation greatly increases the propensity for attacks of periodic paralysis, but is not necessary. Treatment Most patients with the Naþ channel disorders PAM/PMC/HyperPP minimize the frequency and severity of attacks by changes in lifestyle to avoid environmental triggers. Myotonic stiffness responds well to use-dependent Naþ channel blockers, such as local anesthetic derivatives (mexiletine), antiarrhythmics, and Naþ-selective anticonvulsants. Paralytic attacks can be foreshortened or prevented with the carbonic anhydrase inhibitor acetazolamide, although the mechanism for this effect is not well understood. Potassium wasting diuretics have proven somewhat beneficial at reducing the frequency and severity of paralytic attacks. HYPOKALEMIC PERIODIC PARALYSIS Phenotype Familial hypokalemic periodic paralysis (HypoPP) is transmitted in an autosomal dominant pattern. The classic phenotype is recurrent episodes of severe weakness or even flaccid paralysis associated with serum hypokalemia. The first symptomatic attacks usually occur around puberty, which is distinctly later than the onset of HyperPP. The duration of the paralytic episodes is variable, ranging between several minutes to hours or sometimes days. Provocation of the attacks classically occurs hours following heavy carbohydrate ingestion, often late at night or during the early morning hours after a large meal. Similar to HyperPP, prolonged exercise can precipitate
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
189
an attack. Interictal myotonic stiffness is not found in association with HypoPP. The attacks of weakness typically decline in frequency and severity over time, and become rare after the fourth decade. Familial HypoPP can be mimicked by a few acquired disorders. Among these is thyrotoxic periodic paralysis, which is characterized by attacks of hypokalemic flaccid paralysis in the setting of thyrotoxicosis. The increased incidence of thyrotoxic periodic paralysis in the Japanese population suggests a genetic predilection (25), but the majority of cases are sporadic and mapping of susceptibility loci has not been achieved. Laxative abuse or renal Kþ wasting states can induce similar weakness, but life-threatening cardiac arrhythmias usually precede the development of weakness under these circumstances, making the observation of paralysis as an isolated symptom unlikely. Laboratory investigations during an attack often reveal characteristic low serum potassium (usually <2.5 mm), although as with HyperPP, the serum potassium may be normal if the sample is taken during the later stages of an attack. During an attack the fibers are silent, whereas the interictal EMG is normal. The late-onset myopathy is associated with vacuolar changes and T-tubular aggregates that are histologically indistinguishable from the late-onset myopathy in HyperPP (26). Point Mutations of the Voltage-Gated CA21 and Na1 Channels Cause HypoPP HypoPP was linked to chromosome lq.31-32 (27) and mutations were subsequently identified in the CACNAIS gene (28), which encodes the alpha-lS subunit (CaV1.1) of the skeletal muscle voltage-gated Ca2þ channel, also known as the dihydropyridine-sensitive L-type Ca2þ channel. CaV1.1 shares structural homology to the voltage-gated Naþ channel: it is organized into four domains, each of which is composed of six transmembrane segments (29). HypoPP is caused by three different missense mutations of CaV1.1, all at positively charged residues in the S4 segments of the second or fourth domains (Fig. 2) (28), which, as in the Naþ channel, confer voltage dependence to Ca2þ channel function. In the wake of this initial genotypic characterization, several HypoPP kindreds were found to have no linkage to CACNAIS, indicating genetic heterogeneity of this disorder. More recently, a number of kindreds have been linked to SCN4A (30,31). Four different missense mutations have now been reported, all introducing amino acid substitutions at charged residues in the voltage-sensing S4 segment within the second domain of Navl.4 (Fig. 2). In total, Ca2þ channel mutations are found in 60% and Naþ channel mutations in 20% of kindreds with HypoPP. The genetic basis of the remaining 20% is unknown. The clinical history, frequency and severity of paralytic attacks are indistinguishable in Naþ and Ca2þ-channel linked subtypes, although
Copyright 2006 by Taylor & Francis Group, LLC
190
Struyk and Cannon
differences in response to treatment have been reported in small patient series (32). Late-onset proximal myopathy is also common for the two subtypes (32). Penetrance in female carriers is variable regardless of genotype, and affected women may develop late-onset proximal myopathy without ever having recognized acute paralytic attacks (33). Physiological Defects Associated with HypoPP Paralytic attacks associated with HypoPP are due to aberrant, persistent depolarization of the resting potential, which inactivates Naþ channels and renders the fiber inexcitable. The underlying basis of this pathological depolarization has not been firmly established. Pharmacological studies of affected muscle fiber preparations in vitro have excluded a depolarizing effect of an anomalously high inward current carried by Nav1.4 or CaV1.1 (34,35). Gating behavior of HypoPP mutant Ca2þ and Naþ channels have been studied extensively, but a clear explanation for the depolarization-induced weakness and hypokalemia has not emerged. Caþ channel mutants reduce channel expression level and slow the rate of activation, suggesting a loss-offunction defect (21). The physiological link between Ca2þ channel mutations and membrane depolarization remains unclear. A common consequence of HypoPP-associated Naþ channel mutations is enhancement of slow inactivation (31,36). In some Naþ channel mutations, fast inactivation appears to be mildly enhanced as well (31). The greater propensity of HypoPP mutant Naþ channels to inactivate may contribute to membrane inexcitability, but fails to account for the anomalous depolarization during an attack nor does it explain the paroxysmal nature of the disorder. Other experimental evidence indicates that abnormal regulation of potassium conductances generates the instability of the resting membrane potential in HypoPP. Electrophysiological characterization of intercostal muscle fibers derived from HypoPP patients reveals abnormally low potassium currents near the resting potential (34,35). Reduction in Kþ conductance is predicted to result in depolarization, and may contribute to hypokalemia by trapping Kþ in muscle. Alternatively, reduction of serum Kþ may itself be the precipitating stimulus for a paralytic attack, by triggering an abnormal response in the skeletal muscle. These observations have led to the hypothesis that the pathomechanism in HypoPP is a disruption of the resting Kþ conductance that is indirectly coupled to Ca2þ or Naþ mutations by a means that remains to be established. The reduced Kþ conductance increases the susceptibility to prolonged episodes of depolarization-induced inexcitability and weakness. Treatment Acute attacks are self-limited, and most patients manage their symptoms by avoiding triggers. Break through attacks may respond well to oral Kþ
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
191
administration. Aggressive Kþ administration should be avoided, since total body potassium is not depleted during attacks and overshoot hyperkalemia may result as previously sequestered Kþ shifts back to the extracellular compartments. Daily acetazolamide is effective prophylactically in many patients (37). As with HyperPP, the mechanism by which acetazolamide exerts its prophylactic effect is unknown for HypoPP. Some evidence suggests that Naþ -linked channel mutations may be more likely to be unresponsive or exacerbated by acetazolamide administration (32). ANDERSEN’S SYNDROME Phenotype Andersen’s syndrome (AS) is a triad of periodic paralysis, cardiac arrhythmias, and dysmorphic features (38,39). The morphological changes are modest and include clinodactyly, scoliosis, hypertelorism, micrognathia, and short stature. The cardiac abnormalities are varied and range between asymptomatic long-QT syndrome to recurrent torsade de pointes with cardiac arrest. Episodic attacks of paralysis in AS are often accompanied by hypokalemia, although normokalemic paralysis, and rarely hyperkalemia, has been reported (40). Triggers for paralytic attacks are not well described. As in HyperPP and HypoPP, the electrophysiological basis of paralysis is aberrant depolarization of the sarcolemma. The mode of transmission is autosomal dominant, although the phenotypic expression is highly variable both between and within kindreds. Asymptomatic gene carriers are frequently identified, as are individual patients exhibiting only one or two of the triad of symptoms, usually with a further marked variability in severity. Andersen’s Syndrome Is Linked to Mutations of the K1 Channel Kir2.1 The genetic basis of AS was recently identified in several kindreds as mutation of the KCNJ2 gene on the long arm of chromosome 17 (41). KCNJ2 encodes Kir2.1, an inwardly rectifying Kþ channel subunit expressed widely throughout the body, including skeletal muscle, heart, brain, and osteoclasts. The multisystemic manifestations of AS presumably reflect this widespread tissue distribution. Most mutations that cause AS are missense mutations resulting in amino acid substitution, distributed throughout the coding sequence (Fig. 3) (41). Two in-frame deletions, one in the first transmembrane domain and one near the C-terminus, have been reported Kir2.1 subunits contain two membrane-spanning segments, with an intervening pore-forming loop (42). The channel complex is a tetramer of subunits, which can form as homomultimers of Kir2.1 subunits or heteromultimeric tetramers containing related Kþ channel subunits Kir2.2 and
Copyright 2006 by Taylor & Francis Group, LLC
192
Struyk and Cannon
Figure 3 The membrane topology of Kir2.1 is diagrammed, and positions of currently reported Andersen syndrome mutations are overlaid. Amino and carboxyl termini are intracellular. Gray circles represent missense mutations, while gray rectangles depict in-frame deletions. Initial reports of the mutations diagrammed are found in (41,44,45,49,50).
Kir2.3 (four further members of this family have been identified, but their ability to co-assemble with Kir2.1 is not known). The significance of potential heteromultimerization in vivo is not well known. Inward rectifier Kþ channels, such as Kir2.1, conduct inward Kþ current at hyperpolarized potentials much more readily than outward Kþ current in depolarized cells. This feature is important for regulating repolarization at the end of an action potential. The Physiological Basis of Andersen’s Syndrome: Loss of Resting K1 Conductance Insights on the pathophysiological basis of AS have been derived from functional expression studies of mutant Kir2.1 channels investigated in heterologous expression systems such as Xenopus oocytes or mammalian fibroblasts. Under these conditions, subunits bearing AS-related mutations co-assemble with wildtype subunits and exert a dominant negative effect, impairing the Kþ conductivity of the heteromultimeric complexes (41,43–46). Some evidence suggests that mutant subunits can impair membrane trafficking of Kir2.1 multimers (47). The severity of this dominant negative effect varies depending on the point mutation; however, there is no clear correlation between the severity of the clinical phenotype associated with a particular mutation and the reduction in Kþ current in these assays. This dominant negative effect is the basis for our understanding of the pathophysiology of AS mutations in vivo. Reduction or loss of an inward rectifier Kþ current is expected to impede the repolarization phase of the cardiac action potential. In skeletal muscle, this same defect may reduce the stability of the resting potential and increase the propensity for sustained depolarization and Kþ trapping in the muscle. The role of the Kir2.1 conductance in skeletal development remains to be delineated, but it is noteworthy that these channels are expressed in osteoclasts. Moreover, the Kir2.1 null mouse has severe craniofacial defects leading to neonatal lethality (48).
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
193
No consistently effective treatment for the episodic weakness is known for AS, although acetazolamide administration has proven modestly effective in a handful of anecdotal cases. CONCLUSIONS The familial non-dystrophic myotonias and periodic paralyses are all disorders of muscle membrane excitability in which the primary defects are mutations in the coding region of ion channel genes. The molecular genetic identification of these defects and the experimental assessment of their functional consequences have broadened our understanding of the pathophysiological basis for paroxysmal disorders in excitable tissues and refined our views of the roles that different ionic conductances play in tuning the excitability of muscle. The principles learned from the study of these channelopathies will certainly be of tremendous value in designing therapeutic interventions and will also likely provide insights into other disorders of electrical excitability such as epilepsy, cardiac arrhythmia, and some forms of headache. REFERENCES 1. Barchi RL. Myotonia [Review]. Neurologic Clinics 1988; 6(3):473–484. 2. Bryant SH, Morales-Aguilera A. Chloride conductance in normal and myotonic muscle fibers and the action of monocarboxylic acids. J Physiol 1971; 219:367–483. 3. Lipicky RJ, Bryant SH. Sodium, potassium, and chloride fluxes in intercostal muscle from normal goats and goats with hereditary myotonia congenita. J Gen Physiol 1966; 50:89–111. 4. Lipicky RJ, Bryant SH, Salmon JH. Cable parameters, sodium, potassium, chloride, and water content, and potassium efflux in isolated external intercostal muscle of normal volunteers and patients with myotonia congenita. J Clin Invest 1971; 50:2091–2103. 5. Koch MC, Steinmeyer K, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science 1992; 257(5071):797–800. 6. Fahlke C, Knittle T, Gurnett CA, Campbell KP, George AL Jr. Subunit stoichiometry of human muscle chloride channels. J Gen Physiol 1997;109(l): 93–104. 7. Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum Mutat 2002; 19(4):423–434. 8. Adrian RH, Bryant SH. On the repetitive discharge in myotonic muscle fibres. J Physiol 1974; 240(2):505–515. 9. Barchi RL. Muscle membrane chloride conductance and the myotonic syndromes. Electroencephalogr Clin Neurophysiol Supplement 1978; 34:559–570. 10. Fahlke C, Zachar E, Riidel R. Chloride channels with reduced single-channel conductance in recessive myotonia congenita. Neuron 1993; 10:225–232. 11. Deymeer F, Lehmann-Horn F, et al. Electrical myotonia in heterozygous carriers of recessive myotonia congenita. Muscle Nerve 1999; 22(1); 123–125.
Copyright 2006 by Taylor & Francis Group, LLC
194
Struyk and Cannon
12. Steinmeyer K, Lorenz C, Pusch M, Koch MC, Jentsch T. Multimeric structure of C1C-1 chloride channel revealed by mutations in dominant myotonia congenita (Thomsen). EMBO J 1994; 13:737–743. 13. Lehmann-Horn F, Ru¨del R, Dengler R, Lorkovic H, Haass A, Ricker K. Membrane defects in paramyotonia congenita with and without myotonia in a warm environment. Muscle Nerve 1981; 4(5):396–406. 14. Lehmann-Horn F, Ru¨del R, Ricker K, Lorkovic H, Dengler R, Hopf HC. Two cases of adynamia episodica hereditaria: in vitro investigation of muscle cell membrane and contraction parameters. Muscle Nerve 1983; 6(2):113–121. 15. Catterall WA. Molecular properties of voltage-sensitive sodium channels. [Review]. Ann Rev Biochem 1986; 55:953–985. 16. McClatchey AI, Cannon SC, Slaugenhaupt SA, Gusella JF. The cloning and expression of a sodium channel beta 1-subunit cDNA from human brain. Hum Mol Gene 1993; 2(6):745–749. 17. Wallace RH, Wang DW, et al. Febrile seizures and generalized epilepsy associated with a mutation in the Naþ-channel betal subunit gene SCN1B. Nat Genet 1998; 19(4):366–370. 18. McClatchey AI, McKenna-Yasek D, et al. Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel. Nature Genetics 1992; 2(2):148–152. 19. Plassart E, Reboul J, et al. Mutations in the muscle sodium channel gene (SCN4A) in 13 French families with hyperkalemic periodic paralysis and paramyotonia congenita: phenotype to genotype correlations and demonstration of the predominance of two mutations. Eur J Hum Genet 1994; 2110–2124. 20. McClatchey Al, Trofatter J, et al. Dinucleotide repeat polymorphisms at the SCN4A locus suggest allelic heterogeneity of hyperkalemic periodic paralysis and paramyotonia congenita [published erratum appears in Am J Hum Genet 1992 Oct; 51(4):942] [see comments]. Am J Hum Gene 1992; 50(5):896–901. 21. Cannon SC. An expanding view for the molecular basis of familial periodic paralysis. Neuromuscul Disord 2002; 12(6):533–543. 22. Chahine M, George AL Jr, et al. Sodium channel mutations in paramyotonia congenita uncouple inactivation from activation. Neuron 1994; 12(2):281-294. 23. Rudy B. Slow inactivation of the sodium conductance in squid giant axons. Pronase resistance. J Physiol 1978; 283:1–21. 24. Ruff RL. Slow Naþ channel inactivation must be disrupted to evoke prolonged depolarization-induced paralysis. Biophys J 1994; 66(2 Pt 1):542–545. 25. Resnick JS, Dorman JD, Engel WK. Thyrotoxic periodic paralysis. Am J Med 1969; 47(5):831–836. 26. Engel AG. Evolution and content of vacuoles in primary hypokalemic periodic paralysis. Mayo Clin Proc 1970; 45(11):774–814. 27. Fontaine B, Vale-Santos J, et al. Mapping of the hypokalaemic periodic paralysis (HypoPP) locus to chromosome lq31–32 in three European families. Nat Genet l994; 6(3):267–272. 28. Ptacek LJ, Tawil R, et al. Dihydropyridine receptor mutations cause hypokalemic periodic paralysis. Cell 1994; 77(6):863–868. 29. Catterall WA, de Jongh K, et al. Molecular properties of calcium channels in skeletal muscle and neurons. Ann NY Acad Sci 1993; 681:342–355.
Copyright 2006 by Taylor & Francis Group, LLC
Non-dystrophic Myotonias and Periodic Paralyses
195
30. Bulman DE, Scoggan KA, et al. A novel sodium channel mutation in a family with hypokalemic periodic paralysis. Neurology 1999; 53(9):1932–1936. 31. Jurkat-Rott K, Mitrovic N, et al. Voltage-sensor sodium channel mutations cause hypokalemic periodic paralysis type 2 by enhanced inactivation and reduced current. Proc Natl Acad Sci USA 2000; 97(17):9549–9554. 32. Sternberg D, Maisonobe T, et al. Hypokalaemic periodic paralysis type 2 caused by mutations at codon 672 in the muscle sodium channel gene SCN4A. Brain 2001; 124(Pt 6):1091–1099. 33. Elbaz A, Vale-Santos J, et al. Hypokalemic periodic paralysis and the dihydropyridine receptor (CACNL1A3): genotype/phenotype correlations for two predominant mutations and evidence for the absence of a founder effect in 16 Caucasian families. Am J Hum Genet 1995; 56:374–380. 34. Ru¨del R, Lehmann-Horn F, Ricker K, Kuther G. Hypokalemic periodic paralysis: in vitro investigation of muscle fiber membrane parameters. Muscle Nerve 1984; 7(2):110–120. 35. Ruff RL. Insulin acts in hypokalemic periodic paralysis by reducing inward rectifier Kþ current. Neurology 1999; 53(7):1556–1563. 36. Struyk AF, Scoggan KA, Bulman DE, Cannon SC. The human skeletal muscle Na channel mutation R669H associated with hypokalemic periodic paralysis enhances slow inactivation. J Neurosci 2000; 20(23):8610–8617. 37. Griggs RC, Engel WK, Resnick JS. Acetazolamide treatment of hypokalemic periodic paralysis. Prevention of attacks and improvement of persistent weakness. Ann Intern Med 1970; 73(1):39–48. 38. Andersen ED, Krasilnikoff PA, Overvad H. Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies. A new syndrome? Acta Paediatr Scand 1971; 60(5):559–564 39. Tawil R, Ptacek LJ, et al. Andersen’s syndrome: potassium-sensitive periodic paralysis, ventricular ectopy, and dysmorphic features (see comments). Ann Neurol 1994; 35(3):326–330. 40. Sansone V, Griggs RC, et al. Andersen’s syndrome: a distinct periodic paralysis. Ann Neurol 1997; 42(3):305–312. 41. Plaster NM, Tawil R, et al. Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen’s syndrome. Cell 2001; 105(4):511–519. 42. Nichols CG, Lopatin AN. Inward rectifier potassium channels. Annu Rev Physiol 1997; 59:171–191. 43. Preisig-Muller R, Schlichthorl G, et al. Heteromerization of Kir2.x potassium channels contributes to the phenotype of Andersen’s syndrome. Proc Natl Acad Sci USA 2002; 99(11):7774–7779. 44. Andelfinger G, Tapper AR, Welch RC, Vanoye CG, George AL Jr, Benson DW. KCNJ2 mutation results in Andersen syndrome with sex-specific cardiac and skeletal muscle phenotypes. Am J Hum Genet 2002; 71(3):663–668. 45. Tristani-Firouzi M, Jensen JL, et al. Functional and clinical characterization of KCNJ2 mutations associated with LQT7 (Andersen syndrome). J Clin Invest 2002; 110(3):381–388. 46. Lange PS, Er F, Gassanov N, Hoppe UC. Andersen mutations of KCNJ2 suppress the native inward rectifier current IKl in a dominant-negative fashion. Cardiovasc Res 2003; 59(2):321–327.
Copyright 2006 by Taylor & Francis Group, LLC
196
Struyk and Cannon
47. Bendahhou S, Donaldson MR, Plaster NM, Tristani-Firouzi M, Fu YH, Ptacek LJ. Defective potassium channel Kir2.1 trafficking underlies Andersen-Tawil syndrome. J Biol Chem 2003; 278(51):51,779–51,785. 48. Zaritsky JJ, Eckman DM, Wellman GC, Nelson MT, Schwarz TL. Targeted disruption of Kir2.1 and Kir2.2 genes reveals the essential role of the inwardly rectifying K(þ) current in K(þ)-mediated vasodilation. Circ Res 2000; 87(2):160–166. 49. Donaldson MR, Jensen JL, et al. PIP2 binding residues of Kir2.1 are common targets of mutations causing Andersen syndrome. Neurology 2003; 60(1l):1811–1816. 50. Ai T, Fujiwara Y, et al. Novel KCNJ2 mutation in familial periodic paralysis with ventricular dysrhythmia. Circulation 2002; 105(22):2592–2594.
Copyright 2006 by Taylor & Francis Group, LLC
10 The Myotonic Dystrophies—Effects of an RNA Mutation John W. Day Department of Neurology, Institute of Human Genetics, University of Minnesota School of Medicine, Minneapolis, Minnesota, U.S.A.
Laura P. W. Ranum Department of Genetics, Cell Biology and Development, Institute of Human Genetics, University of Minnesota School of Medicine, Minneapolis, Minnesota, U.S.A.
INTRODUCTION The first pathogenic trinucleotide repeat expansions identified, in fragile X mental retardation (FMR) (1) and spinobulbar muscular atrophy (SBMA or Kennedy’s disease) (2), revealed two different pathogenic mechanisms—loss of gene product in recessively inherited FMR, and a pathogenic gain of function in SBMA. In FMR, a non-coding CGG repeat expansion at the 50 end of the FMR1 gene results in a loss of function that is consistent with the recessive inheritance of that disease. SBMA, alternatively, is caused by the expansion of a polyglutamine repeat (encoded by a CAG expansion) within the androgen receptor protein, resulting in a pathogenic protein. The repeat expansions in the two forms of myotonic dystrophy do not demonstrate either of these pathogenic mechanisms because they are non-coding mutations that result in a highly penetrant dominant disease. Clinical and molecular characterization of the myotonic dystrophies has demonstrated a novel disease mechanism
Copyright 2006 by Taylor & Francis Group, LLC
198
Day and Ranum
involving pathogenic effects of repeat expansions that are expressed in RNA but do not encode any protein. CLINICAL FEATURES OF THE MYOTONIC DYSTROPHIES History of the Myotonic Dystrophies Steinert (3), and Batten and Gibb (4) independently described the disorder now known as myotonic dystrophy almost 100 years ago. In addition to the observed myotonia, the initial descriptions focused on skeletal muscle weakness and atrophy to distinguish the new disorder from Thomsen’s previously identified non-dystrophic myotonia (5), which is now known to be caused by point mutations in the gene encoding the muscle chloride channel. The complex multisystemic phenotype of myotonic dystrophy was gradually recognized, with involvement of eyes, heart, endocrine systems, and central nervous system (CNS) that clearly distinguished this disorder from other forms of muscular dystrophy (6). Genetic heterogeneity in myotonic dystrophy was unsuspected until 1992, when testing became available for the first identified form (DM1), which is due to a mutation on chromosome 19 (7,8). In 1994, another multisystemic myotonic disorder was identified (9,10), and referred to as either proximal myotonic myopathy (PROMM) (9,11), proximal myotonic dystrophy (PDM) (12), or myotonic dystrophy type 2 (DM2) (13,14) in an attempt to emphasize differences or similarities with DMl. The substantial clinical overlap of these diseases led to the adoption of a revised nomenclature (15), with DM1 referring to the chromosome 19 form of the disease, and DM2 referring to the new genetically distinct disorder. The clinical features of the two diseases are given in the Table 1, comparing the findings in 234 genetically confirmed cases of DM2 to the recognized DM1 phenotype. Onset and Progression of DM DM1 patients are often diagnosed as having congenital, juvenile, or adultonset disease based on age of onset (6). Due to ascertainment biases (e.g., family and patient awareness of deficits, and medical provider awareness of myotonic dystrophy), patients of any age can have a wide range of developmental and degenerative features, which complicates any detailed characterization of the disease by age of onset. Neonatal Onset Patients with congenital DM1, as described by Harper (16), demonstrate an almost pure form of the developmental deficits associated with DM. The pregnancies that produce these infants are complicated by hyperhydramnios, and the children are born with severe neurological, neuromuscular, and
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
199
Table 1 Comparison of Clinical Features in Myotonic Dystrophy Types 1 and 2 Clinical features of DM2 and DM1 Clinical feature
DM2 n ¼ 234 (21–78 yr)
DM1
Skeletal muscle features Myotonia On EMG Weakness Any weakness on exam Neck flexors Thumb or deep finger flexors Hip flexors Deep knee bend Multisystemic features Cardiac Conduction defect on ECG Cataracts By history or bedside exam
90 82 75 55 64 54
þþþ þþþ þþþ þþþ þ þ
20 60
þþ þþ
Additional laboratory findings (n) Serology Elevated CK (90) Low IgG (20) Low IgM (20) Low testosterone (22) High FSH (26) Insulin insensitivity (16)
90 65 11 29 65 75
þþ þþ þ/ þþ þþ þþ
Note: The abstracted qualitative frequencies of DM1 features are reported as being expected in all patients (þþþ), common among all patients (þþ), well recognized and common late in the course of the disease (þ), recognized but not common (þ/).
musculoskeletal abnormalities. They have craniofacial abnormalities, including tapered chin, high-arched palate and prominent brow, and may be born with arthrogryposis and talipes in addition to other orthopedic abnormalities (6). Mental retardation and global cerebral atrophy are also common in these patients. Some common degenerative features, including cataracts and central hypersomnia, typically occur during adulthood in these patients rather than occurring in infancy or childhood. No definite congenital form of DM2 has been reported (17). Juvenile Onset Cases of DM1 that come to medical attention during childhood typically manifest developmental abnormalities that are less severe than seen in congenital onset cases, though this is in part influenced by ascertainment biases (18). These patients typically have cognitive deficits and learning abnormalities (19) that again distinguish them from DM2, in which a juvenile form has not been described. As in the congenital cases, degenerative features develop as these affected children reach adulthood.
Copyright 2006 by Taylor & Francis Group, LLC
200
Day and Ranum
Adult-Onset DM1 patients typically come to medical attention during adulthood for several reasons: (i) they have congenitally affected children, (ii) other affected family members are identified, (iii) they develop symptoms of the degenerative disease (e.g., weakness, myotonia, cataracts, or gonadal failure). On examination, although some adult onset patients have no recognizable developmental defects, others manifest clear indicators of developmental abnormalities, including the craniofacial changes and a highly arched palate that indicate the effects of their disease in utero. The degenerative features of the disease occur in all adult onset cases over time, but can progress at different rates, with some middle-aged individuals succumbing to the disease over several years and others having a relatively static course for decades (20,21). DM2, given the absence of developmental effects, typically comes to medical attention in adulthood, though myotonia, myalgias, and cataracts can occur within the first two decades of life. Though there may well be disease-specific differences between the degenerative features of DM1 and DM2, these can only be accurately determined by comparing DM2 patients with DM1 individuals who do not manifest any significant developmental components of the disease.
Involvement of Skeletal Muscle in DM The skeletal muscle features in both genetic forms of myotonic dystrophy include progressive weakness, stereotyped changes on biopsy (6,17,22,23), and myotonia. Muscle pain can be a significant feature of both disorders (6,17). The initial pattern of muscle weakness in DM1 and DM2 is detailed in Table 1. At onset both forms of the disease affect neck flexors and distal upper extremity muscles [specifically deep flexors of the thumb and deep flexors of the lateral digits more than medial digits (24)]. As the disease progresses, involvement of the triceps and ankle dorsiflexors typically, though not invariably, precedes involvement of shoulder and hip girdle musculature. Although neck and finger flexor weakness is demonstrable early in the course of DM2, patients with this disease who come to medical attention because of symptomatic weakness typically present with problems associated with hip girdle muscles, which led to the name PROMM (25). In later stages of both DM1 and DM2, diffuse profound weakness can develop, though DM1 involves bulbar, ventilatory, and pelvic floor musculature more notably than does DM2 (6,17). Neither DM1 nor DM2 is associated with the severe myotonia sometimes seen in chloride channelopathies (6,17), though electrical myotonia is seen in almost all adults with both forms of DM [Table 1 (17)] but is notably absent in infants with congenital onset DM1.
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
201
Other Organ System Involvement in DM The most common cardiac effects of DM1 are atrioventricular and intraventricular conduction abnormalities, and sudden death (26,27); all of these features are also seen in DM2 (17). The cataracts in both diseases are stereotypic and indistinguishable, both being posterior subcapsular opacities that are iridescent on slit lamp examination (6,17). Various other features are common to both diseases, including testicular failure (both hypotestosteronism and oligospermia), hypogammaglobulinemia (serum levels of both IgG and IgM are reduced), and insulin resistance (6,17,28,29). Mental retardation is a recognized feature of congenital and juvenile onset DM1 (6) but has not been causally associated with DM2 [although retarded DM2 individuals have been reported (14)]; both DM1 and DM2 subjects develop CNS white matter abnormalities (30). Central hypersomnia is a recognized feature of DM1 that has not yet been specifically investigated in DM2, though daytime sleepiness has been reported in some DM2 subjects (14). GENETICS OF THE MYOTONIC DYSTROPHIES Identification of the DM1 Mutation Prior to identification of the causative mutation, clinicians had already identified non-Mendelian features in DM1 inheritance including anticipation and a maternal transmission bias for congenital forms (6,31). The genetic cause of DM1 was identified in 1992 as a (CTG) n repeat in the 30 -untranslated region of the dystrophia myotonica protein kinase gene DMPK (7,8,32–34), with marked intergenerational instability that was consistent with the observed anticipation. The location of the DM1 mutation in the 30 -untranslated region of a gene meant that DM1 was the first dominantly inherited disease found to be caused by an untranslated repeat expansion; the mutation is transcribed into RNA but not translated into protein. In 1995, the DM1 mutation was also found to be in the promoter region of the immediately adjacent homeodomain gene SIX5 (35). The CTG expansion in DM1 can vary from 80 to more than 4000 repeats in affected individuals, with clinically unaffected individuals having repeat sizes between 50 and 100 CTGs. Intergenerational and somatic instability are observed in which repeat size can increase by 50–80 repeats per year. This may be a factor in the variable rate of progression and phenotypic variability (36,37). There is a rough correlation of DM1 repeat size and age of onset for CTGs < 400 repeats (38). Proposed Mechanisms of DM1 Pathogenesis Haploinsufficiency of Genes in the DM1 Locus How a non-coding repeat causes the multisystemic features of DM1 has been controversial, since most dominant disorders are caused by the altered
Copyright 2006 by Taylor & Francis Group, LLC
202
Day and Ranum
function of a mutant protein product. Expression studies suggest that the mutation interferes with production of both DMPK (39–41), and Six5, possibly through regional effects produced by repeat-induced alterations in chromatin structure (42,43). However, neither DMPK knock-out nor Six5 knock-out mice show the multisystemic features of the disease; DMPK knock-outs have isolated myopathy and cardiac abnormalities (44–46), and Six5 knockouts demonstrate only nuclear cataracts without the iridescent opacities characteristic of DM patients (47,48). The fact that no DMPK or Six5 point mutations have been associated with a DM phenotype further suggests that the multisystemic features of DM1 are not simply caused by DMPK or Six5 haploinsufficiency. RNA Mediated Pathogenesis Another hypothesized mechanism is that the enlarged CUG-containing transcripts accumulate as intranuclear foci and disrupt cellular function (28,49–54). Support for this model comes from a transgenic mouse model (55), in which the CTG expansion is inserted into the 30 end of the gene encoding human skeletal muscle actin, a gene not directly involved in DM1 but with expression limited to skeletal muscle. This mouse model expresses an mRNA with a CUG repeat tract of 250 repeats, and causes the myotonia and myopathic features characteristic of DM1, but because the CUG-containing transgene expression is limited to skeletal muscle the role of the CUG expansion in the multisystemic features of DM was not addressed. Additive Model of DM1 Pathogenesis An additive model has been proposed (56) in which DM1 pathogenesis results from multiple mechanisms: CTG expression in RNA results in myotonia and myopathy; DMPK haploinsufficiency causes the myopathy and cardiac abnormalities; Six5 haploinsufficiency is responsible for the cataracts; and altered expression of additional regional genes is responsible for other aspects of the complex phenotype, including DMWD (57), the DM gene with WD repeats that has been proposed to cause gonadal and CNS abnormalities (58), and FCGRT, the gene encoding the IgG Fc Fragment Receptor and Transporter, located 4 Mb from the CTG expansion and suggested to underlie the hypogammaglobulinemia (59). However, the discovery of the mutation in DM2 makes this model less tenable. Identification of the DM2 Mutation We began studying DM2 in 1992 as an independent approach to defining the underlying pathogenesis of the myotonic dystrophies. In 1998, we linked the DM2 mutation to a 3 cM region at 3q21 (13,14), and subsequently, in 2001, demonstrated that DM2 is caused by a transcribed but untranslated
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
203
CCTG repeat expansion located in intron 1 of the zinc finger protein 9 (ZNF9) gene (60). The DM2 repeat tract contains the complex motif (TG)n (TCTG)n (CCTG)n; the TG, TCTG, and CCTG tracts are all polymorphic in the general population, but only the CCTG portion expands in affected individuals. The CCTG portion of the repeat tract is usually interrupted on normal alleles, but as in other expansion disorders these interruptions are lost on affected alleles [and in an allele of an unaffected individual who possibly carries a premutation (61)]. Although DM2 is generally a milder disease than DM1, the DM2 CCTG expansions can be much larger than the expansions in DM1; CCTG expansions range in size from 75 to 11,000 CCTG repeats (mean 5000 CCTGs) in affected alleles. The smallest pathogenic size is not clear because uncommon shorter expansions are found in individuals with multiple allele sizes in lymphocyte DNA (17,60). The lack of correlation between repeat size and disease severity, and the recent observation that individuals homozygous for large DM2 repeats do not have a more severe disease (62), indicate that larger repeats do not result in increasingly severe pathogenic effects. The DM2 CCTG expansion mutations show both somatic and intergenerational instability to a greater extent than is seen in DM1. In peripheral blood samples, the mutation size heterogeneity caused by somatic instability is so extreme that 20% of DM2 expansions are not detectable by Southern analysis because the DNA at the DM2 locus forms a broad smear without any definable bands. Consequently, DM2 genetic diagnosis depends on the use of a PCR-based assay of the repeat that is not necessary for diagnosis of DM1 or other repeat expansion disorders (17). Although intergenerational decreases in the age of onset have been reported in DM2 families based on clinical criteria (17,63), this result may have been affected by ascertainment biases. Furthermore, the classically expected trend of longer repeat expansions in patients with earlier onset disease has not been observed in DM2, though somatic instability of the CCTG repeat expansion clearly complicates this analysis (17,36). Common Pathogenesis of DM1 and DM2 Both the DM2 CCTG expansion within intron 1 of ZNF9 and the DM1 CTG expansion in DMPK are transcribed into RNA but do not alter the proteincoding portion of either gene. The normal function of ZNF9 as a nucleic acid binding protein appears unrelated to any of the proteins encoded in the DMl region of chromosome 19 (64,65). Similarly, genes in the DM2 region (KIAA1160, Rab 11B, glycoprotein IX, FLJ11632, and FLJ12057) bear no obvious similarity or relationship to the genes at the DMl locus (DMPK, SIX5, DMWD, and FCGRT). Even if the DM2 expansion alters the regulation of ZNF9 or other genes in the DM2 region, dysregulation of these different sets of proteins at the DMl and DM2 loci would not be expected to result in diseases with such strikingly similar multisystemic features. Although the
Copyright 2006 by Taylor & Francis Group, LLC
204
Day and Ranum
additive model of DMl proposes that CUG repeats in RNA cause myotonia and muscular dystrophy, the other DM features, including effects on the heart, eye, endocrine system, and immunoglobulin levels have been ascribed to haploinsufficiency of genes in the DM1 region. The molecular and clinical parallels between DM1 and DM2 strongly indicate that the clinical features common to both diseases including myotonia, muscular dystrophy, cataracts, cardiac arrhythmias, insulin insensitivity and diabetes, hypogammaglobulinemia, and testicular failure are caused by the pathogenic effects of RNA containing the CUG and CCUG expansions (14,17). MOLECULAR PATHOGENESIS OF THE MYOTONIC DYSTROPHIES Evidence of a Toxic RNA Effect Efforts to understand how the DMl CUG expansion expressed at the RNA level could mediate a dominant effect on other genes not localized to the DM1 locus (the so-called ‘‘trans’’ effect) have focused on the identification of RNA binding proteins that might be dysregulated by the CUG repeat motifs. Recent suggestions that ribonuclear inclusions in DM1 and DM2 sequester transcription factors have not yet been confirmed in tissues from affected patients (66). Direct evidence that RNA containing the repeat expansion is responsible for DM pathogenesis includes: (i) a CTG expansion in the 30 UTR of DMPK mRNA inhibits myoblast differentiation (67); (ii) transgenic models with CTG expansions expressed at the RNA level cause myotonia and muscular dystrophy (55,68); (iii) CUG and CCUG containing transcripts accumulate as RNA foci (49,60,69,70); (iv) CUG containing transcripts alter the regulation or localization of RNA binding proteins, including CUG-BP (51) and three different forms of muscleblind (MBNL1, MBLL, and MBXL) (54,69–71); (v) altered RNA binding protein activity caused by the CUG and CCUG RNA expansions result in altered splicing and the abnormal function of several genes, detailed below, that are related to DM pathophysiology including cardiac troponin T, the insulin receptor, chloride channels, tau protein, and myotubularin (28,52,72,73). Gene Splicing Abnormalities in the Myotonic Dystrophies Cardiac Troponin T (cTNT) A landmark discovery showed increased CUG-BP activity in DM1 muscle, leading to altered splicing of cardiac troponin T (cTNT) by binding intronic CUG repeat splicing signals in cTNT pre-mRNA (52). In adult DM1 cardiac and skeletal muscle, cTNT transcripts contain exon 5, resulting in a splice form normally seen in fetal tissue. This was the first demonstrated splicing target of CUG-BP and the first demonstration that the presence
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
205
of elongated CUG repeat expansions in RNA leads to trans alterations in gene splicing. Insulin Receptor A classic clinical feature in both DM1 and DM2 patients is insulin resistance, predisposing patients to diabetes (74). Alternative splicing of the insulin receptor (IR) pre-mRNA is aberrantly regulated in DM1 skeletal muscle in that exon 11 is preferentially excluded, which results in predominant expression of the insulin insensitive splice form, IR-A (28,75). These results have now also been duplicated in DM2 (29), further demonstrating the common pathogenic mechanism responsible for both diseases, and supporting a model in which increased activity of CUG-BP leads to insulin resistance and diabetes in DM1 and DM2 by alternative splicing of the IR. Chloride Channel A classic feature of both DM1 and DM2 is clinical and electrical myotonia, in which voluntary muscle contraction is followed by involuntary repetitive action potentials that prevent relaxation. Skeletal muscle from a transgenic mouse model of DM1 has diminished muscle transmembrane chloride conductance, aberrant splicing of the muscle chloride channel (C1C-1), and loss of C1C-1 protein from the surface membrane. Skeletal muscle from DM1 and DM2 subjects (76) also have aberrant C1C-1 splicing and reduced chloride channel protein, demonstrating the pathophysiological basis of this part of the complex DM phenotype. CUG-BP, which is elevated in DM1 skeletal muscle, binds to the C1C-1 pre-mRNA, resulting in the aberrant pattern of C1C-1 splicing (72). Thus, the C1C-1 splicing abnormalities cause the chloride channelopathy that underlies myotonia in both DM1 and DM2, substantiating the trans-dominant pathogenic role of CUG and CCUG expansions in disease pathogenesis. Tau and Myotubularin Splicing alterations of the microtubule-associated tau mRNA have been observed in CNS tissue from DM1 patients (73) and in a murine model (68), which may underlie various CNS alterations in DM1 and DM2. In addition, altered splicing of the myotubularin-related 1 (MTMR1) gene has been reported in congenital DM1 muscle cells in culture and in skeletal muscle samples from congenital DM1 patients, suggesting a role for MTMR1 in myotonic dystrophy, possibly in the profound muscle atrophy of congenital DM1 (77). Role of Muscleblind and CUG-BP in DM Pathogenesis The role of different RNA binding proteins (CUG-BP and MBNL) in DM pathogenesis has been unclear. Although CUG-BP is upregulated in DM1
Copyright 2006 by Taylor & Francis Group, LLC
206
Day and Ranum
muscle through an yet unknown mechanism, and increased CUG-BP results in a trans-dominant effect on gene splicing, CUG-BP does not co-localize with the ribonuclear inclusions; in contrast, the RNA binding proteins in the muscleblind family do co-localize with the ribonuclear inclusions, but were not initially associated with any specific molecular pathogenic effects. Direct evidence supporting the role of muscleblind in disease pathogenesis comes from the recently developed MBNL1 knockout mouse model of myotonic dystrophy, which has myotonia, myopathy, cataracts, and RNA splicing abnormalities characteristic of DM1 and DM2 (78). There appears to be a relationship between effects of CUG-BP and MBNL1, in that overexpression of CUG-BP causes the same specific alternative splicing changes that occur with depletion of MBNL1. In general, CUG-BP appears to promote splice forms normally involved in fetal development while MBNL1 preferentially leads to adult splice forms. These data predict that overexpression of CUG or CCUG repeat expansions, overexpression of CUG-BP, or depletion of MBNL1 would all result in a similar set of splicing alterations, the downstream effects of which would lead to characteristic molecular and physiological features of the myotonic dystrophies. Pathophysiological Implications of Differences Between DM1 and DM2 Although DM1 and DM2 phenotypes are strikingly similar, they are not identical. DM2 does not show a congenital form, with the attendant craniofacial and musculoskeletal abnormalities, and does not manifest the severe CNS involvement sometimes encountered in DM1 (17). The clinical distinctions between these diseases could result from differences in temporal or spatial expression patterns of the genes containing the expanded repeats (DMPK and ZNF9) and the genes for the various RNA binding proteins, or could be caused by differences in the downstream effects of CUG as opposed to CCUG expansions. Alternatively, the differences between DM1 and DM2 could involve locus-specific genes such as DMPK, SIX5 or DMWD for DM1, and ZNF9 for DM2. A possible mechanism for congenital DM1 is the demonstrated methylation of a genetic insulator at the DM1 locus in congenital cases, which alters DMPK expression so that higher levels of CUG containing transcripts are associated with the more severe congenital phenotype (79). Further clinical and molecular comparisons of DM1 and DM2 are needed to clarify the differences between the two disorders, which will help determine whether there are distinct pathogenic mechanisms responsible for the phenotypic differences, or, alternatively, to what extent the clinical distinctions simply reflect disease-specific differences in pathogenic severity of the CUG and CCUG repeat expansions in RNA.
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
207
REPORTS OF A THIRD FORM OF MYOTONIC DYSTROPHY Our 2001 discovery of the DM2, CCTG expansion allowed for further analysis of the genetic heterogeneity of DM. It now appears that previously reported families with dominant multisystemic myotonic disorders, whether reported as having PROMM, PDM, or DM2, result from either DM1 or DM2 expansions (17). Linkage disequilibrium and haplotype analysis indicate that single founder mutations led to both the CTG expansion in DM1 (80–82) and the CCTG expansion in DM2 (61,83). A family recently suggested to have DM3 was reported and has several clinical features that have not been described in DM1 or DM2 (spongioform encephalopathy, motor neuron degeneration, and dementia), in addition to having features typical of the myotonic dystrophies including cataracts and electrical myotonia (though it remains unclear whether the abnormal EMG spontaneous activity is an intrinsic feature of muscle as is true of the myotonia seen in DM1 and DM2, or is secondary to the observed motor neuron loss in this family) (84). No investigations of ribonuclear inclusions or splicing abnormalities have been reported. Additional genetic and clinical testing will be needed to determine whether the pathogenic pathway involved in this family is related to DM1 and DM2, or is more consistent with the molecular pathogenesis of the tauopathies. Additional families recently reported as possibly having DM3, have characteristic features of myotonic dystrophy, though complete clinical and genetic characterization is pending (85).
SUMMARY The recent clinical and genetic characterization of DM1 and DM2 has now substantiated a third pathogenic mechanism that results from elongated repeat tracts. In addition to the previous recognition that repeat expansions can cause pathogenic loss of gene expression in recessive disorders (e.g., Friedreich ataxia), or cause a novel pathogenic protein in dominantly inherited disorders (e.g., Huntington’s disease), we now realize that in the dominantly inherited myotonic dystrophies, expression of RNA containing CUG and CCUG repeat expansions alters processing of multiple transcripts, leading to abnormal splicing of the chloride channel, insulin receptor, and other genes that underlie the complex multisystemic phenotype. Other molecular mechanisms may be involved in aspects of the myotonic dystrophy phenotype, such as the features that are seen in DM1 but not DM2, but we now have a primary pathophysiological target against which to direct possible therapeutic regimens. Pharmacological approaches can be developed to correct some of the specific features of the disease (e.g., myotonia, and insulin resistance), while stem cell and other genetic therapies are being developed to correct the underlying genetic abnormalities (86).
Copyright 2006 by Taylor & Francis Group, LLC
208
Day and Ranum
REFERENCES 1. Verkerk AJMH, Pieretti M, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65:905–914. 2. La Spada AR, Wilson EM, Lubahn DB, Hardin AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352:77–79. 3. Steinert H. Myopathologische Beitrage 1. Uber das klinischeund anatomische Bild des Muskelschwunds der Myotoniker. Dtsch Z Nervenheilkd 1909; 37: 58–104. 4. Batten F, Gibb H. Myotonia atrophica. Brain 1909; 32:l87–205. 5. Thomsen J. Tonische krampfe in sillkurlich beweglichen Muskeln infole von erebter paychischer disposition (ataxia muscularis). Arch Psychiatr Nervenkr 1876; 6:702–718. 6. Harper PS. Myotonic Dystrophy. London: W.B. Saunders, 2001. 7. Brook JD, McCurrah ME, et al. Molecular basis of myotonic dystrophy: Expansion of a trinucleotide (CTG) repeat at the 30 end of a transcript encoding a protein kinase family member. Cell 1992; 68:799–808. 8. Fu YH, Pizzuti A, et al. An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 1992; 255(5049):1256–1258. 9. Ricker K, Koch MC, et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448–1452. 10. Thornton CA, Griggs RC, Moxley RT. Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35:269–272. 11. Moxley R. Proximal myotonic myopathy: mini-review of a recently delineated clinical disorder. Neuromusc Disord 1996; 6:87–93. 12. Udd B, Krahe R, Wallgren-Petterson C, Falck B, Kalimo H. Proximal myotonic dystrophy—a family with autosomal domiant muscular dystrophy, cataracts, hearing loss and hypogonadism: heterogeneity of proximal myotonic syndromes? Neuromusc Disord 1997; 7:217–228. 13. Raman L, Rasmussen P, Benzow K, Koob M, Day J. Genetic mapping of a second myotonic dystrophy locus. Nat Genet 1998; 19:196–198. 14. Day JW, Roelofs R, Leroy B, Pech I, Benzow K, Ranum LP. Clinical and genetic characteristics of a five-generation family with a novel form of myotonic dystrophy (DM2). Neuromusc Disord 1999; 9(1):19–27. 15. Consortium IMD. New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC). Neurology 2000; 54(6):1218–1221. 16. Harper PS. Congenital myotonic dystrophy in Britain, I. Clinical aspects. Arch Dis Child 1975; 50(7):505–513. 17. Day J, Ricker K, et al. Myotonic dystrophy type 2: molecular, diagnostic and clinical spectrum. Neurol 2003; 60(4):657–664. 18. O’Brien TA, Harper PS. Course, prognosis and complications of childhoodonset myotonic dystrophy. Dev Med Child Neurol 1984; 26(1):62–67.
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
209
19. Steyaert J, de Die-Smulders C, Fryns JP, Goossens E, Willekens D. Behavioral phenotype in childhood type of dystrophia myotonica. Am J Med Genet 2000; 96(6):888–889. 20. de Die-Smulders CE, Howeler CJ, et al. Age and causes of death in adult-onset myotonic dystrophy. Brain 1998; 121 (Pt 8):1557–1563. 21. Mathieu J, Allard P, Potvin L, Prevost C, Begin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurol 1999; 52(8):1658–1662. 22. Vihola A, Bassez G, et al. Histopathological differences of myotonic dystrophy type 1 (DM1) and PROMM/DM2. Neurol 2003; 60(11):1854–1857. 23. Schoser BG, Schneider-Gold C, Kress W, Goebel HH, Reilich P, Koch MC, et al. Muscle pathology in 57 patients with myotonic dystrophy type 2. Muscle Nerve 2004; 29(2):275–281. 24. Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assesment of a diseasespecific muscular impairment rating scale in myotonic dystrophy. Neurol 2001; 56:336–340. 25. Ricker K, Koch M, et al. Proximal myotonic myopathy: clinical features of a multisystem disorder similar to myotonic dystrophy. Arch Neurol 1995; 52:25–31. 26. Phillips MF, Harper PS. Cardiac disease in myotonic dystrophy. Cardiovasc Res 1997; 33(1):13–22. 27. Colleran JA, Hawley RJ, Pinnow EE, Kokkinos PF, Fletcher RD. Value of the electrocardiogram in determining cardiac events and mortality in myotonic dystrophy. Am J Cardiol 1997; 80(11):1494–1497. 28. Savkur RS, Philips AV, Cooper TA. Aberrant regulation of insulin receptor alternative splicing is associated with insulin resistance in myotonic dystrophy. Nat Genet 2001; 29(1):40–47. 29. Savkur RS, Philips AV, et al. Insulin receptor splicing alteration in myotonic dystrophy type 2. Am J Hum Genet 2004; 74(6):1309–1313. 30. Hund E, Jansen O, et al. Proximal myotonic myopathy with MRI white matter abnormalities of the brain. Neurol 1997; 48(1):33–37. 31. Harper PS. Myotonic Dystrophy. 2nd ed. London: W.B. Saunders, 1989. 32. Buxton J, Shelbourne P, et al. Detection of an unstable fragment of DNA specific to individuals with myotonic dystrophy. Nat 1992; 355(6360):547–548. 33. Harley HG, Brook JD, et al. Expansion of an unstable DNA region and phenotypic variation in myotonic dystrophy. Nat 1992; 355:545–546. 34. Mahadevan M, Tsilfidis C, et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 30 untranslated region of the gene. Sci 1992; 255:1253–1255. 35. Boucher CA, King SK, et al. A novel homeodomain-encoding gene is associated with a large CpG island interrupted by the myotonic dystrophy unstable (CTG)n repeat. Hum Mol Genet 1995; 4:1919–1925. 36. Monckton DG, Wong LJ, Ashizawa T, Caskey CT. Somatic mosaicism, germline expansions, germline reversions and intergenerational reductions in myotonic dystrophy males: small pool PCR analyses. Hum Mol Genet 1995; 4(1):1–8. 37. Martorell L, Monckton DG, et al. Progression of somatic CTG repeat length heterogeneity in the blood cells of myotonic dystrophy patients. Hum Mol Genet 1998; 7(2):307–312. 38. Hamshere MG, Harley H, Harper P, Brook JD, Brookfield JF. Myotonic dystrophy: the correlation of (CTG) repeat length in leucocytes with age at
Copyright 2006 by Taylor & Francis Group, LLC
210
39.
40.
41.
42.
43. 44. 45. 46.
47. 48. 49.
50.
51.
52. 53.
54.
55.
Day and Ranum onset is significant only for patients with small expansions. J Med Genet 1999; 36(1):59–61. Fu Y-H, Friedman DL, et al. Decreased expression of myotonin-protein kinase messenger RNA and protein in adult form of myotonic dystrophy. Sci 1993; 260:235–238. Hoffmann-Radvanyi H, Lavedan C, et al. Myotonic dystrophy: absence of CTG enlarged transcript in congenital forms, and low expression of the normal allele. Hum Mol Genet 1993; 2:1263–1266. Novelli G, Gennarelli M, et al. Failure in detecting mRNa transcripts from the mutated allele in myotonic dystrophy muscle. Biochem Mol Biol Int 1993; 29:291–297. Wang Y-H, Amirhaeri S, Kang S, Wells RD, Griffith JD. Preferential nucleosome assembly at DNA triplet repeats from the myotonic dystrophy gene. Sci 1994; 265:669–671. Otten AD, Tapscott SJ. Triplet repeat expansion in myotonic dystrophy alters the adjacent chromatin structure. Proc Natl Acad Sci USA 1995; 92:5465–5469. Jansen G, Groenen PJTA, et al. Abnormal myotonic dystrophy protein kinase levels produce only mild myopathy in mice. Nat Genet 1996; 13:316–324. Reddy S, Smith DB, et al. Mice lacking the myotonic dystrophy protein kinase develop a late onset progressive myopathy. Nat Genet 1996; 13(3):325–335. Berul CI, Maguire CT, Gehrmann J, Reddy S. Progressive atrioventricular conduction block in a mouse myotonic dystrophy model. J Interv Card Electrophysiol 2000; 4(2):351–358. Klesert TR, Cho DH, et al. Mice deficient in Six5 develop cataracts: implications for myotonic dystrophy. Nat Genet 2000; 25(1):105–109. Sarkar PS, Appukuttan B, et al. Heterozygous loss of Six5 in mice is sufficient to cause ocular cataracts. Nat Genet 2000; 25(1):110–114. Taneja BX, McCurrach M, Schalling M, Housman D, Singer RH. Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J Cell Biol 1995; 128:995–1002. Davis BM, McCurrach ME, Taneja KL, Singer RH, Housman DE. Expansion of a CUG trinucleotide repeat in the 30 untranslated region of myotonic dystrophy protein kinase transcripts results in nuclear retention of transcripts. Proc Natl Acad Sci USA 1997; 94(14):7388–7393. Timchenko LT, Timchenko NA, Caskey CT, Roberts R. Novel proteins with binding specificity for DNA CTG repeats and RNA CUG repeats: implications for myotonic dystrophy. Hum Mol Genet 1996; 5(1):115–121. Philips AV, Timchenko LT, Cooper TA. Disruption of splicing regulated by a CUG-binding protein in myotonic dystrophy. Science 1998; 280(5364):737–741. Lu X, Timchenko NA, Timchenko LT. Cardiac elav-type RNA-binding protein (ETR-3) binds to RNA CUG repeats expanded in myotonic dystrophy. Hum Mol Genet 1999; 8(1):53–60. Miller JW, Urbinati CR, et al. Recruitment of human muscleblind proteins to (CUG) (n) expansions associated with myotonic dystrophy. EMBO J 2000; 19(17):4439–4448. Mankodi A, Logigian E, et al. Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science 2000; 289(5485):1769–1773.
Copyright 2006 by Taylor & Francis Group, LLC
The Myotonic Dystrophies—Effects of an RNA Mutation
211
56. Tapscott SJ. Deconstructing myotonic dystrophy. Science 2000; 289(5485): 1701–1702. 57. Alwazzan M, Newman E, Hamshere MG, Brook JD. Myotonic dystrophy is associated with a reduced level of RNA from the DMWD allele adjacent to the expanded repeat. Hum Mol Genet 1999; 8(8):1491–1497. 58. Westerlaken JH, Van der Zee CE, Peters W, Wieringa B. The DMWD protein from the myotonic dystrophy (DM1) gene region is developmentally regulated and is present most prominently in synapse-dense brain areas. Brain Res 2003; 971(1):116–127. 59. Junghans RP, Ebralidze A, Tiwari B. Does (CUG)n repeat in DMPK mRNA ‘paint’ chromosome 19 to suppress distant genes to create the diverse phenotype of myotonic dystrophy? A new hypothesis of long-range cis autosomal inactivation. Neurogenet 2001; 3(2):59–67. 60. Liquori C, Ricker K, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Sci 2001; 293:864–867. 61. Liquori CL, Ikeda Y, et al. Myotonic dystrophy type 2: human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 2003; 73(4):849–862. 62. Schoser BG, Kress W, Walter MC, Halliger-Keller B, Lochmuller H, Ricker K. Homozygosity for CCTG mutation in myotonic dystrophy type 2. Brain 2004; 127(8):1868–1877. 63. Schneider C, Ziegler A, et al. Proximal myotonic myopathy: evidence for anticipation in families with linkage to chromosome 3q. Neurol 2000; 55(3):383–388. 64. Pellizzoni L, Lotti F, Maras B, Pierandrei-Amaldi P. Cellular nucleic acid binding protein binds a conserved region of the 50 UTR of Xenopus laevis ribosomal protein mRNAs. J Mol Biol 1997; 267(2):264–275. 65. Pellizzoni L, Lotti F, Rutjes SA, Pierandrei-Amaldi P. Involvement of the Xenopus laevis Ro60 autoantigen in the alternative interaction of La and CNBP proteins with the 50 UTR of L4 ribosomal protein mRNA. J Mol Biol 1998; 281(4):593–608. 66. Ebralidze A, Wang Y, Petkova V, Ebralidse K, Junghans RP. RNA leaching of transcription factors disrupts transcription in rayotonic dystrophy. Sci 2004; 303(5656):383–387. 67. Amack JD, Paguio AP, Mahadevan MS. Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum Mol Genet 1999; 8(11): 1975–1984. 68. Seznec H, Agbulut O, et al. Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities. Hum Mol Genet 2001; 10(23):2717–2726. 69. Mankodi A, Urbinati CR, et al. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum Mol Genet 2001; 10(19): 2165–2170. 70. Fardaei M, Rogers MT, et al. Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells. Hum Mol Genet 2002; 11(7):805–814.
Copyright 2006 by Taylor & Francis Group, LLC
212
Day and Ranum
71. Fardaei M, Larkin K, Brook JD, Hamshere MG. In vivo co-localisation of MBNL protein with DMPK expanded-repeat transcripts. Nucleic Acids Res 2001; 29(13):2766–2771. 72. Charlet BN, Savkur RS, Singh G, Philips AV, Grice EA, Cooper TA. Loss of the muscle-specific chloride channel in type 1 myotonic dystrophy due to misregulated alternative splicing. Mol Cell 2002; 10(1):45–53. 73. Sergeant N, Sablonniere B, et al. Dysregulation of human brain microtubuleassociated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001; 10(19):2143–2155. 74. Moxley RT, Griggs RC, Goldblatt D. Muscle insulin resistance in myotonic dystrophy: effect of supraphysiologic insulinization. Neurol 1980; 30(10):1077–1083. 75. Seino S, Bell GI. Alternative splicing of human insulin receptor messenger RNA. Biochem Biophys Res Commn 1989; 159(1):312–316. 76. Mankodi A, Takahashi MP, et al. Expanded CUG Repeats Trigger Aberrant Splicing of C1C-1 Chloride Channel Pre-mRNA and Hyperexcitability of Skeletal Muscle in Myotonic Dystrophy. Mol Cell 2002; 10(1):35–44. 77. Buj-Bello A, Furling D, et al. Muscle-specific alternative splicing of myotubularin-related 1 gene is impaired in DM1 muscle cells. Hum Mol Genet 2002; 11(19):2297–2307. 78. Kanadia RN, Johnstone KA, et al. A muscleblind knockout model for myotonic dystrophy. Sci 2003; 302(5652):1978–1980. 79. Filippova GN, Thienes CP, et al. CTCF-binding sites flank CTG/CAG repeats and form a methylation-sensitive insulator at the DM1 locus. Nat Genet 2001; 28(4):335–343. 80. Imbert G, Kretz C, Johnson K, Mandel JL. Origin of the expansion mutation in myotonic dystrophy. Nat Genet 1993; 4(1):72–76. 81. Neville CE, Mahadevan MS, Barcelo JM, Korneluk RG. High resolution genetic analysis suggests one ancestral predisposing haplotype for the origin of the myotonic dystrophy mutation. Hum Mol Genet 1994; 3(1):45–51. 82. Deka R, Majumder PP, et al. Distribution and evolution of CTG repeats at the myotonin protein kinase gene in human populations. Genome Res 1996; 6(2):142–154. 83. Bachinski LL, Udd B, et al. Confirmation of the type 2 myotonic dystrophy (CCTG)n expansion mutation in patients with proximal myotonic myopathy/ proximal myotonic dystrophy of different European origins: a single shared haplotype indicates an ancestral founder effect. Am J Hum Genet 2003; 73(4): 835–848. 84. Le Ber I, Martinez M, et al. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain 2004; 127(9):1979–1992. 85. Meola G, Sansone V, Milanese SD, Udd B, Vihola A, Mancinelli E, Pazzi A, Bachinski L, Moxley R, Krahe R. Lack of DM1-(CTG)n and DM2-(CCTG)n mutations in two families with autosomal dominant muscle weakness, myotonia, and cataracts: DM3? Neurology 2004; 62(suppl 5):A354. 86. Langlois MA, Lee NS, Rossi JJ, Puymirat J. Hammerhead ribozyme-mediated destruction of nuclear foci in myotonic dystrophy myoblasts. Mol Ther 2003; 7(5 Pt 1):670–680.
Copyright 2006 by Taylor & Francis Group, LLC
11 Spinal Muscular Atrophy Stephen J. Kolb and J. Paul Taylor Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.
INTRODUCTION Spinal muscular atrophy (SMA) was first described in 1891 independently by Guido Werdnig working at the Institute of Pathological Anatomy in Graz, Austria, and Johann Hoffman of Heidelberg University (1,2). Their reports presented the clinical and pathological aspects of infantile SMA, including early onset, occurrence among siblings of unaffected parents, progressive weakness, hand tremor, and death from respiratory failure in early childhood. Since the first description of this disease, a broader range of severity and age of onset has been appreciated, and a few separate disease entities have been defined. In 1991, the International Consortium on Childhood SMA defined three clinical subgroups to reflect the broad range of clinical severity (3). All types of SMA linked to chromosome 5q11 are associated with a relative deficiency in the product of the survival motor neuron (SMN ) gene (described below). SMA is one of the most common autosomal recessive diseases, affecting approximately 1 in 6000–10,000 live births, and is the leading hereditary cause of infant mortality (4–7). De novo mutations in the gene responsible for SMA are relatively frequent, and the carrier frequency for disease-causing mutations is estimated at approximately 1 in 50 (8). For unknown reasons, there is a slight male predominance for SMA, particularly with respect to the later onset forms of the disease.
Copyright 2006 by Taylor & Francis Group, LLC
214
Kolb and Taylor
CLINICAL FEATURES OF AUTOSOMAL RECESSIVE SMA The classical form of severe spinal muscular atrophy (SMA type I; Werdnig– Hoffmann disease) has a consistent clinical phenotype that is well recognized by pediatricians and pediatric neurologists (9,10). Children typically present with general hypotonia plus axial and limb weakness within the first few months of life. The legs are affected more than the arms and proximal muscles more than distal muscles leaving residual spontaneous activity in the feet and in the forearms and hands. Facial muscles are typically spared so that the infant usually has a bright normal expression. The intercostal muscles are always affected, whereas the diaphragm is spared, allowing adequate spontaneous respiratory activity until the infants are precipitated into respiratory failure by an incidental respiratory infection or aspiration. With rare exception, children with SMA type I die by two years of age with a median life span of seven months. Nearly 80% of children with SMA type I die by the time they are one year old (10). SMA type II is a less severe form of the disease with onset typically between 6 and 18 months of age. Children affected by SMA type II achieve the ability to sit although they cannot stand or walk unaided. SMA type III, also known as Kugelberg–Welander disease, is a later onset and more slowly progressive form of the disease with signs and symptoms becoming apparent after they attain the ability to walk. Zerres and Rudnik-Schoneborn have proposed that SMA type III be subdivided into types IIIa (onset before three years of age) and IIIb (onset after three years of age) to reflect the different clinical course experienced by these groups (11). The probabilities of being ambulatory 10, 20, and 40 years after onset are 73, 44, and 34%, respectively, in patients with SMA type IIIa, and 97, 89, and 67%, respectively, in patients with SMA type IIIb (11). Very late onset SMA (after the age of 35 years of age) has been referred to as ‘‘SMA type IV’’ and represents the mildest form within the spectrum of the SMA phenotype (12). ‘‘SMA type 0’’ has been used by some to describe severe SMA that presents prenatally (9,13). In this condition fetal movements are absent or markedly reduced and profound weakness and hypotonia are found at birth (13). All patients with SMA share clinical features that result from skeletal muscle denervation (14). Thus, physical examination is universally associated with symmetrical muscle weakness and muscle atrophy as well as decreased or absent deep tendon reflexes. Often, tongue fasciculations and hand tremors are seen. Sensory abnormalities are not detected and sphincter function is normal. Nerve conduction studies reveal normal sensory and motor nerve conduction velocities and electromyogram shows fibrillation potentials, sharp waves, and large motor units consistent with a pattern of acute and chronic denervation. Muscle biopsy shows fiber type grouping and/or atrophic and hypertrophic fibers also characteristic of acute and chronic denervation.
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
215
MOLECULAR GENETICS OF AUTOSOMAL RECESSIVE SMA SMA types I, II, and III were all mapped to chromosome 5q11.2-13.3 in 1990, providing support for the contention that they are allelic disorders (15–18). Two years later, the first prenatal predictions were performed using polymorphic markers linked to the SMA locus (19,20). The physical map of the SMA locus was found to be highly complex containing multicopy repetitive sequences, pseudogenes, and retrotransposon-like sequences suggesting that this region might be unstable (21–23). Indeed, at least 2% of SMA patients have de novo rearrangements (23,24). In 1995, the SMA locus was refined further to reveal an inverted duplication containing four genes: the survival of motor neurons (SMN) gene (25), the gene coding for neuronal apoptosis inhibitory protein (NAIP) (26), the gene coding for p44, a subunit of the basal transcription factor TFIIH (27), and the H4F5 gene (28). Many patients have deletions that span more than one of these genes, however the smallest deletions characterized in SMA patients involved the telomeric copy of the SMN gene (SMN1) (29). The centromeric counterpart, SMN2, differs from SMN1 by a single nucleotide change (C/T transition) at position þ6 in exon 7 (30). This alteration does not change the primary amino acid sequence but alters splicing such that most transcripts produced by SMN2 lack exon 7 (31–33). Thus, approximately 90% of the protein produced by SMN2 is a truncated form that fails to oligomerize and appears to be unstable since it is rapidly degraded. In individuals with normal SMN1 alleles, SMN2 is dispensable since 5–10% of normal individuals lack both copies (34–36). Approximately 94% of individuals with clinically typical SMA lack both copies of SMN1 exon 7 (29). Loss of SMN1 can occur by deletion (these are typically large and include the whole gene) or by gene conversion of SMN1 to SMN2. In the remaining 6% of SMA patients that do not lack both copies of SMN1, there are a substantial number of intragenic (nondeletion) mutations, including missense, nonsense, or splice site mutations (37). These intragenic mutations provide solid evidence that SMN1 is indeed the SMA gene since, unlike many of the large deletions, they do not affect the neighboring genes within the original candidate region. Intragenic mutations are more frequently associated with milder forms of SMA. The severity of the SMA phenotypes appears to be inversely correlated to the level of full-length SMN protein produced (38,39). In the case of SMA, it is the remaining SMN2 genes that are left to provide that full-length protein. Indeed, SMN2 gene copy number is a strong modifier of disease phenotype (40–44). The most commonly used method to genetically confirm the diagnosis of SMA is a qualitative polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) assay (also known as the ‘‘SMN1 deletion assay’’) to detect the homozygous absence of SMN1 exon 7 (37). The PCR-RFLP assay takes advantage of the base differences in exons
Copyright 2006 by Taylor & Francis Group, LLC
216
Kolb and Taylor
7 and 8 to distinguish SMN1 from SMN2. After PCR amplification of this region of the SMN1 gene, a restriction endonuclease is used that digests only the SMN2 exon 7 PCR products because of a restriction site generated by a mismatched reverse primer (37). Approximately 6% of individuals with SMN1-related SMA do not have homozygous SMN1 deletions and will not be identified by the PCRRFLP assay. Most of these affected individuals are compound heterozygotes, having an SMN1 deletion on one chromosome and a point mutation or other nondeletion mutation on the other chromosome (29). In these cases, quantitative SMN1 gene dosage analysis is required to determine whether the patient carries only one copy of SMN1 exon 7. When the index of suspicion is high, and an individual carries only one copy of SMN1 exon 7, sequence analysis may be performed to evaluate for known, or potentially novel, loss-of-function mutations (8). As many as 2% of individuals with SMA have a de novo mutation, i.e., they have a new SMN1 mutation that is not detectable in samples from the parents (24). Since the PCR-RFLP assay cannot distinguish between carriers with one copy of SMN1 and normal individuals with two copies of SMN1, quantitative SMN1 gene dosage analysis is also required to determine SMA carrier status (8). However, approximately 4% of individuals have two or more copies of SMN1 on the same chromosome (4). Thus, there is the potential for a falsely negative test in an individual carrying an SMN1 deletion on one chromosome, but two or more SMN1 copies on the other (8). Thus, risk assessment is an important component of SMA genetic testing to reduce the possibility of a false result. Because of the complexity of SMA genetics, SMA genetic testing should be performed at experienced centers. SMA UNRELATED TO MUTATIONS IN SMN1 There are a number of inherited motor neuron diseases that share overlapping features with SMA, but are genetically distinct and have been referred to as the ‘‘SMA plus’’ syndromes (45). These include SMA with pontocerebellar hypoplasia, SMA with myoclonic epilepsy, and the Brown–Vialetto–van Laere syndrome—a progressive bulbar palsy with progressive neurosensory deafness. SMA with respiratory distress (SMARD), also known as ‘‘diaphragmatic SMA,’’ is a genetically heterogeneous disorder that features progressive loss of anterior horn motor neurons, and is not linked to 5q11.2-13 (46). Unlike SMN1-related SMA, SMARD is characterized by distal-predominant weakness and diaphragmatic paralysis that leads to life-threatening respiratory distress. Arthrogryposis is a heterogeneous syndrome characterized by joint contractures present at birth (47). The major clinical form, arthrogryposis multiplex congenita (AMC), is caused by decreased fetal movements in utero attributable to a large number of conditions, including neuropathies,
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
217
myopathies, connective tissue diseases, and the limited space within the uterus (47). SMA with congenital bone fractures is a rare syndrome characterized by floppiness in infancy and by multiple fractures of the long bones for which linkage to chromosome five has been excluded (48). A particularly severe form of SMN1-unrelated SMA is X-linked and associated with arthrogryposis and congenital fractures (49). Arthrogryposis also has been associated with SMN1-related SMA. In two small series, a total of 6 of 16 patients with ‘‘neurogenic AMC’’ had homozygous deletions for SMN1 (50,51). Another related disease is spinal and bulbar muscular atrophy (SBMA), also known as Kennedy’s disease. SBMA is an X-linked disorder characterized by slowly progressive weakness resulting from degeneration of motor neurons of the brainstem and spinal cord (52). Patients with SBMA often exhibit mild signs of feminization such as gynecomastia and, less frequently, infertility despite normal serum androgen levels. The androgen insensitivity observed in this disorder provided clues to underlying cause, and in 1991 the molecular basis of SBMA was found to be trinucleotide (CAG) repeat expansion in the first exon of the androgen receptor (AR) gene (53). More recently, an autosomal form of SBMA, with more prominent distal weakness, was found to be caused by mutations affecting the dynactin component of the dynein motor complex (54). Of course, the largest group of diseases with phenotypic similarities to SMA is amyotrophic lateral sclerosis (ALS). BASIC RESEARCH ON AUTOSOMAL RECESSIVE SMA: THE SMN COMPLEX SMN is an essential protein. Complete knock-out of SMN results in embryonic lethality in divergent organisms including human, mouse, chicken, C. elegans and S. Pombe (55). In experimental systems, SMN function appears necessary for cell survival independent of cell type. Therefore, it is intriguing and enigmatic that homozygous deletions of SMN1 should lead to selective motor neuron loss in patients with SMA. The basis of cell type specific neuron loss with relative depletion of SMN is a central issue that remains to be resolved. The SMN protein is a 294 amino acid polypeptide that is expressed in all eukaryotes tested so far (except Saccharomyces cerevisiae) and in all cell types of vertebrate organisms. SMN is found in the cytoplasm and the nucleoplasm where it is highly concentrated within discrete bodies called Gems (55,56). The SMN complex is the native functional entity of the SMN polypeptide and is comprised of SMN and six distinct proteins known as Gemins: Gemin2 (formerly SIP1), Gemin3/DP103 (a DEAD-box RNA helicase), Gemin4, Gemin5/p175 (a WD-repeat protein), Gemin6, and Gemin7 (57–64). The Gemin proteins colocalize with SMN in Gems and are present throughout
Copyright 2006 by Taylor & Francis Group, LLC
218
Kolb and Taylor
the cytoplasm. The Gemins are readily isolated by co-immunoprecipitation experiments using anti-SMN antibodies or antibodies to the Gemins, even under stringent high salt conditions and can thus be considered integral components of the SMN complex (65). The most prominent known structural motifs within the Gemin proteins are a DEAD-box RNA helicase motif in Gemin3 (58,60) and an array of 13 WD repeats in Gemin5 (61). It is presumed that the RNA helicase activity of Gemin3 is critical for the function of the formed SMN complex as a whole. The presence of multiple WD repeats in Gemin5 suggests that this protein forms multiple protein– protein interactions and may serve as a platform for the assembly of protein complexes. Taken together, the presence of an RNA helicase and multiple WD repeats in the SMN complex suggests a role in the assembly of ribonucleoproteins. The pre-mRNA splicing reaction is carried out by the spliceosome in the nucleus. The spliceosome contains five small nuclear ribonucleoproteins (snRNPs) that are responsible for recognizing 50 and 30 splice sites located at exon–intron junctions. The assembly of the five snRNPs onto the intron is a highly dynamic process which culminates in the juxtaposition of 50 and 30 splice sites leading to ligation of the adjacent exons and release of the intervening intron. The formation of snRNPs occurs in the cytoplasm and is a stepwise process that requires the ATP-dependent assembly of a seven-membered ring (the Sm core) of common spliceosomal substrate proteins (Sm proteins) around a highly conserved sequence motif of less than 10 nucleotides, called the ‘‘Sm site,’’ present in most snRNAs. The SMN complex interacts with several substrate proteins. These include the Sm proteins and Sm-like (Lsm) proteins of snRNPs, which are essential components of the splicing machinery. Additional substrates are the snoRNP protein fibrillarin and GAR1, hnRNP U, Q and R, RNA helicaseA, coilin, nucleolin, and Epstein–Barr virus nuclear antigen 2 (66–72). It is intriguing that most of the substrates identified currently are constituents of various RNP complexes that are involved in diverse aspects of RNA processing. Remarkably, the SMN complex also binds with high affinity to the snRNA component of snRNPs directly and in a sequence-specific manner (73,74). These observations led to the demonstration of an essential role of the SMN complex in the assembly of the spliceosomal snRNPs (75). The SMN complex not only mediates snRNP assembly, but provides stringent control of the process by ensuring that Sm cores are only formed on the correct snRNA molecules (Fig. 1). In addition to its roles in spliceosomal snRNP assembly, the SMN complex may function in the formation of other RNPs. The SMN complex may play a role in the biogenesis of snoRNP which are involved in the posttranslational processing and modification of ribosomal RNAs (67,68). The SMN complex may also be involved in the biogenesis of RNA polymerase II transcription and processing machinery in the nucleus (76,77). It is clear
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
219
Figure 1 The role of the SMN complex in the assembly of spliceosomal snRNAs. The Sm site-containing snRNAs, U1, U2, U4, U5 as well as the minor spliceosome snRNAs, are transcribed in the nucleus by RNA polyermase II. The primary transcripts contain a monomethylated m7GpppG (m7G) cap structure at the 50 -end and are rapidly exported to the cytoplasm with the nuclear CBC proteins 20 and 80 and the export adaptor phax. The formation of the Sm core is required for the subsequent hypermethylation of the 7-methyl guanosine (m7G) cap of these snRNAs to convert it into a 2,2,7-trimethyl guanosine (m3G or TMG) and for 30 -end maturation (113,114). A properly assembled Sm core and the TMG-cap structure are prerequisite for snRNP import into the nucleus. In the nucleus, the newly imported snRNPs are initially concentrated in Cajal bodies from which they transit to pre-mRNAs for splicing. The SMN complexes in the nucleus are found throughout the nucleoplasm but are particularly concentrated in Gems, the twins of the snRNP-rich CBs. Abbreviations: SMN, survival motor neuron; CBC, cap binding complex; TMG, 2,2,7-trimethyl guanosine; CBs, Cajal bodies. Source: From Ref. 72 with permission.
that the SMN protein, as part of the SMN complex, is involved in the assembly of RNP particles that play critical roles at multiple steps in the processing of mRNAs in cells. It is currently unclear how these functions relate to the loss of motor neurons seen in SMA patients. Much attention is currently being focused on possible unique roles for SMN in the motor neuron. Primary motor neurons isolated from a transgenic SMA mouse model exhibit reduced axon growth in culture compared to motor neurons isolated from wildtype mice (78). Also, overexpression of
Copyright 2006 by Taylor & Francis Group, LLC
220
Kolb and Taylor
SMN in differentiated PC12 cells promotes neurite outgrowth and modulates the localization of b-actin mRNA suggesting that SMN is involved in the transport of specific mRNA molecules in neuronal processes (78). It is clear that SMN has functions, as exemplified by its requirement for snRNP assembly, that are common to all cells, and that SMN is found in neuronal processes. The resolution of whether the clinical symptoms of SMA are caused by deficiencies in functions of SMN that are specific to motor neurons or that are common to all cells but at higher demand in motor neurons will be a critical advance in our understanding of SMA. MODEL SYSTEMS In mice, there is one SMN gene that is equivalent to SMN1. Complete loss of this gene results in an embryonic lethal phenotype as would be expected given the housekeeping functions of SMN (79). Introduction of one or two copies of SMN2 rescues the embryonic lethal phenotype resulting in mice with severe SMA whereas 8–16 copies of SMN2 result in rescue (80,81). This indicated that SMN2 can produce the SMN required to correct the SMA phenotype although it is not currently clear as to when during development or in which specific tissue(s) high levels of SMN are needed. Expression of a known mild SMA missense mutation (A2G) on the severe SMA mouse background results in a mild phenotype (82). Overall, these mouse models can mimic the human disease. However, it is not clear from these murine models whether the global reduction of SMN activity primarily affects neurons, muscle, glia, or all of these cell types to result in the selective loss of motor neurons. Investigators have also disrupted SMN expression in specific cell types including neurons, myocytes, and hepatocytes using the Cre-Lox recombination system (83–85). In each case, this has led to failure of the targeted cell type to develop normally (83–85). C. elegans and Drosophila melanogaster models of SMA have also been developed (86–88). Because of their short generation time, well-annotated genomes, vast array of genetic tools, and the ability to perform unbiased genetic screens, both model systems offer a number of advantages that are a strong complement to mouse model systems. The availability of these models will permit unbiased forward genetic screens that may illuminate the normal function of SMN and its role in disease. THERAPEUTICS Initial treatment strategies for SMA paralleled those for other neuromuscular diseases, in particular ALS. Candidate therapeutic compounds were chosen as potential SMA therapies either because they were known to directly increase muscle strength clinically or they have been shown to improve outcomes in animal models of ALS. Thyrotropin-releasing hormone (TRH)
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
221
produced a modest, transient improvement in muscle tone with no change in strength in one pilot clinical trial involving SMA type II and SMA type III patients (86). Albuterol, which had been shown to increase muscle strength in healthy volunteers, was similarly ineffective (90). Gabapentin, a drug approved for use in patients with postherpetic neuralgia and used by neurologists for neuropathic pain syndromes and refractory generalized epilepsy, prolongs survival in a mouse model of ALS (88). Two large clinical trials using gabapentin in SMA showed no improvement in strength, forced vital capacity (FVC) or functional rating scale (89,90). Riluzole, the only compound thus far proven to slow the progression of ALS, albeit mildly (94,95), has some promise as an SMA therapy. It is well tolerated in SMA patients (96) and improved median survival in an SMA mouse model (97), and a large clinical trial with Riluzole is currently underway. However, while therapies developed for ALS are a logical starting point for SMA therapy development, there is currently no mechanistic link between the two motor neuronopathies. And as opposed to the majority of ALS cases, there is a clear therapeutic goal in SMA: to increase the expression of full-length SMN protein. Thus, the current focus of SMA treatment development is based upon the potential to increase the expression of fulllength SMN protein, either by increasing exon 7 inclusion in SMN2 transcripts or by increasing the overall transcription from the SMN2 gene. All patients with SMA carry functional SMN2 alleles, irrespective of their disease-producing SMN1 mutation, providing a clear therapeutic target. High-throughput screens for small molecule modulators of the SMN2 gene have yielded many compounds that increase full-length SMN levels in cell culture. These include sodium butyrate (98), phenylbutyrate (99), sodium vanadate (100), aclarubicin (101), and indoprofen (102). Of these, the most promising class of compound is the histone deacetylase (HDAC) inhibitor. Indeed, valproic acid, which belongs to this class and is already approved for use in epilepsy has been shown to increase full-length SMN levels in cell culture models of SMA (103,104). HDAC inhibitor activity results in an increase in histone acetylation that can relax tertiary structure of chromatin and facilitate access of the transcriptional machinery to target genes. These compounds appear to increase overall transcription of the SMN2 gene resulting in increases in the functional, full-length SMN protein. Clinical trials using two HDAC inhibitors, valproic acid and sodium butyrate, are currently underway. Genetic strategies to increase exon 7 inclusion are also being pursued. In transient cotransfection experiments, the RNA splicing regulators Tra2a and Tra2b have been shown to favor SMN2 exon 7 inclusion (104,105). Inhibition of hnRNP A1 protein, which functions to inhibit splicing, restores SMN2 exon 7 inclusion in vivo suggesting that the C/T transition in SMN2 creates an exonic splicing silencer at that region (106). This approach has not been limited to the augmentation of RNA splicing modulators.
Copyright 2006 by Taylor & Francis Group, LLC
222
Kolb and Taylor
Antisense oligonucleotides directed toward the 30 splice site of exon 8 have also resulted in SMN2 exon 7 inclusion (107). Finally, chimeric molecules have been designed to mimic the functions of splicing factors that can promote exon 7 inclusion in vitro (108). Targeted expression of exogenous SMN protein to motor neurons remains an additional genetic approach. For this approach, a major hurdle is to deliver the transgene to the relevant, disease-associated cell types. A recent report described the successful expression of human SMN in mouse motor neurons and muscle in vivo using a lentiviral-based gene transfer system (109). This expression improved motor neuron survival and resulted in a small but significant increase in overall survival when applied to a mouse model of SMA. Adenovirus-mediated delivery of SMN to patient cells in culture has also been reported (110). Another potential strategy for SMA therapy is to replace the function of the SMN protein. As mentioned above, SMN is essential for the assembly of snRNPs, and it may play a role in the assembly of other RNA–protein complexes. Cell-based and in vitro assays that measure snRNP assembly will provide interesting tools with which to investigate these fundamental RNA processing mechanisms and to identify small molecules that can enhance these biological processes. There are significant challenges ahead. The design of therapeutic clinical trials for SMA patients is complicated by its distinctive clinical course (111). SMA is unusual among neurodegenerative diseases in that the rate of functional decline appears to slow with the passage of time. These clinical impressions are supported by neurophysiological studies demonstrating precipitous loss of motor units early in the course of the disease (112). Transition from a phase of more obvious decline to a slower chronic phase occurs at widely varying ages. At one end of the spectrum are infants with severe SMA (SMA type I) who appear to enter the slow chronic phase as early as a few months of life if at all; at the other end are individuals with milder forms of SMA (SMA type III) who may not manifest clinical disability until late teen or even early adult years. For this reason, it may be useful to group SMA patients by severity of disease and to design outcome measures and therapies for each group. Current efforts to develop reliable molecular surrogate markers, such as a quantitative blood test of SMN protein expression, hold the promise of providing additional, objective indicators that can be used for prognosis, for determining the natural history of the disease, and for the detection of a therapeutic response in clinical trials. It is further not clear to what degree the weakness seen in SMA patients will be attenuated once therapies are shown to increase SMN levels in patients. Despite these challenges, there is also much reason to be hopeful for SMA patients and their families. The SMN gene was discovered 10 years ago and since then there has emerged an entire, dedicated, multidisciplinary field of study committed to understanding and treating SMA. Remarkable
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
223
coordination between laboratories in the private and public sectors is accelerating the rate of discovery of candidate therapeutic compounds and is creating an infrastructure to facilitate the development and execution of clinical trials for those candidates. Further basic science research to understand where, when, and how much SMN expression is required to prevent motor neuron loss is joined by neuroscientists, geneticists, and cell biologists. This is an exciting and fast paced research area that, over the next 10 years, will yield important lessons not only about how to effectively treat SMA, but about the nature of other neurodegenerative diseases, the motor neuron, RNA processing and more.
REFERENCES 1. Werdnig G. Zwei fru¨hinfantile heredita¨re Fa¨lle von progressiver Muskelatrophie unter dem Bilde der Dystrophie, aber auf neurotischer Grundlage. Arch Psychiatri Nervenkrankheiten, Berlin, 1891; 22:437–481. 2. Hoffmann J. Weitere Beitra¨ge zur Lehre von der progressiven neurotischen Muskeldystrophie. Deutsche Zeitschrift fu¨r Nervenheilkunde, Berlin, 1891; 1: 95–120. 3. Munsat TL, Davies KE. International SMA consortium meeting (26–28 June 1992, Bonn, Germany). Neuromuscul Disord 1992; 2(5–6):423–428. 4. Czeizel A, Hamula J. A Hungarian study on Werdnig-Hoffmann disease. J Med Genet 1989; 26:761–763. 5. Emery AE. Population frequencies of inherited neuromuscular diseases – a world survey. Neuromuscul Disord 1991; 1:19–29. 6. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J Med Genet 1978; 15:409–413. 7. Tangsrud SE, Halvorsen S. Child neuromuscular disease in southern Norway. Prevalence, age and distribution of diagnosis with special reference to nonDuchenne muscular dystrophy. Clin Genet 1988; 34:145–152. 8. Ogino S, Wilson RB. SMN dosage analysis and risk assessment for spinal muscular atrophy. Am J Hum Genet 2002; 70:1596–1598. 9. Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. Eur J Paediatr 1999; 3(2):49–51. 10. Thomas NH, Dubowitz V. The natural history of type I (severe) spinal muscular atrophy. Neuromuscul Disord 1994; 4:497–502. 11. Zerres K, Rudnik-Scho¨neborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol 1995; 52:518–523. 12. Brahe C, Servidei S, Zappata S, Ricci E, Tonali P, Neri G. Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy. Lancet 1995; 346:741–742. 13. MacLeod MJ, Taylor JE, Lunt PW, Mathew CG, Robb SA. Prenatal onset spinal muscular atrophy. Eur J Paediatr Neurol 1999; 3(2):65–72. 14. Nicole S, Diaz CC, Frugier T, Melki J. Spinal muscular atrophy: recent advances and future prospects. Muscle Nerve 2002; 26(1):4–13.
Copyright 2006 by Taylor & Francis Group, LLC
224
Kolb and Taylor
15. Brzustowicz LM, Lehner T, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2–13.3. Nature 1990; 344(6266): 540–541. 16. Gilliam TC, Brzustowicz LM, et al. Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. Nature 1990; 345(6278):823–825. 17. Melki, J, Abdelhak S, et al. Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. Nature 1990; 344(6268):767–768. 18. Melki J, Sheth P, Abdelhak S, Burlet P, Bachelot MF, Lathrop MG, Frezal J, Munnich A. Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. The French Spinal Muscular Atrophy Investigators. Lancet 1990; 336(8710):271–273. 19. Daniels RJ, Suthers GK, et al. Prenatal prediction of spinal muscular atrophy. J Med Genet 1992; 29(3):165–170. 20. Melki J, Abdelhak S, et al. Prenatal prediction of Werdnig-Hoffmann disease using linked polymorphic DNA probes. J Med Genet 1992; 29(3):171–174. 21. Francis MJ, Morrison KE, et al. A contig of non-chimaeric YACs containing the spinal muscular atrophy gene in 5q13. Hum Mol Genet 1993; 2(8): 1161–1167. 22. Kleyn PW, Wang CH, et al. Construction of a yeast artificial chromosome contig spanning the spinal muscular atrophy disease gene region. Proc Natl Acad Sci USA, 1993; 90(14):6801–6805. 23. Melki J, Lefebvre S, et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science 1994; 264(5164):1474–1477. 24. Wirth B, Schmidt T, Hahnen E, Rudnik-Schoneborn S, Krawczak M, MullerMyhsok B, Schonling J, Zerres K. De novo rearrangements found in 2% of index patients with spinal muscular atrophy: mutational mechanisms, parental origin, mutation rate, and implications for genetic counseling. Am J Hum Genet 1997; 61(5):1102–1111. 25. Lefebvre S, Burglen L, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995; 80(1):155–165. 26. Roy N, Mahadevan MS, et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995; 80(1):167–178. 27. Burglen L, Seroz T, Miniou P, Lefebvre S, Burlet P, Munnich A, Pequignot EV, Egly JM, Melki J. The gene encoding p44, a subunit of the transcription factor TFIIH, is involved in large-scale deletions associated with Werdnig-Hoffmann disease. Am J Hum Genet 1997; 60(1):72–79. 28. Scharf JM, Endrizzi MG, Wetter A, Huang S, Thompson TG, Zerres K, Dietrich WF, Wirth B, Kunkel LM. Identification of a candidate modifying gene for spinal muscular atrophy by comparative genomics. Nat Genet 1998; 20(1):83–86. 29. Wirth B. An update of the mutation spectrum of the survival motor neuron gene (SMN1) in autosomal recessive spinal muscular atrophy (SMA). Hum Mutat 2000; 15:228–237. 30. Burglen L, Lefebvre S, Clermont O, Burlet P, Viollet L, Cruaud C, Munnich A, Melki J. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996; 32:479–482.
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
225
31. Jong YJ, Chang JG, Lin SP, Yang TY, Wang JC, Chang CP, Lee CC, Li H, HsiehLi HM, Tsai CH. Analysis of the mRNA transcripts of the survival motor neuron (SMN) gene in the tissue of an SMA fetus and the peripheral blood mononuclear cells of normals, carriers and SMA patients. J Neurol Sci 2000; 173:147–153. 32. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci 1999; 96:6307–6311. 33. Monani UR, Lorson CL, Parsons DW, Prior TW, Androphy EJ, Burghes AH, McPherson JD. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999; 8:1177–1183. 34. Corcia P, Mayeux-Portas V, Khoris J, de Toffol B, Autret A, Muh JP, Camu W, Andres C. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002; 51:243–246. 35. Ge´rard B, Ginet N, Matthijs G, Evrard P, Baumann C, Da Silva F, Ge´rardBlanluet M, Mayer M, Grandchamp B, Elion J. Genotype determination at the survival motor neuron locus in a normal population and SMA carriers using competitive PCR and primer extension. Hum Mutat 2000; 16:253–263. 36. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, Prior TW, Burghes AH. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SMNT and SMNC gene copy number. Am J Hum Genet 1997; 60:1411–1422. 37. Ogino S, Wilson RB. Genetic testing and risk assessment for spinal muscular atrophy (SMA). Hum Genet 2002; 111(6):477–500. 38. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, Munnich A, Dreyfuss G, Melki J. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet 1997; 16:265–269. 39. Gavrilov DK, Shi X, Das K, Gilliam TC, Wang CH. Differential SMN2 expression associated with SMA severity. Nat Genet 1998; 20:230–231. 40. Campbell L, Potter A, Ignatius J, Dubowitz C, Davies K. Genomic variation and gene conversion in spinal muscular atrophy: implications for disease process and clinical phenotype. Am J Hum Genet 1997; 61:40–50. 41. McAndrew PE, Parsons DW, Simard LR, Rochette C, Ray PN, Mendell JR, Prior TW, Burghes AHM. Identification of proximal spinal muscular atrophy carriers and patients by analysis of SmnT and SmnC gene copy number. Am J Hum Genet 1997; 60:1411–1422. 42. Wirth B, Herz M, Wetter A, Moskau S, Hahnen E, Rudnik-Scho¨neborn S, Wienker T, Zerres K. Quantitative analysis of survival motor neuron copies: identification of subtle SMN1 mutations in patients with spinal muscular atrophy, genotype–phenotype correlation and implications for genetic counseling. Am J Hum Genet 1999; 64:1340–1356. 43. Feldko¨tter M, Schwarzer V, Wirth R, Wienker TF, Wirth B. Quantitative analyses of SMN1 and SMN2 based on real-time LightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002; 70:358–368.
Copyright 2006 by Taylor & Francis Group, LLC
226
Kolb and Taylor
44. Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AHM, Prior TW. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med 2002; 4:20–26. 45. Zerres K, Rudnik-Schoneborn S. 93rd ENMC international workshop: non5q-spinal muscular atrophies (SMA)-clinical picture (6–8 April 2001, Naarden, The Netherlands). Neuromuscul Disord 2003; 13(2):179–183. 46. Grohmann K, Varon R, Stolz P, Schuelke M, Janetzki C, Bertini E, Bushby K, Muntoni F, Ouvrier R, Van Maldergem L, Goemans NM, Lochmuller H, Eichholz S, Adams C, Bosch F, Grattan-Smith P, Navarro C, Neitzel H, Polster T, Topaloglu H, Steglich C, Guenther UP, Zerres K, Rudnik-Schoneborn S, Hubner C. Infantile spinal muscular atrophy with respiratory distress type 1 (SMARD1). Ann Neurol 2003; 54(6):719–724. 47. O’Flaherty P. Arthrogryposis multiplex congenita. Neonatal Netw 2001; 20(4): 13–20. 48. Talbot K, Davies KE. Spinal muscular atrophy. Semin Neurol 2001; 21: 189–197. 49. Kobayashi H, Baumbach L, Matise TC, Schiavi A, Greenberg F, Hoffman EP. A gene for a severe lethal form of X-linked arthrogryposis (X-linked infantile spinal muscular atrophy) maps to human chromosome Xp11.3-q11.2. Hum Mol Genet 1995; 4:1213–1216. 50. Bingham PM, Shen N, Rennert H, Rorke LB, Black AW, Marin-Padilla MM, Nordgren RE. Arthrogryposis due to infantile neuronal degeneration associated with deletion of the SMNT gene. Neurology 1997; 49:848–851. 51. Burglen L, Amiel J, Viollet L, Lefebvre S, Burlet P, Clermont O, Raclin V, Landrieu P, Verloes A, Munnich A, Melki J. Survival motor neuron gene deletion in the arthrogryposis multiplex congenita-spinal muscular atrophy association. J Clin Invest 1996; 98:1130–1132. 52. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. A sex-linked recessive trait. Neurology 1968; 18(7):671–680. 53. La Spada AR, Wilson EM, Lubahn DB, Harding AE, Fischbeck KH. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 1991; 352(6330):77–79. 54. Puls I, Jonnakuty C, LaMonte BH, Holzbaur EL, Tokito M, Mann E, Floeter MK, Bidus K, Drayna D, Oh SJ, Brown RH Jr, Ludlow CL, Fischbeck KH. Mutant dynactin in motor neuron disease. Nat Genet 2003; 33(4):455–456. 55. Gubitz AK, Feng W, Dreyfuss G. The SMN complex. Exp Cell Res, 2004; 296(1):51–56. 56. Liu Q, Dreyfuss G. A novel nuclear structure containing the survival of motor neurons protein. Embo J 1996; 15(14):3555–3565. 57. Liu Q, Fischer U, Wang F, Dreyfuss G. The spinal muscular atrophy disease gene product, SMN, and its associated protein SIP1 are in a complex with spliceosomal snRNP proteins. Cell 1997; 90(6):1013–1021. 58. Charroux B, Pellizzoni L, Perkinson RA, Shevchenko A, Mann M, Dreyfuss G. Gemin3: a novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems. J Cell Biol 1999; 147(6):1181–1194.
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
227
59. Charroux B, Pellizzoni L, Perkinson RA, Yong J, Shevchenko A, Mann M, Dreyfuss G. Gemin4. A novel component of the SMN complex that is found in both gems and nucleoli. J Cell Biol 2000; 148(6):1177–1186. 60. Campbell L, Hunter KM, Mohaghegh P, Tinsley JM, Brasch MA, Davies KE. Direct interaction of Smn with dp103, a putative RNA helicase: a role for Smn in transcription regulation? Hum Mol Genet 2000; 9(7):1093–1100. 61. Gubitz AK, Mourelatos Z, Abel L, Rappsilber J, Mann M, Dreyfuss G. Gemin5, a novel WD repeat protein component of the SMN complex that binds Sm proteins. J Biol Chem 2002; 277(7):5631–5636. 62. Pellizzoni L, Baccon J, Rappsilber J, Mann M, Dreyfuss G. Purification of native survival of motor neurons complexes and identification of Gemin6 as a novel component. J Biol Chem 2002; 277(9):7540–7545. 63. Baccon J, Pellizzoni L, Rappsilber J, Mann M, Dreyfuss G. Identification and characterization of Gemin7, a novel component of the SMN complex. J Biol Chem 2002; 277:31,957–31,962. 64. Meister G, Buhler D, Pillai R, Lottspeich F, Fischer U. A multiprotein complex mediates the ATP-dependent assembly of spliceosomal U snRNPs. Nat Cell Biol 2001; 3(11):945–949. 65. Paushkin S, Gubitz AK, Massenet S, Dreyfuss G. The SMN complex, an assemblyosome of ribonucleoproteins. Curr Opin Cell Biol 2002; 14(3):305–312. 66. Hebert MD, Szymczyk PW, Shpargel KB, Matera AG. Coilin forms the bridge between Cajal bodies and SMN, the spinal muscular atrophy protein. Genes Dev 2001; 15(20):2720–2729. 67. Pellizzoni L, Baccon J, Charroux B, Dreyfuss G. The survival of motor neurons (SMN) protein interacts with the snoRNP proteins fibrillarin and GAR1. Curr Biol 2001; 11(14):1079–1088. 68. Jones KW, Gorzynski K, Hales CM, Fischer U, Badbanchi F, Terns RM, Terns MP. Direct interaction of the spinal muscular atrophy disease protein SMN with the small nucleolar RNA-associated protein fibrillarin. J Biol Chem 2001; 276(42):38645–38651. 69. Mourelatos Z, Abel L, Yong J, Kataoka N, Dreyfuss G. SMN interacts with a novel family of hnRNP and spliceosomal proteins. Embo J 2001; 20(19): 5443–5452. 70. Rossoll W, Kroning AK, Ohndorf UM, Steegborn C, Jablonka S, Sendtner M. Specific interaction of Smn, the spinal muscular atrophy determining gene product, with hnRNP-R and gry-rbp/hnRNP-Q: a role for Smn in RNA processing in motor axons? Hum Mol Genet 2002; 11(1):93–105. 71. Lefebvre S, Burlet P, Viollet L, Bertrandy S, Huber C, Belser C, Munnich A. A novel association of the SMN protein with two major non-ribosomal nucleolar proteins and its implication in spinal muscular atrophy. Hum Mol Genet 2002; 11(9):1017–1027. 72. Barth S, Liss M, Voss MD, Dobner T, Fischer U, Meister G, Grasser FA. Epstein-Barr virus nuclear antigen 2 binds via its methylated arginine-glycine repeat to the survival motor neuron protein. J Virol 2003; 77(8):5008–5013. 73. Yong J, Golembe TJ, Battle DJ, Pellizzoni L, Dreyfuss G. snRNAs contain specific SMN-binding domains that are essential for snRNP assembly. Mol Cell Biol 2004; 24(7):2747–2756.
Copyright 2006 by Taylor & Francis Group, LLC
228
Kolb and Taylor
74. Yong J, Pellizzoni L, Dreyfuss G. Sequence-specific interaction of U1 snRNA with the SMN complex. Embo J 2002; 21(5):1188–1196. 75. Yong J, Wan L, Dreyfuss G. Why do cells need an assembly machine for RNA-protein complexes? Trends Cell Biol 2004; 14(5):226–232. 76. Pellizzoni L, Charroux B, Rappsilber J, Mann M, Dreyfuss G. A functional interaction between the survival motor neuron complex and RNA polymerase II. J Cell Biol 2001; 152(1):75–86. 77. Pellizzoni L, Kataoka N, Charroux B, Dreyfuss G. A novel function for SMN, the spinal muscular atrophy disease gene product, in pre-mRNA splicing. Cell 1998; 95(5):615–624. 78. Rossoll W, Jablonka S, Andreassi C, Kroning AK, Karle K, Monani UR, Sendtner M. SMN, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 2003; 163(4):801–812. 79. Schrank B, Gotz R, Gunnersen JM, Ure JM, Toyka KV, Smith AG, Sendtner M. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc Natl Acad Sci USA, 1997; 94(18):9920–9925. 80. Hsieh-Li HM, Chang JG, Jong YJ, Wu MH, Wang NM, Tsai CH, Li H. A mouse model for spinal muscular atrophy. Nat Genet 2000; 24(1):66–70. 81. Monani UR, Sendtner M, et al. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet 2000; 9(3): 333–339. 82. Monani UR, Pastore MT, et al. A transgene carrying an A2G missense mutation in the SMN gene modulates phenotypic severity in mice with severe (type I) spinal muscular atrophy. J Cell Biol 2003; 160(1):41–52. 83. Frugier T, Tiziano FD, Cifuentes-Diaz C, Miniou P, Roblot N, Dierich A, Le Meur M, Melki J. Nuclear targeting defect of SMN lacking the C-terminus in a mouse model of spinal muscular atrophy. Hum Mol Genet 2000; 9(5): 849–858. 84. Cifuentes-Diaz C, Frugier T, Tiziano FD, Lacene E, Roblot N, Joshi V, Moreau MH, Melki J. Deletion of murine SMN exon 7 directed to skeletal muscle leads to severe muscular dystrophy. J Cell Biol 2001; 152(5):1107–1114. 85. Vitte JM, Davoult B, et al. Deletion of murine SMM exon 7 directed to liver leads to severe defect of liver development associated with iron overload. Am J Pathol 2004; 165(5):1731–1741. 86. Miguel-Aliaga I, Culetto E, Walker DS, Baylis HA, Sattelle DB, Davies KE. The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum Mol Genet 1999; 8(12):2133–2143. 87. Miguel-Aliaga I, Chan YB, Davies KE, van den Heuvel M. Disruption of SMN function by ectopic expression of the human SMN gene in Drosophila. FEBS Lett 2000; 486(2):99–102. 88. Chan YB, Miguel-Aliaga I, Franks C, Thomas N, Trulzsch B, Sattelle DB, Davies KE, van den Heuvel M. Neuromuscular defects in a Drosophila survival motor neuron gene mutant. Hum Mol Genet 2003; 12(12):1367–1376.
Copyright 2006 by Taylor & Francis Group, LLC
Spinal Muscular Atrophy
229
89. Tzeng AC, Cheng J, Fryczynski H, Niranjan V, Stitik T, Sial A, Takeuchi Y, Foye P, DePrince M, Bach JR. A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil 2000; 79(5):435–440. 90. Kinali M, Mercuri E, Mani M, De Biasia F, Karatza A, Higgins R, Banks LM, Manzur AY, Muntoni F. Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002; 59(4):609–610. 91. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996; 39:147–157. 92. Miller RG, Moore DH, II, Gelinas DF, Dronsky V, Mendoza M, Barohn RJ, Bryan W, Ravits J, Yuen E, Neville H, Ringel S, Bromberg M, Petajan J, Amato AA, Jackson C, Johnson W, Mandler R, Bosch P, Smith B, Graves M, Ross M, Sorenson EJ, Kelkar P, Parry G, Olney R. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001; 56:843–848. 93. Merlini L, Solari A, Vita G, Bertini E, Minetti C, Mongini T, Mazzoni E, Angelini C, Morandi L. Role of gabapentin in spinal muscular atrophy: results of a multicenter, randomized Italian study. J Child Neurol 2003; 18:537–541. 94. Bensimon GL, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330(9):585–591. 95. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Powe L, Durrleman S, Delumeau JC, Meininger V. A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II. Neurology 1996; 47(6 suppl 4): S242–S250. 96. Russman BS, Iannaccone ST, Samaha FJ. A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003; 60(11):1601–1603. 97. Haddad H, Cifuentes-Diaz C, Miroglio A, Roblot N, Joshi V, Melki J. Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve 2003; 28(4):432–437. 98. Chang JG, Hsieh-Li HM, Jong YJ, Wang NM, Tsai CH, Li H. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci USA, 2001; 98(17):9808–9813. 99. Andreassi C, Angelozzi C, Tiziano FD, Vitali T, De Vincenzi E, Boninsegna A, Villanova M, Bertini E, Pini A, Neri G, Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2003. 100. Zhang ML, Lorson CL, Androphy EJ, Zhou J. An in vivo reporter system for measuring increased inclusion of exon 7 in SMN2 mRNA: potential therapy of SMA. Gene Ther 2001; 8(20):1532–1538. 101. Andreassi C, Jarecki J, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001; 10(24):2841–2849. 102. Lunn MR., Root DE, et al. Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 2004; 11(11):1489–1493.
Copyright 2006 by Taylor & Francis Group, LLC
230
Kolb and Taylor
103. Sumner CJ, Huynh TN, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003; 54(5):647–654. 104. Brichta L, Hofmann Y, Hahnen E, Siebzehnrubl FA, Raschke H, Blumcke I, Eyupoglu IY, Wirth B. Valproic acid increases the SMN2 protein level: a wellknown drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003; 12(19):2481–2489. 105. Hofmann Y, Lorson CL, Stamm S, Androphy EJ, Wirth B. Htra2-beta 1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci USA 2000; 97(17):9618–9623. 106. Kashima T, Manley JL. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat Genet 2003; 34(4):460–463. 107. Lim SR, Hertel KJ. Modulation of survival motor neuron pre-mRNA splicing by inhibition of alternative 30 splice site pairing. J Biol Chem 2001; 276(48): 45476–45483. 108. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003; 10(2):120–125. 109. Azzouz M, Le T, Ralph GS, et al. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J Clin Invest 2004; 114(12):1726– 1731. 110. DiDonato CJ, Parks RJ, Kothary R. Development of a gene therapy strategy for the restoration of survival motor neuron protein expression: implications for spinal muscular atrophy therapy. Hum Gene Ther 2003; 14(2):179–188. 111. Crawford TO. Concerns about the design of clinical trials for spinal muscular atrophy. Neuromuscul Disord 2004; 14(8–9):456–60. 112. Bromberg MB, Swoboda KJ. Motor unit number estimation in infants and children with spinal muscular atrophy. Muscle Nerve 2002; 25:445–447. 113. Mattaj IW. Cap trimethylation of U snRNA is cytoplasmic and dependent on U snRNP protein binding. Cell 1986; 46(6):905–911. 114. Plessel G, Fischer U, Luhrmann R. m3G cap hypermethylation of U1 small nuclear ribonucleoprotein (snRNP) in vitro: evidence that the U1 small nuclear RNA-(guanosine-N2)-methyltransferase is a non-snRNP cytoplasmic protein that requires a binding site on the Sm core domain. Mol Cell Biol 1994; 14(6):4160–4172.
Copyright 2006 by Taylor & Francis Group, LLC
12 Hereditary Spastic Paraplegia Kleopas A. Kleopa The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus
INTRODUCTION Hereditary spastic paraplegia (HSP) encompasses a heterogeneous group of disorders characterized by progressive lower limb spasticity that were first described by Stru¨mpell, Lorrain, and Seeligmu¨ller in the late nineteenth century. Autosomal dominant (AD), autosomal recessive (AR), and X-linked inheritance of HSP have been characterized, as have early and late onset forms of HSP, as well as uncomplicated and complicated HSP phenotypes (1,2), with considerable intrafamilial variation in the age of onset and severity (3–7). The discovery of the molecular genetic mechanisms underlying many forms of HSP in the last decade has provided the basis for a new classification scheme according to genes and loci for these disorders. At least 10 loci for dominant forms, 11 loci for recessive forms, and 3 loci for X-linked HSP have been identified along with an increasing number of causative genes (Table 1). These discoveries provide an insight into the neurobiology of these disorders. CLINICAL AND PATHOLOGICAL FEATURES OF HSP The reported prevalence of HSP varies in different studies from 2 to 10 per 100,000, reflecting differences in epidemiological methodology, the diagnostic criteria used, or geographical factors (2,8). The first symptom of HSP is difficulty walking or delayed walking when onset is in infancy. Leg stiffness, urinary disturbance, and premature wear on footwear are also early
Copyright 2006 by Taylor & Francis Group, LLC
232
Kleopa
Table 1 Molecular Genetic Classification of Inherited Spastic Paraparesis Disease (OMIM number)
Locus
Affected gene/ protein
Phenotype
Autosomal dominant HSP (spastic paraplegia-SPG) SPG3 (182600) 14q11-21 SPG3A/ Uncomplicated Atlastin SPG4 (182601) 2p22-21 SPAST/ Uncomplicated Spastin SPG6 (600363) 15q11.1 NIPA1 Uncomplicated SPG8 (603563) 8q23-24 Uncomplicated SPG9 (601162) 10q23.3-24.2 With cataracts, gastroesophageal reflux and motor neuronopathy SPG10 (604187) 12q13 KIF5A Uncomplicated SPG12 (604805) 19q13 Uncomplicated SPG13 (605280) 2q24-34 HSPD1/Hsp60 Uncomplicated SPG17 (27068511q12-14 BSCL2/Seipin With distal Silver syndrome) amyotrophy SPG19 (607152) 9q33-34 Uncomplicated Autosomal recessive HSP SPG5 (270800) 8p12-13 Uncomplicated SPG7 (602783) 16q24.3 SPG7/ Pure or Paraplegin complicated phenotypes SPG11 (604360) 15q13-15 Pure and complicated phenotypes SPG14 (605229) 3q27-28 With mental retardation and peripheral neuropathy SPG15 (270700) 14q22-24 With distal amyotrophy, mental retardation, retinopathy SPG20 (27590013q12.3 SPG20/Spartin With distal Troyer syndrome) amyotrophy (hands) SPG21 (24890015q21-22 ACP33/ With dementia Mast syndrome) Maspardin and white matter abnormalities
References 55,58,61 36,40 69,70 72 92
76,77 80 83,84 89,90 94 121 95,96
102
124
109
112
27
(Continued)
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
233
Table 1 Molecular Genetic Classification of Inherited Spastic Paraparesis (Continued ) Disease (OMIM number) SPG23
Locus
Affected gene/ protein
1q24-32
SPG24 (607584) 13q14 Infantile onset HSP 2q33 (IAHSP) (607225allelic to ALS2, JPLS) X-linked HSP Xq28 SPG1 (303350allelic to MASA and X-linked hydrocephalus)
SPG2 (312920allelic to PMD)
Xq22
SPG16 (300266)
Xq11.2
ALS2/Alsin
L1CAM
PLP
Phenotype
References
With pigmentary abnormalities of skin and hair, premature aging Uncomplicated With tetraplegia, dysarthria, dysphagia, slow eye movements
118
Mental retardation, hydrocephalus, aphasia, adducted thumbs Pure and complicated phenotypes Pure and complicated phenotypes
125 119
131
138
147–149
Note: Updated information on HSP genes can be found at OMIM (http://www.ncbi.nlm.nih. gov.80/entrez/) and GeneClinics (www.genetests.org) (for abbreviations see text).
manifestations. The age of onset can be from infancy to the eighth decade of life, showing one peak in incidence before six years of age and another one between the second and fourth decades (1). Some patients may have only subclinical involvement (8). The rate of progression and disease severity vary between families and, to a lesser extent, within the same family, while life expectancy is usually normal (1,9). Neurological examination of patients with pure HSP shows symmetric, often severe leg spasticity, predominantly affecting the hamstrings, quadriceps, and ankles, causing the characteristic circumduction and toe walking. Pes cavus and other foot deformities may be found in up to 30% of patients. Mild distal weakness and muscle atrophy, affecting mostly the intrinsic foot muscles and the tibialis anterior, are less common but well-recognized features in patients with long disease duration. However, muscle weakness in HSP is much milder than the spasticity and the reverse should raise doubt
Copyright 2006 by Taylor & Francis Group, LLC
234
Kleopa
about the diagnosis (1–3). Hyperreflexia is almost always found in the legs with extensor plantar responses in the majority of the affected individuals, but ankle reflexes may be absent in some patients. The upper limbs are typically spared, except for mild hyperreflexia in some cases and more severe involvement in rare syndromes discussed further (1,3,10). Mild sensory abnormalities occur in 10–65% of typical HSP cases, especially reduced vibration sense and paresthesias in the lower limbs (1,3). In most patients nerve conduction studies are normal (9,11), suggesting that the clinical findings are due to a central axonopathy rather than peripheral nerve involvement. There is also involvement of the bladder in up to 50% of HSP patients with urgency, hesitancy, and frequency, sometimes progressing to incontinence (1,12). Anal sphincter involvement is unusual and has only been described in combination with urinary symptoms (13). Sexual dysfunction has been reported in only one family, occurring about 10–15 years after the onset of disease (14). The autonomic nervous system has not been systematically studied, but autonomic function tests have been normal in HSP patients with sphincter disturbances (12). HSP is classified as uncomplicated (also referred to as ‘‘pure’’) and complicated. In uncomplicated HSP, spastic paraparesis is the dominating clinical feature, with few other features except for the mild neuropathic, sensory and autonomic features mentioned above. In complicated HSP, spastic paraparesis remains the major manifestation, but additional features are present, including dementia, peripheral neuropathy, epilepsy, optic atrophy, retinopathy, mental retardation, extrapyramidal dysfunction, ataxia, deafness, and icthyosis. Some types of complicated HSP are extremely rare and may have only been described in one or two families. Epilepsy may occur in both AD and recessive forms of complicated HSP syndromes (15–18), and can manifest with many seizure types including myoclonic, simple complex partial, and generalized seizures. The seizures may predate or follow the onset of the spastic paraparesis and are often accompanied by cognitive impairment (16,17). Peripheral neuropathy is a well-recognized feature of complicated HSP, but electrophysiological findings of peripheral neuropathy can also be found in patients with ‘‘pure’’ HSP (19). The clinical severity ranges from asymptomatic sensory involvement detected on clinical examination (20), to severe sensory loss with chronic painless cutaneous ulcers (21). Nerve biopsy shows features of axonal neuropathy (20,22). Coexisting manifestations include optic atrophy (22) or mental retardation (23,24). Dementia is a frequent manifestation of complicated HSP, either as the only additional feature (2,25), or in combination with ataxia, dysarthria, athetosis, or epilepsy (15,16,26,27). Some patients also have a thin corpus callosum and thalamic hypometabolism (28). The dementia in HSP patients is mainly subcortical with impairment of attention, recent memory, visuomotor coordination, and perceptual speed. Features of cortical involvement such as
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
235
dysphasia, agnosia, or dyscalculia are typically not present (25). Cognitive decline, typically after the age of 40 years, has also been increasingly recognized in some forms of ‘‘pure’’ HSP (25,29–32), especially when patients are carefully evaluated by neuropsychological tests (33). There are only a few reports on the neuropathological changes in HSP (see Ref. 2 for review). The major feature is axonal degeneration that is maximal in the terminal portions of the longest descending and ascending tracts within the spinal cord, including the crossed and uncrossed corticospinal tracts to the lower limbs, and from the dorsal column pathways the fasciculus gracilis fibers from the lower limbs. Demyelination and gliosis may accompany the axonal loss. The spinocerebellar tracts can be affected in about 50% of cases (34). In rare cases, neuronal loss in the motor cortex, Clarke’s column, cerebellum, basal ganglia, and anterior horns have also been found (13). Thus, the distal part of the longest central nervous system (CNS) axons is preferentially affected in HSP, indicating a ‘‘dying back’’ process with degeneration beginning distally and then proceeding towards the cell body. GENETICS AND NEUROBIOLOGY OF HSP The extensive clinical heterogeneity of HSP is matched by the emerging genetic heterogeneity. Increasing numbers of different loci and causative genes have been identified in the last decade (Table 1 and Fig. 1), providing important insight into the pathogenic mechanisms of the disease. Autosomal Dominant HSP Autosomal dominant is the most frequent mode of inheritance in pure HSP and accounts for approximately 70% of all cases (35) with linkage to 10 different loci thus far. In most of these loci, genes harboring mutations responsible for HSP have been identified, but clinical genetic testing is not always available or informative. This reflects the large number of genes and the frequent occurrence of specific mutations limited to single families (‘‘private’’ mutations). Chromosome 2p Locus (SPG4) Linkage to the SPG4 locus on chromosome 2p was demonstrated in Autosomal dominant HSP (ADHSP) families from different countries (36,37), distinguishing this disorder from ADHSP mapped earlier to chromosome 14. Subsequent studies have shown that the HSP associated with a chromosome 2p locus is by far the most common ADHSP, accounting for up to 40% of pedigrees (5,38,39). SPG4-linked families are characterized by a mean age of onset ranging from 12 to 43 years (4–6). Marked interfamilial and intrafamilial variation may result from allelic heterogeneity, modifying
Copyright 2006 by Taylor & Francis Group, LLC
236
Kleopa
Figure 1 Localization and putative function of gene products involved in the pathogenesis of HSP. Diagram of a motor neuron with a long myelinated axon. Abbreviations: HSP60, hereditary spastic paraplegia 60; NIPAI, nonimprinted in Prader-Willi/Angelman loci 1; PLP, proteolipid protein; N, nucleus; mitoch, mitochondrion; TGN, trans-Golgi network; ER, endoplasmic reticulum.
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
237
genes, environmental factors, or even difficulty in recognizing the precise onset of symptoms that typically begin insidiously. There is also marked variation in the disease severity, from subclinical involvement in asymptomatic patients with pyramidal signs in the lower limbs and normal or only slightly abnormal gait to patients who are chair bound or bedridden. The majority of SPG4 patients retain the ability to walk independently or with minimal support (4,5). SPG4-linked families frequently manifest late onset dementia or subclinical cognitive dysfunction (16,25,29,31,32). In addition to the typical pathological features of pure HSP, in one SPG4 family with dementia unique features including neuronal loss in the substantia nigra associated with Lewy bodies, and tau positive neurofibrillary tangles in the hippocampus have been described (32). In contrast, prolongation of central motor conduction times or signs of peripheral neuropathy are less frequent in SPG4 linked families compared to other HSP forms (19). SPAST, the first ADHSP gene to be identified by using a positional cloning strategy, is composed of 17 exons spanning a region of 90 kb and encodes for a 616-amino-acid protein of approximately 67.2 kD called spastin (40). Spastin belongs to the group of AAA proteins (ATPases associated with diverse cellular activities) and is expressed in neurons where it is predicted to have a nuclear localization (40,41). AAA proteins play an important role as chaperones in various cellular functions, including cell cycle regulation, protein degradation, organelle biogenesis, and vesicle mediated protein function (42). They share a common 230-amino-acid domain mediating the ATPase function, including the ATP binding and hydrolysis sites, located between amino acids 342 and 599 of spastin (40). Outside this domain spastin shows homology only to a particular subclass of AAA proteins, including the yeast 26S proteasome subunits involved in protein degradation (40). Over 100 different spastin mutations have been identified to date, including missense, nonsense, and splice site mutations in almost all exons, as well as small deletions and insertions leading to major changes in the amino acid sequence of the AAA cassette (39,40,43–49). A specific mutation appears to be unique to most individual kindreds and is rarely shared by unrelated individuals (50), making it difficult to establish clear genotype– phenotype correlations (39,43). However, clinical and electrophysiological differences among patients depending on the type of spastin mutation have been reported (51). Splice site and frameshift mutations lead to unstable mRNA and cause a loss of spastin function through haploinsufficiency (41,45,49). Loss of spastin function leads to disrupted intracellular transport (52), as the threshold level of spastin expression may be critical for axonal preservation in the corticospinal tract (40). Spastin missense mutations do not appear to cause more severe phenotypes as opposed to truncating ones (45). However, the possibility of dominant-negative effects has
Copyright 2006 by Taylor & Francis Group, LLC
238
Kleopa
been raised by recent studies showing that spastin mutants may lead to redistribution of the microtubule cytoskeleton (53). Spastin mutations also cause abnormal perinuclear clustering of mitochondria and peroxisomes, indicating an impairment of kinesin-mediated organelle transport (54). Such alterations may cause energy deficits leading to length-dependent axonal degeneration. Chromosome 14q Locus (SPG3) The first ADHSP locus on 14q was initially discovered in a family with early onset HSP (55). Several families have been subsequently linked to 14q and the SPG3 interval was eventually narrowed to a 2.7 cM region (56–58). SPG3 typically presents in the first or second decade, but mostly before five years of age (7,55–59), and can be mistaken for cerebral palsy (60). Despite earlier onset, eventual disease severity is generally similar to other subtypes of ADHSP (7,56,57). Screening of candidate genes in affected kindreds led to the identification of specific missense mutations in a novel gene (61). SPG3A gene has 14 exons spanning approximately 69 kb and encodes a protein called atlastin (61). Atlastin shows homology with several members of the dynamin family of large GTPases, particularly guanylate-binding protein-1. The dynamins play an important role in endocytosis, secretion and maintenance of mitochondrial form, and in the formation of transport vesicles from the trans-Golgi network through their GTPase activity (62,63). Expression of dominant dynamin mutants in mammalian cells leads to disruption of Golgi structure and function (64). Atlastin is enriched in pyramidal neurons of the cerebral cortex and hippocampus and colocalizes with markers of the Golgi apparatus in cultured neurons (65). Since an intact Golgi apparatus is required for axonal growth (66), the role of atlastin in Golgi membrane dynamics suggests that impaired long axon formation may be a relevant mechanism in SPG3 in addition to distal degeneration of axons. This would be the basis for the very early onset, which led some authors to describe it as a neurodevelopmental, rather than a neurodegenerative disorder. Most reported atlastin mutations affect conserved amino acids in the N-terminal region that contains the conserved GTPase domain (61), or in the RD motif affecting the active side of the GTPase (59). In contrast to spastin, for which most reported mutations are private/unique for each family, half of the SPG3 families reported carry the R239C atlastin mutation. This may be a commonly occurring new mutation or may represent a founder effect from a common ancestral mutation (67). Atlastin mutations are second in frequency to spastin mutations and have been found in 9–38% of ADHSP families (7,61,67,68). Atlastin mutations may be found in families with early or late onset HSP (68). A mutation located close to the carboxy terminus was identified in a family with infancy onset severe HSP
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
239
(60), whereas a truncating mutation was found in another family with milder phenotype (7). Whether atlastin missense mutations could cause a more severe phenotype than the truncating ones suggesting dominant-negative effects remains to be determined. Chromosome 15q Locus (SPG6) Linkage to the SPG6 locus on 15q was reported in a large North American family (69). The age at onset was between 12 and 35 years with a phenotype typical of pure HSP, although relatively severe compared to other loci. Almost one third of affected members required a wheelchair, some as early as 40 years of age. Pes cavus was almost always present in affected members. Using the candidate gene approach, a disease-causing mutation in the NIPA1 (nonimprinted in Prader-Willi/Angelman loci 1) gene was identified in the original and in one further SPG6-linked family (70). The T45R amino acid substitution in the NIPA1 protein affects a highly conserved amino acid in the predicted first of nine transmembrane domains (70). Hydrophobicity analysis indicates that NIPA1 could be a membrane receptor or transporter, but the exact function remains to be determined (71). Although individuals with Prader–Willi syndrome or Angelman syndrome have 15q deletions that include NIPA1 (71), they do not exhibit progressive spastic paraplegia indicating that NIPA1 haploinsufficiency does not cause a phenotype. Therefore, the NIPA1 T45R missense mutation is likely to be pathogenic through a dominant gain-of-function mechanism (70). Chromosome 8q Locus (SPG8) Three ADHSP families from different countries were linked to 8q24 allowing refinement of the SPG8 locus to a 3.4 cM region, but the SPG8 gene has not yet been identified (72–74). The mean age at onset was comparable to SPG4 families, but the otherwise typical ADHSP phenotype was more severe, particularly in the American family, in which two-thirds of affected members over 40 years required the use of a wheelchair (75). One patient from the American family had marked spinal cord atrophy seen in MRI (75). Chromosome 12q Locus (SPG10) The SPG10 locus on 12q13 was identified in a large ADHSP family in which affected family members presented with the typical phenotype of pure HSP and onset ranging from 8 to 40 years of age. Disease severity was variable with some patients requiring a wheelchair whereas others remained asymptomatic at the age of 40 years (76). In the same family, a missense mutation in the motor domain of the neuronal kinesin heavy chain gene KIF5A was subsequently identified (77).
Copyright 2006 by Taylor & Francis Group, LLC
240
Kleopa
Kinesin proteins form a large family of ATPases that function as molecular motors using microtubules as tracks (78). Each kinesin transports specific organelles allowing the intracellular movement of macromolecular cargo from the neuronal cell body to the distal tip of the axon. As most proteins must be transported down the axon after being synthesized in the perikaryon owing to limited protein synthesis within axons themselves, kinesins play an essential role in axonal survival. The SPG10 mutation affects a conserved asparagine residue and likely impairs the stimulation of the motor ATPase by microtubule binding (77). Targeted disruption of the neuronal KIF5A in mice causes axonal degeneration by impairing microtubuledependent axonal transport and accumulation of at least one cargo, neurofilament subunits, in cell bodies (79). The molecular mechanism of SPG10 adds to the growing evidence that both CNS and PNS axonopathies are length-dependent because the longest axons are the most vulnerable to defects in axonal transport. Chromosome 19q Locus (SPG12) The SPG12 locus on 19q13 was first identified in a large Welsh family with ADHSP (80). Subsequent linkage studies narrowed the minimum candidate gene region to a 3.3-cM interval (81,82). In the original SPG12 family mean age at onset was seven years (ranging from 5 to 22) with typical ADHSP phenotype (5,80), whereas in a large SPG12-linked Italian family onset was later, around 14 years, and the phenotype was more severe. Most affected members developed rapidly progressive spastic paraplegia and required use of a wheelchair within four years after onset. As with other HSP subtypes, anticipation was suspected but not yet proven (82). Chromosome 2q Locus (SPG13) The SPG13 locus on 2q24-q34 was first reported in a large French family with ADHSP (83). Compared to SPG4, in the SPG13 family there were significantly more patients with increased reflexes in the upper limbs and with severe functional handicaps. A mutation in the gene encoding mitochondrial chaperonin Hsp60 (heat shock protein 60) was subsequently identified in affected members of the same family (84). Like other chaperonins, Hsp60 is involved in folding and assembly of proteins and is located in the mitochondrial matrix (85). The affected members of the SPG13 family carry the V72I Hsp60 mutation. When co-expressed with the co-chaperonin Hsp10, wild-type human Hsp60, but not the V72I mutant, can support growth of E. coli cells in which the homologous chaperonin genes have been deleted (84). The dominant inheritance in SPG13 may result from haploinsufficiency of Hsp60, especially under stress conditions, or from dominant-negative effects of the mutant on
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
241
the wild-type protein lowering the overall chaperonin activity. Thus, SPG13 can be defined as ‘‘chaperonopathy,’’ emphasizing the role of these proteins in the maintenance of long axons in the CNS. Chromosome 11q Locus (SPG17, Silver Syndrome) Silver first described two families with ADHSP and amyotrophy of the hands (86). Families with similar phenotypes were subsequently reported from different countries (10,87,88). Onset of symptoms varied widely from 8 to 63 years of age and some family members had very mild disease indicating a broad phenotypic variation (88). The typical HSP phenotype is characteristically combined with amyotrophy and weakness of intrinsic hand muscles, most marked in the thenar eminence, so that the disease in some families had been mistaken for amyotrophic lateral sclerosis (10). Nerve conduction velocities were normal or mildly reduced. The disease was linked to a new locus on 11q12-q14 in one of the original families reported by Silver (89). Another family with similar phenotype did not show linkage to 11q, indicating genetic heterogeneity (89). Subsequent linkage studies reduced the candidate gene interval (88) allowing the identification of heterozygous mutations in the BSCL2 gene (90). Eight related Austrian families with distal spinal muscular atrophy (DSMA-V) had the same mutation found in the Silver syndrome, establishing that these are allelic disorders. The BSCL2 gene contains 11 exons spanning at least 14 kb of DNA. It encodes a 398-amino-acid protein, seipin, with at least two hydrophobic amino acid stretches, which is highly expressed in the CNS and in testis (91). Seipin is a glycosylated integral membrane protein of the endoplasmic reticulum and the discovered mutations alter the N-glycosylation site causing aggregate formation (90). Homozygous null mutations of the same gene are associated with congenital lipodystrophy with severe insulin resistance (91), indicating an important role for this protein in diverse cellular functions. Other ADHSP Loci A complicated form of ADHSP in a large Italian pedigree has been linked to the SPG9 locus on chromosome 10q23.3-24.2. Age at onset varied from the first to third decade of life with evidence for anticipation. Spastic paraparesis was associated with gastroesophageal reflux causing persistent vomiting, distal muscle atrophy due to axonal motor neuropathy, and bilateral cataracts (92). Whether the almost identical phenotype of congenital cataracts and spastic paraparesis described previously in another pedigree proves to be associated with the SPG9 locus remains to be determined (93). Another ADHSP locus (SPG19) on 9q was found in an Italian family with typical HSP and onset from 36 to 55 years (94). Motor and sensory nerve conduction velocities obtained in some of the patients were slow in
Copyright 2006 by Taylor & Francis Group, LLC
242
Kleopa
the lower limbs. The disorder progressed slowly and was relatively benign, with only one patient confined to a wheelchair. Autosomal Recessive HSP Autosomal recessive HSP (ARHSP) is less common than the dominant form and includes both uncomplicated and complicated phenotypes. Multiple loci have been identified through linkage studies, often in single, consanguineous families, and some of the responsible genes have been discovered. Chromosome 16q Locus (SPG7) The SPG7 locus on chromosome 16q24.3 was first identified in a large consanguineous Italian family with ARHSP and onset between 25 and 42 years of age. Apart from the typical findings of pure HSP, dysarthria, dysphagia, and optic atrophy were present in some of the affected family members. Nerve conduction studies in one of the patients showed mild axonal neuropathy. All affected individuals were able to walk independently except for the oldest patient (95). Further studies showed that the SPG7 phenotype is heterogeneous with both pure and complicated forms (96,97). In affected individuals of the original SPG7 family a homozygous 9.5 kb deletion was identified in the gene that encodes paraplegin (96). The SPG7 gene is organized into 17 exons spanning approximately 52 kb (98). Screening of further unrelated ARHSP families for paraplegin mutations revealed additional deletion and insertion mutations leading to frameshift (96). However, paraplegin mutations appear to be an overall uncommon cause of HSP, found only in one of 30 English HSP families (99). Paraplegin is a member of the mitochondrial metalloproteases, a subgroup of the AAA protein family, which have both proteolytic and chaperonelike activities at the inner mitochondrial membrane (96). Analysis of muscle biopsies from patients with paraplegin mutations showed typical signs of mitochondrial oxidative phosphorylation defects, including COX-negative and ragged red fibres (96,99). Furthermore, the degree of mitochondrial abnormality correlated with the severity of the disease. Functional analysis at the cellular level showed that paraplegin co-assembles in the mitochondrial inner membrane with the homologous protein, AFG3L2, to form a high molecular mass complex. Loss of paraplegin in fibroblasts from SPG7 patients leads to reduced complex I activity in mitochondria and increased sensitivity to oxidative stress, which can be rescued by exogenous expression of wild-type paraplegin (100). Moreover, paraplegindeficient mice have abnormal mitochondria and impairment of axonal transport leading to distal axonal degeneration (101). Mitochondrial morphologic abnormalities in distal axonal regions occur prior to the first signs of axonal damage and correlate with onset of motor impairment. Axonal swellings result from massive accumulation of organelles and neurofilaments (101).
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
243
Thus, it appears that loss of paraplegin function causes mitochondrial dysfunction, resulting in failure of axonal transport and axonal degeneration (96,101). Chromosome 15q Locus (SPG11) A high percentage of families with recessive HSP have been linked to 15q13–15, the most common ARHSP locus (102). In SPG11-linked families age at onset ranges from the first to the fifth decade of life and the phenotype is variable with both uncomplicated and complicated forms. Some of the additional features reported include atrophy or agenesis of the corpus callosum, periventricular white matter changes demonstrated on MRI, mental retardation in one case, sensorimotor neuropathy in one family, and mild cerebellar dysfunction. The association of HSP with agenesis of the corpus callosum and mental retardation was initially reported in Japanese families that linked to 15q13–15, within the SPG11 locus (103,104) and subsequently in other countries (24,105,106). However, the SPG11 locus is distinct from the locus responsible for agenesis of the corpus callosum and peripheral neuropathy (ACCPN) syndrome. No mutations in the SLC12A6 gene that cause ACCPN could be found in an SPG11 family with thin corpus callosum (106). Some families with the SPG11 phenotype did not link to 15q134–15, suggesting further genetic heterogeneity (104,105). Chromosome 14q22 Locus (SPG15, Kjellin Syndrome) Following rare reports associating macular degeneration and spastic paraplegia, Kjellin reported in 1959 two pairs of brothers from two kindreds who had spastic paraplegia, distal amyotrophy of the hands, mental retardation, and central retinal degeneration (107). While mental retardation was present since birth in all patients, the onset of spastic paraplegia was in the third decade. Similar families were subsequently described with an earlier age of onset, mostly in the second decade, and additional features included sphincter disturbances, dysarthria, mild cerebellar ataxia, and further intellectual deterioration in the second decade (26,108). Two of the families linked to a new locus on 14q22-q24 (109), which is distinct from the SPG3 locus. Chromosome 13q Locus (SPG20, Troyer Syndrome) The combination of spastic paraplegia with distal muscle wasting, especially of the intrinsic hand muscles, was first described in an Ohio Amish group and was called the Troyer syndrome for the surname of many of the affected persons (110). The disorder was also described in a consanguineous Kuwaiti family (111). Onset was in early childhood with dysarthria, distal muscle wasting, difficulty in learning to walk, and in some patients drooling and mild cerebellar signs. Patients usually lost the ability to ambulate by the third or
Copyright 2006 by Taylor & Francis Group, LLC
244
Kleopa
fourth decade (110). Troyer syndrome was linked to 13q12.3 in the original Amish kindred. All affected individuals were homozygous for a frameshift mutation caused by a deletion of A at nucleotide 1110 in the SPG20 gene (112). SPG20 is ubiquitously expressed and encodes for spartin, a 666-amino acid protein of 72 kD that shares similarity with molecules involved in endosomal membrane trafficking and microtubule dynamics, including spastin (112,113). Chromosome 15q21 Locus (SPG21, Mast Syndrome) Mast syndrome is a complicated form of HSP associated with presenile dementia, also described in an Ohio Amish isolate (114). Onset is in the late teens or twenties with slow progression that may lead to akinetic mutism in the most severely affected patients. Developmental delay, motor difficulties, mild incoordination and awkward running, were sometimes noted in childhood (27). In contrast, other patients were perceived as relatively normal until early adulthood, before decline in walking and mental function was evident in the third to fifth decade of life. Thin corpus callosum and white matter abnormalities were found in the MRI (27). The Mast syndrome locus was mapped to 15q22.31 and a homozygous 1-bp insertion in the ACP33 gene was found in all affected patients. The encoded protein, maspardin, localizes to the endosomal trans-Golgi transportation vesicles and may play a role in protein transport and sorting (27). Chromosome 1q Locus (SPG23) A distinctive syndrome consisting of disordered skin and hair pigmentation, progressive spastic paraparesis beginning in childhood, and peripheral neuropathy was described in a Jordanian family. Sural nerve biopsy revealed axonal degeneration. Skin biopsy revealed abnormal epidermal pigmentation but skin fibroblast repair studies were normal and no biochemical defect was found (115,116). A similar phenotype was reported in a few sporadic cases and in a second consanguineous family with spastic paraparesis, muscle wasting, microcephaly, mental retardation, skeletal deformities, and cutaneous manifestations (117). Follow up of that family years later revealed prematurely aged facial appearance with greying of eyebrows and eyelashes. The disorder was linked to a new locus on 1q24-q32, designated SPG23 (118). Infantile Onset HSP Linked to Chromosome 2q33 Eymard-Pierre et al. (119) studied 15 patients from 10 families of different ethnic origins who presented with severe spastic paraparesis starting in the first two years of life with ascending progression to the upper limbs within the next few years. Despite progression to tetraplegia, anarthria, dysphagia, and slow eye movements in the first decade of life, the disease was compatible with long survival. Motor evoked potentials and magnetic resonance imaging
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
245
demonstrated dysfunction of the upper motor neurons, while lower motor neurons were not involved. Linkage analysis demonstrated that Infantile onset HSP (IAHSP) is allelic to juvenile amyotrophic lateral sclerosis at the ALS2 locus on 2q33-q35 and truncation mutations in the ALS2 gene encoding alsin were identified in 4 of the 10 IAHSP families (119). A 1-bp deletion in the ALS2 gene has also been identified in a large consanguineous Pakistani family with a similar phenotype (120). Mutations in regulatory ALS2 regions or genetic heterogeneity may account for the failure to find ALS2 mutation in other IAHSP families. Thus, ALS2 mutations may cause a spectrum of disorders ranging from early onset retrograde (IAHSP) or juvenile onset degeneration of the upper motor neurons with ALS2, or without (juvenile-onset primary lateral sclerosis, JPLS) lower motor neuron involvement. Other ARHSP Loci A locus for pure HSP on chromosome 8p12-q13 (SPG5) was discovered in four Tunisian families (121) and subsequently in families from other countries (122,123). Age at onset varied widely from 1 to 40 years. Further linkage studies narrowed the SPG5A interval, but mutations in several candidate genes were excluded (123). Three further ARHSP loci associated with complicated phenotypes were discovered in single families. The SPG14 locus on 3q27-28 was discovered in a consanguineous Italian family with HSP accompanied by bilateral pes cavus and mild mental retardation. Average age of onset was 30 years. There was evidence of distal motor neuropathy, while sural nerve biopsy in one patient was normal. All affected individuals were able to walk unaided (124). In a consanguineous Saudi Arabian family, five siblings presented at about one year of age when they started to stand with the tendency to walk on tiptoes, spasticity, scissoring gait, clonus, and hyperreflexia. This very early onset HSP was linked to 13q14 (SPG24) (125). Three of the affected and two unaffected individuals also had sensorineural deafness, which segregated as an independent trait. In another consanguineous Italian family four of eight siblings suffered multiple disc herniations presenting with spastic paraplegia, which improved partially after surgery (126). The susceptibility locus for disc herniation and spastic paraplegia was mapped to 6q22.31-24.1 (SPG25).
X-linked HSP Although X-linked HSP (XHSP) is rare, its molecular genetic basis was the first to be discovered in HSP and is relatively well understood. Three different loci have been identified including SPG1, SPG2, and SPG16. Complicated HSP occurs in all types, whereas the pure phenotype has only been linked to SPG2 and SPG16.
Copyright 2006 by Taylor & Francis Group, LLC
246
Kleopa
Xq28 Locus (SPG1) The syndrome of mental retardation, aphasia, shuffling gait, and adducted thumbs (MASA) affecting mostly boys was first described in a MexicanAmerican family (127). In addition, the patients had small body size, microcephaly, exaggerated lumbar lordosis, and hyperreflexia in the lower limbs. The absence of hydrocephalus distinguished the MASA syndrome from X-linked aqueductal stenosis. In similar patients, spastic paraparesis and MASA syndrome were reported as X-linked ‘‘complicated’’ spastic paraplegia type 1 and were linked to Xq28 (128). After the discovery that mutations in the L1 cell adhesion molecule (L1CAM) gene cause X-linked hydrocephalus (129), two different groups showed that mutations in the same gene are also responsible for XHSP (SPG1) and the MASA syndrome (130,131). These allelic disorders appear to form a clinical spectrum with both inter- and intrafamilial phenotypic variability. Affected members with various phenotypes may be found within one family. The L1CAM-related diseases are now referred to as being part of the clinical syndrome corpus callosum hypoplasia, retardation, adducted thumbs, spastic paraplegia, and hydrocephalus (CRASH). L1CAM is an integral membrane glycoprotein member of the immunoglobulin superfamily of cell adhesion molecules mediating cell-to-cell adhesion. It is expressed by neurons and Schwann cells (SC) and plays an essential role in axon outgrowth, myelination and path finding (132). In a mouse model of the CRASH syndrome mutant mice are smaller and less sensitive to touch and pain than wild-type mice. Their hind legs appear weak and uncoordinated, the size of the corticospinal tract is reduced, and the lateral ventricles are often enlarged. Ensheathment of axons is impaired (133). Xq22 Locus (SPG2) X-linked recessive HSP was described in a family, in which the disorder began as ‘‘pure’’ spastic paraparesis, but the patients later developed nystagmus, dysarthria, sensory disturbance, mental retardation, optic atrophy in half of the cases, muscle wasting, and joint contractures, resulting in wheelchair dependency by early adult life (134). Subsequent reports of XHSP included both uncomplicated (135) and ‘‘complicated’’ phenotypes (136), which may even coexist within the same family (137). Linkage studies demonstrated mapping of the SPG2 locus on Xq21 (135–137). Disease causing mutations were found in the proteolipid protein (PLP) gene, confirming that SPG2 and Pelizaeus–Merzbacher disease (PMD), a severe dysmyelinating disease of the CNS, are allelic disorders (138,139). Several PLP mutations have been identified in both ‘‘complicated’’ and pure HSP pedigrees (138–141). Clinical severity correlates with the nature of the mutation and there seems to be a spectrum ranging from pure HSP to severe connatal PMD, with all variations in between.
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
247
The PLP gene encodes two major myelin proteins, DM-20 and PLP, which differ by alternative splicing of exon 3, whose distal end is retained in the mature PLP but not in DM-20 (142). DM-20 is expressed before PLP during development and may play a role in oligodendrocyte maturation (143), while PLP is expressed later and is crucial to myelin sheet compaction (138). The PLP mutation found in SPG2 patients (139) is identical to the mutation identified in the ‘‘rumpshaker’’ mice (144), which, although myelin-deficient, have normal longevity and morphologically normal oligodendrocytes. They show a generalized tremor at about 12 days of age, which then becomes confined to the rear end. In contrast, ‘‘jimpy’’ mice resemble the PMD phenotype and show failure of development and differentiation of oligodendrocytes leading to early death. The jimpy mutation as well as subsequently identified lethal PLP mutations result in truncation of the fourth transmembrane domain in both the PLP and DM-20 (142). They cause increased oligodendrocyte cell death, perhaps due to toxic gain of function effect of misfolded PLP products retained in the endoplasmic reticulum (145). As in the mutant mice, it appears that human mutations altering the structure of both PLP and DM-20 cause different forms of PMD, whereby toxic gain of function mutants are associated with the most severe, connatal PMD phenotypes (146). In contrast, PLP-specific mutations, which leave DM-20 intact, cause SPG2 (138,141). Other XHSP Loci A family with severe XHSP has been reported, in which the patients presented with quadriplegia, motor aphasia, reduced vision, mild mental retardation, and dysfunction of the bowel and bladder. Onset was in the first three months of life with nystagmus and dorsal flexion of the great toes. Motor development was delayed, and spasticity progressed from the lower to the upper extremities. The patients never learned to walk (147). In this and in another pedigree with pure HSP, the disease was linked to Xq11.2 (148). However, mutation analysis on the PLP gene was negative, suggesting the existence of a third XHSP locus (SPG16). An insertion of nucleolus organizer region (NOR) into Xq11.2 was found in a Japanese family with pure HSP, perhaps disrupting the putative HSP gene situated at Xq11.2 (149). DIAGNOSTIC APPROACH AND TREATMENT IN HSP Before making the diagnosis of HSP, either pure or complicated, other inherited disorders should be considered, in which lower extremity spastic weakness is a prominent feature (2). These include inherited leukodystrophies, Friedreich ataxia, Machado–Joseph disease, familial Alzheimer’s disease, familial motor neuron disease, and dopa-responsive dystonia, which are discussed in other chapters of this book. Furthermore, several forms of inherited spastic ataxia (SAX) including SAX1 (150), spastic paraplegia, ataxia, mental retardation
Copyright 2006 by Taylor & Francis Group, LLC
248
Kleopa
(SPAR) (151), AR spastic ataxia of Charlevoix-Saguenay (ARSACS) (152), as well as the Sjogren–Larsson and Fitzsimmons syndromes may be considered, the discussion of which is beyond the scope of this review. Acquired disorders that are potentially treatable may also mimic HSP. Among others, one should exclude multiple sclerosis, tropical spastic paraparesis, neurosyphilis, AIDS, vitamin B12 or E deficiency, and structural spinal cord disorders such as Arnold-Chiari malformation, neoplasms, compression, and arteriovenous malformation. Although useful in excluding alternative diagnoses, laboratory investigations add little to the clinical diagnosis of HSP. Central motor responses are usually delayed or absent from the lower limbs, with normal values from the upper limbs (2,4,19). Somatosensory evoked potentials from the lower limbs may also be small or absent, while nerve conduction studies and EMG are normal in most cases (1,9,19). MRI may exclude focal or diffuse white matter disease, and in some patients with HSP it may show atrophy of the spinal cord and occasionally of the corpus callosum (75,153). Thus, the diagnosis of HSP is based on clinical features (including inheritance pattern and the ‘‘complicated’’ vs. uncomplicated phenotype) in conjunction with exclusion of other disorders. With the discovery of multiple causative genes, molecular genetic testing is now available for HSP. A limited number of clinical laboratories (listed in www.genetests.org) may currently test for mutations in L1CAM, PLP, SPG3A, SPAST (SPG4), NIPA1, SPG7, and SPG20. Prenatal diagnosis is possible for SPG1, SPG2 and SPG7. Thus, molecular genetic diagnosis is possible in over 50% of families with ADHSP but in a fewer number of patients with ARHSP (5,38,39). Research laboratories may sequence additional HSP genes. However, with the number of potential genes to be assessed, it is important to obtain a detailed family history to stratify the molecular diagnostic approach. Treatment for HSP patients is currently symptomatic. Regular physiotherapy should be offered to prevent contractures and improve mobility. Orthopaedic interventions and/or assistive devices may maximize function. Medications that treat spasticity include oral baclofen, dantrolene, tizanidine, as well as intrathecal baclofen in severe cases. Bladder spasticity may improve with oxybutynin. The Spastic Paraplegia Foundation offers resources for patient information and support (http://sp-foundation.org/). CONCLUSION The emerging neurobiological complexity underlying HSP provides the basis for the clinical and genetic heterogeneity. A growing number of different disorders classified as pure or ‘‘complicated’’ HSP share final common pathways of impaired cellular trafficking dynamics and axonal transport. HSP genes encode for proteins that play an essential role in CNS myelination and
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
249
development (PLP/DM20, L1CAM), in mitochondrial function (paraplegin, HSP60), in chaperon and protein trafficking related activities (spastin, atlastin, paraplegin, HSP60, BSCL2, spartin, maspardin, and alsin), and in axonal transport (KIF5A). Dysfunction of these genes leads to the characteristic clinical and neuropathological findings of length-dependent degeneration that is predominant in, but not limited to the motor axons in the CNS. The increasing knowledge of the molecular mechanisms underlying HSP is expected to open the way for the development of effective treatments in the future.
REFERENCES 1. Harding AE. Hereditary ‘‘pure’’ spastic paraplegia: a clinical and genetic study of 22 families. J Neurol Neurosurg Psychiatry 1981; 44:871–883. 2. McDermott C, White K, Bushby K, Shaw P. Hereditary spastic paraparesis: a review of new developments. J Neurol Neurosurg Psychiatry 2000; 69:150–160. 3. Durr A, Brice A, Serdaru M, Rancurel G, Derouesne C, Lyon-Caen O, Agid Y, Fontaine B. The phenotype of ‘‘pure’’ autosomal dominant spastic paraplegia. Neurology 1994; 44:1274–1277. 4. Nielsen JE, Krabbe K, Jennum P, Koefoed P, Jensen LN, Fenger K, Eiberg H, Hasholt L, Werdelin L, Sorensen SA. Autosomal dominant pure spastic paraplegia: a clinical, paraclinical, and genetic study. J Neurol Neurosurg Psychiatry 1998; 64:61–66. 5. Reid E, Grayson C, Rogers M, Rubinsztein D. Locus-phenotype correlations in autosomal dominant pure hereditary spastic paraplegia. A clinical and molecular genetic study of 28 United Kingdom families. Brain 1999; 122:1741–1755. 6. Santorelli FM, Patrono C, Fortini D, Tessa A, Comanducci G, Bertini E, Pierallini A, Amabile GA, Casali C. Intrafamilial variability in hereditary spastic paraplegia associated with an SPG4 gene mutation. Neurology 2000; 55:702–705. 7. Tessa A, Casali C, Damiano M, Bruno C, Fortini D, Patrono C, Cricchi F, Valoppi M, Nappi G, Amabile GA, Bertini E, Santorelli FM. SPG3A: An additional family carrying a new atlastin mutation. Neurology 2002; 59:2002–2005. 8. McMonagle P, Webb S, Hutchinson M. The prevalence of ‘‘pure’’ autosomal dominant hereditary spastic paraparesis in the island of Ireland. J Neurol Neurosurg Psychiatry 2002; 72:43–46. 9. Schady W, Sheard A. A quantitative study of sensory function in hereditary spastic paraplegia. Brain 1990; 113:709–720. 10. Bruyn RP, Scheltens P, Lycklama a Nijeholt J, de Jong JM. Autosomal recessive paraparesis with amyotrophy of the hands and feet. Acta Neurol Scand 1993; 87:443–445. 11. Bruyn RPM, van Dijk JG. Clinically silent dysfunction of dorsal columns and dorsal spinocerebellar tracts in hereditary spastic paraparesis. J Neurol Sci 1994; 125:206–211. 12. Cartlidge NEF, Bone G. Sphincter involvement in hereditary spastic paraplegia. Neurology 1973; 23:1160–1163.
Copyright 2006 by Taylor & Francis Group, LLC
250
Kleopa
13. Schwarz GA, Liu CN. Hereditary (familial) spastic paraplegia; further clinical and pathologic observations. AMA Arch Neurol Psychiatry 1956; 75:144–162. 14. Boustany RM, Fleishnick E, Alper CA, Marazita ML, Spence MA, Martin JB, Kolodny EH. The autosomal dominant form of pure familial spastic paraplegia: clinical findings and linkage analysis of a large pedigree. Neurology 1987; 37:910–915. 15. Webb S, Flanagan N, Callaghan N, Hutchinson M. A family with hereditary spastic paraparesis and epilepsy. Epilepsia 1997; 38:495–499. 16. Heinzlef O, Paternotte C, Mahieux F, Prud’homme JF, Dien J, Madigand M, Pouget J, Weissenbach J, Roullet E, Hazan J. Mapping of a complicated familial spastic paraplegia to locus SPG4 on chromosome 2p. J Med Genet 1998; 35:89–93. 17. Sommerfelt K, Kyllerman M, Sanner G. Hereditary spastic paraplegia with epileptic myoclonus. Acta Neurol Scand 1991; 84:157–160. 18. Mead SH, Proukakis C, Wood N, Crosby AH, Plant G, Warner TT. A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members. J Neurol Neurosurg Psychiatry 2001; 71:788–791. 19. Schulte T, Miterski B, Bornke C, Przuntek H, Epplen JT, Schols L. Neurophysiological findings in SPG4 patients differ from other types of spastic paraplegia. Neurology 2003; 60:1529–1532. 20. Schady W, Smith CM. Sensory neuropathy in hereditary spastic paraplegia. J Neurol Neurosurg Psychiatry 1994; 57:693–698. 21. Cavanagh NPC, Eames RA, Galvin RJ, Brett EM, Kelly RE. Hereditary sensory neuropathy with spastic paraplegia. Brain 1979; 102:79–94. 22. Dillmann U, Heide G, Dietz B, Teshmar E, Schimrigk K. Hereditary motor and sensory neuropathy with spastic paraplegia and optic atrophy: report on a family. J Neurol 1997; 244:562–565. 23. Miyama S, Arimoto K, Kimiya S, Tomi H. Complicated hereditary spastic paraplegia with peripheral neuropathy, optic atrophy and mental retardation. Neuropediatrics 2000; 31:214–217. 24. Coutinho P, Barros J, et al. Clinical heterogeneity of autosomal recessive spastic paraplegias: analysis of 106 patients in 46 families. Arch Neurol 1999; 56:943–949. 25. Webb S, Coleman D, Byrne P, Parfrey N, Burke T, Hutchinson J, Hutchinson M. Autosomal dominant hereditary spastic paraparesis with cognitive loss linked to chromosome 2p. Brain 1998; 121:601–609. 26. Webb S, Patterson V, Hutchinson M. Two families with autosomal recessive spastic paraplegia, pigmented maculopathy, and dementia. J Neurol Neurosurg Psychiatry 1997; 63:628–632. 27. Simpson MA, Cross H, Proukakis C, Pryde A, Hershberger R, Chatonnet A, Patton MA, Crosby AH. Maspardin is mutated in Mast syndrome, a complicated form of hereditary spastic paraplegia associated with dementia. Am J Hum Genet 2003; 73:1147–1156. 28. Ueda M, Katayama Y, Kamiya T, Mishina M, Igarashi H, Okubo S, Senda M, Iwabuchi K, Terashi A. Hereditary spastic paraplegia with a thin corpus callosum and thalamic involvement in Japan. Neurology 1998; 51:1751–1754.
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
251
29. McMonagle P, Byrne P, Hutchinson M. Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia. Neurology 2004; 62:407–410. 30. Tallaksen CM, Guichart-Gomez E, Verpillat P, Hahn-Barma V, Ruberg M, Fontaine B, Brice A, Dubois B, Durr A. Subtle cognitive impairment but no dementia in patients with spastin mutations. Arch Neurol 2003; 60: 1113–1118. 31. Byrne PC, Mc Monagle P, Webb S, Fitzgerald B, Parfrey NA, Hutchinson M. Age-related cognitive decline in hereditary spastic paraparesis linked to chromosome 2p. Neurology 2000; 54:1510–1517. 32. White KD, Ince PG, Lusher M, Lindsey J, Cookson M, Bashir R, Shaw PJ, Bushby KM. Clinical and pathologic findings in hereditary spastic paraparesis with spastin mutation. Neurology 2000; 55:89–94. 33. Tedeschi G, Allocca S, Di Costanzo A, Carlomagno S, Merla F, Petretta V, Toriello A, Tranchino G, Ambrosio G, Bonavita V. Multisystem involvement of the central nervous system in Strumpell’s disease. A neurophysiological and neuropsychological study. J Neurol Sci 1991; 103:55–60. 34. Bruyn RP. The neuropathology of hereditary spastic paraparesis. Clin Neurol Neurosurg 1992; 94(suppl):S16–18. 35. Fink JK, Heiman-Patterson T, et al. Hereditary spastic paraplegia: Advances in genetic research. Neurology 1996; 46:1507–1514. 36. Hazan J, Fontaine B, et al. Linkage of a new locus for autosomal dominant familial spastic paraplegia to chromosome 2p. Hum Mol Genet 1994; 3:1569–1573. 37. Hentati A, Pericak-Vance MA, Lennon F, Wasserman B, Hentati F, Juneja T, Angrist MH, Hung WY, Boustany RM, Bohlega S, Iqbal Z, Huether CH, Ben Hamida M, Siddique T. Linkage of a locus for autosomal dominant familial spastic paraplegia to chromosome 2p markers. Hum Mol Genet 1994; 3: 1867–1871. 38. Fink JK. Advances in the hereditary spastic paraplegias. Exp Neurol 2003; 184(suppl 1):S106–110. 39. Proukakis C, Auer-Grumbach M, Wagner K, Wilkinson PA, Reid E, Patton MA, Warner TT, Crosby AH. Screening of patients with hereditary spastic paraplegia reveals seven novel mutations in the SPG4 (Spastin) gene. Hum Mutat 2003; 21:170. 40. Hazan J, Fonknechten N, et al. Spastin, a new AAA protein, is altered in the most frequent form of autosomal dominant spastic paraplegia. Nat Genet 1999; 23:296–303. 41. Charvin D, Cifuentes-Diaz C, Fonknechten N, Joshi V, Hazan J, Melki J, Betuing S. Mutations of SPG4 are responsible for a loss of function of spastin, an abundant neuronal protein localized in the nucleus. Hum Mol Genet 2003; 12:71–78. 42. Patel S, Latterich M. The AAA team: related ATPases with diverse functions. Trends Cell Biol 1998; 8:65–71. 43. Hentati A, Deng HX, et al. Novel mutations in spastin gene and absence of correlation with age at onset of symptoms. Neurology 2000; 55:1388–1390.
Copyright 2006 by Taylor & Francis Group, LLC
252
Kleopa
44. Lindsey JC, Lusher ME, McDermott CJ, White KD, Reid E, Rubinsztein DC, Bashir R, Hazan J, Shaw PJ, Bushby KM. Mutation analysis of the spastin gene (SPG4) in patients with hereditary spastic paraparesis. J Med Genet 2000; 37:759–765. 45. Fonknechten N, Mavel D, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet 2000; 9:637–644. 46. Meijer IA, Hand CK, Cossette P, Figlewicz DA, Rouleau GA. Spectrum of SPG4 mutations in a large collection of North American families with hereditary spastic paraplegia. Arch Neurol 2002; 59:281–286. 47. Patrono C, Casali C, Tessa A, Cricchi F, Fortini D, Carrozzo R, Siciliano G, Bertini E, Santorelli FM. Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. J Neurol 2002; 249:200–205. 48. Svenson IK, Ashley-Koch AE, et al. Identification and expression analysis of spastin gene mutations in hereditary spastic paraplegia. Am J Hum Genet 2001; 68:1077–1085. 49. Molon A, Montagna P, Angelini C, Pegoraro E. Novel spastin mutations and their expression analysis in two Italian families. Eur J Hum Genet 2003; 11: 710–713. 50. Tallaksen CM, Durr A, Brice A. Recent advances in hereditary spastic paraplegia. Curr Opin Neurol 2001; 14:457–463. 51. Bonsch D, Schwindt A, Navratil P, Palm D, Neumann C, Klimpe S, Schickel J, Hazan J, Weiller C, Deufel T, Liepert J. Motor system abnormalities in hereditary spastic paraparesis type 4 (SPG4) depend on the type of mutation in the spastin gene. J Neurol Neurosurg Psychiatry 2003; 74:1109–1112. 52. McDermott CJ, Grierson AJ, Wood JD, Bingley M, Wharton SB, Bushby KM, Shaw PJ. Hereditary spastic paraparesis: disrupted intracellular transport associated with spastin mutation. Ann Neurol 2003; 54:748–759. 53. Errico A, Ballabio A, Rugarli EI. Spastin, the protein mutated in autosomal dominant hereditary spastic paraplegia, is involved in microtubule dynamics. Hum Mol Genet 2002; 11:153–163. 54. McDermott CJ, Taylor RW, Hayes C, Johnson M, Bushby KM, Turnbull DM, Shaw PJ. Investigation of mitochondrial function in hereditary spastic paraparesis. Neuroreport 2003; 14:485–488. 55. Hazan J, Lamy C, Melki J, Munnich A, de Recondo J, Weissenbach J. Autosomal dominant familial spastic paraplegia is genetically heterogeneous and one locus maps to chromosome 14q. Nat Genet 1993; 5:163–167. 56. Huang S, Zhuyu, Li H, Labu, Baizhu, Lo WHY, Fischer C, Vogel F. Another pedigree with pure autosomal dominant spastic paraplegia (AD-FSP) from Tibet mapping to 14q11.2-q24.3. Hum Genet 1997; 100:620–623. 57. Gispert S, Santos N, Damen R, Voit T, Schulz J, Klockgether T, Orozco G, Kreuz F, Weissenbach J, Auburger G. Autosomal dominant familial spastic paraplegia: reduction of the FSP1 candidate region on chromosome 14q to 7 cM and locus heterogeneity. Am J Hum Genet 1995; 56:183–187. 58. Rainier S, Hedera P, Alvarado D, Zhao X, Kleopa KA, Heiman–Patterson T, Fink JK. Hereditary spastic paraplegia linked to chromosome 14q11-q21: reduction of the SPG3 locus interval from 5.3 to 2.7 cM. J Med Genet 2001; 38:E39.
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
253
59. Muglia M, Magariello A, et al. Further evidence that SPG3A gene mutations cause autosomal dominant hereditary spastic paraplegia. Ann Neurol 2002; 51:794–795. 60. Dalpozzo F, Rossetto MG, Boaretto F, Sartori E, Mostacciuolo ML, Daga A, Bassi MT, Martinuzzi A. Infancy onset hereditary spastic paraplegia associated with a novel atlastin mutation. Neurology 2003; 61:580–581. 61. Zhao X, Alvarado D, Rainier S, Lemons R, Hedera P, Weber CH, Tukel T, Apak M, Heiman-Patterson T, Ming L, et al. Mutations in a newly identified GTPase gene cause autosomal dominant hereditary spastic paraplegia. Nat Genet 2001; 29:326–331. 62. McNiven MA, Cao H, Pitts KR, Yoon Y. The dynamin family of mechanoenzymes: pinching in new places. Trends Biol Sci 2000; 25:115–120. 63. Jones SM, Howell KE, Henley JR, Cao H, McNiven MA. Role of dynamin in the formation of transport vesicles from the trans-Golgi network. Science 1998; 279:573–577. 64. Cao H, Thompson HM, Krueger EW, McNiven MA. Disruption of Golgi structure and function in mammalian cells expressing a mutant dynamin. J Cell Sci 2000; 113:1993–2002. 65. Zhu PP, Patterson A, Lavoie B, Stadler J, Shoeb M, Patel R, Blackstone C. Cellular localization, oligomerization, and membrane association of the hereditary spastic paraplegia 3A (SPG3A) protein atlastin. J Biol Chem 2003; 278:49,063–49,071. 66. Jareb M, Banker G. Inhibition of axonal growth by brefeldin A in hippocampal neurons in culture. J Neurosci 1997; 17:8955–8963. 67. Wilkinson PA, Hart PE, Patel H, Warner TT, Crosby AH. SPG3A mutation screening in English families with early onset autosomal dominant hereditary spastic paraplegia. J Neurol Sci 2003; 216:43–45. 68. Sauter SM, Engel W, Neumann LM, Kunze J, Neesen J. Novel mutations in the Atlastin gene (SPG3A) in families with autosomal dominant hereditary spastic paraplegia and evidence for late onset forms of HSP linked to the SPG3A locus. Hum Mutat 2004; 23:98. 69. Fink JK, Wu CB, Jones SM, Sharp GB, Lange BM, Lesicki A, Reinglass T, Varvil T, Otterud B, Leppert M. Autosomal dominant familial spastic paraplegia: tight linkage to chromosome 15q. Am J Hum Genet 1995; 56:188–192. 70. Rainier S, Chai J-H, Tokarz D, Nicholls RD, Fink JK. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6). Am J Hum Genet 2003; 73:967–971. 71. Chai J-H, Locke DP, Greally JM, Knoll JHM, Ohta T, Dunai J, Yavor A, Eichler EE, Nicholls RD. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons. Am J Hum Genet 2003; 73:898–925. 72. Hedera P, Rainier S, Alvarado D, Zhao X, Williamson J, Otterud B, Leppert M, Fink JK. Novel locus for autosomal dominant hereditary spastic paraplegia, on chromosome 8q. Am J Hum Genet 1999; 64:563–569. 73. Reid E, Dearlove AM, Whiteford ML, Rhodes M, Rubinsztein DC. Autosomal dominant spastic paraplegia: refined SPG8 locus and additional genetic heterogeneity. Neurology 1999; 53:1844–1849.
Copyright 2006 by Taylor & Francis Group, LLC
254
Kleopa
74. Rocco P, Vainzof M, Froehner SC, Peters MF, Marie SKN, Passos-Bueno MR, Zatz M. Brazilian family with pure autosomal dominant spastic paraplegia maps to 8q: analysis of muscle beta 1 syntrophin. Am J Med Genet 2000; 92:122–127. 75. Hedera P, DiMauro S, Bonilla E, Wald J, Eldevik OP, Fink JP. Phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q. Neurology 1999; 53:44–50. 76. Reid E, Dearlove AM, Rhodes M, Rubinsztein DC. A new locus for autosomal dominant ‘pure’ hereditary spastic paraplegia mapping to chromosome 12q13, and evidence for further genetic heterogeneity. Am J Hum Genet 1999; 65: 757–763. 77. Reid E, Kloos M, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am J Hum Genet 2002; 71:1189–1194. 78. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998; 279:519–526. 79. Xia CH, Roberts EA, Her LS, Liu X, Williams DS, Cleveland DW, Goldstein LS. Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavy chain KIF5A. J Cell Biol 2003; 161:55–66. 80. Reid E, Dearlove AM, Osborn O, Rogers MT, Rubinsztein DC. A locus for autosomal dominant ‘‘pure’’ hereditary spastic paraplegia maps to chromosome 19q13. Am J Hum Genet 2000; 66:728–732. 81. Ashley-Koch A, Bonner ER, et al. Fine mapping and genetic heterogeneity in the pure form of autosomal dominant familial spastic paraplegia. Neurogenetics 2001; 3:91–97. 82. Orlacchio A, Kawarai T, Rogaeva E, Song YQ, Paterson AD, Bernardi G, St. George-Hyslop PH. Clinical and genetic study of a large Italian family linked to SPG12 locus. Neurology 2002; 59:1395–1401. 83. Fontaine B, Davoine C-S, Durr A, Paternotte C, Feki I, Weissenbach J, Hazan J, Brice A. A new locus for autosomal dominant pure spastic paraplegia, on chromosome 2q24-q34. Am J Hum Genet 2000; 66:702–707. 84. Hansen JJ, Durr A, Cournu-Rebeix I, Georgopoulos C, Ang D, Nielsen MN, Davoine C-S, Brice A, Fontaine B, Gregersen N, Bross P. Hereditary spastic paraplegia SPG13 is associated with a mutation in the gene encoding the mitochondrial chaperonin Hsp60. Am J Hum Genet 2002; 70:1328–1332. 85. Slavotinek A, Biesecker L. Unfolding the role of chaperones and chaperonins in human disease. Trends Genet 2001; 17:528–535. 86. Silver JR. Familial spastic paraplegia with amyotrophy of the hands. J Neurol Neurosurg Psychiat 1966; 29:135–144. 87. van Gent EM, Hoogland RA, Jennekens FG. Distal amyotrophy of predominantly the upper limbs with pyramidal features in a large kinship. J Neurol Neurosurg Psychiatry 1985; 48:266–269. 88. Windpassinger C, Wagner K, Petek E, Fischer R, Auer-Grumbach M. Refinement of the ‘‘Silver syndrome locus’’ on chromosome 11q12-q14 in four families and exclusion of eight candidate genes. Hum Genet 2003; 114:99–109. 89. Patel H, Hart PE, Warner TT, Houlston RS, Patton MA, Jeffery S, Crosby AH. The Silver syndrome variant of hereditary spastic paraplegia maps to
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
255
chromosome 11q12-q14, with evidence for genetic heterogeneity within this subtype. Am J Hum Genet 2001; 69:209–215. Windpassinger C, Auer-Grumbach M, et al. Heterozygous missense mutations in BSCL2 are associated with distal hereditary motor neuropathy and Silver syndrome. Nat Genet 2004; 36:271–276. Magre J, Delepine M, Khallouf E, Gedde-Dahl T, Jr., Van Maldergem L, Sobel E, Papp J, Meier M, Megarbane A, Lathrop M, Capeau J. Identification of the gene altered in Berardinelli-Seip congenital lipodystrophy on chromosome 11q13. Nat Genet 2001; 28:365–370. Seri M, Cusano R, Forabosco P, Cinti R, Caroli F, Picco P, Bini R, Morra VB, De Michele G, Lerone M, Silengo M, Pela I, Borrone C, Romeo G, Devoto M. Genetic mapping to 10q23.3-q24.2, in a large Italian pedigree, of a new syndrome showing bilateral cataracts, gastroesophageal reflux, and spastic paraparesis with amyotrophy. Am J Hum Genet 1999; 64:586–593. Slavotinek AM, Pike M, Mills K, Hurst JA. Cataracts, motor system disorder, short stature, learning difficulties, and skeletal abnormalities: a new syndrome? Am J Med Genet 1996; 62:42–47. Valente EM, Brancati F, Caputo V, Bertini E, Patrono C, Costanti D, Dallapiccola B. Novel locus for autosomal dominant pure hereditary spastic paraplegia (SPG19) maps to chromosome 9q33-q34. Ann Neurol 2002; 51: 681–685. De Michele G, De Fusco M, Cavalcanti F, Filla A, Marconi R, Volpe G, Monticelli A, Ballabio A, Casari G, Cocozza S. A new locus for autosomal recessive hereditary spastic paraplegia maps to chromosome 16q24.3. Am J Hum Genet 1998; 63:135–139. Casari G, De Fusco M, et al. Spastic paraplegia and OXPHOS impairment caused by mutations in paraplegin, a nuclear-encoded mitochondrial metalloprotease. Cell 1998; 93:973–983. Wilkinson PA, Crosby AH, Turner C, Bradley LJ, Ginsberg L, Wood NW, Schapira AH, Warner TT. A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia. Brain 2004; 127:973–980. Settasatian C, Whitmore SA, Crawford J, Bilton RL, Cleton-Jansen A-M, Sutherland GR, Callen DF. Genomic structure and expression analysis of the spastic paraplegia gene, SPG7. Hum Genet 1999; 105:139–144. McDermott CJ, Dayaratne RK, Tomkins J, Lusher ME, Lindsey JC, Johnson MA, Casari G, Turnbull DM, Bushby K, Shaw PJ. Paraplegin gene analysis in hereditary spastic paraparesis (HSP) pedigrees in northeast England. Neurology 2001; 56:467–471. Atorino L, Silvestri L, Koppen M, Cassina L, Ballabio A, Marconi R, Langer T, Casari G. Loss of m–AAA protease in mitochondria causes complex I deficiency and increased sensitivity to oxidative stress in hereditary spastic paraplegia. J Cell Biol 2003; 163:777–787. Ferreirinha F, Quattrini A, Pirozzi M, Valsecchi V, Dina G, Broccoli V, Auricchio A, Piemonte F, Tozzi G, Gaeta L, Casari G, Ballabio A, Rugarli EI. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J Clin Invest 2004; 113:231–242.
Copyright 2006 by Taylor & Francis Group, LLC
256
Kleopa
102. Martinez-Murillo F, Kobayashi H, Pegoraro E, Galuzzi G, Creel G, Mariani C, Faina E, Ricci E, Alfonso G, Pauli RM, Hoffman EP. Genetic localization of a new locus for recessive familial spastic paraparesis to 15q13–15. Neurology 1999; 53:50–56. 103. Nakamura A, Izumi K, Umehara F, Kuriyama M, Hokezu Y, Nakagawa M, Shimmyozu K, Izumo S, Osame M. Familial spastic paraplegia with mental impairment and thin corpus callosum. J Neurol Sci 1995; 131:35–42. 104. Shibasaki Y, Tanaka H, et al. Linkage of autosomal recessive hereditary spastic paraplegia with mental impairment and thin corpus callosum to chromosome15q13–15. Ann Neurol 2000; 48:108–112. 105. Casali C, Valente EM, et al. Clinical and genetic studies in hereditary spastic paraplegia with thin corpus callosum. Neurology 2004; 62:262–268. 106. Winner B, Uyanik G, Gross C, Lange M, Schulte-Mattler W, Schuierer G, Marienhagen J, Hehr U, Winkler J. Clinical progression and genetic analysis in hereditary spastic paraplegia with thin corpus callosum in spastic gait gene 11 (SPG11). Arch Neurol 2004; 61:117–121. 107. Kjellin K. Familial spastic paraplegia with amyotrophy, oligophrenia, and central retinal degeneration. Arch Neurol 1959; 1:133–140. 108. Mahloudji M, Chuke PO. Familial spastic paraplegia with retinal degeneration. Johns Hopkins Med J 1968; 123:142–144. 109. Hughes CA, Byrne PC, Webb S, McMonagle P, Patterson V, Hutchinson M, Parfrey NA. SPG15, a new locus for autosomal recessive complicated HSP on chromosome 14q. Neurology 2001; 56:1230–1233. 110. Cross HE, McKusick VA. The Troyer syndrome: a recessive form of spastic paraplegia with distal muscle wasting. Arch Neurol 1967; 16:473–485. 111. Farag TI, El-Badramany MH, Al-Sharkawy S. Troyer syndrome: report of the first ‘‘non-Amish’’ sibship and review. Am J Med Genet 1994; 53:383–385. 112. Patel H, Cross H, Proukakis C, Hershberger R, Bork P, Ciccarelli FD, Patton MA, McKusick VA, Crosby AH. SPG20 is mutated in Troyer syndrome, an hereditary spastic paraplegia. Nat Genet 2002; 31:347–348. 113. Ciccarelli FD, Proukakis C, Patel H, Cross H, Azam S, Patton MA, Bork P, Crosby AH. The identification of a conserved domain in both spartin and spastin, mutated in hereditary spastic paraplegia. Genomics 2003; 81:437–441. 114. Cross HE, McKusick VA. The Mast syndrome: a recessively inherited form of presenile dementia with motor disturbances. Arch Neurol 1967; 16:1–13. 115. Abdallat A, Davis SM, Farrage J, McDonald WI. Disordered pigmentation, spastic paraparesis and peripheral neuropathy in three siblings: a new neurocutaneous syndrome. J Neurol Neurosurg Psychiatry 1980; 43:962–966. 116. Lison M, Kornbrut B, Feinstein A, Hiss Y, Boichis H, Goodman RM. ?Progressive spastic paraparesis, vitiligo, premature graying, and distinct facial appearance: a new genetic syndrome in 3 sibs. Am J Med Genet 1981; 9:351–357. 117. Mukamel M, Weitz R, Metzker A, Varsano I. Spastic paraparesis, mental retardation, and cutaneous pigmentation disorder: a new syndrome. Am J Dis Child 1985; 139:1090–1092. 118. Blumen SC, Bevan S, Abu-Mouch S, Negus D, Kahana M, Inzelberg R, Mazarib A, Mahamid A, Carasso RL, Slor H, Withers D, Nisipeanu P,
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
119.
120.
121.
122.
123.
124.
125.
126.
127. 128.
129.
130. 131.
132.
257
Navon R, Reid E. A locus for complicated hereditary spastic paraplegia maps to chromosome 1q24-q32. Ann Neurol 2003; 54:796–803. Eymard-Pierre E, Lesca G, Dollet S, Santorelli FM, di Capua M, Bertini E, Boespflug-Tanguy O. Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene. Am J Hum Genet 2002; 71: 518–527. Gros-Louis F, Meijer IA, Hand CK, Dube M-P, MacGregor DL, Seni M-H, Devon RS, Hayden MR, Andermann F, Andermann E, Rouleau GA. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann Neurol 2003; 53:144–145. Hentati A, Pericak-Vance MA, Hung W-Y, Belal S, Laing N, Boustany R-M, Hentati F, Ben Hamida M, Siddique T. Linkage of ‘pure’ autosomal recessive familial spastic paraplegia to chromosome 8 markers and evidence of genetic locus heterogeneity. Hum Mol Genet 1994; 3:1263–1267. Wilkinson PA, Crosby AH, Turner C, Patel H, Wood NW, Schapira AH, Warner TT. A clinical and genetic study of SPG5A linked to autosomal recessive hereditary spastic paraplegia. Neurology 2003; 61:235–238. Muglia M, Criscuolo C, et al. Narrowing of the critical region in autosomal recessive spastic paraplegia linked to the SPG5 locus. Neurogenetics 2004; 5: 49–54. Vazza G, Zortea M, Boaretto F, Micaglio GF, Sartori V, Mostacciuolo ML. A new locus for autosomal recessive spastic paraplegia associated with mental retardation and distal motor neuropathy, SPG14, maps to chromosome 3q27-q28. Am J Hum Genet 2000; 67:504–509. Hodgkinson CA, Bohlega S, Abu-Amero SN, Cupler E, Kambouris M, Meyer BF, Bharucha VA. A novel form of autosomal recessive pure hereditary spastic paraplegia maps to chromosome 13q14. Neurology 2002; 59:1905–1909. Zortea M, Vettori A, Trevisan CP, Bellini S, Vazza G, Armani M, Simonati A, Mostacciuolo ML. Genetic mapping of a susceptibility locus for disc herniation and spastic paraplegia on 6q23.3-q24.1. J Med Genet 2002:387–390. Bianchine JW, Lewis RC, Jr. The MASA syndrome: a new heritable mental retardation syndrome. Clin Genet 1974; 5:298–306. Winter RM, Davies KE, Bell MV, Huson SM, Patterson MN. MASA syndrome: further clinical delineation and chromosomal localisation. Hum Genet 1989; 82:367–370. Rosenthal A, Jouet M, Kenwrick S. Aberrant splicing of neural cell adhesion molecule l1 messenger RNA in a family with X-Linked hydrocephalus. Nat Genet 1992; 2:107–112. Vits L, Van Camp G, et al. MASA syndrome is due to mutations in the neural cell adhesion gene L1CAM. Nat Genet 1994; 7:408–413. Jouet M, Rosenthal A, Armstrong G, MacFarlane J, Stevenson R, Paterson J, Metzenberg A, Ionasescu V, Temple K, Kenwrick S. X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nat Genet 1994; 7:402–407. Kenwrick S, Watkins A, De Angelis E. Neural cell recognition molecule L1: relating biological complexity to human disease mutations. Hum Mol Genet 2000; 9:879–886.
Copyright 2006 by Taylor & Francis Group, LLC
258
Kleopa
133. Dahme M, Bartsch U, Martini R, Anliker B, Schachner M, Mantei N. Disruption of the mouse L1 gene leads to malformations of the nervous system in mice. Nat Genet 1997; 17:346–349. 134. Johnston AW, McKusick VA. A sex-linked recessive form of spastic paraplegia. Am J Hum Genet 1962; 14:83–94. 135. Keppen LD, Leppert MF, O’Connell P, Nakamura Y, Stauffer D, Lathrop M, Lalouel J-M, White R. Etiological heterogeneity in X-linked spastic paraplegia. Am J Hum Genet 1987; 41:933–943. 136. Goldblatt J, Ballo R, Sachs B, Moosa A. X-linked spastic paraplegia: evidence for homogeneity with a variable phenotype. Clin Genet 1989; 35:116–120. 137. Bonneau D, Rozet J-M, Bulteau C, Berthier M, Mettey R, Gil R, Munnich A, Le Merrer M. X linked spastic paraplegia (SPG2): clinical heterogeneity at a single gene locus. J Med Genet 1993; 30:381–384. 138. Saugier-Veber P, Munnich A, Bonneau D, Rozet J-M, Le Merrer M, Gil R, Boespflug-Tanguy O. X-linked spastic paraplegia and Pelizaeus-Merzbacher disease are allelic disorders at the protiolipid protein locus. Nat Genet 1994; 6:257–261. 139. Kobayashi H, Hoffman EP, Marks HG. The rumpshaker mutation in spastic paraplegia. Nat Genet 1994; 7:351–352. 140. Cambi F, Tang XM, Cordray P, Fain PR, Keppen LD, Barker DF. Refined genetic mapping and proteolipid protein mutation analysis in X-linked pure hereditary spastic paraplegia. Neurology 1996; 46:1112–1117. 141. Cailloux F, Gauthier-Barichard F, Mimault C, Isabelle V, Courtois V, Girard G, Dastugue B, Boespflug-Tanguy O. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Eur J Hum Genet 2000; 8:837–845. 142. Nave K-A. Myelin-specific genes and their mutations in the mouse. In: Jessen KR, Richardson WD, eds. Glial Cell Development. Oxford: Oxford University Press, 2001:177–208. 143. Dickinson PJ, Fanarraga ML, Griffiths IR, Barrie JM, Kyriakides E, Montague P. Oligodendrocyte progenitors in the embryonic spinal cord express DM-20. Neuropathol Appl Neurobiol 1996; 22:188–198. 144. Schneider A, Montague P, Griffiths I, Fanarraga M, Kennedy P, Brophy P, Nave KA. Uncoupling of hypomyelination and glial cell death by a mutation in the proteolipid protein gene. Nature 1992; 358:758–761. 145. Gow A, Southwood CM, Lazzarini RA. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of PelizaeusMerzbacher disease. J Cell Biol 1998; 140:925–934. 146. Gow A, Lazzarini RA. A cellular mechanism governing the severity of Pelizaeus-Merzbacher disease. Nat Genet 1996; 13:422–427. 147. Steinmuller R, Lantigua-Cruz A, Garcia-Garcia R, Kostrzewa M, Steinberger D, Muller U. Evidence of a third locus in X-linked recessive spastic paraplegia. Hum Genet 1997; 100:287–289. 148. Starling A, Rocco P, Cambi F, Hobson GM, Passos Bueno MR, Zatz M. Further evidence for a fourth gene causing X-linked pure spastic paraplegia. Am J Med Genet 2002; 111:152–156.
Copyright 2006 by Taylor & Francis Group, LLC
Hereditary Spastic Paraplegia
259
149. Tamagaki A, Shima M, Tomita R, Okumura M, Shibata M, Morichika S, Kurahashi H, Giddings JC, Yoshioka A, Yokobayashi Y. Segregation of a pure form of spastic paraplegia and NOR insertion into Xq11.2. Am J Med Genet 2000; 94:5–8. 150. Meijer IA, Hand CK, Grewal KK, Stefanelli MG, Ives EJ, Rouleau GA. A locus for autosomal dominant hereditary spastic ataxia, SAX1, maps to chromosome 12p13. Am J Hum Genet 2002; 70:763–769. 151. Hedera P, Rainier S, Zhao XP, Schalling M, Lindblad K, Yuan Q-P, Ikeuchi T, Trobe J, Wald JJ, Eldevik OP, Kluin K, Fink JK. Spastic paraplegia, ataxia, mental retardation (SPAR): a novel genetic disorder. Neurology 2002; 58: 411–416. 152. Engert JC, Berube P, et al. ARSACS, a spastic ataxia common in northeastern Quebec, is caused by mutations in a new gene encoding an 11.5-kb ORF. Nat Genet 2000; 24:120–125. 153. Krabbe K, Nielsen JE, Fallentin E, Fenger K, Herning M. MRI of autosomal dominant pure spastic paraplegia. Neuroradiology 1997; 39:724–727.
Copyright 2006 by Taylor & Francis Group, LLC
13 Mitochondrial Disorders Clotilde Lagier-Tourenne and Michio Hirano Department of Neurology, Columbia University College of Physicians and Surgeons, New York, New York, U.S.A.
INTRODUCTION Mitochondria are essential cellular organelles that convert carbohydrates, lipids, and proteins into usable energy in the form of adenosine triphosphate (ATP) through aerobic metabolism. They originated from aerobic bacteria that formed symbiotic relationships with eukaryotic cells, which benefited from their newly acquired capacity to utilize oxygen. This relationship is unique due, in part, to the fact that mitochondria are the only mammalian subcellular organelles—aside from the nucleus—that contain genetic material. Although mitochondria contain their own DNA (mtDNA), over evolutionary time most of the genes necessary for mitochondrial functions have been transferred to the nuclear DNA (nDNA). Therefore, mitochondrial diseases, that is, genetic diseases resulting in mitochondrial dysfunction, can be due to mutations in either genome. The ubiquitous nature of mtDNA and the peculiar rules of mitochondrial genetics contribute to the extraordinary clinical heterogeneity of mitochondrial disorders. Impairment of oxidative ATP production affects mainly tissues with high-energy requirements, such as skeletal muscle and brain, and results in mitochondrial myopathies or mitochondrial encephalomyopathies. Nevertheless, these disorders affect virtually every organ system in varying combinations resulting in protean clinical manifestations.
Copyright 2006 by Taylor & Francis Group, LLC
262
Lagier-Tourenne and Hirano
To better understand mitochondrial disorders, the functions and properties of mitochondria are reviewed briefly, followed by a description of the molecular mechanisms leading to mitochondria dysfunction. Next, the clinical, histological, and biochemical features shared by mitochondrial diseases will be described followed by a review of the most common mitochondrial syndromes. PRINCIPLES OF MITOCHONDRIAL GENETICS Biochemical Properties Mitochondria are essential to eukaryotic cells because they contain the enzymatic machinery necessary for aerobic metabolism, by which fatty acids, carbohydrates, and amino acids are broken down to form CO2, H2O, and, most importantly, to convert adenosine diphosphate (ADP) to ATP, the energy currency of the cell. The biochemical processes of aerobic metabolism can be classified into five major steps: (1) transport, (2) substrate utilization, (3) Krebs, citric acid, or tricarboxylic acid (TCA) cycle, (4) electron transport chain, and (5) oxidation–phosphorylation coupling (Fig. 1) (1). The electron transport chain, comprised of four enzymes (complexes I–IV), has been the subject of intense clinical and basic investigations over the last two decades. Reducing equivalents (electrons) are carried along these enzymes to create an efflux of protons from the mitochondrial matrix across the inner mitochondrial membrane to generate a transmembrane proton gradient. Oxidative– phosphorylation is the process by which the proton gradient across the mitochondrial inner membrane is converted into ATP. This chapter focuses primarily on diseases caused by respiratory chain enzyme defects which can result either from primary mutations in mtDNA or nuclear DNA. Mitochondrial Genetic Concepts Human mtDNA is a small circular, double-stranded molecule composed of 16,569 base pairs and encodes 37 genes: 13 polypeptides, 22 transfer ribonucleic acids (tRNA) molecules, and 2 ribosomal RNAs (rRNAs) (2). All 13 mtDNAencoded polypeptides are subunits of the respiratory chain (seven in complex I, one in complex III, three in complex IV, and two in complex V). The mitochondrial genome differs from nDNA in several aspects. First, there are no introns within the mtDNA and therefore, the genome is tightly packed with information. Second, each cell contains hundreds to thousands of copies of mtDNA. Third, mtDNA undergoes spontaneous mutations more rapidly than nDNA. Fourth, mtDNA is maternally inherited. These unique properties of mtDNA are responsible for the characteristics that distinguish mitochondrial genetics from mendelian genetics and help to explain many of the clinical peculiarities of mtDNA-related disorders. An important principle of mtDNA genetics is heteroplasmy. Each mitochondrion contains 2–10 copies of mtDNA and, in turn, each cell
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
263
Figure 1 Mitochondrial metabolic pathways.
contains multiple mitochondria; therefore, there are numerous copies of mtDNA in each cell (polyplasmy). Alterations of mtDNA may be present in some (heteroplasmy) or in all (homoplasmy) of the mtDNA molecules. Usually, neutral mutations (or polymorphisms) are homoplasmic. In contrast, most (but not all) pathogenic mtDNA mutations are heteroplasmic. As a consequence of heteroplasmy, the proportion of a deleterious mtDNA mutation can vary widely and a minimum critical number of mutant genomes must be present before tissue dysfunction becomes evident (and related clinical signs become manifest), a concept aptly termed the threshold effect. However, this is a relative concept: tissues with high metabolic demands, such as brain, heart, and muscle, tend to have lower tolerance for mtDNA mutations than metabolically less active tissues (3). Moreover, an individual who harbors a large proportion of mutant mtDNA will be more severely afflicted by the mitochondrial dysfunction than a person with a low percentage of the same mutation; therefore, there is a spectrum of clinical severity among patients with a given mitochondrial mutation.
Copyright 2006 by Taylor & Francis Group, LLC
264
Lagier-Tourenne and Hirano
Another factor that can influence the expression of the same mtDNA mutation in different individuals is the tissue distribution of that mutation. This tissue distribution is dependent on the concept of mitotic segregation. Both organellar division and mtDNA replication are apparently stochastic events unrelated to cell division; thus, the number of mitochondria (and mtDNA) can vary not just in space (i.e., among cells and tissues) but also in time (i.e., during development or aging). Moreover, at cell division, the proportion of mutant mtDNAs in daughter cells may drift, allowing relatively rapid changes in genotype that can translate into changes in phenotype, including the clinical picture, if and when the threshold is crossed. A fifth unusual characteristic of mtDNA is maternal inheritance (4). During the formation of the zygote, mtDNA derives exclusively from the oocyte. Therefore, a mother carrying an mtDNA mutation will pass it on to all of her children, males and females, but only her daughters will transmit it to their progeny in a ‘‘vertical,’’ matrilinear line. This inheritance pattern is important to recognize in determining whether a family is likely to harbor an mtDNA mutation. However, the other features of mitochondrial genetics (e.g., heteroplasmy and the threshold effect) often mask maternal inheritance by causing striking intrafamilial clinical heterogeneity. Maternal relatives harboring lower percentages of an mtDNA mutation may have fewer symptoms (oligosymptomatic) than the proband or may even be asymptomatic. Therefore, in taking the family history, it is important to ask about the presence of subtle symptoms (e.g., short stature, hearing loss, migrainous headache, and isolated exercise intolerance) in maternally related family members. PRIMARY MITOCHONDRIAL DNA MUTATIONS In 1988, the first mtDNA point mutation and large-scale deletions were described (5–8). Since then, there has been an outburst of information relating mtDNA mutations to human mitochondrial disorders including: duplications, single or multiple deletions, and pathogenic point mutations (9). mtDNA Deletions Holt et al. first identified large-scale mtDNA deletions in mitochondrial myopathy patients and soon thereafter, Zeviani et al. pointed out the specific association with progressive external ophthalmoplegia (PEO) or Kearns–Sayre syndrome (KSS) (5,8). The mtDNA deletions range from about 2.0–10.4 kilobases (kb) in length and are mainly confined to an 11-kb region that does not include the origins of mtDNA replication or mtDNA promoter regions (10). About one-third of the mtDNA deletions involve an identical 4977 base pair (bp) segment often referred to as the ‘‘common deletion’’. The majority of mtDNA deletions are flanked by direct DNA sequence repeats, which suggests that they may arise from homologous
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
265
recombination events or slip mispairing (11–13). Most patients with single deletions of mtDNA are sporadic cases suggesting that the recombination events occur in the oocytes or early in embryogenesis. Large-scale mtDNA deletions are often undetectable in mitotically active cells, such as fibroblast and lymphocytes; therefore, molecular diagnosis requires muscle biopsy. Because multiple mtDNA deletions can be identified by polymerase chain reaction (PCR) in muscle from normal aged individuals, clinicians must be careful in their interpretation of PCR-detectable mtDNA deletions. In contrast, Southern blot analysis generally does not reveal mtDNA deletions in aged individuals and is the most appropriate technique to identify single mtDNA duplications, and single or multiple mtDNA deletions. mtDNA Duplications Duplications of mtDNA were initially reported in two patients with KSS, who also harbored single mtDNA deletions (14). Later, maternally inherited duplications associated with deletions were also described (15). Duplicated mtDNA molecules consist of a wild-type mtDNA molecule plus an additional segment corresponding to the deleted mtDNA molecule. Duplications may be the underlying cause of maternally transmitted ‘‘deletions’’ of mtDNA. Studies of one mitochondrial myopathy patient, who harbored both a deletion and a corresponding duplication of the mtDNA, revealed that the deletions, not the duplications, were responsible for the histological abnormalities in skeletal muscle, implying that duplications per se may not be pathogenic (16). mtDNA Point Mutations The first point mutation in human mtDNA was identified by Wallace et al. in patients with Leber hereditary optic neuropathy (LHON) (7). Since then, numerous mtDNA mutations have been related to maternally inherited or sporadic mitochondrial diseases. These mutations can either affect mitochondrial protein synthesis as mutations in rRNA and tRNA genes, or can occur in protein-coding genes causing defects of a specific respiratory chain complex (17). In contrast to deletions and duplications, mtDNA point mutations are generally detectable in DNA from leukocytes, urine sediment, and buccal mucosa (18). NUCLEAR DNA MUTATIONS The nuclear genome encodes hundreds of mitochondrial proteins that are vital for all functions of the organelles. Consequently, mutations of nDNA transmitted by mendelian inheritance can affect the respiratory chain directly or indirectly, potentially impairing a wide variety of mitochondrial
Copyright 2006 by Taylor & Francis Group, LLC
266
Lagier-Tourenne and Hirano
functions. These include mitochondrial motility, protein or metabolite importation, and maintenance of the membrane milieu (Table 1). Finally, a last group of genetic mitochondrial disorders includes defects of intergenomic communication, due to mutations of nDNA genes controlling replication and expression of the mitochondrial genome that in turn alter mtDNA integrity. Mutations in Structural Subunits or Assembly Genes of the Respiratory Chain Complexes Pathogenic mutations in nDNA-encoded structural subunits of complexes I and II have been identified leading to severe infantile or childhood neurological disorders such as Leigh syndrome or leukoencephalopathy (19,20). Other clinical phenotypes associated with complex I deficiency include fatal infantile lactic acidosis, hepatopathy and tubulopathy, cardiomyopathy with or without cataracts, macrocephaly with progressive leukodystrophy, and unspecified encephalomyopathies (21,22). Mutations in complex II subunits have also been associated with familial paragangliomas and pheochromocytomas (23,24). In contrast, autosomal deficiencies of complexes III, IV, or V have not been linked to mutations in nDNA-encoded subunits, but rather to defects of nDNA genes encoding ancillary proteins required for enzyme assembly or insertion of cofactors. For example, mutations in six genes involved in assembly of cytochrome c oxidase (SURF1, SCO1, SCO2, COX10, COX15, and LRPPRC ) have been identified as causes of autosomal recessive cytochrome c oxidase (COX) deficiencies (25–31). In addition, mutations in the assembly factor for complex III, BCS1L, are associated with neonatal proximal tubulopathy, hepatopathy, and encephalopathy (32). Mutations in Genes in Mitochondrial Importation and Motility Identification of mutations in other autosomal genes is leading to new concepts of mitochondrial diseases. For example, the identification of DDP1 gene mutations in X-linked deafness-dystonia (Mohr-Tranebjaerg syndrome) as well as in opticoacoustic nerve atrophy with dementia (Jensen syndrome), comprise the first defect in a mitochondrial importation factor (33). Moreover, mutations in the OPA1 gene in autosomal dominant optic atrophy 1 (Kjer type optic atrophy) indicate that defects of mitochondrial division or biogenesis can cause diseases (34,35). Defects of Intergenomic Communication In 1989, Zeviani et al. described multiple mtDNA deletions in a family with autosomal dominant progressive external ophthalmoplegia (adPEO) (13). The mendelian inheritance pointed to a nDNA mutation and an abnormal interaction of a mutated nDNA-encoded factor with the mitochondrial
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
267
Table 1 Nosological Classification of Mitochondrial Respiratory Chain Disorders Due to Nuclear DNA Mutations Biochemical defect
Clinical phenotype
Defective gene product (if known)
Mutations in genes encoding structural subunits of respiratory chain enzymes Complex I deficiency Encephalomyopathy or NDUFS2, NDUFS4, Leigh syndrome NDUFS8, NDUFV1, NDUFS1, NDUFS7 Complex II deficiency Leigh syndrome Flavoprotein subunit of SDH Hereditary paraganglioma SDHB, SDHC, SDHD or pheochromocytoma Mutations in genes encoding assembly factors for respiratory chain enzymes BCSIL Complex III deficiency Encephalopathy, tubulopathy and hepatopathy Complex IV deficiency Leigh syndrome SURF1 Infantile SCO2 cardioencephalopathy Infantile encephalopathy SCO1, COX 10 Defects of intergenomic communication Autosomal recessive PEO MNGIE Thymidine with multiple D- mtDNA phosphorylase arPEO POLG ARCO Unknown Autosomal dominant PEO adPEO ANT1, Twinkle, POLG with multiple D-mtDNA MtDNA depletion Infantile myopathy TK2 Infantile encephalopathy dGK and hepatopathy Alpers disease POLG Infantile myopathy or Unknown hepatopathy Navaho neurohepatopathy Unknown Defects of the mitochondrial membrane Unknown Coenzyme Q10 deficiency Myoglobinuria, encephalopathy, ragged-red fibers Cerebellar ataxia Unknown Impaired processing of Barth syndrome Tafazzin mitochondrial phospholipids Defects of mitochondrial importation Impaired importation of X-Iinked deafness-dystonia Tim 8/9 proteins (Continued)
Copyright 2006 by Taylor & Francis Group, LLC
268
Lagier-Tourenne and Hirano
Table 1 Nosological Classification of Mitochondrial Respiratory Chain Disorders Due to Nuclear DNA Mutations (Continued ) Biochemical defect
Clinical phenotype
Defects of mitochondrial division and biogenesis Impaired mitochondrial Autosomal dominant optic atrophy 1 Defects of mitochondrial metal metabolism Iron-sulfur metabolism Friedreich ataxia Iron export defect X-linked sideroblastic anemia Other Hereditary spastic paraplegia
Defective gene product (if known) OPA1
Frataxin ABC7
Paraplegin
genome was postulated. Subsequently, mutations in different nuclear genes were identified as causes of secondary mtDNA defects such as multiple deletions, depletion, or both. Multiple mtDNA deletions of different sizes described in adPEO (13) have been associated with mutations in three nuclear genes: adenine nucleotide translocator 1 (ANT1) (36), Twinkle (37), and polymerase gamma (POLG) (38). Mutations in POLG are also responsible for autosomal recessive PEO (arPEO) (38); however, the molecular defect leading to the multiple deletions present in autosomal recessive cardiomyopathy and ophthalmoplegia (ARCO) is not yet known (39). Depletion of mtDNA is the other major defect of intergenomic communication, together with multiple mtDNA deletions described earlier. As the name implies, this is a quantitative rather than qualitative mtDNA abnormality, consisting of markedly decreased levels of mtDNA in one or more tissues (40). The clinical spectrum of mtDNA depletion has been incompletely characterized and is probably more heterogeneous than was initially thought. Four syndromes stand out, all inherited as autosomalrecessive traits: congenital myopathy, infantile myopathy, hepatopathy, and hepatocerebral mtDNA depletion. Loss-of-function mutations in the gene encoding the thymidine phosphorylase (TP) led to the novel concept that nucleotide pool imbalances can affect mtDNA quantity and integrity (41). Indeed, mutations in the TP gene were identified in patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), which is associated with multiple deletions, depletion and site-specific point mutations of mitochondrial DNA (42–44). Deficiency of TP leads to dramatically elevated levels of circulating thymidine and deoxyuridine (45). Alterations of pyrimidine nucleoside metabolism
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
269
are hypothesized to cause imbalances of mitochondrial nucleotide pools that, in turn, may cause somatic alterations of mtDNA. This concept was reinforced when defects of ANT1 were associated with multiple deletions in adPEO (36), and mutations in genes encoding mitochondrial deoxyguanosine kinase (dGK) and thymidine kinase (TK2) were found to cause mtDNA depletion. In these forms of mtDNA depletion syndrome (MDS), defects of mitochondrial nucleoside kinases are thought to cause deficiency of mitochondrial dNTPs, which impedes mtDNA replication. Moreover, an iatrogenic form of mtDNA depletion has also been recognized in patients with acquired immunodeficiency syndrome in whom a mitochondrial myopathy developed during treatment with a nucleoside analogue, zidovudine (Retrovir) (46,47). Thus, inborn and acquired defects of nucleoside and nucleotide metabolism comprise a new group of mitochondrial disorders. GENERAL FEATURES OF MITOCHONDRIAL DISEASES Defects in the electron transport chain and in oxidation–phosphorylation coupling will impair ATP synthesis. In turn, deficiencies in ATP will affect virtually all tissues, causing multisystem diseases collectively described as mitochondrial myopathies or mitochondrial encephalomyopathies. While the clinical heterogeneity of these disorders can be confusing, there are general features that can be helpful in making a preliminary diagnosis. Clinical Features of Mitochondrial Diseases Some patients with mitochondrial diseases have isolated myopathies, encephalopathies, or other single-organ disorders; however, most develop multisystem disorders. Despite the plethora of manifestations, some are frequently present together and should alert the clinician to a mitochondrial etiology (Table 2). Ptosis, PEO, or both are hallmarks of KSS, sporadic PEO, and autosomal dominant or recessive forms of PEO. The onset of ophthalmoparesis is usually insidious and complaints of diplopia and blurred vision due to dysconjugate gaze are uncommon. Patients may note mild worsening of symptoms with fatigue, but the ptosis and ophthalmoparesis do not fluctuate as widely as in myasthenia gravis. Other, ophthalmological signs such as pigmentary retinopathy, optic atrophy, cataracts, and visual field defects are also often present. Limb myopathy is frequent in patients with mitochondrial disorders. Neck flexors may be affected earlier and more severely than neck extensors. As with most myopathies, proximal limb muscles are disproportionately weaker than distal muscles. Patients with mitochondrial myopathies are generally thin with decreased muscle bulk. Many patients with deficiencies
Copyright 2006 by Taylor & Francis Group, LLC
270
Lagier-Tourenne and Hirano
Table 2 Clinical Features of Mitochondrial Diseases Due to Nuclear DNA Mutations Leigh syndrome Onset typically in infancy or childhood, but can occur in adulthood Infantile-onset Typically before age six months in a previously normal infant Developmental arrest or regression, hypotonia, feeding difficulty, respiratory abnormalities, vision loss, oculomotor palsies, and nystagmus. Brain MRI reveals symmetric lesions of the basal ganglia and midline brainstem. Childhood-onset Similar to the infantile-onset patients, but PEO, dystonia, or ataxia may be prominent. Infantile myoclonic epilepsy and leukodystrophy due to complex I deficiency (NDUFVl mutations) Myoclonic epilepsy Hypotonia Developmental delay Leukodystrophy Infantile cardioencephalomyopathy due to complex I deficiency (NDUFS2 mutations) Hypertrophic cardiomyopathy Encephalopathy (ataxia, pyramidal signs, basal ganglia and white matter lesions) Myopathy Optic atrophy Infantile cardioencephalopathy due to SCO2 mutations Progressive hypertrophic cardiomyopathy Encephalopathy with seizures and variable atrophy, migrational defects, neuronal defects, and gliosis Respiratory insufficiency Hypotonia Fatal infantile myopathy (FIM) with cytochrome c oxidase deficiency Diffuse weakness, hypotonia, and respiratory insufficiency due to myopathy Sometimes de Toni-Debre´-Fanconi syndrome Benign infantile myopathy (BIM) with cytochrome c oxidase deficiency Diffuse weakness, hypotonia, and respiratory insufficiency due to myopathy Spontaneous improvement by age 2–3 years Autosomal dominant progressive external ophthalmoplegia (adPEO) Ptosis and PEO generally beginning in young adulthood Ragged-red and cytochrome c oxidase (COX) deficient fibers in skeletal muscle Multiple D-mtDNA Other features include: proximal limb weakness, respiratory insufficiency, depression, peripheral neuropathy, sensorineural hearing loss, cataracts, endocrinopathies. (Continued)
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
271
Table 2 Clinical Features of Mitochondrial Diseases Due to Nuclear DNA Mutations (Continued ) Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) Ptosis and PEO Gastrointestinal dysmotility Demyelinating peripheral neuropathy Cachexia Leukoencephalopathy on MRI scan Autosomal recessive cardiomyopathy ophthalmoplegia (ARCO) Ptosis and PEO Proximal muscle weakness Hypertrophic cardiomyopathy Infantile mtDNA depletion syndromes Myopathic form Feeding difficulty, failure to thrive, hypotonia, weakness, and occasionally PEO Elevated serum creatine kinase (2–30 times the upper limit of normal) Myopathy with COX-deficient fibers and sometimes RRF Hepatopathy Liver failure manifesting as persistent vomiting, failure to thrive, hypotonia, and hypoglycemia. Alpers syndrome Normal early development followed by rapid episodic psychomotor regression, intractable seizures, liver disease Navaho neurohepatopathy (NHH) 4 of the following 6 criteria or 3 plus a positive family history of NHH Sensory neuropathy Motor neuropathy Corneal anesthesia, ulcers, or scars Liver disease Documented metabolic or immunologic derangement Central nervous system demyelination Coenzyme Q10 deficiency Myopathic form Myoglobinuria Encephalopathy (seizures or mental retardation) RRF in muscle biopsy Cerebellar form Cerebellar ataxia with prominent cerebellar atrophy in brain MRI scans Barth syndrome X-Iinked Dilated cardiomyopathy Neutropenia (due to impaired leukocyte maturation) Myopathy with abnormal mitochondria (Continued)
Copyright 2006 by Taylor & Francis Group, LLC
272
Lagier-Tourenne and Hirano
Table 2 Clinical Features of Mitochondrial Diseases Due to Nuclear DNA Mutations (Continued ) Mohr-Tranebjaerg Syndrome (X-linked deafness-dystonia syndrome) X-Iinked Sensorineural hearing loss Dystonia Other features: spasticity, dysphagia, intellectual decline, paranoia, cortical blindness Autosomal dominant optic atrophy 1 (Kjer type optic atrophy) Childhood-onset of insidious optic atrophy manifesting as loss of visual acuity, color vision loss, temporal optic disc pallor, centrocecal scotoma) X-linked sideroblastic anemia with ataxia syndrome (XLSA/A) Hypochromic microcytic anemia Ring sideroblasts in bone marrow Ataxia Corticospinal tract signs
of respiratory chain enzymes may exhibit normal muscle strength with manual testing; yet, they complain of functional impairment due to premature fatigue. While this type of exercise intolerance is intuitively compatible with a defect in aerobic metabolism, the subjective nature of the complaint makes formal exercise testing with measurements of oxygen consumption, maximum work rate, and serum lactate very helpful. Exercise intolerance may be the sole manifestation of an mtDNA mutation (48). Sensorineural hearing loss is also frequently associated with mitochondrial encephalomyopathies. The hearing loss may be asymmetric and fluctuating in severity. A particular mtDNA point mutation has been associated with cases of aminoglycoside-induced deafness (AID) (49). Maternally inherited deafness and diabetes (DAD) is another frequent phenotypic combination observed in patients with mtDNA mutations (50). Finally, peripheral neuropathy, dementia, migraine-like headaches, hypertrophic cardiomyopathy, renal tubular acidosis, short stature, multiple lipomas, and hypoparathyroidism are also common clinical manifestations of respiratory chain enzyme defects. Laboratory Tests in Mitochondrial Diseases Clinical Laboratory Tests Laboratory evaluation of patients with mitochondrial diseases should begin with routine blood tests including complete blood count, serum electrolytes (including calcium and phosphate), liver function tests, blood urea nitrogen, creatinine, lactate, and pyruvate. These tests may reveal dysfunction of the
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
273
parathyroid, kidney, or liver. Serum lactate at rest is frequently elevated and out of proportion to pyruvate in patients with defects of the respiratory chain (e.g., lactate to pyruvate ratio 20:l); however, many patients with well-documented mitochondrial diseases have normal baseline lactate levels that may increase dramatically after moderate exercise. Formal exercise testing with careful measurements of oxygen consumption and near-infrared spectroscopy, although not widely available, are very useful in such patients. Lumbar puncture may show elevated CSF protein, especially in KSS patients where it is often greater than 100 mg/dl. It may also reveal elevated lactate and pyruvate levels, sometimes in patients with normal serum levels. Electrocardiograms may reveal preexcitation or heart block. Electromyography and nerve conduction studies are typically consistent with a myogenic process although neurogenic changes may also be detected. Neuropathologic and neuroradiologic changes fall into five main patterns: 1. Microcephaly and ventricular dilatation, sometimes associated with agenesis of the corpus callosum, are seen in infants with severe congenital lactic acidosis. 2. Bilateral, symmetric lesions of basal ganglia, thalamus, brainstem, and cerebellar roof nuclei are the signatures of Leigh syndrome. 3. Multifocal encephalomalacia, usually involving the cortex of the posterior cerebral hemispheres, corresponds to the ‘‘strokes’’ of the Mitochondrial Encephalomyopathy, Lactic Acidosis, with Stroke-like episodes (MELAS) syndrome. 4. Spongy encephalopathy, predominantly in white matter, is characteristic of KSS. 5. Calcifications of the basal ganglia can be seen in all of these disorders, but in a minority of patients with any syndrome. Special Laboratory Tests Clinical research has contributed greatly to our understanding of mitochondrial disorders and to our diagnostic capabilities. Specialized evaluation for oxidative–phosphorylation defects has evolved from laboratory research to include muscle histochemistry and immunohistochemistry, measurement of oxidative–phosphorylation enzyme activities, and molecular genetic analyses. In patients whose clinical manifestations conform to one of the welldefined mitochondrial diseases associated with specific point mutations of mtDNA, direct genetic testing can be performed using DNA from leukocytes, urinary sediment, or buccal mucosa (18). Muscle biopsy: In the mid-1960s, Shy, Gonatas, and Perez described the typical ultrastructural alterations seen in mitochondrial myopathies (51). These changes include: (1) an overabundance of ultrastructually normal
Copyright 2006 by Taylor & Francis Group, LLC
274
Lagier-Tourenne and Hirano
mitochondria, ‘‘pleoconial myopathy,’’ (2) enlarged mitochondria with disoriented cristae, ‘‘megaconial myopathy,’’ and (3) inclusions within mitochondria, ‘‘paracrystalline’’ and ‘‘osmiophilic’’ inclusions (51). Engel and Cunningham developed a modified Gomori trichrome stain which has been commonly used to identify fibers with subsarcolemmal accumulations of mitochondria, which are referred to as ‘‘ragged-red fibers’’ (RRF) (52). RRFs are generally associated with primary mtDNA mutations that affect mitochondrial protein synthesis, such as point mutations in tRNA genes or large-scale mtDNA deletion that eliminate at least one tRNA gene. Both types of mutations lead to a paucity of normal mitochondrial tRNAs, hence impaired protein synthesis. While none of the known primary nDNA mutations directly affects mitochondrial protein synthesis, defects of intergenomic communication lead to secondary depletion and multiple deletions of mtDNA, thereby producing RRF. Histochemical and immunohistochemical stains for mitochondrial enzymes are also used to identify excessive mitochondrial proliferation and to demonstrate defects of specific enzymes. Indeed, the histochemical stain for succinate dehydrogenase (SDH), which functions as complex II (succinate-CoQ reductase) of the mitochondrial respiratory chain, provides a more sensitive indicator of mitochondrial proliferation than Gomori trichrome stain. The histochemical stain for cytochrome c oxidase (COX; complex IV) often provides vital morphological information. In patients with a pathogenic nDNA mutation in a COX subunit or in a COX assembly factor, histochemistry will show a generalized reduction or absence of COX staining in skeletal muscle. By contrast, in patients with primary or secondary mtDNA mutations, COX histochemistry typically shows a mosaic pattern of fibers with normal and decreased staining. In KSS, MELAS, and MERRF, mitochondrial proliferation is almost always identified in skeletal muscle by the Gomori trichrome stain and SDH histochemistry. In MELAS patients, there is often excessive SDH staining within blood vessel walls, so-called strongly SDH-reactive vessels or SSVs (53,54). Another peculiar characteristic of skeletal muscle from MELAS patients is the relative preservation of COX staining in RRF, in contrast to muscle from KSS and MERRF patients, in which there are abundant COX-negative RRF on serial or double-stained (SDH and COX) sections. Unfortunately for clinicians, the histological abnormalities described above are neither specific nor sensitive enough to define all mitochondrial diseases. Morphologically abnormal muscle mitochondria are sometimes detected in conditions that are not due to primary oxidative–phosphorylation defects, such as inflammatory myopathies (55) and myotonic dystrophy (56). Conversely, some primary mitochondrial disorders have subtle or no morphological abnormalities of mitochondria, including Neuropathy Ataxia, and Retinitis Pigmentosa (NARP), Leber’s hereditary optic neuropathy (LHON), and Leigh syndrome (LS).
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
275
Biochemistry (Respiratory chain enzyme assays): Activities of mitochondrial respiratory chain enzymes can be measured in crude muscle extracts or in isolated mitochondria. Biochemical studies in patients with mtDNArelated disorders yield two main types of results. The first pattern consists of partial defects in the activities of multiple complexes containing mtDNAencoded subunits (I, III, and IV), contrasting with normal or increased activities of SDH (complex II), because all subunits of this enzyme complex are encoded by nDNA. The second pattern is severe deficiency in the activity of one respiratory complex. As a rule, the first pattern is found in patients with mutations impairing mitochondrial protein synthesis such as tRNA genes mutations and mtDNA deletions or depletion. The second is typical of a mutation in a mtDNA or nDNA gene encoding a polypetide subunit of a respiratory chain enzyme complex. Identification of an isolated enzyme deficiency pinpoints the biochemical problem and focuses molecular genetic analyses to identify the causative mutation. For example, isolated monoenzymopathies can be diagnosed for some of the clinical syndromes described above, such as the fatal and benign COX-deficient myopathies. However, some mitochondrial disorders, such as LHON and NARP, may not have any detectable abnormalities of respiratory chain enzymes with routine assays.
SPECIFIC MITOCHONDRIAL DISEASES Progressive External Ophthalmoplegia PEO is defined clinically as a slowly progressive limitation of eye movements until there is complete immobility (ophthalmoplegia). It is usually accompanied by eyelid droop (ptosis). There may or may not be weakness of muscles of the face, oropharynx, neck, or limbs. This condition is clearly heterogeneous, but several distinct syndromes can be recognized, some related to primary abnormalities of mtDNA (with sporadic single deletions or maternally inherited point mutations), and others related to autosomal genes directly affecting mtDNA (defects of intergenomic signaling with multiple deletions of mtDNA). PEO with Single mtDNA Deletions PEO with or without limb weakness: This is a relatively benign condition, often compatible with a normal lifespan. Symptoms usually begin in childhood but may be delayed to adolescence or adult years. Ptosis is often the first symptom, followed by ophthalmoparesis. The disorder is bilateral and symmetric, so diplopia is exceptional. Some patients also have pharyngeal and limb weakness. Although typically sporadic, women with PEO or KSS due to a single-mtDNA deletion have a 4% chance of transmitting the mutation to each child (57).
Copyright 2006 by Taylor & Francis Group, LLC
276
Lagier-Tourenne and Hirano
Kearns–Sayre syndrome: In 1958, Kearns and Sayre defined a syndrome as the combination of: retinitis pigmentosa, external ophthalmoplegia, and complete heart block (58). In 1983, Rowland et al. redefined the KSS by the invariant triad of ophthalmoplegia, pigmentary retinopathy, and onset before age 20 years plus at least one of the following three additional features: cardiac conduction block, cerebellar syndrome, or cerebrospinal fluid (CSF) protein greater than 100 mg/dL (59). In addition to the diagnostic clinical features, KSS patients often have hearing loss and limb weakness. Associated endocrinopathies include diabetes mellitus, hypoparathyroidism, irregular menses, and growth hormone deficiency. Seizures are infrequent and are usually associated with electrolyte disturbances, as may occur in hypoparathyroidism, one of several endocrine disorders sometimes associated with KSS (60). The evolution is characterized by gradual progression of the multisystemic disorders. Placement of a cardiac pacemaker in the setting of impending complete heart block can extend a KSS patient’s life by years. The ataxia and myopathy can be severely debilitating to the extent that some patients are wheelchair-bound in their twenties. Virtually all KSS patients have been sporadic. Laboratory abnormalities: In both conditions, muscle biopsy shows RRFs that are devoid of histochemically demonstrable COX activity. Raised levels of lactate and pyruvate are usually found in blood in both sporadic PEO and KSS. Computed tomography or magnetic resonance imaging (MRI) sometimes shows evidence of leukoencephalopathy, and there may be calcification of basal ganglia. Correspondingly, at postmortem examination, typical cases of KSS show spongy degeneration of the brain. Maternally Inherited PEO with Point Mutations of mtDNA A substantial number of patients with mitochondrial PEO (i.e., PEO and RRF in the muscle biopsy) show maternal inheritance of their syndrome. PEO predominates in this syndrome but is often associated with various combinations of other symptoms, including hearing loss, endocrinopathy, heart block, cerebellar ataxia, or pigmentary retinopathy. There is usually lactic acidosis, and muscle biopsies show RRF. The most common mutation in these patients is the typical A3243G MELAS mutation, but other mutations have also been described, including the A8344G mutation typically seen in MERRF syndrome. The reason for the appearance of PEO in patients with the MELAS mutation is not known, but it may be related to a selective accumulation of mutant mtDNA in extraocular muscle. Autosomal PEO with Multiple Deletions of mtDNA PEO has been described in numerous families with adPEO or autosomalrecessive (arPEO) inheritance. Patients with adPEO gradually develop ptosis
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
277
and ophthalmoparesis during early adulthood and may manifest other symptoms including: proximal limb weakness, respiratory insufficiency, severe depression, ataxia, peripheral neuropathy, sensorineural hearing loss, cataracts, endocrine dysfunction, and parkinsonism (61–63). By contrast, arPEO disorders begin in childhood or adolescence and manifest as multisystem disorders such as mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) or autosomal recessive cardiomyopathy ophthalmoplegia (ARCO) (64). MNGIE is due to mutations in the gene encoding TP and is characterized by ptosis, PEO, peripheral neuropathy, and severe gastrointestinal dysmotility leading to cachexia (65). MRI shows diffuse leukodystrophy, although patients rarely show cognitive defects. Death usually occurs in the fourth or fifth decade. ARCO was identified in two large families from the eastern Arabian peninsula with childhood-onset of PEO, proximal muscle weakness and severe hypertrophic cardiomyopathy (39). The cause of ARCO is not known. Laboratory Abnormalities In all these conditions, muscle biopsy usually shows RRF and COX-negative fibers. Lactic acidosis is usually present but may not be very marked. In MNGIE, nerve conduction studies and nerve biopsies have shown features of both axonal and demyelinating neuropathy. Moreover, biochemical detection of elevated plasma thymidine and deoxyuridine or decreased TP activities in MNGIE patients provides more rapid and cost-effective screening tests than sequencing of the TP gene (66). Molecular Genetics Southern blot analyses of muscle mtDNA in these conditions show multiple bands representing species of mtDNA molecules harboring deletions of different sizes. As previously described, mutations in nuclear genes are responsible for defects of intergenomic communication leading to these secondary mtDNA deletions. Myoclonus Epilepsy with Ragged-Red Fibers Identified as a clinical syndrome in 1980 by Fukuhara et al. myoclonus epilepsy with ragged-red fibers (MERRF) is defined by the clinical features: myoclonus, generalized seizures, ataxia, and COX-negative RRF in the muscle biopsy (67). Symptoms usually begin in childhood, but adult-onset has also been described. Although progression is slow, patients can be severely impaired by the myoclonus, ataxia, or both. The ataxia has been attributed to degeneration of both the posterior column and the cerebellum. Other common clinical manifestations include: hearing loss, family history of affected individuals in the maternal lineage, dementia, exercise intolerance, and lactic
Copyright 2006 by Taylor & Francis Group, LLC
278
Lagier-Tourenne and Hirano
acidosis (60). Large lipomas have been seen in MERRF patients, as well as in oligosymptomatic relatives (68). MERRF was the first multisystem disorder to be associated with an mtDNA point mutation, specifically, A8344G in the transfer RNA lysine (tRNALys) gene (69). Approximately 80% of patients with MERRF have the A8344G mtDNA mutation; however, at least six other mtDNA point mutations and multiple deletions of mtDNA have been pathogenically linked to MERRF (70). MELAS Identified as a distinct clinical syndrome in 1984 by Pavlakis et al. MELAS is characterized by: (1) strokes at a young age and typically before age 40 years, (2) encephalopathy evident as seizures, dementia, or both, and (3) lactic acidosis, RRF or both as manifestations of the respiratory chain defects (71,72). In addition to these cardinal manifestations, other frequent clinical features include: normal early development, myogenic limb weakness, ataxia, myoclonus, migraine-like headaches, recurrent nausea and vomiting, and hearing loss (72). Although the clinical features of ataxia, myoclonus, seizures, and ragged-red fibers are common to both MERRF and MELAS patients, the clinical course of MELAS is punctuated by strokes which are abrupt and often devastating. Typically, the strokes affect the occipital cortex, but may affect other regions of the brain. Both clinical and radiological defects can improve over weeks to months, but virtually always recur (72). The cerebral lesions often do not conform to territories of large vessels, a finding that has led some individuals to use the term stroke-like episodes to distinguish the cerebral insults in MELAS from the more typical ischemic strokes (72). In a few cases, the lesions have affected the temporal lobe mimicking herpes simplex encephalitis (73). Another intriguing feature of MELAS is the infrequent occurrence of the full-syndrome in more than one member within a pedigree, in contradistinction to MERRF families where multiple members typically have the complete syndrome. Usually, maternal relatives of MELAS patients are oligosymptomtic or asymptomatic. Laboratory abnormalities include elevated blood and CSF lactate. Muscle biopsy shows RRF, which are uncharacteristically COX-positive, rather than COX-negative as in most other mtDNA-related diseases. Electrocardiograms may reveal preexcitation in MELAS or MERRF, and heart block in MELAS. Electromyography and nerve conduction studies are typically consistent with a myogenic process although neurogenic changes may be detected in MERRF or MELAS. Fundoscopy may reveal pigmentary retinopathy in MELAS or MERRF, and optic atrophy is sometimes detected in MERRF patients.
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
279
In about 80% of patients, the molecular defect is a point mutation (A3243G) in the tRNALeu(UUR) gene of mtDNA. In the remaining patients, 15 other mutations have been described, some of which affect proteinencoding genes rather than tRNA genes (74). A3243G is the most frequent pathogenic mtDNA mutation with prevalence estimates ranging from 1.4– 16.3 per 100,000 (75,76). In addition to MELAS and maternally inherited PEO, the A3243G mutation has been associated with diabetes mellitus alone or in combination with deafness. The heterogeneity in the clinical expression of the A3243G mutation may be due to varying degrees of heteroplasmy in different tissues; however, other influences, such as nuclear DNA factors, may also play a role. Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP) The combination of NARP is a maternally transmitted multisystem disorder of young adult life, comprising, in various combinations, sensory neuropathy, ataxia, seizures, dementia, and retinitis pigmentosa. Lactic acid in blood may be normal or slightly elevated, and muscle biopsy does not show RRF. The most common molecular defect is a point mutation (T8993G) in the gene that encodes ATPase 6 (77). When this mutation approaches homoplasmic levels, onset is in infancy, and the clinical and neuropathologic features are those of Leigh syndrome [maternally inherited Leigh syndrome (MILS)] (78). A different mutation at the very same nucleotide (T8993C) causes a phenotype similar to MILS but generally milder. Other mutations in the ATPase 6 gene have been associated with Leigh-like syndromes or with familial bilateral striatal necrosis. Leigh Syndrome Leigh syndrome is the most common mitochondrial disorder in infants and children, but is rare in adults (79). Infants may present symptoms at birth or may develop normally for months; however, onset is typically before age six months. The initial manifestations include hypotonia, psychomotor delay, and respiratory insufficiency followed by impaired vision, hearing loss, seizures, ataxia, limb weakness, pyramidal tract signs, and intellectual deterioration. Nystagmus is also common. In patients with later onset, PEO, dystonia, or ataxia may be present. CSF protein content is mildly elevated in 25% of patients. Lactate and pyruvate levels are almost always increased in CSF and, to a lesser degree, in blood and urine. These findings and the histopathology lead to a search for an abnormality of oxidative metabolism. Electroencephalogram changes and abnormal evoked responses are nonspecific. MRI of the brain reveals characteristic symmetric lesions of the periaqueductal region of the midbrain and pons and in the medulla adjacent to the fourth ventricle. Other parts of the central nervous system and peripheral nerves may also be
Copyright 2006 by Taylor & Francis Group, LLC
280
Lagier-Tourenne and Hirano
affected. The lesions are a combination of cell necrosis, demyelination, and vascular proliferation. The condition may be inherited in an autosomal-recessive, X-linked, or maternal pattern, and mutations have been identified in many mitochondrial or nuclear genes involved in energy metabolism. Leber Hereditary Optic Neuropathy (LHON) LHON is a maternally inherited disorder characterized by loss of central vision (80,81). Onset usually occurs in adolescence or early-adult years but may occur from ages 5 to 80 years. Cloudiness of central vision progresses painlessly over weeks, usually first in one eye, to a larger, denser centrocecal scotoma. Both eyes are usually affected within weeks or months, sometimes simultaneously. Color vision is affected, and acuity drops to 20/200 or finger counting. Sometimes, there is later improvement, infrequently striking and occasionally sudden, with severity and possibility of improvement varying with the particular mutation. The fundus may appear normal until optic atrophy supervenes, but at onset, the disc often appears blurred and suggestive of edema. Circumpapillary telangiectatic microangiopathy, without evidence of abnormal vascular permeability, is sometimes observed. The vascular abnormalities may be seen in presymptomatic and asymptomatic relatives and do not invariably predict imminent visual loss, which may never occur. In most patients with LHON, visual disturbance is the only symptom, but cardiac preexcitation is frequently associated. Neurologic examination, however, may reveal subtle neurologic abnormalities, including postural tremor, dystonia, motor tics, parkinsonism with dystonia, or peripheral neuropathy. Several patients (mostly women) with LHON have had multiple sclerosis-like manifestations. The molecular genetic features of LHON are complex and unique. The first and most common primary mtDNA mutation associated with LHON was found in the gene for subunit 4 of complex 1 (7). Two additional common mtDNA mutations in complex I (ND) subunits have been identified: G3460A in ND1 and T14484C in ND6. While these three mtDNA mutations account for >90% of LHON patients, additional mtDNA mutations have been identified in families with LHON. Penetrance rates of the LHON mutations are uncertain; however, some reports estimate that symptoms appear in 20% to 83% of men and 4% to 32% of women at risk (80,81). Sixty percent to 90% of LHON patients are men. The molecular basis for male predominance is not known. No treatment is of proven value. Antioxidants (e.g., idebenone and coenzyme Q10) have also been used to reduce possible damage from reactive oxygen species generated by the impaired oxidative metabolism. According to consensus, tobacco and alcohol should be avoided in family members at risk.
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
281
Infantile Myopathies with Cytochrome c Oxidase (COX) Deficiency Infantile myopathies with COX deficiency are important for clinicians to recognize because the patients with the benign infantile myopathy (BIM) can recover fully if proper medical care is administered (82). Both BIM and fatal infantile myopathy (FIM) with COX deficiency present with congenital generalized muscle weakness, with respiratory muscle insufficiency and lactic acidosis; however, infants with FIM die within the first year of life despite aggressive medical interventions (82). Patients with BIM also present with severe myopathy and lactic acidosis soon after birth, but improve dramatically and are virtually normal by age two and three years (83). Lactic acidosis and muscle histological abnormalities also resolve. Because of the remarkable spontaneous improvement, the syndrome has been called reversible infantile myopathy or BIM. The latter term is misleading because the disorder can be fatal if the patients are not properly managed in the critical first few months of life. The common biochemical and histochemical feature of these patients is COX deficiency in skeletal muscle, sparing heart, brain, and liver. Recurrence of these syndromes in siblings indicates that these disorders are hereditary and probably autosomal recessive. mtDNA Depletion The clinical presentation of this mitochondrial syndrome is variable, even within a single family (40,84). Onset may be congenital or soon after birth, generally leading to death within the first year of life. However, onset can also be in infancy or in childhood with survival through the first decade. A variety of specific clinical phenotypes have been reported: (1) Congenital myopathy, with neonatal weakness and hypotonia requiring assisted ventilation, and death before age one year; renal dysfunction (DeToni–Fanconi syndrome) may also be present, (2) myopathy usually developing around age one year with rapid worsening causing respiratory insufficiency and death within a few years, (3) hepatopathy with hepatomegaly and intractable liver failure causing death within the first year, (4) hepatocerebral mtDNA depletion with onset within the first six months and death usually in the first year, (5) a lower motor neuron disorder resembling spinal muscular atrophy (SMA), and (6) Alpers’ syndrome (infantile poliodystrophy), a progressive encephalohepatopathy that causes death in early childhood (40,84–89). Peripheral neuropathy has also been noted in some patients with later onset. Lactic acidosis is severe in infants with congenital myopathy or hepatopathy, but lactate can be normal or only mildly elevated in children with infantile myopathy. Serum creatine kinase is markedly elevated in children with myopathy. COX-negative ragged-red fibers are prominent in muscle biopsies from patients with congenital myopathy, but may not be seen in early biopsies
Copyright 2006 by Taylor & Francis Group, LLC
282
Lagier-Tourenne and Hirano
from children with infantile myopathy. Southern blot analysis shows a profound defect of mtDNA in muscle (less than 10% of normal) in the congenital form. Patients with the infantile myopathy present only partial mtDNA depletion in muscle (about 30% of normal), with some fibers virtually devoid of mtDNA while others look normal. In the hepatic form, liver biopsy shows mitochondrial proliferation in hepatocytes, and biochemical analysis shows very low activities of all respiratory chain complexes containing mtDNA-encoded subunits. Severe mtDNA depletion in liver is found by Southern blot. Pathogenic mutations in TK2 have been identified in patients with the myopathy or SMA-Uke phenotypes, while mutations in dGK have been associated with hepatocerebral mtDNA depletion (87,90). Some patients with Alpers’ syndrome have had mutations in POLG (89). Thus, abnormalities of nucleoside/nucleotide metabolism are emerging as common causes of intergenomic communication. REFERENCES 1. DiMauro S, Bonilla E. Mitochondrial Encephalomyopathies. In: Rosenberg R, Prusiner S, DiMauro S, Barchi R, eds. The Molecular and Genetic Basis of Neurological Disease. 2nd ed. Boston: Butterworth-Heinemann, 1997:201–235. 2. Anderson S, Bankier AT, Barrel BG, DeBruijin M, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith A, Staden R, Young IG. Sequence and organization of the human mitochondrial genome. Nature 198l; 290:457–465. 3. Wallace DC. Diseases of the mitochondrial DNA. Annu Rev Biochem 1992; 61: 1175–1212. 4. Giles RE, Blanc H, Cann RM, Wallace DC. Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci USA 1980; 77:6715–6719. 5. Holt IJ, Harding AE, Morgan Hughes JA. Deletions of muscle mitochondrial DNA in patients with mitochondrial myopathies. Nature 1988; 331:717–719. 6. Lestienne P, Ponsot G. Keams–Sayre syndrome with muscle mitochondrial DNA deletion. Lancet 1988; 1:885. 7. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza A, Elsas LJ, Nikoskelainen EK. Mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy. Science 1988; 242:1427–1430. 8. Zeviani M, Moraes CT, DiMauro S, Nakase H, Bonilla E, Schon EA, Rowland LP. Deletions of mitochondrial DNA in Kearns-Sayre syndrome. Neurology 1988; 38:1339–1346. 9. Servidei S. Mitochondrial encephalomyopathies: gene mutations. Neuromusc Disord 2004; 14:107–116. 10. Schon EA, Rizzuto R, Moraes CT, Nakase H, Zeviani M, DiMauro S. A direct repeat is a hotspot for large-scale deletions of human mitochondrial DNA. Science 1989; 244:346–349. 11. Mita S, Rizzuto R, Moraes CT, Shanske S, Arnaudo E, Fabrizi GM, Koga Y, DiMauro S, Schon EA. Recombination via flanking direct repeats is a major
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
12.
13.
14. 15.
16.
17. 18.
19.
20.
21.
22.
23.
24.
25.
283
cause of large-scale deletions of human mitochondrial DNA. Nucleic Acids Res 1990; 18:56l–567. Shoffner JM, Lott MT, Voljavec AS, Soueidan SA, Costigan DA, Wallace DC. Spontaneus Kearns-Sayre/chronic external ophthalmoplegia plus syndrome associated with a mtDNA deletion: A slip-replication model and metabolic therapy. Proc Natl Acad Sci 1989; 86:7952–7956. Zeviani M, Servidei S, Gellera C, Bertini E, DiMauro S, DiDonato S. An autosomal dominant disorder with multiple deletions of mitochondria DNA starting at the D-loop region. Nature 1989; 339:309–311. Poulton J, Deadman ME, Gardiner RM. Duplications of mitochondrial DNA in mitochondrial myopathy. Lancet 1989; 1:236–240. Ro¨tig A, Colonna M, Bonnefont IP, Blanche S, Fischer A, Saudubray JM, Munnich A. Mitochondrial DNA deletion in Pearson’s marrow/pancreas syndrome. Lancet 1989; 1:902–903. Manfredi G, Vu TH, Bonilla E, Schon EA, DiMauro S, Arnaudo E, Zhang L, Rowland LP, Hirano M. Association of myopathy with large-scale mitochondrial DNA duplications and deletions: which is pathogenic? Ann Neurol 1997; 42:180–188. DiMauro S, Schon EA. Mitochondrial respiratory-chain diseases. N Engl J Med 2003; 348:2656–2668. Shanske S, Pancrudo J, Kaufmann P, Engelstad K, Jhung S, Lu J, Naini A, DiMauro S, De Vivo DC. Varying loads of the mitochondrial DNA A3243G mutation in different tissues: implications for diagnosis. Am J Med Genet 2004; 130A:134–137. Bourgeron T, Rustin P, Chretien D, Birch-Machin MA, Bourgeois M, Viegas-Pe´quignot E, Munnich A, Ro¨tig A. Mutation of a nuclear succinate dehydrogenase gene results in mitochondrial respiratory chain deficiency. Nat Genet 1995; 11:144–149. Janssen RJ, van den Heuvel LP, Smeitink JA. Genetic defects in the oxidative phosphorylation (OXPHOS) system. Expert Rev Mol Diagn 2004; 4: 143–156. Robinson BH. Human complex I deficiency: clinical spectrum and involvement of oxygen free radicals in the pathogenicity of the defect. Biochim Biophys Acta 1998; 1364:271–286. Loeffen J, Smeitink J, Trijbels F, Janssen AJ, Triepels RH, Sengers RC, van den Heuvel L. Isolated complex I deficiency in children: clinical, biochemical and genetic aspects. Hum Mutat 2000; 15:123–134. Astuti D, Douglas F, Lennard TW, Aligianis IA, Woodward ER, Evans DG, Eng C, Latif F, Maher ER. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357:1181–1182. Young AL, Baysal BE, Deb A, Young WF Jr. Familial malignant catecholamine- secreting paraganglioma with prolonged survival associated with mutation in the succinate dehydrogenase B gene. J Clin Endocrinol Metab 2002; 87: 4101–4105. Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock J, Krishna S, Walker W, Selby J, Glerum DM, Van Coster R, Lyon G, Scalais E, Lebel R, Kaplan P, Shanske S, De Vivo DC, Bonilla E, Hirano M, DiMauro S,
Copyright 2006 by Taylor & Francis Group, LLC
284
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
Lagier-Tourenne and Hirano Schon EA. Fatal infantile cardioencephalomyopathy with cytochrome c oxidase (COX) deficiency and mutations in SCO2, a human COX assembly gene. Nat Genet 1999; 23:333–337. Tiranti V, Hoertnagel K, Carrozzo R, Galimberti C, Munaro M, Granatiero M, Zelante L, Gasparini P, Marzella R, Rocchi M, Bayona-Bafaluy MP, Enriquez J-A, Uziel G, Bertini E, Dionisi-Vici C, Franco B, Meitinger T, Zeviani M. Mutations of SURF-1 in Leigh disease associated with cytochrome c oxidase deficiency. Am J Hum Genet 1998; 63:l609–1621. Zhu S, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert AP, Newbold RF, Wang J-i, Chevrette M, Brown GK, Brown RM, Shoubridge EA. SURF1, encoding a factor involved in the biogenesis of cytochrome c oxidase, is mutated in Leigh syndrome. Nat Genet 1998; 20:337–343. Valnot I, von Kleist-Retzow JC, Barrientos A, Gorbatyuk M, Taanman JW, Mehaye B, Rustin P, Tzagoloff A, Munnich A, Rotig A. A mutation in the human heme A: farnesyltransferase gene (COX10) causes cytochrome c oxidase deficiency. Hum Mol Genet 2000; 9:1245–1249. Valnot I, Osmond S, Gigarel N, Mehaye B, Amiel J, Cormier-Daire V, Munnich A, Bonnefont JP, Rustin P, Rotig A. Mutations of the SCO1 gene in mitochondrial cytochrome c oxidase deficiency with neonatal-onset hepatic failure and encephalopathy. Am J Hum Genet 2000; 67:1104–l109. Antonicka H, Mattman A, Carlson CG, Glerum DM, Hoffbuhr KC, Leary SC, Kennaway NG, Shoubridge EA. Mutations in COX15 produce a defect in the mitochondrial heme biosynthetic pathway, causing early-onset fatal hypertrophic cardiomyopathy. Am J Hum Genet 2003; 72:101–114. Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, Delmonte T, Villeneuve A, Sladek R, Xu F, Mitchell GA, Morin C, Mann M, Hudson TJ, Robinson B, Rioux JD, Lander ES. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci U.S.A 2003; 100:605–610. de Lonlay P, Valnot I, Barrientos A, Gorbatyak M, Tzagoloff A, Taanman JW, Benayoun E, Chretien D, Kadhom N, Lombes A, de Baulny HO, Niaudet P, Munnich A, Rustin P, Rotig A. A mutant mitochondrial respiratory chain assembly protein causes complex III deficiency in patients with tubulopathy, encephalopathy and liver failure. Nat Genet 2001; 29:57–60. Koehler CM, Leuenberger D, Merchant S, Renold A, Junne T, Schatz G. Human deafness dystonia syndrome is a mitochondrial disease. Proc Natl Acad Sci USA 1999; 96:2141–2146. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P, Pelloquin L, Grosgeorge J, Turc-Carel C, Perret E, Astarie-Dequeker C, Lasquellec L, Arnaud B, Ducommun B, Kaplan J, Hamel CP. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26:207–210. Alexander C, Votruba M, Pesch UE, Thiselton DL, Mayer Sf, Moore A, Rodriguez M, Kellner U, Leo-Kottler B, Auburger G, Bhattacharya SS, Wissinger B. OPA1, encoding a dynamin-related GTPase, is mutated in autosomal dominant optic atrophy linked to chromosome 3q28. Nat Genet 2000; 26:211–215.
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
285
36. Kaukonen J, Juselius XK, Tiranti V, Kyttala A, Zeviani M, Comi GP, Keranen S, Peltonen L, Suomalainen A. Role of adenine nucleotide translocator 1 in mtDNA maintenance. Science 2000; 289:782–785. 37. Spelbrink JN, Li FY, Tiranti V, Nikali K, Yuan QP, Tariq M, Wanrooij S, Garrido N, Comi G, Morandi L, Santoro L, Toscano A, Fabrizi GM, Somer H, Croxen R, Beeson D, Poulton J, Suomalainen A, Jacobs HT, Zeviani M, Larsson C. Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria. Nat Genet 2001; 28:223–231. 38. Van Goethem G, Dermaut B, Lofgren A, Martin JJ, Van Broeckhoven C. Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions. Nat Genet 2001; 28:211–212. 39. Bohlega S, Tanji K, Santorelli F, Hirano M, al-Jishi A, DiMauro S. Multiple mitochondrial DNA deletions associated with autosomal recessive ophthalmoplegia and severe cardiomyopathy. Neurology 1996; 46:1329–1334. 40. Moraes CT, Shanske S, Tritschler HJ, Aprille JR, Andreetta F, Bonilla E, Schon EA, DiMauro S. MtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991; 48:492–501. 41. Nishino I, Spinazzola A, Hirano M. Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder. Science 1999; 283:689–692. 42. Hirano M, Silvestri G, Blake D, Lombes A, Minetti C, Bonilla E, Hays AP, Lovelace RE, Butler I, Bertorini TE, Threlkeld AB, Mitsumoto H, Salberg LM, Rowland LF, DiMauro S. Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): Clinical, biochemical and genetic features of an autosomal recessive mitochondrial disorder. Neurology 1994; 44:721–727. 43. Papadimitriou A, Comi GP, Hadjigeorgiou GM, Bordoni A, Sciacco M, Napoli L, Prelle A, Moggio M, Fagiolari G, Bresolin N, Salani S, Anastasopoulos I, Giassakis G, Divari R, Scarlato G. Partial depletion and multiple deletions of muscle mtDNA in familial MNGIE syndrome. Neurology 1998; 51:1086–1092. 44. Nishigaki Y, Marti R, Copeland WC, Hirano M. Site-specific somatic mitochondrial DNA point mutations in patients with thymidine phosphorylase deficiency. J Clin Invest 2003; 111:1913–1921. 45. Marti R, Nishigaki Y, Hirano M. Elevated plasma deoxyuridine in patients with thymidine phosphorylase deficiency. Biochem Biophys Res Commun 2003; 303:14–18. 46. Dalakas M, Illa I, Pezeshkpour GH, Laukaitis JP, Cohen B, Griffin JL. Mitochondrial myopathy caused by long-term zidovudine therapy. New Engl J Med 1990; 322:1098–1105. 47. Amaudo E, Dalakas M, Shanske S, Moraes CT, DiMauro S, Schon EA. Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 1991; 337:508–510. 48. Andreu AL, Hanna MG, Reichmann H, Bruno C, Penn AS, Tanji K, Palllotti F, Iwata S, Bonilla E, Lach B, Morgan-Hughes J, DiMauro S. Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. New Engl J Med 1999b; 341:1037–1044.
Copyright 2006 by Taylor & Francis Group, LLC
286
Lagier-Tourenne and Hirano
49. Prezant TR, Agapian JV, Bohlman MC, Bu X, Oztas S, Qiu W-Q, Arnos KS, Cortopassi GA, Jaber L, Rotter JI, Shohat M, Fischel-Ghodsian N. Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness. Nat Genet 1993; 4:289–294. 50. van den Ouweland JMW, Lemkes HHPJ, Ruitenbeek W, Sandkuij LA, de Vijlder MF, Strnyvenberg PAA, van dKJJP, Maassen JA. Mutation in mitochondrial tRNALeu(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1992; 1:368–371. 51. Shy GM, Gonatas NK, Perez M. Childhood myopathies with abnormal mitochondria. I. Megaconial myopathy-pleoconial myopathy. Brain 1966; 89:133–158. 52. Engel WK, Cunningham CG. Rapid examination of muscle tissue: An improved trichrome stain method for fresh-frozen biopsy sections. Neurology 1963; 13:919–923. 53. Hasegawa H, Matsuoka T, Goto I, Nonaka I. Strongly succinate dehydrogenase-reactive blood vessels in muscles from patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Ann Neurol 1991; 29:601–605. 54. Sakuta R, Nonaka I. Vascular involvement in mitochondrial myopathy. Ann Neurol 1989; 25:594–601. 55. Carpenter S, Karpati G, Eisen AA. A morphologic study of muscle in polymyositis: clues to pathogenesis of different types. Amsterdam: Excerpta Medica, 1975:374–379. 56. Fardeau M. Ultrastructural lesions in progressive muscular dystrophies: a critical study of their specificity. Amsterdam: Excerpta Medica, 1970:98–108. 57. Chinnery PF, DiMauro S, Shanske S, Schon EA, Zeviani M, Mariotti C, Carrara F, Lombes A, Laforet P, Ogier H, Jaksch M, Lochmuller H, Horvath R, Deschauer M, Thorburn DR, Bindoff LA, Poulton J, Taylor RW, Matthews JN, Turnbull DM. Risk of developing a mitochondrial DNA deletion disorder. Lancet 2004; 364:592–596. 58. Kearns TP, Sayre GP. Retinitis pigmentosa, external ophthalmoplegia, and complete heart block. Arch Ophthal 1958; 60:280–289. 59. Rowland LP, Hays AP, DiMauro S, De Vivo DC, Behrens M. Diverse clinical disorders associated with morphological abnormalities of mitochondria. In: Cerri C, Scarlato G, eds. Mitochondrial Pathology in Muscle Diseases. Padua: Piccin Editore, 1983:141–158. 60. Hirano M, DiMauro S. Clinical features of mitochondrial myopathies and encephalomyopathies. In: Lane RJM, ed. Handbook of Muscle Disease. New York: Marcel Dekker Inc. USA, 1996:479–504. 61. Servidei S, Zeviani M, Manfredi G, Ricci E, Silvestri G, Bertini E, Gellera C, Di Mauro S, Di Donato S, Tonali P. Dominantly inherited mitochondrial myopathy with multiple deletions of mitochondrial DNA: clinical, morphologic, and biochemical studies. Neurology 1991; 41:1053–1059. 62. Suomalainen A, Kaukonen J. Diseases caused by nuclear genes affecting mtDNA stability. Am J Med Genet 2001; 106:53–61. 63. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, Oldfors A, Rautakorpi I, Peltonen L, Majamaa K, Somer H, Suomalainen A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase
Copyright 2006 by Taylor & Francis Group, LLC
Mitochondrial Disorders
64.
65.
66.
67.
68.
69.
70. 71.
72.
73. 74. 75.
76.
287
gamma mutations: clinical and molecular genetic study. Lancet 2004; 364: 875–882. Hirano M, Marti R, Ferreiro-Barros C, Vila MR, Tadesse S, Nishigaki Y, Nishino I, Vu TH. Defects of intergenomic communication: autosomal disorders that cause multiple deletions and depletion of mitochondrial DNA. Semin Cell Dev Biol 2001; 12:417–427. Nishino I, Spinazzola A, Papadimitriou A, Hammans S, Steiner I, Hahu CD, Connolly AM, Verloes A, Guimara˜es J, Maillard I, Hamano H, Donati MA, Semrad CE, Russell JA, Andreu AL, Hadjigeorgiou GM, Vu TH, Tadesse S, Nygaard TG, Nonaka I, Hirano I, Bonilla E, Rowland LP, DiMauro S, Hirano M. MNGIE: An autosomal recessive disorder due to thymidine phosphorylase mutations. Ann Neurol 2000; 47:792–800. Marti R, Spinazzola A, Tadesse S, Nishino I, Nishigaki Y, Hirano M. Definitive diagnosis of mitochondrial neurogastrointestinal encephalomyopathy by biochemical assays. Clin Chem 2004; 50:120–124. Fukuhara N. MERRF: A clinicopathological study. Relationship between myoclonus epilepsies and mitochondrial myopathies. Rev Neurol 1991; 147: 476–479. Holme E, Larsson NG, Oldfors A, Tulinius M, Sahlin P, Stenman G. Multiple symmetric lipomas with high levels of mtDNA with the tRNALys A > G(8344) mutation as the only manifestation of disease in a carrier of myoclonus epilepsy and ragged-red fibers (MERRF) syndrome. Am J Hum Genet 1993; 52:551–556. Shoffner JM, Lott MT, Lezza AMS, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNALys mutation. Cell 1990; 6l:931–937. Hirano M. Myoclonus epilepsy with ragged-red fibers. In: Gilman S, ed. Medlink Neurology. San Diego: Medlink Corporation, 2004. Pavlakis SG, Phillips PC, DiMauro S, De Vivo DC, Rowland LP. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes: a distinctive clinical syndrome. Ann Neurol 1984; 16:481–488. Hirano M, Pavlakis S. Mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes (MELAS): current concepts. J Child Neural 1994; 9:4–13. Johns DR, Stein AG, Wityk R. MELAS syndrome masquerading as herpes simplex encephalitis. Neurology 1993; 43:2471–2473. Hirano M. MELAS. In: Gilman S, ed. Medlink Neurology. San Diego: Medlink Corporation, 2004. Chinnery PF, Johnson MA, Wardell TM, Singh-Kler R, Hayes C, Brown DT, Taylor RW, Bindoff LA, Turnbull DM. The epidemiology of pathogenic mitochondrial DNA mutations. Ann Neurol 2000; 48:188–193. Majamaa K, Moilanen JS, Uimonen S, Remes AM, Salmela PI, Karppa M, Majamaa-Voltti KA, Rusanen H, Sorri M, Peuhkurinen KJ, Hassinen JJE. Epidemiology of A3243G, the mutation for mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes: prevalence of the mutation in an adult population. Am J Hum Genet 1998; 63:447–454.
Copyright 2006 by Taylor & Francis Group, LLC
288
Lagier-Tourenne and Hirano
77. Holt IJ, Harding AE, Petty RK, Morgan Hughes JA. A new mitochondrial disease associated with mitochondrial DNA heteroplasmy. Am J Hum Genet 1990; 46:428–433. 78. Santorelli FM, Shanske S, Macaya A, De Vivo DC, DiMauro S. The mutation at nt 8993 of mitochondrial DNA is a common cause of Leigh syndrome. Ann Neurol 1993; 34:827–834. 79. Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951; 14:216–221. 80. Newman NJ. Hereditary optic neuropathies. In: Miller NR, Newman NJ, eds. Walsh Hoyt’s Clinical Neuro-Ophthalmology. 5th ed. Baltimore: Williams & Wilkins, 1998:741–773. 81. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retin Eye Res 2004; 23:53–89. 82. DiMauro S, Lombes A, Nakase H, Mita S, Fabrizi GM, Tritschler HJ, Bonilla E, Miranda AF, De Vivo DC, Schon EA. Cytochrome c oxidase deficiency. Pediatr Res 1990; 28:536–541. 83. DiMauro S, Nicholson JF, Hays AP, Eastwood AB, Koenigsberger R, DeVivo DC. Benign infantile mitochondrial myopathy due to reversible cytochrome c oxidase deficiency. Trans Am Neurol Assoc 1981; 106:205–207. 84. Moraes CT, Ricci E, Arnaudo E, Bonilla E, DiMauro S, Schon EA. Quantitative Defects of Mitochondrial DNA. New York: Raven Press, 1993c; 1:97–108. 85. Vu TH, Sciacco M, Tanji K, Nichter C, Bonilla E, Chatkupt S, Maertens P, Shanske S, Mendell JR, Koenigsberger MR, Sharer L, Schon EA, DiMauro S, De Vivo DC. Clinical manifestations of mitochondrial DNA depletion. Neurology 1998; 50:1783–1790. 86. Boustany RN, Aprille JR, Halperin J, Levy H, DeLong GR. Mitochondrial cytochrome deficiency presenting as a myopathy with hypotonia, external ophthalmoplegia, and lactic acidosis in an infant and as fatal hepatopathy in a second cousin. Ann Neurol 1983; 14:462–470. 87. Mandel H, Szargel R, Labay V, Elpeleg O, Saada A, Shalata A, Anbinder Y, Berkowitz D, Hartman C, Barak M, Eriksson S, Cohen N. The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA. Nat Genet 2001; 29:337–341. 88. Mancuso M, Salviati L, Sacconi S, Otaegui D, Camano P, Marina A, Bacman S, Moraes CT, Carlo JR, Garcia M, Garcia-Alvarez M, Monzon L, Naini AB, Hirano M, Bonilla E, Taratuto AL, DiMauro S, Vu TH. Mitochondrial DNA depletion: mutations in thymidine kinase gene with myopathy and SMA. Neurology 2002; 59:1197–1202. 89. Naviaux RK, Nguyen KV. POLG mutations associated with Alpers’ syndrome and mitochondrial DNA depletion. Ann Neurol 2004; 55:706–712. 90. Saada A, Shaag A, Mandel H, Nevo Y, Eriksson S, Elpeleg O. Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy. Nat Genet 2001; 29:342–344.
Copyright 2006 by Taylor & Francis Group, LLC
14 Friedreich Ataxia Martin B. Delatycki, Michael C. Fahey, and Louise Corben Bruce Lefroy Centre for Genetic Health Research, Murdoch Childrens Research Institute, Royal Children’s Hospital, Victoria, Australia
Andrew Churchyard Monash Institute for Neurological Disease, Southern Health, Monash Medical Centre, Victoria, Australia
INTRODUCTION The disease now known as Friedreich ataxia (FRDA) was originally described in five publications by Nikolaus Friedreich over the period 1863–1877 (1–5). Since then a great deal has been learned about its pathogenesis, which has led to significant conceptual therapeutic advances although the translation to treatment that alters the natural history is yet to be made. FRDA is the most common inherited ataxia (6). Prior to the availability of molecular diagnosis, FRDA was estimated to affect about 1:50,000 Caucasians with an estimated carrier prevalence of 1:110 (7). More recent studies based on molecular data suggest a higher incidence with a carrier rate of 1:60–1:90 (8,9). FRDA is seen in India, North Africa, and the Middle East but is exceedingly rare among Asians and in those of African descent (10).
CLINICAL FEATURES Diagnostic criteria for FRDA were proposed by Geoffrey (11) and revised by Harding (12). Since the molecular basis of FRDA has been defined, these
Copyright 2006 by Taylor & Francis Group, LLC
290
Delatycki et al.
Table 1 Comparison of Symptom Frequency in Four Series of FRDA Patients. The figures are the percentage of individuals with FRDA in that study who have that clinical feature Harding (12) (N ¼ 115) Gait ataxia Limb ataxia Lower limb muscle weakness Diminished vibration sense Pes cavus Dysarthria Extensor plantar response Cardiomyopathy Diabetes Scoliosis Reflexes LL Sphincter disturbance Decreased visual acuity Hearing loss
Durr et al. (13) Delatycki et al. Lamont et al. (N ¼ 140) (18) (N ¼ 51) (15) (N ¼ 56)
– 99 88
100 99 67
100 100 –
100 100 53
73
78
88
87
55 97 89
55 91 79
74 95 74
– 91 96
66 10 79 0.9 –
63 32 60 12 23
65 8 78 2 41
– – – 13 –
18
13
–
–
8
13
–
–
have proven to be highly specific but lacking in sensitivity (13,14). The frequency in percentages of common symptoms is shown in Table 1. The mean age of symptom onset was 10.5 years in Harding’s series of 115 patients (12), and was 15.5 years in a later series of 140 patients with molecularly proven disease (13). Ataxia is the presenting feature in the vast majority of cases (13–19). The natural history of FRDA is characterized by slow progression of neurological symptoms; however, detailed analysis of this has not been undertaken, and thus it remains an important area of future research (20). Lifespan is decreased with an average age of death of 37.5 years (based on Harding’s series published in 1981) (12), but the mean survival from disease onset in more recent studies has been reported as 36 years (21). The modest discrepancy in these numbers may reflect both improved therapy of the medical complications of FRDA in more recent times and the recognition of less severely affected individuals. The most common cause of death is cardiomyopathy, either by production of arrhythmias or by congestive heart failure. Neurological Features Ataxia results from a combination of spinocerebellar dysfunction and impaired proprioception. Central nervous system dysfunction results in
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
291
extensor plantar reflexes, weakness, and corticospinal tract dysfunction (22). The ankle and knee jerks are absent in typical cases due to an axonal neuropathy (12,13,23) associated with reduced or absent sensory nerve action potentials (15,24). Optic atrophy is found in 30%, with or without decreased visual acuity (12). Eye signs include fixation instability with square wave jerks and flutter. Saccades are inaccurate with dysmetria and slowed pursuit (23,25,26). Hearing loss occurs in 13% of patients (13). A small number of studies have examined general cognition as well as visual and auditory reaction times in people with FRDA (27–29). While there is little impairment in general cognition, there is a significant slowing in reaction and movement time when compared with controls. More complex cognitive function such as verbal span, letter fluency, acquisition and consolidation of verbal information, and complex visuo-perceptual and visuo-constructive abilities may be affected based on a single study (29). Neuroimaging is usually normal early in disease. In advanced disease there may be atrophy of the cerebral hemispheres, cerebellum (mainly the dentate nucleus), brainstem, and cervical cord (30,31). These findings correlate with the clinical severity of the disease. Cardiac Features Echocardiography demonstrates concentric ventricular hypertrophy in 62–68% of individuals with FRDA (32,33) and diastolic dysfunction is commonly seen (34). The electrocardiogram is abnormal in the majority with T wave inversion, left axis deviation, and repolarization abnormalities (32,35,36). Dyspnea, palpitations, hypertension, and ankle edema are observed in 10–30% of patients (12,35). Diabetes Mellitus The incidence of diabetes mellitus is 8–30% and an additional proportion have impaired glucose tolerance (12–14,18,37). The mechanisms are poorly understood. Non-autoimmune loss of islet cells (38), abnormal regulation of insulin receptors (39), and lower insulin release (37) have been implicated. Other Features Scoliosis is present in about 66% of individuals with FRDA when assessed clinically (40) but is present in essentially all when assessed radiographically (41). Pes cavus is seen in about two-thirds of those with FRDA and equinovarus deformity becomes more common with disease progression (42). Differential Diagnoses The differential diagnoses for FRDA are listed in Table 2. Disorders that lead to derangement of vitamin E absorption and transport can present with features indistinguishable from FRDA. Head titubation, lower
Copyright 2006 by Taylor & Francis Group, LLC
292
Delatycki et al.
Table 2 Differential Diagnosis of FRDA Deficiency of vitamin E Malabsorption a Tocopherol transporter protein deficiency Abetalipoproteinaemia Early onset cerebellar ataxia with retained reflexes (EOCA) Hexosaminidase A deficiency L-2-Hydroxyglutaric acidemia Adrenoleukodystrophy
incidence of associated motor neuropathy, slower disease course, and retinitis pigmentosa are more common in low vitamin E states than FRDA (43). Ataxia with vitamin E deficiency (AVED) is due to mutations in the a-tocopherol transfer protein gene on chromosome 8 (44). b-hexosaminidase A deficiency that underlies Tay Sachs disease can also result in an FRDA phenocopy (45). PATHOLOGY The main sites of pathology in FRDA are the dorsal root ganglia, posterior columns of the spinal cord, the corticospinal tracts, and the heart. Macroscopically the spinal cord is small with the posterior and lateral columns particularly affected (6). Demyelination (presumptively secondary to axonal degeneration) occurs in the posterior columns and, in particular, the large fibers arising in the dorsal root ganglia. There is striking involvement of Clarke’s columns. The corticospinal tract involvement explains the findings of up-going plantar responses in almost all patients and spasticity in some patients (46). There is loss of Purkinje cells in the cerebellar cortex and the deep cerebellar nuclei: in particular the dentate nuclei, from which efferent cerebellar fibers originate, are affected by marked neuronal loss (47–49). Neuronal loss occurs in the gracile and cuneate nuclei of the brainstem where the dorsal column tracts terminate (49). A distal axonopathy affecting larger myelinated nerve fibers is also present (50) and is due to a dying back process from the periphery (51). The most common cardiac lesion is hypertrophic cardiomyopathy, but hypokinetic cardiomyopathy has also been reported. This pattern usually occurs following cardiac hypertrophy (52). Iron deposits in the myocardium have been reported (53,54). Cardiac pathology consists mainly of cellular hypertrophy, diffuse fibrosis, and focal myocardial necrosis (55,56). MOLECULAR GENETICS The gene mutated in FRDA was mapped to chromosome 9 in 1988 (57) and cloned in 1996 (58). Initially called X25 and later changed to FRDA, the
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
293
gene contains seven exons (1–5a,5b,6). The most common transcript arises from exons 1–5a, and yields a 210 amino acid protein, frataxin. In 98% of mutant alleles there is a GAA triplet repeat expansion in the first intron of FRDA (58); the other 2% of mutant alleles are point mutations (59). Normally there are 33 or fewer GAA triplets, while in pathological expansions there are from 67 to more than 1000 triplets (60). FRDA is expressed in heart, liver, skeletal muscle, and pancreas (61). FRDA expression studies in the central nervous system have revealed high levels of expression in the spinal cord, less in the cerebellum, and very little in the cerebral cortex. mRNA levels are very low or undetectable in patients compared to controls. Reduced mRNA levels result from the GAA repeat interfering with transcription elongation (62). This appears to occur from the formation of triplexes (resulting in sticky DNA) by DNA carrying expanded GAA repeats (63,64). The level of mRNA transcription is inversely related to the size of the GAA repeat (65,66). The GAA expansion of FRDA may cause gene silencing at least in part due to position effect variegation, and the degree of gene silencing may modify disease severity (67). Intergenerational Instability As in other trinucleotide repeat disorders, the GAA repeat that underlies FRDA is unstable in its transmission from parent to offspring (68). Maternal transmission may result in a larger or smaller allele in offspring. In contrast, the GAA repeat size almost always decreases when transmitted by a male (16,69–71). The size of the triplet repeat influences the direction of instability with smaller alleles being more prone to increase in size and larger ones to decrease. Studies on sperm from FRDA patients indicate that instability occurs pre- and post-zygotically (70,71). A small percentage of alleles are beyond the size found in the normal range but are smaller than alleles considered pathogenic for FRDA. These have been called premutation alleles (8,9,60,70). Such alleles are prone to very large expansions in one generation; however GAG interruptions appear to prevent expansions (9). Most expansions of this type do not cause FRDA because the allele inherited from the other parent is likely to be normal. Therefore, the incidence of such events is unknown. In vivo studies of replication fork progression of GAA repeats cloned into Saccharomyces cerevisiae plasmids demonstrate that premutation and disease-size repeats stalled the replication fork progression, while normalsize repeats do not affect replication (72). The stalling of replication fork progression predisposes to repeat expansion; this is hypothesized to be more likely with longer repeats.
Copyright 2006 by Taylor & Francis Group, LLC
294
Delatycki et al.
Genotype–Phenotype Correlation A number of studies have examined the correlation between the size of the GAA repeats and the presence and timing of various features of the disease (13–19). About 50% of the variation in the age of onset is accounted for by the size of the smaller allele. The GAA repeat length in each allele is important in predicting the age of onset and some features of FRDA. The smaller of the two alleles is more important in this regard. Features whose presence has consistently been shown to be associated with GAA repeat length include cardiomyopathy, diabetes mellitus, and scoliosis (13,14,17,18). As in other trinucleotide repeat disorders, repeat sizes cannot be used to accurately predict prognosis in an individual without a substantial degree of uncertainty (68). Disease severity is also influenced by the mitochondrial haplotype with the U mitochondrial haplotype being associated with an average delay of five years in disease onset and a reduced rate of cardiomyopathy when compared to other haplotypes (73). Most (but not all) cases of typical FRDA are linked to the FRDA locus (74–77). A second locus, FRDA2, has been found on chromosome 9p but no specific gene or disease-associated mutation has been identified (78,79). Late onset Friedreich ataxia (LOFA), defined as onset of FRDA after 25 years of age, and FRDA with retained reflexes (FARR), are linked to the same locus as typical FRDA (80–83). The Acadian form of FRDA (FRDA-Acad) is characterized by slower progression than classical FRDA and is not associated with cardiomyopathy and diabetes mellitus. Spastic ataxia is also seen in the Acadian population (SPA-Acad). Both FRDAAcad and SPA-Acad are linked to the same chromosome 9 locus as classical FRDA (57,84). These linkage findings were all confirmed by mutation analysis of FRDA (13–15,17).
PATHOGENESIS Although the precise function of frataxin is still a subject of intense study and debate, much has been learned about the pathogenesis of FRDA through the discovery of the human gene in 1996, the subsequent deletion of the yeast frataxin homolog (YFH1) and the development of mouse models. Soon after FRDA was cloned, it was shown that frataxin is localized to mitochondria. The N-terminal region of frataxin was predicted by detailed sequence comparison with known proteins, to contain a mitochondrial targeting sequence (85,86). Subsequently, using frataxin fused to a reporter protein, human frataxin was shown to be a nuclear encoded mitochondrial protein (86,87). Knockout (KO) of the YFH1 gene (yielding Dyfh1 cells) in S. cerevisiae causes an accumulation of iron in the mitochondria at the expense of cytosolic
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
295
iron and increased sensitivity to oxidative stress (86–90). Dyfh1 cells show a deficiency in activity of complex IV of the respiratory chain and, to a lesser extent, reduction in the activity of complex V. Mitochondrial proteins containing iron–sulfur (Fe/S) clusters such as aconitase are also deficient (88). Frataxin in yeast may have an iron storage function. Park et al. have suggested that frataxin catalyzes oxidation of Fe2þ to Fe3þ and also chaperones Fe2þ to proteins including ferrocheletase and ISU-type proteins to support heme and Fe/S cluster biosynthesis (91). They suggest that frataxin polymerizes in the presence of Fe2þ and O2 and the frataxin polymer then stores Fe3þ. Several further lines of evidence implicate Yfh1p involvement in the biosynthesis of Fe/S clusters in yeast. When the mitochondrial iron concentration in Dyfh1 cells is kept low by the addition of the iron chelator bathophenanthroline sulfonate (BPS), the activity of aconitase, which contains extremely labile Fe/S clusters, is reduced by more than 50% compared to a wild-type strain (92). This suggests that incorporation of the Fe/S clusters into aconitase may be impaired in a manner that is unrelated to iron toxicity. The depletion of Yfh1p by regulated gene expression leads to a primary reduction in activities of Fe/S cluster containing proteins in mitochondria with mitochondrial iron accumulation being a secondary event (93). The observation that mitochondrial iron accumulation is likely to be a secondary event resulting from the reduced activity of the Fe/S cluster containing proteins is supported by the observation that defects in the assembly of cellular Fe/S proteins in yeast are generally associated with the accumulation of mitochondrial iron (94,95). Bulteau et al. studied the etiology of the reduced activity of Fe/S cluster containing proteins in yeast with reduced frataxin production (96). They examined mitochondrial aconitase activity in this yeast and showed that frataxin protects the Fe/S cluster from disassembly and promotes enzyme reactivation. In mice, KO of the FRDA gene causes early embryonic lethality (97). This indicates an important role for frataxin in embryonic development and suggests the milder phenotype displayed by people with FRDA is due to residual frataxin expression (61). Through a conditional gene-targeting approach, mouse models have been created in which FRDA is selectively inactivated in neuronal and cardiac tissues (98). These first mammalian models have progressive pathophysiological and biochemical features of the human disease; cardiomyopathy, a sensory nerve defect and Fe/S enzyme deficiency. These features precede intramitochondrial iron deposits, indicating that in mice, iron accumulation is a secondary phenomenon. A specific inducible neurological KO mouse has been developed which has progressive mixed cerebellar and sensory ataxia (99). A moderate decrease in succinate dehydrogenase, a Fe/S cluster containing enzyme, has been demonstrated while iron accumulation was shown to be a modest and late phenomenon.
Copyright 2006 by Taylor & Francis Group, LLC
296
Delatycki et al.
Frataxin appears to have the same function in humans as in yeast and mice (100). For example, human frataxin can complement the defect seen in Dyfh1 cells (101) and the insertion of the human frataxin gene in the mouse KO rescues these mice (102,103). In human FRDA fibroblasts, the level of mitochondrial iron is significantly higher than in control fibroblasts (104). Furthermore, a generalized decrease in the activity of Fe/S cluster complex containing proteins (both mitochondrial and cytosolic aconitase and respiratory chain complexes I– III) has also been observed in heart tissue from two FRDA patients (105). Microarray studies on three human cell lines looking for frataxin-dependent transcripts have found that the only functional hypothesis supported by the identification of frataxin-dependent genes is that frataxin is involved in Fe/S cluster synthesis (106). That antioxidant enzyme levels are significantly different in blood in FRDA patients compared to controls is further evidence for the role of oxidative stress in the pathogenesis of FRDA (107). Additionally, there is evidence that oxidative stress induces actin glutathionylation and subsequent impairment of cytoskeletal function in FRDA fibroblasts (108). In summary, it appears that the primary role of frataxin is related to Fe/S cluster biosynthesis resulting in a reduction of Fe/S cluster containing proteins. This leads to reduced cellular energy production and can result in increased production of free radicals (109). Mitochondrial iron accumulation appears to be a secondary event. It is likely that this contributes to the production of reactive oxygen species leaking from the respiratory chain, leading to the formation of free radicals through Fenton chemistry. These radicals are expected to further reduce Fe/S protein levels as these proteins are exquisitely sensitive to oxidative stress (110,111). These interactions, in addition to the disruption of energy production, ultimately lead to neuronal death (87,88). MANAGEMENT OF PATIENTS WITH FRDA There is little objective literature regarding management of FRDA. Intervention has been based on evidence gained from other neurodegenerative diseases or single case reports (112). Based on our experience in a dedicated FRDA clinic we have produced a protocol for clinical management of FRDA (Table 3). With ongoing natural history research, evidence-based protocols can be derived. There is sound evidence that people with chronic progressive neurological disease benefit from long-term specialist multidisciplinary care (113–116). This approach incorporates a team of specialist clinicians including medical staff, allied health, and members of the patient population. A multidisciplinary model of care for people with FRDA ensures proactive, rather than reactive disease management. The significant symptoms of FRDA impacting on functional capacity are sensory ataxia, muscle weakness, spasticity, and associated bony changes
Copyright 2006 by Taylor & Francis Group, LLC
System
Assessment
Frequency
Possible findings
Intervention Pharmacological management of spasticity and bladder function. Splinting for upper and lower limbs. Stretching program. Prescription of adaptive equipment. Intervention for dysphagia including video-fluoroscopy if indicated Pharmacological management of arrhythmias and cardiac failure. Pacemaker Pharmacological treatment of diabetes if present Visual aid prescription
Neurological
Neurological assessment. Physical therapy assessment. Occupational therapy assessment. Speech pathology assessment
Annual or symptomatic
Progressive ataxia, spasticity, impaired bladder function, sensory changes, dysarthria, dysphagia, reduction in capacity to participate in daily activities
Cardiac
Electrocardiogram and echocardiogram
Annual or symptomatic
Endocrine
Fasting blood sugar and hemoglobin A1C Ophthalmological examination
Annual or symptomatic
T wave inversion in inferolateral chest leads, concentric ventricular hypertrophy, and diastolic dysfunction Diabetes mellitus
Ocular
Three yearly or symptomatic
(Continued) Copyright 2006 by Taylor & Francis Group, LLC
297
Decreased visual acuity, optic atrophy, oculomotor abnormalities, interference in daily activities
Friedreich Ataxia
Table 3 Clinical Management Protocol for FRDA
298
Table 3
Clinical Management Protocol for FRDA (Continued )
System
Assessment
Frequency
Possible findings
Intervention Prescription of appropriate mobility, seating and adaptive equipment. Upper and lower limb splinting. Foot surgery. Botulinum toxin injection. Community based rehabilitation and maintenance program Hearing aid prescription
Musculoskeletal
Musculoskeletal examination. Physical therapy assessment. Occupational therapy assessment
Annual or symptomatic
Scoliosis, pes cavus, ankle equinovarus deformity. Reduced passive and active range of movement. Reduction in capacity to participate in daily activities
Auditory
Hearing assessment
Hearing impairment
Psychosocial
Psychosocial assessment
Three yearly or symptomatic Annual or symptomatic
Counseling (individual and group)
Delatycki et al.
Copyright 2006 by Taylor & Francis Group, LLC
Response to initial diagnosis and disease process (both for patient and family). Grief regarding loss of function, roles, etc.
Friedreich Ataxia
299
such as scoliosis and foot deformity. From a functional perspective, these symptoms interfere with the ability to mobilize, transfer, and attend to personal daily tasks. The capacity to stand and transfer independently is the most significant contributor to ongoing maintenance of independence. Many patients with FRDA experience progressive equinovarus deformity. This interferes with the capacity to transfer and therefore increases caregiver burden. Prevention of this deformity by stretching and exercise programs is imperative. Correction of this deformity by splinting and botulinum toxin followed by an ongoing rehabilitation program can result in significantly improved functional performance (42). In cases where deformity is not reducible, surgery followed by an intensive rehabilitation program should be considered. Spasticity can have a significant negative effect on the capacity to participate in daily activities and therefore quality of life (117). People with FRDA require proactive management of spasticity in both upper and lower limbs. Preventive interventions such as use of a standing frame, stretching, and splinting (for both upper and lower limbs) are recommended (117). Medications such as baclofen are often necessary and botulinum toxin injection can also be of benefit (42). Scoliosis, if untreated, may be associated with pelvic obliquity, pain, restricted cardio-respiratory function, and uneven weight distribution on the seating surface (118). Appropriate wheelchair and seating prescription is essential to minimize progression of scoliosis. Surgery is recommended for scolioses greater than 60 and should be considered for curves between 40 and 60 (41). Swallowing difficulties are common in FRDA and may predispose to aspiration pneumonia. Dysarthria can also be severe and impact on quality of life. Proactive speech pathology assessment and management are essential to manage these issues. Cardiac complications should be monitored routinely and managed as these represent potentially treatable causes of morbidity and mortality. Dysrhythmias should be managed with antiarrhythmic agents and pacemaker insertion as indicated. While some individuals with FRDA have clinically significant and progressive cardiomyopathy, many other individuals will have subclinical cardiac findings that remain stable over time; however annual screening is still recommended. As with any chronic neurodegenerative disease, significant psychosocial morbidity is seen in individuals and families affected by FRDA. A proactive approach to these issues should be adopted from the time of diagnosis onwards. The presence of depression should be identified and appropriately managed. At all times, the autonomy of the individual with FRDA should be respected in management issues. Genetic counseling should be provided to families (40). Carrier, prenatal and preimplantation testing are possible utilizing molecular genetic testing.
Copyright 2006 by Taylor & Francis Group, LLC
300
Delatycki et al.
POTENTIAL PHARMACOLOGICAL THERAPIES FOR FRDA The rapid increase in knowledge regarding the pathogenesis of FRDA has led to a number of pharmacological therapies being considered, and some have been tried in people with FRDA. Antioxidants Antioxidants detoxify free radicals and therefore are of potential benefit in FRDA because of the role of oxidative damage in FRDA (119). Idebenone is a short chain analogue of coenzyme Q10 (120–122). A preliminary study and open label trials of idebenone (5–10 mg/kg/day) showed a reduction of cardiac hypertrophy in FRDA patients; no serious side effects were reported (123–125). Additionally, idebenone delays the demise of the cardiac conditional FRDA KO mouse model by about 25% (126). A year long randomized placebo-controlled trial found idebenone treatment was associated with moderate, though persisting, effects on cardiac hypertrophy; however, no benefit on neurological status was demonstrated (127). Besides a reduction in cardiac hypertrophy, Buyse et al. showed an improvement of regional myocardial function using quantitative cardiac strain and strain rate imaging (128). An editorial that accompanied these two publications recommended that idebenone should not yet be routine therapy for FRDA because the clinical significance of the effects of idebenone is unclear (129). Coenzyme Q10 (400 mg/day) plus vitamin E (2100 IU/day) has been evaluated, but both neurological and echocardiographic evaluations did not show any benefit after six months of treatment in an open-label trial (130).31P magnetic resonance spectroscopy demonstrated partial reversal of the surrogate biochemical markers cardiac phosphocreatine and skeletal muscle adenosine triphosphate after three months of treatment (130). Mitoquinone (MitoQ) is an antioxidant selectively targeted to mitochondria, resulting in a 100- to 500-fold accumulation of the construct in mitochondria (131). The ubiquinone derivative is embedded in the inner membrane of the mitochondrion where it is reduced by the respiratory chain to ubiquinol, which is an effective antioxidant that prevents lipid peroxidation and regenerates vitamin E (132–134). MitoQ is 800 times more potent than idebenone in protecting FRDA fibroblasts from death due to endogenous oxidative stress generated by glutathione synthesis inhibition (135). This drug has not yet been tested in people with FRDA. Iron Chelators Since excess mitochondrial iron is likely to play a role in the pathology of FRDA, iron chelators have potential in the treatment of FRDA. Desferioxamine (DFO), a parenteral iron chelator used in the treatment of iron overload conditions (such as transfusion dependent hemoglobinopathies), has
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
301
been tried in FRDA (136). The results have not been published, however, DFO is not likely to be beneficial as it cannot efficiently mobilize iron from iron loaded mitochondria (137,138). Deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one; L1) is an orally active iron chelator that is more effective than DFO in the removal of myocardial iron in patients with b-thalassemia (139). Even though no toxic effects from L1 were seen in healthy volunteers (140), the use of L1 in FRDA must be studied very carefully, since significant toxicity is possible. A group of iron chelators, 2-pyridylcarboxaldehyde isonicotinoyl hydrazone (PCIH) analogs, have been specifically designed to target mitochondrial iron pools (141). Several PCIH analogs show very high activity in mobilizing 59Fe from 59Fe-loaded mitochondria in reticulocytes. These agents are therefore being studied as potential therapies for FRDA (141). Glutathione Peroxidase Mimetics By blocking the rate-limiting enzyme in glutathione (GSH) synthesis, g-glutamyl cysteine synthase, with L-buthionine (S,R)-sulfoximine (BSO), cells become partly depleted of GSH and more susceptible to endogenous oxidative stress. FRDA fibroblasts are more sensitive to BSO treatment than control fibroblasts by a viability assay (142). FRDA fibroblasts treated with glutathione peroxidase (GPX) mimetics (ebselen, monoselenide, diselenide) showed increased viability. Further studies are needed to address the toxicity of GPX mimetics in humans before human FRDA trials can be considered. Increase Expression of Frataxin FRDA is due to reduction of frataxin expression to a few percent of normal levels, with a correlation between disease severity and residual levels of frataxin expression (61). A mouse model with 25–30% of normal frataxin levels did not show any phenotypic abnormalities (143). Therefore, it is estimated that a 5–10 fold increase in frataxin expression could be therapeutic, while lower levels of induction could still reduce disease severity and progression. A low level of enhancement of FRDA gene expression by hemin and butyric acid was initially demonstrated in BHK21 stable cell lines (144). Subsequently, resistance to cisplatin in a cancer cell line was associated with an increase in frataxin expression (145), and 3-nitropropionic acid was found to increase frataxin expression in human lymphoblasts and in transgenic rat PC12 cells (146). Gene and Cell Therapy Supplementing the mutant FRDA gene with a normal copy of the gene by gene therapy or by the transplantation of stem cells with normal frataxin
Copyright 2006 by Taylor & Francis Group, LLC
302
Delatycki et al.
production may be the most direct ways of overcoming the frataxin deficiency. However, there are limitations in applying such techniques safely and with high efficiency to many hard-to-reach tissues. CONCLUSION FRDA was initially characterized as a childhood onset disorder and now is recognized to have a variable phenotype that includes onset in middle adulthood. The severity of neurological features and involvement of other organ systems varies based on genetic mutation as well as other factors. During the last decade there has been great progress toward understanding the pathophysiology of FRDA and development of therapeutic targets that are now entering clinical trials.
REFERENCES 1. Friedreich N. Uber degenerative Atrophie der spinalen Hinterstrange. Virchow’s Arch Path Anat 1863; 26:391–419. 2. Friedreich N. Uber degenerative Atrophie der spinalen Hinterstrange. Virchow’s Arch Path Anat 1863; 26:433–459. 3. Friedreich N. Uber degenerative Atrophie der spinalen Hinterstrange. Virchow’s Arch Path Anat 1863; 27:1–26. 4. Friedreich N. Uber ataxie mit besonderer berucksichtigung der hereditaren formen. Virchow’s Arch Path Anat 1876; 68:145–245. 5. Friedreich N. Uber ataxie mit besonderer berucksichtigung der hereditaren formen. Virchow’s Arch Path Anat 1877; 70:140–152. 6. Harding A. The hereditary Ataxias and Related Disorders. Edinburgh: Churchill Livingstone, 1984. 7. Filla A, De Michele G, et al. Prevalence of hereditary ataxias and spastic paraplegias in Molise, a region of Italy. J Neurol 1992; 239:351–353. 8. Epplen C, Epplen J, et al. Differential stability of the (GAA)n tract in the Friedreich ataxia (STM7) gene. Hum Genet 1997; 99:834–836. 9. Cossee M, Schmitt M, et al. Evolution of the Friedreich’s ataxia trinucleotide repeat expansion: Founder effect and premutation. Proc Natl Acad Sci USA 1997; 94:7452–7457. 10. Pandolfo M. Friedreich ataxia. Semin Pediatr Neurol 2003; 10:163–172. 11. Geoffroy G, Barbeau A, et al. Clinical description and roentgenologic evaluation of patients with Friedreich’s ataxia. Can J Neurol Sci 1976; 3: 279–286. 12. Harding AE. Friedreich’s ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinical features. Brain 1981; 104:589–620. 13. Durr A, Cossee M, et al. Clinical and genetic abnormalities in patients with Friedreich’s ataxia. N Engl J Med 1996; 335:1169–1175.
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
303
14. Filla A, De Michele G, et al. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet 1996; 59:554–560. 15. Lamont PJ, Davis MB, Wood NW. Identification and sizing of the GAA trinucleotide repeat expansion of Friedreich’s ataxia in 56 patients. Clinical and genetic correlates. Brain 1997; 120:673–680. 16. Monros E, Molto MD, et al. Phenotype correlation and intergenerational dynamics of the Friedreich ataxia GAA trinucleotide repeat. Am J Hum Genet 1997; 61:101–110. 17. Montermini L, Richter A, et al. Phenotypic variability in Friedreich ataxia: role of the associated GAA triplet repeat expansion. Ann Neurol 1997; 41:675–682. 18. Delatycki M, Paris D, et al. A clinical and genetic study of Friedreich ataxia in an Australian population. Am J Med Genet 1999; 87:168–174. 19. Mateo I, Llorca J, et al. Expanded GAA repeats and clinical variation in Friedreich’s ataxia. Acta Neurol Scand 2004; 109:75–78. 20. Lynch DR, Farmer JM, et al. Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 2002; 59:743–747. 21. De Michele G, Perrone F, et al. Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich’s disease: a retrospective study on 119 patients. Neurology 1996; 47:1260–1264. 22. Beauchamp M, Labelle H, et al. Natural history of muscle weakness in Friedreich’s ataxia and its relation to loss of ambulation. Clin Orthop 1995; 311:270–275. 23. Schols L, Amoiridis G, et al. Friedreich’s ataxia. Revision of the phenotype according to molecular genetics. Brain 1997; 120:2131–2140. 24. Ackroyd RS, Finnegan JA, Green SH. Friedreich’s ataxia. A clinical review with neurophysiological and echocardiographic findings. Arch Dis Child 1984; 59:217–221. 25. Furman JM, Perlman S, Baloh RW. Eye movements in Friedreich’s ataxia. Arch Neurol 1983; 40:343–346. 26. Moschner C, Perlman S, Baloh RW. Comparison of oculomotor findings in the progressive ataxia syndromes. Brain 1994; 117:15–25. 27. Botez-Marquard T, Botez MI. Cognitive behavior in heredodegenerative ataxias. Eur Neurol 1993; 33:351–357. 28. White M, Lalonde R, Botez-Marquard T. Neuropsychologic and neuropsychiatric characteristics of patients with Friedreich’s ataxia. Acta Neurol Scand 2000; 102:222–226. 29. Wollmann T, Barroso J, et al. Neuropsychological test performance of patients with Friedreich’s ataxia. J Clin Exp Neuropsychol 2002; 24:677–686. 30. Junck L, Gilman S, et al. Structural and functional brain imaging in Friedreich’s ataxia. Arch Neurol 1994; 51:349–355. 31. De Michele G, Di Salle F, et al. Magnetic resonance imaging in ‘‘typical’’ and ‘‘late onset’’ Friedreich’s disease and early onset cerebellar ataxia with retained tendon reflexes. Ital J Neurol Sci 1995; 16:303–308. 32. Alboliras ET, Shub C, et al. Spectrum of cardiac involvement in Friedreich’s ataxia: clinical, electrocardiographic and echocardiographic observations. Am J Cardiol 1986; 58:518–524.
Copyright 2006 by Taylor & Francis Group, LLC
304
Delatycki et al.
33. Morvan D, Komajda M, et al. Cardiomyopathy in Friedreich’s ataxia: a Dopplerechocardiographic study. Eur Heart J 1992; 13:1393–1398. 34. Dutka DP, Donnelly JE, et al. Echocardiographic characterization of cardiomyopathy in Friedreich’s ataxia with tissue Doppler echocardiographically derived myocardial velocity gradients. Circulation 2000; 102:1276–1282. 35. Harding AE, Hewer RL. The heart disease of Friedreich’s ataxia: a clinical and electrocardiographic study of 115 patients, with an analysis of serial electrocardiographic changes in 30 cases. Q J Med 1983; 52:489–502. 36. Dutka DP, Donnelly JE, et al. Marked variation in the cardiomyopathy associated with Friedreich’s ataxia. Heart 1999; 81:141–147. 37. Finocchiaro G, Baio G, et al. Glucose metabolism alterations in Friedreich’s ataxia. Neurology 1988; 38:1292–1296. 38. Schoenle EJ, Boltshauser EJ, et al. Preclinical and manifest diabetes mellitus in young patients with Friedreich’s ataxia: no evidence of immune process behind the islet cell destruction. Diabetologia 1989; 32:378–381. 39. Fantus IG, Seni MH, Andermann E. Evidence for abnormal regulation of insulin receptors in Friedreich’s ataxia. J Clin Endocrinol Metab 1993; 76:60–63. 40. Delatycki M, Williamson R, Forrest S. Friedreich ataxia: an overview. J Med Genet 2000; 37:1–8. 41. Labelle H, Tohme S, et al. Natural history of scoliosis in Friedreich’s ataxia. J Bone Joint Surg Am 1986; 68:564–572. 42. Delatycki M, Holian A, et al. Surgery for equinovarus deformity in Friedreich’s ataxia improves mobility and independence. Clin Orthop 2005; 430:138–141. 43. Benomar A, Yahyaoui M, et al. Clinical comparison between AVED patients with 744 del A mutation and Friedreich ataxia with GAA expansion in 15 Moroccan families. J Neurol Sci 2002; 198:25–29. 44. Ouahchi K, Arita M, et al. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet 1995; 9: 141–145. 45. Perlman SL. Late-onset Tay-Sachs disease as a Friedreich ataxia phenocopy. Arch Neurol 2002; 59:1832. 46. Murayama S, Bouldin TW, Suzuki K. Pathological study of corticospinaltract degeneration in Friedreich’s ataxia. Neuropathol Appl Neurobiol 1992; 18:81–86. 47. Oppenheimer DR. Brain lesions in Friedreich’s ataxia. Can J Neurol Sci 1979; 6:173–176. 48. Lamarche JB, Lemieux B, Lieu HB. The neuropathology of ‘‘typical’’ Friedreich’s ataxia in Quebec. Can J Neurol Sci 1984; 11:592–600. 49. Koenig M, Durr A. Friedreich’s ataxia. In: Klockgether T, ed. Handbook of Ataxia Disorders. New York: Marcel Dekker, 2000. 50. Jitpimolmard S, Small J, et al. The sensory neuropathy of Friedreich’s ataxia: an autopsy study of a case with prolonged survival. Acta Neuropathol 1993; 86:29–35. 51. Hughes JT, Brownell B, Hewer RL. The peripheral sensory pathway in Friedreich’s ataxia. An examination by light and electron microscopy of the posterior nerve roots, posterior root ganglia, and peripheral sensory nerves in cases of Friedreich’s ataxia. Brain 1968; 91:803–818.
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
305
52. Casazza F, Morpurgo M. The varying evolution of Friedreich’s ataxia cardiomyopathy. Am J Cardiol 1996; 77:895–898. 53. Sanchez-Casis G, Cote M, Barbeau A. Pathology of the heart in Friedreich’s ataxia: review of the literature and report of one case. Can J Neurol Sci 1977; 3:349–354. 54. Lamarche J, Shapcott D, et al. Cardiac Iron Deposits in Friedreich’s Ataxia. New York: Marcel Dekker, 1993. 55. Hewer R. The heart in Friedreich’s ataxia. Br Heart J 1969; 31:5–14. 56. Unverferth DV, Schmidt WR II, et al. Morphologic and functional characteristics of the heart in Friedreich’s ataxia. Am J Med 1987; 82:5–10. 57. Chamberlain S, Shaw J, et al. Mapping of mutation causing Friedreich’s ataxia to human chromosome 9. Nature 1988; 334:248–250. 58. Campuzano V, Montermini L, et al. Friedreich’s ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science 1996; 271:1423–1427. 59. Pook MA, Al-Mahdawi SA, et al. Identification of three novel frameshift mutations in patients with Friedreich’s ataxia. J Med Genet 2000; 37:38e. 60. Montermini L, Andermann E, et al. The Friedreich ataxia GAA triplet repeat: premutation and normal alleles. Hum Mol Genet 1997; 6:1261–1266. 61. Campuzano V, Montermini L, et al. Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet 1997; 6:1771–1780. 62. Grabczyk E, Kumari D, Usdin K. Fragile X syndrome and Friedreich’s ataxia: two different paradigms for repeat induced transcript insufficiency. Brain Res Bull 2001; 56:367–373. 63. Vetcher AA, Wells RD. Sticky DNA formation in vivo alters the plasmid dimer/monomer ratio. J Biol Chem 2004; 279:6434–6443. 64. Napierala M, Dere R, et al. Structure-dependent recombination hot spot activity of GAA. TTC sequences from intron 1 of the Friedreich’s ataxia gene. J Biol Chem 2004; 279:6444–6454. 65. Bidichandani SI, Ashizawa T, Patel PI. The GAA triplet-repeat expansion in Friedreich ataxia interferes with transcription and may be associated with an unusual DNA structure. Am J Hum Genet 1998; 62:111–121. 66. Ohshima K, Montermini L, et al. Inhibitory effects of expanded GAA. TTC triplet repeats from intron I of the Friedreich ataxia gene on transcription and replication in vivo. J Biol Chem 1998; 273:14588–14595. 67. Saveliev A, Everett C, et al. DNA triplet repeats mediate heterochromatinprotein-1-sensitive variegated gene silencing. Nature 2003; 422:909–913. 68. Timchenko LT, Caskey CT. Trinucleotide repeat disorders in humans: discussions of mechanisms and medical issues. FASEB J 1996; 10:1589–1597. 69. Pianese L, Cavalcanti F, et al. The effect of parental gender on the GAA dynamic mutation in the FRDA gene. Am J Hum Genet 1997; 60:460–463. 70. Delatycki MB, Paris D, et al. Sperm DNA analysis in a Friedreich ataxia premutation carrier suggests both meiotic and mitotic expansion in the FRDA gene. J Med Genet 1998; 35:713–716. 71. De Michele G, Cavalcanti F, et al. Parental gender, age at birth and expansion length influence GAA repeat intergenerational instability in the X25 gene:
Copyright 2006 by Taylor & Francis Group, LLC
306
72. 73. 74.
75. 76.
77.
78. 79.
80.
81.
82.
83.
84.
85. 86.
87. 88.
Delatycki et al. pedigree studies and analysis of sperm from patients with Friedreich’s ataxia. Hum Mol Genet 1998; 7:1901–1906. Krasilnikova MM, Mirkin SM. Replication stalling at Friedreich’s ataxia (GAA)n repeats in vivo. Mol Cell Biol 2004; 24:2286–2295. Giacchetti M, Monticelli A, et al. Mitochondrial DNA haplogroups influence the Friedreich’s ataxia phenotype. J Med Genet 2004; 41:293–295. Fujita R, Agid Y, et al. Confirmation of linkage of Friedreich ataxia to chromosome 9 and identification of a new closely linked marker. Genomics 1989; 4:110–111. Chamberlain S, Shaw J, et al. Genetic homogeneity at the Friedreich ataxia locus on chromosome 9. Am J Hum Genet 1989; 44:518–521. Pandolfo M, Sirugo G, et al. Friedreich ataxia in Italian families: genetic homogeneity and linkage disequilibrium with the marker loci D9S5 and D9S15. Am J Hum Genet 1990; 47:228–235. Sirugo G, Keats B, et al. Friedreich ataxia in Louisiana Acadians: demonstration of a founder effect by analysis of microsatellite-generated extended haplotypes. Am J Hum Genet 1992; 50:559–566. Kostrzewa M, Klockgether T, et al. Locus heterogeneity in Friedreich ataxia. Neurogenetics 1997; 1:43–47. Christodoulou K, Deymeer F, et al. Mapping of the second Friedreich’s ataxia (FRDA2) locus to chromosome 9p23–p11: evidence for further locus heterogeneity. Neurogenetics 2001; 3:127–132. Klockgether T, Chamberlain S, et al. Late-onset Friedreich’s ataxia. Molecular genetics, clinical neurophysiology, and magnetic resonance imaging. Arch Neurol 1993; 50:803–806. De Michele G, Filla A, et al. Late onset Friedreich’s disease: clinical features and mapping of mutation to the FRDA locus. J Neurol Neurosurg Psychiatry 1994; 57:977–979. Palau F, De Michele G, et al. Early-onset ataxia with cardiomyopathy and retained tendon reflexes maps to the Friedreich’s ataxia locus on chromosome 9q. Ann Neurol 1995; 37:359–362. Klockgether T, Zuhlke C, et al. Friedreich’s ataxia with retained tendon reflexes: molecular genetics, clinical neurophysiology, and magnetic resonance imaging. Neurology 1996; 46:118–121. Keats BJ, Ward LJ, et al. ‘‘Acadian’’ and ‘‘classical’’ forms of Friedreich ataxia are most probably caused by mutations at the same locus. Am J Med Genet 1989; 33:266–268. Gibson TJ, Koonin EV, et al. Friedreich’s ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci 1996; 19:465–468. Koutnikova H, Campuzano V, et al. Studies of human, mouse and yeast homologues indicate a mitochondrial function for frataxin. Nat Genet 1997; 16:345–351. Babcock M, Silva DD, et al. Regulation of mitochondrial iron accumulation by Yfh 1p, a putative homolog of frataxin. Science 1997; 276:1709–1712. Foury F, Cazzalini O. Deletion of the yeast homologue of the human gene associated with Friedreich’s ataxia elicits iron accumulation in mitochondria. FEBS Lett 1997; 411:373–377.
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
307
89. Wilson R, Roof D. Respiratory deficiency due to loss of mitochondrial DNA in yeast lacking the frataxin homologue. Nat Genet 1997; 16:352–357. 90. Radisky DC, Babcock MC, Kaplan J. The yeast frataxin homologue mediates mitochondrial iron efflux. Evidence for a mitochondrial iron cycle. J Biol Chem 1999; 274:4497–4499. 91. Park S, Gakh O, et al. Yeast frataxin sequentially chaperones and stores iron by coupling protein assembly with iron oxidation. J Biol Chem 2003; 278: 31340–31351. 92. Foury F. Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett 1999; 456:281–284. 93. Muhlenhoff U, Richhardt N, et al. The yeast frataxin homolog Yfh1p plays a specific role in the maturation of cellular Fe/S proteins. Hum Mol Genet 2002; 11:2025–2036. 94. Lill R, Kispal G. Maturation of cellular Fe–S proteins: an essential function of mitochondria. Trends Biochem Sci 2000; 25:352–356. 95. Muhlenhoff U, Lill R. Biogenesis of iron-sulfur proteins in eukaryotes: a novel task of mitochondria that is inherited from bacteria. Biochim Biophys Acta 2000; 15:2–3. 96. Bulteau A-L, O’Neill H, et al. Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity. Science 2004; 305:242–245. 97. Cossee M, Puccio H, et al. Inactivation of the Friedreich ataxia mouse gene leads to early embryonic lethality without iron accumulation. Hum Mol Genet 2000; 9:1219–1226. 98. Puccio H, Simon D, et al. Mouse models for Friedreich ataxia exhibit cardiomyopathy, sensory nerve defect and Fe–S enzyme deficiency followed by intramitochondrial iron deposits. Nat Genet 2001; 27:181–186. 99. Simon D, Seznec H, et al. Friedreich ataxia mouse models with progressive cerebellar and sensory ataxia reveal autophagic neurodegeneration in dorsal root ganglia. J Neurosci 2004; 24:1987–1995. 100. Pandolfo M. Molecular pathogenesis of Friedreich ataxia. Arch Neurol 1999; 56:1201–1208. 101. Cavadini P, Gellera C, et al. Human frataxin maintains mitochondrial iron homeostasis in Saccharomyces cerevisiae. Hum Mol Genet 2000; 9:2523–2530. 102. Pook MA, Al-Mahdawi S, et al. Rescue of the Friedreich’s ataxia knockout mouse by human YAC transgenesis. Neurogenetics 2001; 3:185–193. 103. Sarsero J, Li L, et al. Human BAC-mediated rescue of the Friedreich ataxia knockout mutation in transgenic mice. Mamm Genome 2004; 15:370–382. 104. Delatycki MB, Camakaris J, et al. Direct evidence that mitochondrial iron accumulation occurs in Friedreich ataxia. Ann Neurol 1999; 45:673–675. 105. Rotig A, de Lonlay P, et al. Aconitase and mitochondrial iron–sulphur protein deficiency in Friedreich ataxia. Nat Genet 1997; 17:215–217. 106. Tan G, Napoli E, et al. Decreased expression of genes involved in sulfur amino acid metabolism in frataxin-deficient cells. Hum Mol Genet 2003; 12:1699–1711. 107. Tozzi G, Nuccetelli M, et al. Antioxidant enzymes in blood of patients with Friedreich’s ataxia. Arch Dis Child 2002; 86:376–379.
Copyright 2006 by Taylor & Francis Group, LLC
308
Delatycki et al.
108. Pastore A, Tozzi G, et al. Actin glutathionylation increases in fibroblasts of patients with Friedreich’s ataxia: A potential role in the pathogenesis of the disease. J Biol Chem 2003; 278:42588–42595. 109. Lenaz G, Bovina C, et al. Role of mitochondria in oxidative stress and aging. Ann NY Acad Sci 2002; 959:199–213. 110. Fridovich I. Superoxide radical and superoxide dismutases. Annu Rev Biochem 1995; 64:97–112. 111. Beinert H, Holm RH, Munck E. Iron–sulfur clusters: nature’s modular, multipurpose structures. Science 1997; 277:653–659. 112. Harris-Love MO, Siegel KL, et al. Rehabilitation management of Friedreich ataxia: lower extremity force-control variability and gait performance. Neurorehabil Neural Repair 2004; 18:117–124. 113. Bennett B. Increasing collaboration within a multidisciplinary neurorehabilitation team: the early stages of a small action research project. J Clin Nurs 1998; 7:227–231. 114. Wagner EH. The role of patient care teams in chronic disease management. BMJ 2000; 320:569–572. 115. Trend P, Kaye J, et al. Short-term effectiveness of intensive multidisciplinary rehabilitation for people with Parkinson’s disease and their carriers. Clin Rehabil 2002; 16:717–725. 116. Wade DT, Gage H, et al. Multidisciplinary rehabilitation for people with Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2003; 74:158–162. 117. Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. CMAJ 2003; 169:1173–1179. 118. Larsson EL, Aaro S, et al. Weight distribution in the sitting position in patients with paralytic scoliosis: pre- and postoperative evaluation. Eur Spine J 2002; 11:94–99. 119. Moosmann B, Behl C. Antioxidants as treatment for neurodegenerative disorders. Expert Opin Investig Drugs 2002; 11:1407–1435. 120. Suno M, Nagaoka A. Inhibition of lipid peroxidation by a novel compound (CV-2619) in brain mitochondria and mode of action of the inhibition. Biochem Biophys Res Commun 1984; 125:1046–1052. 121. Nagaoka A, Suno M, et al. Effects of idebenone (CV-2619) on neurological deficits, local cerebral blood flow, and energy metabolism in rats with experimental cerebral ischemia. Nippon Yakurigaku Zasshi 1984; 84:303–309. 122. Yamazaki N, Take Y, et al. Beneficial effect of idebenone (CV-2619) on cerebral ischemia-induced amnesia in rats. Jpn J Pharmacol 1984; 36:349–356. 123. Rustin P, Kleist-Retzow J-CV, et al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia. Lancet 1999; 354:477–479. 124. Hausse AO, Aggoun Y, et al. Idebenone and reduced cardiac hypertrophy in Friedreich’s ataxia. Heart 2002; 87:346–349. 125. Rustin P, Rotig A, et al. Heart hypertrophy and function are improved by idebenone in Friedreich’s ataxia. Free Radic Res 2002; 36:467–469. 126. Seznec H, Simon D, et al. Idebenone delays the onset of cardiac functional alteration without correction of Fe–S enzymes deficit in a mouse model for Friedreich ataxia. Hum Mol Genet 2004; 13:1017–1024.
Copyright 2006 by Taylor & Francis Group, LLC
Friedreich Ataxia
309
127. Mariotti C, Solari A, et al. Idebenone treatment in Friedreich patients: Oneyear-long randomized placebo-controlled trial. Neurology 2003; 60:1676–1679. 128. Buyse G, Mertens L, et al. Idebenone treatment in Friedreich’s ataxia: Neurological, cardiac, and biochemical monitoring. Neurology 2003; 60:1679–1681. 129. Filla A, Moss AJ. Idebenone for treatment of Friedreich’s ataxia? Neurology 2003; 60:1569–1570. 130. Lodi R, Hart PE, et al. Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich’s ataxia. Ann Neurol 2001; 49:590–596. 131. Kelso GF, Porteous CM, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: antioxidant and antiapoptotic properties. J Biol Chem 2001; 276:4588–4596. 132. Ingold KU, Bowry VW, et al. Autoxidation of lipids and antioxidation by alpha-tocopherol and ubiquinol in homogeneous solution and in aqueous dispersions of lipids: unrecognized consequences of lipid particle size as exemplified by oxidation of human low density lipoprotein. Proc Natl Acad Sci USA 1993; 90:45–49. 133. Kagan VE, Serbinova EA, et al. Assay of ubiquinones and ubiquinols as antioxidants. Methods Enzymol 1994; 234:343–354. 134. Maguire JJ, Wilson DS, Packer L. Mitochondrial electron transport-linked tocopheroxyl radical reduction. J Biol Chem 1989; 264:21462–21465. 135. Jauslin ML, Meier T, et al. Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants. FASEB J 2003; 17:1972–1974. 136. Smith JC, Kushner JP, et al. Evidence for mitochondrial iron overload in patients with Friedreich’s Ataxia. Proceedings of the Friedreich’s Research Conference. National Institutes of Health, Bethesda, MD, 1999. 137. Ponka P, Borova J, et al. Mobilization of iron from reticulocytes. Identification of pyridoxal isonicotinoyl hydrazone as a new iron chelating agent. FEBS Lett 1979; 97:317–321. 138. Ponka P, Grady RW, et al. The effect of various chelating agents on the mobilization of iron from reticulocytes in the presence and absence of pyridoxal isonicotinoyl hydrazone. Biochim Biophys Acta 1984; 802:477–489. 139. Anderson LJ, Wonke B, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360:516–520. 140. Stobie S, Tyberg J, et al. Comparison of the pharmacokinetics of 1,2-dimethyl-3hydroxypyrid-4-one (L1) in healthy volunteers, with and without co-administration of ferrous sulfate, to thalassemia patients. Int J Clin Pharmacol Ther 1993; 31:602–605. 141. Richardson DR, Mouralian C, et al. Development of potential iron chelators for the treatment of Friedreich’s ataxia: ligands that mobilize mitochondrial iron. Biochim Biophys Acta 2001; 1536:133–140. 142. Jauslin ML, Wirth T, et al. A cellular model for Friedreich Ataxia reveals small-molecule glutathione peroxidase mimetics as novel treatment strategy. Hum Mol Genet 2002; 11:3055–3063.
Copyright 2006 by Taylor & Francis Group, LLC
310
Delatycki et al.
143. Miranda CJ, Santos MM, et al. Frataxin knockin mouse. FEBS Lett 2002; 512:291–297. 144. Sarsero JP, Li L, et al. Upregulation of expression from the FRDA genomic locus for the therapy of Friedreich ataxia. J Gene Med 2003; 5:72–81. 145. Ghazizadeh M. Cisplatin may induce frataxin expression. J Nippon Med Sch 2003; 70:367–371. 146. Turano M, Tammaro A, et al. 3-Nitropropionic acid increases frataxin expression in human lymphoblasts and in transgenic rat PC12 cells. Neurosci Lett 2003; 350:184–186.
Copyright 2006 by Taylor & Francis Group, LLC
15 Autosomal Dominant Ataxias Susan L. Perlman Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, California, U.S.A.
INTRODUCTION The autosomal dominant (AD) ataxias are a group of disorders affecting the cerebellum and its afferent and efferent pathways. Their pattern of inheritance can be explained on the basis of mutation in a single gene. The trait controlled by this gene is deemed dominant if it manifests in the heterozygote – an AD ataxia is caused by a mutant allele that produces the ataxic phenotype in the affected individual, despite the presence of a normal allele on the second homologous chromosome. This can occur in a number of different ways. Most gene mutations result in an inactive gene product. Recessive disorders require both alleles to be defective, as one functioning normal allele will usually produce enough gene product to maintain normal function. If the function of the remaining normal allele is not sufficient to maintain normal cellular function, the resulting haploinsufficiency will cause dominant disease by ‘‘loss of function.’’ This mechanism may manifest later in life, when the activity of the normal gene may be lost in certain cell types due to an acquired problem, but most often occurs when the gene involved controls a critical rate-limiting step in a metabolic pathway or a regulatory or structural process that is sensitive to gene dosage effects. The mutant protein might also interfere with the action of the corresponding normal protein (dominant-negative effect), producing a similar loss of function. Most identified mutations to-date in the dominant ataxias, however, cause disease primarily by a toxic ‘‘gain of function.’’ The most common
Copyright 2006 by Taylor & Francis Group, LLC
312
Perlman
example is the CAG/CTG triplet repeat expansion in a coding region of the gene, which produces a mutant protein with an expanded polyglutamine sequence that triggers oxidative stress or premature apoptosis; interferes with normal cellular protein interaction, processing, or degradation; or affects other genes or gene products. There is evidence that suggests that the protein region containing the polyglutamine repeat is cleaved by caspases to produce fragments that enter the neuronal nucleus. These fragments aggregate in the cytoplasm and the nucleus, where chaperone proteins and proteosomal complexes act to refold or dispose of the fragments, to reduce aggregate formation. Aggregates that do form sequester other proteins, protein complexes (including proteosomes), and transcription factors to form inclusion bodies. Neuronal dysfunction ensues (possibly through activation of apoptotic cascades/glutamate receptor mechanisms, free radical production/ mitochondrial dysfunction, and axon transport defects), and cell death results. Recent studies in SCA2 have shown that the presence of cytoplasmic inclusions, in the absence of nuclear inclusions, is sufficient to cause neuronal death, possibly by disruption of the Golgi complex (1). These pathologic molecular mechanisms are seen as potential sites for therapeutic intervention and have been recently reviewed by several authors (2–11). The CAG/CTG triplet repeat expansion in the gene may be ‘‘unstable,’’ with a risk of expanding further during generational transfer (meiosis). Longer repeat lengths are associated with earlier age of onset and more severe phenotype, and triplet repeat disorders can show ‘‘anticipation’’ of upto 10–20 years earlier onset in succeeding generations. Similarly, an asymptomatic individual with a high normal or borderline expansion may pass on a fully expanded/disease-causing allele, a pattern of inheritance now known to underlie some forms of ‘‘new dominant’’ mutation (12). Advances in molecular genetic technology have focused on the CAG/ CTG expansion process and utilized the presence of larger than normal CAG/CTG sequences as possible markers for candidate genes for neurologic disease (13,14). The use of the repeat expansion detection (RED) methodology and other CAG/CTG dependent techniques may have preferentially identified the SCAs now attributable to triplet repeat dysfunction [12 of 27 proposed spinocerebellar ataxias (SCA) have had causative genes and mutations identified, six of which are CAG/CTG expansions]. Newer technologies may well be required to fully uncover all the molecular pathologies involved in causing autosomal dominant ataxia. The same mutation in a known genotype may result in a phenotype (age of onset, rate of disease progression, disease severity, and neurologic features) that varies from individual to individual. In the polyglutamine disorders, age of onset inversely correlates with CAG repeat length, and the size of the triplet repeat may influence other aspects of the phenotype as well (15,16). Phenotypic variability may also be due to a number of other genetic and non-genetic factors, including tissue mosaicism, other ‘‘modifying’’
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
313
genetic loci/promoters/polymorphisms, and lifestyle or environmental factors [e.g., the origin and effects of anti-gliadin antibodies found in patients with genetic ataxias (17–19)]. While some progress has been made in identifying the role of mosaicism in certain inherited ataxias [SCA1 (20), SCA2 (21), SCA3 (22,23)], research in the pursuit of modifying genes has only just begun [SCA3 (15,24)]. Epidemiologic factors are almost completely unexplored in these disorders. There is also no agreement as to which neurologic features of an SCA are directly due to the effects of the mutant gene and which might be related to other factors influencing disease progression, as the molecular basis of brain regional susceptibility within and between the SCAs is not fully understood (25–28). Transgenic animal models (Caenorhabditis elegans, Drosophila, Danio rerio/zebrafish, and mice) have been generated to further research into these molecular genetic mechanisms. There are now mouse models for SCA1 (29,30), 2 (31), 3 (32), 7 (33), 8 [Drosophila (34)], and DRPLA (35,36), which are serving to define the subcellular localization of pathogenesis and to act as templates for therapeutic intervention [chaperone overexpression (37,38), histone deacetylase inhibition (39), small inhibitory RNA action (10)] (40). An excellent introduction to medical genetics and methods of DNA testing can be found in a recent review by Pulst (41). The dominantly inherited ataxic disorders include the typical SCA, which now number 27 (including SCAs 1–26 and SCA with tremor and dyskinesia, due to mutation in the gene for fibroblast growth factor 14); the episodic ataxias (EA 1–5); and the atypical spinocerebellar ataxias, which may have prominent features other than ataxia. Of this latter group, only Dentatorubral– Pallidoluysian Atrophy/DRPLA) and Gerstmann–Straussler–Schienker/GSS disease will be mentioned here. There are excellent recent clinical reviews of the episodic ataxias (42–49). DRPLA has also recently been reviewed (50–52). Detailed overviews of the inherited prion diseases are continuing to evolve (53–58). Continuing updates can be searched at www.ncbi.nlm.nih.gov (PubMed, OMIM) and www.neuro.wustl.edu/neuromuscular/ataxia. Pathogenetic classification would group SCA1–3, 6, 7, 17, and DRPLA as polyglutamine disorders; SCA14, SCA due to FGF14, and GSS as resulting from point mutations; SCA6 and EA1 and 2 as channelopathies; and SCA8, 10, and 12 as repeat expansions outside the coding region that result in decreased gene expression. The molecular bases of SCAs 4, 5, 11, 13, 15, 16, and 18–25 are still unknown. THE TYPICAL DOMINANT ATAXIAS These SCAs have an incidence of 1–5 per 100,000 (SCA3 being the most common, followed by SCAs 1, 2, 6, 7, and 8; the others being quite rare) and an average age of onset in the third decade. They are difficult to distinguish on clinical grounds, but all share features of gait ataxia and slurred
Copyright 2006 by Taylor & Francis Group, LLC
314
Perlman
speech, on the basis of loss of cerebellar and brainstem neurons. The presence of certain associated features might be helpful in choosing the most likely diagnosis (Table 1), and neuroimaging may aid in that choice (59,60), but only genetic testing will be definitive. Gene testing is currently commercially available for only 10 of the SCAs, but will identify a mutant gene in about 50% of familial cases. Individuals with no family history, but an otherwise consistent clinical presentation, may be found to have a genetic cause 1–5% of the time, most commonly SCA6, fragile X-tremor ataxia syndrome (FXTAS), or late-onset Friedreich’s ataxia (an autosomal recessive disease) (61). SCA gene mutations may also be found in apparently sporadic cases when the family history is unclear or a parent is found to have an unstable triplet repeat expansion in the borderline range. A careful work-up should be done in all apparently sporadic cases, to also rule out acquired causes of ataxia. Some testing should be done even in individuals with a confirmed genetic cause, as the presence of a secondary factor (nutritional deficiency, thyroid dysfunction) can contribute to the phenotype. The diagnostic evaluation of patients with ataxia has been extensively reviewed in a recent publication (62). On-line resources to find commercial laboratories performing SCA testing can be found at www.geneclinics.org. These tests may cost $250–500 apiece—and the entire battery of available tests could run over $3000, posing a financial barrier to exact diagnosis in many cases. Harding’s seminal phenotypic classification of the AD cerebellar ataxias (ADCAI—Cerebellar syndrome plus pyramidal signs, supranuclear ophthalmoplegia, extrapyramidal signs, and dementia; ADCAII—Cerebellar syndrome plus pigmentary maculopathy; and ADCAIII—‘‘Pure’’ cerebellar syndrome, mild pyramidal signs) (63) may provide some guidance in prioritizing choices for gene testing (Table 2). It is increasingly recognized that access to genetic testing for the inherited ataxias can significantly improve patient management and family counseling (64). The molecular genetic features of the SCAs are summarized in Table 3. SCA1 Clinical Features Onset has been reported as young as four years of age and into the eighth decade, but is most common in the fourth decade. The initial course is one of pancerebellar dysfunction (gait ataxia, limb ataxia, dysarthria, and gaze-evoked nystagmus), but progressive pontine involvement leads to slowing of saccades and ophthalmoparesis. Pyramidal changes underlie the commonly seen spasticity, hyperreflexia, and extensor plantar responses. Mixed axonal peripheral neuropathies are seen in about half the patients, usually in those with higher CAG repeats. Amyotrophy is also reported. Frontal subcortical executive dysfunction is also found in about half. With disease progression, bulbar dysfunction with dysphagia, stridor, and vocal
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
315
Table 1 Associated Features in the Differential Diagnosis of the Spinocerebellar Ataxias Ataxic disorder SCA1 SCA2 SCA3
SCA4 SCA5 SCA6 SCA7 SCA8 SCA9 (reserved) SCA10 SCA11 SCA12 SCA13 SCA14 SCA15 SCA16 SCA17 SCA18 SCA19 SCA20 SCA21 SCA22 SCA23 SCA24 (reserved) SCA25 SCA26 SCA due to FGF14 EA-1
Typical associated clinical features beyond ataxia and dysarthria Hyperreflexia/spasticity, cerebellar tremor, dysphagia, optic atrophy Slow saccades, hyporeflexia, cerebellar tremor, Parkinsonism, dementia Nystagmus, spasticity (onset <35 yr), neuropathy (onset >45 yr), basal ganglia features, lid retraction, facial fasciculations Sensory axonal neuropathy, pyramidal signs Bulbar signs, otherwise ‘‘pure cerebellar’’ Nystagmus (often downbeat), otherwise ‘‘pure cerebellar,’’ onset >50 yr Macular pigmentary retinopathy, slow saccades, pyramidal signs Nystagmus, cerebellar tremor Nystagmus, seizures Nystagmus, hyperreflexia Nystagmus, arm tremor, hyperreflexia Nystagmus, hyperreflexia, mental & motor retardation, childhood onset Head tremor or myoclonus Nystagmus, hyperreflexia Nystagmus, head and hand tremor Dementia, psychosis, extrapyramidal features, hyperreflexia, seizures Nystagmus, Babinski sign, sensory-motor axonal neuropathy Cognitive impairment, nystagmus, tremor, myoclonus Palatal tremor, dysphonia Cognitive impairment, extrapyramidal features, hyporeflexia Nystagmus, hyporeflexia Slow saccades, pyramidal signs, sensory neuropathy Nystagmus, sensory neuropathy, gastric pain and vomiting Pure cerebellar Limb tremor, orofacial dyskinesia, cognitive/behavioral/ mood changes Brief episodes of ataxia or choreoathetosis, interictal neuromyotonia Phenytoin or carbamazepine responsive (Continued)
Copyright 2006 by Taylor & Francis Group, LLC
316
Perlman
Table 1 Associated Features in the Differential Diagnosis of the Spinocerebellar Ataxias (Continued ) Ataxic disorder EA-2
EA-3
EA-4
EA-5
DRPLA GSS
Typical associated clinical features beyond ataxia and dysarthria Episodes of ataxia lasting hours, interictal nystagmus, fatigue/weakness Acetazolamide responsive Episodes of ataxia with diplopia and vertigo, defective smooth pursuit Not acetazolamide responsive Kinesigenic episodes of ataxia and vertigo, with diplopia and tinnitus Acetazolamide responsive Similar to EA-2, but later-onset; generalized, absence, and myoclonic seizures Acetazolamide responsive Epilepsy, myoclonus (onset < 20 yr); Dementia, psychosis, choreoathetosis (onset > 20 yr) Dementia, pyramidal signs
cord paralysis; chorea or dystonia; and optic atrophy occur (65,66). The first decade of symptoms is one of progressive disability, while the second decade has greater morbidity and mortality, a general rule for most of the typical dominant ataxias. Laboratory Testing Brain MRI shows pontine and cerebellar atrophy. Magnetic resonance spectroscopy (MRS) may reveal early pontine change (67). Clinical severity has been found to correlate with quantitative volumetric, diffusion MRI and proton MR spectroscopy findings in the brainstem, suggesting possible use as a biomarker (68). Electronystagmography confirms this physiologically (69,70). Motor evoked potentials are abnormal, with slowed peripheral and central motor conduction times (71). Pathology Loss of neurons and neuronal connections occurs in the cerebellum (dentate nucleus, Purkinje cells), brainstem (inferior olive, red nucleus, and substantia nigra), spinal cord (spinocerebellar tract, Clarke’s nucleus, posterior columns, and anterior horn), and basal ganglia (globus pallidus externa). In the mouse model, there is early loss of Purkinje cell dendritic spines and branches, and symptomatology occurs before visible nuclear aggregates or cell loss are seen (72). (text continues on page 326)
Copyright 2006 by Taylor & Francis Group, LLC
Characteristic feature Pure cerebellar phenotype and MRI Complex phenotype, but pure cerebellar atrophy on MRI Brainstem involvement or atrophy on MRI Pyramidal involvement, hyperreflexia Extrapyramidal involvement Peripheral nerve involvement or hyporeflexia on the basis of spinal long tract changes Supratentorial features or MRI findings
Ocular features
Prominent postural/action tremor
Episodic features Early-onset (<20 yr) Most can have rare cases with early-onset
Genetic syndromes to consider ADCAIII—SCA5, 6, 8, 10, 11, 14, 15, 16, 22, 26 ADCAI—SCA4,18, 21, 23, 25, SCA due to FGF14 ADCAI—SCA1, 2, 3, 7, 13, DRPLA ADCAI—SCA1, 3, 4, 7, 8, 11, 12, 23 ADCAI—SCA1, 2, 3, 12, 21, DRPLA, FGF14 SCA1, 2, 3, 4, 8, 12, 18, 19, 21, 22, 25, FGF14 Cerebral atrophy—SCA2, 12, 17, 19 Subcortical white matter changes – DRPLA Dementia—SCA2, 7, 13, 17, 19, 21, DRPLA; or milder cognitive defects—SCA1, 2, 3, 6, 12; FXTAS Mental retardation—SCA13, 21, FGF14 Seizures—SCA7, 10, EA-5, DRPLA Psychosis—SCA3, 17, DRPLA, FGF14 Slow saccades—SCA1, 2, 3, 7, 23 Downbeat nystagmus—SCA6, EA-2 Maculopathy/ADCAII—SCA7 SCA2, 8, 12, 16, 19, 21, FGF14; FXTAS Palatal tremor—SCA20 (dentate calcification) Myoclonus—SCA1, 2, 3, 6, 7,14,19, DRPLA EA1-5, SCA6 Childhood—SCA2, 7,13,25, DRPLA, FGF14 Young adult—SCA1, 2, 3, 21
317
(Continued)
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
Table 2 Prioritizing Genetic Testing, as Tests Continue to Become Available
Prioritizing Genetic Testing, as Tests Continue to Become Available (Continued ) Genetic syndromes to consider
Characteristic feature Late-onset (>50 yr) Most can have rare cases with late-onset Rapid progression (death in <10 yr) (Average progression to disability is 5–10 yr, to death 10–20 yr) Slow progression over decades Anticipation/intergenerational DNA instability [usually paternal > maternal; maternal > paternal indicated by (m)] Variable phenotype
318
Table 2
SCA6 Early-onset SCA2, 3, 7, DRPLA SCA4, 5, 8, 11, 13, 14, 15, 16, 18, 20, 21, 22, 23, FGF14 Normal lifespan—SCA5, 6, 11, 18, FGF14 SCA1, 2, 3, 4, 5 (m), 6 (not due to repeat size), 7, 8 (m), 10, ?19, 20, ?21, 22, DRPLA SCA2, 3, 4, 5, 7, 14, 15, 17, GSS
Note: See www.geneclinics.org for test availability. Copyright 2006 by Taylor & Francis Group, LLC
Perlman
Ataxic disorder
Gene locus
SCA1
6p23
SCA2
SCA3/MachadoJoseph disease
SCA4
12q24
Gene/Product Ataxin-1
CAG expansion/coding exon
Ataxin-2
Normal < 39 repeats Disease-causing > 44 If not CAT interruption, diseasecausing 39–44 CAG expansion/coding exon
14q24.3-q31 Ataxin-3
16q22.1
Mutation
Unknown
Prevalence 6–27% of dominant ataxias worldwide
13–18% of dominant ataxias worldwide
Autosomal Dominant Ataxias
Table 3 Molecular Genetics of the Spinocerebellar Ataxias
Normal < 33 repeats, with CAA interruption. Disease-causing 33, with no CAA interruption (two patients with interrupted 34 expansion) CAG expansion/coding exon 23–36% of dominant ataxias Normal < 41 repeats worldwide Disease-causing 45 Homozygous mutant genes cause earlier-onset, more severe disease. Families in Utah & Germany; 6 Linkage studies with DNA families in Japan with laterpolymorphisms point to location, no onset pure cerebellar CAG expansion found despite syndrome evidence of anticipation. (Continued) 319
Copyright 2006 by Taylor & Francis Group, LLC
320
Table 3
Molecular Genetics of the Spinocerebellar Ataxias (Continued )
Ataxic disorder
Gene locus
SCA5
11p11-q11
SCA6
SCA7
SCA8
Copyright 2006 by Taylor & Francis Group, LLC
Unknown
Mutation
Linkage studies with DNA polymorphisms point to location, maternal anticipation suggests gene instability of unknown mechanism. CAG expansion/coding exon 19p13 CACNa1A/P/Qtype Normal < 19 repeats calcium channel Disease-causing 19 subunit (disease mechanisms may result Homozygous mutant genes cause earlier-onset, more severe disease. from both CAG repeat Allelic with EA-2 (gene truncations) and channelopathy and hemiplegic migraine (missense processes) mutations) CAG expansion/coding exon 3p21.1-p12 Ataxin-7 Component of Normal < 28 repeats TFTC-like Disease-causing 37 transcriptional Intermediate 28–36, may expand into complexes (disease disease range, especially with mechanisms may result paternal transmission from both CAG repeat and transcriptional dysregulatory processes) CTG expansion at 30 end 13q21 Normal product is an untranslated RNA that Normal < 80 repeats Disease-causing 80–300, although functions as a gene expansions in this range occur in regulator non-ataxic persons and in other neurologic diseases Expansions >300 may not cause disease in SCA8 pedigrees
Prevalence Lincoln family in US; families in Germany & France
10–30% of dominant ataxias worldwide
2–5% of dominant ataxias worldwide; may be more common in Sweden & Finland
2–4% of dominant ataxias worldwide; genetic testing results may be open to interpretation
Perlman
SCA9(reserved)
Gene/Product
SCA11
SCA12
SCA13 SCA14
Ataxin-10 Gene product essential for cerebellar neuronal survival
Mexican families (ataxia and epilepsy); 5 Brazilian families (no epilepsy)
2 British families
German-American family; may account for up to 7% of ADCA in India.
French family—7 of 8 affected members were women Japanese (axial myoclonus), English/Dutch, Dutch, and French (broader age of onset, cognitive impairment) families described. Incomplete penetrance. 321
Copyright 2006 by Taylor & Francis Group, LLC
Pentanucleotide repeat (ATTCT) expansion in intron 9, probable loss of function mutation Normal 22 repeats Disease 800–4500 Intergenerationally more likely to contract than expand 15q14-q21.3 Unknown Linkage studies with DNA polymorphisms point to location, possible evidence of anticipation in one family suggest intergenerational instability. 5q31-q33 PPP2R2B/brain specific CAG expansion in 50 untranslated region of gene, possibly upstream regulatory subunit of from transcription start site and protein phosphatase 2A affecting gene transcription. Minimal (serine/threonine intergenerational instability. phosphatase) 19q13.3Unknown Linkage studies with DNA q13.4 polymorphisms point to location 19q13.4PRKCG/Protein kinase Missense mutations in conserved qter Cg (serine/threonine residues of C1/exon 4—regulatory kinase) domain and in catalytic domain of the enzyme. Increased intrinsic activity of mutant enzyme moves intraneuronal distribution from cytosol to plasma membrane. May reduce expression of ataxin-1 in Purkinje cells, and mutant ataxin-1 may reduce expression of PRKCG 22q13
Autosomal Dominant Ataxias
SCA10
(Continued)
322
Table 3
Molecular Genetics of the Spinocerebellar Ataxias (Continued )
Ataxic disorder
Gene locus
SCA15
3p24.2-pter Unknown Region may contain gene(s) for three linked or allelic disorders
SCA16 SCA17/ Huntington disease-like 4
Unknown
Mutation Linkage studies with DNA polymorphisms point to location
Linkage studies with DNA polymorphisms point to location CAG/CAA expansion TATA box-binding protein (DNA binding Normal 42 repeats Disease-causing 45 subunit of RNA Intermediate 43–48, with incomplete polymerase II penetrance. transcription Minimal intergenerational instability. factorD (TFIID), Homozygous mutant genes cause essential for the earlier-onset, more severe disease. expression of all protein-encoding genes; Variable phenotypes include similarities to Huntington’s disease, disease mechanisms Parkinson’s disease, Alzheimer’s may result from both disease, and variant JacobCAG repeat and Creutzfeldt disease transcriptional dysregulatory processes)
Prevalence One Australian family (pure cerebellar), 2 Japanese families (with tremor/myoclonus), and one family with autosomal dominant congenital nonprogressive cerebellar ataxia One Japanese family Japanese, German, Italian, and French families
Perlman
Copyright 2006 by Taylor & Francis Group, LLC
8q22.1q24.1 6q27
Gene/Product
7q22-q32
Unknown
SCA19
1p21-q21
Unknown
SCA20
11p13-q11
Near SCA5 locus, gene/ product unknown
SCA21
7p21–15
Unknown
SCA22
1p21-q23
Unknown
SCA23
20p13–12.3 Unknown
SCA24(reserved) SCA25
2p15–21
Unknown
SCA26
19p13.3
Unknown
SCAduetoFGF14
13q34
Fibroblast growth factor 14
Linkage studies with DNA polymorphisms point to location Linkage studies with DNA polymorphisms point to location; possibly allelic with SCA22 Linkage studies with DNA polymorphisms point to location; repeat expansion detection did not show CAG/CTG or ATTCT/ AGAAT repeat expansions Linkage studies with DNA polymorphisms point to location; evidence of anticipation suggests intergenerational instability. Linkage studies with DNA polymorphisms point to location; possibly allelic with SCA19, but without cognitive impairment Linkage studies with DNA polymorphisms point to location Linkage studies with DNA polymorphisms point to location Linkage studies with DNA polymorphisms point to location Missense and frameshift mutations
One Irish-American family One Dutch family
Anglo-Celtic family in Australia
One French family
One Chinese family
One Dutch family
One southern French family. Incomplete penetrance. One family of Norwegian ancestry Dutch, German, and French families 323
(Continued)
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
SCA18
Ataxic disorder
Gene locus
EA-1
12p13
EA-2
19p13
EA-3
Not identified Not identified 2q22-q23
EA-4 EA-5
KCNA 1/Potassium voltage-gated channel component CACNa1A/P/Qtype voltage-gated calcium channel subunit
Unknown Unknown CACNB4b4/P/Qtype voltage-gated calcium channel subunit; two domains interact with a1 subunit.
Mutation
Prevalence
Rare families worldwide. Missense mutations cause altered neuronal excitability in CNS and PNS. Point mutations in exons and introns Rare families worldwide. De novo mutations in 25% of (nonsense, missense) and small cases. deletions; mutations cause reduced calcium channel activity in CNS and PNS. Allelic with familial hemiplegic migraine and SCA6; 2 families with CAG expansion and phenotype of episodic ataxia. Linkage excluded to EA-1 and EA-2 North Carolina families Linkage excluded to EA-1 and EA-2. Clinically different from EA-3. Point mutations leading to aminoacid substitution or premature stop codon; mutations cause altered calcium channel activity in CNS.
Canadian Mennonite family French-Canadian family (phenotype similar to EA-2 with later-onset, incomplete penetrance). German family with seizures. Michigan family with phenotype of juvenile myoclonic epilepsy (premature stop codon).
Perlman
Copyright 2006 by Taylor & Francis Group, LLC
Gene/Product
324
Table 3 Molecular Genetics of the Spinocerebellar Ataxias (Continued )
GSS
12p13.31
20p12
Atrophin-1 Required in diverse developmental processes; interacts with even-skipped homeobox 2 repressor function.
PrP/prion protein
1–5% of dominant ataxias CAG expansion/coding exon worldwide; 10–20% of ADCA Normal < 26 in some areas of Japan. Disease-causing 49 Intermediate 37–48, may expand into disease range, especially with paternal transmission. Homozygous mutant genes cause earlier-onset, more severe disease; homozygous intermediate genes may cause a recessive predominantly spinal syndrome. Allelic with Haw River syndrome (no seizures). Rare families worldwide. Point mutations causing aminoacid substitutions in PrP or octapeptide insertions, resulting in proteinase K resistant form of protein which accumulates in CNS.
Autosomal Dominant Ataxias
DRPLA
Note: See www.ncbi.nlm.nih.gov (PubMed, OMIM) and www.neuro.wustl.edu/neuromuscular/ataxia for continuing updates.
Copyright 2006 by Taylor & Francis Group, LLC
325
326
Perlman
Molecular Genetic Features (See also Table 3) The SCA1 gene was identified and cloned in 1994 by the collaborative efforts of the laboratories of Zoghbi and Orr (73). Disease results from a CAG trinucleotide repeat expansion in the reading frame of the gene, producing a polyglutamine expansion in the protein product. The normal CAG range is from 6 to 38 repeats. The intermediate range, 39–44 repeats, will cause disease if CAT interruptions in the sequence are lacking. Disease has been associated with repeat expansions from 41 to 83. Lack of CAT interruptions in the CAG sequence predisposes to meiotic enlargement of the triplet repeat disease-causing range or to expansion from a non-disease causing size to a disease-causing size. Increased numbers of CAG repeats correlate with earlier onset, greater severity, and the appearance of upper motor neuron features, but not with increased rapidity of progression. Earlier onset with a generational increase in CAG length (anticipation) is seen more with paternal than maternal transmission and may lower age of onset by 10 years per generation. In homozygotes, disease severity corresponds to the size of the larger allele (65). The protein product (ataxin-1) is found in cytoplasm systemically and in the nucleus in neuronal cells. The intranuclear inclusions of SCA1 occur in neurons most affected by disease (Purkinje cells), stain for ubiquitinated ataxin-1, and interact with leucine-rich acidic nuclear protein (LANP), ubiquitin, and HSP-40 chaperone. LANP may play a key role in neuronal development and/or neurodegeneration by its interactions with microtubule associated proteins, so its sequestration in the inclusions could impair maintenance of dendritic structure (74), even before other polyglutaminemediated pathologic processes occur. SCA2 Clinical Features Onset usually is between five years of age and into the seventh decade, with 40% becoming symptomatic before the age of 25. Very small repeat expansions (33) are associated with onset in the ninth decade, and very large expansions (>200) are associated with onset before the age of one (75). The initial course is one of pancerebellar degeneration with early apparent slowed saccades, tremor and titubation, myoclonus, chorea, facial fasciculations, and reduced reflexes. Axonal sensory polyneuropathy affecting the lower extremities (especially vibratory sensation) is seen in 80% and increases with age. Amyotrophy, leg weakness, or upgoing toes occur in only 20%. With longer duration of illness, ophthalmoplegia (nuclear and supranuclear), dysphagia, reduced deep tendon reflexes, bladder/sphincter disturbance, and cognitive impairment become apparent in about 50% of patients, reflecting progressive pontine, neuropathic, and cerebral involvement. With earlier
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
327
onset disease, more rapid progression, greater slowing of saccade velocity (76), more severe bulbar dysfunction, and more notable involuntary movements (myoclonus, dystonia, and myokymia) are seen. L-dopa-responsive Parkinsonism may occasionally be the presenting or predominant feature in a family or individual (77). Anticipation in families, more commonly with paternal transmission, can be up to 26 years per generation and averages 20 years. Laboratory Testing Brain MRI shows severe pontine and cerebellar atrophy. However, there was no correlation found between clinical severity and quantitative volumetric, diffusion MRI and proton MR spectroscopy findings in the brainstem (68). Pathology The most prominent neuronal loss is seen in the brainstem, affecting pontine nuclei and the inferior olives. Changes are also seen in Purkinje cells and white matter of the cerebellum, substantia nigra, and the cerebral subcortical white matter. Spinal cord pathology occurs in Clarke’s nucleus and spinocerebellar tracts, posterior columns and dorsal root ganglia, and corticospinal tracts. Molecular Genetic Features (See also Table 3) The SCA2 gene was identified and cloned by three separate research groups in three countries by three different methods and reported in back to back articles in 1996 (78–80). Disease results from a CAG trinucleotide repeat expansion in the reading frame of the gene, producing a polyglutamine expansion in the protein product, whose normal function is not known, but may be involved in translational regulation (81). Normal alleles (14–32 repeats, most common 22) often have stabilizing CAA interruptions in the CAG sequence, while > 95% of patients have no interruptions. An interrupted 34-CAG repeat allele has been reported in two sporadic patients (82). Disease-causing expansions range from 33 to 77 in the adult form of the illness (most common 37 repeats), while the infantile and childhood forms may have expansions exceeding 200 repeats. Intergenerational expansions are more common with paternal transmissions, and anticipation can be up to 26 years. The protein product (ataxin-2) is expressed in brain and systemic tissue, with the highest levels in ependyma and choroids plexus, followed by Purkinje cells, substantia nigra neurons, and trochlear nuclei. Levels of protein increase with age in SCA2, and there is increased perinuclear staining for the protein over time. Mutant ataxin-2 disrupts the Golgi apparatus (1) and induces cell death without nuclear aggregates (31), although aggregates can be seen in brainstem nuclei and are more likely with very large CAG expansions.
Copyright 2006 by Taylor & Francis Group, LLC
328
Perlman
SCA3 Clinical Features SCA3/Machado-Joseph disease, the most common of the typical dominant spinocerebellar ataxias, has several allelic clinical syndromes that vary in age of onset and symptomatology, although within families the clinical presentation usually remains consistent, despite the occurrence of anticipation (paternal > maternal). An affected male parent will transmit the abnormal allele 73% of the time (83,84). Larger CAG repeat expansions contribute to earlier onset, more rapid progression, and more dystonia and spasticity. Homozygotes will have an earlier onset, more severe presentation. The most common presentation (type III) is a typical dominant ataxia, onset in the fourth to seventh decade, with spasticity, progressive axonal sensory (especially temperature discrimination) > motor polyneuropathy (54%), ophthalmoparesis with both vestibular and nuclear features, facial and lingual fasciculations, and autonomic dysfunction. Sleep disturbance due to restless legs syndrome and periodic leg movements of sleep is common. These features reflect spinopontine atrophy and are most commonly seen in patients of German or Dutch-African descent. The original discussions of ‘‘Machado-Joseph disease,’’ in the AzoreanPortuguese population, emphasized the ataxia, extrapyramidal features, and ‘‘bulging eyes’’ and noted additional phenotypes. Type I was the earliest onset (age 5–30 years), with a more spastic/dystonic presentation. Type II had onset in the fourth decade and shared features of Types I and III. Type IV was the oldest onset and more likely to present as L-dopa responsive Parkinsonism or as a peripheral neuropathy with fasciculations, amyotrophy, and sensory loss. A fifth type with spastic paraparesis has been described in Japanese pedigrees. The clinical syndrome may overlap with DRPLA (extrapyramidal features) or multiple system atrophy (MSA) (extrapyramidal and autonomic features). Laboratory Testing Brain MRI shows an enlarged fourth ventricle and mild cerebellar and brainstem atrophy. Electronystagmography confirms impaired vestibuloocular reflex gain, and nerve conduction velocity studies confirm small motor and sensory action potential amplitudes, consistent with axonal loss. Pathology Basal ganglia pathology is prominent, with changes in globus pallidus interna, subthalamic nucleus, substantia nigra, and red nucleus. There is also notable change in cerebellar connections, in the dentate nucleus, spinocerebellar tracts, and pontine nuclei. Inferior olives are spared. Cranial nerve nuclei in the brainstem show involvement. Mild spinal cord changes are seen in Clarke’s nucleus, anterior horn, and posterior column.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
329
Molecular Genetic Features (See also Table 3) The SCA3 gene was cloned in 1994, revealing a CAG trinucleotide repeat expansion in the reading frame of the gene, producing a polyglutamine expansion in the protein product (ataxin-3), whose function is unknown (85). Ataxin-3 is located in the cytoplasm of the neuronal soma and processes. Ataxin-3-containing ubiquitinated intranuclear inclusions are found only with disease-causing mutations in affected brain areas, where conformationally altered protein is bound to the nuclear matrix. The presence of a polymorphism near the CAG expansion region has made possible research into the use of small inhibitory RNAs to selectively reduce the production of mutant ataxin-3 (11). SCA4 Clinical Features SCA4 has also been found to have at least two distinct phenotypes. In a Scandinavian-American family in Utah and a German family, a progressive cerebellar syndrome with sensory > motor axonal polyneuropathy, onset in the second to sixth decade, was described (86). Distal weakness is seen in about 20%. While tendon reflexes are typically absent in the lower extremities, plantar responses have been noted to be extensor in 10–20%. Anticipation of 5–7 years per generation is seen. Progression is typically slow over decades. A pure cerebellar syndrome has also been reported in Japanese families, onset in the fifth to eighth decade (87), beginning with midline and lower extremity dysfunction and progressing to fine finger incoordination, with saccadic pursuit, dysarthria, and hypotonia in over 50%. Laboratory Testing Brain MRI shows cerebellar atrophy. Electrodiagnostic studies confirm the axonal neuropathy, with sensory action potential absence in >90% and motor action potential reduction in 38%. Pathology Atrophy and loss of Purkinje cells is seen in the cerebellum, with accompanying loss of dorsal root ganglion cells and of axons in the posterior columns of the spinal cord and axons in peripheral nerve. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product or the mechanism of damage caused by the mutant protein. Despite the presence of anticipation, analysis of nine CAG/CTG tracts in the candidate region revealed no evidence for a repeat expansion (88). No other candidate genes have been identified (87).
Copyright 2006 by Taylor & Francis Group, LLC
330
Perlman
SCA5 Clinical Features SCA5 was first reported in an American pedigree descended from the paternal grandparents of Abraham Lincoln (89). It has also been reported in a German kindred (90). Onset is in the second to fifth decade, with a mean age of 33 years. Anticipation is probable. The features of a predominantly cerebellar syndrome also include downbeat nystagmus, impaired smooth pursuit, and in some families horizontal gaze palsy, facial myokymia, and impaired vibration sense. Laboratory Testing Brain MRI shows atrophy of the cerebellar vermis and hemispheres, with sparing of brainstem and supratentorial structures. Nerve conduction studies are normal. Pathology This Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA6 Clinical Features SCA6, a CAG repeat expansion disorder, has onset typically in the fifth or sixth decade (60% are over the age of 50), with onset in the third or fourth decade occurring with larger CAG repeat expansions or homozygosity/ compound heterozygosity. There is intergenerational stability in the repeat size, so generational variation in age of onset or severity may relate to factors other than repeat size. Twenty-seven percent of cases may appear to be sporadic. SCA6 represents 10–30% of the dominant ataxias. The first symptoms may be episodic sensations of vertigo or instability on turning, which slowly progress over decades to a typical cerebellar syndrome, affecting speech and truncal stability, more than limb incoordination. Progression to use of a wheelchair may occasionally occur in the first decade. Two families with CAG expansions retained a phenotype of episodic ataxia. Downbeating nystagmus is a common oculomotor feature, but all cerebellar-mediated eye findings (horizontal gaze-evoked nystagmus, rebound nystagmus, impaired vestibule-ocular reflex, impaired smooth pursuit, but normal saccade velocities and VOR gain) can be seen. Vestibularmediated symptoms may cause a sense of imbalance with head movement, but other brainstem features occur only late in the disease (dysphagia).
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
331
Some patients have a mild sensory neuropathy with loss of vibration and proprioception. Bradykinesia and frontal subcortical dementia may occur. Laboratory Testing Brain MRI shows cerebellar hemispheric and vermian atrophy, with slight atrophy of the red nucleus. Mild pontine and middle cerebellar peduncular atrophy have also been reported (91). Single-fiber and microelectrode electrophysiologic studies of the neuromuscular junction are normal, as opposed to jitter and blocking, reduced endplate potential and quantal content, and ultrastructurally smaller nerve terminals seen in EA-2, which has myasthenic weakness as an associated symptom. Pathology Pathology is localized to the cerebellum and its connections, with loss of Purkinje cells and mild changes in the inferior olivary nucleus and dentate nucleus. Intranuclear inclusions are not seen. Molecular Genetic Features (See also Table 3) In 1997, by genotype survey, Zhuchenko et al., found a CAG repeat expansion in the CACNA1A gene in eight unrelated families who showed a very similar clinical picture consisting predominantly of mild but slowly progressive cerebellar ataxia of the limbs and gait, dysarthria, nystagmus, and mild vibratory and proprioceptive sensory loss (92). Normal CAG lengths are 4–19. Disease-causing are 20–31 repeats. SCA6 is allelic to familial hemiplegic migraine and EA-2 (93). Familial hemiplegic migraine Type I is commonly caused by one of several reported missense point mutations in the CACNA1A gene—e.g., T666M which causes hemiplegic migraine (severe with coma in 50%) with nystagmus in 86%; R583Q where ataxia not nystagmus can be seen in 81%; and D715E with relatively fewer hemiplegic attacks (64%) and possible tremor (94). Familial hemiplegic migraine Type II, however, has similar features (including cerebellar dysfunction), but results from mutations in ATP1A2 on chromosome 1q23, encoding a Naþ/Kþ -ATPase subunit (95). EA-2 results from nonsense (R1281X, and R1549X) or missense (C27Y, G293R, F1406C, F1493S, R1666H, and E1761K) point mutations in the CACNA1A gene, or occasionally small deletions. It is characterized by acetazolamideresponsive attacks of ataxia (with vertigo or generalized weakness in 50%) interictal nystagmus, and a slowly progressive baseline cerebellar deficit (44). Both of these allelic disorders have an average age of onset before 20 years, and the episodes (hemiplegic migraine or ataxia with nystagmus) may be triggered by emotional or physical stress. The attacks of hemiplegia, however, can last days, whereas the attacks of ataxia last just a few hours. SCA6 pedigrees may show increased numbers of individuals with vascular headaches, vertigo, motion sickness, or epilepsy, without ataxia. The
Copyright 2006 by Taylor & Francis Group, LLC
332
Perlman
episodic features of SCA6 may respond to acetazolamide, as do the episodic features of EA-2. Ongoing research has put in place a detailed understanding of the molecular genetics and pathophysiology of the voltage-gated calcium channel in progressive cerebellar ataxia. Some debate remains about whether SCA6 is primarily a glutamine expansion disorder or a channelopathy (96). A loss-of-function model has been proposed, whereby the mutant protein interferes with the ability of the calcium channel to reduce Ca2þ influx and abolishes the cell-deathpreventing effect of the normal Ca2þ channel (97). SCA7 Clinical Features The only confirmed genetic cause of ADCAII (ataxia with retinal degeneration), SCA7 is also a CAG trinucleotide repeat expansion and has a broad age of onset (1 month to 76 years), dependent on the size of the CAG repeat expansion. Earlier onset disease is more severe and may lead to death in as little as two years, while the later onset presentations may progress slowly over decades. Paternal transmission is associated with anticipation of 20 or more years per generation. Expansions from the intermediate range of repeats in an asymptomatic parent to the symptomatic range in an affected child may also occur. The typical onset is in adolescence with repeats in the mid-range. Ataxia may be the first symptom, but with larger CAG expansions macular degeneration may precede ataxia by 10 years. Early blue–green color blindness is reported, followed by macular degeneration and visual loss in 83%. Blindness occurs in about 28% of those affected. Ophthalmoplegia (supranuclear and with slow saccades and ptosis) develops in 70%. Pyramidal signs and hearing loss are also reported. The infantile form includes features of microcephaly, cardiac failure, hepatomegaly, hemangiomas, and capillary leak syndrome, as well as developmental delay, hypotonia, and a rapidly fatal course. With the smallest expansions, patients may become only mildly symptomatic at an advanced age. Laboratory Testing Brain MRI shows early pontine and cerebellar atrophy (98). Ophthalmologic studies reveal pigmentary retinopathy in 43% and optic atrophy in 69%. There is no peripheral nerve change. Pathology Purkinje cell, inferior olive, and dentate nuclear changes are prominent. Subthalamic nucleus and substantia nigra show involvement, in addition to cerebral atrophy, loss of anterior horn cells, and reduced axons in posterior columns, spinocerebellar tracts, and pyramidal tracts.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
333
Intranuclear inclusions are seen, most frequently in the inferior olivary neurons, where 60% are ubiquitinated. They do not contain LANP. Some protein may also accumulate in the cytoplasm of affected neurons. Mitochondrial abnormalities are occasionally reported in muscle and liver, with reduced Complex IV activity. Molecular Genetic Features (See also Table 3) The SCA7 gene was cloned in 1997, revealing a CAG trinucleotide repeat expansion in the reading frame of the gene, producing a polyglutamine expansion in the protein product (ataxin-7) (99). Normal CAG lengths are 4–27 repeats, with 10 being the most common. Disease-causing expansions range from 37 to >200. The average expansion in typical late-adolescent onset disease is 54–55 repeats. The infantile form is associated with expansions >200 repeats. Shorter expansions (38–43 repeats) may remain asymptomatic until later adulthood. Expansions in the intermediate range (28–36 repeats) are rare in the general population, but occur with increased frequency in SCA7 pedigrees—leading to the risk of de novo expansion (usually in paternal transmission) into the disease-causing range. Parent to child transmission can increase the repeat size four- to nine-fold. Ataxin-7 is localized in the nucleus (matrix and nucleolus). It is an integral component of the mammalian SAGA-like complexes TFTC (TATAbinding protein-free TAF-containing complex) and STAGA (SPT3/TAF9/ GCN5 acetyltransferase complex), which are involved in transcription (100). Over-expression of mutant ataxin-7 in neuronal and extra-neuronal cells causes fibrillar caspase-3 containing inclusion formation and changes in proteosomes, components of the toxic gain of function proposed for triplet repeat disorders. It also inhibits function of the cone-rod homeobox protein (CRX) in photoreceptors, an innocent bystander effect that may be the cause of the associated maculopathy (101). SCA8 Note—The name SCA8 was previously assigned to the recessively inherited infantile onset spinocerebellar ataxia (IOSCA), mapped to 10q24 by a Finnish group in 1995 (102), but has been reassigned to reflect the classification system for the dominant ataxias accepted and monitored by the HUGO Nomenclature Committee (103–105). Clinical Features SCA8, the result of a CTG expansion, has a uniform presentation in families, but may vary from family to family or in apparent sporadic cases. It may present from the first year of life until the eighth decade, the average age of onset being in the fifth decade. Incomplete penetrance may make the dominant transmission difficult to recognize in an isolated individual presenting with
Copyright 2006 by Taylor & Francis Group, LLC
334
Perlman
ataxia. Gait, trunk, and limb ataxia, dysarthria, and impaired smooth pursuit are seen in 100% of cases, with horizontal nystagmus in 67%, sensory neuropathy (vibratory sense reduction) in 25%, and spastic dysarthria with increased deep tendon reflexes and extensor plantar responses in those most severely affected. Progression is slow, with ambulatory aids often not being required during the first 20 years of illness. Symptom severity correlates with repeat length and age (106,107). One case with congenital onset presented with severe cerebellar symptoms in the first year, myoclonic epilepsy at three years, and mental retardation. Presentation typical of idiopathic Parkinson’s disease with late onset of disease, resting tremor in the limbs, rigidity, bradykinesia, and a good response to levodopa has also been noted (108). Laboratory Testing Brain MRI shows cerebellar vermis and hemispheric atrophy. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The clinical syndrome of SCA8, first reported in 1999, is associated with an expanded CTG repeat in the 30 untranslated region of transcribed RNA from the SCA8 gene, which is felt to act as a gene regulator (109). CTG expansions in transcribed but untranslated DNA are also associated with myotonic dystrophy Type I (19q13.2-q13.3) (CTG) (110) and Type II (3q13.3-q24) (CCTG) (111). The SCA8 transcript is found in brain and at low levels in lung. Its CTG repeat has five ranges: a very short normal length (15–21 repeats) in 19%; a short normal length (22–37 repeats, 24 the most common) in 80%; an intermediate ‘‘normal’’ length (40–91 repeats) in 0.7%, although 80 repeats has caused symptoms in some families; a disease-causing length (100–155 repeats, occasionally up to 300 repeats); and a very large asymptomatic range (300–800 repeats), which with intergenerational transmission can contract back into the symptomatic range. The CTG expansion is very unstable and may expand or contract, with maternal anticipation (11 to þ600 repeats) more prominent than paternal (86 to þ16 repeats). Affected SCA8 individuals have usually inherited the CTG expansion from the mother. There is no correlation of age of onset or disease severity with CTG size. Somatic mosaicism is reported in normal and expanded transcripts. Individuals from SCA8 pedigrees with diseasecausing expansions may be asymptomatic, and CTG expansions have been reported in normal and disease control populations (Parkinson’s disease, Alzheimer’s disease, SCA1, SCA3, and SCA6). The pathophysiologic behavior of this CTG expansion is still not completely understood.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
335
SCA9 This section is reserved. SCA10 Clinical Features SCA10 is also the result of a disease-causing expansion in transcribed but untranslated DNA, in this case a pentanucleotide repeat (ATTCT). It is a rare SCA, being originally described in a set of Mexican families (112) and more recently in five Brazilian families (113). The phenotypes differ between the two populations. In the Mexican pedigrees, onset is between the ages of 10 and 40, with gait ataxia (which may progress to wheelchair use), followed by limb ataxia, dysarthria, gaze-evoked nystagmus, and smooth pursuit fragmentation. Complex partial seizures with/without secondary generalization contribute to morbidity and mortality and are seen in 50% of patients, either at onset or with disease progression. Personality changes are reported in some (apathy, and depressed affect). The Brazilian families did not develop seizures. Anticipation is seen, especially with paternal inheritance, and may move up disease onset by 20 years. Laboratory Testing Brain MRI shows cerebellar atrophy. EEG shows epileptiform discharges in about 50%. Nerve conduction studies are normal. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The clinical syndrome of SCA10, first reported in 2000, is associated with an expanded ATTCT repeat in intron 9 of the SCA10 gene (112). The normal range of repeats is 10–22 uninterrupted ATTCT sequences. The diseasecausing range is from 800 to 4500 repeats. The gene product, ataxin-10, is predominantly cytoplasmic and perinuclear in localization and restricted to olivocerebellar regions. Blocking of SCA10 in neuronal cells by small interfering RNAs results in increased apoptosis of cerebellar neurons, suggesting a loss-of-function process in SCA10 patients, although the associated epiloptogenesis has not yet been explained (114). Family-dependent factors may alter the frequency of the seizure phenotype (115). The ATTCT expansion is unstable and may expand or contract by hundreds of repeats, more so with paternal transmission. There is somatic mosaicism, observed in leukocytes, lymphoblastoid cells, buccal cells, and
Copyright 2006 by Taylor & Francis Group, LLC
336
Perlman
sperm. A larger number of repeats correlates with younger age of onset, but other factors may influence the rest of the clinical phenotype. SCA11 Clinical Features This SCA has been reported in two British families (116). Its age of onset is 17–33 years, presenting with a slowly progressive gait disorder, dysarthria, saccadic pursuit, horizontal > vertical gaze-evoked nystagmus, and hyperreflexia. Limb ataxia develops in about 93%. Life expectancy is normal. Anticipation was possible in one family. Laboratory Testing Brain MRI shows cerebellar atrophy. Nerve conduction studies are normal. Pathology Pathology is unknown. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA12 Clinical Features SCA12 was reported in a German-American family with a progressive gait ataxia with dysarthria and head/arm tremor (117). It showed onset between the ages of 8 and 55 years, with average onset in the fourth decade. Onethird of patients had eye movement abnormalities, with slow saccades, saccadic pursuit, and nystagmus. Tendon reflexes were increased in 80% and mild axonal sensory > motor polyneuropathy was noted in 80%. Thirtythree percent had facial myokymia. Axial dystonia and bradykinesia were reported to occur. Dementia was noted in the oldest patients. More recent surveys have shown a notable incidence in India, where SCA12 may account for 7% of all ADCA (118). Laboratory Testing Brain MRI shows cortical and cerebellar atrophy. Nerve conduction velocities confirm axonal loss. Pathology Pathology has not yet been reported.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
337
Molecular Genetic Features (See also Table 3) SCA12 is associated with an expansion of a CAG repeat in the 50 untranslated region of the gene PPP2R2B, possibly upstream from the transcription start site. PPP2R2B encodes a brain-specific regulatory subunit of the protein phosphatase PP2A. Normal repeat length is 7–32. Disease-causing repeat lengths are from 55 to 93 uninterrupted repeats. There is minor repeat size instability over generations. It is possible that an expansion mutation in PPP2R2B may influence PPP2R2B expression, perhaps altering the activity of PP2A, an enzyme implicated in multiple cellular functions, including cell cycle regulation, tau phosphorylation, and apoptosis (119). This would be another example (see SCA6, SCA10, and SCA17) of a repeat expansion possibly causing a loss of function process, rather than a toxic gain of function. SCA13 Clinical Features SCA13 has been reported in one French family, where seven or eight affected members were women (120). The clinical picture was one of a slowly progressive, childhood-onset gait ataxia, with dysarthria in 88%, moderate mental retardation (IQ, 62–76), and mild developmental delays in motor skills. Horizontal gaze-evoked nystagmus was present in 75%. Increased deep tendon reflexes were also seen. Loss of ability to walk could develop after four or more decades. Anticipation was not seen, although one patient had onset in the fifth decade. Laboratory Testing Brain MRI shows cerebellar and pontine atrophy. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA14 Clinical Features SCA14 has been reported in several ethnic groups, with varying phenotypes. English/Dutch (121), Dutch (122), and French (123) studies have described a very slowly progressive gait ataxia onset in the fourth decade
Copyright 2006 by Taylor & Francis Group, LLC
338
Perlman
(range 10–60 years of age), with tremor of head and extremities in younger onset patients. Limb ataxia affected legs more than arms, with dysarthria, and brisk ankle jerks. Some family members developed cognitive impairment (French), dystonia (Dutch), or peripheral neuropathy. Limb myoclonus was most commonly seen in patients with onset <27 years, while the later onset patients had a more pure ataxia. The Japanese patients had a narrower age of onset, beginning with intermittent axial myoclonus progressing to ataxia. They did not develop dementia (124). Some patients with the mutation were asymptomatic, suggesting incomplete penetrance. Laboratory Testing Brain MRI shows cerebellar atrophy. Pathology Reduced staining for PRKCG and ataxin-1 in Purkinje cells was seen, while calbindin staining was preserved (125). Molecular Genetic Features (See also Table 3) SCA14 results from missense mutations in protein kinase Cg (PRKCG), either in conserved residues in C1, the cysteine-rich region of exon 4 (regulatory domain) (H101Y, Gly118Asp, S119P, and G128D) or in the catalytic domain of the enzyme (F643L). The protein product is a serine/threonine kinase, with high expression in the brain, especially cerebellar cortex and spinal cord. This mutation seems to increase the intrinsic activity of the enzyme and moves its intraneuronal distribution from cytosol to plasma membrane (126,127). Mutant PRKCG may reduce expression of ataxin-1 in Purkinje cells, and mutant ataxin-1 may reduce expression of PRKCG (128). The complete interaction of pathophysiologic mechanisms involved has not yet been determined. SCA15 Clinical Features SCA15 was initially described in one Australian family with a slowly progressive, often mild, pure cerebellar ataxia (129). Onset varied between ages 10 and 50 years, with average age of onset 26 years. Eighty-six percent of patients had limb ataxia and 71% gait ataxia. Gaze-evoked nystagmus, saccade dysmetria, and dysarthria were also seen. Patients usually remained ambulatory. Two Japanese families, also with a slowly progressive ataxia, but with the addition of postural and action tremor/myoclonus, seemed to link to a locus that overlapped the Australian locus (130). Most recently, another Australian family with a dominantly inherited nonprogressive congenital ataxia and cognitive disability (with variable features of dysarthria,
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
339
dysmetria, dysdiadochokinesia, nystagmus, dystonic movements, and cerebellar hypoplasia on imaging) was also found to link to a locus that overlapped the same region (131). These three conditions may be allelic. Laboratory Testing Brain MRI shows superior vermian atrophy. Nerve conduction velocities are normal. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA16 Clinical Features SCA16 has been reported in one Japanese family with a slowly progressive cerebellar ataxia affecting gait, limb, and speech, and associated impaired smooth pursuit and nystagmus, with rotatory head tremor in 15%. Age of onset was between 20 and 66 years (average 40 years), with no anticipation (132). Laboratory Testing Brain MRI shows cerebellar atrophy. Nerve conduction velocities are normal. Pathology Pathology has not been reported. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA17 Clinical Features SCA17 is a polyglutamine disorder reported in several ethnic groups with varying phenotypes. Age of onset ranged from the first year of life to the seventh decade (average onset in the third decade). SCA17 was first reported in 1999 in a sporadic Japanese patient with ataxia and intellectual deterioration, associated with de novo expansion of the CAG repeat of the TATAbinding protein (TBP) gene (133). In 2001, two German families were reported with an AD degenerative multisystem disorder including ataxia and intellectual impairment, but also involvement of the pyramidal, extrapyramidal, and possibly autonomic system (134). Later that year, four Japanese families
Copyright 2006 by Taylor & Francis Group, LLC
340
Perlman
were reported with ataxia, bradykinesia, and dementia (135). In 2003, four German families were identified with features of ataxia, dysarthria, and dysphagia, with most showing psychiatric symptoms, including depression, disorientation, aggression, paranoia, and dementia. Dystonia and extrapyramidal movements were occasionally present (136). In a 4-generation Italian family, the earliest onset case was reported, apparently reflecting a 13-repeat expansion from the affected parent. The child had onset at age three with ataxic gait with foot intrarotation and dysarthria. At the age of 13, she had developed loss of sphincter control, seizures, tremor, spasticity, hyperreflexia, extensor plantar responses, and mental retardation (137,138). Huntington’s disease-like phenotypes (in addition to cerebellar ataxia, patients exhibited psychiatric disturbances, dementia, and chorea) were reported in Germany (139) and Italy (140), while in Japan a homozygous case was also noted to have an HD-like phenotype, without an earlier age of onset (141). Incomplete penetrance was identified in France, in a pedigree that manifested severe psychiatric features, dementia, axial rigidity, and seizures, reminiscent of juvenile HD (142). In the latest stages of disease, patients were bedridden, anarthric, dysphagic, and incontinent. Laboratory Testing Brain MRI shows cerebellar and cerebral atrophy. Pathology Postmortem brain tissue from one patient from the Japanese pedigrees showed shrinkage and moderate loss of small neurons with gliosis predominantly in the caudate nucleus and putamen, with similar but moderate changes in the thalamus, frontal cortex, and temporal cortex (135). Moderate Purkinje cell loss and an increase of Bergmann glia were seen in the cerebellum. Immunocytochemical analysis performed with anti-ubiquitin and anti-TBP antibodies showed neuronal intranuclear inclusion bodies. Most neuronal nuclei were diffusely stained with 1C2 antibody, which recognizes expanded polyglutamine tracts (135). The immunoreactive inclusion bodies were much more widely distributed throughout the brain gray matter than in other SCAs. In the homozygous HD-like phenotype, there was mild neuronal loss with compaction of the neuropil in the cerebral cortex, mild loss of neurons in the striatum, and moderate loss of Purkinje cells in the cerebellum (141). Many 1C2-positive neuronal nuclei were present in the deep layers of the cerebral cortex, as well as in the putamen and cerebellum. Diffuse intranuclear polyglutamine aggregate accumulation was found in a wide range of CNS regions beyond those affected by neuronal loss. In the juvenile HD-like phenotype, the brain showed diffuse atrophy in all brain regions, with the cerebellum most affected (140). There was severe neuronal loss and gliosis in the striatum, the dorsomedial thalamic nucleus, and inferior olive. Neuronal intranuclear inclusions stained with anti-TBP and 1C2.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
341
Molecular Genetic Features (See also Table 3) SCA17 is caused by a CAG trinucleotide repeat expansion in the reading frame of the gene for the TATA box-binding protein, producing a polyglutamine expansion in the protein product (a DNA binding subunit of RNA polymerase II transcription factor D/TFIID). TFIID is essential for the expression of all protein-encoding genes, so the disease mechanism of SCA17 could involve both polyglutamine-mediated toxic gain of function (suggested by the intranuclear aggregates) and transcriptional dysregulation. The normal CAG repeat length is 25–42 repeats. Disease-causing expansions are in the 45–66 repeat range, the largest expansions causing childhood-onset disease. Intermediate CAG repeats (43–48) have incomplete penetrance. There is no predictable meiotic instability, but there may be occasional large variations, as indicated above. SCA18 Clinical Features SCA18 has been reported in one Irish-American family, with progressive gait and limb ataxia, head tremor, panmodal sensory loss, and neurogenic muscular atrophy (143). Weakness was present in 70%, the Romberg test was positive, and deep tendon reflexes were reduced or absent. Some patients had nystagmus or extensor plantar responses. Hearing loss was present in 20%. There was no cognitive involvement. Onset was between 13 and 27 years of age. Disease progression was slow, leading to use of a wheelchair in the later stages. Lifespan was normal. Laboratory Testing Brain MRI shows mild cerebellar atrophy. Nerve conduction studies show a sensory axonal neuropathy. Electromyogram shows denervation, and muscle biopsy is consistent with neurogenic atrophy. Pathology Outside of neurogenic atrophy on muscle biopsy, pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA19 Clinical Features SCA19 was identified in a Dutch family with a mild, progressive ataxic gait disorder, postural tremor, saccadic pursuit, and mild cognitive impairment
Copyright 2006 by Taylor & Francis Group, LLC
342
Perlman
for abstract reasoning (144,145). Onset was between 20 and 45 years of age. Myoclonus (cortical or spinal) was present in 30%. Vibratory and joint position senses were reduced. Deep tendon reflexes were reduced in 60%, but increased in 20%. Laboratory Testing Brain MRI shows marked cerebellar hemisphere atrophy, but mild vermian and cerebral atrophy. Transcranial magnetic stimulation shows slightly increased central conduction times. Nerve conduction velocities have occasional mild reduction. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) SCA19 has a genetic locus that overlaps the locus for SCA22 and may be allelic. The gene has not yet been cloned and nothing is known about its protein product. SCA20 Clinical Features SCA20 has been described in one Anglo-Celtic family in southeastern Australia (146). Onset was between age 19 and 64 years, average 46 years, but with anticipation of 10 years in the next generation. The most common presenting symptom was dysarthria, followed by gait ataxia and upper limb ataxia. There was slow disease progression, with minimal risk of becoming wheelchair-dependent. Other variable features included palatal tremor or myoclonus, mild pyramidal signs, hypermetric saccades, and mild nystagmus. Laboratory Testing Brain CT scan shows calcification of the dentate Nucleus and brain MRI scan shows pan-cerebellar atrophy with low signal in the dentate. Nerve conduction studies are normal. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) SCA20 maps to a locus near the SCA5 locus. The gene has not yet been cloned and nothing is known about its protein product.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
343
SCA21 Clinical Features SCA21 has been described in a French family (147). Age of onset was between 6 and 30 years, average 17 years. Anticipation appeared to be present. There was a slowly progressive cerebellar syndrome, affecting gait, limbs (85%), and speech (85%). Extrapyramidal features were seen (akinesia in 80%, rigidity in 30%, and tremor in 60%, non-L-dopa responsive). Deep tendon reflexes were reduced in 90%. Cognitive impairment was present in some patients, ranging from mild to severe. Laboratory Testing Brain MRI shows cerebellar atrophy with normal brainstem and basal ganglia. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The SCA21 locus was mapped in 2002 (148). The gene has not yet been cloned and nothing is known about its protein product. SCA22 Clinical Features Reported in a Chinese Han family with a pure cerebellar ataxia (149), this SCA may be allelic to SCA19 (150). Age of onset was similar, with slightly earlier onset reported (age 10–46 years) and more clear evidence for anticipation. It was more purely cerebellar, with slowly progressive gait and truncal ataxia, limb incoordination, scanning speech, dysphagia, and gaze-evoked nystagmus (67%). Hyporeflexia was present to a greater extent (89%). Myoclonus, tremor, sensory loss, and cognitive impairment were not seen. Laboratory Testing Brain MRI shows homogeneous cerebellar atrophy with a normal brainstem. Electromyogram and nerve conduction studies are normal. Brainstem auditory and somatosensory evoked potentials are abnormal. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) SCA22 has a genetic locus that overlaps the locus for SCA19 and may be allelic.
Copyright 2006 by Taylor & Francis Group, LLC
344
Perlman
The gene has not yet been cloned and nothing is known about its protein product. SCA23 Clinical Features Reported in a Dutch family, SCA 23 is a slowly progressive typical cerebellar ataxia, involving gait, limb, and speech (in 60%), with slow saccades, ocular dysmetria, pyramidal signs (hyperreflexia in 80%, extensor plantar responses in 40%), and vibratory sense loss in the legs (60%) (151). Age of onset is 43–56 years, average 50 years. Laboratory Testing Brain MRI shows cerebellar atrophy. Pathology Neuropathological examination in one affected subject showed neuronal loss in the Purkinje cell layer, dentate nuclei and inferior olives; thinning of cerebellopontine tracts; demyelination of posterior and lateral columns in the spinal cord; and ubiquitin-positive intranuclear inclusions in nigral neurons that were considered to be Marinesco bodies. Molecular Genetic Features (See also Table 3) The gene has not yet been cloned and nothing is known about its protein product. SCA24 This section is reserved. SCA25 Clinical Features SCA25 was reported in one family in southern France (152). Age of onset is usually in childhood, but ranges from 17 months to 39 years. Anticipation has not been seen, but incomplete penetrance is reported. Symptom onset is variable within families, but includes progressive ataxia of gait (leading to wheelchair dependence), hypotonia, and nystagmus or slow saccades in some patients. Dysarthria is not seen. However, sensory neuropathy is universal, with vibration loss at the ankles and loss of pain sensitivity in some patients. Deep tendon reflexes are absent at the ankles and may be reduced elsewhere. Episodic gastric pain and vomiting are common, possibly on a neuropathic basis.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
345
Laboratory Testing Brain MRI shows global, severe cerebellar atrophy, with normal brainstem. Nerve conduction velocities show absent sensory action potentials, but normal motor nerve velocities. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The SCA25 locus has been mapped to a region with several candidate genes, none of which yet has been found to have a disease-associated mutation. No pathological expansions were found at the protein or at the DNA level using the 1C2 antibody and the RED method, respectively. The gene has not yet been cloned and nothing is known about its protein product. SCA26 Clinical Features SCA26 was reported in a six-generation family of Norwegian ancestry (153). Age of onset is from 26 to 60 years. No significant anticipation has been observed. Symptoms include pure cerebellar ataxia of trunk and limbs, dysarthria, and irregular visual pursuit movements. No motor or sensory deficits, extensor plantar responses, fasciculations, seizures, or cognitive dysfunction have been seen. Laboratory Testing Brain MRI shows cerebellar atrophy, with normal pons and medulla. Pathology Pathology has not yet been reported. Molecular Genetic Features (See also Table 3) The SCA26 locus has been mapped to a region (19p13.3) with approximately 100 known and predicted genes and adjacent to the genes for Cayman ataxia and SCA6. RED analysis did not detect abnormal CAG repeats. The gene has not yet been cloned and nothing is known about its protein product or mechanism of neurodegeneration. SCA Due to FGF14 Clinical Features Described in a Dutch family with ataxia, tremor, and dyskinesia, this SCA was found to result from mutation in the gene for fibroblast growth factor
Copyright 2006 by Taylor & Francis Group, LLC
346
Perlman
14 (FGF14) (154). Onset was in childhood, with tremor of limbs and head, exacerbated by stress and exercise. Ataxia of arms > legs developed in the late teens, then gait ataxia between the ages of 27 and 40. Dysarthria and nystagmus were present, as well as orofacial dyskinesias. Vibratory sensation was reduced at the ankles in some patients. Cognitive impairment was present, and psychiatric episodes (depression, and aggression) occurred in 50% of affected individuals. Gait ataxia was disabling by the seventh or eighth decade. Anticipation was not seen. Laboratory Testing Brain MRI may show cerebellar atrophy. Nerve conduction studies show mild axonal neuropathy. Pathology Pathology is not yet reported. Molecular Genetic Features (See also Table 3) This SCA results from missense or frameshift mutations (e.g., F145S) in the gene for fibroblast growth factor 14, which belongs to a subclass of fibroblast growth factors that are expressed in the developing and adult central nervous system (155). FGF14-deficient mice developed ataxia and a paroxysmal hyperkinetic movement disorder and had reduced responses to dopamine agonists, suggesting a function for FGF14 in neuronal signaling, axonal trafficking, and synaptosomal function (156). CONCLUSION Autosomal dominant cerebellar ataxias constitute one of the most clinically, neuropathologically, and genetically diverse groups of neurodegenerative disorders. Currently available genetic testing can identify the responsible gene mutation in approximately 50–80% of the families with spinocerebellar ataxia. Many new loci have been mapped, often in single families, but the responsible genes have not yet been identified. Currently, the variety of genetic mutations and pathogenetic mechanisms involved in causing cerebellar degeneration in the SCAs makes it difficult to think toward the design of universally applicable disease-modifying therapies (157). REFERENCES 1. Huynh DP, Yang HT, Vakharia H, Nguyen D, Pulst SM. Expansion of the polyQ repeat in ataxin-2 alters its Golgi localization, disrupts the Golgi complex and causes cell death. Hum Mol Genet 2003; 12:1485–1496. 2. Taroni F, DiDonato S. Pathways to motor incoordination: the inherited ataxias. Nat Rev Neurosci 2004; 5:641–655.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
347
3. Schols L, Bauer P, Schmidt T, Schulte T, Riess O. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3:291–304. 4. Michalik A, Van Broeckhoven C. Pathogenesis of polyglutamine disorders: aggregation revisited. Hum Mol Genet 2003; 12 Spec No 2:R173–186. 5. La Spada AR, Taylor JP. Polyglutamines placed into context. Neuron 2003; 38:681–684. 6. Shakkottai VG, Chou CH, et al. Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest 2004; 113:582–590. 7. Tarlac V, Storey E. Role of proteolysis in polyglutamine disorders. J Neurosci Res 2003; 74:406–416. 8. Michalik A, Van Broeckhoven C. Protasome degrades soluble expanded polyglutamine completely and efficiently. Neurobiol Dis 2004; 16:202–211. 9. Wyttenbach A. Role of heat shock proteins during polyglutamine neurodegeneration: mechanisms and hypothesis. J Mol Neurosci 2004; 23:69–96. 10. Xia H, Mao Q, Eliason SL, et al. RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia. Nat Med 2004; 10: 816–820. 11. Li Y, Yokota T, Matsumura R, Taira K, Mizusawa H. Sequence-dependent and independent inhibition specific for mutant ataxin-3 by small interfering RNA. Ann Neurol 2004; 56:124–129. 12. Takano H, Cancel G, Ikeuchi T, et al. Close associations between prevalences of dominantly inherited spinocerebellar ataxias with CAG-repeat expansions and frequencies of large normal CAG alleles in Japanese and Caucasian populations. Am J Hum Genet 1998; 63:1060–1066. 13. Pujana MA, Volpini V, et al. Uncloned expanded CAG/CTG repeat sequences in autosomal dominant cerebellar ataxia (ADCA) detected by the repeat expansion detection (RED) method. J Med Genet 1998; 35:99–102. 14. Liu YF, Yang YC. SCA db: Spinocerebellar ataxia candidate gene database. Bioinformatics 2004; 20:2656–2661. 15. Cancel G, Durr A, et al. Molecular and clinical correlations in spinocerebellar ataxia 2: a study of 32 families. Hum Mol Genet 1997; 6:709–715. 16. David G, Durr A, et al. Molecular and clinical correlations in autosomal dominant cerebellar ataxia with progressive macular dystrophy (SCA7). Hum Mol Genet 1998; 7:165–170. 17. Bushara KO, Goebel SU, Shill H, Goldfarb LG, Hallett M. Gluten sensitivity in sporadic and hereditary cerebellar ataxia. Ann Neurol 2001; 49:540–543. 18. Hadjivassiliou M, Grunewald R, et al. Gluten ataxia in perspective: epidemiology, genetic susceptibility and clinical characteristics. Brain 2003; 126:685–691. 19. Abele M, Schols L, Schwartz S, Klockgether T. Prevalence of antigliadin antibodies in ataxia patients. Neurology 2003; 60:1674–1675. 20. Sasaki H. [Unstable expansion of CAG repeat and molecular mechanism of neurodegeneration in SCA1]. Nippon Rinsho 1999; 57:801–804. 21. Matsuura T, Sasaki H, et al. Mosaicism of unstable CAG repeats in the brain of spinocerebellar ataxia type 2. J Neurol 1999; 246:835–839. 22. Goto J, Watanabe M, et al. Machado–Joseph disease gene products carrying different carboxyl termini. Neurosci Res 1997; 28:373–377.
Copyright 2006 by Taylor & Francis Group, LLC
348
Perlman
23. Maciel P, Lopes-Cendes I, Kish S, Sequeiros J, Rouleau GA. Mosaicism of the CAG repeat in CNS tissue in relation to age at death in spinocerebellar ataxia type 1 and Machado-Joseph disease patients. Am J Hum Genet 1997; 60:993–996. 24. Maciel P, Gaspar C, et al. Study of three intragenic polymorphisms in the Machado-Joseph disease gene (MJD1) in relation to genetic instability of the (CAG)n tract. Eur J Hum Genet 1999; 7:147–156. 25. Watase K, Venken KJ, Sun Y, Orr HT, Zoghbi HY. Regional differences of somatic CAG repeat instability do not account for selective neuronal vulnerability in a knock-in mouse model of SCA1. Hum Mol Genet 2003; 12: 2789–2795. 26. Cancel G, Gourfinkel-An I, Stevanin G, et al. Somatic mosaicism of the CAG repeat expansion in spinocerebellar ataxia type 3/Machado-Joseph disease. Hum Mutat 1998; 11:23–27. 27. Matilla A, Koshy BT, Cummings CJ, Isobe T, Orr HT, Zoghbi HY. The cerebellar leucine-rich acidic nuclear protein interacts with ataxin-1. Nature 1997; 389:974–978. 28. La Spada AR, Fu YH, et al. Polyglutamine-expanded ataxin-7 antagonizes CRX function and induces cone-rod dystrophy in a mouse model of SCA7. Neuron 2001; 31:913–927. 29. Clark HB, Orr HT. Spinocerebellar ataxia type 1–modeling the pathogenesis of a polyglutamine neurodegenerative disorder in transgenic mice. J Neuropathol Exp Neurol 2000; 59:265–270. 30. Zu T, Duvick LA, et al. Recovery from polyglutamine–induced neurodegeneration in conditional SCA1 transgenic mice. J Neurosci 2004; 24: 8853–8861. 31. Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 2000; 26:44–50. 32. Cemal CK, Carroll CJ, et al. YAC transgenic mice carrying pathological alleles of the MJD1 locus exhibit a mild and slowly progressive cerebellar deficit. Hum Mol Genet 2002; 11:1075–1094. 33. Grote SK, La Spada AR. Insights into the molecular basis of polyglutamine neurodegeneration from studies of a spinocerebellar ataxia type 7 mouse model. Cytogenet Genome Res 2003; 100:164–174. 34. Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr Biol 2004; 14:302–308. 35. Sato T, Oyake M, et al. Transgenic mice harboring a full-length human mutant DRPLA gene exhibit age-dependent intergenerational and somatic instabilities of CAG repeats comparable with those in DRPLA patients. Hum Mol Genet 1999; 8:99–106. 36. Schilling G, Wood JD, et al. Nuclear accumulation of truncated atrophin-1 fragments in a transgenic mouse model of DRPLA. Neuron 1999; 24:275–286. 37. Cummings CJ, Sun Y, et al. Over-expression of inducible HSP70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 2001; 10:1511–1518.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
349
38. Yoshida H, Yoshizawa T, Shibasaki F, Shoji S, Kanazawa I. Chemical chaperones reduce aggregate formation and cell death caused by the truncated Machado-Joseph disease gene product with an expanded polyglutamine stretch. Neurobiol Dis 2002; 10:88–99. 39. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci USA 2003; 100:2041–2046. 40. Watase K, Zoghbi HY. Modelling brain diseases in mice: the challenges of design and analysis. Nat Rev Genet 2003; 4:296–307. 41. Pulst SM. Introduction to Medical Genetics and Methods of DNA Testing. In: Pulst SM, ed. Genetics of Movement Disorders. San Diego: Academic Press, 2003:2–17. 42. Kullmann DM, Hanna MG. Neurological disorders caused by inherited ion-channel mutations. Lancet Neurol 2002; 1:157–66. 43. Klein A, Boltshauser E, Jen J, Baloh RW. Episodic ataxia type 1 with distal weakness: a novel manifestation of a potassium channelopathy. Neuropediatrics 2004; 35:147–149. 44. Jen J, Kim GW, Baloh RW. Clinical spectrum of episodic ataxia type 2. Neurology 2004; 62:17–22. 45. Jen JC, Baloh RW. Genetics of episodic ataxia. Adv Neurol 2002; 89:459–461. 46. Baloh RW, Jen JC. Genetics of familial episodic vertigo and ataxia. Ann N Y Acad Sci 2002; 956:338–345. 47. Damji KF, Allingham RR, et al. Periodic vestibulocerebellar ataxia, an autosomal dominant ataxia with defective smooth pursuit, is genetically distinct from other autosomal dominant ataxias. Arch Neurol 1996; 53:338–344. 48. Steckley JL, Ebers GC, Cader MZ, McLachlan RS. An autosomal dominant disorder with episodic ataxia, vertigo, and tinnitus. Neurology 2001; 57:1499–1502. 49. Escayg A, Jones JM, Kearney JA, Hitchcock PF, Meisler MH. Calcium channel beta 4 (CACNB4): human ortholog of the mouse epilepsy gene lethargic. Genomics 1998; 50:14–22. 50. Le Ber I, Camuzat A, et al. Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. Arch Neurol 2003; 60:1097–1099. 51. Tsuji S. [Dentatorubral-pallidoluysian atrophy (DRPLA)–discovery of the disease DRPLA gene the pathophysiology]. Rinsho Shinkeigaku 2000; 40: 1287–1289. 52. Licht DJ, Lynch DR. Juvenile dentatorubral-pallidoluysian atrophy: new clinical features. Pediatr Neurol 2002; 26:51–54. 53. Bianca M, Bianca S, Vecchio I, Raffaele R, Ingegnosi C, Nicoletti F. GerstmannStraussler-Scheinker disease with P102L-V129 mutation: a case with psychiatric manifestations at onset. Ann Genet 2003; 46:467–469. 54. Knight RS, Will RG. Prion diseases. J Neurol Neurosurg Psychiatry 2004; 75(suppl 1):i36–i42. 55. Bratosiewicz-Wasik J, Wasik TJ, Liberski PP. Molecular approaches to mechanisms of prion diseases. Folia Neuropathol 2004; 42(suppl A):33–46.
Copyright 2006 by Taylor & Francis Group, LLC
350
Perlman
56. Kovacs GG, Kalev O, Budka H. Contribution of neuropathology to the understanding of human prion disease. Folia Neuropathol 2004; 42(suppl A): 69–76. 57. Flechsig E, Hegyi I, Leimeroth R, et al. Expression of truncated PrP targeted to Purkinje cells of PrP knockout mice causes Purkinje cell death and ataxia. EMBO J 2003; 22:3095–3101. 58. Kovacs GG, Voigtlander T, Gelpi E, Budka H. Rationale for diagnosing human prion disease. World J Biol Psychiatry 2004; 5:83–91. 59. Klockgether T, Skalej M, et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain 1998; 121 (Pt 9):1687–1693. 60. Murata Y, Kawakami H, et al. Characteristic magnetic resonance imaging findings in spinocerebellar ataxia 6. Arch Neurol 1998; 55:1348–1352. 61. Moseley ML, Benzow KA, et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 1998; 51:1666–1671. 62. Perlman S. Diagnostic Evaluation of Ataxic Patients. In: Pulst SM, ed. Genetics of Movement Disorders. San Diego: Academic Press, 2003:253–272. 63. Harding AE. The clinical features and classification of the late onset autosomal dominant cerebellar ataxias. A study of 11 families, including descendants of the ‘the Drew family of Walworth’. Brain 1982; 105:1–28. 64. Smith CO, Lipe HP, Bird TD. Impact of presymptomatic genetic testing for hereditary ataxia and neuromuscular disorders. Arch Neurol 2004; 61: 875–880. 65. Goldfarb LG, Vasconcelos O, et al. Unstable triplet repeat and phenotypic variability of spinocerebellar ataxia type 1. Ann Neurol 1996; 39:500–506. 66. Abe T, Abe K, Tsuda T, Itoyama Y, Tamai M. Ophthalmological findings in patients with spinocerebellar ataxia type 1 are not correlated with neurological anticipation. Graefes Arch Clin Exp Ophthalmol 2001; 239:722–728. 67. Mascalchi M, Tosetti M, et al. Proton magnetic resonance spectroscopy in an Italian family with spinocerebellar ataxia type 1. Ann Neurol 1998; 43:244–252. 68. Guerrini L, Lolli F, et al. Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 2004; 127:1785–1795. 69. Buttner N, Geschwind D, Jen JC, Perlman S, Pulst SM, Baloh RW. Oculomotor phenotypes in autosomal dominant ataxias. Arch Neurol 1998; 55:1353–1357. 70. Burk K, Fetter M, et al. Autosomal dominant cerebellar ataxia type I: oculomotor abnormalities in families with SCA1, SCA2, and SCA3. J Neurol 1999; 246:789–797. 71. Schols L, Amoiridis G, Langkafel M, Schols S, Przuntek H. Motor evoked potentials in the spinocerebellar ataxias type 1 and type 3. Muscle Nerve 1997; 20:226–228. 72. Clark HB, Burright EN, et al. Purkinje cell expression of a mutant allele of SCA1 in transgenic mice leads to disparate effects on motor behaviors, followed by a progressive cerebellar dysfunction and histological alterations. J Neurosci 1997; 17:7385–7395.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
351
73. Banfi S, Servadio A, et al. Identification and characterization of the gene causing type 1 spinocerebellar ataxia. Nat Genet 1994; 7:513–520. 74. Opal P, Garcia JJ, Propst F, Matilla A, Orr HT, Zoghbi HY. Mapmodulin/ leucine–rich acidic nuclear protein binds the light chain of microtubuleassociated protein 1B and modulates neuritogenesis. J Biol Chem 2003; 278: 34691–34699. 75. Moretti P, Blazo M, et al. Spinocerebellar ataxia type 2 (SCA2) presenting with ophthalmoplegia and developmental delay in infancy. Am J Med Genet A 2004; 124:392–396. 76. Velazquez-Perez L, Seifried C, et al. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol 2004; 56:444–447. 77. Furtado S, Payami H, et al. Profile of families with parkinsonism-predominant spinocerebellar ataxia type 2 (SCA2). Mov Disord 2004; 19:622–629. 78. Nechiporuk A, Lopes-Cendes I, et al. Genetic mapping of the spinocerebellar ataxia type 2 gene on human chromosome 12. Neurology 1996; 46:1731–1735. 79. Sanpei K, Takano H, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996; 14:277–284. 80. Imbert G, Saudou F, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996; 14:285–291. 81. Ciosk R, DePalma M, Priess JR. ATX-2, the C. elegans ortholog of ataxin 2, functions in translational regulation in the germline. Development 2004; 131:4831–4841. 82. Costanzi-Porrini S, Tessarolo D, Abbruzzese C, Liguori M, Ashizawa T, Giacanelli M. An interrupted 34-CAG repeat SCA-2 allele in patients with sporadic spinocerebellar ataxia. Neurology 2000; 54:491–493. 83. Takiyama Y, Sakoe K, et al. Single sperm analysis of the CAG repeats in the gene for Machado-Joseph disease (MJD1): evidence for non-Mendelian transmission of the MJD1 gene and for the effect of the intragenic CGG/GGG polymorphism on the intergenerational instability. Hum Mol Genet 1997; 6:1063–1068. 84. Rubinsztein DC, Leggo J. Non-Mendelian transmission at the MachadoJoseph disease locus in normal females: preferential transmission of alleles with smaller CAG repeats. J Med Genet 1997; 34:234–236. 85. Kawaguchi Y, Okamoto T, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8:221–228. 86. Flanigan K, Gardner K, et al. Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 1996; 59:392–399. 87. Hirano R, Takashima H, et al. Fine mapping of 16q-linked autosomal dominant cerebellar ataxia type III in Japanese families. Neurogenetics 2004. 88. Hellenbroich Y, Bubel S, et al. Refinement of the spinocerebellar ataxia type 4 locus in a large German family and exclusion of CAG repeat expansions in this region. J Neurol 2003; 250:668–671.
Copyright 2006 by Taylor & Francis Group, LLC
352
Perlman
89. Ranum LP, Schut LJ, Lundgren JK, Orr HT, Livingston DM. Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11. Nat Genet 1994; 8:280–284. 90. Burk K, Zuhlke C, et al. Spinocerebellar ataxia type 5: clinical and molecular genetic features of a German kindred. Neurology 2004; 62:327–329. 91. Nagaoka U, Suzuki Y, et al. Regional differences in genetic subgroup frequency in hereditary cerebellar ataxia, and a morphometrical study of brain MR images in SCA1, MJD and SCA6. J Neurol Sci 1999; 164:187–194. 92. Zhuchenko O, Bailey J, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltagedependent calcium channel. Nat Genet 1997; 15:62–69. 93. Mantuano E, Veneziano L, Jodice C, Frontali M. Spinocerebellar ataxia type 6 and episodic ataxia type 2: differences and similarities between two allelic disorders. Cytogenet Genome Res 2003; 100:147–153. 94. Haan J, Kors EE, et al. Toward a molecular genetic classification of familial hemiplegic migraine. Curr Pain Headache Rep 2004; 8:238–243. 95. Spadaro M, Ursu S, et al. A G301R Naþ/Kþ -ATPase mutation causes familial hemiplegic migraine type 2 with cerebellar signs. Neurogenetics 2004; 5:177–185. 96. Frontali M. Spinocerebellar ataxia type 6: channelopathy or glutamine repeat disorder? Brain Res Bull 2001; 56:227–231. 97. Matsuyama Z, Yanagisawa NK, et al. Polyglutamine repeats of spinocerebellar ataxia 6 impair the cell-death-preventing effect of CaV2.1 Ca2þ channel–lossof-function cellular model of SCA6. Neurobiol Dis 2004; 17:198–204. 98. Bang OY, Lee PH, Kim SY, Kim HJ, Huh K. Pontine atrophy precedes cerebellar degeneration in spinocerebellar ataxia 7: MRI-based volumetric analysis. J Neurol Neurosurg Psychiatry 2004; 75:1452–1456. 99. David G, Abbas N, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997; 17:65–70. 100. Helmlinger D, Hardy S, et al. Ataxin-7 is a subunit of GCN5 histone acetyltransferase-containing complexes. Hum Mol Genet 2004; 13:1257–1265. 101. Chen S, Peng GH, et al. Interference of Crx-dependent transcription by ataxin-7 involves interaction between the glutamine regions and requires the ataxin-7 carboxy-terminal region for nuclear localization. Hum Mol Genet 2004; 13:53–67. 102. Nikali K, Suomalainen A, Terwilliger J, Koskinen T, Weissenbach J, Peltonen L. Random search for shared chromosomal regions in four affected individuals: the assignment of a new hereditary ataxia locus. Am J Hum Genet 1995; 56:1088–1095. 103. Povey S, Lovering R, Bruford E, Wright M, Lush M, Wain H. The HUGO Gene Nomenclature Committee (HGNC). Hum Genet 2001; 109:678–680. 104. Wain HM, Lush M, Ducluzeau F, Povey S. Genew: the human gene nomenclature database. Nucleic Acids Res 2002; 30:169–171. 105. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. Guidelines for human gene nomenclature. Genomics 2002; 79:464–470. 106. Mosemiller AK, Dalton JC, Day JW, Ranum LP. Molecular genetics of spinocerebellar ataxia type 8 (SCA8). Cytogenet Genome Res 2003; 100:175–183.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
353
107. Ikeda Y, Dalton JC, et al. Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia. Am J Hum Genet 2004; 75:3–16. 108. Wu YR, Lin HY, et al. Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson’s disease. Clin Genet 2004; 65:209–214. 109. Erdmann VA, Barciszewska MZ, Szymanski M, Hochberg A, de Groot N, Barciszewski J. The non-coding RNAs as riboregulators. Nucleic Acids Res 2001; 29:189–193. 110. Brook JD, McCurrach ME, et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 30 end of a transcript encoding a protein kinase family member. Cell 1992; 68:799–808. 111. Liquori CL, Ricker K, et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293:864–867. 112. Matsuura T, Yamagata T, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 2000; 26:191–194. 113. Teive HA, Roa BB, et al. Clinical phenotype of Brazilian families with spinocerebellar ataxia 10. Neurology 2004; 63:1509–1512. 114. Marz P, Probst A, et al. Ataxin-10, the spinocerebellar ataxia type 10 neurodegenerative disorder protein, is essential for survival of cerebellar neurons. J Biol Chem 2004; 279:35542–35550. 115. Grewal RP, Achari M, et al. Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10. Arch Neurol 2002; 59:1285–1290. 116. Worth PF, Giunti P, Gardner-Thorpe C, Dixon PH, Davis MB, Wood NW. Autosomal dominant cerebellar ataxia type III: linkage in a large British family to a 7.6-cM region on chromosome 15q14–21.3. Am J Hum Genet 1999; 65:420–426. 117. Holmes SE, O’Hearn EE, et al. Expansion of a novel CAG trinucleotide repeat in the 50 region of PPP2R2B is associated with SCA12. Nat Genet 1999; 23:391–392. 118. Srivastava AK, Choudhry S, et al. Molecular and clinical correlation in five Indian families with spinocerebellar ataxia 12. Ann Neurol 2001; 50:796–800. 119. Holmes SE, Hearn EO, Ross CA, Margolis RL. SCA12: an unusual mutation leads to an unusual spinocerebellar ataxia. Brain Res Bull 2001; 56:397–403. 120. Herman-Bert A, Stevanin G, et al. Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation. Am J Hum Genet 2000; 67:229–235. 121. Brkanac Z, Bylenok L, et al. A new dominant spinocerebellar ataxia linked to chromosome 19q13.4-qter. Arch Neurol 2002; 59:1291–1295. 122. van de Warrenburg BP, Verbeek DS, et al. Identification of a novel SCA14 mutation in a Dutch autosomal dominant cerebellar ataxia family. Neurology 2003; 61:1760–1765. 123. Stevanin G, Hahn V, et al. Mutation in the catalytic domain of protein kinase C gamma and extension of the phenotype associated with spinocerebellar ataxia type 14. Arch Neurol 2004; 61:1242–1248.
Copyright 2006 by Taylor & Francis Group, LLC
354
Perlman
124. Yamashita I, Sasaki H, et al. A novel locus for dominant cerebellar ataxia (SCA14) maps to a 10.2-cM interval flanked by D19S206 and D19S605 on chromosome 19q13.4-qter. Ann Neurol 2000; 48:156–163. 125. Chen DH, Brkanac Z, et al. Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet 2003; 72:839–849. 126. Verbeek DS, Knight MA, Harmison GG, Fischbeck KH, Howell BW. Protein kinase C gamma mutations in spinocerebellar ataxia 14 increase kinase activity and alter membrane targeting. Brain 2004. 127. Yabe I, Sasaki H, et al. Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol 2003; 60:1749–1751. 128. Skinner PJ, Vierra-Green CA, Clark HB, Zoghbi HY, Orr HT. Altered trafficking of membrane proteins in purkinje cells of SCA1 transgenic mice. Am J Pathol 2001; 159:905–913. 129. Knight MA, Kennerson ML, et al. Spinocerebellar ataxia type 15 (sca15) maps to 3p24.2-3pter: exclusion of the ITPR1 gene, the human orthologue of an ataxic mouse mutant. Neurobiol Dis 2003; 13:147–157. 130. Hara K, Fukushima T, et al. Japanese SCA families with an unusual phenotype linked to a locus overlapping with SCA15 locus. Neurology 2004; 62:648–651. 131. Dudding TE, Friend K, Schofield PW, Lee S, Wilkinson IA, Richards RI. Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus. Neurology 2004; 63:2288–2292. 132. Miyoshi Y, Yamada T, et al. A novel autosomal dominant spinocerebellar ataxia (SCA16) linked to chromosome 8q22.1–24.1. Neurology 2001; 57:96–100. 133. Koide R, Kobayashi S, et al. A neurological disease caused by an expanded CAG trinucleotide repeat in the TATA-binding protein gene: a new polyglutamine disease? Hum Mol Genet 1999; 8:2047–2053. 134. Zuhlke C, Hellenbroich Y, et al. Different types of repeat expansion in the TATA-binding protein gene are associated with a new form of inherited ataxia. Eur J Hum Genet 2001; 9:160–164. 135. Nakamura K, Jeong SY, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10:1441–1448. 136. Rolfs A, Koeppen AH, et al. Clinical features and neuropathology of autosomal dominant spinocerebellar ataxia (SCA17). Ann Neurol 2003; 54:367–375. 137. Maltecca F, Filla A, et al. Intergenerational instability and marked anticipation in SCA-17. Neurology 2003; 61:1441–1443. 138. De Michele G, Maltecca F, et al. Dementia, ataxia, extrapyramidal features, and epilepsy: phenotype spectrum in two Italian families with spinocerebellar ataxia type 17. Neurol Sci 2003; 24:166–167. 139. Bauer P, Laccone F, et al. Trinucleotide repeat expansion in SCA17/TBP in white patients with Huntington’s disease-like phenotype. J Med Genet 2004; 41:230–232. 140. Bruni AC, Takahashi-Fujigasaki J, et al. Behavioral disorder, dementia, ataxia, and rigidity in a large family with TATA box-binding protein mutation. Arch Neurol 2004; 61:1314–1320.
Copyright 2006 by Taylor & Francis Group, LLC
Autosomal Dominant Ataxias
355
141. Toyoshima Y, Yamada M, et al. SCA17 homozygote showing Huntington’s disease-like phenotype. Ann Neurol 2004; 55:281–286. 142. Stevanin G, Fujigasaki H, et al. Huntington’s disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 2003; 126:1599–1603. 143. Brkanac Z, Fernandez M, et al. Autosomal dominant sensory/motor neuropathy with Ataxia (SMNA): Linkage to chromosome 7q22-q32. Am J Med Genet 2002; 114:450–457. 144. Schelhaas HJ, Ippel PF, Hageman G, Sinke RJ, van der Laan EN, Beemer FA. Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia. J Neurol 2001; 248:113–120. 145. Verbeek DS, Schelhaas JH, Ippel EF, Beemer FA, Pearson PL, Sinke RJ. Identification of a novel SCA locus (SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21-q21. Hum Genet 2002; 111:388–393. 146. Knight MA, Gardner RJ, et al. Dominantly inherited ataxia and dysphonia with dentate calcification: spinocerebellar ataxia type 20. Brain 2004; 127: 1172–1181. 147. Devos D, Schraen-Maschke S, et al. Clinical features and genetic analysis of a new form of spinocerebellar ataxia. Neurology 2001; 56:234–238. 148. Vuillaume I, Devos D, Schraen-Maschke S, et al. A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. Ann Neurol 2002; 52:666–670. 149. Chung MY, Lu YC, Cheng NC, Soong BW. A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23. Brain 2003; 126:1293–1299. 150. Schelhaas HJ, Verbeek DS, Van de Warrenburg BP, Sinke RJ. SCA19 and SCA22: evidence for one locus with a worldwide distribution. Brain 2004; 127:E6; author reply E7. 151. Verbeek DS, van de Warrenburg BP, Wesseling P, Pearson PL, Kremer HP, Sinke RJ. Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13–12.3. Brain 2004; 127:2551–2557. 152. Stevanin G, Bouslam N, et al. Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p. Ann Neurol 2004; 55:97–104. 153. Yu G-Y, Howell MJ, et al. Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. ann Neurol 2005; 57:349–354. 154. van Swieten JC, Brusse E, et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet 2003; 72:191–199. 155. Smallwood PM, Munoz-Sanjuan I, et al. Fibroblast growth factor (FGF) homologous factors: new members of the FGF family implicated in nervous system development. Proc Natl Acad Sci USA 1996; 93:9850–9857. 156. Wang Q, Bardgett ME, et al. Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron 2002; 35:25–38. 157. Perlman SL. Symptomatic and disease-modifying therapy for the progressive ataxias. Neurologist 2004; 10:275–289.
Copyright 2006 by Taylor & Francis Group, LLC
16 Huntington’s Disease: Mechanisms of Pathogenesis and Development of New Therapies Blair R. Leavitt Department of Medical Genetics, Centre for Molecular Medicine and Therapeutics, and Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
Lynn A. Raymond Department of Psychiatry, Division of Neurology, Department of Medicine, and Brain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada
CLINICAL, PATHOLOGIC, AND GENETIC FEATURES OF HUNTINGTON’S DISEASE Huntington’s Disease (HD) is an autosomal dominant neurodegenerative disorder with an estimated prevalence of 0.5–1 in 10,000 individuals of European descent (1). HD is characterized by the insidious development of motor, cognitive, and psychiatric disturbances with an inexorable progression towards complete disability and eventual death averaging 18 years after the onset of symptoms (2). George Huntington first characterized the cardinal features of the disease that now bears his name in a report published in 1872 (3). This concise treatise outlined the distinctive choreiform movement disorder, the hereditary nature of the chorea, and the frequent association of the chorea with psychiatric disease (‘‘a tendency to insanity and suicide’’). In 1983, the genetic defect in HD was mapped to chromosome
Copyright 2006 by Taylor & Francis Group, LLC
358
Leavitt and Raymond
4p16.3 (4), and 10 years later the causative mutation was identified following a massive effort by a collaborative research consortium (5). HD is caused by an expanded CAG trinucleotide repeat sequence in the HD gene encoding for the huntingtin protein. The movement disorder in HD consists of both abnormal involuntary movements such as chorea or dystonia, and abnormalities of voluntary movement, such as abnormal saccades, bradykinesia, dysphagia, dysarthria, impaired fine motor coordination, and gait disturbance. Functional disability in HD is better correlated with the severity of the voluntary movement impairments than with the severity of the classic ‘‘Huntington’s chorea’’ (6). Early in the course of HD, chorea, hypotonia and hyper-reflexia usually predominate, but as the disease progresses, rigidity and bradykinesia become progressively severe (2). Cognitive defects in HD usually progress at a similar rate to the motor disturbances and usually begin with a subtle slowing of intellectual processes, dis-inhibition and reduced mental flexibility, eventually developing into a slowly progressive ‘‘subcortical dementia’’ (7). Aphasia and agnosia are uncommon, whereas a prominent loss of cognitive speed, flexibility, and concentration are the hallmark cognitive changes. Memory recall is generally affected more than memory storage in HD (8). Depression, apathy, and irritable or impulsive behavior are the most common psychiatric manifestations of HD, and the expression of these symptoms varies widely both in onset and in progression (9). Obsessive-compulsive symptoms and frank psychosis also occasionally develop during the course of the illness. Cachexia is an almost invariant feature of HD as the disease progresses, with a marked loss of body weight occurring over time despite maintenance of a previously adequate caloric intake suggesting that an altered metabolic state may be associated with progression of the disease (10). Juvenile-onset HD, sometimes termed the Westphal variant of HD, occurs in about 5% to 10% of patients and is characterized by a predominantly akinetic-rigid presentation with spasticity, bradykinesia, and dystonia (11). Unlike adult-onset HD, the juvenile form is often complicated by myoclonus and seizures, with seizures occurring in up to one-third of juvenile HD patients. In contrast, there is no increased frequency of seizures in adult-onset HD cases compared to the general public (12). Chorea is a variable finding and may occur early or not at all; when present, it is often gradually superseded by spasticity and rigidity. Parkinsonian features may be the primary abnormalities in those affected under the age of 20 years and can make diagnosis difficult if the family history is not available. Rapid intellectual deterioration, apathy, personality changes, and academic problems at school are common presenting complaints. In general, the larger the CAG repeat expansion and earlier the age of onset of HD, the more likely that rigidity and bradykinesia will be the major neurologic features (13).
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
359
Figure 1 HD is caused by an expanded CAG trinucleotide repeat sequence in exon 1 of the HD gene that encodes for an expanded polyglutamine stretch near the N-terminus of the huntingtin protein. The mutant huntingtin protein is believed to have altered physical and functional properties, which lead to a novel toxic gain of function (and possibly an additional loss of huntingtin’s normal function), resulting in selective neurodegeneration in specific brain regions. The brain regions which demonstrate the earliest and most extensive neuronal loss in HD include the striatum, and to a lesser extent, the cerebral cortex, globus pallidus, and thalamic and subthalamic nuclei.
The hallmark neuropathologic feature of HD is early neuronal loss in the caudate and putamen (striatum). The medium-sized spiny neurons of the striatum are selectively vulnerable to neurodegeneration in HD (14) (Fig. 1). These neurons receive massive excitatory (glutamatergic) inputs from wide areas of neocortex and thalamus, and make efferent inhibitory projections (GABAergic) to the globus pallidus and substantia nigra (15). The other major cell type of the striatum, the aspiny interneurons, are relatively resistant to degeneration in HD. Loss of pyramidal projection neurons in layers
Copyright 2006 by Taylor & Francis Group, LLC
360
Leavitt and Raymond
V and VI of the cerebral cortex (16) and the CA1 region of hippocampus (17) is also a feature of the selective neuronal cell death in HD (Fig. 1). As the disease progresses, degenerative changes become more generalized and include other brain regions such as the globus pallidus, subthalamic nucleus, substantia nigra, cerebellum, and thalamus (14) (Fig. 1). Nuclear and cytoplasmic intracellular inclusions are also a pathologic feature of HD and the other polyglutamine diseases; these inclusions are insoluble, ubiquitinated protein aggregates that sequester a variety of cellular proteins including full-length and truncated fragments of huntingtin. The presence of neuronal intranuclear huntingtin inclusions was first definitively recognized in transgenic mice (18). Subsequent immuno-histochemical analyses demonstrated the presence of neuronal huntingtin inclusions in post-mortem brain material from HD patients (19) and patients with other polyglutamine disorders (20). Despite the presence of aggregates in these disorders, their role in the pathogenesis of HD is unclear. In juvenile onset HD, the neuropathology is much less specific, and the degenerative changes occur earlier and are more widespread than in adult-onset cases (including loss of neurons within the cerebellum and brainstem) (1). Intranuclear inclusions are much more common and present from an earlier stage than in adult-onset HD (19). The underlying genetic defect in HD is the expansion of a CAG trinucleotide repeat in the first exon of the HD gene that produces a huntingtin protein with an expanded polyglutamine tract (5) (Fig. 1). Expanded HD alleles containing greater than 35 CAG repeats are associated with the eventual development of the clinical phenotype of HD, with earlier age of onset occurring with larger repeat sizes (21). Due to the inverse correlation of CAG repeat length with the age of onset of HD symptoms, CAG repeat sizes between 36 and 39 are associated with very late onset leading to the appearance of reduced penetrance for this repeat range (22). The CAG repeat expansion in the HD gene is a dynamic mutation, and the length of the CAG repeat is unstable during somatic development and during vertical transmission of the gene from parent to child. Larger CAG repeat sizes exhibit greater instability, and paternal transmission of the CAG repeat allele is more likely to result in expansion rather than contraction of the CAG repeat length (23). The unstable nature of the CAG expansion in HD provides the molecular basis for the clinical phenomenon of anticipation, defined as decreasing age of onset, or increasing severity of disease in successive generations. From this brief review of the clinical manifestations, genetics, and neuropathology of HD, it is clear that any proposed mechanisms of HD pathogenesis must include explanations for the earlier age of onset that occurs with larger CAG expansions, age-related factors contributing to the late onset of the disease, the role of huntingtin aggregation and inclusion formation, and the selective neuronal degeneration seen in HD.
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
361
ANIMAL MODELS OF HD Prior to the cloning of the HD gene, the only animal models of HD available were generated by the administration of specific neurotoxins. Intrastriatal injection of kainate, a glutamate agonist, in rodents induces neurodegeneration of medium spiny neurons similar to that observed in HD (24,25). More specific striatal lesions that spare the large cholinergic interneurons of the striatum and are also associated with behavioral features characteristic of HD are produced by intrastriatal injections of the selective NMDA receptor agonist quinolinic acid into rodents and primates (26–30). Similar striatal lesions are induced by inhibition of mitochondrial function with toxins such as 3-nitroporoprionic acid or malonate (31,32). Importantly, the neurodegenerative effects of these mitochondrial toxins can be blocked by pretreatment with NMDA receptor antagonists such as MK801 or APV leading to the hypothesis that they induce neuronal death by a mechanism of ‘‘indirect excitoxicity’’ (33). In general, HD models generated by administration of neurotoxins have provided important insights into the basic mechanisms of neuronal cell death; however, more genetically accurate transgenic models of HD now exist. Genetic Mouse Models of HD Following the identification of the causative CAG repeat expansion mutation in the HD gene, three independent groups created ‘‘knock-out’’ mice with targeted disruption of Hdh, the mouse HD gene (34–36). The huntingtin knock-out was embryonic lethal, clearly not a model for HD, and suggested that huntingtin is essential for proceeding through gastrulation during embryonic development. Interestingly, one group reported that mice heterozygous for targeted disruption of the Hdh gene and expressing only half the normal levels of wild-type htt, develop late-onset neuronal degeneration in the basal ganglia in adulthood (35). This result was later confirmed in these mice based on a detailed sterological anaylsis (37). Targeted partial disruption of the Hdh gene leading to dramatically reduced huntingtin levels leads to reduced body size, movement abnormalities, and increased ventricular volume in mice (38). Furthermore, post-natal conditional deletion of the Hdh gene in mice caused neurodegeneration and a motor phenotype that is similar to that described in transgenic mouse models of HD (39). These studies and a variety of other evidence suggest that the loss of wild-type htt function may play a role in the selective pattern and timing of neurodegeneration in HD (40). The CAG expansion in HD and other polyglutamine disorders is generally accepted to primarily result in a toxic gain of function of the resultant proteins. The proposed gain of function mechanism for the HD mutation suggests that the creation of an accurate mouse model replicating the phenotype and neuropathology of HD requires the stable introduction of
Copyright 2006 by Taylor & Francis Group, LLC
362
Leavitt and Raymond
a mutant copy of the HD gene into the genome of mice. Various lines of transgenic mice expressing different forms of the mutant HD gene have been generated and will be discussed below: (i) mice expressing a fragment of transgenic mutant htt, (ii) mice expressing full-length transgenic mutant htt, and (iii) mice with a modified Hdh gene containing an expanded CAG repeat region (‘‘htt knock-in’’ mice). A summary of the current mouse models of HD is updated regularly and maintained on the website of the Hereditary Disease Foundation: http://www.hdfoundation.org/ PDF/hdmicetable.pdf. Fragment HD Transgenic Mice The HD gene contains 67 exons and spans an enormous genomic distance of over 210 kb, making it very difficult to manipulate the full-length gene using standard transgenic techniques (41). The CAG trinucleotide repeat is present in exon 1 of the HD gene, and several groups have produced HD mouse models that are transgenic for small fragments of the HD gene, including exon 1. One of the most important breakthroughs in HD research came with the development of transgenic mice expressing exon 1 of the HD gene with 115–156 repeats under control of the first 1 kb of HD regulatory gene sequences (42). These R6 lines of mice express the first 69 amino acids of human htt, representing 3% of the total protein at various levels (R6/1, R6/2, and R6/5), and develop a progressive neurological phenotype—with the highest levels of transgenic protein corresponding to earliest onset of phenotype in the R6/2 line. The most extensively studied line (R6/2) has motor deficits (gait and rotarod testing) as early as five weeks of age followed by progressive weight loss, clasping, tremor, convulsions, and diabetes with death occurring at 10–14 weeks (43). Despite the severe behavioral phenotype, the brains of R6/2 mice do not have evidence of selective neuronal loss in the striatum or cortex, although overall brain size is reduced by 20% with some striatal atrophy. Pathological studies of these mice using an N-terminal anti-huntingtin antibody identified the presence of immunoreactive neuronal intranuclear inclusions (18). This finding led directly to the first identification of intranuclear htt inclusions in human HD brain tissue (19). A cDNA construct encoding an N-terminal fragment (171 residues) of htt with 82 glutamine repeats under the prion protein promoter was used to create another fragment HD model (44). These transgenic mice also develop motor dysfunction, htt inclusions, diabetes and early death, although they express lower levels of the mutant htt fragment than R6/2, the phenotype is more variable, and the progression more protracted (45). A conditional transgenic model was developed by using an exon 1 construct with 94 CAG repeats under the control of the tetracycline-regulatable system, which enables the expression of the transgenic protein to be turned off (46). When the mutant exon 1 htt transgene is expressed, these mice develop nuclear
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
363
aggregates and motor anomalies similar to the other exon 1 models, but these changes are reversible when transgene expression is shut down. This model provides convincing evidence that some elements of the motor phenotype and htt inclusions are dynamic, and further suggest that decreasing levels of mutant protein will improve or even reverse symptoms of HD. Full-Length HD Transgenic Mice Yeast artificial chromosomes (YACs) containing the entire genomic region of the full-length human HD gene including all endogenous regulatory elements were used to generate a YAC transgenic mouse model of HD (47). These mice express human transgenic htt with 18, 46, or 72 polyglutamine repeats in a normal developmental and cell-specific regulation pattern. Unlike other transgenic HD mice, YAC transgenic mice rescue the embryonic lethality of the htt knock-out, providing definitive evidence that the mutant protein retains the developmental function of wild-type htt (48). Over a prolonged 12-month timeline, YAC72 mice develop a progressive motor phenotype, neuronal dysfunction, and selective striatal neurodegeneration similar to that seen in HD (47). The phenotype and neuronal loss precede the development of classic nuclear htt inclusions in these mice, providing evidence that inclusions are not required for initiation of the HD pathogenic process. Mice were also generated expressing full-length mutant htt from a cDNA construct with 48 or 89 CAG repeats under control of the CMV promoter, developing a slow motor and neuropathologic phenotype (49). More recently, a YAC128 mouse model has been developed that expresses high levels of mutant htt with 128 polyglutamines, and develops a more rapid and consistent phenotype, making this line of transgenic mice extremely useful for pre-clinical experimental therapeutic trials (50). Knock-in HD Transgenic Mice In theory, transgenic mouse models of HD generated by the selective introduction of CAG expansions into the mouse Hdh gene (HD knock-in models) should represent the ideal genetic model of HD. To date, four knock-in mouse models of HD have been published (51–54). Unfortunately, while being accurate genetic models of HD, the various knock-in HD mouse models have modest and inconsistent behavioral phenotypes. Neuropathological changes in knock-in models include robust nuclear htt inclusion formation with aging, but none of these models have convincing evidence for selective striatal or cortical neurodegeneration. Invertebrate Models of HD In addition to mammalian transgenic HD animal models, a number of groups have made fly (Drosophila melanogaster) and worm (Caenorhabditis elegans) models of HD (55–61). These models share some of the basic
Copyright 2006 by Taylor & Francis Group, LLC
364
Leavitt and Raymond
features identified in mammalian models of HD, including evidence of abnormal behavioral phenotypes, neuronal dysfunction, neuronal death, and inclusion formation. Genetic screens can be rapidly performed in these lower model organisms and have the potential to identify novel pathways and mechanisms involved in basic polyglutamine pathogenesis (61). However, the significant differences between the nervous systems of these organisms and mice and man suggest that caution be employed before results from these approaches are applied to mammalian systems. Any findings from flies, worms, or other non-mammalian model systems will need extensive further characterization and confirmation in mammalian HD models.
PATHOGENESIS OF HD Role of Gain/Loss in Function of Huntingtin Data suggest that HD pathogenesis results from the combined effects of loss-of-function of wild-type htt and a gain-in-function of huntingtin (htt) with the expanded polyglutamine (polyQ) tract, referred to hereafter as mutant htt. Wild-type htt demonstrates anti-apoptotic properties in vitro (62), as well as in mouse peripheral tissues in vivo (63). Some of these effects can be explained by wild-type htt’s positive regulation of brain-derived neurotrophic factor (BDNF) expression, via sequestration of the transcriptional repressor REST/NRSF (64,65). Since BDNF is a pro-survival factor for striatal neurons, the loss of wild-type htt expression in HD mice models may contribute to disease pathogenesis (66). Consistent with this hypothesis, depletion of wild-type htt in adult mouse forebrain results in neurodegeneration (39). On the other hand, humans with deletions in the HD gene (67), as well as mice deficient in htt expression (34–36), do not exhibit an HD-like phenotype; moreover, a single copy of mutant HD can rescue embryonic lethality in htt-deficient mice (68). These genetic data suggest that loss of wild-type htt function cannot fully explain HD pathogenesis. A toxic gain-in-function in mutant htt may result from a conformational change induced by the polyQ expansion, leading to novel interactions with intracellular proteins and/or facilitating self-association (69,70). Aggregates of short (40 kDa) N-terminal fragments of polyQ-expanded htt have been demonstrated in the brains of humans dying with HD, as well as in transgenic mice models of HD, and in cell cultures of mutant htt-transfected primary neurons and cell lines (18,19,71–73). These aggregates can be found in both cytoplasm and nucleus, and are often ubiquitinated in neurons of the cortex and neostriatum (19). Neuritic aggregates have been shown to impair neurotransmitter release (74,75) as well as axonal transport (76,77), although one study suggested that mutant htt fragments were sufficient, in the absence of aggregatation, for impairment of axonal transport (78). As well, other cellular proteins can be found associated with these aggregates,
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
365
including chaperone proteins and constituents of proteasomes (79), and depletion of such proteins from the cytosol may contribute to cellular dysfunction. Whereas evidence suggests that cytoplasmic aggregates impair neuronal function, nuclear localization of mutant htt fragments is particularly toxic to cells (80,81). Such nuclear fragments can sequester transcription factors (82), altering the balance of gene transcription (83,84). Proteolysis and Aggregation of Huntingtin Although the discovery of mutant htt aggregates has triggered a high interest in developing therapies to slow or prevent aggregation, the role of aggregates in HD pathogenesis is far from clear. For example, the distribution of htt aggregates visible at the light microscope level in HD human and mouse brain is not well correlated with neuronal loss (47,85,86). In fact, certain manipulations that decrease mutant htt ubiquitination, and/or the appearance of aggregates visible at the light microscope level, actually promote cellular toxicity (80,87). On the other hand, these results may be explained by the proposal that aggregation at the submicroscopic level, in the form of soluble oligomers, is more toxic to cells (88,89). As well, two studies show a clear correlation between approaches that decrease brain aggregate load and improved survival in the R6/2 mouse model (46,90). Evidence suggests that mutant htt must first be cleaved to shorter fragments in order to translocate to the nucleus, and that cleavage also facilitates aggregate formation (73,91,92). Huntingtin proteolysis is mediated in part by activation of the proapoptotic cysteine proteases caspases-2, -3, -6, and -7 (93–97) and by activation of the calpains, a Ca2þ-dependent family of enzymes (96,98,99). Other studies also support a critical role for caspases in HD pathogenesis. For example, caspase-1 inhibition slows progression in the R6/2 mouse model of HD (100,101), and caspase-8 is activated by interactions with expanded polyQ tracts in vitro and is found in the activated form in the brains of patients with HD (102). These studies indicate that caspase and calpain activitation, as well as huntingtin cleavage and/or aggregation, may play important roles in HD pathogenesis. Protein Interactions and Cellular Dysfunction in HD Mice Models The molecular triggers of caspase and calpain activations, as well as huntingtin proteolysis, are not well understood. Moreover, since huntingtin is widely expressed in the brain, as are the proteases that cleave it, the basis for selective neuronal vulnerability remains unexplained. It is possible that proteins interacting with huntingtin in a polyglutamine-dependent manner confer selectivity due to differential expression patterns. Huntingtinassociated protein 1 (HAP1) and huntingtin-interacting protein 1 (HIP1) show increased and decreased strength, respectively, of association with huntingtin as polyQ length increases (103,104). Both are enriched in brain
Copyright 2006 by Taylor & Francis Group, LLC
366
Leavitt and Raymond
but their distribution does not correlate with selective neuronal vulnerability in HD. HAP1 is associated with motor proteins involved in microtubuledependent intracellular transport (105) and synaptic vesicle release (75), functions found to be altered in HD mice models (74–77). HIP1 is involved in clathrin-mediated endocytosis, suggesting that surface protein and receptor trafficking may also be altered in HD (106,107). In addition to HAP1 and HIP1, huntingtin interacts with a ubiquitin conjugating enzyme (108) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (109), as well as several members of the WW domain family of proteins (110); the latter are involved in regulation of cellular signaling pathways, channel function, and protein processing. Together, these findings suggest that mutant htt may disrupt a wide variety of cellular functions but still do not explain the pattern of neuronal degeneration found in HD. Excitotoxicity and Selective Neuronal Degeneration in HD Excitotoxicity is a term used to describe excessive neuronal activation by the transmitter glutamate, leading to cell stress and/or death from influx of sodium, calcium and water; the N-methyl-D-aspartate type glutamate receptor (NMDAR) plays a major role in mediating this process (for review see Ref. 111). Before the HD gene was identified, it was discovered that excitotoxins could reproduce many of the neurochemical, neuropathological and behavioural features of HD in rodents and non-human primates (see section on ‘‘Animal Models of HD’’). Systemic injection of the mitochondrial toxins 3-nitropropionic acid or malonate produced a similar pattern of striatal neuronal degeneration that was dramatically attenuated by NMDAR antagonists (112,113) (see section on ‘‘Animal Models of HD’’). These data suggest that mitochondria in striatal MSNs are more susceptible to injury than those in other neuronal populations and brain regions, consistent with recent data (114), and that reduced mitochondrial function—including less buffering capacity for calcium and free radicals, as well as lower energy stores—exacerbates toxicity induced by NMDAR activation. Moreover, in autopsy material from brains of humans with HD, there is a disproportionate loss of striatal NMDARs, suggesting that neurons with high expression of these receptors are more vulnerable to degeneration (115,116). Recent studies in the YAC transgenic mouse model expressing fulllength human htt with 46Q or 72Q (YAC46 and YAC72, respectively— see section on ‘‘Genetic Mouse Models of HD’’) support the notion that over-activation of NMDARs contributes to the selective neuronal degeneration found in HD. Increased susceptibility to NMDAR-mediated neuronal death was demonstrated in vivo by intrastriatal injection of the NMDAR agonist quinolinate, and in vitro in dissociated striatal neurons cultured from neonatal animals exposed to NMDA (117). Moreover, electrophysiological recordings showed increased NMDAR current density, and NMDA
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
367
application produced enhanced intracellular calcium responses as well as mitochondrial depolarization (a marker of cell stress) for striatal neurons from YAC72 and YAC46 mice compared to wild-type controls (117,118). NMDA also induced dramatically higher levels of caspase-3 activity in striatal neurons from YAC72 and YAC46 mice compared with wild-type mice (117,118), and glutamate has been shown to trigger cleavage of htt via calpain activation in a clonal striatal cell line (99). These results suggest a link between NMDAR-mediated neuronal stress and htt proteolysis. Notably, striatal MSNs express a higher proportion of NR2B-type NMDARs compared with other brain regions (119–122), and mutant htt has been shown to selectively potentiate current and toxicity mediated by NMDARs containing NR2B and not NR2A in a transfected non-neuronal cell line (123,124). Together, these data suggest that an interaction between mutant htt and NR2B-containing NMDARs could explain, in part, why striatal MSNs are targeted in HD. In contrast to results in the YAC transgenic mice, some of the other mice models of HD that express only short fragments of htt have not shown enhanced vulnerability to NMDAR-mediated excitotoxicity (125,126). However, at least in one model (R6/2), striatal neurons were also more resistant to oxidative stress induced by a variety of other stimuli (127,128), and the development of resistance to NMDAR-mediated toxicity in these mice was well correlated with changes in intracellular calcium handling and aggregate load (129). Consistent with the lack of enhanced vulnerability to excitotoxicity, striatal neurons from the R6/2 mice showed no significant difference in NMDAR-mediated current density compared with wild-type mice when recordings were made in the absence of magnesium, although a subgroup of neurons exhibited reduced magnesium sensitivity, suggesting changes in NMDAR subunit composition in this mouse model (130). These data suggest that enhanced NMDAR-induced excitotoxicity is associated with expression of the full-length human HD gene. The results are also consistent with the idea that excitotoxicity is involved in selective neuronal degeneration, since R6/2 mice exhibit widespread htt aggregates and brain atrophy but no selective neuronal degeneration (18), whereas the YAC transgenic mice show selective degeneration of mainly striatal neurons with few aggregates, similar to the neuropathology observed in human adult-onset HD (47,50). In addition to the strong evidence for enhanced NMDAR function, there are data to indicate that other pathways contribute to altered neuronal calcium homeostasis. Mitochondria isolated from fibroblasts of humans with HD or the brains of mutant YAC transgenic mice exhibit more depolarized resting membrane potentials and lower thresholds for the calcium-induced permeability transition pore formation associated with apoptosis (131). These changes in mitochondrial function suggest that the toxic effects of stimuli that increase neuronal intracellular calcium, including excitotoxicity,
Copyright 2006 by Taylor & Francis Group, LLC
368
Leavitt and Raymond
will be enhanced in the presence of mutant htt. As well, it has recently been demonstrated that mitochondria isolated from rat striatum show increased sensitivity to calcium-induced depolarization compared with mitochondria from rat cortex, suggesting an additional mechanism for selective striatal degeneration in HD (114). The high level of dopamine release in the neostriatum may also contribute to enhanced oxidative stress and selective neuronal degeneration (132). Furthermore, recent studies show evidence of increased glutamate release from cortical afferents to striatal neurons in the early symptomatic stage of disease in the R6/2 mice (133), as well as an interaction between mutant htt and inositol-3-phosphate receptors to increase receptor sensitivity for inducing calcium release from intracellular stores (134). Figure 2 illustrates many of the changes in neuronal function observed with expression of mutant htt, as discussed in this section. Clearly
Figure 2 Cartoon representing some of the changes observed in neuronal function with expression of mutant huntingtin. Many of the changes shown in the medium spiny striatal neuron converge to alter intracellular calcium homeostasis and promote proteolysis and initiation of cell death pathways. Additional changes are observed more generally, in a variety of neuronal and other cell types, including proteasomal dysfunction and impaired axonal transport (depicted in the cortical neuron), as well as transcriptional dysregulation (not shown).
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
369
a better understanding of the factors influencing selective neuronal degeneration, as well as the signaling cascades involved in neuronal dysfunction/ death triggered by excitotoxicity, will facilitate future development of more effective therapies in HD. PRECLINICAL TRIALS IN MOUSE MODELS OF HD The development of transgenic mouse models of HD is a critical step in accelerating the development of new therapeutic approaches for this devastating neurodegenerative disease. The majority of therapeutic trials in mice to date have been performed in exon 1 htt fragment mouse models, (45,135). Pre-clinical trials have attempted to interfere with the pathogenic processes described above: htt proteolysis, htt aggregation and transcriptional dysregulation, excitotoxicity, and other less well-established mechanisms. Evidence that inhibiting caspase-dependent proteolysis and apoptosis in HD may be beneficial was provided by a study on the treatment of R6/2 mice with either a broad-spectrum caspase inhibitor (zVAD-fmk) or by crossing these mice to mice with a dominant negative caspase 1 inhibitor which improved motor performance and survival (100). Minocycline, a tetracycline analogue that has been proposed to act as a caspase inhibitor in addition to potential therapeutic effects blocking mitochondrial apoptotic mechanisms and inflammation, was also reported to improve motor function and prolong survival in R6/2 mice. Several recent trials have failed to replicate this protective effect in this mouse model and in the N171– 82Q model, leaving the effectiveness of this agent in question (136,137). The bile acid taurosodeoxycholic acid inhibits apoptosis by unknown mechanisms, and was effective in improving motor performance and striatal atrophy in R6/2 mice, although no effect on survival was reported (138). Aggregation of htt, formation of intranuclear inclusions, and transcriptional dysregulation have also been identified as potential therapeutic targets in HD (83), and several trials in R6/2 mice have suggested that interference with this mechanism is protective in this model. Systemic treatment of R6/2 mice with congo red, a histochemical dye that blocks aggregation of htt and other misfolded proteins in vitro, resulted in modest increases in survival and decreased htt aggregate burden (90). A recent report of benefit on rotarod performance, weight, and survival following addition of a disaccharide, trehalose, to the drinking water of R6/2 mice is also suggested to be via inhibition of htt aggregation (139). The histone deacetylase (HDAC) inhibitors suberoylanilide hydroxyamic acid (SAHA) and sodium butyrate, are thought to modulate gene transcription and possibly reverse the transcriptional dysregulation caused by intranuclear htt inclusions. Therapeutic trials of these agents have prevented neurodegeneration in a polyglutamine fly model (58) and have also shown modest improvements in the motor
Copyright 2006 by Taylor & Francis Group, LLC
370
Leavitt and Raymond
phenotype and prolonged survival of R6/2 mice (140,141). Taken together these trials suggest that blockade of htt aggregation or the effects of intranuclear inclusions on transcription may be an effective therapeutic approach worth pursuing in HD. A number of agents which are proposed to improve mitochondrial function and/or block NMDAR-mediated excitotoxicity have been tested in mouse models of HD with varying degrees of efficacy. Dichloroacetate treatment improved survival in both the N171–82Q and R6/2 mice, possibly by increasing respiratory chain efficiency (142). The respiratory chain cofactors creatine and Co-enzyme Q10 are two of the best studied agents in mouse models of HD and have shown improved motor performance and survival in both the R6/2 and N171–82Q mouse models, both alone and in combination with the NMDA receptor antagonist remacemide (143–145). Unfortunately, the CARE-HD trial failed to demonstrate a functional benefit for this regimen over three years in a large cohort of HD patients (discussed further). Two other drugs currently approved for use in humans for other disorders have also shown promise in the R6/2 model; Riluzole—a glutamate release blocker (146), and lithium chloride—which protects from apoptosis by increasing Bcl-2 levels (147). Other potential mechanisms of HD pathogenesis that have been targeted in pre-clinical R6/2 mouse trials include: inflammation (148), transglutaminase activity (149,150), and oxidative stress (148,151).
CLINICAL TRIALS IN HD Treatments to Delay Onset or Slow Progression of HD Results of in vitro studies have suggested a variety of therapeutic targets for delaying onset and/or slowing progression of HD, including: suppressing glutamatergic neurotransmission and especially that mediated by subtypes of NMDA receptors, improving mitochondrial function and cellular energy levels, buffering free radicals to reduce oxidative stress, reducing inflammatory responses and protease activation, interfering with htt proteolysis and/ or aggregation, and restoring balance for transcriptional regulation. Several of these approaches have met with success in preclinical trials in HD mice and fly models (see above). However, only a few agents have made it through the first stages of human clinical testing. The largest randomized, placebo-controlled trial to date of agents that reduce excitotoxicity and improve mitochondrial function was CARE-HD, testing remacemide (a use-dependent NMDAR antagonist) and Coenzyme Q10, alone and in combination (152). This trial included 340 subjects followed over 2.5 years. Although Coenzyme Q10 appeared to slow progression by 13% in the early stages of HD as assessed by a functional scale, this difference was not statistically significant; remacemide reduced chorea but
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
371
produced no change in rate of functional decline. Further study of Coenzyme Q10 is planned, to include a higher dose, larger number of subjects and longer duration of study. Agents that suppress excitotoxicity by reducing glutamate release, such as lamotrigine and riluzole, have also been studied. In a relatively small, randomized controlled trial (RCT), lamotrigine slowed progression over a 30-month period by ~10% on a functional scale, but the result was not significant (153). Riluzole reduced chorea in an 8-week tolerability study (154), and is currently under study in a larger RCT in Europe for efficacy in slowing progression on a functional scale. Creatine (5–10 gm/day) and OPC-14117, which improve cellular energy stores and reduce oxidative stress, respectively, have been shown to be tolerated by subjects with HD (155–157), but in one-year trials creatine has not shown efficacy in slowing disease progression (155,156). Finally, minocycline, which reduces inflammatory responses mediated by glia and also shows efficacy in suppressing apoptotic neuronal death in vitro, has undergone a brief RCT for tolerability in subjects with HD (169), with plans for a larger RCT. Symptomatic Treatments Although no form of therapy has yet been shown to significantly alter the natural progression of HD, many of the motor and psychiatric symptoms of HD can be ameliorated by judicious intervention. Currently, there are no effective drug interventions that improve cognitive impairment in HD. Most of the current symptomatic treatment recommendations for the practical symptomatic management of HD are not evidence-based, and are derived from clinical experience, case reports, or small randomized trials (158). While the gait disorder, incoordination and voluntary movement disorder in HD have no effective therapy at present, several agents are available which can suppress involuntary movements in HD. The pharmacologic treatment of chorea is best undertaken only when the involuntary movements become severe enough to significantly impact functional activity. Drugs that act to decrease dopaminergic neurotransmission such as the neuroleptics (classic and atypical), and the dopamine-depleting agent tetrabenezine, are useful in reducing chorea. However, the risks of potential adverse side effects (such as depression induced by tetrabenezine) must be balanced against the potential benefits of suppressing chorea. Haloperidol has long been considered the first-line therapy for chorea in HD, and while no adequate clinical trials have been performed, it has empirically been found to supress choreiform movements in HD patients (159,160). However, in addition to dose-related side effects such as sedation, treatment of chorea with classic neuroleptics carries a significant hazard of adverse effects, notably dystonia, parkinsonism, and tardive dyskinesia (161).
Copyright 2006 by Taylor & Francis Group, LLC
372
Leavitt and Raymond
The atypical neuroleptic olanzepine is our currently recommended agent for the suppression of chorea in HD. Symptomatic benefit in HD with olanzapine therapy has been reported in several case reports (162–164), as well as in two small open-label trials (165,166), although high doses up to 30 mg per day may be required to adequately suppress chorea. The mechanism of action by which olanzapine has its anti-choreic effects is unknown, but it may act through a glutaminergic mechanism, or by action at adrenergic, muscarinic, seratonin, dopamine, or histamine receptors (167). Compared with conventional antipsychotics such as haloperidol, the use of olanzapine is associated with fewer and less severe adverse effects (161). In HD, the lack of significant extrapyramidal side effects is the most important benefit of olanzepine over the classic neuroleptics. Olanzepine does have dose-related sedative effects which can limit use, and causes increased appetite and weight gain in up to 30% of patients. In our clinical experience the increased weight gain is a common side effect of olanzepine in HD patients, and is beneficial for those patients with cachexia. Based on our clinical experience, standard pharmacotherapy is generally very effective for the common neuropsychiatric manifestations in HD, although good clinical trial data is again lacking to support this indication (158). Most depressed or obsessive-compulsive HD patients respond well to standard doses of tricyclic, SSRI or atypical antidepressant medications. Benzodiazepines can be useful adjuncts in anxious or agitated patients, and psychotic symptoms generally respond well to standard doses of either typical or atypical neuroleptics (159). The approach to symptomatic treatment in HD ideally involves the coordinated efforts of a multidisciplinary team composed of medical, nursing, social service, and physical/occupational therapy modalities (159). Medications can be very helpful in suppressing specific symptoms at one stage of the illness, but may have a detrimental effect at later stages and need to be constantly re-evaluated as the natural history of the disease evolves. HD patients tend to be acutely susceptible to the cognitive and motor side effects of many medications. Ideally, symptomatic drug treatment should only be initiated when symptoms begin to impair function, initial doses should be low and titrated gradually based on clinical response, and in general polypharmacy should be avoided. Many patients also obtain benefit from physical, speech, and occupational therapy. As dysphagia becomes more severe during the progression of the disease, a formal swallowing evaluation can yield practical suggestions for decreasing the risk of aspiration. Eventually, feeding via a gastrostomy tube will need to be presented as an option to the patient and family. Supportive family-based counseling is also a critical component of HD care. In addition to the affected patient, family members at risk and the unaffected spouse often have significant emotional problems that require specific interventions and support.
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
373
CONCLUSIONS Since the identification of the HD gene in 1993, the establishment of cellular and animal models of HD has rapidly accelerated knowledge of the pathogenic mechanisms. Based on studies in these models, a variety of potential therapeutic agents have been identified. The challenge for the near future is to select the agents that will be brought forward to human clinical trials. It will be critical to choose well because of the large number of subjects, as well as amount of time and funding required to prove efficacy in slowing progression of HD. Moreover, a wide variety of HD animal models are currently available, each with unique features that are similar as well as distinct from characteristics of human HD. Making decisions on therapeutic agents based on experimental therapeutic trials in individual animal models is difficult, and new therapeutic agents should have proven efficacy in several animal models prior to moving to human trials (168). To streamline this process, a centralized system for prioritizing agents for clinical testing has been developed (SET-HD; www.huntingtonproject.org). With this wealth of information and potential therapeutic agents, the future for therapy in HD looks promising. REFERENCES 1. Harper PS. Huntington’s Disease: London: WB Saunders Co, 1991. 2. Hayden MR. Huntington’s Chorea. Berlin: Springer, 1981. 3. Huntington G. On Chorea. The Medical and Surgical Reporter: A Weekly Journal 1872; 26(15):317–321. 4. Gusella JF, Wexler NS, et al. A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 1983; 306(5940):234–238. 5. Huntington’s Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 1993; 72:971–983. 6. Feigin A, Kieburtz K, et al. Functional decline in Huntington’s disease. Mov Disord 1995; 10(2):211–214. 7. Zakzanis KK. The subcortical dementia of Huntington’s disease. J Clin Exp Neuropsychol 1998; 20(4):565–578. 8. Butters N, Wolfe J, Martone M, Granholm E, Cermak LS. Memory disorders associated with Huntington’s disease: verbal recall, verbal recognition and procedural memory. Neuropsychologia 1985; 23(6):729–743. 9. Anderson KE, Marder KS. An overview of psychiatric symptoms in Huntington’s disease. Curr Psychiatry Rep 2001; 3(5):379–388. 10. Sanberg PR, Fibiger HC, Mark RF. Body weight and dietary factors in Huntington’s disease patients compared with matched controls. Med J Aust 1981; 1(8):407–409. 11. Bittenbender JB, Quadfasel FA. Rigid and akinetic forms of Huntington’s chorea. Arch Neurol 1962; 7:275–288.
Copyright 2006 by Taylor & Francis Group, LLC
374
Leavitt and Raymond
12. van Dijk JG, van der Velde EA, Roos RA, Bruyn GW. Juvenile Huntington’s disease. Hum Genet 1986; 73(3):235–239. 13. Campbell AM, Corner B, Norman RM, Urich H. The rigid form of Huntington’s disease. J Neurol Neurosurg Psychiatry 1961; 24:71–77. 14. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP, Jr. Neuropathological classification of Huntington’s disease. J Neuropathol Exp Neurol 1985; 44(6):559–577. 15. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989; 12(10):366–375. 16. Hedreen JC, Peyser CE, Folstein SE, Ross CA. Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease. Neurosci Lett 1991; 133(2):257–261. 17. Spargo E, Everall IP, Lantos PL. Neuronal loss in the hippocampus in Huntington’s disease: a comparison with HIV infection. J Neurol Neurosurg Psychiatry 1993; 56(5):487–491. 18. Davies SW, Turmaine M, et al. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 1997; 90(3):537–548. 19. DiFiglia M, Sapp E, et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997; 277(5334): 1990–1993. 20. Robitaille Y, Lopes-Cendes I, Becher M, Rouleau G, Clark AW. The neuropathology of CAG repeat diseases: review and update of genetic and molecular features. Brain Pathol 1997; 7(3):901–926. 21. Andrew SE, Goldberg YP, et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease. Nat Genet 1993; 4(4):398–403. 22. Duyao M, Ambrose C, et al. Trinucleotide repeat length instability and age of onset in Huntington’s disease. Nat Genet 1993; 4(4):387–392. 23. Telenius H, Kremer HP, et al. Molecular analysis of juvenile Huntington’s disease: the major influence on (CAG)n repeat length is the sex of the affected parent. Hum Mol Genet 1993; 2(10):1535–1540. 24. Coyle JT, Schwarcz R. Lesion of striatal neurones with kainic acid provides a model for Huntington’s chorea. Nature 1976; 263(5574):244–246. 25. McGeer EG, McGeer PL. Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature 1976; 263(5577):517–519. 26. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB. Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid. Nature 1986; 321(6066):168–171. 27. Beal MF, Kowall NW, Ferrante RJ, Cippolloni PB. Quinolinic acid striatal lesions in primates as a model of Huntington’s disease. Ann Neurol 1989; 26:137. 28. Hantraye P, Riche D, Maziere M, Isacson O. A primate model of Huntington’s disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon. Exp Neurol 1990; 108(2):91–104. 29. Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF. Excitotoxin lesions in primates as a model for Huntington’s disease: histopathologic and neurochemical characterization. Exp Neurol 1993; 119(1):46–71.
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
375
30. Sanberg PR, Calderon SF, Giordano M, Tew JM, Norman AB. The quinolinic acid model of Huntington’s disease: locomotor abnormalities. Exp Neurol 1989; 105(1):45–53. 31. Beal MF. Neurochemistry and toxin models in Huntington’s disease. Curr Opin Neurol 1994; 7(6):542–547. 32. Alexi T, Hughes PE, Faull RL, Williams CE. 3-Nitropropionic acid’s lethal triplet: cooperative pathways of neurodegeneration. Neuroreport 1998; 9(11):R57–64. 33. Greene JG, Greenamyre JT. Bioenergetics and glutamate excitotoxicity. Prog Neurobiol 1996; 48(6):613–634. 34. Duyao MP, Auerbach AB, et al. Inactivation of the mouse Huntington’s disease gene homolog Hdh. Science 1995; 269(5222):407–410. 35. Nasir J, Floresco SB, et al. Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 1995; 81(5):811–823. 36. Zeitlin S, Liu JP, Chapman DL, Papaioannou VE, Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat Genet 1995; 11(2):155–163. 37. O’Kusky JR, Nasir J, Cicchetti F, Parent A, Hayden MR. Neuronal degeneration in the basal ganglia and loss of pallido-subthalamic synapses in mice with targeted disruption of the Huntington’s disease gene. Brain Res 1999; 818(2):468–479. 38. Auerbach W, Hurlbert MS, et al. The HD mutation causes progressive lethal neurological disease in mice expressing reduced levels of huntingtin. Hum Mol Genet 2001; 10(22):2515–2523. 39. Dragatsis I, Levine MS, Zeitlin S. Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice. Nat Genet 2000; 26(3):300–306. 40. Cattaneo E, Rigamonti D, Goffredo D, Zuccato C, Squitieri F, Sipione S. Loss of normal huntingtin function: new developments in Huntington’s disease research. Trends Neurosci 2001; 24(3):182–188. 41. Ambrose CM, Duyao MP, et al. Structure and expression of the Huntington’s disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somat Cell Mol Genet 1994; 20(1):27–38. 42. Mangiarini L, Sathasivam K, et al. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996; 87(3):493–506. 43. Bates GP, Mangiarini L, Mahal A, Davies SW. Transgenic models of Huntington’s disease. Hum Mol Genet 1997; 6(10):1633–1637. 44. Schilling G, Becher MW, et al. Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin [published erratum appears in Hum Mol Genet 1999 May; 8(5):943]. Hum Mol Genet 1999; 8(3):397–407. 45. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington’s disease. Nat Rev Neurosci 2004; 5(5):373–384. 46. Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 2000; 101(1):57–66.
Copyright 2006 by Taylor & Francis Group, LLC
376
Leavitt and Raymond
47. Hodgson JG, Agopyan N, et al. A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999; 23(1):181–192. 48. Hodgson JG, Smith DJ, et al. Human huntingtin derived from YAC transgenes compensates for loss of murine huntingtin by rescue of the embryonic lethal phenotype. Hum Mol Genet 1996; 5(12):1875–1885. 49. Reddy PH, Williams M, et al. Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA. Nat Genet 1998; 20(2):198–202. 50. Slow EJ, van Raamsdonk J, et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington’s disease. Hum Mol Genet 2003; 12(13):1555–1567. 51. Shelbourne PF, Killeen N, et al. A Huntington’s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999; 8(5):763–774. 52. Wheeler VC, White JK, et al. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000; 9(4):503–513. 53. Lin CH, Tallaksen-Greene S, et al. Neurological abnormalities in a knock-in mouse model of Huntington’s disease. Hum Mol Genet 2001; 10(2):137–144. 54. Menalled LB, Sison JD, et al. Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington’s disease knock-in mice. J Neurosci 2002; 22(18):8266–8276. 55. Faber PW, Alter JR, MacDonald ME, Hart AC. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc Natl Acad Sci USA 1999; 96(1):179–184. 56. Parker JA, Connolly JB, Wellington C, Hayden M, Dausset J, Neri C. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc Natl Acad Sci USA 2001; 98(23):13,318–13,323. 57. Jackson GR, Salecker I, et al. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 1998; 21(3):633–642. 58. Steffan JS, Bodai L, et al. Histone deacetylase inhibitors arrest polyglutaminedependent neurodegeneration in Drosophila. Nature 2001; 413(6857):739–743. 59. Marsh JL, Walker H, et al. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum Mol Genet 2000; 9(1):13–25. 60. Mitchell A. A fly’s eye view of Huntington’s disease. Nature 1998; 395 (6705):841. 61. Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science 2000; 287(5459):1837–1840. 62. Rigamonti D, Bauer JH, et al. Wild-type huntingtin protects from apoptosis upstream of caspase-3. J Neurosci 2000; 20(10):3705–3713. 63. Leavitt BR, Guttman JA, et al. Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo. Am J Hum Genet 2001; 68(2):313–324. 64. Zuccato C, Ciammola A, et al. Loss of huntingtin-mediated BDNF gene transcription in Huntington’s disease. Science 2001; 293(5529):493–498.
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
377
65. Zuccato C, Tartari M, et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003; 35(1):76–83. 66. Zhang Y, Li M, et al. Depletion of wild-type huntingtin in mouse models of neurologic diseases. J Neurochem 2003; 87(1):101–106. 67. Persichetti F, Carlee L, et al. Differential expression of normal and mutant Huntington’s disease gene alleles. Neurobiol Dis 1996; 3(3):183–190. 68. White JK, Auerbach W, et al. Huntingtin is required for neurogenesis and is not impaired by the Huntington’s disease CAG expansion. Nat Genet 1997; 17:404–410. 69. Ross CA. When more is less: pathogenesis of glutamine repeat neurodegenerative diseases. Neuron 1995; 15(3):493–496. 70. MacDonald ME, Gusella JF. Huntington’s disease: translating a CAG repeat into a pathogenic mechanism. Curr Opin Neurobiol 1996; 6(5):638–643. 71. Scherzinger E, Lurz R, et al. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 1997; 90(3):549–558. 72. Hackam AS, Singaraja R, et al. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J Cell Biol 1998; 141(5):1097–1105. 73. Martindale D, Hackam A, et al. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat Genet 1998; 18(2):150–154. 74. Edwardson JM, Wang CT, et al. Expression of mutant huntingtin blocks exocytosis in PC12 cells by depletion of complexin II. J Biol Chem 2003; 278(33): 30849–30853. 75. Li H, Wyman T, Yu ZX, Li SH, Li XJ. Abnormal association of mutant huntingtin with synaptic vesicles inhibits glutamate release. Hum Mol Genet 2003; 12(16):2021–2030. 76. Lee WC, Yoshihara M, Littleton JT. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington’s disease. Proc Natl Acad Sci USA 2004; 101(9):3224–3229. 77. Gunawardena S, Her LS, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 2003; 40(1):25–40. 78. Szebenyi G, Morfini GA, et al. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 2003; 40(1):41–52. 79. Tobin AJ, Signer ER. Huntington’s disease: the challenge for cell biologists. Trends Cell Biol 2000; 10(12):531–536. 80. Saudou F, Finkbeiner S, Devys D, Greenberg ME. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 1998; 95(1):55–66. 81. Peters MF, Nucifora FC Jr, et al. Nuclear targeting of mutant Huntingtin increases toxicity. Mol Cell Neurosci 1999; 14(2):121–128. 82. Nucifora FC, Jr., Ellerby LM, et al. Nuclear localization of a non-caspase truncation product of atrophin-1, with an expanded polyglutamine repeat, increases cellular toxicity. J Biol Chem 2003; 278(15):13047–13055. 83. Cha JH. Transcriptional dysregulation in Huntington’s disease. Trends Neurosci 2000; 23(9):387–392.
Copyright 2006 by Taylor & Francis Group, LLC
378
Leavitt and Raymond
84. Chan EY, Luthi-Carter R, et al. Increased huntingtin protein length reduces the number of polyglutamine- induced gene expression changes in mouse models of Huntington’s disease. Hum Mol Genet 2002; 11(17):1939–1951. 85. Gutekunst CA, Li SH, et al. Nuclear and neuropil aggregates in Huntington’s disease: relationship to neuropathology. J Neurosci 1999; 19(7):2522–2534. 86. Kuemmerle S, Gutekunst CA, et al. Huntington aggregates may not predict neuronal death in Huntington’s disease. Ann Neurol 1999; 46(6):842–849. 87. Steffan JS, Agrawal N, et al. SUMO modification of Huntingtin and Huntington’s disease pathology. Science 2004; 304(5667):100–104. 88. Poirier MA, Li H, Macosko J, Cai S, Amzel M, Ross CA. Huntingtin spheroids and protofibrils as precursors in polyglutamine fibrilization. J Biol Chem 2002; 277(43):41032–41037. 89. Kayed R, Head E, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003; 300(5618):486–489. 90. Sanchez I, Mahlke C, Yuan J. Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders. Nature 2003; 421(6921):373–379. 91. Kim M, Lee HS, et al. Mutant huntingtin expression in clonal striatal cells: dissociation of inclusion formation and neuronal survival by caspase inhibition. J Neurosci 1999; 19(3):964–973. 92. Wellington CL, Leavitt BR, Hayden MR. Huntington’s disease: new insights on the role of huntingtin cleavage. J Neural Transm Suppl 2000; 58:1–17. 93. Goldberg YP, Nicholson DW, Rasper DM, et al. Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract [see comments]. Nat Genet 1996; 13(4):442–449. 94. Wellington CL, Ellerby LM, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem 1998; 273(15):9158–9167. 95. Wellington CL, Singaraja R, et al. Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate formation in neuronal and nonneuronal cells. J Biol Chem 2000; 275(26):19,831–19,838. 96. Kim YJ, Yi Y, et al. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington’s disease brains, associate with membranes, and undergo calpain-dependent proteolysis. Proc Natl Acad Sci USA 2001; 98(22):12,784–12,789. 97. Wellington CL, Ellerby LM, et al. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington’s disease. J Neurosci 2002; 22(18):7862–7872. 98. Gafni J, Ellerby LM. Calpain activation in Huntington’s disease. J Neurosci 2002; 22(12):4842–4849. 99. Goffredo D, Rigamonti D, et al. Calcium-dependent Cleavage of Endogenous Wild-type Huntingtin in Primary Cortical Neurons. J Biol Chem 2002; 277(42):39,594–39,598. 100. Ona VO, Li M, Vonsattel JP, et al. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington’s disease [see comments]. Nature 1999; 399(6733):263–267. 101. Chen M, Ona VO, et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington’s disease. Nat Med 2000; 6(7):797–801. taf/DynaPage.taf?file¼/nm/journal/v796/n797/
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
102.
103. 104.
105. 106.
107.
108. 109. 110.
111. 112.
113.
114.
115.
116. 117.
118.
379
full/nm0700_0797.html taf/DynaPage.taf?file¼/nm/journal/v0706/n0707/abs/ nm0700_0797.html. Sanchez I, Xu CJ, Juo P, Kakizaka A, Blenis J, Yuan J. Caspase-8 is required for cell death induced by expanded polyglutamine repeats [see comments]. Neuron 1999; 22(3):623–633. Li XJ, Li SH, et al. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 1995; 378(6555):398–402. Kalchman MA, Koide HB, et al. HIP1, a human homologue of S. cerevisiae Sla2p, interacts with membrane- associated huntingtin in the brain. Nat Genet 1997; 16(1):44–53. Li SH, Gutekunst CA, Hersch SM, Li XJ. Interaction of huntingtin-associated protein with dynactin P150Glued. J Neurosci 1998; 18(4):1261–1269. Metzler M, Legendre-Guillemin V, et al. HIP1 functions in clathrin-mediated endocytosis through binding to clathrin and adaptor protein 2. J Biol Chem 2001; 276(42):39271–39276. Metzler M, Li B, et al. Disruption of the endocytic protein HIP1 results in neurological deficits and decreased AMPA receptor trafficking. Embo J 2003; 22(13):3254–3266. Kalchman MA, Graham RK, et al. Huntingtin is ubiquitinated and interacts with a specific ubiquitin-conjugating enzyme. J Biol Chem 1996; 271(32):19385–19394. Burke JR, Enghild JJ, et al. Huntingtin and DRPLA proteins selectively interact with the enzyme GAPDH. Nat Med 1996; 2(3):347–350. Faber PW, Barnes GT, Srinidhi J, Chen J, Gusella JF, MacDonald ME. Huntingtin interacts with a family of WW domain proteins. Hum Mol Genet 1998; 7(9):1463–1474. Rothman SM, Olney JW. Excitotoxicity and the NMDA receptor–still lethal after eight years. Trends Neurosci 1995; 18(2):57–58. Beal MF, Brouillet E, et al. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 1993; 13(10):4181–4192. Greene JG, Porter RH, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an ‘‘excitotoxic’’ lesion in rat striatum. J Neurochem 1993; 61(3):1151–1154. Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, Dubinsky JM. Increased susceptibility of striatal mitochondria to calciuminduced permeability transition. J Neurosci 2003; 23(12):4858–4867. Albin RL, Young AB, et al. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease [see comments]. N Engl J Med 1990; 322(18):1293–1298. Young AB, Greenamyre JT, et al. NMDA receptor losses in putamen from patients with Huntington’s disease. Science 1988; 241(4868):981–983. Zeron MM, Hansson O, et al. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron 2002; 33(6):849–860. Zeron MM, Fernandes HB, et al. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington’s disease. Mol Cell Neurosci 2004; 25(3):469–479.
Copyright 2006 by Taylor & Francis Group, LLC
380
Leavitt and Raymond
119. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB Jr, Young AB. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 1995; 15(7 Pt 2):5297–5307. 120. Kuppenbender KD, Standaert DG, Feuerstein TJ, Penney JB Jr, Young AB, Landwehrmeyer GB. Expression of NMDA receptor subunit mRNAs in neurochemically identified projection and interneurons in the human striatum. J Comp Neurol 2000; 419(4):407–421. 121. Christie JM, Jane DE, Monaghan DT. Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites. J Pharmacol Exp Ther 2000; 292(3): 1169–1174. 122. Li L, Fan M, et al. Role of NR2B-type NMDA receptors in selective neurodegeneration in Huntington’s disease. Neurobiol Aging 2003; 24(8):1113–1121. 123. Chen N, Luo T, et al. Subtype-specific enhancement of NMDA receptor currents by mutant huntingtin. J Neurochem 1999; 72(5):1890–1898. 124. Zeron MM, Chen N, et al. Mutant huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 2001; 17(1):41–53. 125. Petersen A, Chase K, Puschban Z, DiFiglia M, Brundin P, Aronin N. Maintenance of susceptibility to neurodegeneration following intrastriatal injections of quinolinic acid in a new transgenic mouse model of Huntington’s disease. Exp Neurol 2002; 175(1):297–300. 126. Hansson O, Peters n A, Leist M, Nicotera P, Castilho RF, Brundin P. Transgenic mice expressing a Huntington’s disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 1999; 96(15):8727–8732. 127. Petersen A, Hansson O, et al. Mice transgenic for exon 1 of the Huntington’s disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6- hydroxydopamine. Eur J Neurosci 2001; 14(9):1425–1435. 128. Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington’s disease is dependent on age and CAG repeat length. J Neurochem 2001; 78(4):694–703. 129. Hansson O, Guatteo E, et al. Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. Eur J Neurosci 2001; 14(9):1492–1504. 130. Cepeda C, Ariano MA, et al. NMDA receptor function in mouse models of Huntington’s disease. J Neurosci Res 2001; 66(4):525–539. 131. Panov AV, Gutekunst CA, et al. Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines. Nat Neurosci 2002; 5(8):731–736. 132. Petersen A, Mani K, Brundin P. Recent advances on the pathogenesis of Huntington’s disease. Exp Neurol 1999; 157(1):1–18. 133. Cepeda C, Hurst RS, et al. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease. J Neurosci 2003; 23(3):961–969.
Copyright 2006 by Taylor & Francis Group, LLC
Huntington’s Disease: Pathogenesis and New Therapies
381
134. Tang TS, Tu H, et al. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003; 39(2):227–239. 135. Schilling G, Savonenko AV, et al. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 2004; 187(1):137–149. 136. Smith DL, Woodman B, et al. Minocycline and doxycycline are not beneficial in a model of Huntington’s disease. Ann Neurol 2003; 54(2):186–196. 137. Diguet E, Rouland R, Tison F. Minocycline is not beneficial in a phenotypic mouse model of Huntington’s disease. Ann Neurol 2003; 54(6):841–842. 138. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci USA 2002; 99(16): 10671–10676. 139. Tanaka M, Machida Y, et al. Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington’s disease. Nat Med 2004; 10(2): 148–154. 140. Ferrante RJ, Kubilus JK, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington’s disease mice. J Neurosci 2003; 23(28):9418–9427. 141. Hockly E, Richon VM, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc Natl Acad Sci U.S.A. 2003; 100(4):2041–2046. 142. Andreassen OA, Ferrante RJ, et al. Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington’s disease. Ann Neurol 2001; 50(1): 112–117. 143. Ferrante RJ, Andreassen OA, et al. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J Neurosci 2000; 20(12):4389–4397. 144. Ferrante RJ, Andreassen OA, et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington’s disease. J Neurosci 2002; 22(5):1592–1599. 145. Andreassen OA, Dedeoglu A, et al. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol Dis 2001; 8(3):479–491. 146. Schiefer J, Landwehrmeyer GB, et al. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington’s disease. Mov Disord 2002; 17(4):748–757. 147. Wood NI, Morton AJ. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington’s disease mutation. Brain Res Bull 2003; 61(4):375–383. 148. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF. Lipoic acid improves survival in transgenic mouse models of Huntington’s disease. Neuroreport 2001; 12(15):3371–3373. 149. Karpuj MV, Becher MW, et al. Prolonged survival and decreased abnormal movements in transgenic model of Huntington’s disease, with administration of the transglutaminase inhibitor cystamine. Nat Med 2002; 8(2):143–149.
Copyright 2006 by Taylor & Francis Group, LLC
382
Leavitt and Raymond
150. Dedeoglu A, Kubilus JK, et al. Therapeutic effects of cystamine in a murine model of Huntington’s disease. J Neurosci 2002; 22(20):8942–8950. 151. Klivenyi P, Ferrante RJ, Gardian G, Browne S, Chabrier PE, Beal MF. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington’s disease. J Neurochem 2003; 86(1):267–272. 152. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 2001; 57(3):397–404. 153. Kremer B, Clark CM, et al. Influence of lamotrigine on progression of early Huntington’s disease: a randomized clinical trial. Neurology 1999; 53(5): 1000–1011. 154. Huntington Study Group. Dosage effects of riluzole in Huntington’s disease: a multicenter placebo-controlled study. Neurology 2003; 61(11):1551–1556. 155. Verbessem P, Lemiere J, et al. Creatine supplementation in Huntington’s disease: a placebo-controlled pilot trial. Neurology 2003; 61(7):925–930. 156. Tabrizi SJ, Blamire AM, et al. Creatine therapy for Huntington’s disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61(1):141–142. 157. Huntington Study Group. Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington’s disease. The Huntington Study Group. Neurology 1998; 50(5):1366–1373. 158. Bonelli RM, Hofmann P. A review of the treatment options for Huntington’s disease. Expert Opin Pharmacother 2004; 5(4):767–776. 159. Rosenblatt A, Ranen, N.G., Nance, M.A., Paulsen, J.S. A Physician’s Guide to the Management of Huntington’s Disease. 2nd ed. New York: Huntington’s Disease Society of America, 1999. 160. Grimbergen YA, Roos RA. Therapeutic options for Huntington’s disease. Curr Opin Invest Drugs 2003; 4(1):51–54. 161. Tollefson GD, Beasley CM, Jr, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154(9):1248–1254. 162. Dipple HC. The use of olanzapine for movement disorder in Huntington’s disease: a first case report. J Neurol Neurosurg Psychiatry 1999; 67(1):123–124. 163. Bogelman G, Hirschmann S, Modai I. Olanzapine and Huntington’s disease. J Clin Psychopharmacol 2001; 21(2):245–246. 164. Bonelli RM, Niederwieser G, Tribl GG, Koltringer P. High-dose olanzapine in Huntington’s disease. Int Clin Psychopharmacol 2002; 17(2):91–93. 165. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington’s disease: an open label study. Clin Neuropharmacol 2002; 25(5):263–265. 166. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington’s disease. Acta Neurol Scand 2002; 105(6):441–444. 167. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 1999; 37(3):177–193. 168. Bates GP, Hockly E. Experimental therapeutics in Huntington’s disease: are models useful for therapeutic trials? Curr Opin Neurol 2003; 16(4):465–470 169. Huntington Study Group. Minocycline safety and tolerability in Huntington’s disease. Neurology 2004; 63(3):547–549.
Copyright 2006 by Taylor & Francis Group, LLC
17 Wilson’s Disease George J. Brewer Department of Human Genetics and Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, U.S.A.
INTRODUCTION AND HISTORICAL OVERVIEW An American neurologist, Samuel Alexander Kinnier Wilson, working in England, originally described the syndrome that bears his name (1). He noted the concomitant occurrence of a neurological movement disorder associated with liver disease and often associated with behavioral symptoms. At autopsy these patients had disease of the liver and of certain structures in the brain including the lenticular nuclei, leading to the name he used, hepatolenticular degeneration. Later, two ophthalmologists, Kayser and Fleischer, independently described the brownish-green corneal rings that are present in many patients with this syndrome (2,3). It took several observations of elevated copper in various anatomical locations before it was realized that copper accumulation was etiologically involved (4,5). After the demonstration that copper balance was controlled by biliary excretion of copper (6), it was shown that Wilson’s patients have defective biliary excretion of copper (7). Meanwhile it was observed that a copper containing serum protein, ceruloplasmin, was usually at quite low levels in Wilson’s disease patients (8,9). Later, the disease was shown to be inherited as an autosomal recessive disease (10). The first really effective oral therapy was a chelator, penicillamine, developed by Walshe in 1956 (11), and Walshe followed up with a second chelator, trientine, for penicillamine-intolerant patients (12). Schouwink first
Copyright 2006 by Taylor & Francis Group, LLC
384
Brewer
used zinc therapy, describing its use in two patients in his thesis in the Netherlands (13). His work was followed up with further zinc studies by Hoogenraad, also in the Netherlands (14). Independently, my group developed zinc therapy as a Wilson’s disease treatment in the United States, after observing zinc-induced copper deficiency in sickle cell disease patients (15,16). Zinc acts by reducing the intestinal absorption of copper (17). The causative gene, which produces a copper binding ATPase called ATP7B, has been identified (18–20). Already over 200 causative mutations have been identified, making it difficult to use mutation screening for diagnosis in most populations (21). Several books and reviews on various aspects of Wilson’s disease have been published, and these can be consulted for more background on various aspects of the disease (22–33). PATHOPHYSIOLOGY The damage in Wilson’s disease is due to oxidant injury from copper (22–33). The key role of copper is shown by the association of liver and brain damage with copper accumulation in those organs, and by the cessation of injury and partial repair when drugs are used which reduce copper levels. This role is further confirmed by finding that the causal gene codes for a copper binding enzyme that regulates copper excretion in the bile. The evidence for oxidant damage includes the demonstration that copper causes Heinz body type damage to erythrocytes and glutathione depletion, both known to be oxidant related events (34–36). There are several other types of evidence showing oxidant damage from copper to the cell membrane, mitochondria, and nuclear components of cells (32). The typical Western diet contains about 1.00.25 mg of copper/day (37–40). Adults have obligatory losses of about 0.75 mg/day, indicating an average excessive intake of about 0.25 mg/day (32). The liver is responsible for maintaining copper balance, and excretes the excess in the bile for loss in the stool (6). The ATP7B protein is a key step in that pathway, and when both copies of the gene are defective due to mutation, copper begins to accumulate, first in the liver, where the major stores are held, and then elsewhere, such as in the brain. The ATP7B protein also plays a role in the incorporation of copper into ceruloplasmin. Apoceruloplasmin (the protein prior to copper attachment) is made by the liver, and in the absence of copper incorporation, is either not secreted normally into the blood and/ or has a shortened turnover time, causing the low blood ceruloplasmin in Wilson’s disease. GENETICS AND EPIDEMIOLOGY As already mentioned, the causative gene is ATP7B (18–20), which has considerable homology to the causative gene in Menke’s disease, ATP7A.
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
385
ATP7B is expressed primarily in the liver, which fits with the function already discussed, copper excretion into bile, while ATP7A is much more broadly expressed, which fits with the widespread functional and copper accumulation abnormalities in Menke’s disease. In most populations, no single mutation, or small group of mutations, is sufficiently common to allow diagnosis by mutation screening using current technology (32). For example, in the United States, the most common mutation, His1069 Gln, accounts for about 30% of all mutations, but after that frequencies fall off rapidly into the 1% or lower range. Thus, most U.S. patients are compound heterozygotes. Worldwide, over 200 causative mutations have been described (21). In occasional populations, due to founder effects, one or a few mutations may be frequent enough to be useful diagnostically. On the other hand, once a patient is diagnosed, siblings can be evaluated very accurately by haplotype analysis. Polymorphic markers on both sides of the Wilson locus on chromosome 13 are analyzed, and it is determined if a given sibling shares two, one, or zero chromosome 13s with the patient, indicating affected, carrier, or clear, respectively. As we will discuss, Wilson’s disease can present clinically with either hepatic or neurologic symptoms predominating, and with considerable variation in age of onset. There have been attempts to carry out genotype–phenotype correlations, i.e., to see if certain mutations are correlated with specific phenotypic characteristics (41). In general, these attempts have not been very successful (32,42). They are hampered to some degree by most patients being compound heterozygotes. It has been stated that patients with the common mutation His1069 Gln are more likely to present later and with neurologic disease (41). However, it is always possible that the genetic background associated with having that mutation is the more important factor (32). In fact, it seems quite likely that numerous genetic factors determining such things as the strength of oxidant defense mechanisms in specific tissues, the level of metallothionein (which by sequestering copper can protect against toxicity) induction in specific tissues, and numerous other factors will strongly influence when and where toxicity will occur (32). Effects of the environment must not be forgotten. For example, copper is absorbed much more poorly from vegetable foods than from meat (43,44). Thus, the choice of eating less meat, or the economic forces causing less meat to be purchased, can probably delay onset of the disease. Wilson’s disease appears to be present in most populations, basically a result of the mutation rate, similar to most other rare recessive diseases. The frequency may vary a little, especially in relatively isolated populations where founder effects can play a significant role. The general frequency number that is used is 1 in 40,000 (23,24,32). This number is soft, being determined in part by autopsy series, where under-diagnosis may occur unless postmortem copper studies are done. We attempted to strengthen the estimate
Copyright 2006 by Taylor & Francis Group, LLC
386
Brewer
of frequency by using the frequency of His1069 Gln in a series of U.S. Wilson’s patients, then determining the heterozygous frequency of His1069 Gln in newborn blood samples (45). This estimate of the frequency of Wilson’s disease was 1 in 55,000, but with a very wide confidence interval. If we use 1 in 40,000 this results in a U.S. case load of about 6000, if they were all diagnosed and lived a normal life span, and a heterozygote frequency of about 1 in 100.
CLINICAL PRESENTATIONS Hepatic Presentation About half of Wilson’s disease patients present with liver disease, typically in their late teenage years, and this may become clinically apparent in three different forms. One form is hepatitis, usually with jaundice and elevated serum transaminase enzymes. If undiagnosed, the hepatitis often resolves, only to recur, perhaps several times. This often leads to the misdiagnosis of chronic active hepatitis, inferring a viral or autoimmune origin. The second form is that a hepatitis episode results in liver failure, meaning that the liver is not keeping up with its synthetic and metabolizing functions. Thus, the albumin will usually be low, the bilirubin elevated, coagulation factors low, and transaminase enzymes high. Ascites, peripheral edema, and hepatic encephalopathy may be present. The third form is the discovery of cirrhosis, perhaps by coincidence during workup for something else, or perhaps by one of the complications of the resulting portal hypertension, such as bleeding esophageal or gastric varices. Such a patient who drinks alcohol even moderately may be misdiagnosed as alcoholic cirrhosis. The clinical presentation of liver disease from Wilson’s disease tends to occur in the second and third decades of life in the U.S. and other Western countries, although the possible age of presentation is quite broad from childhood until the fifties (32). In India and some other Far Eastern countries, the age of presentation tends to be much younger, often in children 10 years of age or younger (46–48). Psychiatric Presentation Behavioral abnormalities are quite common in the neurologic presentation of Wilson’s disease (49,50). About 25% of Wilson’s patients first present with behavioral abnormalities, typically in late teen age years through early thirties in Western countries, and quite a bit younger in India and the Far East. Behavioral abnormalities can antedate neurologic symptoms by a year or two. However, our rule of thumb in seeing patients with movement disorder symptoms is that behavioral abnormalities antedating neurologic symptoms by more than three years may not be related to Wilson’s disease.
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
387
The most common abnormality is personality change, which includes irritability, emotionality, bouts of anger, anxiety, hypermania, sexual preoccupation or loss of inhibitions, excessive hand washing, and others (49,50). Depression is also very common. Cognitive changes may occur but are often misdiagnosed because the patient has difficulty focusing on tasks, shortterm memory is affected, and motor skills are often defective. In their study, Dening and Berrios (51) describe incongruous behavior, irritability, aggression, and personality change as common. They paint a typical picture of odd, reckless, disinhibited behavior with loss of impulse control. Neuropsychologic tests that have been administered to patients at the time of diagnosis or early in therapy often reveal mild abnormalities, and can be abnormal even in presymptomatic patients (52). There are a number of publications on the psychiatric and behavioral disorder in Wilson’s disease other than those cited which the interested reader can consult (53–60). The paper by Lauterbach et al. (60) provides a good discussion of the complicated interconnections of the brain which may help explain why both neurologic and psychological symptoms can result from the injuries in Wilson’s disease. Later when we discuss treatment, we will discuss the effect of anticopper therapy on the behavioral aspects of this disease. Rarely do behavioral abnormalities alone lead to the correct diagnosis of Wilson’s disease. This is unfortunate because if it did, it would allow treatment before the onset of neurologic symptoms and prevent permanent neurologic deficits. Rather, these patients are usually given other diagnoses. Often they are accused of substance abuse because of their young age. Even though these patients have not shown enough liver disease problems to come to clinical attention, by this time they almost all have underlying liver disease. Neurologic Presentation About 50% of Wilson’s patients ultimately develop neurologic symptoms. This includes the 25% who first present with behavioral symptoms and then develop neurologic symptoms, and the 25% who present with neurologic symptoms without any obvious antecedent behavioral problems. The areas of the brain that are affected are those that coordinate movement, hence the classification of Wilson’s disease as a movement disorder, alongside much more common movement disorders such as Parkinson’s disease, Huntington’s disease, essential tremor, and many other rarer disorders (26–30,61). The neurologic symptoms of Wilson’s disease can be explained by three basic defects: tremor, dystonia, and incoordination (32). Thus, dysarthria, which is very common, can be explained by dystonia and/or incoordination of the muscles involved in speech. The dysarthria is often hypokinetic (low volume) in addition to the problems making certain
Copyright 2006 by Taylor & Francis Group, LLC
388
Brewer
sounds. The dysarthria of Wilson’s disease is not pathognomonic, so it is not possible to make the diagnosis based on the speech pattern. Tremor occurs in about one-third of neurologic Wilson patients, and again is not of a pathognomonic nature. I once saw a patient whose Wilson’s disease had been supposedly ruled out by the tremor not being ‘‘wing beating’’; this is inappropriate. Wing beating tremor does occur, but so do a variety of other types of tremor. Incoordination begins with difficulty with fine tasks—handwriting, typing, buttoning, etc., and gradually progresses to interfere with coordination of larger muscle groups, such as those involved in bringing food to mouth, handling larger objects, and walking. Classically, the handwriting in Wilson’s disease is said to be micrographic, possibly due to hypokinesia, or possibly an adaptation by the patient to keep their handwriting from being excessively sloppy (24). However, in my experience the handwriting is much more often simply very sloppy, not necessarily small. Dystonia may begin with what appear to be muscle cramps in fingers, toes, hands, feet, arms, or legs. Later it may progress to the point where it pulls these body parts into increasingly unphysiologic positions, producing much pain in the process. Even the muscle groups of the neck and back may become involved, twisting the head and/or torso. Individual patients at the time they are first diagnosed have various combinations of tremor, incoordination, and dystonia, and of varying severity. Thus, a given patient may have mild disease, perhaps with mild dysarthria, and a little tremor, to very severe disease producing an anarthric, bedridden patient with severe tremor, whose limbs and body are in fixed positions. These differences are primarily related to disease progression. All patients start out with mild disease, but some are not diagnosed until they have progressed to severe disease. Hence the critical role of early recognition and diagnosis. Anticopper treatment can essentially prevent this progression. Other Types of Clinical Involvement Wilson’s patients often have additional clinical findings (32). These may be found coincidentally as the patient is being worked up because of one of the presentations already described, or may on occasion be a factor in triggering a Wilson’s workup and diagnosis in the first place. Another eye abnormality, besides Kayser–Fleischer (KF) rings, is sunflower cataract. Patients may have diploplia, or abnormal eye movements. Disturbances of the autonomic nervous system are fairly frequent, and include postural hypotension, abnormal sweating, and bladder, bowel, and sexual dysfunction (62–64). Migraine-type headaches occur, as does epilepsy, both of which appear to be causally related to copper toxicity in some patients. Cholelithiasis and urolithiasis are more common in Wilson’s
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
389
disease. Women usually stop menstruating sometime before presenting clinically with Wilson’s disease. A type of osteoarthritis, particularly of the knee, is fairly common. Cardiac abnormalities have been reported (65–67), but in my experience, the heart is not affected by Wilson’s disease. Abnormalities in the urine can occur (23,32). Presymptomatic Patients Usually as part of a family workup, but occasionally because of a chance finding (e.g., Kayser–Fleischer rings seen on a routine eye examination), patients will be diagnosed in an asymptomatic state. We call these presymptomatic patients under the assumption that the disease is 100% penetrant, and these patients are doomed to become ill unless treated prophylactically. Since the disease is inherited as an autosomal recessive, 25% of a newly diagnosed patient’s siblings are at risk for also being affected. Since prophylactic anticopper treatment will prevent these patients from ever becoming ill (68,69), it is important to screen and work up these siblings aggressively, as an important component of preventive medicine. Other more distant relatives also have an increased risk (children of a patient, 1:200; nieces and nephews, 1:600; cousins, 1:800, compared to the 1:40,000 population risk) and may also deserve screening.
RECOGNITION, SCREENING, AND DIAGNOSIS Recognition A major problem in Wilson’s disease is the recognition by clinicians that particular types of patients may have Wilson’s disease, and be very treatable. The occasional Wilson’s patient presenting with hepatitis is buried and often lost amongst hundreds of patients with viral or other types of hepatitis. The same with cirrhosis; the Wilson’s patient will be a rare patient among many with cirrhosis secondary to alcohol abuse, hepatitis C, hepatosteatosis, etc. On the neurology side, other causes of tremor, such as Parkinsonism, essential tremor, etc., are much, much more common than Wilson’s disease. The same is true of many of the other features of the movement disorder, often misdiagnosed for a while as due to Parkinsonism. The situation is even worse on the behavioral side. Given the frequency of abnormal behavior due to substance abuse, life’s stresses, or whatever, it is a rare psychiatrist who recognizes that the young person under evaluation with a six months history of odd and obnoxious behavior, might have Wilson’s disease. I think we can do better, and in hopes of helping the cause of early recognition, Table 1 provides a list of the types of patients various specialists and other health care workers should look for as possible Wilson’s candidates.
Copyright 2006 by Taylor & Francis Group, LLC
390
Brewer
Table 1 Patients That Should be Screened for Wilson’s Disease Neurologic area Patients 50 years or younger with recent onset (five years) with: Dysarthria Tremor or involuntary movements Dystonia Incoordination Diagnosis of Parkinsonism Diagnosis of essential tremor Psychiatric area Patients 50 years or younger with recent onset (three years) with: Loss of ability to focus on tasks Loss of emotional control Depression Loss of sexual inhibition or other bizarre behavior Hepatic area Patients 50 years or younger with: Viral negative hepatitis or elevated transaminase enzymes Chronic hepatitis Cirrhosis, without a definitive diagnosis as to cause Liver failure, without a definitive diagnosis as to cause
Screening Screening tests are listed in Table 2. The two most useful screening tests are Kayser–Fleischer (KF) ring examination by an ophthalmologist with a slit lamp, and 24 hours urine copper determination. KF ring examination is extremely useful in the neurologic/behavioral presentations. In our experience, 178/179 patients presenting in this manner were positive for KF rings. Only very rarely have patients been reported with what appeared to be KF rings who did not have Wilson’s disease. So by a simple referral to an ophthalmologist, a neurologist seeing a relatively young patient with tremor or Parkinson-like symptoms, or a psychiatrist seeing a relatively young patient with new and odd behavior, can essentially rule Wilson’s disease in or out. This examination is not as useful in patients with liver disease because the KF rings are present less often, perhaps only 50% of the time, particularly in younger patients. If present though, they help the gastroenterologist a great deal in getting to the right diagnosis. The 24 hours urine copper is also very valuable as a screening tool, but more cumbersome to obtain (Table 2). In my experience it is always elevated over 100 mg in untreated patients (normal 20–50). The procedure must be done with trace element free collecting materials to avoid contamination, and in a laboratory with the equipment and skills to measure the low levels of copper present in urine. The only other caveat is that long standing liver
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
391
Table 2 Values or Findings in Screening Tests for Wilson’s Disease
Test
Normal Values
24-hour urine 20–50 mg copper
Symptomatic Affected Patients >100 mg
Carriers
Presymptomatic Affected Patients
<100 mg >65 mg 90% <65 mg
KayserFleischer ring exam
Not Present Not Present in patients present with neurologic and psychiatric symptoms Present in most hepatic patients unless they are very young
Present in 30–40%
Serum Cp
20–35 Often below 10. Low mg/dL normal to normal in about 15%
Same as symptomatic patients
80% > 20 20% < 20
Reprinted from: Kluwer Academic Publishers, Boston, Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management. 2001, George J Brewer, page 31, Chapter 3. Simple approaches to screening and definitive diagnosis, Table 3.1, with kind permission of Springer Science and Business Media. (Reference 32).
disease, particularly with an obstructive component, can elevate liver and urine copper. Serum ceruloplasmin is often the first and only screening test used by many physicians, but has serious drawbacks (Table 2). First, it is only abnormally low in about 80–85% of Wilson patients. Second, it abnormally low in about 15–20% of heterozygous carriers of the Wilson gene. Thus, it should only be used to affect index of suspicion. Other screening tests that have been suggested include a radiocopper test, but it does not differentiate carriers from affected individuals (22). Another test is a penicillamine ‘‘provocative’’ test, looking at copper excretion after a dose of penicillamine. This test, too, probably does not differentiate carriers and affected persons. We have already discussed why mutation screening is not useful in most populations. On the other hand, haplotype analysis is very effective for screening siblings of an affected patient (32). Definitive Diagnosis Some combinations of screening tests can be considered definitive, and these are listed in Table 3. For example, KF rings plus a urine copper over 100 mg in a neurologic/behavioral patient, or a sibling of an affected person, can be considered definitive. We usually recommend at least two positive tests, to mitigate against the occasional error in any test. Even ophthalmologists (usually those who have never seen KF rings) occasionally miss them, or
Copyright 2006 by Taylor & Francis Group, LLC
392
Brewer
Table 3 Diagnostic Scenarios not Requiring a Liver Biopsy Patient Has Wilson’s Disease Typical neurological symptoms KF rings and Elevated urine copper (over 100 mg/24 hours) Sibling of affected patient Elevated urine copper (over 100 mg/24 hours), or Haplotype analysis identical to affected sibling KF rings discovered by ophthalmologist Elevated urine copper (over 100 mg/24 hours) Hepatic presentation Elevated urine copper(over 100 mg/24 hours— in absence of long-standing liver failure or obstruction) and Cp less than 10 mg/dL Patient Does Not Have Wilson’s Disease Movement disorder type neurological symptoms No KF rings and Normal urine copper (50 mg or less/24 hours) Sibling of affected patient Normal urine copper (50 mg or less/24 hours—if age 15 years or older) Hepatic disease Near normal urine copper (60 mg or less/24 hours) Reprinted from: Kluwer Academic Publishers, Boston, Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management 2001, George J Brewer, page 43, Chapter 3. Simple approaches to screening and definitive diagnosis, Table 3.4, with kind permission of Springer Science and Business Media. (Reference 32).
see them when they are not there. In the liver disease patient we usually prefer to get a liver biopsy because of the occasional occurrence of cholestatic syndromes that cause a high urine copper.
TREATMENT WITH ANTICOPPER DRUGS There are three commercially available anticopper drugs and a fourth well on its way to development. We will discuss them in the sequence in which they were introduced. Penicillamine Penicillamine was introduced in 1956 and was the first orally effective anticopper drug (11). It is a reductive chelator which means that it reduces copper, in the process lowering copper’s binding affinity to proteins, and then binding the copper itself, with excretion of the complex in the urine. The reductive step is important, because chelators that do not do this, such
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
393
as EDTA, even though they have a high affinity for copper, are ineffective in causing copper excretion. Penicillamine is given in doses of 1.0 g/day, often as 500 mg twice daily or 250 mg four times daily, avoiding food 1/2 hour before and two hours after each dose. It causes a great increase in urinary copper excretion in Wilson patients, often to several milligrams/day. It is generally effective in producing a negative copper balance, and with one exception noted below, to allow subsequent partial clinical recovery. It is also effective in preventing the onset of disease when used prophylactically in presymptomatic patients (68). There are two negative features of penicillamine use in Wilson’s disease. The first is the long list of side effects of penicillamine therapy (22). These include a common (25%) hypersensitivity, bone marrow suppression including aplastic anemia, autoimmune disorders such as Goodpasture’s syndrome or lupus erythematosis, a variety of skin manifestations, hepatotoxicity, nephrotoxicity, and on and on. The second is neurologic deterioration when used as initial therapy in neurologically presenting patients (70). This may happen as often as 50% of the time, and half of the patients who worsen may never recover. The mechanism of this may be due to mobilization of hepatic copper with further elevation of brain copper. Trientine Trientine was introduced in 1982 as a replacement for penicillamine in penicillamine-intolerant patients (12). It is also a chelator but acts less aggressively than penicillamine. It is used in doses similar to penicillamine, with the same food avoidance, and causes a modest increase in urine copper, to 1.0 or 2.0 mg/day. It is also generally effective in producing a negative copper balance. Trientine shares some of the toxicities of penicillamine, but they appear to be much less frequent (32). Proteinuria, iron deficiency, lupus nephritis, and lupus erythematosis have been the main ones. The risk of neurologic worsening with trientine when used as initial therapy in neurologically presenting patients is less than with penicillamine, but still exists (71). Zinc After several years of work by our group (15–17,22,26–30,37,69) zinc was approved by the FDA in January 1997 for maintenance therapy in Wilson’s disease. Zinc acts by inducing intestinal cell metallothionein, which blocks absorption of food copper and endogenously secreted copper (17). The adult dose is 50 mg three times daily, each dose separated from food and beverages other than water by at least one hour. It is also generally effective in producing a negative copper balance.
Copyright 2006 by Taylor & Francis Group, LLC
394
Brewer
The only toxicity of zinc is gastric discomfort or burning in about 10% of patients, particularly with the first morning dose (16). Such patients are advised to take their first dose mid-morning rather than upon arising. They also may use a small amount of protein food (lunchmeat, cheese, jello) to mitigate the discomfort. Tetrathiomolybdate Tetrathiomolybdate (TM) is being developed as a fast acting anticopper drug for initial treatment of acutely ill Wilson’s disease patients (72–75). TM is not yet commercially available. It acts by forming a tripartite complex with protein and copper. Given with food, it complexes food copper and food protein and prevents the absorption of this bound copper. Given between meals, it is well absorbed and in the blood complexes available copper with albumin. The copper in this complex is unavailable for cellular uptake. The complex is metabolized in the liver and the components excreted in the bile. TM is rapidly effective in producing a negative copper balance and in mitigating further copper toxicity. The side effects of TM in Wilson’s disease are, first, bone marrow suppression due to overtreatment, leading to anemia and/or leukopenia. This is quickly responsive to dose reduction. A second side effect is further elevation of transaminase enzymes, probably due to shifting copper pools from metallothionein in the liver. This, too, is responsive to dose reduction. Recommended Therapy My recommendations for therapy for different stages of Wilson’s disease are given in Table 4. I would like to emphasize that the days are gone when once the diagnosis is made, the physician simply prescribes penicillamine. We now have additional anticopper drugs, and they should be used differentially according to the patient’s status. 1. Initial therapy—neurologic/psychiatric presentation. It is important that penicillamine be avoided in this situation, if at all possible, because of its 50% risk of making the patient neurologically worse (70). Trientine seems to have an intermediate risk of neurologic worsening estimated currently at about 18% (71). Zinc, in our opinion is too slow acting to be optimal. Because none of these drugs are optimal for this type of patient, we have developed TM to fill this therapeutic niche (72–75). Most of our work has been done with 20 mg three times daily with food and 20 mg three times daily between meals for eight weeks (120 mg/day). We usually start zinc concurrently at 50 mg two times daily, and increase this to three times daily as the patient goes off TM, for maintenance therapy.
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
395
Table 4 Therapy Recommendations for Wilson’s Disease First choice Maintenance therapy (adult and pediatric) Treatment of presymptomatic patients (adult and pediatric) Treatment of pregnant patients Initial treatment neurologic/psychiatric Hepatic
Second choice
Third choice
Zinc
Trientine
Penicillamine
Zinc
Trientine
Penicillamine
Zinc
Trientine
Tetrathiomolyb- Trientine plus date plus zinc zinc Trientine plus Penicillamine zinc plus zinc
Zinc alone
This therapy has been very effective in preserving neurologic function. Only 2 of 55 patients (3.6%) have had neurologic worsening by our criteria (75), compared to the 50% estimate for penicillamine (70). Occasional patients may worsen irrespective of the drug used, probably due to the natural history of the disease. The 120 mg/day TM regimen causes anemia/leukopenia about 10–15% of the time, probably due to overtreatment and bone marrow depletion of copper. The anemia/leukopenia tends to come on after 4–5 weeks of treatment and resolves with halving the TM dose. This TM regimen also causes an elevation of serum transaminase enzymes in 10–15% of the patients. Again this side effect comes on after 4–5 weeks and is responsive to halving the dose. Because of the timing of these side effects, and their favorable response to halving the dose, we are now evaluating a TM regimen which gives a full dose (120 mg/day) for two weeks then a half dose (60 mg/day) for 14 weeks. TM is not yet commercially available and as of this writing the only practical way a patient can receive this therapy is to join a clinical trial protocol at the University of Michigan. Until TM is available commercially, other options for initial therapy of neurologic patients include trientine and accepting some risk of worsening, or zinc and accepting some risk of progression (Table 4). 2. Initial therapy—hepatic presentation. Here we are dealing with medical therapy. Some patients present with hepatic failure so severe that only hepatic transplantation will save their lives. The prognostic index of Nazer et al. (76) as well as other recent publications (32,77), provides guidance as to how to triage patients for transplantation versus medical therapy.
Copyright 2006 by Taylor & Francis Group, LLC
396
Brewer
The medical therapy of choice at this time, in our opinion, is a combination of trientine and zinc (Table 4) (77). Zinc is added because it induces hepatic metallothionein, which will bind up some of the excessive hepatic copper. Trientine is used because an additional faster acting agent is required, and we choose it over penicillamine because of a better safety profile. We give the combination for 4–6 months, than continue with zinc alone. 3. Maintenance and presymptomatic therapy. Our first choice is zinc, because of its superior safety, followed by trientine (Table 4). 4. Therapy in children. Initial therapy in children would be the same as discussed earlier under initial therapy, with dose reductions in younger children. For maintenance therapy we recommend zinc with dose reductions as previously published (78), with trientine as second choice. 5. Therapy during pregnancy. Pregnant women should be on anticopper therapy during pregnancy to protect their own health. Zinc is our first choice, with trientine as second (Table 4). Penicillamine has some known teratogenic effects. We recommend not controlling copper levels too tightly during pregnancy, since copper deficiency is known to be teratogenic.
PROGNOSIS Patients who are neurologically and/or behaviorally symptomatic improve considerably during anticopper therapy. Usually real improvement does not begin until 5–6 months after therapy is started, and then continues for about 18 months (74,75). Most of the improvement occurs by 24 months after the initiation of therapy, assuming good compliance with therapy. Occasionally, patients will report some improvement in one or more symptom occurring after the two-year period. The degree of remaining disability depends usually upon the severity to begin with. Patients with mild disease often make a complete recovery, those with moderate disease usually have a little residual, and those with severe disease often end up with significant disabilities. Throughout the 2-year primary recovery period, it is important that a hopeful prognosis be kept in front of the patient, and the prolonged period of recovery continually emphasized. In addition, the patient should maintain as much function as possible through exercise, physical therapy, speech therapy, and occupational therapy as appropriate and as available. Beginning during the second year, the patient and family should begin thinking about the future, and what type of school, occupation, etc., the patient might undertake.
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
397
Improvement in behavioral problems generally follows the improvement in neurologic symptoms. While there is evidence that long treated patients test at least mildly abnormal in a number of psychosocial tests (79–83), they generally recover their functional skills and most are capable of living a productive life. Recovery of hepatic function in terms of normalizing liver function and liver status tests generally occurs during the first year (16). Most patients have some degree of liver disease that remains, but in most cases, barring other insults to the liver, it will last patients the rest of their lives. The main risk factor over time in neurologic patients with residual damage, if they have some degree of dysphagia, is aspiration, producing aspiration pneumonia or chronic lung disease. If patients have some degree of incoordination, they are at some risk for falls and accidents of other types. Patients who have enough residual cirrhosis to produce portal hypertension are at some risk from variceal bleeding. REFERENCES 1. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain 1912; 34:295–509. 2. Kayser B. Ueber einen Fall von angeborener gru¨nlicher Verfa¨rbung der kornea. Klin Mbl Augenheilk 1902; 40:22–25. 3. Fleischer B. Zwei weitere Fa¨lle von gru¨nliche Verfa¨rbung der Kornea. Klin Mbl Augenheilk 1903; 41:489–491. 4. Glazebrook AJ. Wilson’s disease. Edinburgh Med J 1945; 52:83–87. 5. Cumings JN. The copper and iron content of brain and liver in the normal and in hepato-lenticular degeneration. Brain 1948; 71:410–415. 6. Ravestyn AH. Metabolism of copper in man. Acta Med Scand 1944; 118: 163–196. 7. Frommer DJ. Defective biliary excretion of copper in Wilson’s disease. Gut 1974; 15:125–129. 8. Scheinberg IH, Gitlin D. Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson’s disease). Science 1952; 116:484–485. 9. Bearn AG, Kunkel HG. Biochemical abnormalities in Wilson’s disease. J Clin Invest 1952; 31:616. 10. Bearn AG. A genetical analysis of thirty families with Wilson’s disease (hepatolenticular degeneration). Ann Hum Genet 1960; 24:33–43. 11. Walshe JM. Penicillamine. A new oral therapy for Wilson’s disease. Am J Med 1956; 21:487–495. 12. Walshe JM. Treatment of Wilson’s disease with trientine (triethylene tetramine) dihydrochloride. Lancet 1982; 1:643–647. 13. Schouwink G. De hepatocerebrale degeneratie, me een onderzoek naar de zinktofwisseling. MD Thesis, University of Amsterdam 1961. 14. Hoogenraad TU, van Hattum J, van den Hamer CJA. Management of Wilson’s disease with zinc sulphate. Experience in a series of 27 patients. J Neurol Sci 1987; 77:137–146.
Copyright 2006 by Taylor & Francis Group, LLC
398
Brewer
15. Brewer GJ, Hill GM, Prasad AS, Cossack ZT, Rabbani P. Oral zinc therapy for Wilson’s disease. Ann Intern Med 1983; 99:314–320. 16. Brewer GJ, Dick RD, Johnson VD, Brunberg JA, Kluin KL, Fink JK. Treatment of Wilson’s disease with zinc: XV Long-term follow-up studies. J Lab Clin Med 1998; 132:264–278. 17. Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. The treatment of Wilson’s disease with zinc: X. Intestinal metallothionein induction. J Lab Clin Med 1992; 120:380–386. 18. Bull PC, Thomas GR, Rommens JM, Forbes JR, Cox DW. The Wilson’s disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5(4):327–337. 19. Tanzi RE, Petrukhin K, et al. The Wilson’s disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5(4): 44–50. 20. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson’s disease. Biochem Biophys Res Commun 1993; 197:271–277. 21. Cox DW, Roberts EA. Wilson’s disease. GeneClinics, University of Washington, Seattle. Online. Available: http://www.geneclinics.org/profiles/wilson/details. html. 22. Brewer GJ, Yuzbasiyan-Gurkan V. Wilson’s disease. Medicine 1992; 71:139–164. 23. Scheinberg IH, Sternlieb I. Wilson’s disease. In: Smith LH Jr, ed. Major Problems in Internal Medicine. Philadelphia: W.B. Saunders, 1984:23. 24. Hoogenraad TU. Wilson’s disease. In: Warlow CP, Van Gijn J, eds. Major Problems in Neurology. London: W.B. Saunders, 1996:30. 25. Schilsky ML. Wilson’s disease: Genetic basis of copper toxicity and natural history. Semin Liver Dis 1996; 16:83–95. 26. Brewer GJ. Wilson’s disease. Curr Treat Options Neurol 2000; 2(3):193–203. 27. Brewer GJ, Fink JK, Hedera P. Diagnosis and treatment of Wilson’s disease. Semin Neurol 1999; 19(3):261–270. 28. Brewer GJ. Recognition, diagnosis and management of Wilson’s disease. Exp Biol Med 2000; 223(1):39–49. 29. Brewer GJ. Raulin Award Lecture: Wilson’s disease therapy with zinc and tetrathiomolybdate. J Trace Elem Exp Med 2000; 3:51–61. 30. Fink JK, Hedera P, Brewer GJ. Hepatolenticular degeneration (Wilson’s disease). Neurologist 1999; 5:171–185. 31. Steindl P, Ferenci P, Dienes HP, Grimm G, Pabinger I, Madl C, MaierDobersberger T, Herneth A, Dragosics B, Meryn S, Knoflach P, Granditsch G, Gangl A. Wilson’s disease in patients presenting with liver disease: A diagnostic challenge. Gastroenterology 1997; 113:212–218. 32. Brewer GJ. Wilson’s Disease: A Clinician’s Guide to Recognition, Diagnosis, and Management. Boston: Kluwer, 2001. 33. Brewer GJ. Wilson’s Disease for the Patient and Family: A Patient’s Guide to Wilson’s Disease and Frequently Asked Questions about Copper. Philadelphia: Xlibris, 2001. 34. Deiss A, Lee GR, Cartwright GE. Hemolytic anemia in Wilson’s disease. Ann Intern Med 1970; 73:413–418.
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
399
35. Ishmael J, Gopinath C, Howell JMC. Experimental chronic copper toxicity in sheep. Biochemical and haematological studies during the development of lesions in the liver. Res Vet Sci 1972; 13:22–29. 36. Metz EN. Mechanism of hemolysis by excess copper (abstract). Clin Res 1969; 7:32. 37. Hill GM, Brewer GJ, Prasad AS, Hydrick CR, Hartmann DE. Treatment of Wilson’s disease with zinc: I. Oral zinc therapy regimens. Hepatology 1987; 7:522–528. 38. Holden JM, Wolf WR, Mertz W. Zinc and copper in self selected diets. J Am Diet Assoc 1979; 75:23–28. 39. Klevay LM, Reck SJ, Barcome DP. Evidence of dietary copper and zinc deficiencies. JAMA 1979; 241:1916–1918. 40. Reiser S, Smith JC Jr, Mertz W, Holbrook JT, Scholfield DJ, Powell AS, Canfield WK, Canary JJ. Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am J Clin Nutr 1985; 42:242–251. 41. Thomas GR, Forbes JR, Roberts EA, Walshe JM, Cox DW. The Wilson’s disease gene: spectrum of mutations and their consequences. Nat Genet 1999; 9:210–217. 42. Okada T, Shiono Y, Hayashi H, Satoh H, Sawada T, Suzuki A, Takeda Y, Yano M, Michitaka K, Onji M, Mauchi H. Mutational analysis of ATP7B and genotype–phenotype correlation in Japanese with Wilson’s disease. Hum Mutat 2000; 15:454–462. 43. Srikumar TS, Johansson GK, Ockerman P-A, Gustafsson J-A, Akesson B. Trace element status in healthy subjects switching from a mixed to a lactovegetarian diet for 12 mo. Am J Clin Nutr 1992; 55:1–6. 44. Brewer GJ, Yuzbasiyan-Gurkan V, Dick R, Wang Y, Johnson V. Does a vegetarian diet control Wilson’s disease? JACN 1993; 2:527–530. 45. Olivarez L, Caggana M, Pass KA, Ferguson P, Brewer GJ. Estimate of the frequency of Wilson’s disease in the U.S. Caucasian population: A mutation analysis approach. Ann Hum Genet 2001; 64:459–463. 46. Dastur DK, Manghani DK, Wadia NH. Wilson’s disease in India I. Geographic, genetic, and clinical aspects in 16 families. Neurology 1968; 18: 21–31. 47. Bhave S, Bavdekar A, Pandit A. Changing pattern of chronic liver disease (CLD) in India. Indian J Pediatr 1994; 61:675–682. 48. Bhave SA, Purohit GM, Pradhan AV, Pandit AN. Hepatic presentation of Wilson’s disease. Indian Pediatr 1987; 24:385–393. 49. Brewer GJ. Behavioral abnormalities in Wilson’s disease. In: Weiner WJ, Lang AE, Anderson KE, eds. Behavioral Neurology of Movement Disorders, 2nd ed. Philadelphia: Lippincott Williams & Wilkins 2005; 262–274. 50. Akil M, Brewer GJ. Psychiatric and behavioral abnormalities in Wilson’s disease. In: Weiner WJ, Lang AE, eds. Advances in Neurology. Vol. 65. Behavioral Neurology of Movement Disorders. New York: Raven Press, 1995:171–178. 51. Dening TR, Berrios GE. Wilson’s disease: Psychiatric symptoms in 195 cases. Arch Gen Psychiatry 1989; 46:1126–1134.
Copyright 2006 by Taylor & Francis Group, LLC
400
Brewer
52. Rathbun JK. Neuropsychological aspects of Wilson’s disease. Int J Neurosci 1996; 85:221–229. 53. Jackson GH, Meyer A, Lippmann S. Wilson’s disease: Psychiatric manifestations may be the clinical presentation. Postgrad Med 1994; 95:135–138. 54. Scheinberg IH, Sternlieb I, Richman J. Psychiatric manifestations in patients with Wilson’s disease. Birth Defects 1968; 4:85–99. 55. Knehr CA, Bearn AG. Psychological impairment in Wilson’s disease. J Nerv Ment Dis 1956; 124:251–255. 56. Dening TR. The neuropsychiatry of Wilson’s disease: A review. Int J Psychiatry Med 1991; 21:135–148. 57. McDonald LV, Lake CR. Psychosis in an adolescent patient with Wilson’s disease: Effects of chelation therapy. Psychosom Med 1995; 57:202–204. 58. Oder W, Grimm G, et al. Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol 1991; 238:281–287. 59. Goldstein NP, Ewert JC, et al. Psychiatric aspects of Wilson’s disease (hepatolenticular degeneration): results of psychometric tests during long-term therapy. Am J Psychiatry 1968; 124:11. 60. Lauterbach EC, Cummings JL, et al. Neuropsychiatric correlates and treatment of lenticulostriatal diseases: A review of the literature and overview of research opportunities in Huntington’s, Wilson’s, and Fahr’s diseases. A report of the ANPA Committee on Research. J Neuropsychiatry 1998; 10:249–266. 61. Starosta-Rubinstein S, Young AB, Kluin K, Hill GM, Aisen AM, Gabrielsen T, Brewer GJ. Clinical assessment of 31 patients with Wilson’s disease. Correlations with structural changes on MRI. Arch Neurol 1987; 44:365–370. 62. Bhattacharya K, Velickovic M, Schilsky M, Kaufmann H. Autonomic cardiovascular reflexes in Wilson’s disease. Clin Auton Res 2002; 12(3):190–192. 63. Meenakshi-Sundaram S, Taly AB, Kamath V, Arunodaya GR, Rao S, Swamy HS. Autonomic dysfunction in Wilson’s disease—a clinical and electrophysiological study. Clin Auton Res 2002; 12(3):185–189. 64. Brewer GJ. Editorial: Autonomic dysfunction in Wilson’s disease. Clin Auton Res 2002; 12(3):139–140. 65. Azevedo EM, Scaff M, Barbosa ER, Gouveia-Neto AE, Canelas HM. Heart involvement in hepatolenticular degeneration. Acta Neurol Scand 1978; 58: 296–303. 66. Kuan P. Fatal cardiac complications of Wilson’s disease. Am Heart J 1982; 104:314–316. 67. Factor SM, Cho S, Sternlieb I, Scheinberg IH, Goldfischer S. The cardiomyopathy of Wilson’s disease: Myocardial alterations in nine cases. Virch Arch A Pathol Anat 1982; 397:301–311. 68. Sternlieb I, Scheinberg IH. Prevention of Wilson’s disease in asymptomatic patients. N Engl J Med 1968; 278:352–359. 69. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Johnson V, Wang Y. Treatment of Wilson’s disease with zinc: XIII. Therapy with zinc in presymptomatic patients from the time of diagnosis. J Lab Clin Med 1994; 123:849–858. 70. Brewer GJ, Terry CA, Aisen AM, Hill GM. Worsening of neurologic syndrome in patients with Wilson’s disease with initial penicillamine therapy. Arch Neurol 1987; 44:490–493.
Copyright 2006 by Taylor & Francis Group, LLC
Wilson’s Disease
401
71. Brewer GJ, Schilsky M, Hedera P, Carlson MD, Fink JK, Askari FK, Kluin K, Lorincz M, Shneider B, Velickovic M, Blitman S, Mojica J, Vila N. Double blind study of initial therapy of neurological Wilson’s disease. J Invest Med 2003; 51(suppl 2), S369. 72. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tanakow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson’s disease with tetrathiomolybdate. Arch Neurol 1991; 48:42–47. 73. Brewer GJ, Dick RD, Johnson V, Wang Y, Yuzbasiyan-Gurkan V, Kluin KJ, Fink JK, Aisen A. Treatment of Wilson’s disease with ammonium tetrathio"molybdate: I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994; 51:545–554. 74. Brewer GJ, Johnson V, Dick RD, Wang Y, Kluin KJ, Fink JK, Brunberg JA. Treatment of Wilson’s disease with ammonium tetrathiomolybdate: II. Initial therapy in 33 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 1996; 53:1017–1025. 75. Brewer GJ, Hedera P, Kluin KJ, Carlson MD, Askari F, Dick RB, Sitterly JA, Fink JK. Treatment of Wilson’s Disease with tetrathiomolybdate III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy. Arch Neurol 2003; 60:378–385. 76. Nazer H, Ede RJ, Mowat AP, Williams R. Wilson’s disease: clinical presentation and use of prognostic index. Gut 1986; 27:1377–1381. 77. Askari FK, Greenson J, Dick RD, Johnson VD, Brewer GJ. Treatment of Wilson’s disease with Zinc XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc. J Lab Clin Med 2003; 142(6):385–390. 78. Brewer GJ, Dick RD, Johnson VD, Fink JK, Kluin KJ, Daniels S. Treatment of Wilson’s disease with zinc: XVI. Treatment during the pediatric years. J Lab Clin Med 2001; 137(3):191–198. 79. Portala K, Westermark K, et al. Psychopathology in treated Wilson’s disease determined by means of CPRS expert and self-ratings. Acta Psychiat Scand 2000; 101:104–109. 80. Portala K, Westermark K, et al. Personality traits in treated Wilson’s disease determined by means of the Karolinska Scales of Personality (KSP). Eur Psychiatry 2001; 16:362–371. 81. Portala K, Westermark K, et al. Sleep in patients with treated Wilson’s disease. A questionnaire study. Nord J Psychiatry 2002; 56(4):291–297. 82. Portala K, Levander S, et al. Pattern of neuropsychological deficits in patients with treated Wilson’s disease. Eur Arch Psychiatry Clin Neurol 2001; 252(6): 262–268. 83. Portala K. Psychopathology in Wilson’s Disease Thesis. Acta Universitatis Upsaliensis, Uppsala, 2001.
Copyright 2006 by Taylor & Francis Group, LLC
18 Neurogenetics of Dystonia and Paroxysmal Dyskinesias Jennifer Friedman Department of Neurology, Children’s Hospital and Health Center, San Diego, California, U.S.A.
David G. Standaert MassGeneral Institute for Neurodegenerative Disorders, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, U.S.A.
DYSTONIA Dystonia is a class of disorders in which the role of genetics has become increasingly apparent. Dystonia is not a diagnosis, rather it is a descriptive term which identifies a class of symptoms. Dystonia is characterized by sustained muscle contractions, frequently causing twisting and repetitive movements, or abnormal postures (1). Dystonia may be seen in isolation or as the predominant symptom of disease. Isolated dystonias may be constant or task-specific, e.g., occurring only when writing or even exclusively when playing a particular musical instrument. Dystonia may also occur in association with a variety of other abnormalities of the nervous system, including neurodegenerative disorders, structural lesions of the basal ganglia, and after pharmacological blockade of dopaminergic receptors. Several specific genetic etiologies for dystonia have been identified, including disorders with autosomal dominant (AD) and recessive, and X-linked phenotypes. In addition, mitochondrial mutations producing predominantly dystonic symptoms have been described. Interestingly, most of
Copyright 2006 by Taylor & Francis Group, LLC
404
Friedman and Standaert
the genetically determined dystonias have highly variable penetrance and considerable phenotypic variation even within single families. Moreover, there is also evidence for susceptibility genes for dystonia, which may interact with environmental triggers such as repetitive use in determining the development of dystonic disorders. Clinical Classifications of Dystonia Dystonias are classified in several different ways (Table 1). From a clinical perspective, the most useful classifications are by the age of onset and distribution of symptoms (2–5). These features have both diagnostic and prognostic significance. Marsden et al. (6,7), first pointed out that the age of onset of most dystonias is a predictor of the subsequent course: Early age at onset predicts a more severe course and higher likelihood of spread to multiple body parts (8). A subsequent study in the Ashkenazi Jewish population (which has a high prevalence of a genetically determined generalized dystonia, DYT1) demonstrated that there was a bimodal distribution of the ages at onset, with a nadir at 27 years (8,9). This age is often used as the dividing point between ‘‘early’’ and ‘‘late’’ onset dystonia, even in individuals who are not of Ashkenazi background. The distribution of symptoms is also an important and useful clinical descriptor. Current nomenclature divides the clinical forms of dystonia into focal, segmental (involving two or more contiguous body regions), multifocal (involving two or more non-contiguous body regions), and generalized (involving the legs and at least one other body part) (3,5). Hemidystonia, which might be considered segmental or multifocal, is classified separately from the other groups to reflect the fact that unlike the other forms it is often related to a demonstrable structural abnormality of the brain (5).
Table 1 Approaches to the Classification of Dystonias By Age at Onset Early onset (<27 yr) Late onset (>27 yr) By Distribution Focal Segmental Multifocal Generalized Hemidystonia By Etiology Primary Primary-plus Secondary Heredodegenerative Psychogenic
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
405
Classification of Dystonia by Etiology Recent efforts at classifying dystonias have attempted to move past clinical observation, and to classify dystonias by etiological mechanisms. This effort has not been simple or straightforward, largely because the understanding of the basic mechanisms underlying dystonia is incomplete. In addition, in many of these disorders no clear neuropathological abnormality has been identified. At present, the most widely accepted and useful approach divides dystonias into five categories by Etiology (Table 1) (3). In primary dystonia, dystonia is the only symptom and no underlying injury or disease can be identified. Primary dystonias include both apparent sporadic cases as well as defined genetic disorders. Dystonia plus is the term applied to patients with dystonia and additional features, such as myoclonus, parkinsonism, or a paroxysmal course. This group includes patients with genetic biochemical defects, such as abnormalities of dopamine synthesis, but excludes those with neurodegenerative diseases. Secondary dystonia is used to describe dystonias arising after a wide variety of insults to the nervous system, including stroke, traumatic brain injury, or injury to the limbs. Heredodegenerative dystonia is used to describe the dystonia found in association with progressive degenerative neurological disorders, including Parkinson’s disease, Multiple Systems Atrophy, Wilson’s disease, and mitochondrial disorders (3). The fifth group is apparent dystonias of psychogenic origin. The inclusion of this group reflects the fact that diagnosis of dystonia depends on the skills of the clinician, and in some cases the diagnosis may be in doubt. Further discussion in this chapter will focus on the genetics of the first two categories of dystonia: the primary dystonias and dystonia-plus syndromes. These are the categories where the most progress has been made in defining the underlying mechanism of the disease. It is important to acknowledge, however, that the forms of dystonia currently recognized as genetic in origin account for only a small fraction of the total number of cases of dystonia. In a clinical population, most cases are currently classified as idiopathic or sporadic primary dystonia (10). As the understanding of the underlying mechanisms continues to improve, this group should shrink in size with corresponding growth in the numbers of dystonia with an identifiable etiology. Genetic Classifications of Dystonia In addition to the clinically based classifications of dystonia, a genetically based nomenclature has arisen. Loci are assigned consecutive symbols preceded by ‘‘DYT.’’ Currently DYT1 to DYT15 are assigned. Some, but not all, of the gene symbols currently in use have been approved by the Nomenclature Committee of the Human Genome Organization (8,11,12). A confusing feature of this system is that when specific genes have been identified as the underlying etiology, some of the symbols have been reassigned. For example, the locus previously described as DYT5 is currently
Copyright 2006 by Taylor & Francis Group, LLC
406
Friedman and Standaert
designated GCH1, reflecting the identification of mutations in the gene for GTP cyclohydrolase I as the underlying defect in most cases. It should also be kept in mind that for most of the DYT subcategories, individuals or families with similar phenotypes but without linkage to described loci or mutations in known genes have been identified, suggesting locus heterogeneity. The Neural Mechanisms of Dystonia A mechanistic approach is an important framework for understanding the genetic origins of disease. Despite the recent progress in understanding how movements are controlled, the neural mechanism of dystonia remains largely a mystery, and an adequate model is lacking. It is important to recognize that dystonia is a disorder of the central nervous system, and not of the musculoskeletal system. This is illustrated dramatically in patients where dystonia has been treated by physical or chemical denervation of the overactive muscles (e.g., with botulinum toxin). Even if the involved muscles are treated successfully, the abnormal posture often reappears as additional muscle groups are recruited to the task. Thus, the problem is not in the muscles, but rather in the central representation of normal posture. This is not to say that the peripheral nervous system is unimportant. Indeed, the occurrence of dystonia after injury to peripheral nerves is a well-established phenomenon. Sensory input can also make an important contribution to the maintenance of dystonic postures, exemplified by the ‘‘geste antagoniste,’’ a maneuver or position that through cutaneous stimulation at particular sites can greatly diminish the severity of dystonia in some patients. The search for the mechanism of dystonia has been difficult because of the lack of clear structural abnormalities in the brain. Both in primary dystonias and in dystonia plus, routine neuropathological examination is normal. Two principal mechanisms have been implicated in the disease, which may be inter-related: abnormalities of dopaminergic neurotransmission in the basal ganglia and abnormalities of synaptic plasticity in the cerebral cortex. There is considerable evidence that dystonia can arise as a consequence of abnormal dopaminergic transmission in the basal ganglia. Acute dystonic reactions are often observed after treatment with potent dopamine D2-receptor antagonists such as prochlorperazine or haloperidol (13). In patients with secondary dystonia as a result of stroke, the lesions are often located in the putamen or pallidum, targets of dopaminergic inputs (14). A number of the dystonia-plus syndromes have been shown to result from biochemical abnormalities of dopamine synthesis and release (described further), and the gene responsible for DYT1 primary dystonia is strongly expressed by dopaminergic neurons (15). Although the connection to the dopaminergic system supports the view that dystonia is a basal ganglia disease, the current models of basal
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
407
ganglia circuitry do not clearly account for the motor abnormalities seen in dystonia. The circuit diagrams were developed largely from observations in animals models of Parkinson’s and Huntington’s disease, and are built around ideas about the role of dopamine in regulating the activity of neurons in the striatum (caudate and putamen), the principal input structure of the basal ganglia (16). In recent years, it has become increasingly clear that a ‘‘wiring diagram’’ approach is overly simplistic, and it is important to consider not only the connections of the basal ganglia, but also the nature of the information flowing through these pathways (17,18). Only relatively limited direct studies of the electrical activity of brain neurons in dystonia have been conducted, but these have revealed in many cases abnormal activity of output neurons in the basal ganglia (19,20). Studies in humans with dystonia by using neuroimaging and electrophysiological approaches have pointed to abnormalities in synaptic connectivity and plasticity outside the basal ganglia. Positron emission tomography (PET) and functional magnetic resonance imaging studies (fMRI) have revealed that dystonia is associated with abnormal activity in multiple regions of the brain, including motor cortex, supplementary motor areas, and cerebellum as well as structures of the basal ganglia (21–26), but in most cases it is not clear which of these is the primary defect and which are downstream modifications of activity. Using transcranial magnetic stimulation, it has been demonstrated that one feature of many focal task-specific dystonias is a ‘‘remapping’’ of the motor cortex, so that the area of cortex with direct influence over movements of the affected body part is greatly enlarged (27–29). There is also a prominent abnormality of cortical inhibition (30). Both of these observations suggest an underlying abnormality of synaptic plasticity, but the specific etiology of these functional abnormalities remains unclear. Recent morphometric studies have demonstrated abnormalities in the thickness of the cortical mantle in focal dystonia. Interestingly, these are present bilaterally, suggesting that in these individuals there is abnormal cortical structure even when no dystonia is detected clinically (31). An important focus of current research is ‘‘bridging the gap’’ between these mechanistic approaches to dystonia and the genetic etiologies as they are uncovered. In some cases, particularly the disorders of dopamine biosynthesis, considerable progress has been made. In other cases, the connection is much less apparent at present, and will require further understanding of the mechanisms of dystonia on a systems as well as cell biological level.
GENETICS OF PRIMARY DYSTONIAS DYT1: Early Onset Generalized Dystonia; Oppenheim’s Dystonia The most common cause of early onset generalized dystonia is DYT1 dystonia (or ‘‘Oppenheim’s Dystonia’’) caused by three base pair deletion
Copyright 2006 by Taylor & Francis Group, LLC
408
Friedman and Standaert
(GAG deletion) in the DYT1 gene (4,32–36). This mutation accounts for approximately 74% of early onset limb dystonia in the general population and for roughly 90% of early onset limb dystonia in those of Ashkenazi Jewish descent (35). The increased incidence in the Ashkenazi Jewish population is due to the occurrence of a founder mutation in this population (32). DYT1 dystonia is inherited in an AD fashion, although the penetrance is only about 30% (9,37). The average age of onset is about 12 years, and onset after age 30 is very uncommon, although in rare cases symptoms have developed as late as 65 years (12,32). In those manifesting DYT1 dystonia, the severity can vary considerably, even within the same family (38–41). The dystonia typically begins in a limb (50% leg and 50% arm) and subsequently generalizes. Those with onset in the arm tend to begin later and are somewhat less likely to generalize than those with onset in the lower limb. Craniocervical or axial onset does occur but is less common (12,32,39). Rare cases with atypical features have been described (42). The dystonia can be quite severe and disabling, and the response to treatment is not completely satisfactory. Anticholinergic therapy, baclofen, and surgical approaches are often useful. The lack of phenotypic expression in 60–70% of individuals who carry the DYT1 mutation suggests the existence of modifying factors, either genetic or environmental, although the nature of these are unknown at present. Recently, a second mutation in the DYT1 gene, an 18 bp deletion of the carboxy terminus, has been identified in a pedigree with familial dystonia and myoclonus (43). The DYT1 gene encodes the protein torsinA (44,45). The encoded protein is 332 amino acids in length, corresponding to a predicted mass of 37,800 Da. There is a predicted amino terminal hydrophobic leader sequence, as well as potential sites for both glycosylation and phosphorylation. TorsinA is a member of the class of ‘‘ATPases associated with a variety of cellular activities’’ (AAAþ proteins, also see Chapter on hereditary spastic paraparesis) (45,46). Many of these proteins are chaperones that mediate protein folding or conformational change. All share a Mgþþ/ATP binding domain, an AAA-specific region, and form six-membered oligomeric rings. Other members of this class are N-ethylmalimide-sensitive factor (NSF) that is involved in vesicle fusion and release, dynein, and the Clp ATPase/HSP 100 proteins, which are stress-induced molecular chaperones and proteases. The mRNA for torsinA is expressed by dopamine neurons in the substantia nigra, as well as by neurons in other regions including the hippocampus and cerebellum (15). The functions of torsinA are largely unknown. The hydrophobic leader sequence suggests it is likely to be membrane-associated. In cellular models, over-expressed wild-type and mutant torsinA are found in the endoplasmic reticulum (47,48). A binding partner of torsinA is the molecular motor protein, kinesin, suggesting it has a role in vesicular transport (49). Over-expression of mutant torsinA results in multiple abnormal ER-derived
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
409
cytoplasmic membrane inclusions. TorsinA is also found in association with the nuclear envelope, which is contiguous with the cytoplasmic ER (50–52). In cellular models as well as transgenic animals, the presence of the mutation that caused dystonia is reported to enhance the localization of the protein to the nuclear envelope (53). All of these mechanisms, of course, represent the effects of expressing torsinA at very high levels. Whether such abnormalities may occur at more physiologic levels of expression is unknown. Pathological studies of human brain from DYT1 dystonia are few. No definite evidence for neurodegeneration has been described thus far. There is no obvious alteration in the structure or density of dopaminergic neurons in the substantia nigra (54), but careful quantitative studies have not been performed yet. Studies of dopamine and its metabolites suggested an alteration of dopamine turnover, but the small number of cases available for these measurements limits the strength of this conclusion (55). Most studies have not observed any evidence for abnormal aggregation of torsinA in DYT1 cases, although a recent report has described ubiquitinated intraneuronal inclusions in three cases (56). Although the clinically apparent prevalence of the GAG deletion mutation in DYT1 is only about 30%, recent evidence from functional imaging studies suggests that patterns of neural activity may be abnormal even in apparent asymptomatic carriers (57). In two cohorts of clinically nonmanifesting carriers, Eidelberg et al. (58) have identified an abnormal pattern of regional cerebral metabolism, with increases in the posterior putamen and globus pallidus, cerebellum, and supplementary motor area. Clinically unaffected carriers also demonstrate abnormalities on motor sequence learning tasks, along with patterns of activation during the tasks that differ from normal subjects, most notable for enhanced activity of cerebellar structures (57). These data suggest that the DYT1 carrier state is associated with abnormal functional organization of motor learning and control, even when dystonia is not apparent. DYT6: Mixed Focal and Generalized Dystonia DYT6 is a form of mixed focal and generalized primary dystonia. The locus was identified in two Mennonite families comprising 220 individuals by Almasy et al. (59). The features were similar to DYT1 dystonia, except that the age of onset was later (18.9 years) and there was more prominent cranial, rather than limb, involvement. The locus has been linked to 8p21-q22, and subsequent investigation has traced the disorder in the two families to a common ancestor. The obligate linkage region has been narrowed to 23 cM, but the gene responsible remains unknown (60). Interestingly, both manifesting and nonmanifesting carriers from these families demonstrate abnormal patterns of cerebral metabolism very similar to those seen in DYT1 dystonia (57).
Copyright 2006 by Taylor & Francis Group, LLC
410
Friedman and Standaert
DYT7: Adult-Onset Focal Dystonia The majority of cases of focal dystonia are classified as sporadic, but 25% of patients with focal dystonia have similarly affected relatives (61). This suggests that the underlying genetic contributions may be more significant than is currently appreciated. In a single family from Northern Germany, a gene responsible for AD focal dystonia with reduced penetrance has been localized to chromosome 18p (62). In this family, average age of onset is 43 years (range 28–70). Family members present with a variety of forms of dystonia including; spasmodic dysphonia, craniocervical dystonia, writer’s cramp, and/or torticollis. Symptoms remain focal or multifocal in all cases. Several studies described linkage disequilibrium for several chromosome 18p markers in additional sporadic cases of focal dystonia in patients from Northwest Germany (63) and in members of affected families of Central European origin (64). Subsequent investigations have failed to replicate this observation (60,65,66). In other families with similar phenotype, linkage to 18p has been excluded, (67) suggesting that most cases of focal dystonia are not due to mutations on chromosome 18.
DYT13: Early Onset Focal and Generalized Dystonia The locus for DYT13 was identified in a large Italian kindred with 11 definitely affected family members (68). The phenotype in this family is similar to that of DYT6, with cranial, cervical and upper limb dystonia, with early onset (mean age 15.6 years). The locus has been linked to a region on the short arm of chromosome 1 (60,69).
GENETICS OF DYSTONIA PLUS SYNDROMES The dystonia plus disorders are characterized by the presence of dystonia together with additional symptoms, and the absence of neurodegeneration or other structural abnormality of the brain. The additional symptoms may include parkinsonism, myoclonus, or a paroxysmal expression of the dystonic movements. Many of the dystonia plus disorders are genetic in origin (Table 2), and several arise from genetic mutations that alter the biochemical synthesis or release of dopamine (5,12). Dopa-Responsive Dystonia; Segawa’s Syndrome Dopa-responsive dystonia with diurnal fluctuation, or Segawa’s syndrome, is characterized clinically by childhood-onset dystonia with dramatic and sustained response to relatively low doses of levodopa (70,71). Inheritance
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
411
Table 2 Hereditary Forms of Primary and Primary Plus Dystonias Genetic designation Inheritance Primary dystonia Early onset DYT1 dystonia— generalized DYT6 Adolescent— onset dystonia— mixed DYT7 Adult—onset dystonia— focal DYT13 Early onset dystonia— mixed Primary plus dystonia GCH1 Dopa(formerly responsive DYT5) dystonia— Segawa’s TH Doparesponsive dystonia— TH deficiency DopaDYT14 responsive dystonia 6-PTPS 6-pyruvoyltetrahydropterin synthase deficiency Sepiapterin SPR reductase deficiency Dihyropteridine DHPR reductase deficiency Aromatic LAADC amino acid decarboxylase deficiency
Chromosomal location
Gene product
OMIM identifiers
AD
9q34
TorsinA
605204, 128100
AD
8p21-8p22
Unknown
602629
AD
18p
Unknown
602124
AD
1p36.32p36.13
Unknown
607671
AD
14q22.1q22.2
GTP cyclohydrolase I
600225, 128230
AR
11p15.5
Tyrosine hydroxylase
605407, 191290
AD
14ql3
Unknown
607195
AR
11q22.3q23.3
261640
AR
2p14-p12
6-pyruvoyltetrahydropterin synthase Sepiapterin reductase
AR
4p15.31
AR
7p11
182125
Dihyropteri- 261630 dine reductase Aromatic L- 107930 amino acid decarboxylase (Continued)
Copyright 2006 by Taylor & Francis Group, LLC
412
Friedman and Standaert
Table 2 Hereditary Forms of Primary and Primary Plus Dystonias (Continued ) Genetic designation Inheritance MyoclonusDYT11 AD dystonia MyoclonusDYT15 AD dystonia Rapid onset DYT12 AD dystonia parkinsonism Paroxysmal dystonias and dyskinesias DYT8 AD Paroxysmal nonkinesigenic dyskinesia (PNKD) DYT9 AD Choreoathetosis/ spasticity episodic (CSE) DYT10 AD Paroxysmal kinesigenic choreoathetosis (PKC)
Chromosomal location 7q21-31 18p11
Gene product e-Sarcoglycan Unknown
OMIM identifiers 159900 607488
19ql3
128235 Naþ/KþATPase a3 subunit
2q33-q35
Unknown
118800
1p21-p13.3 Unknown
601042
16p11.2q12.1
128200
Unknown
Listed are the name of the disorder, genetic designation (symbols approved by the Human Genome Organization are used where available), the pattern of inheritance (AD—autosomal dominant, AR—autosomal recessive), chromosomal location of the gene, the product of the gene, and the identifiers listed in Online Mendelian Inheritance in Man (OMIM; http://www.ncbi.nlm.nih. gov/Omim/).
is usually AD with variable penetrance. Patients with this disorder typically present with a dystonic gait abnormality and subsequently develop parkinsonian features (70,72) though wide phenotypic variability has been reported (73–78). The average age of onset is six years though it can range from infancy to adulthood (79). Penetrance is 2–4 times higher in females (87–100%) than in males (38–55%) (73,80). Classically, dystonic symptoms are most severe later in the day and are improved or absent in the morning (diurnal fluctuation) or after a nap (sleep benefit) (79). Sustained and complete response to levodopa without adverse effects of long-term treatment distinguishes Segawa’s syndrome clinically from other types of early onset parkinsonism with dystonia (70,81). About half of the patients with the clinical characteristics of Segawa’s syndrome have identifiable genetic defects in the gene for the enzyme GTP
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
413
cyclohydrolase I (GCH1) (75,78,82–84). GCH1 is required for the biosynthesis of tetrahydrobiopterin, an essential cofactor for phenylalanine, tyrosine and tryptophan hydroxylases. Patients with a mutation in this gene have lowered tetrahydrobiopterin levels and thus impaired production of dopamine, other catecholamines and serotonin. Administration of levodopa bypasses the defect in dopamine synthesis, and can provide a long-lasting curative treatment for affected patients (70,81). Genetic testing for mutations in GCH1 is available, and may be useful in confirming the diagnosis. However, as the currently available tests will identify only about half of the cases, all patients with a suggestive clinical phenotype should have a therapeutic trial of levodopa treatment (300–1000 mg daily). In those cases where the diagnosis remains unclear, an oral phenylalanine loading test or analysis of CSF pterins and neurotransmitter metabolites may be helpful (82,85). Measurement of neopterin and biopterin levels as well as GTPCH activity in cytokine-stimulated fibroblasts may also be useful in establishing a diagnosis (86). Other genetic mechanisms may produce a Segawa’s syndrome phenotype. Although the inheritance of disease caused by GCH1 mutations is usually AD, recessive forms with mutations in both alleles have also been described (87). In addition, another autosomal recessive form of this disorder has been described in association with mutations in the tyrosine hydroxylase (TH) gene. Typically, however, mutations in the TH gene lead to a more severe phenotype (discussed further below). Another locus for dopa responsive dystonia has been identified in a single family. This disorder has been designated DYT14 and maps to chromosome 14q13, clearly outside the GCH1 gene (88).
Other Abnormalities of Dopamine Biosynthesis Associated with Dystonia and Parkinsonism A number of other genetic abnormalities of catecholamine biosynthesis can produce dystonia. A dramatic phenotype is observed in infants with defects in tyrosine hydroxylase, which converts tyrosine to levodopa. Only a very small number of these cases have been identified (89–91). Affected infants may present with parkinsonian and dystonic features early in life. The phenotype is variable, and may also include axial hypotonia, ptosis, developmental motor delay, hypokinesia, and appendicular rigidity without clearly associated dystonia (91–93). Treatment with levodopa bypasses this defect and may produce marked improvement. A similar clinical phenotype may be observed with defects in aromatic amino acid decarboxylase, which converts levodopa to dopamine, but this defect is much more difficult to treat because there is a combined deficit in both dopamine and serotonin production and the enzyme defect renders levodopa ineffective (94–100).
Copyright 2006 by Taylor & Francis Group, LLC
414
Friedman and Standaert
Other disorders of catecholamine biosynthesis which may present with dystonia include 6-pyruvoyltetrahydropterin synthase deficiency (101); sepiapterin reductase deficiency; and dihydropteridine reductase deficiency (102). Further discussion of these rare disorders can be found in Hyland et al. (85) DYT11: Myoclonus-Dystonia Myoclonus-dystonia is a non-progressive disorder characterized by dystonic movements and postures in association with involuntary, lightning-like jerks (103). In most cases, this disorder is inherited in an AD fashion with reduced penetrance (103), although apparently sporadic cases may also be observed. Interestingly, the gene undergoes maternal imprinting such that those who inherit the mutated gene from their fathers are far more likely to display symptoms than those who inherit the gene from their mothers (104). Symptoms generally begin in childhood or adolescence and in many cases respond favorably to small amounts of alcohol (105,106). Some individuals in families with myoclonus dystonia display myoclonus without associated dystonia, suggesting that hereditary essential myoclonus is the same disorder (103,105,106). In nine families linkage to chromosome 7q21-q31 has been established (107). Using positional cloning, five different mutations in the gene for e-sarcoglycan (SGCE) have been identified in six German families (108). SGCE is a component of the dystrophin–glycoprotein complex. Four other sarcoglycan family members are known (a,b,g, and d); mutations in these other family members have been linked to limb-girdle muscular dystrophies but not to CNS disease (109). All of the mutations in SCGE appear to result in loss of function of the protein. This is unusual for an AD disorder, but this feature as well as the incomplete penetrance may be accounted for by the maternal imprinting of the SCGE gene (110). The mechanism by which defects in SCGE lead to the clinical features of myoclonus and dystonia remains unclear. There are also other genetic mechanisms that can produce a clinical phenotype similar to DYT11. A number of cases, both sporadic and familial have been described without mutation in SGCE (111,112). In addition, single variants in the dopamine D2 receptor (DRD2) and DYT1 genes were found in combination with SGCE mutations in two myoclonus dystonia families (43,113). Also, another family with myoclonus dystonia without a mutation in either SGCE or DRD2 has recently been described (114,115) and mapped to chromosome 18p11. This syndrome is designated DYT15. DYT12: Rapid Onset Dystonia-Parkinsonism Rapid onset dystonia-parkinsonism is a disease with a striking phenotype. Affected individuals develop symptoms over a period of hours to days, with
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
415
limb and cranial dystonia, bradykinesia and postural instability. Once they occur, the symptoms often persist throughout life. The disorder is inherited in an AD pattern. The onset is usually in young adults, and often is triggered by a stressful event such as fever, prolonged exercise or childbirth (116–118). The locus was linked to 19q13.2 (119). A recent analysis of candidate genes in the implicated region of chromosome 19 has revealed that the underlying mutation is a defect in the Naþ/Kþ-ATPase a3 gene (120). This is an electrogenic sodium pump responsible for the maintenance of ionic gradients. Six different mutations were identified in seven unrelated families with the DYT12 phenotype. All seem to inhibit the function of the Naþ/Kþ pump. Interestingly, mutations in another member of the Naþ/Kþ-ATPase family, a2, have been implicated in familial hemiplegic migraine (121,122). The mechanisms by which defects in an electrogenic sodium pump lead to the clinical phenotype of abrupt and persistent dystonia is unclear. One possibility is that the metabolic abnormality predisposes a critical population of neurons to injury, and in the face of a systemic stress they undergo permanent functional change or perhaps even cell death. Only a single brain from an individual with DYT12 has been examined, and no clear evidence for neurodegeneration was observed in this case (118). Clearly, further examination of this question is required.
GENETICS OF PAROXYSMAL DYSTONIAS AND DYSKINESIAS Paroxysmal dystonia is a unique clinical phenotype, where patients have discrete episodes of abnormal movements including hyperkinesias, dystonia, chorea, athetosis and ballism (123,124). Between these events, in most cases, clinical examination is normal. The abnormal movements may be triggered by activity (kinesigenic) or may occur at rest (non-kinesigenic). It is important to distinguish these disorders from other paroxysmal disease such as epilepsy or arrhythmias. Indeed, a nocturnal paroxysmal disorder originally described as hypnogenic dystonia has recently been shown to be a form of nocturnal frontal lobe epilepsy, caused by a mutation in the a4 subunit of the neuronal nicotinic acetylcholine receptor (125). Many of the paroxysmal dystonias are genetic, although both sporadic and secondary forms may occur. DYT8 and DYT9: Paroxysmal Non-kinesigenic Dyskinesias DYT8, or paroxysmal non-kinesigenic dyskinesia (PNKD), was first described in a single large family where it was inherited in an AD fashion (126). Symptoms in this and subsequently identified families typically began shortly after birth but in some cases did not manifest until later childhood or adolescence. Attacks were precipitated by emotional stress, fatigue, and intake of chocolate
Copyright 2006 by Taylor & Francis Group, LLC
416
Friedman and Standaert
or alcohol. Attacks were frequently preceded by aura and followed by uni- or bilateral dystonic or choreathetotic dyskinesias of two minutes to four hours duration. Frequency of episodes varied considerably from 20 per day to twice per year (127). The gene for this condition was mapped in four additional families to chromosome 2q33-q35 (128–131). This region of the chromosome contains a cluster of genes for sodium channels (e.g., anion exchanger SLC4A3) (128–131), but no mutation has been identified thus far (132). Phenotypically similar families not linked to chromosome 2 or 16 have also been described (67). A more complex paroxysmal phenotype is illustrated by DYT9, also known as choreoathetosis/spasticity episodic (CSE). A single family with this syndrome has been described (133). Individuals in this pedigree display episodic involuntary movements with dystonic posture of the limbs associated with dysarthria, paresthesias and double vision. Paroxysms are usually 20 minutes in duration with a frequency ranging from twice per day to twice per year. Episodes are precipitated by physical exercise, emotional stress, sleep deprivation and consumption of alcohol. In contrast to other forms of paroxysmal dystonia, five of eighteen affected members of this pedigree displayed spastic paraplegia between attacks. The gene for this disorder has been mapped to chromosome 1p (133). DYT10: Paroxysmal Kinesigenic Choreoathetosis Paroxysmal kinesigenic choreoathetosis (PKC) is the most frequent of the paroxysmal dyskinesias. Inheritance appears to be AD with reduced penetrance, although many cases appear sporadic. Symptoms begin in childhood to early adulthood. In contrast to the non-kinesigenic forms, dyskinesias are precipitated by sudden movements or startle, tend to have a later age of onset, and respond to anticonvulsant therapy (12,123,127,134). Attacks are of short duration (<5 min) and may occur frequently, often several times a day. Linkage has been established in eight Japanese families to 16p11.2-q12.1. Some families also have an increased incidence of infantile seizures. The overlap of clinical symptoms between this disorder and three other syndromes which all map to the same region on chromosome 16p— benign familial infantile convulsions, infantile convulsions and paroxysmal choreoathetosis (135), as well as rolandic epilepsy with paroxysmal exercise induced dystonia and writers cramp (136) suggests that these may be allelic disorders (137–139). Genetic Susceptibility to Dystonia Despite the substantial number of different genetic defects that are now known to cause dystonia, it is also clear that these account for only a very small fraction of the total number of cases of dystonia, and most forms are
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
417
still classified as sporadic. Therefore the diagnosis is primarily based on clinical evaluation. Genetic testing based on clinical phenotype may be informative in some individuals to confirm a diagnosis and provide genetic counseling to at-risk family members. Due to features of reduced penetrance and variable expressivity, which are common in many hereditary forms of dystonia, counseling families can be complicated. It is likely that there are genetic factors that increase or decrease the risk of dystonia, but few have been worked out in any detail. A family history of dystonia as well as a family history of tremor have been reported to increase the risk of dystonia (140,141). Co-occurrence of dystonia in a small number of twin pairs has also been reported (142,143). One gene which has been implicated in several independent case-control studies is the dopamine D5 receptor (144,145). It has also been reported that the e4 allele of apolipoprotein E, which has a strong effect on the incidence of Alzheimer’s disease, is associated with an early age of onset of dystonia (146). Clearly, more extensive study of genetic risk factors will be required to fully appreciate the contribution of genetics to the occurrence of dystonia. REFERENCES 1. Jankovic J, Fahn S. Dystonic Disorders. In: Jankovic J, Tolosa E, eds. Parkinson’s Disease and Movement Disorders. Baltimore: Williams and Wilkins, 1993: 337–374. 2. Marsden CD. Investigation of dystonia. Adv Neurol 1988; 50:35–44. 3. Fahn S, Bressman SB, Marsden CD. Classification of dystonia. Adv Neurol 1998; 78:1–10. 4. Bressman SB, De Leon D, Raymond D, Ozelius LJ, Breakefield XO, Nygaard TG, Almasy L, Risch NJ, Kramer PL. Clinical-genetic spectrum of primary dystonia. Adv Neurol 1998; 78:79–92. 5. Fahn S. Concept and classification of dystonia. Adv Neurol 1988; 50:1–8. 6. Marsden CD, Harrison MJ. Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain 1974; 97:793–810. 7. Marsden CD. Dystonia: the spectrum of the disease. Res Publ Assoc Res Nerv Ment Dis 1976; 55:351–367. 8. Bressman SB. Dystonia genotypes, phenotypes, and classification. Adv Neurol 2004; 94:101–107. 9. Bressman SB, De Leon D, Brin MF, Risch N, Burke RE, Greene PE, Shale H, Fahn S. Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol 1989; 26:612–620. 10. Nutt JG, Muenter MD, Aronson A, Kurland LT, Melton LJ. Epidemiology of focal and generalized dystonia in Rochester, Minnesota. Mov Disord 1988; 3:188–194. 11. Muller U, Steinberger D, Nemeth AH. Clinical and molecular genetics of primary dystonias. Neurogenetics 1998; 1:165–177. 12. Klein C, Breakefield XO, Ozelius LJ. Genetics of primary dystonia. Semin Neurol 1999; 19:271–280.
Copyright 2006 by Taylor & Francis Group, LLC
418
Friedman and Standaert
13. Marsden CD. Is tardive dyskinesia a unique disorder? Psychopharmacology Suppl 1985; 2:64–71. 14. Calne DB, Lang AE. Secondary dystonia. Adv Neurol 1988; 50:9–33. 15. Augood SJ, Martin DM, Ozelius LJ, Breakefield XO, Penney JB Jr, Standaert DG. Distribution of the mRNAs encoding torsinA and torsinB in the normal adult human brain. Ann Neurol 1999; 46:761–769. 16. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosciences 1989; 12:366–375. 17. Obeso JA, Rodriguez MC, DeLong MR. Basal ganglia pathophysiology. A critical review. Adv Neurol 1997; 74:3–18. 18. Parent A, Cicchetti F. The current model of basal ganglia organization under scrutiny. Mov Disord 1998; 13:199–202. 19. Vitek JL, Giroux M. Physiology of hypokinetic and hyperkinetic movement disorders: model for dyskinesia. Ann Neurol 2000; 47:S131–140. 20. Vitek JL, Chockkan V, Zhang JY, Kaneoke Y, Evatt M, DeLong MR, Triche S, Mewes K, Hashimoto T, Bakay RA. Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus. Ann Neurol 1999; 46: 22–35. 21. Chase TN, Tamminga CA, Burrows H. Positron emission tomographic studies of regional cerebral glucose metabolism in idiopathic dystonia. Adv Neurol 1988; 50:237–241. 22. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Przedborski S, Fahn S. The metabolic topography of idiopathic torsion dystonia. Brain 1995; 118:1473–1484. 23. Eidelberg D, Moeller JR, Antonini A, Kazumata K, Nakamura T, Dhawan V, Spetsieris P, de Leon D, Bressman SB, Fahn S. Functional brain networks in DYT1 dystonia. Ann Neurol 1998; 44:303–312. 24. Lang A. Dopamine agonists and antagonists in the treatment of idiopathic dystonia. Adv Neurol 1988; 50:561–570. 25. Leenders KL, Quinn N, Frackowiak RS, Marsden CD. Brain dopaminergic system studied in patients with dystonia using positron emission tomography. Adv Neurol 1988; 50:243–247. 26. Perlmutter JS, Stambuk MK, Markham J, Black KJ, McGee-Minnich L, Jankovik J, Moerlein SM. Decreased [18F]Spiperone binding in putamen in idiopathic local dystonia. J Neurosci 1997; 17:843–850. 27. Hallett M. The Neurophysiology of dystonia. Arch Neurol 1998; 55:601–603. 28. Ikoma K, Samii A, Mercuri B, Wassermann EM, Hallett M. Abnormal cortical motor excitability in dystonia. Neurology 1996; 46:1371–1376. 29. Byl NN. Focal hand dystonia may result from aberrant neuroplasticity. Adv Neurol 2004; 94:19–28. 30. Hallett M. Dystonia: abnormal movements result from loss of inhibition. Adv Neurol 2004; 94:1–9. 31. Garraux G, Bauer A, Hanakawa T, Wu T, Kansaku K, Hallett M. Changes in brain anatomy in focal hand dystonia. Ann Neurol 2004; 55:736–739. 32. Bressman SB, De Leon D, Kramer PL, Ozelius LJ, Brin MF, Greene PE, Fahn S, Breakefield XO, Risch NJ. Dystonia in Ashkenazi Jews: clinical characterization of a founder mutation. Ann Neurol 1994; 36:771–777.
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
419
33. Kramer PL, Heiman GA, et al. The DYT1 gene on 9q34 is responsible for most cases of early limb-onset idiopathic torsion dystonia in non-Jews. Am J Hum Genet 1994; 55:468–475. 34. Ozelius LJ, Kramer PL, et al. Strong allelic association between the torsion dystonia gene (DYT1) and loci on chromosome 9q34 in Ashkenazi Jews. Am J Hum Genet 1992; 50:619–628. 35. Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, De Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17:40–48. 36. Warner TT, Fletcher NA, Davis MB, Ahmad F, Conway D, Feve A, Rondot P, Marsden CD, Harding AE. Linkage analysis in British and French families with idiopathic torsion dystonia. Brain 1993; 116:739–744. 37. Risch NJ, Bressman SB, De Leon D, Brin MF, Burke RE, Greene PE, Shale H, Claus EB, Cupples LA, Fahn S. Segregation analysis of idiopathic torsion dystonia in Ashkenazi Jews suggests autosomal dominant inheritance. Am J Hum Genet 1990; 46:533–538. 38. Bressman SB, Hunt AL, et al. Exclusion of the DYT1 locus in a non-Jewish family with early-onset dystonia. Mov Disord 1994; 9:626–632. 39. Bressman SB, Sabatti C, Raymond D, De Leon D, Klein C, Kramer PL, Brin MF, Fahn S, Breakefield X, Ozelius LJ, Risch NJ. The DYT1 phenotype and guidelines for diagnostic testing. Neurology 2000; 54:1746–1752. 40. Valente EM, Warner TT, Jarman PR, Mathen D, Fletcher NA, Marsden CD, Bhatia KP, Wood NW. The role of DYT1 in primary torsion dystonia in Europe. Brain 1998; 121:2335–2339. 41. Opal P, Tintner R, Jankovic J, Leung J, Breakefield XO, Friedman J, Ozelius L. Intrafamilial phenotypic variability of the DYT1 dystonia: from asymptomatic TOR1A gene carrier status to dystonic storm. Mov Disord 2002; 17: 339–345. 42. Kabakci K, Hedrich K, Leung JC, Mitterer M, Vieregge P, Lencer R, Hagenah J, Garrels J, Witt K, Klostermann F, Svetel M, Friedman J, Kostic V, Bressman SB, Breakefield XO, Ozelius LJ, Pramstaller PP, Klein C. Mutations in DYT1: extension of the phenotypic and mutational spectrum. Neurology 2004; 62: 395–400. 43. Leung JC, Klein C, Friedman J, Vieregge P, Jacobs H, Doheny D, Kamm C, De Leon D, Pramstaller PP, Penney JB, Eisengart M, Jankovic J, Gasser T, Bressman SB, Corey DP, Kramer P, Brin MF, Ozelius LJ, Breakefield XO. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 2001; 3:133–143. 44. Ozelius LJ, Hewett JW, Page CE, Bressman SB, Kramer PL, Shalish C, De Leon D, Brin MF, Raymond D, Corey DP, Fahn S, Risch NJ, Buckler AJ, Gusella JF, Breakefield XO. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17:40–48. 45. Breakefield XO, Kamm C, Hanson PI. TorsinA: movement at many levels. Neuron 2001; 31:9–12.
Copyright 2006 by Taylor & Francis Group, LLC
420
Friedman and Standaert
46. Neuwald AF, Aravind L, Spouge JL, Koonin EV. AAAþ: A class of chaperonelike ATPases associated with the assembly, operation, and disassembly of protein complexes. Genome Res 1999; 9:27–43. 47. Hewett J, Gonzalez-Agosti C, Slater D, Ziefer P, Li S, Bergeron D, Jacoby DJ, Ozelius LJ, Ramesh V, Breakefield XO. Mutant torsinA, responsible for earlyonset torsion dystonia, forms membrane inclusions in cultured neural cells. Hum Mol Genet 2000; 9:1403–1413. 48. Kustedjo K, Bracey MH, Cravatt BF. TorsinA and its torsion dystoniaassociated mutant forms are lumenal glycoproteins that exhibit distinct subcellular localizations. J Biol Chem 2000; 275:27933–27939. 49. Kamm C, Boston H, Hewett J, Wilbur J, Corey DP, Hanson PI, Ramesh V, Breakefield XO. The early onset dystonia protein torsinA interacts with kinesin light chain 1. J Biol Chem 2004; 279:19882–19892. 50. Gonzalez-Alegre P, Paulson HL. Aberrant cellular behavior of mutant torsinA implicates nuclear envelope dysfunction in DYT1 dystonia. J Neurosci 2004; 24:2593–2601. 51. Hewett J, Ziefer P, Bergeron D, Naismith T, Boston H, Slater D, Wilbur J Schuback D, Kamm C, Smith N, Camp S, Ozelius LJ, Ramesh V, Hanson PI, Breakefield XO. TorsinA in PC12 cells: localization in the endoplasmic reticulum and response to stress. J Neurosci Res 2003; 72:158–168. 52. Bragg DC, Camp SM, Kaufman CA, Wilbur JD, Boston H, Schuback DE, Hanson PI, Sena-Esteves M, Breakefield XO. Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience 2004; 125:651–661. 53. Goodchild RE, Dauer WT. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. Proc Natl Acad Sci USA 2004; 101:847–852 (Epub 2004 Jan 7). 54. Rostasy K, Augood SJ, Hewett JW, Leung JC, Sasaki H, Ozelius LJ, Ramesh V, Standaert DG, Breakefield XO, Hedreen JC. TorsinA protein and neuropathology in early onset generalized dystonia with GAG deletion. Neurobiol Dis 2003; 12:11–24. 55. Augood SJ, Hollingsworth Z, Albers DS, Yang L, Leung JC, Muller B, Klein C, Breakefield XO, Standaert DG. Dopamine transmission in DYT1 dystonia: a biochemical and autoradiographical study. Neurology 2002; 59:445–448. 56. Olanow C, McNaught K. Neuropathology in DYT1/torsinA-linked dystonia. Mov Disord 2004; 19(suppl 9):S112. 57. Carbon M, Trost M, Ghilardi MF, Eidelberg D. Abnormal brain networks in primary torsion dystonia. Adv Neurol 2004; 94:155–161. 58. Trost M, Carbon M, Edwards C, Ma Y, Raymond D, Mentis MJ, Moeller JR, Bressman SB, Eidelberg D. Primary dystonia: is abnormal functional brain architecture linked to genotype? Ann Neurol 2002; 52:853–856 59. Almasy L, Bressman SB, Raymond D, Kramer PL, Greene PE, Heiman GA, Ford B, Yount J, de Leon D, Chouinard S, Saunders-Pullman R, Brin MF, Kapoor RP, Jones AC, Shen H, Fahn S, Risch NJ, Nygaard TG. Idiopathic torsion dystonia linked to chromosome 8 in two Mennonite families. Ann Neurol 1997; 42:670–673.
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
421
60. Ozelius LJ. Update on the genetics of primary torsion dystonia loci DYT6, DYT7, and DYT13 and the dystonia-plus locus DYT12. Adv Neurol 2004; 94:109–112. 61. Waddy HM, Fletcher NA, Harding AE, Marsden CD. A genetic study of idiopathic focal dystonias. Ann Neurol 1991; 29:320–324. 62. Leube B, Rudnicki D, Ratzlaff T, Kessler KR, Benecke R, Auburger G. Idiopathic torsion dystonia: assignment of a gene to chromosome 18p in a German family with adult onset, autosomal dominant inheritance and purely focal distribution. Hum Mol Genet 1996; 5:1673–1677. 63. Leube B, Hendgen T, Kessler KR, Knapp M, Benecke R, Auburger G. Sporadic focal dystonia in northwest Germany: molecular basis on chromosome 18p. Ann Neurol 1997; 42:111–114. 64. Leube B, Hendgen T, Kessler KR, Knapp M, Benecke R, Auburger G. Evidence for DYT7 being a common cause of cervical dystonia (torticollis) in Central Europe. Am J Med Genet 1997; 74:529–532. 65. Klein C, Ozelius LJ, Hagenah J, Breakefield XO, Risch NJ, Vieregge P. Search for a founder mutation in idiopathic focal dystonia from Northern Germany. Am J Hum Genet 1998; 63:1777–1782. 66. Leube B, Auburger G. Questionable role of adult-onset focal dystonia among sporadic dystonia patients. Ann Neurol 1998; 44:984–985. 67. Munchau A, Valente EM, Davis MB, Stinton V, Wood NW, Quinn NP, Bhatia KP. A Yorkshire family with adult-onset cranio-cervical primary torsion dystonia. Mov Disord 2000; 15:954–959. 68. Bentivoglio AR, Del Grosso N, Albanese A, Cassetta E, Tonali P, Frontali M. Non-DYT1 dystonia in a large Italian family. J Neurol Neurosurg Psychiatry 1997; 62:357–360. 69. Valente EM, Bentivoglio AR, Cassetta E, Dixon PH, Davis MB, Ferraris A, Ialongo T, Frontali M, Wood NW, Albanese A. Identification of a novel primary torsion dystonia locus (DYT13) on chromosome 1 p36 in an Italian family with cranial-cervical or upper limb onset. Neurol Sci 2001; 22:95–96. 70. Nygaard TG. Dopa-responsive dystonia. Delineation of the clinical syndrome and clues to pathogenesis. Adv Neurol 1993; 60:577–585. 71. Segawa M, Nomura Y, Nishiyama N. Autosomal dominant guanosine triphosphate cyclohydrolase I deficiency (Segawa disease). Ann Neurol 2003; 54(suppl 6):S32–45. 72. Segawa M, Nomura Y. Hereditary progressive dystonia with marked diurnal fluctuation. In: Segawa M, ed. Hereditary Progressive Dystonia With Marked Diurnal Fluctuation. New York, NY: Parthenon Publishing, 1993; 3:3–19. 73. Steinberger D, Weber Y, Korinthenberg R, Deuschl G, Benecke R, Martinius J, Muller U. High penetrance and pronounced variation in expressivity of GCH1 mutations in five families with dopa-responsive dystonia. Ann Neurol 1998; 43:634–639. 74. Robinson R, McCarthy GT, Bandmann O, Dobbie M, Surtees R, Wood NW. GTP cyclohydrolase deficiency; intrafamilial variation in clinical phenotype, including levodopa responsiveness. J Neurol Neurosurg Psychiatry 1999; 66: 86–89.
Copyright 2006 by Taylor & Francis Group, LLC
422
Friedman and Standaert
75. Bandmann O, Daniel S, Marsden CD, Wood NW, Harding AE. The GTPcyclohydrolase I gene in atypical parkinsonian patients: a clinico-genetic study. J Neurol Sci 1996; 141:27–32. 76. Bandmann O, Nygaard TG, Surtees R, Marsden CD, Wood NW, Harding AE. Dopa-responsive dystonia in British patients: new mutations of the GTP-cyclohydrolase I gene and evidence for genetic heterogeneity. Hum Mol Genet 1996; 5:403–406. 77. Bandmann O, Valente EM, Holmans P, Surtees RA, Walters JH, Wevers RA, Marsden CD, Wood NW. Dopa-responsive dystonia: a clinical and molecular genetic study. Ann Neurol 1998; 44:649–656. 78. Bandmann O, Marsden CD, Wood NW. Atypical presentations of doparesponsive dystonia. Adv Neurol 1998; 78:283–290. 79. Segawa M, Hosaka A, Miyagawa F, Nomura Y, Imai H. Hereditary progressive dystonia with marked diurnal fluctuation. Adv Neurol 1976; 14:215–233. 80. Furukawa Y, Lang AE, Trugman JM, Bird TD, Hunter A, Sadeh M, Tagawa T, St George-Hyslop PH, Guttman M, Morris LW, Hornykiewicz O, Shimadzu M, Kish SJ. Gender-related penetrance and de novo GTP-cyclohydrolase I gene mutations in dopa-responsive dystonia. Neurology 1998; 50: 1015–1020. 81. Nygaard TG, Marsden CD, Fahn S. Dopa-responsive dystonia: long-term treatment response and prognosis. Neurology 1991; 41:174–181. 82. Furukawa Y, Kish SJ. Dopa-responsive dystonia: recent advance’s and remaining issues to be addressed. Mov Disord 1999; 14:709–715. 83. Ichinose H, Ohye T, et al. Hereditary progressive dystonia with marked diurnal fluctuation caused by mutations in the GTP cyclohydrolase I gene. Nat Genet 1994; 8:236–242. 84. Jeon BS, Jeong JM, Park SS, Lee MC. Dopa-responsive dystonia: a syndrome of selective nigrostriatal dopamine deficiency. Adv Neurol 1998; 78:309–317. 85. Hyland K, Arnold LA, Trugman JM. Defects of biopterin metabolism and biogenic amine biosynthesis: clinical diagnostic, and therapeutic aspects. Adv Neurol 1998; 78:301–308. 86. Bonafe L, Thony B, Leimbacher W, Kierat L, Blau N. Diagnosis of doparesponsive dystonia and other tetrahydrobiopterin disorders by the study of biopterin metabolism in fibroblasts. Clin Chem 2001; 47:477–485. 87. Hwu WL, Wang PJ, Hsiao KJ, Wang TR, Chiou YW, Lee YM. Doparesponsive dystonia induced by a recessive GTP cyclohydrolase I mutation. Hum Genet 1999; 105:226–230. 88. Grotzsch H, Pizzolato GP, Ghika J, Schorderet D, Vingerhoets FJ, Landis T, Burkhard PR. Neuropathology of a case of dopa-responsive dystonia associated with a new genetic locus, DYT14. Neurology 2002; 58:1839–1842. 89. Bartholome K, Ludecke B. Mutations in the tyrosine hydroxylase gene cause various forms of L-dopa-responsive dystonia. Adv Pharmacol 1998; 42:48–49. 90. Ludecke B, Dworniczak B, Bartholome K. A point mutation in the tyrosine hydroxylase gene associated with Segawa’s syndrome. Hum Genet 1995; 95:123–125. 91. Ludecke B, Knappskog PM, Clayton PT, Surtees RA, Clelland JD, Heales SJ, Brand MP, Bartholome K, Flatmark T. Recessively inherited L-DOPA-responsive
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
92.
93.
94.
95. 96.
97.
98.
99.
100.
101.
102.
103. 104.
105.
423
parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 1996; 5:1023–1028. Brautigam C, Wevers RA, Jansen RJ, Smeitink JA, de Rijk-van Andel JF, Gabreels FJ, Hoffmann GF. Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 1998; 44:1897–1904. van den Heuvel LP, Luiten B, Smeitink JA, de Rijk-van Andel JF, Hyland K, Steenbergen-Spanjers GC, Janssen RJ, Wevers RA. A common point mutation in the tyrosine hydroxylase gene in autosomal recessive L-DOPA-responsive dystonia in the Dutch population. Hum Genet 1998; 102:644–646. Abeling NG, van Gennip AH, Barth PG, van Cruchten A, Westra M, Wijburg FA. Aromatic L-amino acid decarboxylase deficiency: a new case with a mild clinical presentation and unexpected laboratory findings. J Inherit Metab Dis 1998; 21: 240–242. Hyland K, Clayton PT. Aromatic amino acid decarboxylase deficiency in twins. J Inherit Metab Dis 1990; 13:301–304. Hyland K, Surtees RA, Rodeck C, Clayton PT. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 1992; 42:1980–1988. Korenke GC, Christen HJ, Hyland K, Hunneman DH, Hanefeld F. Aromatic L-amino acid decarboxylase deficiency: an extrapyramidal movement disorder with oculogyric crises. Eur J Paediatr Neurol 1997; 1:67–71. Maller A, Hyland K, Milstien S, Biaggioni I, Butler IJ. Aromatic L-amino acid decarboxylase deficiency: clinical features, diagnosis, and treatment of a second family. J Child Neurol 1997; 12:349–354. Swoboda KJ, Hyland K, Goldstein DS, Kuban KC, Arnold LA, Holmes CS, Levy HL. Clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency. Neurology 1999; 53:1205–1211. Swoboda KJ, Saul JP, McKenna CE, Speller NB, Hyland K. Aromatic L-amino acid decarboxylase deficiency: overview of clinical features and outcomes. Ann Neurol 2003; 54(suppl 6):S49–55. Hanihara T, Inoue K, Kawanishi C, Sugiyama N, Miyakawa T, Onishi H, Yamada Y, Osaka H, Kosaka K, Iwabuchi K, Owada M. 6-Pyruvoyltetrahydropterin synthase deficiency with generalized dystonia and diurnal fluctuation of symptoms: a clinical and molecular study. Mov Disord 1997; 12: 408–411. Nomura Y, Uetake K, Yukishita S, Hagiwara H, Tanaka T, Tanaka R, Hachimori K, Nishiyama N, Segawa M. Dystonias responding to levodopa and failure in biopterin metabolism. Adv Neurol 1998; 78:253–266. Gasser T. Inherited myoclonus-dystonia syndrome. Adv Neurol 1998; 78: 325–334. Grabowski M, Zimprich A, Lorenz-Depiereux B, Kalscheuer V, Asmus F, Gasser T, Meitinger T, Strom TM. The epsilon-sarcoglycan gene (SGCE), mutated in myoclonus-dystonia syndrome, is maternally imprinted. Eur J Hum Genet 2003; 11:138–144. Quinn NP, Rothwell JC, Thompson PD, Marsden CD. Hereditary myoclonic dystonia, hereditary torsion dystonia and hereditary essential myoclonus: an area of confusion. Adv Neurol 1988; 50:391–401.
Copyright 2006 by Taylor & Francis Group, LLC
424
Friedman and Standaert
106. Quinn NP. Essential myoclonus and myoclonic dystonia. Mov Disord 1996; 11:119–124. 107. Klein C, Schilling K, Saunders-Pullman RJ, Garrels J, Breakefield XO, Brin MF, de Leon D, Doheny D, Fahn S, Fink JS, Forsgren L, Friedman J, Frucht S, Harris J, Holmgren G, Kis B, Kurlan R, Kyllerman M, Lang AE, Leung J, Raymond D, Robishaw JD, Sanner G, Schwinger E, Tabamo RE, Tagliati M. A major locus for myoclonus-dystonia maps to chromosome 7q in eight families. Am J Hum Genet 2000; 67:1314–1319. 108. Zimprich A, Grabowski M, Asmus F, Naumann M, Berg D, Bertram M, Scheidtmann K, Kern P, Winkelmann J, Muller-Myhsok B, Riedel L, Bauer M, Muller T, Castro M, Meitinger T, Strom TM, Gasser T. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001; 29:66–69. 109. Lim LE, Campbell KP. The sarcoglycan complex in limb-girdle muscular dystrophy. Curr Opin Neurol 1998; 11:443–452. 110. Asmus F, Gasser T. Inherited myoclonus-dystonia. Adv Neurol 2004; 94: 113–119. 111. Schule B, Kock N, Svetel M, Dragasevic N, Hedrich K, De Carvalho Aguiar P, Liu L, Kabakci K, Garrels J, Meyer EM, Berisavac I, Schwinger E, Kramer PL, Ozelius LJ, Klein C, Kostic V. Genetic heterogeneity in ten families with myoclonus-dystonia. J Neurol Neurosurg Psychiatry 2004; 75:1181–1185. 112. Valente EM, Misbahuddin A, Brancati F, Placzek MR, Garavaglia B, Salvi S, Nemeth A, Shaw-Smith C, Nardocci N, Bentivoglio AR, Berardelli A, Eleopra R, Dallapiccola B, Warner TT. Analysis of the epsilon-sarcoglycan gene in familial and sporadic myoclonus-dystonia: evidence for genetic heterogeneity. Mov Disord 2003; 18:1047–1051. 113. Klein C, Brin MF, Kramer P, Sena-Esteves M, de Leon D, Doheny D, Bressman S, Fahn S, Breakefield XO, Ozelius LJ. Association of a missense change in the D2 dopamine receptor with myoclonus dystonia. Proc Natl Acad Sci USA 1999; 96:5173–5176. 114. DA, Bulman D, George-Hyslop PS, Lang AE. Inherited myoclonus-dystonia: evidence supporting genetic heterogeneity. Mov Disord 2001; 16:106–110. 115. Grimes DA, Han F, Lang AE, St George-Hyssop P, Racacho L, Bulman DE. A novel locus for inherited myoclonus-dystonia on 18p11. Neurology 2002; 59:1183–1186. 116. Dobyns WB, Ozelius LJ, Kramer PL, Brashear A, Farlow MR, Perry TR, Walsh LE, Kasarskis EJ, Butler IJ, Breakefield XO. Rapid-onset dystoniaparkinsonism. Neurology 1993; 43:2596–2602. 117. Brashear A, Butler IJ, Hyland K, Farlow MR, Dobyns WB. Cerebrospinal fluid homovanillic acid levels in rapid-onset dystonia-parkinsonism. Ann Neurol 1998; 43:521–526. 118. Pittock SJ, Joyce C, O’Keane V, Hugle B, Hardiman MO, Brett F, Green AJ, Barton DE, King MD, Webb DW. Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred. Neurology 2000; 55:991–995. 119. Kamm C, Leung J, Joseph S, Dobyns WB, Brashear A, Breakefield XO, Ozelius LJ. Refined linkage to the RDP/DYT12 locus on 19q13.2 and evaluation of GRIK5 as a candidate gene. Mov Disord 2004; 19:845–847.
Copyright 2006 by Taylor & Francis Group, LLC
Neurogenetics of Dystonia and Paroxysmal Dyskinesias
425
120. De Carvalho Aguiar P, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M, Linazasoro G, Borg M, Tijssen MA, Bressman SB, Dobyns WB, Brashear A, Ozelius LJ. Mutations in the Na(þ)/K(þ)-ATPase alpha3 Gene ATP1A3 Are Associated with Rapid-Onset Dystonia Parkinsonism. Neuron 2004; 43:169–175. 121. De Fusco M, Marconi R, Silvestri L, Atorino L, Rampoldi L, Morgante L, Ballabio A, Aridon P, Casari G. Haploinsufficiency of ATP1A2 encoding the Naþ/Kþ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33:192–196. 122. Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari MD, van den Maagdenberg AM. Novel mutations in the Naþ, Kþ-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 2003; 54:360–366. 123. Fahn S. Paroxysmal Dyskinsias. In: Marsden CD, Fahn S, eds. Movement Disorders 3. Oxford: Butterworth-Heineman, 1994:310–345. 124. Bhatia KP. The paroxysmal dyskinesias. J Neurol 1999; 246:149–155. 125. Phillips HA, Scheffer LE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q 13.2. Nat Genet 1995; 10:117–118. 126. Mount L, Reback S. Familial paroxysmal choreoathetosis: preliminary report on an hitherto undescribed clinical syndrome. Archives of Neurology and Psychiatry 1940; 44:841–847. 127. Demirkiran M, Jankovic J. Paroxysmal dyskinesias: clinical features and classification. Ann Neurol 1995; 38:571–579. 128. Fouad GT, Servidei S, Durcan S, Bertini E, Ptacek LJ. A gene for familial paroxysmal dyskinesia (FPD1) maps to chromosome 2q. Am J Hum Genet 1996; 59:135–139. 129. Fink JK, Rainer S, Wilkowski J, Jones SM, Kume A, Hedera P, Albin R, Mathay J, Girbach L, Varvil T, Otterud B, Leppert M. Paroxysmal dystonic choreoathetosis: tight linkage to chromosome 2q. Am J Hum Genet 1996; 59:140–145. 130. Jarman PR, Davis MB, Hodgson SV, Marsden CD, Wood NW. Paroxysmal dystonic choreoathetosis. Genetic linkage studies in a British family. Brain 1997; 120:2125–2130. 131. Raskind WH, Bolin T, Wolff J, Fink J, Matsushita M, Lift M, Lipe H, Bird TD. Further localization of a gene for paroxysmal dystonic choreoathetosis to a 5-cM region on chromosome 2q34. Hum Genet 1998; 102:93–97. 132. Grunder S, Geisler HS, Rainier S, Fink JK. Acid-sensing ion channel (ASIC) 4 gene: physical mapping, genomic organisation, and evaluation as a candidate for paroxysmal dystonia. Eur J Hum Genet 2001; 9:672–676. 133. Auburger G, Ratzlaff T, et al. A gene for autosomal dominant paroxysmal choreoathetosis/spasticity (CSE) maps to the vicinity of a potassium channel gene cluster on chromosome 1p, probably within 2 cM between D1S443 and D1S197. Genomics 1996; 31:90–94. 134. Kertesz A. Paroxysmal kinesigenic choreoathetosis. An entity within the paroxysmal choreoathetosis syndrome. Description of 10 cases, including 1 autopsied. Neurology 1967; 17:680–690.
Copyright 2006 by Taylor & Francis Group, LLC
426
Friedman and Standaert
135. Swoboda KJ, Soong BW, McKenna C, Brunt ER, Litt M, Bale JF, Jr., Ashizawa T, Bennett LB, Bowcock AM, Roach ES, Gerson D, Matsuura T, Heydemann PT, Nespeca MP, Jankovic J, Leppert M, Ptacek LJ. Paroxysmal kinesigenic dyskinesia and infantile convulsions. Clinical and linkage studies. 2000. Neurology 2001; 57:S42–48. 136. Guerrini R, Bonanni P, Nardocci N, Parmeggiani L, Piccirilli M, De Fusco M, Aridon P, Ballabio A, Carrozzo R, Casari G. Autosomal recessive rolandic epilepsy with paroxysmal exercise-induced dystonia and writer’s cramp: delineation of the syndrome and gene mapping to chromosome 16p12–11.2. Ann Neurol 1999; 45:344–352. 137. Caraballo R, Pavek S, Lemainque A, Gastaldi M, Echenne B, Motte J, Genton P, Cersosimo R, Humbertclaude V, Fejerman N, Monaco AP, Lathrop MG, Rochette J, Szepetowski P. Linkage of benign familial infantile convulsions to chromosome 16p12-q12 suggests allelism to the infantile convulsions and choreoathetosis syndrome. Am J Hum Genet 2001; 68:788–794. 138. Nemeth AH. The genetics of primary dystonias and related disorders. Brain 2002; 125:695–721. 139. Lotze T, Jankovic J. Paroxysmal kinesigenic dyskinesias. Semin Pediatr Neurol 2003; 10:68–79. 140. Defazio G, Berardelli A, Abbruzzese G, Lepore V, Coviello V, Acquistapace D, Capus L, Carella F, De Berardinis MT, Galardi G, Girlanda P, Maurri S, Albanese A, Bertolasi L, Liguori R, Rossi A, Santoro L, Tognoni G, Livrea P. Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group. J Neurol Neurosurg Psychiatry 1998; 64:25–32. 141. Fletcher NA, Harding AE, Marsden CD. A case-control study of idiopathic torsion dystonia. Mov Disord 1991; 6:304–309. 142. Factor SA. Cervical dystonia in twins. Mov Disord 2002; 17:846–847. 143. Wunderlich S, Reiners K, Gasser T, Naumann M. Cervical dystonia in monozygotic twins: case report and review of the literature. Mov Disord 2001; 16:714–718. 144. Misbahuddin A, Placzek MR, Warner TT. Focal dystonia is associated with a polymorphism of the dopamine D5 receptor gene. Adv Neurol 2004; 94: 143–146. 145. Placzek MR, Misbahuddin A, Chaudhuri KR, Wood NW, Bhatia KP, Warner TT. Cervical dystonia is associated with a polymorphism in the dopamine (D5) receptor gene. J Neurol Neurosurg Psychiatry 2001; 71:262–264. 146. Matsumoto S, Nishimura M, Sakamoto T, Asanuma K, Izumi Y, Shibasaki H, Kamatani N, Nakamura T, Kaji R. Modulation of the onset age in primary dystonia by APOE genotype. Neurology 2003; 60:2003–2005.
Copyright 2006 by Taylor & Francis Group, LLC
19 Inherited Epilepsies Yr Sigurdardottir Department of Pediatrics, University Hospital Iceland, Reykjavik, Iceland
Annapurna Poduri Division of Epilepsy and Neurophysiology, Children’s Hospital Boston, Boston, Massachusetts, U.S.A.
INTRODUCTION Epilepsy, defined by recurrent, unprovoked seizures, is a relatively common neurologic disorder with a prevalence of 4–8 per 1000 in the United States (1). The hereditary transmission of seizure disorders has long been suspected in humans, and carefully designed epidemiologic studies have identified a substantial genetic contribution to epilepsy (2,3). These studies have shown that close relatives of index cases have an increased risk of epilepsy compared to the general population, and twin studies have shown higher concordance in monozygotic twins when compared with dizygotic pairs (4). There are over one hundred single gene (Mendelian) disorders whose phenotype includes recurrent seizures (OMIM). These conditions are usually so rare, however, that collectively they only shed light on the etiology of epilepsy in a mere fraction of patients with epilepsy. Nonetheless, it is through the study of these disorders and their genetic underpinnings that we may better understand cortical excitability, seizure threshold, and other aspects of human epilepsy. More often, we face the more complex situation of genetic susceptibility to epilepsy that does not follow a clear Mendelian inheritance pattern. When the genetics of epilepsy was comprehensively reviewed in 1980 by Newmark and Penry (5), the evidence for the genetic basis of epilepsy rested
Copyright 2006 by Taylor & Francis Group, LLC
428
Sigurdardottir and Poduri
largely on animal models and the examination of pedigrees of families with epilepsy. In the past 25 years, emerging discoveries in molecular genetics have confirmed the genetic basis for many epilepsy syndromes, and in some cases the putative mechanisms for epileptogenesis have been established. The mapping of single gene disorders starts with the identification of families with multiple affected members, preferably with a single seizure phenotype. The clinician’s task is paramount in identifying appropriate index cases. The next step is to perform linkage analysis to map a disorder to a chromosomal region. If this can be accomplished, positional cloning techniques can be employed to identify the specific gene involved. Subsequently, functional studies can be performed to assess the function of the associated gene product and its role in epileptogenesis. In the future, such advances should lead to a more precise and targeted pharmaceutical approaches to epilepsy than we have now. There are, of course, numerous conditions such as structural brain malformations and inborn errors of metabolism that include epilepsy in their phenotype and have known or presumed genetic etiologies. We will focus this chapter, however, on diseases that are defined chiefly by epilepsy. Table 1 outlines inherited epilepsies for which there is evidence for an involved chromosomal region or locus. Note that there are multiple genes or loci listed for some conditions and that multiple, allelic disorders are found at some loci. Other epilepsy syndromes with a suspected but as yet unconfirmed genetic component are listed in Table 2. The important concepts of single gene disorders can be illustrated by focusing on the channelopathies that are associated with epilepsy and some of the myoclonic epilepsy syndromes that follow clear patterns of inheritance. Some of these disorders demonstrate genetic heterogeneity, with several separate mutations at different loci producing the same clinical phenotype. The so-called ‘‘idiopathic’’ generalized and localization-related epilepsies of childhood and adolescence are examples of epilepsies with both single gene and complex, presumed polygenetic, inheritance. CHANNELOPATHIES The channelopathies represent the prototype of epilepsies with single gene abnormalities that give rise to abnormalities in proteins plausibly involved in mechanisms of epileptogenesis. It is not surprising that epilepsy, a condition defined by abnormally synchronous neuronal events giving rise to repeated seizures, can be associated with, if not caused by, abnormalities of ion channel structure or function. Animal models of ion channel defects have established the connection between disease-producing mutations and their associated clinical phenotypes. Several human epilepsy syndromes illustrate the importance of ion channels in the development of seizures and epilepsy. Interestingly, while most of the mouse models involve homozygous mutations
Copyright 2006 by Taylor & Francis Group, LLC
Chromosal locus
– CLN1 CLN1 ATP1A2 – – CACNB4 FEB3 SCN2A SCN2A – SCN1A SCN1A CLCN2 CLCN2 CLCN2 FEB4 GABRG2 GABRG2 GABRA1 EJM1 – EFHC1 NEU1 EPM2B
Epilepsy syndrome Childhood absence evolving to juvenile myoclonic epilepsy Infantile NCL (Santavuori–Haltia) Some adult NCL (Kufs) Benign familial infantile convulsions (BFIC)a (199) Benign adult familial myoclonic epilepsy (BAFME)a Autosomal dominant cortical myoclonus and epilepsy (ADCME) Juvenile myoclonic epilepsy (JME)a Familial febrile convulsions (FFC)a Benign familial neonatal/infantile convulsions (BFNIC) Generalized epilepsy with febrile seizures plus (GEFSþ)a Benign familial infantile convulsions (BFIC)a Generalized epilepsy with febrile seizures plus (GEFSþ)a Severe myoclonic epilepsy of infancy (SMEI)a Childhood absence epilepsy (CAE) (ECA3) Juvenile absence epilepsy (JAE) Juvenile myoclonic epilepsy (JME)a Familial febrile convulsions (FFC)a Childhood absence epilepsy (CAE) (ECA2) Generalized epilepsy with febrile seizures plus (GEFSþ)a Juvenile myoclonic epilepsy (JME)a Generalized tonic–clonic seizures of awakening Juvenile myoclonic epilepsy (JME)a Juvenile myoclonic epilepsy (JME)a Sialidosis types I and II Lafora body diseasea
Inheritance AD AR AR AD AD AD Complex AD AD AD AD AD De novo Complex Complex Complex AD Complex AD Complex AD Complex AD AR AR (Continued)
Copyright 2006 by Taylor & Francis Group, LLC
429
1p 1p32 1p32 1q23 2p11.1-2q12.2 2p11.1-2q12.2 2q22-q23 2q23-q24 2q23-q24.3 2q23-q24.3 2q24 2q24 2q24 3q26-qter 3q26 3q26 5q14-q15 5q31.1 5q34 5q34 6p 6p11 6p12-p11 6p21.3 6p22
Gene
Inherited Epilepsies
Table 1 Epilepsy Syndromes with Established Genetic Basis by Chromosomal Locus
430
Table 1
Epilepsy Syndromes with Established Genetic Basis by Chromosomal Locus (Continued )
Chromosal locus
Gene EPM2A CLN7 CLN8 – FEB1 – KCNQ3 – LGI
11p15.5 12p13.31 13q21.1-q32 15q14 15q21-q23 16p12.1 16p12-q12 16p12-q12
CLN2 DRPLA CLN5 CHRNA7 CLN6 CLN3 – –
Copyright 2006 by Taylor & Francis Group, LLC
Lafora body diseasea Late infantile NCL (Turkish) Childhood NCL Northern epilepsy variant Childhood absence epilepsy (CAE) (ECA1) Familial febrile convulsions (FFC)a Benign adult familial myoclonic epilepsy (BAFME)a Benign familial neonatal convulsions (BFNC)a Partial epilepsy with auditory features Autosomal dominant lateral temporal lobe epilepsy (ADLTE) Late infantile NCL (Jansky–Bielschowsky) Dentatorubral pallidoluysian atrophy (DRPLA) Late infantile NCL (Finnish) Juvenile myoclonic epilepsy (JME)a Late infantile NCL (variant) Juvenile NCL (Spielmeyer–Vogt) Benign familial infantile convulsions (BFIC)a Infantile convulsions and choreoathetosis (ICCA)
Inheritance AR AR AR Complex AD AD AD AD AD AR AD (CAGn) AR Complexa AR AR AD AD
Sigurdardottir and Poduri
6q23-q25 8pter-p22 8p23 8q24 8q13-q21 8q23.3-q24.11 8q24.22 10q 10q22-q24
Epilepsy syndrome
–
16p13 19q12-q13.1 19p13 19q13.1 19p13.3 20q13.2 20q13.32-13.33 21q22.3 22q12 Xp21.3-p22.1 Xp22.3 Mitochondrial loci
– – CACNA1A SCN1B FEB2 CHRNA4 KCNQ2 CSTB – ARX STK9 MTTK MTTLI MTTH MTTS1
Rolandic epilepsy with paroxysmal exercise-induced dystonia and writer’s cramp Familial idiopathic myoclonic epilepsy of infancy (200) Benign familial infantile convulsions (BFIC)a Episodic ataxia type 2 with seizures Generalized epilepsy with febrile seizures plus (GEFSþ)a Familial febrile convulsions (FFC)a Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) Benign familial neonatal convulsions (BFNC)a Unverricht–Lundborg disease Familial partial epilepsy with variable foci (FPEVF) (201) X-linked infantile spasmsa (202) X-linked infantile spasmsa (203) Myoclonic epilepsy with ragged red fibers (MERRF)a
AR AR AD AD, sporadic AD AD AD AD AR AD X-linked X-Iinked Mitochondrial Mitochondrial Mitochondrial Mitochondrial
Inherited Epilepsies
16p12-11.2
a denotes diseases that have been associated with multiple loci. A dash (–) indicates that the information is not established. Abbreviations: CAGn, CAG repeat expansion; NCL, neuronal ceroid lipofuscinosis.
Copyright 2006 by Taylor & Francis Group, LLC
431
432
Sigurdardottir and Poduri
Table 2 Epilepsy Syndromes with Presumed Genetic Basis Benign myoclonic epilepsy of infancy Familial temporal lobe epilepsy Febrile seizures Common generalized epilepsies of childhood (most cases) Childhood absence epilepsy Juvenile absence epilepsy Juvenile myoclonic epilepsy Benign Epilepsy with Centro-Temporal Spikes (BECTS) Myoclonic-astatic epilepsy (Doose’s syndrome) Reading epilepsy
of channel-associated proteins, the majority of the channelopathies associated with human disease display an autosomal dominant (AD) pattern of inheritance. An exception is childhood absence epilepsy (CAE), in which the T-type calcium channel appears to be the site of abnormality but inheritance appears to be multifactorial in most cases; this condition is discussed below in the ‘‘Generalized Epilepsy Syndromes’’ section. Calcium Channelopathies: Mouse Models and Human Disease Several autosomal recessive (AR) mouse mutants with epilepsy have been identified. The best known is the tottering (tg) mutant, which has ataxia and absence epilepsy with generalized spike-wave (SW) discharges on electroencephalogram (EEG) (6). In 1996, Fletcher et al. identified a mutation in a gene that encodes the a1A subunit of the voltage-gated calcium channel (VGCC) in the tottering mouse mutant (7). This remains a prototype of a single gene mutation causing epilepsy. Three additional allelic mouse mutants—leaner (tgla), rolling Nagoya (tgrol), and rocker (rkr)—all demonstrate ataxia with or without seizures (7–9). VGCCs are composed of four primary subunits (a1, b, g, and a2d) that are believed to be arranged in a 1:1:1:1 stoichiometry. Several mouse mutants have been identified with mutations in the b, g, and a2d subunits, all demonstrating seizure phenotypes (Table 3). Since generalized epileptiform discharges and absence epilepsy dominate the clinical manifestations in these animal models, one might expect that calcium channel subunit mutations would be associated with epilepsy in humans. Until recently, however, the three allelic human disorders with mutations in the CACNA1A gene on chromosome 19—familial hemiplegic migraine (FHM), spinocerebellar ataxia type 6 (SCA6), and episodic ataxia type 2 (EA2)—were not associated with epilepsy, although EEG abnormalities had been described (10). There is mounting evidence that mutations in VGCC subunits cause human epilepsy. CACNA1A mutations have been identified in a family with
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
433
Table 3 P/Q Calcium Channel Mouse Mutant Models
Subunit alA a2d2 b4 g2 g3
Mouse chromosomal locus
Mouse phenotype
Human chromosomal locus
Human phenotype
8 9 2 15 –
tg, tgla, tgrol rkr du lh stg, stg-wag
19p13.1 3p21.3-21.2 2q22-23 22cen-qter 16p13.3-12
FHM, EA2, SCA6, sz – ataxia, sz, JME – Chorea, infantile sz
A dash (–) indicates that the information is not established. Abbreviations: tg, tottering; tgla, leaner; tgrol, Nagoya rolling; rkr, rocker; FHM, familial hemiplegic migraine; du, ducky (30); lh, lethargic (24); EA2, episodic ataxia type 2; SCA6, spinocerebellar ataxia type 6; sz, seizures; JME, juvenile myoclonic epilepsy; stg, stargazer (31); stg-wag, waggler.
EA2, generalized epileptiform discharges on EEG, and childhood seizures (11). Another report of a patient with developmental delay, ataxia, and epilepsy identified a de novo CACNA1A mutation (12). Human epilepsy has also been found in patients with mutations in the b and g subunits of the calcium channel as well. The fact that most patients with EA2 do not have epilepsy supports the concept that a critical level of channel dysfunction may be required before SW activity is generated and clinical seizures appear (11–14). The mechanisms by which mutated calcium channels lead to the development of epilepsy have been extensively studied in the above mentioned spontaneous mouse mutants harboring homozygous mutations in genes encoding various subunits of the calcium channel complex (15–18). Some mutants have increased expression of tyrosine hydroxylase, a key enzyme in noradrenergic biosynthesis (19), while in other mutants increased numbers of GABA-B receptors seem to result in thalamo-cortical hypersynchronization that leads to generalized seizures (17). Other Clinical Epilepsy Syndromes Associated with Channelopathies In addition to EA2 with seizures, there are several clinical syndromes characterized chiefly by epilepsy that have been associated with mutations in channel-encoding genes. The epilepsies associated with channelopathies are summarized in Table 4. Benign Familial Neonatal Convulsions The syndrome of benign familial neonatal convulsions (BFNC) was first described in the mid-1960s by Rett and Teubel (20) and Bjerre and Corelius (21). This AD syndrome is characterized by unprovoked seizures in the neonatal period, which remit within a few months of life and are followed
Copyright 2006 by Taylor & Francis Group, LLC
434
Table 4 Inherited Channelopathies Associated with Epilepsy Epilepsy syndrome Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) Benign familial neonatal convulsions (BFNC) Benign familial infantile convulsions (BFIC)
Familial febrile convulsions (FFC)
Copyright 2006 by Taylor & Francis Group, LLC
Gene
Protein
Chromosomal locus
AD
CHRNA4
nAch-R
20q13.2
AD
KCNQ2
VGPC
20q13.32-13.33 (EBNl)
AD
KCNQ3 ATP1A2
VGPC Na/K-ATPase
8q24.22 (EBN2) 1q23
AD
– – – SCN2A
– – – VGSC
2q24 16p12-q12 19q12-q13.1 2q23-q24.3
CACNA1A
VGCC
19p13
FEB1 FEB2 FEB3 FEB4
– – – –
8q13-q21 19p13.3 2q23-q24 5q14-q15
AD, some de novo AD
Sigurdardottir and Poduri
Benign familial neonatal/infantile convulsions (BFNIS) Episodic ataxia type 2 (EA2) with seizures
Inheritance
Type 3 Infantile convulsions and choreoathetosis (ICCA) Severe myoclonic epilepsy of infancy Severe myoclonic epilepsy of infancy atypical variant
AD
AD
SCN1B SCN1A SCN2A GABRG2 –
VGSC VGSC VGSC GABA-A-R –
19q13.1 2q24 2q23-q24.3 5q34 16p12-q12
De novo
SCN1A
VGCC
2q24
GABRG2 SCN2A
GABA-A-R VGSC
5q31.1-q33.1 2q23-q24.3
Inherited Epilepsies
Generalized epilepsy with febrile seizures plus (GEFSþ) Type l Type 2
A dash (–) indicates that the information is not established. Abbreviations: nAch-R, nicotinic acetylcholine receptor; GABA-A-R, GABA-A receptor; VGCC, voltage-gated calcium channel; VGPC, voltage-gated potassium channel; VGSC, voltage-gated sodium channel.
Copyright 2006 by Taylor & Francis Group, LLC
435
436
Sigurdardottir and Poduri
by normal psychological development. The seizures are clinically heterogeneous and consist of eye twitching, occasional tonic posturing, and often clonic movements of extremities. Ictal EEG recordings typically reveal a period of voltage attenuation followed by bilateral rhythmic spiking during the tonic–clonic phase (22–24). BFNC is usually categorized as a generalized epilepsy although some reports of focal EEG features have challenged that view (23,24). Each seizure is brief, typically less than two minutes in duration, but up to 40 seizures per day can occur. Patients with BFNC usually respond well to treatment and experience a lasting remission, although the prevalence of subsequent epilepsy is higher than in the general population (15% vs. 1%). In 1989, this disease was mapped to chromosome 20, and in 1992 further analysis narrowed the region to 20q13.32-13.33 (25,26). Evidence for genetic heterogeneity surfaced quickly when in 1991 a family with clinical BFNC mapped to chromosome 8q24.22 (27). In the late 1990s, both involved loci were found to contain genes encoding voltagegated potassium channel subunits, the chromosome 20 gene encoding KCNQ2 and the chromosome 8 gene KCNQ3 (28,29). Numerous different mutations within these genes have been found, all leading to a similar disease phenotype (25–30), and no clear difference has been found between the clinical presentations of individuals with mutations in KCNQ2 and KCNQ3. Functional studies of the role of voltage-gated potassium channels in cortical excitability have shown that wild-type KCNQ2 and KCNQ3 channels are associated with a current comparable to the native M-current, a slowly activating–deactivating potassium current that plays a critical role in determining the subthreshold electrical excitability of neurons (31,32). Mutated channels have smaller associated potassium currents, and recent studies have shown that a 25% reduction of the M-current can lead to epilepsy (33). The age dependency of this syndrome remains fascinating, and most researchers hypothesize that the KCQN2 and KCNQ3 genes are most actively transcribed in the first weeks of life. A recently described family with a clinical BFNC phenotype has been found to have a pericentric inversion of chromosome 5 (34), and one family with BFNC phenotype and AR inheritance was described in 1991 (35). This further points to considerable genetic heterogeneity, and it is likely that more loci will be identified with time. Benign Familial Infantile Convulsions and Infantile Convulsions and Choreoathetosis Benign familial infantile convulsion (BFIC) is another benign AD epilepsy syndrome of early infancy. It is characterized by an age of seizure onset around six months of age (range 3–9 months) with resolution by 12 months of age and no subsequent neurologic abnormalities. The seizures are typically partial or secondarily generalized and respond well to antiepileptic medication. BFIC was first described by Vigevano et al. (36) in 1992. He
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
437
reported five Italian infants with the typical phenotype, each with a family history of infantile seizures. Seventeen additional families were reported soon afterwards (37,38). Linkage analysis in eight affected Italian families ruled out involvement of the BFNC locus on chromosome 20 (39), and the BFIC gene was later linked to chromosome 19 in five of these eight families (40). The report of a second locus at 16p12-q12 demonstrates the genetic heterogeneity of BFIC (41–43). Three overlapping clinical entities are seen with mutations at this second locus. The earliest described was the BFIC phenotype. Since then, families with infantile convulsions and choreoathetosis (ICCA), a kinesigenic movement disorder, have been reported (43,44), as well as others with paroxysmal kinesogenic choreoathetosis (PKC), a movement disorder without seizures (45). These three syndromes are thought to be allelic disorders (41). Specific mutations at this locus have not been identified. A databank gene scan of this region has not identified a sequence corresponding to an ion channel gene, but several sodium-glucose co-transporters have been identified as potential candidates. Benign Familial Neonatal/Infantile Seizures Kaplan and Lacey (46) reported a family in which 12 members had idiopathic neonatal or early infantile seizures inherited in an AD pattern. The age of onset ranged from 2 days to 3.5 months, representing an intermediate between BFNC and BFIC. Seizures occurred in clusters, over a period of hours to days. None of the patients developed a subsequent seizure disorder, and all had normal psychological development. A few years later, one of two families initially reported as BFNC was found to have an intermediate age of onset, more typical of Benign familial neonatal/infantile seizures (BFNIS) than BFNC (47,48). This family has been extensively studied and has not shown linkage to the BFNC loci on chromosomes 8 and 20. Linkage to 2q23-q24.3 was established (49), and a mutation in a voltage-gated sodium channel alpha subunit gene (SCN2A) was verified in 2002 (50). Berkovic et al. (51) recently reported missense mutations in the SCN2A gene in eight families with a BFNIS phenotype. In these families, ictal EEG showed a posterior temporal onset, and the clinical features were that of a secondarily generalized partial seizure. In a few cases, interictal EEG showed generalized epileptiform discharges. All affected members responded well to antiepileptic drugs and remained seizure free after 12 months of age. Voltage-gated sodium channels have one pore-forming a subunit and two b subunits that modulate channel-gating kinetics (52). Whole-cell patch clamp recordings of wild-type and mutated channels have shown the mutant channel to inactivate more slowly, whereas the sodium channel conductance was normal. Prolonged residence in the open state of the mutant channel may augment sodium influx and thereby underlie the neuronal hyperexcitability that induces or facilitates seizure activity (52).
Copyright 2006 by Taylor & Francis Group, LLC
438
Sigurdardottir and Poduri
Familial Febrile Convulsions and Generalized Epilepsy with Febrile Seizures Plus Febrile seizures affect approximately 2–4% of children under six years of age and are by far the most common seizure disorder (53). Up to 6% of children with febrile seizures later develop ongoing epilepsy with afebrile seizures (54). Twin studies have confirmed a major impact of genetic factors in the etiology of febrile seizures (55), and rare families exhibit AD inheritance (56–59). Several loci (19p13.3, 8q13-q21, 2q23-q24, 5q14-q15) have been related to familial febrile convulsions (FFC) (56–59). In one family with febrile and afebrile seizures, a nonsense mutation in the MASS1 (monogenic audiogenic seizure susceptibility 1) gene was discovered (60). Although this loss-of-function mutation may be responsible for the seizure phenotype in this particular family, it is not likely that MASS1 mutations contribute to the cause of febrile seizures in the majority of cases. In the same report, 47 other families with febrile seizures were found not to harbor mutations at this site (60). In 1997, a subset of patients with familial febrile seizures was identified and their condition termed generalized epilepsy with febrile seizures plus (GEFSþ) by Scheffer and Berkovic (61). In the family they described, the most common phenotype was denoted as febrile seizures plus (FSþ), comprised of childhood-onset febrile seizures. Unlike members of kindreds with a typical FFC phenotype, patients with FSþ had seizures with fever continuing beyond six years of age as well as afebrile seizures. Other phenotypes included FSþ and absence seizures, FSþ and myoclonic seizures, FSþ and atonic seizures, and the most severely affected individual had myoclonicastatic epilepsy (MAE). Seizures usually ceased by mid-childhood (median 11 years). Singh et al. (62) reported the seizure phenotypes of 63 patients in nine families with epilepsy consistent with the GEFSþ syndrome. Approximately 50% had febrile convulsions, 25% had febrile seizures plus (FSþ), and 27% had FSþ mixed with other seizure types (atonic, myoclonic, absence, complex partial, or myoclonic-astatic). Inheritance was AD with approximately 60% penetrance. Wallace et al. (63) established linkage to chromosome 19q13.1 in a large family with GEFSþ and later identified a mutation in a voltage-gated sodium channel a subunit (SCN1B) gene in that region. This is known as GEFSþ type 1. GEFSþ type 2 has since been described with a mutation in the SCN1A gene on chromosome 2q24 (64–66). An additional mutation in the SCN2A gene on chromosome 2q23-q24.3 was reported in a family with febrile and afebrile seizures (52). These genes code for voltage-gated sodium channel a subunits. In addition to these sodium channel subunit mutations, a mutation in a gene coding for a GABA-A receptor g2 subunit gene (GABRG2) has been found in a family with a third phenotype, GEFSþ type 3 (67). The exact manner by which mutated sodium channels give rise to epilepsy is not known. The fast inactivating sodium current is the principal
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
439
current responsible for the depolarizing phase of the action potential and thus is essential for neuronal excitation in general (68). Pentylenetetrazole, a drug that causes convulsions in experimental models, prolongs sodium-carried action potentials (69), and multiple antiepileptic drugs work by manipulating sodium channel gating (68). It therefore came as no surprise when functional studies of channels with SCN1A, SCN2A, and SCN1B mutations showed prolonged opening of sodium channels, which would hypothetically lead to increased excitability and seizures (52,70). Computer simulation studies have found that despite each individual mutation having a unique effect on the action potential, the end result of all four mutations (SCN1A, SCN2A, SCN1B, GBRG2) is an increased propensity to fire repetitive action potentials (71). More research is needed to understand why a static change in channel properties would lead to a paroxysmal disorder like epilepsy. Severe Myoclonic Epilepsy of Infancy Severe myoclonic epilepsy of infancy (SMEI) is a rare disorder (1:40,000) characterized by generalized tonic, clonic, and tonic–clonic seizures that are frequently initially induced by fever and begin during the first year of life (72,73). Later, patients also manifest other seizure types, including absence, myoclonic, and simple and complex partial seizures. Psychomotor development is initially normal but plateaus during the second year of life. SMEI is considered a malignant epilepsy syndrome due to its effect on psychomotor development as well as the tendency for ongoing intractable seizures. SMEI was first described by Dravet in 1978 (72), and the first suggestion that it might be due to a single gene disorder was in 1992 when monozygotic twins exhibiting the SMEI phenotype were reported (74). Singh et al. (75) reported 12 probands with SMEI and a family history of seizures and proposed that SMEI was the most severe phenotype of GEFSþ. Having observed similarities in the phenotype of SMEI and GEFSþ, Claes et al. (76) screened seven unrelated patients with clinical SMEI for mutations in the neuronal voltagegated sodium channel a-subunit gene SCN1A and identified a mutation in each patient (four frameshift, one nonsense, one splice-donor, one missense). These patients did not have a family history of seizures, and all of the mutations were de novo mutations. Since then it has become clear that SMEI, although most often sporadic, can be seen within GEFSþ families and depicts the most devastating clinical form of the GEFSþ spectrum (77–80). Multiple SCN1A mutations as well as a GABRG2 mutation (5q31.1-q33.1) have been reported in patients with SMEI (81). An SCN2A mutation has also been described in a patient with an atypical SMEI phenotype (82). Functional studies of the mutated channels have shown various types of dysfunctional channels with some forms leading to complete loss of channel function (82,83). In all types the end result is a state of hyperexcitability and epilepsy.
Copyright 2006 by Taylor & Francis Group, LLC
440
Sigurdardottir and Poduri
Autosomal Dominant Nocturnal Frontal Lobe Epilepsy The last channelopathy-related epilepsy disorder that we will cover in detail is autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). In this syndrome, patients experience brief nocturnal motor seizures with hyperkinetic or tonic manifestations. Seizure onset is in childhood, and psychomotor development is usually normal (84). Milder cases are often undiagnosed or misdiagnosed as nightmares or other sleep disorders, whereas patients with more severely affected family members with frequent nocturnal seizures are more readily identified. ADNFLE was first described in 1994 in five families, the largest of which mapped to chromosome 20q13.2 (85–87). Further studies of this family led to the identification of a mutation in the neuronal nicotinic acetylcholine receptor a4 subunit (CHRNA4) gene in affected family members (88). Genetic heterogeneity has been demonstrated by Phillips et al. (89), who established linkage to chromosome 15q24 in a separate family. This region is close to a cluster of genes coding for acetylcholine receptor subunits (CHRNA3/ CHRNA5/CHRNB4), but the exact mutation has not been identified. Other families linked to chromosome 1q21 were found to have CHRNB2 (b2) acetylcholine receptor subunit mutations (90–92). Another report describing patients with the classical ADNFLE phenotype excluded linkage to any of the known neuronal acetylcholine receptor subunit genes (93). The CHRNA4 (a4) and CHRNB2 (b2) subunits assemble to form the active receptor (a4b2) (94). Therefore, it is not surprising that similar phenotypes are seen with mutations in either one (95). There is some evidence that a gain of function in mutant (a4b2) receptors might be at the root of the neuronal dysfunction causing epileptic seizures (96). A single case study reported a decrease in the seizure frequency of an ADNFLE patient during use of a transdermal nicotine patch (97). In time, the mechanisms of the acetylcholine receptor subunits and their role in the development of epilepsy should become clearer. MYOCLONIC EPILEPSIES Myoclonic epilepsy is a key finding in several hereditary syndromes. Some of these have been described in one or a few families, and the gene locus or product has not been identified. Other syndromes have been well characterized clinically, and more recent advances in molecular genetics have confirmed their genetic basis. We will review both the malignant progressive myoclonic epilepsies as well as the benign myoclonic epilepsy syndromes. SMEI is discussed above in the section covering channelopathies. Progressive Myoclonic Epilepsy The constellation of myoclonus, epilepsy, ataxia, and cognitive deterioration forms the typical phenotype of progressive myoclonic epilepsy (PME).
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
441
There are six main conditions that fall into this category; they are listed in Table 5. Not all are associated with dementia, but typically PME represents a progressive encephalopathy with intractable epilepsy and myoclonus. Some of the individual diseases discussed below have typical features that may distinguish them from the others. The importance of refining a diagnosis to specific clinical entity, and when possible a specific genetic diagnosis, lies in the need for establishing a prognosis and for genetic counseling for families of affected patients. Most of the PMEs are inherited in an AR fashion. Exceptions include dentatorubral pallidoluysian atrophy (DRPLA), which has AD inheritance, and the mitochondrially inherited myoclonic epilepsy with ragged red fibers (MERRF). Unverricht–Lundborg Disease Familial myoclonus with progressive mental and motor decline was first described by Unverricht and Lundborg in the late 1800s (98,99). This AR disorder, also called Baltic myoclonus, presents with convulsions between 6 and 13 years of age. Asynchronous myoclonus, predominantly in the proximal muscles of the extremities, begins 1–5 years later (100). The stimulussensitive myoclonic jerks are mild at first but become so violent late in the clinical course that a patient can be thrown to the floor. Mental deterioration is usually present but is not a prominent finding, while emotional lability is a typical feature. Psychotic symptoms are rare. Signs of cerebellar ataxia are seen in later stages. Antiepileptic therapy and better supportive therapy in recent years have led to a marked improvement in survival, but there is no cure. Unverricht–Lundborg disease has been diagnosed worldwide, but its prevalence is highest in Finland (1:20,000) where approximately 100 cases had been identified by 1980, half of all known cases in the world at that time (101). Areas of high incidence also include Northern Africa, Southern France, and in the Eastern Mediterranean region (102–104). EEG findings include slowing of the posterior background rhythm, episodic 4–6 Hz bilateral sharp waves, and polyspikes with myoclonus activated by photic stimulation (105). Treatment with N-acetylcysteine or levetiracetam decreases seizure frequency but does not have any effect on the ataxia or myoclonus (106,107). Valproic acid has also been found to be beneficial, while phenytoin has a detrimental effect on seizures and myoclonus (108). Lehesjoki et al. (109) mapped Unverricht–Lundborg disease to chromosome 21q22.3. The same group sequenced the cystatin B gene (CSTB) from affected individuals and identified two different mutations in the gene (108). Two groups reported a 12 base pair unstable repeat expansion of the 50 flanking region CSTB in affected individuals; this has since been found to be the most common mutation in Unverricht–Lundborg disease (110,111). Two to three repeats are considered normal, up to 17 repeats are considered a premutation state, and clinical signs are seen in individuals with 30–80
Copyright 2006 by Taylor & Francis Group, LLC
Table 5 Myoclonic Epilepsies with Established Genetic Basis
A. Progressive myoclonic epilepsies Unverricht–Lundborg disease Lafora body disease Sialidosis types I and II Neuronal ceroid lipofuscinosis Infantile (Santavuori–Haltia) Late infantile (Jansky–Bielschowsky) Late infantile (Finnish) Late infantile (Portuguese, Costa Rican) Late infantile (Turkish) Childhood Northern epilepsy variant Juvenile (Spielmeyer–Vogt) Adult (Kufs) Dentatorubral pallidoluysian atrophy (DRPLA) Myoclonic epilepsy with ragged red fibers (MERRF)
Inheritance
Gene
Protein
Chromosomal
AR AR AR AR
CSTB EPM2A EPM2B NEU1
Cystatin B Laforin Malin Neuraminidase
21q22.3 6q23-q25 6p22 6p21.3
AR AR AR AR AR AR AR AR, AD AD, CAG repeat Mitochondrial
CLN1 CLN2 CLN5 CLN6 CLN7 CLN8 CLN3 CLN4 DRPLA MTTK
PPT TPP-I – – – – Battenin PPT (minority) Atrophin-1 Mitochondrial proteins
1p32 11p15.5 13q21.1-q32 15q21-q23 8pter-p22 8pter-p22 16p12.1 1p32 (minority) 12p13.31 Mitochondrial loci
B. Benign myoclonic epilepsies Autosomal dominant cortical myoclonus and epilepsy (ADCME) Benign adult familial myoclonic epilepsy (BAFME) Familial idiopathic myoclonic epilepsy of infancy A dash (–) indicates that the information is not established.
Copyright 2006 by Taylor & Francis Group, LLC
AD
–
–
2p11.1-2q12.2
AD
–
–
AR
–
–
2p11.1-2q12.2 8q23.3-q24.11 16p13
Sigurdardottir and Poduri
MTTL1 MTTH MTTS1
442
Epilepsy syndrome
Inherited Epilepsies
443
repeats (112). Among those with overt clinical manifestations, no correlation has been found between number of repeats and disease severity or age of onset. The repeat expansions of most other repeat expansion diseases lie within the coding regions of the involved genes (113). In the case of CSTB, the repeat expansion is outside the coding region but still results in a marked decrease in CSTB expression (112). CSTB repeat expansion has been shown to lead to apoptosis and decreased neuronal survival, but how that relates to epilepsy remains to be established (112,114). Lafora Body Disease Lafora body disease, or myoclonic epilepsy of Lafora, is an AR disorder that usually presents around 15 years of age with generalized tonic–clonic seizures and/or myoclonus. Rapid and severe mental deterioration ensues, often with psychotic features (115,116). No treatment is available, and survival is usually less than 10 years after onset. Histologic studies of multiple tissues, including brain, muscle, liver, and heart, reveal intracellular polyglucosan inclusions, called Lafora bodies, which play a key role in the diagnosis of this devastating disorder (115,117). Lafora bodies are found in myoepithelial cells surrounding axillary apocrine glands; outside the axilla, they are found in the cells composing the ducts of the eccrine glands (118). Andrade et al. (118) found that all patients with Lafora body disease (with EPM2A or NHLRC1 mutations) exhibit Lafora bodies in both eccrine and apocrine glands. A patient later found to have genetically proven Unverricht–Lundborg disease was erroneously diagnosed with Lafora disease due to a ‘‘false’’ positive axillary (apocrine) biopsy while an exocrine biopsy was negative. Andrade et al. favor biopsy of skin outside the axilla for the diagnosis of Lafora body disease. In 1992, Lehesjoki et al. (119) excluded linkage to chromosome 21q22.3, the locus for CSTB, in three families with Lafora body disease. A few years later, nine families with Lafora body disease were mapped to chromosome 6q23-q25 (120). Since then, mutations in a gene encoding the laforin protein, also known as EPM2A, have been found in patients with Lafora body disease (121). Genetic heterogeneity was suspected early on since at least 20% of affected patients did not map to the chromosome 6q23-q25 locus (122). Chan et al. (123,124) linked four families with Lafora body disease to chromosome 6p22 in 2003 and described mutations in the NHLRC1 gene in 26 families with clinical Lafora body disease. This second involved gene is also known as EPM2B and encodes the protein malin. The role of laforin and malin in the pathophysiology of Lafora body disease is not yet understood. Cherry-Red Spot Myoclonus Syndrome Cherry-red spot myoclonus syndrome, or sialidosis type I, is an AR disorder that typically presents in adolescence with severe myoclonus and tonic–clonic seizures. This is followed by progressive visual loss, macular cherry-red spots,
Copyright 2006 by Taylor & Francis Group, LLC
444
Sigurdardottir and Poduri
and ataxia. Dementia does not usually occur. The characteristic macular cherry-red spot is seen on fundoscopic examinations and is useful for diagnostic purposes. Cherry-red spot myoclonus (sialidosis type I) is the milder form, while sialidosis type II has an earlier onset and significant dysmorphic features, leading to earlier diagnosis (125). Sialidoses are caused by a deficiency of the enzyme neuraminidase and are characterized by the progressive lysosomal storage of sialidated glycopeptides and oligosaccharides (126). Swallow et al. (127) first reported a neuraminidase deficiency in cultured fibroblasts from two adolescent brothers with progressive visual loss and myoclonus. Mutations in the neuraminidase gene were found in one patient with sialidosis type I and two patients with sialidosis type II, suggesting the two forms are allelic disorders (128). There is a close correlation between the residual activity of the mutant enzymes and the clinical severity of disease (type I vs. type II phenotypes) (129). No known curative therapy is available for these disorders, although bone marrow transplantation might be a future alternative (130). 5-Hydroxytryptophan has been shown to decrease the myoclonus in at least one patient with cherry-red spot myoclonus syndrome (131). Neuronal Ceroid Lipofuscinoses The neuronal ceroid lipofuscinoses (NCLs) are a group of diseases characterized by dementia, seizures, progressive visual failure, and intralysosomal accumulations of lipopigments in granular, curvilinear, or fingerprint patterns (132–136). These disorders include infantile Santavuori–Haltia disease (CLN1), late infantile Jansky–Bielschowsky disease (CLN2), late infantile form (CLN5, CLN6, CLN8), juvenile Spielmeyer–Vogt disease or Batten disease (CLN3), and adult-onset Kufs disease (CLN4). There are also approximately a dozen atypical variants. What follows is an overview of each disease and its genetic abnormality. Infantile NCL The infantile form of NCL is Santavuori–Haltia disease (CLN1), first described by Santavuori in 1973 (133). Onset is most often in the first year of life, ranging between 8 and 18 months, with rapid psychomotor deterioration, blindness by age two years, ataxia, and muscular hypotonia. Microcephaly and myoclonic jerks are also features while convulsions are rare (137). The unique clinical picture of these patients supported this being a separate entity from other NCLs, and in the early 1980s Baumann and Markesbery (138) found unique inclusions in circulating lymphocytes and the central nervous system in patients with presumed Santavuori–Haltia disease. Jarvela et al. (139) studied 15 Finnish families with Santavuori–Haltia disease and excluded involvement of the CLN3 gene in these families. They went on to map these families to chromosome 1p32. Mutations in the palmitoyl-protein thioesterase (PPT) gene have since been identified, and PPT activity was found to be undetectable in
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
445
brain tissue from two Finnish individuals with Santavuori–Haltia disease (140). A relatively simple enzyme assay is available for both postnatal and prenatal diagnosis (141). There is a report describing patients with an adult-onset NCL with a PPT gene mutation, but this represents an exception (142). Late infantile NCL Jansky–Bielschowsky disease (CLN2), the classical late infantile form of neuronal ceroid lipofuscinosis typically presents between the ages of two and four years with seizures, myoclonus, mental retardation, and ataxia. The condition was first described in the literature in 1926 (132). EEG findings are characterized by slow posterior background activity and pseudoperiodic high-voltage slow SW complexes, mostly in the posterior regions (143). In one study, magnetic resonance imaging (MRI) abnormalities included cerebral atrophy and hyperintensity of the periventricular white matter on T2-weighted images; magnetic resonance spectroscopy revealed a decrease in NAA, increases in myo-inositol and glutamine/glutamate, and undetectable lactate (144). Postmortem examinations have shown decreased brain weight, evidence of neuronal loss, and intralysosomal inclusions with a curvilinear pattern (145). Sleat et al. (146) identified a single lysosomal protein absent in patients with late infantile NCL, and the gene encoding this protein was mapped to chromosome 11p15.5 (147). The involved protein is tripeptidyl amino peptidase-I (TPP-I), a lysosomal peptidase (148). Prenatal and postnatal testing is available (149,150). A majority of late infantile NCL patients are homozygous or compound heterozygous for CLN2 mutations, resulting in complete loss of enzymatic activity (151). As with the other NCLs, there is no treatment and the course is steadily progressive. Other late infantile variants of NCL The other late infantile forms of NCL have a clinical picture of late infantile NCL but gene defects other than CLN2 mutations. CLN5 is a Finnish variant characterized by a slightly later onset than Jansky–Bielschowsky disease, with typical onset between four and seven years. The disease progresses more slowly in individuals with CLN5 mutations, and survival is prolonged. This disease has been mapped to chromosome 13q21.1-q32 (152). CLN6 is a subtype of late infantile NCL that has been mapped to 15q21-q23 (153) and observed in Portuguese and Costa Rican kindreds. CLN7 is a late infantile Turkish variant NCL that has a slightly later onset than Jansky–Bielschowsky disease at approximately five years of age; it has been mapped to chromosome 8pter-p22. It is thought to be allelic to Northern Epilepsy, a childhood onset NCL found in Finland (154). Visual loss is not a prominent feature of Northern Epilepsy, there is no myoclonus, and the clinical progression is slower than that of the allelic Turkish variant NCL (155).
Copyright 2006 by Taylor & Francis Group, LLC
446
Sigurdardottir and Poduri
Juvenile NCL Juvenile NCL (Spielmeyer–Vogt disease or Batten disease) is among the most common neurodegenerative diseases of childhood with an incidence of 1:21,000 (156). The onset of juvenile NCL is around 5–10 years of age with rapid deterioration of vision and a slower but progressive deterioration of intellect. Seizures and psychotic behavior are seen in later stages. The fundi show pigmentary degeneration. The pathologic features are severe widespread neuronal degeneration resulting in retinal atrophy, massive loss of brain substance, vacuolated lymphocytes, and curvilinear bodies on electronic microscopy (157,158). CLN3, the mutated gene in juvenile NCL, was mapped to chromosome 16 in 1990 and to chromosome 16p12.1 in 1994 (159,160). Most patients carry a 1.02 kb deletion removing nucleotides 461–677 from the coding region of the responsible protein, but various other mutations (missense, nonsense, splice site and intronic mutations, as well as small deletions and insertions) have been identified (161). There is ongoing investigation regarding the function of this protein and the predilection for this disease to affect the central nervous system. No treatment is known, and patients progress often rapidly to a vegetative state and death. Adult-onset NCL Adult-onset NCL (Kufs disease) has clinical onset at approximately 30 years (162). Berkovic et al. (163) have delineated two clinical phenotypes of Kufs disease. Type A begins with PME, which is followed by dementia and ataxia. Type B is characterized by dementia with cerebellar and/or extrapyramidal motor symptoms. Neither type is associated with retinal degeneration or blindness. MRI typically reveals cerebral and cerebellar atrophy within six years of disease onset. All patients showed fingerprint profiles in electron microscopy of skin cells. A few patients have a PPT gene mutation like that seen in Santavuori–Haltia disease (164), but a majority of patients lack that mutation. The gene or genes responsible for the majority of Kufs disease are unknown at this time. Dentatorubral Pallidoluysian Atrophy Dentatorubral pallidoluysian atrophy (DRPLA) is an AD disorder due to a CAG trinucleotide repeat expansion in the DRPLA gene (chromosome 12p13.31), which encodes atrophin 1 (165). The disorder can present in a variety of forms at a variety of ages, but one of the more common is an adolescent presentation with myoclonic epilepsy followed by dementia, ataxia, and choreoathetosis (166). The major neuropathologic finding is degeneration of the dentatorubral and pallidoluysian systems. DRPLA is relatively common in Japan, where three clinical forms have been classified: an ataxic-choreoathetoid form, a pseudo-Huntington form, and a myoclonic
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
447
epilepsy form (167). The size of the CAG repeat expansion correlates with the age of onset (168). The normal CAG repeat size is 7–23, and it is expanded to more than 49 repeats in clinically affected patients. Expansion is usually (although not invariably) associated with paternal transmission (165). Treatment is supportive, and survival is 20 to 40 years. Myoclonic Epilepsy with Ragged-Red Fibers Myoclonic epilepsy with ragged-red fibers (MERRF) is a well-known mitochondrial disorder, the phenotype of which includes myoclonic seizures, generalized tonic–clonic seizures, and a paroxysmal hearing disturbance (169). Mental deterioration, muscle atrophy, weakness, and truncal ataxia are also seen. Lactate levels in both blood and cerebrospinal fluid are elevated, and neuroimaging shows cerebral atrophy and bilateral calcification of the basal ganglia. Muscle biopsies show ragged-red fibers. Inheritance follows a mitochondrial pattern, from mother to offspring, with considerable variability in phenotypic severity. MERRF is associated with mutations in one of at least four known mitochondrial genes (MTTK, MTTL1, MTTH, MTTS1). An in-depth overview of mitochondrial disorders can be found in Chapter 13 (Mitochondrial Disorders). Benign Myoclonic Epilepsies There are at least two familial myoclonic epilepsy syndromes with relatively benign course and an established genetic basis, listed in Table 5. Benign Adult Familial Myoclonic Epilepsy Benign adult familial myoclonic epilepsy (BAFME) and familial adult myoclonic epilepsy (FAME) refer to the same condition, characterized by distal myoclonus (also referred to as cortical tremor), generalized myoclonus, infrequent generalized tonic–clonic seizures, and preserved cognition. Characteristic electrophysiological findings included generalized polyspike-wave discharges and activation with photic stimulation on EEG and abnormally large cortical potentials on somato-sensory evoked potentials (SSEPs) (170). Two groups of Japanese families were studied, with age of onset ranging from 13 to 18 years in one study (171) and 18 to 45 years in another (170). An associated genetic locus was identified in 1999 at chromosome 8q23.3-q24.11 in these same families (170,171). Genetic heterogeneity was established for this condition when analysis of a European pedigree with a very similar phenotype demonstrated linkage at chromosome 2p11.1-2q12.2 (172). Autosomal Dominant Cortical Myoclonus and Epilepsy Guerrini et al. (173) described a family with a similar but clinically distinct syndrome called autosomal dominant cortical myoclonus and epilepsy (ADCME). The syndrome is defined by distal myoclonus and generalized
Copyright 2006 by Taylor & Francis Group, LLC
448
Sigurdardottir and Poduri
tonic–clonic seizures but may also include complex partial seizures, intractable epilepsy, and mild mental retardation in some individuals. In addition to generalized EEG abnormalities similar to those seen in patients with BAFME, some patients had focal abnormalities in the frontotemporal regions. ADCME maps to chromosome 2p11.1-2q12.2 (173), making the disorder allelic to BAFME in the European kindred.
GENERALIZED EPILEPSY SYNDROMES Most of the age-dependent idiopathic generalized epilepsy syndromes, although known to have a genetic predisposition, do not follow true Mendelian inheritance patterns. We will review the known genetic contribution to three common generalized epilepsy syndromes. Table 6 lists the known chromosomal locations and genes associated with these conditions, but it is important to remember that these abnormalities have been found in only a minority of cases with these clinical conditions and do not fully explain the genetic basis of the generalized epilepsies. Childhood Absence Epilepsy CAE is a well-known age-dependent epilepsy syndrome, presenting with frequent brief absence seizures between 3 and 12 years of age. The EEG
Table 6 Generalized Epilepsy Syndromes with Associated Genetic Abnormalities Gene
Protein
Chromosomal locus
Complex
– GABRG2 CLCN2 CLCN2
– GABA-A-R CIC-2 CIC-2
8q24 5q31.1 3q26-qter 3q26
Complex
CACNB4
VGCC
2q22-q23
CLCN2 GABRAl EFHCl CHRNA7
CIC-2 GABA-A-R – nAch-R
3q26 5q34 6p12-11(EJMl) 15q14
Epilepsy syndrome
Inheritance
Childhood absence epilepsy CAE1 CAE2 CAE3 Juvenile absence epilepsy (JAE) Juvenile myoclonic epilepsy (JME)
Complex
A dash (–) indicates that the information is not established. Abbreviations: CIC-2, voltage-gated chloride channel; GABA-A-R, GABA-A receptor; nAch-R, nicotinic acetylcholine receptor; VGCC, voltage-gated calcium channel.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
449
shows 3 Hz generalized SW discharges correlating to patients’ clinical events. These children tend to respond well to medication, and seizures typically remit by late adolescence. Generalized tonic-clonic seizures may occur (174). CAE usually occurs sporadically, but familial forms are seen. One form of familial CAE, designated ECA1, has been linked to chromosome 8q24, but the gene has not been identified (175,176). Another familial form of CAE, with or without febrile seizures, ECA2, is caused by mutations in the GABRG2 gene on 5q31.1 (177). A third form, ECA3, has been described in a family where affected individuals have various seizure phenotypes including absence seizures in childhood. In this family, a mutation in the CLCN2 gene on 3q26-qter has been identified (178).
Juvenile Absence Epilepsy Juvenile absence epilepsy (JAE) is another well-known age-dependent epilepsy syndrome that manifests as absence seizures around 10–12 years of age. The frequency of absence seizures is lower than in CAE, while the frequency of generalized tonic–clonic seizures and the probability of ongoing epilepsy into adulthood are considerably higher (179). While most cases of JAE are sporadic, families with the classic JAE phenotype as well as a mixed JAE/myoclonic epilepsy picture have been described. Members of one JAE pedigree have been found to have a CLCN2 gene mutation (178,180), while in others the loci involved have not been identified.
Juvenile Myoclonic Epilepsy Juvenile myoclonic epilepsy (JME) is a genetically heterogeneous disorder. Forty to 50% of patients with JME have a family history of epilepsy (181). JME usually presents in adolescence with myoclonic jerks as well as myoclonic seizures upon awakening. Generalized tonic–clonic seizures are seen in up to 90% of patients with JME. This syndrome is benign with respect to its excellent response to valproic acid, but relapses are common after drug tapering and lifelong antiepileptic medication is usually required. The characteristic interictal EEG shows 4–6 Hz bihemispheric synchronous polyspike and wave discharges (182). The genetics of JME are complex, and most families do not follow a strict Mendelian inheritance pattern. Early reports believed it to be an AR disorder, while recent evidence suggests an AD pattern with low penetrance (183,184). Numerous single case or family studies have led to the identification of mutations in various genes, none of which make the major etiologic contribution to JME. These include mutations in an a1 subunit GABA-A receptor gene (GABRA1), a VGCC b4 subunit gene (CACNB4), and a chloride channel-2 gene (CLCN2) (178,185,186).
Copyright 2006 by Taylor & Francis Group, LLC
450
Sigurdardottir and Poduri
LOCALIZATION-RELATED EPILEPSY SYNDROMES Localization-related epilepsy, also called partial epilepsy, occurs in patients whose seizures are thought to arise in a focal region of cortex. ADNFLE is one such condition, and it is discussed in the section on channelopathies. Two other examples of localization-related epilepsy with known genetic associations are discussed below. A brief summary of these conditions is found in Table 7; we expect this list to expand in the coming years. Benign Epilepsy with Centro-Temporal Spikes Linkage to chromosome 15q14 has been established not only for JME (187) and other types of idiopathic generalized epilepsy (188), but also for the characteristic EEG trait of benign epilepsy with centro-temporal spikes (BECTS), also known as benign rolandic epilepsy (BRE) (189). The inheritance of this EEG pattern is reported to be AD with age-related penetrance (190). Classical BECTS presents between 2 and 13 years of age with simple partial seizures, including hemifacial motor movements, oropharyngeal gurgling or hypersalivation with speech arrest, and sensory and motor phenomena in the extremities. These progress occasionally to generalized tonic–clonic seizures (191). Most seizures are nocturnal. Children with BECTS who require medication—for daytime or recurrent generalized seizures—respond well to carbamazepine. The condition resolves by the mid- to late-teens. There is a unique subset of BECTS with speech dyspraxia and a more definitive AD pattern of inheritance, for which a locus has not yet been established (192). In another distinct syndrome, rolandic epilepsy is seen with paroxysmal exercise-induced dystonia and writer’s cramp; this syndrome maps to the centromeric region of chromosome 16, 16p12-11.2 (193). Overall, however, the inheritance of BECTS—as for the majority of CAE, JAE, and JME—is likely to be multifactorial (194). Autosomal Dominant Lateral Temporal Lobe Epilepsy Familial temporal lobe epilepsy was first reported in 1995 (195). In the patients described, disease onset was in childhood or early adolescence, and the condition was characterized by rare seizures, prominent auditory symptoms thought to be simple partial seizures, and normal interictal EEGs. Linkage analysis in this family showed strong evidence for localization to chromosome 10q22-q24 (195). The term autosomal dominant lateral temporal lobe epilepsy (ADLTE) has been applied to this disorder. Additional families were later found to map to the same region, and the putative gene has been identified as the LGI (leucine-rich glioma inactivated) gene (196–198). The specific manner by which these mutations lead to localization-related epilepsy is not yet understood.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
Table 7 Localization-Related Epilepsy Syndromes with Established Genetic Basis Epilepsy syndrome Autosomal dominant lateral temporal lobe epilepsy (ADLTE) Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) Benign epilepsy with centro-temporal spikes with speech dyspraxia Familial partial epilepsy with variable foci (FPEVF) Rolandic epilepsy with paroxysmal exerciseinduced dystonia and writer’s cramp Partial epilepsy with auditory features
Inheritance
Gene
Protein
Chromosomal locus
AD
LGI
–
10q22-q24
AD
CHRNA4
nAch-R
20q13.2
AD
–
–
–
AD
–
–
22q12
AR
–
–
16p12-11.2
AD
–
–
10q
A dash (–) indicates that the information is not established. Abbreviation: nAch-R, nicotinic acetylcholine receptor.
Copyright 2006 by Taylor & Francis Group, LLC
451
452
Sigurdardottir and Poduri
CONCLUSION Neurogenetics is shaping our approach to clinical diagnosis in epilepsy at a remarkable pace. The study of pedigrees with well-defined epilepsy syndromes has led to the identification of several involved genes. The fact that a number of the known gene products associated with epilepsy are ion channel proteins substantiates theories that abnormalities in channel function give rise to seizures. We can certainly look forward to an increasingly thorough understanding of the fundamental mechanisms that underlie human epilepsy. Further study will enrich and expand upon our current knowledge, and we will be better equipped as clinicians to diagnose and counsel patients with epilepsy. It would not be surprising to see future clinical epilepsy classification schemes reflect the genetic basis of many of the epilepsies. Ultimately, a more detailed molecular understanding of this complex set of conditions should enhance our ability to develop targeted treatment strategies for individual types of epilepsy. REFERENCES 1. Hauser WA, Hesdorrfer DH. Epilepsy: Frequency, Causes and Consequences. New York: Demos Press, 1990. 2. Lennox WG. J Am Med Assoc 1951; 146:259. 3. Ottman R. Genetic epidemiology of epilepsy. Epidemiol Rev 1997; 19:120–128. 4. Lennox WG. Epilepsy and Related Disorders. Vol. 1 Boston: Little, Brown, 1960:532–574. 5. Newmark ME, Penry JK. Genetics of Epilepsy: A Review. New York: Raven Press, 1980. 6. Noebels JL, Sidman RL. Inherited epilepsy: Spike-wave and focal motor seizures in the mutant mouse tottering. Science 1979; 204:1334–1336. 7. Fletcher CF, Lutz CM, O’Sullivan TN, Shaughnessy JD, Hawkes R, Frankel WN, Copeland NG, Jenkins NA. Absence epilepsy in tottering mutant mice is associated with calcium channel defects. Cell 1996; 87:607–617. 8. Oda S. A new allele of the tottering locus, rolling mouse Nagoya, on chromosome No. 8 in the mouse. Jpn J Genet 1981; 56:295–299. 9. Zwingmann TA, Neumann PE, Noebels JL, Herrup K. Rocker is a new variant of the voltage-dependent calcium channel gene CACNAIA. J Neurosci 2001; 21(4):1169–1178. 10. Neufeld MY, Nisipeanu P, Chistik V, Korczyn AD. The electroencephalogram in acetazolamide-responsive periodic ataxia. Movement Disord 1996; 11:283–288. 11. Sigurdardottir LY, Dlugos DJ, Solomon D, Kim GW, Baloh RW, Jen J. A mutation in CACNA1A causing familial episodic ataxia and epilepsy. (In Progress). 12. Denier C, Ducros A, Vahedi K, Joutel A, Thierry P, Ritz A, Castelnovo G, Deonna T, Gerard P, Devoize JL, Gayou A, Perrouty B, Soisson T, Autret A, Warter JM, Vighetto A, VanBogaert P, Alamowitch S, Roullet E,
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
13.
14.
15.
16. 17.
18.
19.
20. 21. 22.
23. 24. 25.
26.
27.
453
Tournier-Lasserve E. High prevalence of CACNA1A truncations and broader clinical spectrum in episodic ataxia type 2. Neurology 1999; 52:1816–1822. Ophoff RA, Terwindt GM, et al. Familial hemiplegic migraine and episodic ataxia type 2 are caused by mutations in the Caþþ channel gene CACNL1A4. Cell 1996; 87:543–552. Guida S, Trettel F, Pagnutti S, Mantuano E, Tottene A, Veneziano L, Fellin T, Spadaro M, Stauderman K, Williams M, Volsen S, Ophoff R, Frants R, Jodice C, Frontali M, Pietrobon D. Complete loss of P/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2. Am J Hum Gen 2001; 68(3):759–764. Levitt P, Noebels JL. Mouse mutant tottering: Selective increase of locus ceruleus axons in a defined single-locus mutation. Proc Natl Acad Sci USA 1981; 78:4630–4634. Noebels JL. A single gene error of noradrenergic axon growth synchronizes central neurones. Nature 1984; 310:409–411. Qiao X, Noebels JL. Genetic and phenotypic heterogeneity of inherited spikewave epilepsy: two mutant gene loci with independent cerebral excitability defects. Brain Res 1991; 555:43–50. Lin FH, Cao Z, Hosford DA. Increased number of GABAB receptors in the lethargic (lh/lh) mouse model of absence epilepsy. Brain Res 1993; 608: 101–106. Hess EJ, Wilson MC. Tottering and leaner mutations perturb transient developmental expression of tyrosine hydroxylase in embryologically distinct Purkinje cells. Neuron 1991; 6(1):123–132. Rett A, Teubel R. Neugeborenenkraempfe im Rahmen einer epileptisch belasteten Familie Wien Klin Wschr 1964; 76:609–613. Bjerre I, Corelius E. Benign familial neonatal convulsions. Acta Paediatr Scand 1968; 57:557–561. Sigurdardottir LY, Singh N, Leppert M, Dlugos D, Ryan SR. P25: Benign familial neonatal convulsions: ictal EEG in a patient with a novel KCNQ2 mutation. 29th Annual Meeting of the Child Neurology Society, St. Louis, Missouri, October 25–28, 2000. Aso K, Watanabe K. Benign familial neonatal convulsions: generalized epilepsy. Pediatr Neurol 1992; 8(3):226–228. Bye AM. Neonate with benign familial neonatal convulsions: recorded generalized and focal seizures. Pediatr Neurol 1994; 10(2):164–165. Leppert M, Anderson VE, Quattlebaum T, Stauffer D, O’Connell P, Nakamura Y, Lalouel JM, White R. Benign familial neonatal convulsions linked to genetic markers on chromosome 20. Nature 1989; 337(6208):647–648. Malafosse A, Leboyer M, Dulac O, Navelet Y, Plouin P, Beck C, Laklou H, Mouchnino G, Grandscene P, Vallee L, Guilloud-Bataille M, Samolyk D, Baldy-Moulinier M, Feingold J, Mallet J. Confirmation of linkage of benign familial neonatal convulsions to D20S19 and D20S20. Hum Genet 1992; 89:54–58. Ryan SG, Wiznitzer M, Hollman CH, Torres MC, Szekeresova M, Schneider S. Benign familial neonatal convulsions: evidence for clinical and genetic heterogeneity. Ann Neurol 1991; 29:469–473.
Copyright 2006 by Taylor & Francis Group, LLC
454
Sigurdardottir and Poduri
28. Singh NA, Charlier C, Stauffer D, DuPont BR, Leach RJ, Melis R, Ronen GM, Bjerre I, Quattlebaum T, Murphy JV, McHarg ML, Gagnon D, Rosales TO, Peiffer A, Anderson VE, Leppert M. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat Genet 1998; 18(l):25–29. 29. Biervert C, Schroeder BC, Kubisch C, Berkovic SF, Propping P, Jentsch TJ, Steinlein OK. A potassium channel mutation in neonatal human epilepsy. Science 1998; 279(5349):403–406. 30. Charlier C, Singh NA, Ryan SG, Lewis TB, Reus BE, Leach RJ, Leppert M. A pore mutation in a novel KQT-like potassium channel gene in an idiopathic epilepsy family. Nat Genet 1998; 18:53–55. 31. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen IS, Dixon JE, McKinnon D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998; 282(5395):1890–1893. 32. Brown DA, Adams PR. Muscarinic suppression of a novel voltage-sensitive Kþ current in a vertebrate neurone. Nature 1980; 283(5748):673–676. 33. Schroeder BC, Kubisch C, Stein V, Jentsch TJ. Moderate loss of function of cyclic-AMP-modulated KCNQ2/KCNQ3 Kþ channels causes epilepsy. Nature 1998; 396(6712):687–690. 34. Concolino D, Lembo MA, Rossi E, Giglio S, Coppola G, Miraglia Del Gı´udice E, Strisciuglio P. Familial pericentric inversion of chromosome 5 in a family with benign neonatal convulsions. J Med Genet 2002; 39(3):214–216. 35. Schiffmann R, Shapira Y, Ryan SG. An autosomal recessive form of benign familial neonatal seizures. Clin Genet 1991; 40:467–470. 36. Vigevano F, Fusco L, Di Capua M, Ricci S, Sebastianelli R, Lucchini P. Benign infantile familial convulsions. Eur J Pediatr 1992; 151:608–612. 37. Lee WL, Low PS, Rajan U. Benign familial infantile epilepsy. J Pediatr 1993; 123:588–590. 38. Echenne B, Humbertclaude V, Rivier F, Malafosse A, Cheminal R. Benign infantile epilepsy with autosomal dominant inheritance. Brain Dev 1994; 16:108–111. 39. Malafosse A, Beck C, Bellet H, Di Capua M, Dulac O, Echenne B, Fusco L, Lucchini P, Ricci S, Sebastianelli R, Feingold J, Baldy-Moulinier M, Vigevano F. Benign infantile familial convulsions are not an allelic form of the benign familial neonatal convulsions gene. Ann Neurol 1994; 35(4):479–478. 40. Guipponi M, Rivier F, Vigevano F, Beck C, Crespel A, Echenne B, Lucchini P, Sebastianelli R, Baldy-Moulinier M, Malafosse A. Linkage mapping of benign familial infantile convulsions (BFIC) to chromosome 19q. Hum Mol Genet 1997; 6:473–477. 41. Caraballo R, Pavek S, Lemainque A, Gastaldi M, Echenne B, Motte J, Genton P, Cersosimo R, Humbertclaude V, Fejerman N, Monaco AP, Lathrop MG, Rochette J, Szepetowski P. Linkage of benign familial infantile convulsions to chromosome 16p12–q12 suggests allelism to the infantile convulsions and choreoathetosis syndrome. Am J Hum Genet 2001; 68:788–794. 42. Weber YG, Berger A, Bebek N, Maier S, Karafyllakes S, Meyer N, Fukuyama Y, Halbach A, Hikel C, Kurlemann G, Neubauer B, Osawa M, Pu¨st B, Rating D, Saito K, Stephani U, Tauer U, Lehmann-Horn F, Jurkat-Rott K, Lerche H.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
43.
44.
45. 46. 47.
48. 49.
50.
51.
52.
53. 54. 55.
56.
455
Benign familial infantile convulsions: linkage to chromosome 16p12–q12 in 14 families. Epilepsia 2004; 45(6):601–609. Szepetowski P, Rochette J, Berquin P, Piussan C, Lathrop GM, Monaco AP. Familial infantile convulsions and paroxysmal choreoathetosis: a new neurological syndrome linked to the pericentromeric region of human chromosome 16. Am J Hum Genet 1997; 61:889–898. Swoboda KJ, Soong B-W, McKenna C, Brunt ERP, Litt M, Bale JF Jr, Ashizawa T, Bennett LB, Bowcock AM, Roach ES, Gerson D, Matsuura T, Heydemann PT, Nespeca MP, Jankovic J, Leppert M, Ptacek LJ. Paroxysmal kinesigenic dyskinesia and infantile convulsions: clinical and linkage studies. Neurology 2000; 55:224–230. Bennett LB, Roach ES, Bowcock AM. A locus for paroxysmal kinesigenic dyskinesia maps to human chromosome 16. Neurology 2000; 54:125–130. Kaplan RE, Lacey DJ. Benign familial neonatal-infantile seizures. Am J Med Genet 1983; 16:595–599. Shevell MI, Sinclair DB, Metrakos K. Benign familial neonatal seizures: clinical and electroencephalographic characteristics. Pediatr Neurol 1986; 2:272–275. Lewis TB, Shevell MI, Andermann E, Ryan SG, Leach RJ. Evidence of a third locus for benign familial convulsions. J Child Neurol 1996; 11:211–214. Malacarne M, Gennaro E, et al. Benign familial infantile convulsions: mapping of a novel locus on chromosome 2q24 and evidence for genetic heterogeneity. Am J Hum Genet 2001; 68:1521–1526. Heron SE, Crossland KM, Andermann E, Phillips HA, Hall AJ, Bleasel A, Shevell M, Mercho S, Seni MH, Guiot MC, Mulley JC, Berkovic SF, Scheffer IE. Sodium-channel defects in benign familial neonatal-infantile seizures. Lancet 2002; 360:851–852. Berkovic SF, Heron SE, Giordano L, Marini C, Guerrini R, Kaplan RE, Gambardella A, Steinlein OK, Grinton BE, Dean JT, Bordo L, Hodgson BL, Yamamoto T, Mulley JC, Zara F, Scheffer IE. Benign familial neonatalinfantile seizures: characterization of a new sodium channelopathy. Ann Neurol 2004; 55:550–557. Sugawara T, Tsurubuchi Y, Agarwala KL, Ito M, Fukuma G, MazakiMiyazaki E, Nagafuji H, Noda M, Imoto K, Wada K, Mitsudome A, Kaneko S, Montal M, Nagata K, Hirose S, Yamakawa K. A missense mutation of the Naþ channel alpha II subunit gene Na(v)1,2 in a patient with febrile and afebrile seizures causes channel dysfunction. PNAS 2001; 98(11):6384–6389. Hauser WA. The prevalence and incidence of convulsive disorders in children. Epilepsia 1994; 35(suppl 2):Sl–S6. Annegers JF, Hauser WA, Elveback LR, Kurland LT. The risk of epilepsy following febrile convulsions. Neurology 1979; 29(3):297–303. Kjeldsen MJ, Kyvik KO, Friis ML, Christensen K. Genetic and environmental factors in febrile seizures: a Danish population-based twin study. Epilepsy Res 2002; 51(l–2):167–177. Wallace RH, Berkovic SF, Howell RA, Sutherland GR, Mulley JC. Suggestion of a major gene for familial febrile convulsions mapping to 8q13–21. J Med Genet 1996; 33:308–312.
Copyright 2006 by Taylor & Francis Group, LLC
456
Sigurdardottir and Poduri
57. Johnson EW, Dubovsky J, Rich SS, O’Donovan CA, Orr HT, Anderson VE, Gil-Nagel A, Ahmann P, Dokken CG, Schneider DT, Weber JL. Evidence for a novel gene for familial febrile convulsions, FEB2, linked to chromosome 19p in an extended family from the Midwest. Hum Mol Genet 1998; 7:63–67. 58. Peiffer A, Thompson J, Charlier C, Otterud B, Varvil T, Pappas C, Barnitz C, Gruenthal K, Kuhn R, Leppert M. A locus for febrile seizures (FEB3) maps to chromosome 2q23–24. Ann Neurol 1999; 46:671–678. 59. Nakayama J, Hamano K, Iwasaki N, Nakahara S, Horigome Y, Saitoh H, Aoki T, Maki T, Kikuchi M, Migita T, Ohto T, Yokouchi Y, Tanaka R, Hasegawa M, Matsui A, Hamaguchi H, Arinami T. Significant evidence for linkage of febrile seizures to chromosome 5q14–q15. Hum Mol Genet 2000; 9:87–91. 60. Nakayama J, Fu Y-H, Clark AM, Nakahara S, Hamano K, Iwasaki N, Matsui A, Arinami T, Ptacek LJ. A nonsense mutation of the MASS1 gene in a family with febrile and afebrile seizures. Ann Neurol 2002; 52:654–657. 61. Scheffer IE, Berkovic SF. Generalized epilepsy with febrile seizures plus: a genetic disorder with heterogeneous clinical phenotypes. Brain 1997; 120: 479–490. 62. Singh R, Scheffer IE, Crossland K, Berkovic SF. Generalized epilepsy with febrile seizures plus: a common childhood-onset genetic epilepsy syndrome. Ann Neurol 1999; 45:75–81. 63. Wallace RH, Wang DW, Singh R, Scheffer IE, George AL Jr, Phillips HA, Saar K, Reis A, Johnson EW, Sutherland GR, Berkovic SF, Mulley JC. Febrile seizures and generalized epilepsy associated with a mutation in the Na(þ)channel beta-1 subunit gene SCN1B. Nat Genet 1998; 19:366–370. 64. Baulac S, Gourfinkel-An I, Picard F, Rosenberg-Bourgin M, Prud’homme JF, Baulac M, Brice A, LeGuern E. A second locus for familial generalized epilepsy with febrile seizures plus maps to chromosome 2q21–q33. Am J Hum Genet 1999; 65:1078–1085. 65. Moulard B, Guipponi M, Chaigne D, Mouthon D, Buresi C, Malafosse A. Identification of a new locus for generalized epilepsy with febrile seizures plus (GEFSþ) on chromosome 2q24–q33. Am J Hum Genet 1999; 65: 1396–1400. 66. Escayg A, MacDonald BT, Meisler MH, Baulac S, Huberfeld G, An-Gourfinkel I, Brice A, LeGuern E, Moulard B, Chaigne D, Buresi C, Malafosse A. Mutations of SCN1A, encoding a neuronal sodium channel, in two families with GEFSþ2. Nat Genet 2000; 24:343–345. 67. Baulac S, Huberfeld G, Gourfinkel-An I, Mitropoulou G, Beranger A, Prud’homme JF, Baulac M, Brice A, Bruzzone R, LeGuern E. First genetic evidence of GABA(A) receptor dysfunction in epilepsy: a mutation in the gamma-2subunit gene. Nat Genet 2001; 28:46–48. 68. Kohling R. Voltage-gated sodium channels in epilepsy. Epilepsia 2002; 43(11):1278–1295. 69. Feher O, Erdelyi L, Papp A. The effect of pentylenetetrazol on the metacerebral neuron of Helix pomatia. Gen Physiol Biophys 1988; 7(5):505–516.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
457
70. Kearney JA, Plummer NW, Smith MR, Kapur J, Cummins TR, Waxman SG, Goldin AL, Meisler MH. A gain-of-function mutation in the sodium channel gene Scn2a results in seizures and behavioral abnormalities. Neuroscience 2001; 102(2):307–317. 71. Spampanato J, Aradi I, Soltesz I, Goldin AL. Increased neuronal firing in computer simulations of sodium channel mutations that cause generalized epilepsy with febrile seizures plus. J Neurophysiol 2004; 91(5):2040–2050. 72. Dravet C. Les epilepsies graves de l’enfant. Vie Med 1978; 8:543–548. 73. Dravet C, Bureau M, Guerrini R, Giraud N, Roger J. Severe myoclonic epilepsy in infants. In: Roger J, Dravet C, Bureau M, Dreifuss FE, Perret A, Wolf P, eds. Epileptic Syndromes in Infancy, Childhood, and Adolescence. 2nd ed. London: John Libbey, 1992:75–88. 74. Fujiwara T, Nakamura H, Watanabe M, Yagi K, Seino M, Nakamura H. Clinicoelectrographic concordance between monozygotic twins with severe myoclonic epilepsy in infancy. Epilepsia 1990; 31:281–286. 75. Singh R, Andermann E, Whitehouse WPA, Harvey AS, Keene DL, Seni M-H, Crossland KM, Andermann F, Berkovic SF, Scheffer IE. Severe myoclonic epilepsy of infancy: F extended spectrum of GEFSþ? Epilepsia 2001; 42(7): 837–844. 76. Claes L, Del-Favero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001; 68:1327–1332. 77. Ohmori I, Ouchida M, Ohtsuka Y, Oka E, Shimizu, K. Significant correlation of the SCNlA mutations and severe myoclonic epilepsy in infancy. Biochem Biophys Res Commun 2002; 295:17–23. 78. Sugawara T, Mazaki-Miyazaki E, Fukushima K, Shimomura J, Fujiwara T, Hamano S, Inoue Y, Yamakawa K. Frequent mutations of SCNlA in severe myoclonic epilepsy in infancy. Neurology 2002; 58:1122–1124. 79. Nabbout R, Gennaro E, et al. Spectrum of SCNlA mutations in severe myoclonic epilepsy of infancy. Neurology 2003; 60:1961–1967. 80. Wallace RH, Hodgson BL, Grinton BE, Gardiner RM, Robinson R, RodriguezCasero V, Sadleir L, Morgan J, Harkin LA, Dibbens LM, Yamamoto T, Andermann E, Mulley JC, Berkovic SF, Scheffer IE. Sodium channel alpha 1-subunit mutations in severe myoclonic epilepsy of infancy and infantile spasms. Neurology 2003; 61(6):765–769. 81. Harkin LA, Bowser DN, Dibbens LM, Singh R, Phillips F, Wallace RH, Richards MC, Williams DA, Mulley JC, Berkovic SF, Scheffer IE, Petrou S. Truncation of the GABA(A)-receptor gamma-2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 2002; 70:530–536. 82. Kamiya K, Kaneda M, Sugawara T, Mazaki E, Okamura N, Montal M, Makita N, Tanaka M, Fukushima K, Fujiwara T, Inoue Y, Yamakawa K. A nonsense mutation of the sodium channel gene SCN2A in a patient with intractable epilepsy and mental decline. J Neurosci 2004; 24(11):2690–2698. 83. Lossin C, Rhodes TH, Desai RR, Vanoye CG, Wang D, Carniciu S, Devinsky O, George AL Jr. Epilepsy-associated dysfunction in the voltage-gated neuronal sodium channel SCN1A. J Neurosci 2003; 23(36):1289–1295.
Copyright 2006 by Taylor & Francis Group, LLC
458
Sigurdardottir and Poduri
84. Oldani A, Zucconi M, Asselta R, Modugno M, Bonati MT, Dalpra L, Malcovati M, Tenchini ML, Smirne S, Ferini-Strambi L. Autosomal dominant nocturnal frontal lobe epilepsy. A video-polysomnographic and genetic appraisal of 40 patients and delineation of the epileptic syndrome. Brain 1998; 121:205–223. 85. Scheffer IE, Hopkins IJ, Harvey AS, Berkovic SF. New autosomal-dominant partial epilepsy syndrome. Pediatr Neurol 1994; 11:95. 86. Scheffer IE, Bhatia KP, Lopes-Cendes I, Fish DR, Marsden CD, Andermann E, Andermann F, Desbiens R, Keene D, Cendes F, Manson JI, Constantinou JEC, Mclntosh A, Berkovic SF. Autosomal dominant nocturnal frontal epilepsy: a distinctive clinical disorder. Brain 1995; 118:61–73. 87. Phillips HA, Scheffer IE, Berkovic SF, Hollway GE, Sutherland GR, Mulley JC. Localization of a gene for autosomal dominant nocturnal frontal lobe epilepsy to chromosome 20q13.2. Nat Genet 1995; 10:117–118. 88. Steinlein OK, Mulley JC, Propping P, Wallace RH, Phillips HA, Sutherland GR, Scheffer IE, Berkovic SF. A missense mutation in the neuronal nicotinic acetylcholine receptor alpha-4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet 1995; 11:201–203. 89. Phillips HA, Scheffer IE, Crossland KM, Bhatia KP, Fish DR, Marsden CD, Howell SJL, Stephenson JBP, Tolmie J, Plazzi G, Eeg-Olofsson O, Singh R, Lopes-Cendes I, Andermarnn E, Andermann F, Berkovic SF, Mulley JC. Autosomal dominant nocturnal frontal-lobe epilepsy: genetic heterogeneity and evidence for a second locus at 15q24. Am J Hum Genet 1998; 63: 1108–1116. 90. Gambardella A, Annesi G, De Fusco M, Patrignani A, Aguglia U, Annesi F, Pasqua AA, Spadafora P, Oliveri RL, Valentino P, Zappia M, Ballabio A, Casari G, Quattrone A. A new locus for autosomal dominant nocturnal frontal lobe epilepsy maps to chromosome 1. Neurology 2000; 55:1467–1471. 91. De Fusco M, Becchetti A, Patrignani A, Annesi G, Gambardella A, Quattrone A, Ballabio A, Wanke E, Casari G. The nicotinic receptor beta-2 subunit is mutant in nocturnal frontal lobe epilepsy. Nat Genet 2000; 26:275–276. 92. Phillips HA, Favre I, Kirkpatrick M, Zuberi SM, Goudie D, Heron SE, Scheffer IE, Sutherland GR, Berkovic SF, Bertrand D, Mulley JC. CHRNB2 is the second acetylcholine receptor subunit associated with autosomal dominant nocturnal frontal lobe epilepsy. Am J Hum Genet 2001; 68:225–231. 93. Bonati MT, Combi R, Asselta R, Duga S, Malcovati M, Oldani A, Zucconi M, Ferini-Strambi L, Dalpra L, Tenchini ML. Exclusion of linkage of nine neuronal nicotinic acetylcholine receptor subunit genes expressed in brain in autosomal dominant nocturnal frontal lobe epilepsy in four unrelated families. J Neurol 2002; 249(8):967–974. 94. Elliott KJ, Ellis SB, Berckhan KJ, Urrutia A, Chavez-Noriega LE, Johnson EC, Velicelebi G, Harpold MM. Comparative structure of human neuronal alpha(2)–alpha(7) and beta(2)–beta(4) nicotinic acetylcholine receptor subunits and functional expression of the alpha(2), alpha(3), alpha(4), alpha(7), beta(2), and beta(4) subunits. J Mol Neurosci 1996; 7:217–228.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
459
95. McLellan A, Phillips HA, Rittey C, Kirkpatrick M, Mulley JC, Goudie D, Stephenson JB, Tolmie J, Scheffer IE, Berkovic SF, Zuberi SM. Phenotypic comparison of two Scottish families with mutations in different genes causing autosomal dominant nocturnal frontal lobe epilepsy. Epilepsia 2003; 44(4): 613–617. 96. Bertrand D, Picard F, Le Hellard S, Weiland S, Favre I, Phillips H, Bertrand S, Berkovic SF, Malafosse A, Mulley J. How mutations in the nAChRs can cause ADNFLE epilepsy. Epilepsia 2002; 43(S5):112–122. 97. Willoughby JO, Pope KJ, Eaton V. Nicotine as an antiepileptic agent in ADNFLE: an N-of-one study. Epilepsia 2003; 44(9):1238–1240. Erratum in Epilepsia 2003; 44(10):1363. 98. Unverricht H. Ueber familiaere Myoclonie. Dtsch Z Nervenheilk 1895; 7: 32–67. 99. Lundborg HB. Die Progressive Myoklonusepilepsie (Unverricht’s Myoklonie). Vol. 8 Uppsala: Almqvist and Wiksell, 1903:567–570. 100. Noad KB, Lance JW. Familial myoclonic epilepsy and its association with cerebellar disturbance. Brain 1960; 83:618–630. 101. Koskiniemi M, Donner M, Toivakka E, Norio R. Progressive myoclonus epilepsy (PME). In: Eriksson AW, Forsius HR, Nevanlinna HR, Workman PL, Norio RK, eds. Population Structure and Genetic Disorders. New York: Academic Press, 1980:669–672. 102. Genton P, Michelucci R, Tassinari CA, Roger J. The Ramsay Hunt syndrome revisited: Mediterranean myoclonus versus mitochondrial encephalomyopathy with ragged-red fibers and Baltic myoclonus. Acta Neurol Scand 1990; 81(1):8–15. 103. Labauge P, Ouazzani R, M’Rabet A, Grid D, Genton P, Dravet C, Chkili T, Beck C, Buresi C, Baldy-Moulinier M, Malafosse A. Allelic heterogeneity of Mediterranean myoclonus and the cystatin B gene. Ann Neurol 1997; 41(5):686–689. 104. Mazarib A, Xiong L, Neufeld MY, Birnbaum M, Korczyn AD, Pandolfo M, Berkovic SF. Unverricht–Lundborg disease in a five-generation Arab family: instability of dodecamer repeats. Neurology 2001; 57(6):1050–1054. 105. Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991; 8(3): 261–274. 106. Edwards MJ, Hargreaves IP, Heales SJ, Jones SJ, Ramachandran V, Bhatia KP, Sisodiya S. N-acetylcysteineUnverricht–Lundborg disease: variable response possible side effects. Neurology 2002; 59(9):1447–1449. 107. Kinrions P, Ibrahim N, Murphy K, Lehesjoki AE, Jarvela I, Delanty N. Efficacy of levetiracetam in a patient with Unverricht–Lundborg progressive myoclonic epilepsy. Neurology 2003; 60(8):1394–1395. 108. Pennacchio LA, Lehesjoki AE, Stone NE, Willour VL, Virtaneva K, Miao J, D’Amato E, Ramirez L, Faham M, Koskiniemi M, Warrington JA, Norio R, de la Chapelle A, Cox DR, Myers RM. Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1). Science 1996; 271: 1731–1734.
Copyright 2006 by Taylor & Francis Group, LLC
460
Sigurdardottir and Poduri
109. Lehesjoki AE, Koskiniemi M, Sistonen P, Miao J, Hastbacka J, Norio R, de la Chapelle A. Localization of a gene for progressive myoclonus epilepsy to chromosome 21q22. Proc Natl Acad Sci 1991; 88:3696–3699. 110. Virtaneva K, D’Amato E, Miao J, Koskiniemi M, Norio R, Avanzini G, Franceschetti S, Michelucci R, Tassinari CA, Omer S, Pennacchio LA, Myers RM, Dieguez-Lucena JL, Krahe R, de la Chapelle A, Lehesjoki AE. Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nat Genet 1997; 15:393–396. 111. Lafreniere RG, Rochefort DL, Chretien N, Rommens JM, Cochius JI, Kalviainen R, Nousiainen U, Patry G, Farrell K, Soderfeldt B, Federico A, Hale BR, Cossio OH, Sorensen T, Pouliot MA, Kmiec T, Uldall P, Janszky J, Pranzatelli MR, Andermann F, Andermann E, Rouleau GA. Unstable insertion of the 5-prime flanking region of the cystatin B gene is the most common mutation in progressive myoclonus epilepsy type 1, EPMI. Nat Genet 1997; 15:298–302. 112. Lalioti MD, Antonarakis SE, Scott HS. The epilepsy, the protease inhibitor and the dodecamer: progressive myoclonus epilepsy, cystatin b and a 12-mer repeat expansion. Cytogenet Genome Res 2003; 100(l–4):213–223. 113. Richards RI. Dynamic mutations: a decade of unstable expanded repeats in human genetic disease. Hum Mol Genet 2001; 10(20):2187–2194. 114. Lehesjoki AE. Molecular background of progressive myoclonus epilepsy. EMBO J 2003; 22(14):3473–3478. 115. Harriman DGF, Millar JHD. Progressive familial myoclonic epilepsy in 3 families: its clinical features and pathological basis. Brain 1955; 78: 325–349. 116. Janeway R, Ravens JR, Pearce LA, Odor DL, Suzuki K. Progressive myoclonus epilepsy with Lafora inclusion bodies. I. Clinical, genetic, histopathologic and biochemical aspects. Arch Neurol 1967; 16:565–582. 117. Yokoi S, Austin J, Witmer F, Sakai M. Studies in myoclonus epilepsy (Lafora body forms). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch Neurol 1968; 19:15–33. 118. Andrade DM, Ackerley CA, Minett TSC, Teive HAG, Bohlega S, Scherer SW, Minassian BA. Skin biopsy in Lafora disease: genotype–phenotype correlations and diagnostic pitfalls. Neurology 2003; 61:1611–1614. 119. Lehesjoki AE, Koskiniemi M, Pandolfo M, Antonelli A, Kyllerman M, Wahlstrom J, Nergardh A, Burmeister M, Sistonen P, Norio R, de la Chapelle A. Linkage studies in progressive myoclonus epilepsy: Unverricht– Lundborg and Lafora’s diseases. Neurology 1992; 42:1545–1550. 120. Serratosa JM, Delgado-Escueta AV, Posada I, Shih S, Drury I, Berciano J, Zabala JA, Antunez MC, Sparkes RS. The gene for progressive myoclonus epilepsy of the Lafora type maps to chromosome 6q. Hum Mol Genet 1995; 4:1657–1663. 121. Minassian BA, Lee JR, Herbrick JA, Huizenga J, Soder S, Mungall AJ, Dunham I, Gardner R, Fong CG, Carpenter S, Jardim L, Satishchandra P, Andermann E, Snead OC III, Lopes-Cendes I, Tsui LC, Delgado-Escueta AV, Rouleau GA, Scherer SW. Mutations in a gene encoding a novel protein
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
122.
123.
124.
125. 126.
127.
128.
129.
130.
131.
132.
133.
134.
461
tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet 1998; 20:171–174. Serratosa JM, Gomez-Garre P, Gallardo ME, Anta B, Beltran-Valero de Bernabe D, Lindhout D, Augustijn PB, Tassinari CA, Michelucci R, Malafosse A, Topcu M, Grid D, Dravet C, Berkovic SF, Rodriguez de Cordoba S. A novel protein tyrosine phosphatase gene is mutated in progressive myoclonus epilepsy of the Lafora type (EPM2). Hum Mol Genet 1999; 8:345–352. Chan EM, Bulman DE, Paterson AD, Turnbull J, Andermann E, Andermann F, Rouleau GA, Delgado-Escueta AV, Scherer SW, Minassian BA. Genetic mapping of a new Lafora progressive myoclonus epilepsy locus (EPM2B) on 6p22. J Med Genet 2003; 40:671–675. Chan EM, Young EJ, Ianzano L, Munteanu I, Zhao X, Christopoulos CC, Avanzini G, Elia M, Ackerley CA, Jovic NJ, Bohlega S, Andermann E, Rouleau GA, Delgado-Escueta AV, Minassian BA, Scherer SW. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet 2003; 35:125–127. Lowden JA, O’Brien JS. Sialidosis: a review of human neuraminidase deficiency. Am J Hum Genet 1979; 31:1–18. Spranger JW, Wiedemann HR, Tolksdorf M, Graucob E, Caesar R. Lipomucopolysaccharidose: eine neue Speicherkrankheit. Z Kinderheilk 1968; 103: 285–306. Swallow DM, Evans L, Stewart G, Thomas, PK, Abrams JD. Sialidosis type I: cherry red spot-myoclonus syndrome with sialidase deficiency and altered electrophoretic mobility of some enzymes known to be glycoproteins. II. Enzyme studies. Ann Hum Genet 1979; 43:27–35. Bonten E, van der Spoel A, Fornerod M, Grosveld G, d’Azzo A. Characterization of human lysosomal neuraminidase defines the molecular basis of the metabolic storage disorder sialidosis. Genes Dev 1996; 10:3156–3169. Bonten EJ, Arts WF, Beck M, Covanis A, Donati MA, Parini R, Zammarchi E, d’Azzo A. Novel mutations in lysosomal neuraminidase identify functional domains and determine clinical severity in sialidosis. Hum Mol Genet 2000; 9:2715–2725. Krivan G, Timar L, Goda V, Reti M, Remenyi P, Masszi T. Bone marrow transplantation in non-malignant disorders. Bone Marrow Transplant 1998; 22(suppl 4):S80–S83. Gascon G, Wallenberg B, Daif AK, Ozand P. Successful treatment of cherry red spot-myoclonus syndrome with 5-hydroxytryptophan. Ann Neurol 1988; 24(3):453–455. Hassin GB. Amaurotic family idiocy: late infantile type (Bielschowsky) with the clinical picture of decerebrate rigidity. Arch Neurol Psychiatr 1926; 16: 708–727. Santavuori P, Haltia M, Rapola J, Raitta C. Infantile type of so-called neuronal ceroid-Iipofuscinosis. Part I. A clinical study of 15 patients. J Neurol Sci 1973; 18:257–267. Sjogren T. Die juvenile amaurotische Idiotic Klinische und erblichkeitsmedizinische Untersuchungen. Hereditas 1931; 14:197–426.
Copyright 2006 by Taylor & Francis Group, LLC
462
Sigurdardottir and Poduri
135. Kufs H. Ueber eine Spatform der amaurotischen Idiotie und ihre heredofamiliaren Grundlagen. Z Ges Neurol Psychiatr 1925; 95:169–188. 136. Hagberg B, Sourander P, Svennerholm L. Late infantile progressive encephalopathy with disturbed poly-unsaturated fat metabolism. Acta Paediatr Scand 1968; 57:495–499. 137. Hagberg B, Haltia M, Sourander P, Svennerholm L, Eeg-Olofsson O. Polyunsaturated fatty acid lipidosis ceroid lipofuscinosis. I. Clinical and morphological aspects. Acta Paediatr 1974; 63:753–763. 138. Baumann RJ, Markesbery WR. Santavuori disease: diagnosis by leukocyte ultrastructure. Neurology 1982; 32:1277–1281. 139. Jarvela I, Schleutker J, Haataja L, Santavuori P, Puhakka L, Manninen T, Palotie A, Sandkuijl LA, Renlund M, White R, Aula P, Peltonen L. Infantile form of neuronal ceroid lipofuscinosis (CLN1) maps to the short arm of chromosome 1. Genomics 1991; 9:170–173. 140. Vesa J, Hellsten E, Verkruyse LA, Camp LA, Rapola J, Santavuori P, Hofmann SL, Peltonen L. Mutations in the palmitoyl protein thioesterase gene causing infantile neuronal ceroid lipofuscinosis. Nature 1995; 376: 584–588. 141. Voznyi YV, Keulemans JLM, Mancini GMS, Catsman-Berrevoets CE, Young E, Winchester B, Kleijer WJ, van Diggelen OP. A new simple enzyme assay for pre- and postnatal diagnosis of infantile neuronal ceroid lipofuscinosis (INCL) and its variants. J Med Genet 1999; 36:471–474. 142. van Diggelen OP, Thobois S, Tilikete C, Zabot MT, Keulemans JL, van Bunderen PA, Taschner PE, Losekoot M, Voznyi YV. Adult neuronal ceroid lipofuscinosis with palmitoyl-protein thioesterase deficiency: first adult-onset patients of a childhood disease. Ann Neurol 200; 50(2):269–272. 143. Veneselli E, Biancheri R, Buoni S, Fois A. Clinical and EEG findings in 18 cases of late infantile neuronal ceroid lipofuscinosis. Brain Dev 2001; 23(5): 306–311. 144. Seitz D, Grodd W, Schwab A, Seeger U, Klose U, Nagele T. MR imaging and localized proton MR spectroscopy in late infantile neuronal ceroid lipofuscinosis. Am J Neuroradiol 1998; 19(7):1373–1377. 145. Gonatas NK, Gambetti P, Baird H. A second type of late infantile amaurotic idiocy with multilamellar cytosomes. J Neuropathol Exp Neurol 1968; 27: 371–389. 146. Sleat DE, Donnelly RJ, Lackland H, Liu CG, Sohar I, Pullarkat RK, Lobel P. Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis. Science 1997; 277:1802–1805. 147. Sharp JD, Wheeler RB, Lake BD, Savukoski M, Jarvela IE, Peltonen L, Gardiner RM, Williams RE. Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21–23. Hum Mol Genet 1997; 6:591–595. 148. Goebel HH, Kominami E, Neuen-Jacob E, Wheeler RB. Morphological studies on CLN2. Eur J Paediatr Neurol 2001; 5(suppl A):203–207. 149. Sohar I, Sleat DE, Jadot M, Lobel P. Biochemical characterization of a lysosomal protease deficient in classical late infantile neuronal ceroid lipofuscinosis (LINCL) and development of an enzyme-based assay for diagnosis and
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
150.
151.
152.
153.
154.
155.
156. 157. 158. 159.
160.
161.
162. 163.
463
exclusion of LINCL in human specimens and animal models. J Neurochem 1999; 73:700–711. Berry-Kravis E, Sleat DE, Sohar I, Meyer P, Donnelly R, Lobel P. Prenatal testing for late infantile neuronal ceroid lipofuscinosis. Ann Neurol 2000; 47:254–257. Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, Kohlschutter A. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet 2002; 112:347–354. Savukoski M, Klockars T, Holmberg V, Santavuori P, Lander ES, Peltonen L. CLN5, a novel gene encoding a putative transmembrane protein mutated in Finnish variant late infantile neuronal ceroid lipofuscinosis. Nat Genet 1998; 19:286–288. Gao H, Boustany RMN, Espinola JA, Cotman SL, Srinidhi L, Antonellis KA, Gillis T, Qin X, Liu S, Donahue LR, Bronson RT, Faust JR, Stout D, Haines JL, Lerner TJ, MacDonald ME. Mutations in a novel CLN6-encoded transmembrane protein cause variant neuronal ceroid lipofuscinosis in man and mouse. Am J Hum Genet 2002; 70:324–335. Hirvasniemi A, Lang H, Lehesjoki AE, Leisti J. Northern epilepsy syndrome: an inherited childhood onset epilepsy with associated mental deterioration. J Med Genet 1994; 31:177–182. Ranta S, Topcu M, Tegelberg S, Tan H, Ustubutun A, Saatci I, Dufke A, Enders H, Pohl K, Alembik Y, Mitchell WA, Mole SE, Lehesjoki AE. Variant late infantile neuronal ceroid lipofuscinosis in a subset of Turkish patients is allelic to Northern epilepsy. Hum Mutat 2004; 23:300–305. Santavuori P, Lauronen L, Kirveskari E, Aberg L, Sainio K, Autti T. Neuronal ceroid lipofuscinoses in childhood. Neurol Sci 2000; 21(3 suppl):S35–S41. Goebel HH. The neuronal ceroid-lipofuscinoses. Semin Pediatr Neurol 1996; 3:270–278. Dolman CL, Chang E. Visceral lesions in amaurotic familial idiocy with curvilinear bodies. Arch Pathol 1972; 94:425–430. Lerner TJ, Boustany RMN, MacCormack K, Gleitsman J, Schlumpf K, Breakefield XO, Gusella JF, Haines JL. Linkage disequilibrium between the juvenile neuronal ceroid lipofuscinosis gene and marker loci on chromosome 16p12.1. Am J Hum Genet 1994; 54:88–94. Gardiner M, Sandford A, Deadman M, Poulton J, Cookson W, Reeders S, Jokiaho I, Peltonen L, Eiberg H, Julier C. Batten disease (Spielmeyer–Vogt disease, juvenile onset neuronal ceroid-lipofuscinosis) gene (CLN3) maps to human chromosome 16. Genomics 1990; 8:387–390. Munroe PB, Mitchison HM, O’Rawe AM, Anderson JW, Boustany RM, Lerner TJ, Taschner PEM, de Vos N, Breuning MH, Gardiner RM, Mole SE. Spectrum of mutations in the Batten disease gene, CLN3. Am J Hum Genet 1997; 61: 310–316. Zeman W, Hoffman J. Juvenile and late forms of amaurotic idiocy in one family. J Neurol Neurosurg Psychiatr 1962; 25:352–362. Berkovic SF, Carpenter S, Andermann F, Andermann E, Wolfe LS. Kufs’ disease: a critical reappraisal. Brain 1988; 111:27–62.
Copyright 2006 by Taylor & Francis Group, LLC
464
Sigurdardottir and Poduri
164. Zeman W, Hoffman J. Juvenile and late forms of amaurotic idiocy in one family. J Neurol Neurosurg Psychiatr 1962; 25:352–362. 165. Nagafuchi S, Yanagisawa H, Sato K, Shirayama T, Ohsaki E, Bundo M, Takeda T, Tadokoro K, Kondo I, Murayama N, Tanaka Y, Kikushima H, Umino K, Kurosawa H, Furukawa T, Nihei K, Inoue T, Sano A, Komure O, Takahashi M, Yoshizawa T, Kanazawa I, Yamada M. Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet 1994; 6:14–18. 166. Smith JK, Conda VE, Malamud N. Unusual form of cerebellar ataxia: combined dentato-rubral and pallido-Luysian degeneration. Neurology 1958; 8:205–209. 167. Hirayama K, Iizuka R, Maehara K, Watanabe T. Clinicopathological study of dentatorubro-pallidoluysian atrophy. Part 1. Its clinical form and analysis of symptomatology. Shinkei Kenkyu no Shinpo 1981; 25:725–736. 168. Koide R, Ikeuchi T, Onodera O, Tanaka H, Igarashi S, Endo K, Takahashi H, Kondo R, Ishikawa A, Hayashi T, Saito M, Tomoda A, Miike T, Naito H, Ikuta F, Tsuji S. Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet 1994; 6:9–13. 169. Fukuhara N, Tokiguchi S, Shirakawa K, Tsubaki T. Myoclonus epilepsy associated with ragged-red fibers (mitochondrial abnormalities): disease entity or a syndrome? Light- and electron-microscopic studies of two cases and a review of the literature. J Neurol Sci 1980; 47:117–133. 170. Mikami M, Yasuda T, Terao A, Nakamura M, Ueno S, Tanabe H, Tanaka T, Onuma T, Goto Y, Kaneko S, Sano A. Localization of a gene for benign adult familial myoclonic epilepsy to chromosome 8q23.3–q24.1. Am J Hum Genet 1999; 65(3):745–751. 171. Plaster NM, Uyama E, Uchino M, Ikeda T, Flanigan KM, Kondo I, Ptacek LJ. Genetic localization of the familial adult myoclonic epilepsy (FAME) gene to chromosome 8q24. Neurology 1999; 53(6):1180–1183. 172. Striano P, Chifari R, Striano S, de Fusco M, Elia M, Guerrini R, Casari G, Canevini MP. A new benign adult familial myoclonic epilepsy (BAFME) pedigree suggesting linkage to chromosome 2p11.1–q12.2. Epilepsia 2004; 45(2): 190–192. 173. Guerrini R, Bonanni P, Patrignani A, Brown P, Parmeggiani L, Grosse P, Brovedani P, Moro F, Aridon P, Carrozzo R, Casari G. Autosomal dominant cortical myoclonus and epilepsy (ADCME) with complex partial and generalized seizures: A newly recognized epilepsy syndrome with linkage to chromosome 2p11.1–q12.2. Brain 2001; 124(Pt 12):2459–2475. 174. Loiseau P. Childhood absence epilepsies. In: Roger J, Dravet C, Bureau M, eds. Epileptic Syndromes in Infancy, Childhood and Adolescence. London: John Libbey, 1985:106–420. 175. Fong GCY, Shah PU, Gee MN, Serratosa JM, Castroviejo IP, Khan S, Ravat SH, Mani J, Huang Y, Zhao HZ, Medina MT, Treiman LJ, Pineda G, Delgado-Escueta AV. Childhood absence epilepsy with tonic–clonic seizures and electroencephalogram 3–4-Hz spike and multispike-slow wave complexes: linkage to chromosome 8q24. Am J Hum Genet 1998; 63: 1117–1129.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
465
176. Morita R, Miyazaki E, Shah PU, Castroviejo IP, Delgado-Escueta AV, Yamakawa K. Exclusion of the JRK/JH8 gene as a candidate for human childhood absence epilepsy mapped on 8q24. Epilepsy Res 1999; 37:151–158. 177. Wallace RH, Marini C, Petrou S, Harkin LA, Bowser DN, Panchal RG, Williams DA, Sutherland GR, Mulley JC, Scheffer IE, Berkovic SF. Mutant GABA(A) receptor gamma-2-subunit in childhood absence epilepsy and febrile seizures. Nat Genet 2001; 28:49–52. 178. Haug K, Warnstedt M, et al. Mutations in CLCN2 encoding a voltage-gated chloride channel are associated with idiopathic generalized epilepsies. Nat Genet 2003; 33:527–532. 179. Wolf P. Juvenile absence epilepsy. In: Roger P, Bureau M, Dravet C, eds. Epileptic syndromes in infancy, childhood and adolescence. London: John Libbey, 1992:307–312. 180. Sander T, Schulz H, et al. Genome search for susceptibility loci of common idiopathic generalised epilepsies. Hum Mol Genet 2000; 9:1465–1472. 181. Delgado-Escueta AV, Enrile-Bascal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984; 34:285–294. 182. Dreifuss FE. Juvenile myoclonic epilepsy: characteristics of a primary generalized epilepsy. Epilepsia 1989; 30(suppl 4):Sl–S7. 183. Panayiotopoulos C, Obeid T. Juvenile myoclonic epilepsy: an autosomal recessive disease. Ann Neurol 1989; 25:440–443. 184. Whitehouse WP, Rees M, Curtis D, Sundqvist A, Parker K, Chung E, Baralle D, Gardiner RM. Linkage analysis of idiopathic generalized epilepsy (IGE) and marker loci on chromosome 6p in families of patients with juvenile myoclonic epilepsy: no evidence for an epilepsy locus in the HLA region. Am J Hum Genet 1993; 53:652–662. 185. Cossette P, Liu L, Brisebois K, Dong H, ’Lortie A, Vanasse M, Saint-Hilaire JM, Carmant L, Verner A, Lu WY, Wang YT, Rouleau GA. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet 2002; 31:184–189. 186. Escayg A, De Waard M, Lee DD, Bichet D, Wolf P, Mayer T, Johnston J, Baloh R, Sander T, Meisler MH. Coding and noncoding variation of the human calcium-channel beta(4)-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66:1531–1539. 187. Elmslie FV, Rees M, Williamson MP, Kerr M, Kjeldsen MJ, Pang KA, Sundqvist A, Friis ML, Chadwick D, Richens A, Covanis A, Santos M, Arzimanoglou A, Panayiotopoulos CP, Curtis D, Whitehouse WP, Gardiner RM. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Genet 1997; 6(8):1329–1334. 188. Sander T. The genetics of idiopathic generalized epilepsy: implications for the understanding of its aetiology. Mol Med Today 1996; 2(4):173–180. 189. Neubauer BA, Fiedler B, Himmelein B, Kampfer F, Lassker U, Schwabe G, Spanier I, Tarns D, Bretscher C, Moldenhauer K, Kurlemann G, Weise S, Tedroff K, Eeg-Olofsson O, Wadelius C, Stephani U. Centrotemporal spikes in families with rolandic epilepsy: linkage to chromosome 15q14. Neurology 1998; 51(6):1608–1612.
Copyright 2006 by Taylor & Francis Group, LLC
466
Sigurdardottir and Poduri
190. Eeg-Olofsson O. The genetics of benign childhood epilepsy with centrotemporal spikes. In: Berkovic SF, Genton P, Hirsch, Picard F, eds. Genetics of Focal Epilepsies. London: John Libbey, 1999:35–42. 191. Loiseau P. Idiopathic and benign partial epilepsies. In: Wyllie E, ed. The Treatment of Epilepsy, Principles and Practice. 3rd ed. Philadelphia, PA: Lippincott Williams and Wilkins, 2001:475–484. 192. Scheffer IE, Jones L, Pozzebon M, Howell RA, Saling MM, Berkovic SF. Autosomal dominant rolandic epilepsy and speech dyspraxia: a new syndrome with anticipation. Ann Neurol 1995; 38:633–642. 193. Guerrini R, Bonanni P, Nardocci N, Parmeggiani L, Piccirilli M, De Fusco M, Aridon P, Ballabio A, Carrozzo R, Casari G. Autosomal recessive rolandic epilepsy with paroxysmal exercise-induced dystonia and writer’s cramp: delineation of the syndrome and gene mapping to chromosome 16p12–11.2. Ann Neurol 1999; 45(3):344–352. 194. Vadlamudi L, Harvey AS, Connellan MM, Milne RL, Hopper JL, Scheffer IE, Berkovic SF. Is benign rolandic epilepsy genetically determined? Ann Neurol 2004; 56(l):129–132. 195. Ottman R, Risch N, Hauser WA, Pedley TA, Lee JH, Barker-Cummings C, Lustenberger A, Nagle KJ, Lee KS, Scheuer ML, Neystat M, Susser M, Wilhelmsen KC. Localization of a gene for partial epilepsy to chromosome 10q. Nat Genet 1995; 10:56–60. 196. Poza JJ, Saenz A, Martinnez-Gil A, Cheron N, Cobo AM, Urtasun M, MartiMasso JF, Grid D, Beckmann JS, Prud’homme JF, Lopez de Munain A. Autosomal dominant lateral temporal epilepsy: clinical and genetic study of a large Basque pedigree linked to chromosome 10q. Ann Neurol 1999; 45: 182–188. 197. Brodtkorb E, Gu W, Nakken KO, Fischer C, Steinlein OK. Familial temporal lobe epilepsy with aphasic seizures and linkage to chromosome 10q22–q24. Epilepsia 2002; 43:228. 198. Gu W, Brodtkorb E, Steinlein OK. LGI1 is mutated in familial temporal lobe epilepsy characterized by aphasic seizures. Ann Neurol 2002; 52:364–367. 199. Vanmolkot KR, Kors EE, Hottenga JJ, Terwindt GM, Haan J, Hoefnagels WA, Black DF, Sandkuijl LA, Frants RR, Ferrari MD, van den Maagdenberg AM. Novel mutations in the Naþ, Kþ-ATPase pump gene ATP1A2 associated with familial hemiplegic migraine and benign familial infantile convulsions. Ann Neurol 2003; 54(3):360–366. 200. Zara F, Gennaro E, Stabile M, Carbone I, Malacarne M, Majello L, Santangelo R, de Falco FA, Bricarelli FD. Mapping of a locus for a familial autosomal recessive idiopathic myoclonic epilepsy of infancy to chromosome 16p13. Am J Hum Genet 2000; 66(5):1552–1557. 201. Berkovic SF, Serratosa JM, Phillips HA, Xiong L, Andermann E, Diaz-Otero F, Gomez-Garre P, Martin M, Fernandez-Bullido Y, Andermann F, Lopes-Cendes I, Dubeau F, Desbiens R, Scheffer IE, Wallace RH, Mulley JC, Pandolfo M. Familial partial epilepsy with variable foci: clinical features and linkage to chromosome 22q12. Epilepsia 2004; 45(9):1054–1060.
Copyright 2006 by Taylor & Francis Group, LLC
Inherited Epilepsies
467
202. Stromme P, Mangelsdorf ME, Scheffer IE, Gecz J. Infantile spasms, dystonia, and other X-linked phenotypes caused by mutations in Aristaless related homeobox gene, ARX. Brain Dev 2002; 24(5):266–268. 203. Kalscheuer VM, Tao J, Donnelly A, Hollway G, Schwinger E, Kubart S, Menzel C, Hoeltzehbein M, Tommerup N, Eyre H, Harbord M, Haan E, Sutherland GR, Ropers HH, Gecz J. Disruption of the serine/threonine kinase 9 gene causes severe X-linked infantile spasms and mental retardation. Am J Hum Genet 2003; 72(6):1401–1411.
Copyright 2006 by Taylor & Francis Group, LLC
20 Leukodystrophies James Y. Garbern Department of Neurology, Wayne State University School of Medicine, Detroit, Michigan, U.S.A.
INTRODUCTION Hereditary disorders of myelin formation or its maintenance comprise the ‘‘leukodystrophies,’’ a term derived from leuko ‘‘white’’ and dystroph ‘‘defective nutrition’’ (1). These disorders are characterized based on biological and pathologic features rather than a common clinical syndrome. We will apply the term to monogenic disorders primarily affecting myelin formation or its upkeep, although the nosology of leukodystrophies is more complex (2). The clinical syndromes vary extensively, from severe neonatal encephalopathy to virtually asymptomatic conditions. Complicating the diagnosis of leukodystrophies is the fact that normal early neurologic development depends upon myelination, which mainly occurs during infancy and early childhood (3). Thus, what constitutes a normal examination, both by magnetic resonance imaging (MRI) as well as clinically, varies significantly by age. In addition, temporal patterns of neurologic signs from hereditary myelin disorders vary as well, from developmental delay neonatally, to progressive deterioration after a period of normal development. These temporal patterns are better understood if their biological bases are appreciated. Disorders that interfere with normal myelination are characterized by early onset developmental delay and neurologic signs, whereas those that primarily affect the maintenance of myelin (typically involving enzymes that
Copyright 2006 by Taylor & Francis Group, LLC
470
Garbern
degrade lipids) permit normal early childhood development that is followed by breakdown of myelin and progressive neurologic decline. In addition, inheritance patterns span the full Mendelian range, in addition to maternal inheritance associated with mitochondrial disorders, with attendant implications for genetic counseling. In the past, without a distinct clinical syndrome, the diagnosis of leukodystrophy could be made only after cerebral biopsy or autopsy, but MRI now commonly establishes the diagnosis. However, not all myelin disorders have readily appreciated changes on MRI. Recognition of white matter abnormalities must also account for the changes in MRI appearance of white matter during the course of normal development. Radiologists define myelin by its appearance on MRI scans. Normal myelination is characterized by shortening of the T1 and T2 relaxation times in the white matter, meaning that myelin will be light in intensity relative to gray matter on T1-weighted scans, but dark relative to gray matter on T2-weighted images (3–7). These changes may reflect the dehydration of white matter during myelination. In normal infants, myelination has occurred at birth in the pons and cerebellum; followed by the posterior limb of the internal capsule, the optic radiations and splenium of the corpus callosum by three months; the frontal, parietal, and occipital white matter by 8–12 months; and the temporal white matter by around 12 months. The adult pattern of myelination is normally acquired by 18 months of age. While obvious discrepancies from normal should be apparent by this age, close scrutiny and detailed understanding of the normal patterns of myelination may enable earlier suspicion or diagnosis of myelination abnormalities. Somewhat arbitrary decisions were made to compile the list of diseases discussed here, and new diseases will be discovered. Many diseases affect myelination or its maintenance (such as neuronal ceroid lipofuscinosis and mucolipidoses), but cause significant disruption of other organs or neurons as well. These will not be discussed here. An early scheme for classification of leukodystrophies was based on the histochemical staining properties of white matter. While all leukodystrophies have reduced staining with conventional myelin stains, such as Luxol Fast Blue or Sudan Black, the tinctorial properties of the white matter differed and served as one basis for classification. Thus, with orthochromatic leukodystrophies the white matter that remains stains similarly to normal white matter. In contrast, in metachromatic leukodystrophy the abnormal white matter stains aberrantly. The following classification is based on current understanding of the causes of leukodystrophies (Table 1). DISORDERS OF MYELIN LIPID METABOLISM While the bulk of myelin is lipid, no classical leukodystrophies are known that are caused by mutations in genes encoding enzymes responsible for
Copyright 2006 by Taylor & Francis Group, LLC
Disorder
Inheritance
Gene
Locus
OMIM
MRI pattern
XR
ALDP
Xq28
300100
Posterior
AR
SLC17A5
6q14-q15
Global
AR
ARSA
22q13.31qter
604369/ 604322 250100
AR
SUMF1
3p26
272200
Global
Krabbe disease AR Megalencephalic AR leukoencephalopathy with subcortical cysts Canavan AR
GALC MLC1
14q31 22qter
245200 604004
Global Anterior temporal cysts/ Global
ASPA
17pter-p13
271900
Global
PCWH
AD
SOX10
22q13
602229
Global
Alexander disease
AD
GFAP
17q21
137780
Frontal
Adrenoleukodystrophy/ Adrenomyeloneuropathy Salla disease Metachromatic leukodystrophy Multiple sulfatase deficiency
Frontal/ global
PNS D
D
Analyte VLCFA
Other signs Addison disease
D
C/R
Sialic acid
C/R
Sulfatide
C/R
Sulfatide and mucopolysaccharides
C/R
C/R
D
–
Testing
NAA urine, CSF
Macrocephaly
C/R
Waardenburg/ R Hirschsprung Macrocephaly C/R
471
(Continued) Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
Table 1 Leukodystrophies
Leukodystrophies (Continued )
Disorder
Inheritance
Gene
472
Table 1
Locus
OMIM
MRI pattern
VWM/CACH
AR
EIF2B1-5
2p23.3;1;14 q24;12;3 q27
603896
Globall/ cystic degeneration Global Global Arrested myelination
PMD/SPG2 PMLD Sjo¨gren-Larsson
XR/XD AR AR
PLP1 GJA12 ALDH3A2
Xq22 1q41q42 17p11.2
300401 608804 270200
Cockayne syndrome
AR
CKN1/ ERCC6
5q12.1/ 10q11
216400
Arrested myelination
Cerebrotendinous/xanthomatosis
AR
CYP27A1
2q33-qter
213700
Global/ focal
PNS
Analyte
Other signs
Testing C/R
D Mixed
C/R R C/R
Abnormal DNA repair D
Cholestanol
Short stature/ skin changes/ retinopathy C/R Short stature, progeroid features, photosenstive C/R Cholesterol deposits in skin and tendons/ retinal degeneration
Copyright 2006 by Taylor & Francis Group, LLC
Garbern
AD: Most cases are spordic and reproductively unfit. Abbreviations: OMIM, Online Inheritance in Man Database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db¼OMIM); AD, autosomal dominant; AR, autosomal recessive; XR, X-linked recessive; XD: X-linked dominant; MRI, magnetic resonance imaging; PNS, peripheral neuropathy D, demyelinating; VLCFA, very long chain fatty acids; NAA, N-acetyl aspartate; C, clinical testing available; R, research testing available (contact information listed at http://www.genetests.org).
Leukodystrophies
473
myelin lipid synthesis. Mice deficient in fatty acid synthase die in utero, reflecting the importance of lipids in critical processes in addition to myelination (8). Lack of the relatively myelin-specific lipids galactocerebroside and sulfatide results in severe dysmyelination in mice that are deficient in UDP-galactose:ceramide galactosyltransferase (CGT; in humans, uridine diphosphate glycosyltransferase 8; UGT8; MIM 601291), which is required for GalC synthesis (9). Therefore, it is likely that mutations in the human UGT8 gene would cause a recessive leukodystrophy. Disorders of myelin lipid breakdown are among the best known human leukodystrophies. All are recessive, as with most enzyme-encoding gene mutations. The age of onset and rate of progression of these lysosomal storage diseases reflect the degree of residual enzyme activity in the CNS and the normal turnover of individual lipids. Since myelin synthesis may not be affected in these disorders, myelin may form normally, but neurologic signs develop later as myelin turnover proceeds. Accumulation of storage products disrupts oligodendrocyte function and myelin integrity with accompanying clinical signs. In addition, storage products or their derivatives may be directly toxic, as proposed for Krabbe disease, which is characterized by psychosine (galactosylsphinosine) accumulation. Psychosine, like other lipids, has detergent properties, and may also have other cytotoxic effects. Lysosomal Storage Diseases Metachromatic Leukodystrophy (MIM 250100) Description and clinical manifestations: Metachromatic leukodystrophy (MLD) is characterized by metachromatic staining (from sulfatide) of the white matter, pituitary gland, liver, kidney, and testes (10–14). Sulfatide, a sulfated glycolipid, accumulates from reduced activity of arylsulfatase A (ARSA), the lysosomal enzyme that releases galactose-3-sulfate from sulfatides (15,16). This reduced activity results from mutations in the ARSA gene (17–19). Over 100 MLD-related ARSA mutations have been found according to the Human Gene Mutation Database (HGMD) (20). Their frequencies differ between different ethnic groups. MLD is an autosomal recessive disease that is usually classified by the age of onset into late infantile, early and late juvenile, and adult forms. The late infantile and early juvenile forms are the most common. The late infantile form begins typically between the first and second year, and the clinical course is subdivided into four stages (21). In the first stage, a child who has already learned to walk becomes unsteady and requires support to stand. Flaccid weakness and hypotonia occur in the legs or all four limbs. Muscle stretch reflexes may be diminished or absent. Genu recurvatum is often present. This stage lasts from a few months to a year or more. In the second stage, which may last only a few months, the child can sit but no longer stand; cognitive regression begins; speech is impaired due to a combination
Copyright 2006 by Taylor & Francis Group, LLC
474
Garbern
of dysarthria and aphasia; ataxia and nystagmus are noted; and spasticity develops in the legs and possibly the arms, even though deep tendon reflexes may remain diminished from peripheral neuropathy. The child may also complain of intermittent pain in the arms and legs. In stage 3, the child is quadriplegic and bedridden, with decorticate, decerebrate, or dystonic posturing. Bulbar and pseudobulbar palsies cause difficulty in maintaining normal breathing. While speech is no longer distinct, the child may be able to smile and respond. In stage 4, which lasts from a few months to a decade or more, the child is blind, deaf, without speech or volitional movement. The juvenile form begins clinically between 4 and 12 years, and is subdivided based on whether the onset is before or after six years of age. The disease is characterized by impaired school performance and behavioral disturbances, such as confusion or bizarre behavior, incontinence, gait disturbance, dysarthria, and extrapyramidal dysfunction. The disease progresses to states that correspond to stages 3 and 4 of the late infantile form (22). The late juvenile form progresses more slowly than does the late infantile and early juvenile variants, and the duration of the illness may be longer than 20 years. Onset in the adult form can range from 12 to over 70 years. The initial symptoms typically affect behavior, manifesting as personality change or in poor school or work performance. There is anxiety, emotional lability, poor memory, and disorganized thinking. Symptoms of depression, schizophrenialike psychosis, feelings of depersonalization, or paranoia often lead to a diagnosis of psychiatric disorder. A survey of 129 patients revealed an overall incidence of psychosis in 53%, auditory hallucinations in 18%, delusions in 27%, and a psychosis was diagnosed in 35% (23). Peripheral neuropathy may also be the initial manifestation (24). Many, but not all, patients develop demyelinating peripheral neuropathy. Dystonic posturing may occur. In the later and final stages, bulbar and spastic quadriparesis, decorticate posturing, and optic atrophy occur. Most commonly the duration of the illness is between 5 and 10 years, but in some patients it may last decades. Most MLD patients develop focal or generalized seizures that may be subclinical electrographic seizures (25,26). Some patients have a nonfunctioning gall bladder, although symptoms related to gall bladder involvement are overshadowed by the neurological manifestations. Gall bladder complications can include polypoid masses or papillomatous fronds, cholecystitis, and hyperbilirubinemia (27). Kim et al. (28) performed abdominal ultrasonograms in seven consecutive patients with MLD and found abnormal findings in four. Etiology: MLD is caused by deficiency of ARSA activity. The enzyme is encoded by the ARSA gene at chromosomal locus 22q13.31-qter. The coding region spans eight exons and predicts a primary protein sequence of 507 amino acids with an 18 amino acid leader sequence. ARSA is a protein of
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
475
62 kDa. The protein contains three N-glycosylation sites. More than 100 MLD-related ARSA mutations have been entered in the HGMD or described (20). Among MLD - causing ARSA mutations, about 85% are nucleotide substitutions and about 13% are small deletions. One small insertion and one small combined insertion - deletion have been reported thus far. As with most recessive diseases, the prevalence of MLD and of specific diseasecausing alleles differs among different ethnic groups. The biological and clinical effects of the mutations vary. MLD mutations can be functionally divided into two broad groups: null (0 or I) alleles associated with no enzymatic activity and R (or A) alleles that are associated with some residual enzyme activity (19). The most common null allele is a mutation at the first base in intron 2 (459þ1G > A) that leads to the loss of a splice donor site. This is one of the most frequent mutations (25% of 140 MLD alleles), and leads to a deficiency of ARSA messenger RNA (mRNA). No ARSA protein can be detected. Patients homozygous for this mutation have the most severe form of the disease. The P426L R allele is the second most frequent mutation and is present in about 15% of MLD patients. Patients with this mutation have normal production of enzymatically active ARSA, but, within the lysosome, the mutant enzyme has a reduced half-life. In most cases, persons homozygous for this mutation have the adult and sometimes the juvenile form of MLD. About 12% of MLD patients have the I179S mutation. Patients who are compound heterozygous for a null allele and an R allele show intermediate grades of clinical severity, such as the juvenile form of the disease. However, the variation in severity among patients with identical genotypes can be remarkable, and prediction of the clinical course for an individual based on genotype alone is not reliable (19,29–31). As with other metabolic diseases, the best screening test is measurement of enzyme activity or of the storage product in body fluids. Complicating the laboratory diagnosis is the discovery of so-called pseudodeficiency (Pd) alleles (32). Pd does, in fact, cause partial deficiency of ARSA but since only 5–10% of ARSA activity is sufficient to prevent sulfatide accumulation, it does not cause neurologic signs (33). Pd alleles complicate diagnosis and identification of MLD carriers based on the biochemical assay. The Pd condition is associated with two mutations in the ARSA gene: the A2723 ! G, which removes the polyadenylation signal site of the mRNA, and the A1788 ! G, which results in the loss of an N-glycosylated asparagine in the protein (34). This latter mutation causes a severe deficiency of a 2.1 kb mRNA, with resultant diminished synthesis of ARSA. The Pd allele has a population frequency of 7–15% (35). The MLD mutations can occur also within this allele (36,37). Numerous reports suggest a relationship between the condition of MLD/ Pd compound heterozygotes and the development of nonprogressive neurological symptoms (38–41). That only a fraction of MLD/Pd compound heterozygotes develops symptoms suggests that other genetic or environmental factors contribute to the development of the neurological phenotype.
Copyright 2006 by Taylor & Francis Group, LLC
476
Garbern
Molecular and cellular pathogenesis: The main pathological feature of MLD is demyelination and the deposition of metachromatic granules in both the central nervous system (CNS) and peripheral nervous system (PNS). The demyelination in the CNS is widespread but spares the U-fibers, while the peripheral nerves show segmental demyelination (42). The metachromatic granules, which under the electron microscope consist of lamellae and vacuoles and are referred to as ‘‘tuffstone bodies’’ (43), are present not only in the nervous system, where they are prominent in microglial cells, oligodendrocytes, and Schwann cells, but also in the kidney, gallbladder, retina, rectal tissue, and other tissues. The accumulation of sulfatide, the pathognomonic feature of MLD (13,14), is caused by deficiency of ARSA, or more rarely by a deficiency of the sulfatide activator, SAP (PSAP; see below). The mechanisms responsible for the demyelination are not clearly defined. Sulfatide accumulation may induce alterations within myelinating cells. Accumulation of sulfatide in oligodendrocytes has been noted in a five-month-old fetus, at a time when myelin structure was still intact (44). Another potential mechanism is that abnormally high sulfatide content may cause myelin instability (45). Sulfogalactosylsphingosine, which may be cytotoxic, is present in abnormally high concentrations in the tissues of MLD patients and may have a role in demyelination (46). Data obtained in mouse models suggest that microglial activation in MLD and other lysosomal storage disorders contributes to demyelination (47,48). A ‘‘knockout’’ mouse model of MLD has been developed (47). The mice have the expected deficiency of ARSA activity and, starting at the age of 9–10 months, accumulate sulfatide in neuronal and non-neuronal tissues. During the second year of life they develop demyelinating lesions, and neurological examination reveals impairment of motor coordination and learning. Availability of these animals provides important new opportunities for the clarification of pathogenesis and for testing therapeutic interventions. Epidemiology: MLD is inherited in an autosomal recessive manner, with an incidence of 1 in 40,000 in Northern Sweden (49) but about 1 in 100,000 in the United States (50). A Habbanite community in Israel, where consanguineous marriages are relatively common, has a reported an incidence of 1.3% associated with a 17% carrier frequency (51). Diagnostic evaluation: The first description of the use of MRI, the most useful screening test for leukodystrophies, in MLD appeared in 1991 (52). Kim et al. (53) have reviewed the MR findings in seven patients with late infantile MLD. Only one serial neuroradiological study has been performed on a patient with late infantile MLD (54). As described in the previous studies the brain MRI initially shows a diffuse symmetric hyperintense, but nonenhancing, signal in the periventricular and subcortical supratentorial white matter on T2-weighted images, usually beginning in the
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
477
anterior white matter, but sparing the arcuate fibers. As the disease progresses, other structures are involved such as the corpus callosum, cerebellar white matter, corticospinal tracts, internal capsules, and thalami. In the late stages, the U-fibers are involved and atrophy appears. Another common manifestation is a tigroid pattern of demyelination, as observed in Pelizaeus– Merzbacher disease (53,55). Recently, diffusion weighted imaging performed in a case of lateinfantile MLD revealed a cytotoxic edematous pattern in the deep white matter, suggesting a restriction of mobility of water molecules within the abnormal portions of myelin sheaths, consequent to the impaired myelin turnover (56). Magnetic resonance spectroscopy (MRS) of patients with MLD reveals reduced choline, a marker of myelin turnover (57), but further studies on additional patients will be needed to ascertain the usefulness of this observation. Single positron emission computed tomography (SPECT) imaging in one patient with adult-onset MLD showed reduced cerebral perfusion in the frontal lobes, a nonspecific finding (58). CT scans remain very useful for the identification of calcifications, which suggests other acquired or hereditary diseases (cytomegalovirus infection, Aicardi–Goutierres syndrome, and Cockayne disease). Peripheral neuropathy is usually present in MLD patients with the late infantile or juvenile forms, but may be absent in adult-onset patients. When present, it manifests as a demyelinating neuropathy with progressive and severe reduction of nerve conduction velocities; later in the disease, nerve action potentials are diminished in amplitude with prolonged latencies, suggesting late axonal injury, as is common in other primary demyelination peripheral neuropathies (59). Neurophysiological signs of peripheral neuropathy may be present while patients are still asymptomatic. The combined presence of PNS and CNS white matter abnormalities helps to differentiate MLD and Krabbe leukodystrophy from Pelizaeus–Merzbacher disease, multiple sclerosis and other disorders that affect the CNS only. Metachromatic deposits can be demonstrated in sural nerve biopsies. This procedure was used frequently in the past, but is now replaced by less invasive biochemical and molecular studies. Biochemical tests: The specific diagnosis depends on biochemical procedures and mutation analysis. Since the reduction in ARSA activity can be caused by a wide variety of mutations, and genetic analysis may miss some mutations such as those in regulatory regions or introns, direct biochemical analysis of ARSA activity to detect ARSA deficiency is generally the first step since its assay can be combined with enzymatic assay for other lysosomal enzymes. Certain factors have to be taken into careful consideration. There is considerable variability in enzyme activities among individuals (60), and ARSA activity in cultured fibroblasts varies with culture conditions (61). The presence of the Pd allele, which accounts for 5–15% of residual activity,
Copyright 2006 by Taylor & Francis Group, LLC
478
Garbern
may lead to the incorrect diagnosis, incorrect assignment of carrier status, and incorrect assessment of risk of having an affected child. Differentiation of these possible conditions requires the analysis of sulfatides in a 24-hour urine collection and molecular analysis. Large quantities of sulfatides can be detected in the urinary sediment of affected individuals and its measurement on the 24-hour collection may aid in diagnosis in all cases in which ARSA activity values are not clearly diagnostic for MLD (62). Normal ARSA activity is observed in MLD patients with SAP-B deficiency, because the colorimetric assay used for determining ARSA activity does not depend on this activator. In these patients sulfatiduria is positive. The most commonly used ARSA assay uses p-nitrocatechol sulfate as the substrate and employs conditions that minimize the contribution of arylsulfatase B (63). The use of labeled cerebroside sulfate (64) or a fluorescent compound as substrates (65) may help in distinguishing MLD from Pd patients. Additional means of distinction between the two disorders are the sulfatide loading test (66) and the measurement of urinary sulfatide levels (67,68). The sulfatide loading test measures the ability of cultured fibroblasts to convert 35S labeled sulfatide to inorganic sulfate. This capacity is reduced more severely in MLD patients than in people with the Pd allele. Urinary sulfatide excretion is increased in patients with MLD, but is normal or only minimally increased in patients with Pd. Mutation analysis: Mutation analysis provides an increasingly important diagnostic tool. While more than 100 MLD-related ARSA mutations have been described, roughly 50% of the MLD alleles remain unidentified. The three most common mutations (459þ1G > A, P426L, and I179S) are present in less than 50% of the patients. The other mutations described are usually private mutations. Therefore, most of the patients remain undiagnosed at a molecular level if only common mutation screening is performed. In cases where the more common point mutations have been excluded, but prenatal or preimplantation genetic diagnosis is under consideration, then gene scanning or sequencing can be pursued. The Pd allele has a population frequency of 7–15% (35). It can be identified with DNA-based assays, but its detection cannot rule out the concomitant presence of an MLD allele. In fact, the coexistence of MLD and Pd mutation in the same allele has been estimated at 2.5–13% in MLD patients; in view of the frequent occurrence of the Pd allele in the general population, this finding is not surprising. SAP deficiency also has to be considered in the presence of ARSA activity within normal range and elevated urinary sulfatides. Thus, judicious use of mutation analysis combined with biochemical assays is needed for correct diagnosis, management and counseling of patients and families affected by MLD and related disorders. Prevention: Reproductive planning in conjunction with genetic counseling is currently the main method for the prevention of MLD. An affected
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
479
fetus can be identified prenatally (69) and prenatal diagnosis can be offered to all couples with a previously affected child. Carrier identification may be achieved by assays of ARSA deficiency (51), but there is overlap with normal individuals (38). It is of critical importance for prenatal diagnosis and carrier identification to distinguish MLD from the benign Pd condition. This distinction is discussed in the section on diagnostic workup. In families where the molecular defects have been identified in affected members, mutation analysis provides the most accurate method for prenatal diagnosis and carrier identification. When mutation analysis is available, preimplantation genetic diagnosis is possible (70). Management: Dietary regimens, pharmacological agents, and attempts at enzyme replacement have not had a favorable effect on the clinical course or biochemical abnormalities (50). At present, no effective therapy is available for MLD except for bone marrow transplantation (BMT) or stem cell transplantation (SCT) in selected cases (71–74). Therefore, the main management remains symptomatic and includes: 1. Physical therapy and antispasticity drugs to improve the ability to walk independently or with aids as long as possible, and to minimize contractures and complications related to relative immobility. Periodic rehabilitation medicine and/or orthopedic evaluations may be helpful in preventing or treating orthopedic complications such as scoliosis and contractures. 2. Respiratory therapy and adequate control of pulmonary infections, which are quite frequent as a consequence of dysphagia. 3. Adequate support of calories, vitamins, and minerals, which may require, in the advanced stages, a nasogastric tube or a permanent gastrostomy. 4. Antiepileptic drugs to control seizures, which may not be clinically evident and therefore require electroencephalographic monitoring. 5. Adjustment of school environment and counseling to maintain contact with family and friends and activities. 6. Psychiatric intervention and medications to control psychosis and behavioral symptoms may be required. BMT and SCT can be effective treatments in some lysosomal disorders (74–77). Their therapeutic efficacy relies on the migration of donor-derived cells of the monocyte–macrophage lineage into diseased target organs where they replace the resident enzyme-deficient population. The donor-derived cells that migrate to the tissues can become a local and steady source of the missing enzyme. In selected MLD patients, such as in the very early stage of the juvenile and adult forms, BMT and SCT may delay the onset and slow the progression of the disease. Furthermore, BMT or SCT represents a valid therapeutic option in patients with late infantile onset if
Copyright 2006 by Taylor & Francis Group, LLC
480
Garbern
performed at a presymptomatic stage with a therapeutic ‘‘window’’ of at least one year, a condition that is generally fulfilled in the presence of an affected sibling, where the clinical outcome of an untreated child can be reasonably predicted. BMT has no efficacy if performed in symptomatic patients with early onset or in advanced stages of late-onset patients. Thus, only a minority of MLD patients can benefit from BMT (74). The number of patients eligible for BMT is further reduced by the availability of an HLA-compatible donor. In addition, BMT is associated with fairly high morbidity/mortality due to conditioning regimens, rejection, failure of engraftment, and graft versus host disease. A novel transplantation approach for MLD includes the use of mesenchymal stem cells (MSC) (73). Recently, six MLD patients, who previously underwent successful BMT from HLA-identical siblings, received allogeneic MSC from the same donors. Nerve conduction velocity (NCV) studies of three of these patients showed slight improvement, but without any significant clinical benefit. Further studies are required to better understand the potential therapeutic efficacy of MSC transplant for MLD. The absence of robust therapies emphasizes the need for the development of innovative therapeutic approaches, such as gene therapy. Despite previous encouraging results based on the use of retroviral vectors (78–80), retroviral gene transfer into ARSA-deficient hematopoietic stem cells cannot prevent or control the phenotype of transplanted MLD mice (81). Lentiviral vectors, capable of high efficiency of infection and long term and sustained expression of transgenes into non dividing cells, represent a unique therapeutic tool for enzyme delivery into the CNS (82). Using this approach, it is possible to correct both central and peripheral neuropathology and clinical impairments in the MLD mouse and is an especially promising potential therapy for MLD. Multiple Sulfatase Deficiency (MIM 272200) and Sulfatide Activator Deficiency (MIM 249900) Accumulation of sulfatides and clinical manifestations that resemble MLD can be caused by at least two other genetic disorders. In multiple sulfatase deficiency (MSD; MIM #272200), children are more severely affected than those with late infantile MLD and have clinical features of both infantile MLD and mucopolysaccharidosis (MPS) (50,83). While they may learn to stand and say a few words, affected children usually fail to attain the early normal developmental milestones that most children with late infantile MLD achieve. MPS-like features such as coarse facial features, hepatosplenomegaly, rib flaring, stiff joints, and deformities of the acetabulum and sternum may occur. Ichthyosis (from steroid sulfatase deficiency) frequently develops. The disease advances during the second year, when the children lose the ability to stand, sit, or speak. Death often occurs before 10 years of age, but some patients have survived to the second or third decade. A somewhat milder variant, albeit with corneal clouding and severe dysotosis multiplex,
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
481
but with only mild or moderate mental retardation, has been reported in Saudi Arabia (84). In MSD, the activities of at least eight sulfatases are deficient (85), due to a defect in posttranslational modification. The gene mutated in MSD, sulfatase modifying factor 1 (SUMF1) (86,87), encodes a factor that is both an essential and a limiting factor for multiple sulfatases. This factor is required for a posttranslational modification at the catalytic sites of sulfatases, where Ca-formylglycine is generated by a cysteine modification. With sulfatide activator protein deficiency (MIM #249900), the clinical manifestations are similar to those of MLD, and range in severity equivalent to late infantile to adult MLD (88,89). This syndrome is caused by mutations affecting the sphingolipid activator saposin (SAP; SAP-B) (90); ARSA activity is normal. In addition to saposin B, other products of the prosaposin or PSAP gene, which also encodes saposins A, C, and D, can be perturbed, and cause an MLD- or Gaucher-like clinical syndrome. The molecular biology of the SAP deficiency has been clarified. The SAP, also referred to as SAP-1 or SAP-B, is derived from a larger precursor molecule, prosaposin. The prosaposin (PSAP) gene occupies about 20 kb on the long arm of chromosome 10 (90). Epidemiology and management of MSD and SAP deficiency: Approximately, 50 cases of MSD have been reported (50,84,91). Few cases of SAP deficiency are described, but this variant may be underdiagnosed. Management of MSD and SAP deficiency is similar to that of MLD. Krabbe Disease (Globoid Cell Leukodystrophy; GLD; MIM 245200) Clinical description: Krabbe disease was first described in children with a syndrome that began during infancy and was characterized by tonic spasms, nystagmus, periodic fever, muscular rigidity, progressive quadriplegia, and early death (92–94). Postmortem examination revealed loss of myelin staining especially in the cerebellum, degeneration of long spinal tracts, and gliosis. Blood vessel sheaths were infiltrated by granule-containing cells that were described as globoid cells. These deposits are enriched in cerebrosides that accumulate due to lack of galactosylceramidase (95,96). The initial clinical reports of Krabbe disease described the early infantile presentation (92). This presentation, which accounts for over 90% of patients, begins before six months of age in most cases, and as early as in the first three months of age in 25% of cases (97). It has four stages (94): Presymptomatic stage: Infants generally are able to fix and follow visual targets, smile interactively and reach for objects. Stage 1 (3 to 4 months): Photic and auditory sensitivity, extreme irritability, intermittent neurogenic fever, developmental arrest followed by regression, and tonic spasms with normal to reduced muscle stretch reflexes.
Copyright 2006 by Taylor & Francis Group, LLC
482
Garbern
Stage 2: Permanent opisthotonus, tonic flexion of arms and extension of legs, rapid loss of nearly all previously acquired skills, myoclonic jerks, seizures, optic atrophy, blindness and more frequent febrile episodes. Stage 3 (usually before 12 months): Immobile, decerebrate but no longer rigid, and unable to feed. Children can uncommonly present in the neonatal period; prenatal onset was first suggested when a five-month-old fetus was noted to have the characteristic neuropathological findings (98). The cerebrospinal fluid protein is usually elevated (99). The late infantile variant is much less common and begins between 19 months and four years of age (100). These children have normal intelligence or only moderate retardation during the first years, but gradually develop ataxia, weakness, spasticity, and dysarthria. Visual loss accompanied by optic atrophy, mental regression, occasional seizures, deafness, and normal peripheral nerves are the characteristic findings. Spinocerebellar degeneration associated with peripheral neuropathy, but without visual loss or dementia, has been reported (101). As in other forms of Krabbe disease, cerebrospinal fluid protein is usually, but not always elevated (100). Late-onset forms of Krabbe disease have been defined as juvenile onset (4 years to 19 years), and adult onset (>20 years of age) (102–104). These patients usually have optic nerve pallor, pes cavus, slowly progressive spastic tetraplegia, sensory-motor demyelinating neuropathy, symmetric T2 hyperintense parieto-occipital white matter, and preserved mental function (102,105). Cerebrospinal fluid protein is frequently normal. Survival into the third to fourth decades is possible with juvenile-onset disease. Adult-onset patients can present in the fourth to fifth decades with signs of motor neuron disease, mild and patchy demyelinating peripheral neuropathy, mild elevation of cerebrospinal fluid protein, and mild T2 hyperintensity of deep cerebral white matter (106,107). Survival into the seventh decades is possible. Pathogenesis and pathophysiology: Krabbe disease, an autosomal recessive disorder, is caused by deficiency of the enzyme galactosylceramidase (GalC; EC 3.2.1.46; galactosylceramide b-galactosidase; galactocerebrosidase) that catalyzes the catabolism of galactosylceramide. The GALC gene lies at 14q31 (108,109) and spans 17 exons over a 60 kb interval (110). The GALC cDNA encodes a 669 residue protein of about 80 kDa with a 26 amino acid leader sequence (111). The protein is further cleaved to 50 kDa amino terminal and 30 kDa carboxy terminal subunits. Molecular and cellular pathogenesis: The typical neuropathological findings in Krabbe disease include generalized brain atrophy with replacement of the central white matter by gliotic tissue. There is severe loss of oligodendroglia, myelin, and axons with dense astrocytic proliferation, and the presence of ‘‘globoid cells,’’ phagocytic cells of 30–50 m in diameter filled with
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
483
periodic acid-Schiff (PAS) stained material ringed by a chain of multiple nuclei. The cells are likely of macrophage–microglial origin. In the murine model of Krabbe disease (the twitcher mouse) (112), oligodendrocytes undergo apoptosis (113). Myelin loss is seen in peripheral nerves; however, typical globoid cells are usually not observed (114). Biochemical analysis of Krabbe disease brains demonstrated the accumulation of the glycolipid, galactosylceramide, within a fraction of brain that was enriched in globoid cells (115). Experimentally, galactosylceramide injected into the cerebral cortex produces globoid cells (116). However, total glycolipid and sulfatide levels in white matter from these brains were reduced (14). Malone and Suzuki confirmed that galactosylceramidase was deficient in the leukocytes, brain, liver, and spleen of Krabbe patients (117,118). Galactosylceramidase hydrolyzes other glycolipids containing a terminal beta-galactose group, such as lactosylceramide, monogalactosyl diglyceride, and galactosylsphingosine (psychosine) in addition to galactosylceramide (119–121). Analogous to ARSA, galactosylceramidase requires a sphingolipid activator protein (saposin A or C) that helps solubilize the protein–lipid complex (122). Saposin A and saposin C also activate the degradation of galactosylsphingosine (122). Lack of the lysosomal enzyme, GM1 ganglioside bgalactosidase, which hydrolyzes GM1 ganglioside, causes GM1 gangliosidosis. Under certain conditions GM1 ganglioside beta-galactosidase can hydrolyze galactosylceramide, but not psychosine (galactosylsphingosine) (123). Though galactosylceramide does not accumulate in the white matter of Krabbe patients except in the globoid cells (115), psychosine is increased in the brains of patients with Krabbe disease (124). Psychosine, normally present at only trace levels in the CNS, causes oligodendrocyte apoptosis in culture that can be reduced by protein kinase C activators, by galactosylceramidase, or by sequestering psychosine (125). Thus, psychosine, but not galactosylceramide, may accumulate in the brains of Krabbe disease patients and may be responsible for a significant amount of the observed cellular pathology and paradoxical relative lack of galactocerebroside accumulation (124). The psychosine-induced apoptotic depletion of oligodendroglial cells could cause abnormal myelination and reduce the amount of galactocerebroside that would otherwise accumulate. Over 60 mutations affecting GALC are associated with Krabbe disease including base transitions, polymorphisms, and deletions. Approximately 40–50% of cases of infantile Krabbe disease affecting children of Northern European ancestry have an allele that has a 30-kb deletion beginning in intron 10 and extending past the 30 end of the gene (126,127). This deletion allele also has a C to T transition at position 502, a polymorphism seen in only about 4% of the population. Most of the mutations causing infantile-onset disease are located in the region encoding the 30-kDa subunit of the enzyme, suggesting that this subunit is critical for the normal functioning of the enzyme (97). Adult-onset cases may also have the 502/del mutation on one allele, but many
Copyright 2006 by Taylor & Francis Group, LLC
484
Garbern
other mutations (occurring predominantly in the region coding for the 50 kDa subunit) have been found (103,105–107,128–130). Epidemiology: Krabbe disease is an autosomal recessive disorder that has been reported worldwide. Most reports probably underestimate the incidence of Krabbe disease; an estimate from Sweden suggested an incidence of 1.9 in 100,000 (131), whereas in Japan the estimate was 1 in 100,000 to 1 in 200,000 (132). In Germany, the incidence was estimated as 0.6 per 100,000 live births (133). In a highly inbred Israeli community the incidence was 1 per 6000 live births (134). Diagnostic evaluation: An infant suspected of having Krabbe disease should have an MRI scan to evaluate the white matter. Understanding the progression of normal myelination aids the interpretation of MRI abnormalities seen in infantile-onset Krabbe patients. The posterior limb of the internal capsule is normally myelinated by birth, but infants with early infantile Krabbe disease have abnormal T1 and T2 intensities in this area. As the disease progresses, these areas and gray matter atrophy, even as normal patterns of myelination are developing in the frontal areas (135–137). In infantile Krabbe disease, cerebellar white matter and the pyramidal tracts are usually abnormal. These white matter abnormalities, seen as abnormal T1 and T2 contrast signal, most often affect the pyramidal tracts, the posterior corpus callosum, and parieto-occipital white matter (137). As the disease progresses all of the white matter structures become abnormal. Anomalously low signal in the thalamus on T2-weighted images and high signal on T1-weighted images can be found, suggesting a paramagnetic effect due to hydrophilic material (138). These regions at postmortem have abundant globoid cells and macrophages, some with calcium deposits. Adult-onset Krabbe disease can present with relatively mild changes in the posterior corpus callosum and parieto-occipital white matter (103,106,107,139). Electrophysiological studies are helpful in evaluation of Krabbe disease. Husain studied 26 patients and reported slow nerve conductions in all children with early and in 20% of children with childhood onset disease, whereas 88% of early infantile Krabbe children and 40% of late onset Krabbe children had abnormal brainstem auditory evoked potentials (BAEPs) (140). The severity of abnormalities on electrophysiological testing correlated with severity of abnormalities on MRI scans. Electroencephalograms (EEGs) are usually normal early in the course of disease, but generalized slowing and multifocal epileptic spikes, which may not always be associated with motor activity, are typical in the later stages (140,141). Cerebrospinal fluid in patients with early and late infantile forms of Krabbe disease shows elevated protein (frequently 75–500 mg/dL) with normal cell counts (97). Ultrastructural studies of skin biopsies may identify electron dense inclusions in eccrine sweat glands similar to those seen in Krabbe disease Schwann cells (142,143).
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
485
Since galactocerebroside does not accumulate to significant and consistent levels in body fluids of Krabbe patients, measurement of galactosylceramidase activity in serum, leukocytes, or cultured fibroblasts is the only specific test for confirming the diagnosis of Krabbe disease. Genetic testing is the definitive test that when positive will permit prenatal or preimplantation genetic diagnosis. Defects in saposin A, similar to those of sulfatide activator protein deficiency, may cause Krabbe disease in the setting of normal galactocerebrosidase enzyme levels (144). Prognosis and complications: Children with the early infantile Krabbe disease have a poor prognosis, and rarely live beyond two years of age (99). Children with late infantile Krabbe disease may survive for one to five years or more after neurologic signs arise. Adult onset patients have been reported who have survived until the seventh decade (106). Management: Therapy for Krabbe disease is limited. BMT has shown limited benefits in small series of patients. Five children with Krabbe disease (four juvenile, one infantile) who received hematopoietic SCT had significant improvements in their neurologic symptoms (145). Children transplanted well into the course of the illness have not improved following the procedure. While not as extensively studied as with other lysosomal disorders, BMT and SCT remain among the more promising future therapies for this devastating condition (77,146). Supporting the application of BMT and SCT for treatment of Krabbe are demonstrations of significant benefit of BMT in treating the twitcher mouse, a bona fide model of Krabbe disease (147–149). Once neurologic signs begin, therapies such as BMT are less effective and associated with significant morbidity and mortality. At these later stages, treatment is limited to symptomatic and supportive measures. The severe irritability can be treated with either benzodiazepines or low doses of morphine (150). Other supportive measures are as described for treatment of complications of MLD (above). Matsuda et al. (151) observed that saposin A deficient female mice that were kept continuously pregnant had improved neurologic outcome compared to affected nonpregnant females. The benefit of pregnancy could be replicated with pharmacologic administration of estrogen. While the mechanism of this beneficial effect was not proven, it may be mediated by down-regulation of some immunological mediators such as Tumor necrosis factor-alpha. Pharmacologic therapies to reduce galactocerebrosidase substrate buildup have shown promise, again using twitcher mice. L-cycloserine, which reduces sphingosine synthesis by inhibiting 3-ketodyhydrosphingosine synthase, prolonged the lives of twitcher mice (152). Combined with BMT, L-cycloserine therapy was even more effective (153,154). In principal, gene replacement therapy using viral vectors is a viable strategy. Transgenic ‘‘cure’’ of the twitcher mouse has been accomplished
Copyright 2006 by Taylor & Francis Group, LLC
486
Garbern
using genomic DNA (155). Ex vivo transduction of hematopoietic stem cells, as with MLD mice, is a potential therapy. Lipid Metabolism Disorders Salla Disease (Sialic aciduria, Finnish variant: MIM 604369) Aula et al. described children with an autosomal recessive disorder characterized by normal infantile development followed at 6 to 24 months of age by progressive cognitive decline, seizures, dystonia, ataxia and hypotonia, followed by spastic paraparesis or quadriparesis (155a). Most cases have been reported from Scandinavia, where the carrier prevalence can be as high as 1 per 100. Coarsening of facial features may appear during adulthood, but is not present during childhood, although short stature is common. Although children typically learn to walk and speak, by 20 years of age they have typically become wheelchair confined and have cognitive capabilities of about a 2 year old (155b). Survival is probably shortened, but survival into the eighth decade has been reported. MR imaging demonstrates abnormal signal throughout the cerebral white matter, although with relative sparing of the internal capsule (155c). The cerebellar white matter almost always has a normal appearance. Tissues, such as skin, show storage deposits typical of lysosomal storage disease, but biochemical assays for lysosomal enzymes are normal. Urine sialic acid (N-acetyl neuraminic acid; NANA) is elevated (155d). Brain MR spectroscopy reveals elevation in a resonance most likely due to NANA rather than to NAA (155e). There is no specific therapy for Salla disease, so treatments are limited to symptomatic management. Salla disease is caused by mutations in the SLC17A5 gene, which encodes sialin (155f) and is allelic to the more severe infantile acid storage disorder (ISSD: MIM 269920). Sialin is an intrinsic lysosomal membrane protein required for export of sialic acid released by catabolism of lysosomal enzymes and glycolipids, to the cytoplasm. How the defect in sialic acid transport leads to the biochemical and clinical syndrome are not well understood. Null mutations of SLC17A5 lead to ISSD, while those with some residual activity lead to Salla disease. At least one mutation causes misfolded sialin, which is retained in the endoplasmic reticulum (155g). Sjo¨gren–Larsson Syndrome (SLS; MIM 270200) Sjo¨gren and Larsson exhaustively described an autosomal recessive syndrome that is prevalent in Sweden and characterized by short stature, macular degeneration, severe pruritic ichthyosis, spastic quadriparesis, developmental delay, seizures, and mental retardation (156). Sjo¨gren–Larsson syndrome (SLS) patients subsequently were found to have a characteristic leukodystrophy characterized by arrested myelination (157–163). SLS fibroblasts have
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
487
a defect in oxidation of fatty alcohols (164,165), and mutations in the aldehyde dehydrogenase, family 3, subfamily A, member 2, or ALDH3A2 (also fatty alcohol: NAD þ oxidoreductase and fatty aldehyde dehydrogenase) gene cause SLS (166). Clinical features: The triad of ichthyosis, spasticity, and mental retardation constitutes the major clinical signs of SLS. The dermatologic features are usually characterized by brown-yellow discoloration and wrinkled hyperkeratosis that usually develops in the latter half of the first year of life. The ichythyosis generally spares the face and is associated with severe pruritis. Spastic paraparesis develops gradually during the first two years of life. While SLS children may learn to walk, they become wheelchair dependent during later childhood or adolescence. Cognition typically is mild to moderately impaired. Macular degeneration characterized by the presence of retinal crystals, sometimes referred to as ‘‘glistening white dots,’’ is present in all patients (167,168). Photophobia and poor visual acuity are common symptoms. Seizures may occur, but are generally easily managed. Some patients can have a milder syndrome, with less severe dermatologic and neurologic signs. The cerebral MRI shows delayed myelination during the first years of life. The cerebellar white matter is normal, and the internal capsule, splenium, and genu of the corpus callosum are also spared. T2-weighted scans show a zone of high signal in the periventricular white matter with either frontal or parieto-occipital predominance (163). MRS shows peaks at 1.2–1.3 and 1.3 ppm that may correspond to elevated levels of free lipids and their derivatives (161,163). In addition, elevated levels of creatine, choline, and inositol are found, suggesting demyelination and gliosis. The diagnosis is usually established by assay of ALDH3A2 activity in cultured skin fibroblasts, but the diagnosis can also be made by measurement of leukotriene B4 (LTB4), 20-hydroxy-LTB4 and 20-COOH-LTB4 in urine. Levels of LTB4 and 20-OH-LTB4 are elevated, while that of 20-COOH-LTB4 is absent (168) due to inability of ALDH3A2 to oxidize LTB4 to 20-COOH-LTB4 (169). Direct genetic diagnosis is now available and enables prenatal and preimplantation genetic diagnosis. Epidemiology: The prevalence in Vasterbotten county in Sweden was 8.3 per 100,000, suggesting a founder effect and inbreeding. For Sweden overall the prevalence was 0.4 per 100,000, which is roughly the global prevalence (156,168). Molecular pathogenesis: The defect in ALDH3A2 impairs oxidation of aldehydes to their corresponding carboxylic acids. The precise role of this in myelin, in the eye and in skin is not well understood, but may relate in part to turnover of lipids. In the skin, the accumulation of LTB4, a pro-inflammatory compound, likely accounts for the ichthyosis and pruritis (168).
Copyright 2006 by Taylor & Francis Group, LLC
488
Garbern
Management: Definitive therapy for SLS is not available at this time. There are no published reports on the use of growth hormone to correct the short stature in SLS patients. There are some promising disease-specific treatments. LTB4 synthesis inhibitors would be beneficial at least with respect to the pruritis (169–172). Whether this strategy benefits the ocular and CNS components of the disease is not known. Cerebrotendinous Xanthomatosis (CTX; MIM 213700) CTX is a slowly progressive syndrome of ataxia, spastic paraparesis, palatal myoclonus, dementia, cataracts, and tendinous xanthomas. Pathologic examination shows lipid deposits in the deep cerebellar and cerebral ganglia, partial myelin loss and gliosis. Menkes et al. (173) found elevated levels of cholestanol in CTX brain specimens. Setoguchi et al. (174) found that bile acid production in CTX is reduced, even though activity of cholesterol7a-hydroxylase, the rate-limiting enzyme in bile acid synthesis, is increased. Oftebro et al. (175) found that CTX patient mitochondria were unable to 27-hydroxylate 5b-cholestane-3a, 7a12a-triol. Cali et al. (176,177) found that CTX patients are deficient in sterol 27 hydroxylase, now called CYP27A1 (cytochrome P450, subfamily 27A, polypeptide 1). Clinical syndrome: Chronic infantile diarrhea is the earliest possible sign in CTX and probably is caused by the defect in bile acid metabolism (178–181). Juvenile cataracts are the presenting sign in about 75% of individuals with CTX and usually appear in the first decade (182). Tendon xanthomas are a typical finding that usually appears in the second or third decades, and affects the Achilles, elbow and wrist extensor, patellar and neck tendons. Xanthomas also can occur in internal organs, including lung, bones, and brain. A variety of neurologic signs can occur, including mental retardation, and dementia, psychiatric symptoms such as paranoid delusions, hallucinations, depression, agitation, spastic paraparesis or quadriparesis, ataxia, extrapyramidal abnormalities, and seizures. Palatal myoclonus appears to be an infrequent manifestation of CTX. Peripheral neuropathy with features of both demyelinating and axonal neuropathy has been described (183–189). Premature cardiovascular disease has been reported in CTX patients (190,191), however, others argue that factors other than CYP27A1 deficiency account for the vasculopathy, and that CYP27A1 deficiency is not a direct cause of lipoprotein abnormalities seen in some CTX patients (192). Diagnostic evaluation: The brain MRI shows cerebellar atrophy, diffuse and/or focal increase of T2 intensity in cerebral or cerebellar white matter that does not involve the U-fibers (193–201). Symmetric elevated T2 or FLAIR signal in the cerebellar white matter adjacent to the dentate nuclei is characteristic (198,200,202). MR spectroscopy is helpful and shows reduced
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
489
N-acetylaspartate, suggesting axonal dysfunction and increased lactate, suggesting mitochondrial dysfunction (200). Electrophysiological studies have shown slowing of nerve conduction in some patients (183,185,203), and neuropathy in others (189). It is possible that neurogenic changes are secondary to primary demyelination, as has been seen with CMT1 (204–209). Delay in central conduction velocities has also been reported (187,188,210). CTX can be diagnosed clinically when the classic findings are present. It is distinguished from other xanthomatous conditions by the findings of high blood and tissue cholestanol levels, which are 5–10 times above normal, low to normal blood cholesterol levels, marked reduction of chenodeoxycholic acid, and especially increased bile alcohol levels in blood or urine, which can be 500–1000 fold or more than the normal levels. Identification of homozygous or compound heterozygous mutations in CYP27A1 confirms the diagnosis of CTX and enables straightforward presymptomatic and preimplantation genetic diagnosis. Although all confirmed cases of CTX have mutations in CYP27A1, mutations affecting genes encoding cofactors required for CYP27A1 activity, adrenodoxin and adrenodoxin reductase, potentially could also cause CTX-like illness, analogous to sulfatide activator protein deficiency and MLD-like disease. Molecular pathogenesis: CYP27A1 deficiency precludes bile acid synthesis, leading to accumulation of aberrantly hydroxylated bile alcohols. Reduced levels of bile acids lead to high activity of 7a-hydroxylase, the ratelimiting enzyme in bile acid synthesis. This in turn results in high levels of bile alcohols, such as cholestanol, in body fluids and tissues. Management: CTX is a treatable leukodystrophy. In addition to supportive and symptomatic care as outlined for other leukodystrophies, specific therapies are indicated. Chenodeoxycholic acid (CDCA), a drug used to medically treat cholelithiasis, has been effective in reversing the biochemical abnormalities and in stabilizing and even reversing the clinical condition in CTX patients by bypassing the metabolic block (211,212). Long-term CDCA treatment (750 mg/day in adults) normalizes the bile acid metabolic derangement and corrects the biochemical abnormalities and neurophysiologic abnormalities (213). CDCA treatment combined with HMG-CoA reductase inhibitors has been proposed as a therapy as well (214), but lovastatin and cholestyramine were found ineffective in reducing abnormal bile alcohol synthesis (215). Canavan Disease (Canavan–van Bogaert–Bertrand Disease MIM 271900) Clinical manifestations and intial description: Canavan disease is an autosomal recessive disorder of macrocephaly, severe mental and motor retardation and spongy white matter degeneration of the brain (218) with
Copyright 2006 by Taylor & Francis Group, LLC
490
Garbern
a high prevalence of this disorder in the Ashkenazim, in which the carrier frequency has been reported to be as high as 1 in 37 (216–221). This disorder results from mutations in the ASPA gene (coding for aspartoacylase) and gives rise to N-acetylaspartic aciduria (222–224). Patients with classic Canavan disease have developmental delay, beginning as early as three to six months of age (225). Around six months of age, the head enlarges disproportionately to somatic growth, and may reach the 90th percentile or more by one year of age. Extremity and truncal hypotonia is an early and generally persistent sign. Seizures and blindness (with optic atrophy) typically occur during the second year. Irritability and sleep abnormalities are common. Feeding difficulties and dysphagia ensue, and most children do not survive beyond the first decade. Some may live beyond that with attentive care. In these cases, hypotonia evolves into spasticity with persistent quadriparesis and poor cognitive functioning (266). Milder clinical variants with onset at four to five years of age and more gradual neurologic decline have also been described (227,228). Adult variants have not been reported. Pathogenesis and pathophysiology: While aspartoacylase deficiency is the cause of Canavan disease (223,224), how inability to hydrolyze Nacetylaspartate (NAA) causes disease remains uncertain. NAA reaches very high concentrations in the mammalian brain (8–10 mM), making it the second most abundant organic acid (next to glutamate) in brain (229). Numerous attempts to deduce NAA function have been inconclusive (230–232). The striking spongiform change in white matter observed in Canavan disease suggests that NAA is important in the formation and/ or maintenance of myelin, although roles as a neurotransmitter, osmoregulator, or protein synthesis regulator have been suggested (230,232–235). NAA is synthesized in the gray matter in neuronal mitochondria by the enzyme aspartate-N-acetyltransferase (ANAT) (236–238). In contrast, aspartoacylase (ASPA) is specific to oligodendrocytes, the myelinating cells of the CNS (239–243). NAA can serve as a precursor for myelin lipid synthesis (244–246). While key elements remain to be verified, a compelling hypothesis has emerged that NAA, synthesized in neurons, is axonally transported, released, and taken up by oligodendrocytes that hydrolyze it with ASPA to acetate and aspartate. These enter multiple metabolic pathways, including lipid synthesis. Chakraborty et al. (247) have recently provided direct support for this concept in the optic nerve and Madavarao et al. have further demonstrated myelin synthesis is severely impaired in Aspa deficient mice and in Canavan disease (187a). While the primary function of NAA may be to serve as an osmolyte, the proposed mechanism would explain the spongiform change as the result of the high extracellular or high glial levels of NAA, which when injected directly into the brain is neurotoxic (248).
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
491
Canavan disease is autosomal recessive. The ASPA gene lies at 17pter-p13 (249). Over 50 ASPA mutations have been catalogued, but two mutations, Glu285Ala and Tyr231Stop, account for over 95% of Canavan mutations among Ashkenazim (219–221,250,251). While first recognized in Ashkenazi patients, Canavan disease is found in other ethnic groups as well, where other mutations are found (219,252–260). Epidemiology: Canavan disease occurs in all ethnic groups but is best recognized in the Ashkenazi Jewish population where the carrier frequency is very high (219,220). With carrier testing for Canavan disease and other recessive diseases common among this ethnic group, the number of affected children has declined. Diagnostic evaluation: With an appropriate clinical suspicion of leukodystrophy, MR imaging of the brain should be performed. Early white matter abnormalities are seen in the cerebral white matter including U-fibers, with less noticeable changes in cerebellar and brainstem white matter (261–263). Serial examinations should be obtained if clinical suspicion persists but early MR studies are normal or inconclusive. An important tool for screening for Canavan disease is MRS. NAA is particularly well suited for MRS and can be reliably measured in vivo (264). It is best to request measurement of NAA and other metabolites in an area of white matter, where NAA is normally metabolized and where it accumulates in Canavan disease (265,266). Definitive diagnosis of Canavan disease begins with biochemical testing for NAA in urine, where levels are usually over 100-fold greater than normal. NAA is also elevated in blood and cerebrospinal fluid (CSF). Measurement of aspartoacylase activity in cultured fibroblasts is possible, but usually not needed if NAA levels in blood or urine are diagnostic. Once the biochemical diagnosis of Canavan is established, genetic confirmation should be obtained, especially if other family members require testing or prenatal or preimplantation diagnosis is being considered. It is important to understand the type of testing being performed at the laboratory, since some laboratories restrict testing to specific point mutations, such as the common Ashkenazi mutations, and would miss other mutations. Management: There is no specific treatment for Canavan disease, with symptomatic management as described for other leukodystrophies. Bone marrow or hematopoietic stem cell transplantation is not likely to be effective since microglia do not normally express aspartoacylase (personal observations). Therapy of Canavan disease with recombinant viruses expressing aspartoacylase is the most promising therapy being developed. There is an ongoing trial to test adeno-associated virus 2 (AAV2) vectors to provide aspartoacylase in Canavan patients (267). While results of this trial are awaited, there has been some success in treating a rat model of Canavan disease, the tremor rat (268,269) and a mouse aspartoacylase ‘‘knock-out’’ (270).
Copyright 2006 by Taylor & Francis Group, LLC
492
Garbern
Peroxisomal disorder Adrenoleukodystrophy and adrenomyeloneuropathy(MIM 300100) Description and clinical manifestations: ALD is an X-linked recessive disorder affecting the adrenal glands and white matter (271–273). It is associated with elevation in very long chain fatty acids (VLCFA) and defective b-oxidation of VLCFA in ALD patients resulting from mutations in the ABCD1 (formerly the ALDP) gene that encodes the adrenoleukodystrophy (ALDP) protein (274–278). The term adrenoleukodystrophy should be reserved for the X-linked disorder caused by mutations of the ABCD1 gene that involves the brain clinically or radiographically. The designation adrenomyeloneuropathy is reserved for the allelic syndrome that primarily involves the spinal cord and peripheral nerves, without cerebral involvement. The term neonatal ALD has been used to describe an autosomal recessive disorder that results from defects in peroxisomal biogenesis and should be considered a subtype of Zellweger syndrome. ALD classically begins during childhood, usually between 5 and 15 years of age, with (1) behavioral changes, including withdrawn, pseudo-autistic and/or hyperactive behavior, (2) visual impairment, (3) auditory impairment, and (4) signs of parietal lobe dysfunction, such as apraxia. As the disease progresses, gait disturbance and ataxia appear, often with asymmetric involvement initially. About one-third of patients develop seizures, which may herald more rapid progression that leaves the child bedridden, spastic, quadriplegic, and totally dependent for daily functions (279–281). Adrenal insufficiency occurs in over 90% of childhood onset disease but the temporal course does not mirror that of the neurologic signs. Hyperpigmentation due to increased ACTH levels often occurs. Isolated Addison disease may be caused by mutations in the ABCD1 gene. Milder disease variants are recognized and can begin during adulthood. First described by Griffin et al. (282) adrenomyeloneuropathy (AMN) usually presents around 20–30 years of age with leg stiffness and clumsiness. Clinical signs of spastic paraparesis, dorsal column deficits, neurogenic bladder, erectile dysfunction, and mild peripheral neuropathy develop relatively slowly. Cognitive dysfunction occurs in about 40% of patients, and Addison’s disease in 85%. Gait disturbance progresses gradually over about 10–15 years, and may necessitate use of ambulatory aids or confining the patient to a wheelchair. In one series, 35% of over 1400 patients had childhood onset (281), similar to the proportion of childhood ALD in Auborg’s group of 378 patients (283). AMN is the most common adult form, and occurred in about 30% of patients in the Kennedy Krieger Institute series (281) and in 37% of patients in France (283). Five to 20% of patients with ABCD1 mutations do not have neurologic disability. Half of these patients have adrenal insufficiency and are referred to as the ‘‘Addison only’’ phenotype. A significant proportion of male
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
493
patients with Addison disease have elevated VLCFA (284–287). These patients and those who are neurologically intact without adrenal insufficiency are at risk of developing childhood cerebral ALD or AMN, but onset of neurologic signs may be delayed until the fourth decade or later. A Japanese patient with ALD has presented as a spinocerebellar syndrome (288). While ALD is generally regarded as an X-linked recessive disorder, about 40% of heterozygotes develop neurologic signs and symptoms, typically consistent with AMN (289). Rarely, presumably due to unfavorably skewed X inactivation, girls can present with childhood ALD. Pathogenesis and pathophysiology: ALD is caused by mutations in the ABCD1 gene, which is homologous to peroxisomal membrane protein 70. It is a member of the adenosine 50 -triphosphate-binding cassette (ABC) superfamily, a group of proteins that is involved in membrane transport. ABCD1 encodes a peroxisomal membrane ‘‘half transporter,’’ that probably is responsible for transport of VLCFA into peroxisomes for further metabolism. Over 670 ABCD1 mutations have been identified thus far (catalogued at www.x-ald.nl). Most families have unique or ‘‘private’’ mutations and there is no clear-cut genotype–phenotype correlation. ABCD1 knockout mice have mild neurologic signs compared to ALD patients, and do not develop the striking MRI changes or inflammatory changes characteristic of the human disease (although they do accumulate VLCFA) (290–292). The mechanism whereby VLCFAs accumulate in ALD patients is still unclear (293). The accumulation of VLCFAs logically could be explained by the observation that degradation of VLCFA by peroxisomal oxidation was impaired in cultured fibroblasts of ALD patients (276). The gene encoding VLCFA CoA synthetase (VLCS), which initiates the catabolism of VLCFA was a candidate gene for ALD. McGuinness et al. (294) recently found, however, that VLCFA oxidation was not altered in tissues of ABCD1 knockout mice, an animal model for ALD. This group provided evidence that the primary biochemical defect was interference with interactions between mitochondria, where fatty acid synthesis occurs, and peroxisomes, the site of fatty acid degradation by beta oxidation. Increased levels of long chain fatty acids, such as C16:0, impaired peroxisomal VLCFA oxidation. Thus, increased long chain fatty acid levels are the primary abnormality in ALD, and elevation of VLCFA is a secondary effect in this new model. The role of ABCD1 in this model is unclear but this explanation will likely force reexamination of long held predictions. In the earlier model, it was thought to be involved in either transport of VLCFA or of VLCS into peroxisomes. However, localization of VLCS to peroxisomal membranes is not perturbed in ALD fibroblasts. Further study will be necessary to clarify the key functions of ABCD1. How VLCFA accumulation leads to neurologic and adrenocortical damage is unclear. There is not a clear correlation between severity of the
Copyright 2006 by Taylor & Francis Group, LLC
494
Garbern
biochemical defect and neurological impairment or disease progression (295). Rather, the extent of perivascular lymphocytic infiltration in the white matter is the determining factor in childhood cerebral disease (296,297). There is true demyelination, mediated by mononuclear cells, of white matter. The accumulation of VLCFA in myelin may lead to vulnerability to an inflammatory ‘‘second hit’’ mediated by cytokines such as interleukin-1 and oligodendrocyte-toxic tumor necrosis factor-alpha (298,299). Inflammation leads to demyelination and oligodendrocyte loss. The inflammatory phase of the illness generally correlates with rapid clinical deterioration. The inflammatory component is mild or absent in patients with AMN, where more subtle mechanisms, such as appearance of gangliosides that contain VLCFA and interfere with axo-glial interactions, may operate, causing a ‘‘dying back’’ axonal degeneration (300). How the inflammatory phase is initiated is not understood. The adrenocortical pathology is characterized by accumulation of lamellar lipid striations that contain cholesterol esterified with VLCFA, which is thought to be cytotoxic (273). Similar cellular inclusions occur in the testis in Leydig cells (301). Epidemiology: The most recent estimate of ALD in the United States is that 1 per 21,000 males is affected, and that 1 per 14,000 women is heterozygous for ALD. In France, the most recent estimate is that about 1 per 15,000 males is affected by ALD (302). Differential diagnosis: Early in the disease, the main differential diagnoses for the childhood onset cerebral form of ALD are attention deficit hyperactivity disorder (ADHD) or mild autism (Asperger syndrome). In ALD the loss of cognitive abilities, handwriting skills, vision, and/or auditory discrimination are important clues that differentiate this disease from ADHD or Asperger. The differential diagnosis of more advanced cerebral ALD adds seizure disorders, neoplasms, meningoencephalitis, acute disseminated encephalomyelitis, and other leukodystrophies. The differential diagnosis of AMN should include spastic paraparesis, both acquired (e.g., transverse myelitis) and familial forms, spinal cord compression, spinal vascular malformations, multiple sclerosis, spinal neoplasm, and Chiari malformation. Differentiation between X-linked ALD and autosomal recessive neonatal ALD is very important, since the two disorders have very different inheritance. The significantly more severe clinical syndrome caused by so-called neonatal ALD should permit diagnosis of this from the X-linked syndrome, which does not have signs of cranial dysmorphism: peculiar facies, prominent forehead, dolichocephaly, low set ears, anteverted nares and wide nasal bridge, cataracts, esotropia, and epicanthal folds. Biochemical testing reveals elevations of pipecolic acid and phytanic acid in addition to VLCFA, reflective of a more extensive peroxisomal disorder.
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
495
Heterozygous females can develop neurologic signs, typically similar to AMN. If such a female has no family history of ALD the diagnosis can be elusive without a high index of clinical suspicion. The syndrome is frequently mistaken for multiple sclerosis. Symmetric parietal–occipital white matter abnormalities on MRI can suggest the disease, although this finding is present in only a small fraction of these females. VLCFA levels in the blood are elevated (303). Diagnostic evaluation: The initial diagnosis is often suggested on the basis of the brain MRI scan, which in about 85% of cases shows symmetric parieto-occipital periventricular white matter changes best appreciated on T2-weighted or fluid attenuated inversion recovery (FLAIR) scans (304). About 15% of ALD patients curiously have initial MRI changes in the frontal white matter (305). The MRI is also valuable in predicting the clinical course of disease and subtyping the syndrome (305,306). Children whose MRI scans remain normal at seven years of age are not likely to develop the cerebral form of ALD. Gadolinium contrast enhancement of lesions is a poor prognostic finding, however (307). Less than 5% of heterozygous women tested have brain MRI abnormalities suggestive of ALD (308). While standard MRI imaging studies are normal in these women, newer MR techniques such as MRS may be more sensitive to differences from normal. Elevated levels of VLCFA are the essential finding in ALD. All male patients and about 80% of female heterozygotes have high VLFCA levels (309). Blood VLCFA levels are also increased in other peroxisomal disorders, such as the Zellweger syndrome and neonatal ALD. The latter two disorders are clinically distinguishable from ALD, and biochemically also have elevations in phytanic acid and pipecolic acid, both of which are normal in ALD. Confirmation of ALD by mutation analysis is now possible, and of value not only for definitively establishing the diagnosis, but also enabling reliable prenatal and preimplantation genetic testing. Prognosis: The cerebral form of ALD carries the most severe prognosis. Once clinical signs of cerebral involvement are apparent, clinical decline proceeds at an alarming rate, and leads to a quadriplegic and totally dependent state within two years. Patients may remain in a severely disabled state for many years with attentive care. Loes et al. (306) have developed a quantitative scoring system for MRI scans of ALD patients that is helpful for estimating the likelihood of clinical progression. This has particular importance in selecting patients for BMT or SCT therapy. However, up to 30–40% of patients with ABCD1 mutations have a relatively mild AMN syndrome. While the Loes score is helpful in predicting which patients are likely to worsen, there are no reliable tests for predicting whether an asymptomatic child will have a poor or mild outcome. Mutation analysis and biochemical testing results correlate poorly with clinical outcome, and even null mutations due to large deletions can have a mild phenotype (278).
Copyright 2006 by Taylor & Francis Group, LLC
496
Garbern
The prognosis with AMN and ‘‘Addison-only’’ syndrome is considerably more favorable than that of ALD and is often compatible with normal lifespan. About 40% of these patients ultimately develop some evidence of cerebral involvement (310). Some AMN patients progress rapidly after developing cerebral abnormalities. Other complications are decubitus ulcers, bowel perforation secondary to constipation, or urinary infections. Adrenal insufficiency occurs in most patients, and can manifest as weakness, vomiting, and hypotension that can be provoked by minor infections. This potentially life-threatening complication readily responds to hormone replacement. Management: The treatment of adrenal insufficiency is important, and is managed as with primary adrenal insufficiency. Annual measurements of ACTH levels and of serum electrolytes should be done to monitor for adrenal insufficiency in patients who have not yet developed the complication and to evaluate therapy in those who are on replacement therapy, such as oral hydrocortisone 20–25 mg in the morning, and 10–15 mg in the afternoon. While corticosteroids correct the adrenal insufficiency, they do not alter the neurologic disease. The treatment of the increased VLCFA levels has received much attention because of the remarkable story of Lorenzo’s oil. Lorenzo’s oil is a mixture of glyceryl trioleate and glyceryl trierucate oils with erucic acid, the key ingredient that lowers VLCFA in cultured ALD fibroblasts and in ALD patients as well (311–313). These monounsaturated fatty acids reduce synthesis of saturated VLCFAs, presumably by competitive inhibition. Recent clinical trials have suggested that Lorenzo’s oil, which does not help children with active cerebral disease (312), may help slow the disease in presymptomatic individuals (293,313,313a). Lorenzo’s oil is generally well tolerated, but can cause symptomatic thrombocytopenia (314,315). BMT can arrest or even improve neurologic function in patients at the early stages of cerebral ALD (293,316–319), but is not effective once significant neurologic signs have developed. Related therapy using umbilical cord blood transplants is being explored, but requires further study. Imprecision in predicting clinical outcome in presymptomatic children complicates the assessment of these aggressive therapies that have significant morbidity and mortality. Pharmacologic therapy based on known aspects of disease biology and biochemistry has been tested or proposed. Beta interferon, which reduces the rate of multiple sclerosis exacerbations, failed to benefit patients with demyelinating lesions due to ALD (320). Other treatments focused more directly on the biochemical defect are promising. 4-phenylbutyrate (4PB) improves VLCFA catabolism in cultured ALD fibroblasts and in the ABCD1 knockout mouse, in which it also normalizes VLCFA blood levels (321). 4PB probably acts by different mechanisms, including altering expression of several genes including ABCD2 (formerly ALDR), which encodes a
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
497
peroxisomal protein homologous to ABCD1 that partially complement ABCD1-deficient fibroblasts (321). 4PB may also directly augment VLCFA metabolism in both mitochondria and peroxisomes, separate from its effects on ABCD2 (322). 4PB was well tolerated in a brief clinical trial in AMN patients and moreover did lower levels of VLCFA (323). Further studies are needed to determine the safety and efficacy of this promising agent. Statins, the pharmacological inhibitors of 3-hydroxy-3-methylglutaric acid coenzyme A reductase (HMG), promote oxidation of VLCFA and lower their levels in fibroblasts from ALD patients (324). In a small clinical trial, Lovastatin lowered VLCFA blood levels in a group of 12 ALD and AMN patients, although no definite clinical improvement was observed in this short-term study (325). Symptomatic and supportive care is also important. In addition, intrathecal baclofen has been reported to be quite effective; however, patients and their caretakers should be alert to signs of intrathecal baclofen withdrawal, which can cause severe spasticity, delirium, seizures, and life-threatening hyperthermia which respond to prompt reinstallation of intrathecal baclofen (326,327). Astrocytic Leukodystrophy Alexander Disease (MIM 203450) Description and clinical manifestations: Alexander is a progressive disorder of megalencephaly, hydrocephalus, developmental delay, quadriparesis, and seizures (328). Pathologic examination of the brain noted the widespread occurrence of astrocytic inclusions called Rosenthal fibers (RFs), and symmetric white matter abnormalities that are especially prominent in the frontal lobes. Although Alexander disease is probably an autosomal dominant disorder, virtually all cases are sporadic, since affected individuals do not reach reproductive age. The lack of familial cases impeded identification of the involved gene since standard linkage analysis was not possible. The fortuitous recognition of RFs in transgenic mice that overexpressed glial fibrillary acidic protein (GFAP), the major intermediate filament specific to astrocytes, prompted analysis of the GFAP gene in Alexander disease patients. Heterozygous mutations in the GFAP gene were identified in 11 of 12 infantile onset AD patients and in one juvenile onset patient (329). The most common presentation of Alexander disease is the infantile variant, which becomes apparent during the first or second year with developmental delay, followed by loss of acquired abilities, quadriparesis, cognitive impairment, seizures, and megalencephaly. The head circumference is usually greater than the 98th percentile between 6 and 18 months of age. Head enlargement may be due to obstructive hydrocephalus secondary to aqueductal stenosis caused by subependymal RFs, and can cause more rapid clinical decline. These patients usually do not live beyond the first decade.
Copyright 2006 by Taylor & Francis Group, LLC
498
Garbern
Juvenile Alexander disease may not become apparent until adolescence, when bulbar signs are prominent and associated with ataxia and spastic quadriparesis. Cognitive function may only be mildly, if at all, affected, but brainstem dysfunction can be life threatening (330–333). Juvenile onset patients can have focal lesions (334). Adult onset Alexander disease is the least common form of the disease, and resembles the juvenile onset disease, although with later onset and slower progression (332,335–339). Presentation with palatal myoclonus and abnormal eye movements can occur (340). Cases with patchy white matter lesions that may resemble those of multiple sclerosis have been described (338). Etiology: Most instances of infantile and juvenile Alexander disease are new mutations that are likely to be autosomal dominant, but are not transmitted since patients usually are not reproductively fit. The affected gene encodes GFAP, the main intermediate filament in, and specific to, astrocytes (329). In the adult variant, the autosomal dominant nature of GFAP mutations has been demonstrated (337,341,342). Pathogenesis: While there may also be locus heterogeneity, since there are cases of pathologically demonstrated Alexander disease in which no mutations have been identified (329,343), the cause of Alexander disease in the majority of cases is mutations in the GFAP gene (329). To date, 23 point mutations, all missense, have been catalogued (http://www.waisman.wisc.edu/alexander/index.html). GFAP is a rod-shaped protein, like other members of the intermediate filament family of proteins. As with many other dominant disorders, mutations may exert a dominant gain-of-function effect that leads to the mutated GFAP associating both with itself and also with its normal counterpart, forming aggregates that accumulate as RFs. RFs are round or elongated astrocytic hyaline bodies that stain with eosin, Luxol Fast blue, and hematoxylin. At the electron microscopic level, RFs are osmiophilic, granular, nonmembrane-bound bodies up to 50 mm or more in size. RFs occur at astrocytic processes and end-feet and are prominent at subpial, subependymal, and perivascular locations in Alexander disease, as well as diffusely in the white matter. They contain GFAP, aB-crystallin, and heat shock protein 27 (hsp27). Another mechanism, suggested by the observation that GFAP transgenic mice develop RFs, is that the mutated GFAP increases expression of GFAP, which in some way is toxic to astrocytes. Whether RFs are cytotoxic, per se, or represent a protective cellular response to the mutated protein has not been resolved. Study of ‘‘knock-in’’ mice with human disease-associated mutations in a GFAP-null background may help clarify key pathogenic mechanisms (344,345). Interestingly, GFAP-null mice have very minimal neurologic abnormalities further strengthening the hypothesis that disease-causing mutations act in a gain-of-function manner (346).
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
499
One of the most interesting facets of Alexander disease is the dramatic white matter change, suggesting a disturbance of oligodendrocyte dysfunction, even though the mutation targets astrocytes. This observation points to an important role for astrocytes in myelin function, as inferred experimentally in GFAP-null mice (347). Astrocytic function may be more important in the frontal lobe white matter since the changes are more prominent there. Alternatively, in the well-established role of astrocytes in forming the blood–brain barrier, GFAP mutations may disrupt the barrier, which would be consistent with observations that lesions enhance with contrast on MR imaging (348). Epidemiology: The true incidence is not known in the United States. A study of leukodystrophies in Germany indicated that Alexander disease constituted about 1.6% of all leukodystrophies. Differential diagnosis: Infantile Alexander disease should be distinguished from other leukodystrophies associated with megalencephaly, including Canavan disease, glutaric aciduria type I, and megalencephalic leukoencephalopathy with subcortical cysts (MLC), which each can be clinically similar to Alexander disease, but are usually more slowly progressive. The CACH syndrome should also be distinguished from Alexander disease, but this disorder is more slowly progressive and MRI scans do not show contrast enhancement. Adult cases need to be distinguished from multiple sclerosis and tumors. Diagnostic evaluation: An infant presenting with megalencephaly, developmental delay, and hypotonic quadriparesis should have MRI imaging and biochemical testing to evaluate conditions outlined in the previous section and other leukodystrophies as well. Symmetric frontal white matter abnormalities, with relative sparing of the occipital and cerebellar white matter should raise suspicion for Alexander disease. Contrast enhancement, especially around the frontal horns and basal ganglia, is characteristic of Alexander disease. MRS is helpful to exclude Canavan disease. Definitive testing can now be accomplished by GFAP gene analysis, obviating the need to perform brain biopsy. In the event brain biopsy shows RFs, GFAP mutation analysis should be performed. Prognosis and complications: The infantile form of disease has a poor prognosis and children typically do not survive beyond 5–10 years. With some of these children rapid decline may be due to obstructive hydrocephalus due to aqueductal stenosis, which can be temporized with shunting. Clinical decline as well as severity of neurologic signs is less in the juvenile and adult onset forms of disease. Management: No specific therapy is available for Alexander disease. Supportive and symptomatic management as described for other
Copyright 2006 by Taylor & Francis Group, LLC
500
Garbern
leukodystrophies is necessary. In addition, the added complication of obstructive hydrocephalus may necessitate ventriculo-peritoneal shunting.
Leukodystrophies Caused by Myelin Structural Proteins Pelizaeus–Merzbacher Disease and Spastic Paraplegia 2 (PMD/SPG2;MIM 312080/312920) Friedrich Pelizaeus described a family with an unusual disease for which he also noted ‘‘that the disease is passed on by the mother but does not hurt her’’ (349), consistent with what we now know is consistent with an X-linked mode of inheritance (350,351). Ludwig Merzbacher re-investigated 12 affected individuals from the same family and performed neuropathological analysis on the brain of one member. He identified the widespread loss of myelin in the cortical white matter (352). Merzbacher noted that the disease began in early neonatal life with aimless, wandering eye movements, followed by nystagmus. Infants failed to develop normal head control and displayed tremors or shaking movements of the head. The disease slowly progressed, with additional signs including bradylalia, scanning speech, ataxia and intention tremor of the upper limbs, spastic contractions of the lower limbs, athetosis, and cognitive impairment (349,352). Seitelberger subsequently described a disorder with similar pathology (353). There was nearly complete absence of myelin sheaths, and a profound loss of oligodendrocytes. Seitelberger suggested that this disease, designated the connatal form of PMD, was similar to that of Pelizaeus and Merzbacher, designated the classical form of PMD. In addition, he noted that in both disorders the absence of myelin was the primary biochemical defect, suggesting that both were leukodystrophies. Zeman et al. (354) emphasized the X-linked recessive inheritance of the disorder and speculated that the defect in PMD affected a proteolipid. Hudson et al. and Trofatter et al. (355–357) demonstrated mutations affecting the major protein component of myelin, proteolipid protein 1 (PLP1; also known as lipophilin or Folch-Lees protein, formerly PLP), cause PMD. Boespflug-Tanguy and collaborators identified several patients with PLP1 mutations who presented with spastic paraplegia without the other signs of PMD [(358), also reviewed in Ref. (359)]. Evaluation of additional patients with X-linked spastic paraplegia and mutations in the PLP1 gene showed that this syndrome could exist as either a ‘‘complicated’’ or a milder ‘‘pure’’ form in which the clinical phenotype is confined to lower limb spasticity. Clinical manifestations of PMD/SPG2: PMD usually presents in one of three typical patterns. The most severe form of disease, connatal PMD, begins during the first weeks of life, and is associated with hypotonia,
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
501
respiratory distress, stridor, nystagmus, and sometimes seizures. Because of the prominence of hypotonia and respiratory symptoms, connatal PMD can be confused with motor neuron disease or spinal muscular atrophy (300). Individuals with connatal PMD develop severe spasticity with little voluntary movement, and never ambulate. They have very poor head control and cannot sit unsupported. Growth is poor, and expressive language usually does not develop, although understanding of language is acquired to a limited degree. These individuals usually die before the second or third decade of life. The most common form of disease, classic PMD, begins during the neonatal period, usually within the first two to four months, and is associated with nystagmus, hypotonia with lower extremity weakness, and head titubation. Respiration is normal. Muscle tone progresses to spasticity later during childhood. Motor milestones are also delayed in classic PMD, and most individuals never walk independently. Patients with this disease develop spastic quadriparesis. Ataxia of trunk and limb movements is also a prominent feature of classic PMD, and dystonic posturing and movements may occur. Most individuals acquire some expressive and receptive language, which may even approach normal levels, but patients are usually dysarthric and have some degree of cognitive disability. These patients can survive until the sixth decade of life. The mildest form of PMD merges clinically with X-linked spastic paraparesis (SPG2). This disease usually begins/presents within the first five years of life, and is associated with mild to severe spastic paraplegia. There may also be limb and gait ataxia. Patients with SPG2 may have nystagmus as an early sign (358,361) or it may manifest later sign as end-gaze rather than primary position nystagmus (362,363). Motor milestones are usually delayed, but most individuals learn to walk independently during childhood; this ability may be lost later in life. Language skills and intelligence can be normal. Individuals with this form of PMD usually have a normal life span and may reproduce (358). Females heterozygous for a PLP1 gene mutation may have neurological signs and symptoms but are rarely the propositus in a PMD family. Usually symptomatic females do not have neurologic signs until adulthood, when they develop an SPG2 syndrome. Occasionally girls can have signs of PMD during infancy and childhood, but they may resolve with maturation (364). A proposed mechanism to explain this interesting phenomenon is discussed later. Some patients with PMD, typically with a complicated spastic paraparesis phenotype, have a demyelinating peripheral neuropathy (365). The neuropathy in these patients is mild, however, and not usually clinically significant (365). Etiology of PMD/SPG2: PMD and SPG2 are caused by mutations of the PLP1 gene. The most frequent cause of PMD (60–70% of cases) is duplication of the segment of the long arm of the X chromosome containing
Copyright 2006 by Taylor & Francis Group, LLC
502
Garbern
the PLP1 gene (366–369). PLP1 duplications are typically tandem in nature, involving a large genomic segment that includes neighboring genes (366, 370,371). In addition to duplications, triplications and quintuplication of the PLP1 locus also cause PMD (370). Striking variation in the position of the breakpoints occurs in different PMD families (370,371), unlike the duplication in Charcot–Marie-Tooth disease type 1A (CMT1A) (372). The duplicated segment can be as large as five megabases, which is over 150 times the size of the PLP1 locus (371). Therefore, not only might PLP1 be overexpressed in these patients, but also so might be a number of other X-linked genes. Only a fraction of genes are sensitive to dosage effects, and in the segments of the X chromosome duplicated in the PMD patients, PLP1 is apparently the sole gene in this region of the X chromosome for which changes in copy number cause phenotypic aberrations. Most families with duplications have a classical PMD phenotype (368,370,371). Unequal sister chromatid exchange in male meiosis is the major mechanism leading to duplication of the PLP1 gene (369,371). Additional mechanisms of genomic rearrangements operate at the PLP1 locus, as indicated by several families in which the duplicated copy invades another spot on the X chromosome (373). Despite the large number of duplications arising from sister chromatid exchange, the reciprocal recombination event, namely deletion of the PLP1 locus, rarely occurs (372,374). Deletion of PLP1 encompasses a much smaller segment of the X chromosome, with only two neighboring genes (372). The deletion of larger sections of the X chromosome may cause lethality or infertility. Based on the deletion breakpoints in the three identified families, a mechanism of DNA breakage followed by nonhomologous end-joining (NHEJ) similar to that proposed in some cancers (375–380) causes deletions spanning the PLP1 locus (381). Such a mechanism may also generate PLP1 duplications. In addition to the loss-of-function mutations arising from deletion events, point mutations in the PLP1 coding region at the initiation codon (382) or the second codon (363) are null for PLP1 expression. Unlike the PLP1 deletions characterized to date, these null point mutations allow for a direct examination of PLP1 loss without complicating considerations from deletion of those genes neighboring PLP1, namely the RAS superfamily member RAB9L and the thymosin b family member TMSNB (381). About 20% of PMD patients have point mutations (single base changes or small deletions or insertions) at the PLP1 locus that alter the amino acid sequence of the PLP/DM20 proteins. These include missense, nonsense, frame shift, and splicing mutations, all of which produce abnormal PLP/DM20 proteins. Of the abnormal PLP/DM20 proteins, most result in severely affected patients through a toxic gain of function (see below), while the remainder create milder disease that may be categorized as loss of function. Approximately 100 distinct mutations have been discovered to date, most of which result in missense substitutions (http:// www.geneclinics.org/profiles/pmd/pmd-table3.html).
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
503
PLP1 splice site mutations have been uncovered in PMD patients. Some of these are not located at the strictly conserved positions in the donor and acceptor splice sites, including a deletion of 19 bp within intron 3 and 26 bp in intron 5 (383,384). Although the spliced products have not been characterized in these families, splicing mutations most likely result in skipping of an exon, an event that would create an internally deleted and possibly a frame-shifted abnormal PLP1 protein. However, mutations within intron 3 that eliminate the donor splice site may leave the DM20 transcript and protein unscathed. The atypical splicing mutations at the PLP1 locus (383,384) suggest that even more splicing mutations may be found in PMD/SPG2 patients, as sequencing efforts usually concentrate on coding regions and intron/exon junctions. Point mutations in the regulatory regions of the PLP1 gene potentially could alter the expression of PLP1 without affecting the protein sequence. A putative promoter mutation has been reported in a PMD family at -34 of the PLP1 gene (385). Whether this alters PLP/DM20 expression in the reported family is not known. Additional undefined changes may occur within PLP1 regulatory elements or splice sites that affect PLP1 expression. Nonetheless, the C to T transition at -34 is of interest as it is within the area bound by the RNA polymerase complex prior to the initiation of transcription at the upstream initiation site. Clinical testing: All patients with typical signs of PMD eventually develop MRI findings consistent with a leukodystrophy, with diffusely increased signal intensity within the central white matter of the cerebral hemispheres, cerebellum, and brainstem, best seen on either T2-weighted or fluid attenuated inversion recovery (FLAIR) sequences. Indeed, the MRI abnormalities are often the first observations that lead to consideration of PMD or other leukodystrophies. Patients with the spastic paraplegia phenotype have similar MRI changes, but these may be patchy in nature (386,387) or very subtly abnormal in comparison to those of patients with the more severe forms of PMD (351,384,388). Definitive diagnosis of PMD or SPG2 requires demonstration of a mutation in PLP1. Approximately 80% of patients with clinical, genetic, and MRI features consistent with PMD have PLP1 mutations. Some of the 20% of PMD patients without PLP1 mutations have mutations in the GJA12 gene (389) (see below). PLP1 mutations can arise spontaneously with fairly high frequency, and the distribution of mutations in sporadic cases is similar to that of familial ones (369). The genetic etiology for the remaining patients is not known, but may be due either to mutations in areas of the PLP1 gene not routinely analyzed (introns and regulatory regions) or the presence of an additional autosomal or X-linked mutation causing the same phenotype (390). Because duplication of the PLP1 region is the most common cause of PMD, identification of a PLP1 gene duplication is the most efficient initial
Copyright 2006 by Taylor & Francis Group, LLC
504
Garbern
genetic screening test for diagnosing PMD. The duplications are of variable size, but are usually found within an 800-kb region of the X chromosome including the PLP1 gene (366,368,370,371). The duplicated region can also be found, however, at some distance from Xq22. One PLP1 duplication has been identified at Xp22 and a second at Xq28 (370,373). Both interphase fluorescent in situ hybridization (FISH) and quantitative polymerase chain reaction (QPCR) can detect PLP1 duplications (366,376,383,391). Duplications smaller than 50 kb, however, may not be resolved by FISH, while QPCR does not provide cytogenetic information on the location of the duplication, which could have genetic counseling implications (391,392). For these reasons, both interphase FISH and QPCR should be employed for the molecular genetic diagnosis of PMD. If neither interphase FISH nor QPCR demonstrates a PLP1 duplication, direct sequence analysis of the PLP1 gene should be performed. The PLP1 gene encodes a relatively small protein of 277 amino acids (831 bp of DNA) and the coding sequences are contained within only seven exons. Using automated sequencing methods, therefore, it is cost effective and technically straightforward to obtain the DNA sequence of the PLP1 exons and portions of their surrounding introns. When a small mutation is found, it is sometimes possible to design an allele-specific oligonucleotide hybridization test or a simple PCR/restriction digestion assay to detect the mutation, which can be particularly helpful for assessment of carrier status in females (383). Prenatal DNA diagnosis of PMD in affected males at risk for the disease has been accomplished by several groups of investigators and is now currently available at several centers (393). A PLP1 duplication in an at-risk male fetus has been identified using both interphase FISH (394) and QPCR (395). A PLP1 point mutation in an at-risk male fetus, however, has not been reported, although prenatal testing has successfully excluded such mutations (396,397). Preimplantation genetic diagnosis (PGD) for PMD is possible. Direct identification of a PLP1 duplication in single cells is technically difficult and might not be reliably distinguished from DNA replication, but indirect identification of the duplication-bearing X chromosome is possible by multiplex PCR amplification of polymorphic repeats that flank the PLP1 gene, and could potentially be used for PGD. Differential diagnosis: Other diagnostic considerations for individuals with the clinical features of PMD include MLD, ALD, Krabbe disease, Salla disease, Cockayne disease, Pelizaeus–Merzbacher-like disease, and Canavan disease. Most of these diseases, however, are not associated with nystagmus, which is common in PMD. Their diagnosis can usually be made by analysis of the appropriate enzyme or analyte. PMLD is established by analysis of the GJA12 gene. In addition, the white matter abnormalities in these conditions are often regional rather than diffuse: the occipital white
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
505
matter is most affected in ALD, while the frontal white matter is most affected in MLD. Infants with merosin deficiency can also have dramatically increased T2 signal in the cerebral white matter, but the presence of severe weakness and hypotonia and the absence of nystagmus should direct the clinician toward consideration of myopathy. A fatal X-linked syndrome of ataxia, blindness, deafness, and mental retardation has been described and is linked to Xq21-24, but the MRI does not show a pattern of leukodystrophy, and mutations in the PLP1 coding regions have been excluded (398). Finally, mutations in the cell adhesion molecule gene L1CAM cause X-linked spastic paraplegia type 1 (SPG1), a disorder associated with mental retardation and adducted thumbs which is allelic to the MASA syndrome (mental retardation, aphasia, shuffling gait, adducted thumbs) and X-linked hydrocephalus (399). MRIs of these disorders may show enlarged ventricles or agenesis of the corpus callosum, but not the diffuse abnormalities of white matter consistent with a leukodystrophy. Epidemiology: The incidence of PMD is not known precisely, but was estimated in Germany to account for about 6.5% of leukodystrophies in that country, or about 1 per 750,000 births (or 1/375,000 male births) (133). The true incidence may well be higher since the diagnosis is not infrequently missed. In a survey in the Czech Republic, the incidence was estimated at 1 per 70,000 births (399a). Molecular pathogenesis of PMD: PMD and SPG2 are caused by mutations affecting the most abundant protein in CNS myelin, proteolipid protein 1 (PLP1). PLP1 is unusually hydrophobic, and its name derives from the observations that it is soluble in organic solvents rather than aqueous buffers (400). In addition to a high composition of hydrophobic amino acids, six fatty acid chains are covalently linked to the PLP1 molecule (401). These fatty acids may mediate the association of PLP1 with the adjacent lipid leaflet in compact myelin (402). Acylation occurs autocatalytically at a stage following translation of PLP1 mRNA, a temporal pattern consistent with a role for this posttranslational modification in the stabilization and/or compaction of myelin (403,404). PLP1 is synthesized in the rough endoplasmic reticulum as a tetraspan intrinsic membrane protein with both termini on the cytoplasmic face (405,406) and subsequently transported through the Golgi complex, where other myelin lipid constituents such as cholesterol and galactocerebroside associate with PLP1 in ‘‘rafts’’ (407). Raft formation is one of the initial stages of myelin assembly, followed by the vesicular transport of PLP1 to the myelin membrane. PLP1 is extremely well conserved. PLP1 gene structure is preserved among tetrapods and readily discernible in the primordial gene of the lipophilin family present in invertebrates (408). Mammals share a nearly identical coding capacity for PLP1. Moreover, no amino acid polymorphisms have been detected in the thousands of coding regions sequenced in the human
Copyright 2006 by Taylor & Francis Group, LLC
506
Garbern
PLP1 gene. The PLP1 gene has seven exons (409). The third exon contains an internal donor splice site which is used to generate transcripts encoding the smaller (20 kDa) DM20 isoform. While identical to PLP1 in topology, DM20 is missing part of the intracellular loop that contains two acylation sites, an absence accounting for the altered conformation and physical properties of DM20 (405,410,411). DM20 is expressed during embryonic development before PLP1, but is present at about 20% the level of PLP1 in mature CNS white matter (412). The two proteins can form heteromers (413). PLP1 and DM20 perform distinct roles in the maintenance of myelin structure, since DM20 cannot fully compensate for deficiency of PLP1 in myelin (402,408). Other functions have been proposed for PLP1/DM20 based on features of these lipophilin family members resembling channel proteins, the detection of secreted fragments of PLP1/DM20, and the expression in other glial cells and outside of the nervous system (414,415). PLP1 may act as a sensor in transmitting information across the lipid bilayer (416) as PLP1, but not DM20, interacts with av-integrin as part of a signaling complex (417). Apart from oligodendrocytes, the PLP1 gene is transcriptionally active in the nervous system in olfactory ensheathing cells (418), satellite cells (419), and Schwann cells (363,420,421), where the predominant isoform expressed is DM20 (422). Schwann cell expression of PLP1/DM20 is an order of magnitude lower than that observed in oligodendrocytes, and most of the proteins produced are not normally incorporated into the myelin sheath (363,423). A low level of PLP1/DM20 expression also occurs outside of the nervous system, in the heart (424), fetal thymus, spleen (425), thyroid, testes and skin (Skoff, unpublished). In general, cells other than myelinating oligodendrocytes favor the synthesis of DM20 over PLP1. Even in oligodendrocytes, the DM20 expression profile does not always coincide with myelination, as immature oligodendrocytes selectively express DM20 (426–430). Gow and Lazzarini proposed that differences in clinical severity in patients with PLP1 coding region mutations reflect differential effect of the specific mutation on the folding and intracellular trafficking of the protein [reviewed in Ref. (431)]. Mutations that affect the folding and transport to the cell surface of both PLP1 and DM20 cause the most severe PMD phenotypes and oligodendrocyte cell death, while mutations that impair transport of PLP1 but not DM20 produce a less severe PMD phenotype that is not associated with oligodendrocyte cell death (416,432). Since mutations in which no mutant protein is synthesized cause a relatively mild syndrome, the predominant effect of PLP1 missense mutations is probably due to misfolded PLP1 gene products. The cellular and molecular effects of the accumulation of misfolded PLP1 and DM20 in the rough endoplasmic reticulum (RER) of oligodendrocytes, rather than the absence of these proteins in the myelin sheath, cause the clinical signs and symptoms of PMD. The protein misfolding also explains the effect of these mutations on female carriers. Female dogs that are heterozygous for a severe mutation
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
507
in the canine Plp1 have neurological abnormalities early in life, but by adulthood are clinically normal, have normal numbers of oligodendrocytes, and express very little mutant PLP1 messenger RNA (433). Female PMD carriers are also usually clinically unaffected, although some may have transient neurological abnormalities as children (364). In some PMD families, however, female heterozygotes are clinically affected (349). Because of random inactivation of the X chromosome on which the PLP1 gene is located, females who are heterozygous for PLP1 mutations should express the abnormal protein in approximately 50% of their oligodendrocytes. Oligodendrocytes expressing a more severe PLP1 mutation, however, in which both PLP1 and DM20 are affected, undergo increased cell death and are eliminated during myelination and replaced by normal oligodendrocytes. In contrast, oligodendrocytes expressing a less severe PLP1 mutation, which does not cause cell death, are not eliminated, thus producing abnormal myelin and neurological dysfunction. Paradoxically then, females who are heterozygous for the less severe PLP1 mutations are more likely to experience neurological difficulties as adults than are females who are heterozygous for the more severe PLP1 alleles (364,434,435). Similar observations have been noted with experimental and naturally occurring murine PLP1 mutations (Ian Griffiths, DVM, PhD, personal communication). How does accumulation of misfolded DM-20/PLP1 in the ER of oligodendrocytes affect their function? Several lines of evidence point to the involvement of the unfolded protein response (UPR), a network of genes that are induced in response to unfolded proteins and regulate expression of molecular chaperones, transcription factors, caspases, and other genes [reviewed in Ref. (436)]. Two bZip transcription factors, CHOP (CEBPbhomologous protein) and ATF3, are induced during the UPR and cause apoptosis when overexpressed in transfected cells. Expression of CHOP, ATF3, and several other RER-resident molecular chaperones are induced in oligodendrocytes in response to the synthesis of mutant PLP1 gene products, implicating the UPR in the pathogenesis of oligodendrocyte cell death in PMD (437). These investigators also discovered that rumpshaker (rsh) mice without a functional Chop gene (rsh/chop-null double mutants) have more severe disease than rsh mice, directly implicating CHOP expression in the pathogenesis of PMD. It is thus likely that the set of genes induced during the UPR plays a role in PMD pathogenesis by protecting oligodendrocytes from the toxic effects of misfolded DM20 and PLP1. Protein misfolding has been implicated in several other neurodegenerative diseases, including Alzheimer, Parkinson, and Huntington disease (438–440). The morphological features associated with protein accumulation in these diseases include amorphous aggregates in the RER, cytoplasm, or nucleus, and intermediate filament-containing aggresomes in the cytoplasm (441). Perinuclear inclusions are also observed in a variety of cell types, particularly in cultured cells treated with proteasome complex
Copyright 2006 by Taylor & Francis Group, LLC
508
Garbern
inhibitors, and are thought to form when the RER-to-cytoplasm delivery of unfolded proteins exceeds degradation by the proteasome complex. Aggresome-like inclusions are rarely found in PMD, however, because myelinating oligodendrocytes do not normally synthesize intermediate filaments. Proliferating oligodendrocyte precursor cells express vimentin and nestin in culture, but the expression of these genes stops as the cells differentiate (442). Although protein misfolding has been implicated in all of these diseases, the molecular mechanisms of oligodendrocyte cell death in PMD may thus be different than those in the more classic neurodegenerative diseases. A second pathogenic mechanism in PMD is the overexpression of PLP1 in patients with duplications or even greater dosage increases of the PLP1 gene. Excessive amounts of normal PLP1 proteins accumulate in the late endosome and lysosomal compartments of rodent cells overexpressing PLP1 (443). Since PLP1 typically associates with cholesterol and other lipids to form myelin ‘‘rafts’’ as it traffics through the Golgi compartment (407), the shunting of excess PLP1 into the endosomal/lysosomal compartment effectively drains myelin lipids from the Golgi (443). Presumably the transport and assembly of myelin constituents is altered in cells overexpressing PLP1. Thus, while abnormal PLP1 proteins trigger a protein misfolding response in the rough endoplasmic reticulum, excessive PLP1 proteins create an imbalance in myelin constituents that adversely affects the subsequent stage of nascent myelin assembly in the Golgi network. A third mechanism of molecular pathogenesis in PMD/SPG2 occurs by loss of function in patients with a deletion of the PLP1 gene (374,381,444) or with point mutations at the beginning of the coding region that preclude translation (363,382). These patients have less severe forms of the disease, with the PLP1 deletions giving rise to either a complicated form of SPG2 or a mild form of PMD (381). In mice lacking Plp1, oligodendrocytes develop normally and assemble a myelin sheath, yet defects in the intraperiod line of these sheaths translate into reduced conduction velocities and impaired motor coordination (445–449). In addition, null mutations also produce axonal pathology (see below). These pathological changes suggest there is an absolute requirement for PLP1 both to maintain the structure of compact myelin, and to maintain axonal integrity and function. Thus, the absence of PLP1 would neither trigger the unfolded protein response nor derail myelin assembly, but would instead negatively affect maintenance of the myelin sheath. Axonal damage has been found in both PMD and its animal models, which is important for understanding the pathogenesis of demyelinating disease and its treatment (450–453). Garbern et al. (453) have found evidence for axonal damage in both mice and patients with a PLP1 null mutation by a combination of direct pathological examination of brain tissue and MRS. The axonal injury is not due to demyelination, since myelin is intact in both patients and experimental animals, or oligodendrocyte cell
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
509
death, since these cells appear healthy and ensheath axons. The extent of axonal injury increases with age, and probably accounts for the progression of neurological signs and symptoms. In addition, the axonal degeneration is length dependent, suggesting that impaired axonal transport is a cause. Edgar et al. (454) have directly demonstrated that Plp1-deficient optic nerves have reduced axonal transport. Interestingly, retrograde transport was disturbed earlier and to a greater extent than was anterograde transport. These data suggest that progressive axonal damage is not only a common feature of the pathogenesis of PMD, but it may also be clinically relevant. Because axonal degeneration occurs without significant demyelination, it probably arises from the absence or perturbation of PLP1-mediated oligodendrocyte–axonal interactions (455). Consistent with this notion, Scherer and collaborators have shown that axoglial junctions at the paranodal region are disrupted in md rats, an animal model with a Plp1 point mutation, and that these changes are probably involved in disease pathogenesis (456). No simple correlation has been found between a particular PLP1 mutation or genotype, and the clinical manifestation of the disease or phenotype. Although most patients with duplications have the classic form of PMD (371), some have the more severe connatal form (457), while others have a milder spastic paraparesis. Inoue and co-workers recently analyzed the duplication size and structure in 20 families with PMD and suggested that the size of the PLP1 duplication correlated with the clinical phenotype, so that patients with larger duplications had more severe disease (371). In a similar study of 16 families with PLP1 duplications, however, Hobson and co-workers did not confirm this finding (Hobson et al., in preparation), suggesting that other structural features of the duplication, such as the location, breakpoint, or orientation may also play a role. Callioux et al. (384) recently compared the clinical phenotype and genotype in 33 families with PLP1 point mutations. They found that single amino acid changes within evolutionarily conserved regions of the protein produced the most severe disease, while substitutions of less conserved amino acids, protein truncations, null mutations, and mutations within the PLP1-specific region (amino acids 116–150) produced a milder form of disease. Although exceptions to this rule occur, more severe forms of disease are likely to be associated with missense mutations within highly conserved regions of the protein. Garbern et al. (363,453) analyzed several families with PLP1 mutations in which no protein product was produced, so-called null mutations. These patients all had a relatively mild spastic paraparesis which progressed during adolescence and an associated demyelinating peripheral neuropathy identified during electrophysiological testing. The neuropathy was not correlated with disease severity, and was not found in patients with either duplications or point mutations in which protein was produced. Taken together, these
Copyright 2006 by Taylor & Francis Group, LLC
510
Garbern
data suggest that individuals with a relatively mild form of disease and peripheral neuropathy are likely to have a null mutation. Management and future prospects: Currently, there is no therapy for patients with PMD apart from supportive and symptomatic care. Developing disease-specific therapies will require understanding of the genetic bases of disease. The observation that most patients with PMD have a gene duplication and thus overexpress PLP1, or have a point mutation causing a gain of function precludes simple replacement gene therapy, even if appropriate delivery vehicles become available. For most patients, the more appropriate goal might be the reduction of PLP1 expression, such as through siRNA or antisense RNA therapy, since lack of PLP1 results in a less severe syndrome than connatal or classic PMD. The finding that axonal degeneration is clinically relevant in the pathogenesis of PMD also raises the possibility that therapy directed at maintaining the integrity of axons might be effective in this disorder. Pharmacologic modulation of the UPR potentially could improve myelination by preventing oligodendrocyte apoptosis. Cellular therapy, such as transplantation of oligodendrocyte precursors into the CNS, has shown potential in animal models of PMD (458–464) and might therefore be effective in patients. Cellular therapy has not yet reversed the clinical deficits in animal models, however, and for maximum effectiveness, this therapy may need to be initiated either in utero or shortly after birth. Pelizaeus–Merzbacher-Like Disease (PMLD; MIM 608804) Uhlenberg et al. (389) identified a syndrome caused by mutations in the GJA12 gene, which encodes the GJA12 gap junction protein (connexin 46.6). The GJA12 gene lies at 1q41–q42, and mutations result in the autosomal recessive Pelizaeus–Merzbacher-like disease (PMLD) syndrome. In one consanguineous Turkish family and in two nonconsanguineous families in whom PLP1 mutations had been excluded, the clinical syndrome began with nystagmus between birth and three months of age followed by delayed developmental milestones. Only one of the five children walked, and she became wheelchair dependent after just 1.5 years of independent ambulation. Four of the five children developed partial seizures, and most had mild slowing of motor and sensory nerve conduction velocity in the legs. The MRI abnormalities were indistinguishable from those found in PMD. While mice deficient in either Gjb1 (connexin 32) or Gja12 (connexin 47 in the mouse) display no behavioral abnormalities, mice that lacked both Gjb1 (connexin 32) and Gja12 develop a fatal hypomyelinating syndrome, demonstrating an important, but as yet to be characterized, role in CNS myelination (404,405). Mutations in the human GJB1 cause X-linked Charcot-Marie-Tooth disease (CMTX1; MIM 302800), a peripheral neuropathy. Interestingly, some CMTX1 patients develop transient central
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
511
neurologic signs associated with brain white matter abnormalities, particularly in the posterior corpus callosum and parietal white matter (466–472). Uhlenberg and colleagues did not find GJB1 mutations in their PMLD families, showing that both GJB1 and GJA12 may have important biological roles in man that are not manifested in mice, which are able to compensate for deficiency of either connexin alone, but not both together. Disorder of protein synthesis CACH/Vanishing White Matter (CACH/VWM; MIM 603896) This syndrome has been described as childhood ataxia with central nervous system hypomyelination (CACH) (473) and as vanishing white matter disease (VWM) (474). Subsequently, the Cree leukoencephalopathy (475,476) and leukoencephalopathy with ovarian failure (477–479) were discovered to be allelic to CACH/VWM. The syndrome is characterized by delayed ataxia, quadriparesis, and optic atrophy that may worsen in a stepwise fashion and is associated with leukodystrophy and cystic degeneration of the cerebral white matter. The syndrome is caused by autosomal recessive mutations affecting any of five subunits of the eIF2B translation initiation factor (480,481). Clinical Syndromes Many phenotypes of CACH/VWM can occur, from a severe infantile form to an adult-onset form. The infantile form rapidly progresses after a period of relatively normal early development, followed by loss of acquired abilities, ataxia, impaired consciousness, and irritability that often follow a febrile illness or relatively minor head trauma (482,483). Among the North American Cree Indians, the syndrome is characterized by seizures, spastic quadriparesis, hyperpnea, vomiting, and loss of abilities that begin at about three to six months of age and is fatal by about two years of age (475). In the early childhood form, children have normal early development, although there may be mild motor or cognitive delay. Ataxia is the first significant sign and develops between one and five years of age. Neurologic deterioration may occur with febrile illness or mild head trauma (473,474,484). Later, progressive spastic quadriparesis, vision loss, dysarthria, dysphagia, and seizures ensue, although there may be relative stability at times. Peripheral nerve function remains normal, and cognition is relatively spared. There can be great intra- and inter-familial variability in progression rates. Patients with the juvenile form of CACH/VWM have onset of symptoms between about five and 15 years of age. The syndrome is similar to that of the early childhood form, but with slower progression, and even periods of relative stability and clinical improvement of motor function (473,485). Rapid deterioration ending in fatality can unfortunately occur (485).
Copyright 2006 by Taylor & Francis Group, LLC
512
Garbern
The adult-onset form of CACH/VWM may present with transient motor or visual symptoms and signs followed by behavioral, cognitive, and/or motor decline. Some patients develop ovarian failure, sometimes without overt neurologic signs (although the brain MRI is abnormal) (479,486). Primary ovarian failure may be the presenting syndrome in some women. Other organs can be involved as well, including the lens, kidneys, and liver (426). Patients who are compound heterozygotes for mutations in a subunit of eIF2B can remain asymptomatic even when another family member has neurologic signs; therefore, there may be genetic modifiers or environmental factors that have an important effect on disease pathogenesis (487). Etiology: Recessive mutations in any of the genes encoding subunits of the eIF2B translation initiator factor cause CACH/VWM (480,481). Patients can either be homozygous or compound heterozygous for mutations in a given gene (eIF2B1 through eIF2B5). Diagnostic evaluation: With the above clinical syndromes and MRIs that show diffuse nonenhancing white matter abnormalities (including the U-fibers but sparing the putamen) and evolve into cystic areas with the imaging and MRS characteristics of cerebrospinal fluid, the diagnosis of CACH/ VWM should be entertained (474). Mutations have been found in more than 95% of patients with a characteristic syndrome and MRI findings. The eIF2B5 gene is the most frequently affected subunit gene, accounting for 18 of the 37 known mutations (http://www.genetests.org/profiles/cach/ index.html and at http://www.hgmd.org). Mutations affecting subunits 2, 3, and 5 of eIF2B are associated with ovarian failure and white matter disease. Pathologically, CACH/VWM is characterized by cavitation of the white matter, with relative sparing of axons (483,488–490). Where the white matter has not been destroyed, there are increased numbers of oligodendrocytes with ‘‘foamy’’ cytoplasm and that express oligodendrocyte-specific markers such as carbonic anhydrase II (490). There is also marked apoptosis of oligodendrocytes, leading to the cavitation of white matter. Molecular pathogenesis: The eIF2B translation initiation factor is a complex of five subunits that activates initiation factor 2 (eIF2) from an inactive GDP-bound form to an active eIF2–GTP complex, permitting formation of the 43S complex, and initiating protein translation. How mutations in this ubiquitous protein complex cause such a restricted syndrome is not clear (491–494). Presumably oligodendrocytes, among the most biosynthetically active cells in the body during active myelination, that are deficient in one of the eIF2B subunits cannot meet the demands of myelination, triggering apoptosis. While this explanation would be reasonable for the infantile syndrome, it does not explain the adult-onset disease adequately. The frequent clinical worsening with febrile illness suggests that the mutations may cause thermoinstability of the affected protein, but direct examination of this
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
513
possibility failed to confirm the hypothesis (494). All mutations tested thus far impair eIF2B activity. Since mutations alter protein structure, misfolding of eIF2B subunits may activate the UPR, as with some PLP1 mutations (discussed above). So far, all mutations are either missense mutations or result in altered splicing of the affected gene. Null mutations would likely be lethal, as is the case in Saccharomyces. Epidemiology: The precise incidence and prevalence of CACH/ VWM are not known at this time, but it may be as common as MLD (http://www.genetests.org/profiles/cach/index.html). Differential diagnosis: MRI can help differentiate CACH/VWM from other leukodystrophies. Most of the leukodystrophies do not have cystic degeneration, and tend to spare the U-fibers and/or have a regional brain predilection. Some mitochondrial disorders such as pyruvate dehydrogenase and pyruvate carboxylase deficiencies may cause very similar MRI changes that can be difficult to distinguish from those seen in CACH/ VWM (495,496). MR spectroscopy can be very helpful in these cases, showing elevation of cerebral lactate (496). In some cases, evaluation of tissue mitochondrial function may be needed. In megalencephaly with leukoencephalopathy and cystic degeneration (MLC), subcortical cysts are always present in the anterior temporal area and sometimes elsewhere, but do not show the diffuse changes characteristic of CACH/VWM. In Alexander disease the white matter changes usually occur with frontal predominance and there is a relatively unique pattern of contrast enhancement that is not seen in CACH/VWM (348). Management: Specific treatment is not available for CACH/VWM. In view of the frequent acceleration of disease with fever, it is logical to recommend aggressive treatment, and prevention of infections. Disorders of uncertain pathophysiology Cockayne Syndrome (MIM 216400) Description and clinical manifestations: Cockayne (497,498) syndrome is a multisystem disorder of dwarfism, cataracts, optic atrophy with pigmentary retinitis without spicules characteristic of retinitis pigmentosa, mental retardation, facial dysmorphism, and deafness (497–500). Clinical features have been interpreted to mimic progeria and fibroblasts show abnormalities of DNA repair (501). CKN1 mutations (also CSA) cause Cockayne (502) syndrome, while a clinically similar but more severe syndrome, Cockayne syndrome II, is caused by mutations in the excision-repair cross-complementing rodent repair deficiency, complementation group 6 gene, ERCC6 (CSB) (503).
Copyright 2006 by Taylor & Francis Group, LLC
514
Garbern
Cockayne syndrome is an autosomal recessive syndrome characterized by short stature, microcephaly, mental retardation, dental caries, malformed ears, slender nose, hypertension, hepatosplenomegaly, skeletal abnormalities, characteristic senile appearance, retinopathy, sensorineural hearing loss, and leukodystrophy (504). Growth failure begins postnatally during the first two years of life in a child with normal stature at birth. By four to five years, the child is at least two standard deviations below the mean. The characteristic facial appearance that gives the child ‘‘wizened’’ facies also develops over the first few years. Mental retardation of moderate to severe degree, ataxia, and extreme skin photosensitivity to sunlight are common. In contrast to xeroderma pigmentosum, skin malignancies are not common. Dry scaly skin and thin hair are often present. Eye abnormalities are prominent in Cockayne syndrome. Abnormalities include a fine pigmentary retinopathy that worsens over time and is associated with abnormal electroretinography. Other findings include cataracts, nystagmus, strabismus, and decreased lacrimation, but functional vision is often not noticeably affected. Sensorineural deafness occurs later in childhood and can be mild to severe. Deafness may impair speech, which is usually delayed, but most children learn to speak, and are socially interactive. Endocrine, renal, and hepatic abnormalities may also occur. As a result of both central and peripheral nervous system myelin abnormalities, children develop progressive spastic paraparesis, ataxia, dystonia, and cognitive decline. Joint contractures, including scoliosis, are common late in the course of the disease. The disease is typically fatal by early adulthood. Lowry et al. (505) recognized children with abnormalities present at birth that resembled the major features of Cockayne syndrome, and that carried an even poorer prognosis. This is now designated Cockayne syndrome II. Etiology: Cockayne syndrome I and II are autosomal recessive syndromes that result from abnormalities in the transcription-coupled repair (TCR) subpathway of nucleotide excision repair (NER) (506,507). The syndromes are caused by mutations in the CKN1 (CSA) and ERCC6 (CSB) genes. Pathogenesis and pathophysiology: Defects in the transcriptioncoupled DNA repair subpathway cause Cockayne syndromes I and II. This defect can be detected directly in Cockayne syndrome patient fibroblasts which cannot repair ultraviolet (UV) light-induced DNA damage (506). UV irradiation impairs DNA repair in normal and Cockayne syndrome cells, but the latter do not recover as do healthy cells, which regain the ability to repair DNA from transcriptionally active regions (508). The transcription-coupled DNA repair is a part of the so-called nucleotide excision repair pathway that is important for repair of DNA damage (509–511). Classic
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
515
genetic complementation experiments in cultured patient fibroblasts were instrumental in defining major pathways involved in DNA repair (501). The gene for Cockayne syndrome I, CKN1 (also CSA), was assigned to complementation group A and identified as a WD repeat protein (named after the occurrence of tryptophan-aspartate repeats) (512). WD repeat proteins are involved with diverse cellular regulatory functions, including gene regulation, signal transduction, and apoptosis (513). The gene for Cockayne syndrome II, ERCC6 (also CSB), was assigned to complementation group B and is an excision repair gene (514,515). ERCC6 belongs to a family of ATPases that are not involved in unwinding DNA (515). The precise function(s) of ERCC6 are not well understood, but it may have a more prominent role in repair of oxidative DNA damage (507,516). How the defects in CKN1 and ERCC6 cause the observed neurologic syndrome is poorly understood, but in addition to their roles in DNA repair, they probably are also involved in transcription (511). Epidemiology: Cockayne syndrome is very rare and precise estimates of its incidence and prevalence are not known. Differential diagnosis: The non-neurologic features of Cockayne syndrome are distinctive enough to enable ready distinction from other leukodystrophies. The photosensitivity is also seen in children with xeroderma pigmentosum, with which it shares biological similarity since both conditions are caused by defects in proteins involved in DNA repair. Xeroderma pigmentosum is generally distinguished from Cockayne syndrome by the increased incidence of skin neoplasms in xeroderma pigmentosum and the lack of leukodystrophy. Sjo¨gren–Larsson syndrome is characterized by short stature, mental retardation, skin abnormalities, photophobia, seizures, macular degeneration, and arrested myelination. The skin rash is pruritic and icthyotic and should be distinguishable clinically. DNA repair in fibroblasts is normal. Diagnostic evaluation: The clinical syndrome of Cockayne syndrome is distinctive and should be considered in a child with acquired short stature, typical facies, mental retardation, photosensitive skin, ataxia, and pigmentary retinopathy. The MRI shows a delayed myelination pattern, with myelin in the basal ganglia, internal capsule, splenium and genu, similar to that in Sjogren–Larsson syndrome. Children with Cockayne syndrome generally have thickened skulls, however, and the skin photosensitivity, facial appearance, and ocular findings should be distinguishable clinically from Sjogren–Larsson syndrome. Screening for Cockayne syndrome is most often accomplished by testing fibroblasts for ability to repair UV lightinduced DNA damage. Direct genetic testing for CKN1 and ERCC6 is available in a few laboratories.
Copyright 2006 by Taylor & Francis Group, LLC
516
Garbern
Prognosis: Cockayne syndrome patients may survive into the third or fourth decades, and some exceptional patients have lived even longer (507). Management: There is currently no specific therapy for Cockayne syndrome, but attention needs to be paid to the unique complications of the disorder. Protection from UV light is important to minimize dermatologic complications. Unfortunately, growth hormone does not improve stature (504). Low vision and hearing impaired skills should be taught in anticipation of blindness and deafness occurring. Treatment of hypertension, renal, dental, and orthopedic complications should be anticipated. Megalencephalic Leukoencephalopathy with Cysts (MLC: MIM 604004) Megalencephalic leukoencephalopathy with cysts (MLC) is an autosomal recessive syndrome originally described in 1995 (518). Excessive head growth was apparent during the first year of life in patients, after which it stabilized at about the 98th percentile. Early development was usually at most mildly delayed, and most children learned to walk independently. During early childhood, slow progression of spastic quadriparesis, ataxia, and dysarthria occurs. Cognition is generally relatively well preserved until late in the course of the disease. Seizures are common. Children are unusually sensitive to minor head trauma, which can provoke seizures or impairment of consciousness. Occasionally patients may present only with macrocephaly without neurologic abnormalities, even by teenage years, and then have slow progression with retention of independent ambulation until middle adulthood. Survival data are limited, but survival into the third through fifth decades appears to be typical. There can be considerable intra and interfamilial variability in disease onset and progression. MLC is caused in some patients by mutations in the MLC1 gene but there is likely locus heterogeneity (519). The MRI findings in MLC are diagnostic and characterized by (1) diffusely mildly swollen cerebral white matter, with relative sparing of the cerebellar white matter and central white matter (corpus callosum, internal capsule, and brainstem tracts), (2) subcortical cysts that are always present in the anterior temporal lobes and usually in the fronto-parietal regions as well, and (3) subsequent replacement of white matter swelling by cerebral atrophy. Pathologically, there are numerous vacuoles in the myelin, suggesting lamellar splitting along the intraperiod line (520). Epidemiology: MLC is rare with higher rates in communities where consanguinity is more prevalent, including Turkey (521), the Agarwal community in Eastern India (522,523), and among Libyan Jews (524,525). MLC has characteristic MRI findings and a relatively mild disease course. Some
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
517
specific points can differentiate MLC from (1) Alexander disease, which has frontal predominance of MRI abnormalities and contrast enhancement (348) and does not usually undergo cystic degeneration and from (2) CACH/VWM, which has more widespread cystic changes, does not have megalencephaly, and is usually more clinically severe. Etiology: About 65% of MLC patients are homozygous or compound heterozygotes for MLC1 mutations (519,526). Existence of another locus is suspected. Thus far, all patients with mutations in MLC1 have a leukoencephalopathy; no other phenotypes have been observed. Management: There is no specific therapy for MLC. Genetic confirmation of a MLC1 mutation enables prenatal and preimplantation testing in addition to definitive diagnosis of this disorder. Molecular pathogenesis: The biological role of MLC1 is not known, but its structure suggests that it is an integral membrane protein of relatively recent evolutionary origin. It is expressed widely throughout the CNS and in extraneuronal tissues as well. Peripheral Demyelinating Neuropathy, Central Demyelinating Leukodystrophy, Waardenburg Syndrome and Hirschsprung Disease (PCWH; MIM 277580) Inoue et al. (527,528) described several patients with severe abnormalities, including long-segment Hirschsprung megacolon, congenital hypomyelinating peripheral neuropathy, sensorineural deafness, white forelock, dysmorphic facies, and impaired brain myelination. They have designated this syndrome PCWH, for the major features of Peripheral demyelinating neuropathy, Central dysmyelinating leukodystrophy, Waardenburg syndrome, and Hirschsprung disease. The disorder is allelic to one form of the Waardenburg–Shah syndrome (MIM 277580) caused by null mutations of the SOX10 gene. Patients with PCWH so far are all heterozygous for spontaneous mutations in the last exon of SOX10 (529). Clinical findings: The syndrome begins with recognition of longsegment Hirschsprung megacolon, which requires surgical treatment; other early signs include severe hypotonia due to the congenital dysmyelinating peripheral neuropathy, and skin pallor. Nystagmus can be present at birth, or develop later. Developmental delay and sensorineural deafness are present in all patients. The most severely affected patients have cerebral white matter abnormalities that resemble those seen in PMD. White forelock and heterochromia iridis are apparent during infancy or childhood. Most patients have spastic paraplegia, though some patients may learn to walk. Patients described thus far are new mutations, but the mode of inheritance should be autosomal dominant. Most patients though are not reproductively fit.
Copyright 2006 by Taylor & Francis Group, LLC
518
Garbern
Diagnosis: The combination of clinical signs should be highly suggestive of the syndrome. Direct SOX10 mutation detection, which should reveal an exon 5 nonsense mutation, confirms the diagnosis. Molecular pathogenesis: The SOX10 gene encodes a transcription factor of the high mobility group family. SOX10 has been implicated in the regulation of expression of several CNS and PNS myelin genes as well as in regulation of genes important in neural crest development (529–535). Mutations that are responsible for the full PCWH syndrome generate transcripts that escape nonsense-mediated decay (NMD) RNA surveillance and encode products with truncations in the transactivation domain, but do not affect the DNA binding domain of the protein (529). These truncated SOX10 products act in a dominant-negative fashion and bind to target DNA sequences with greater affinity than does the normal SOX10 protein. Transcripts with nonsense mutations in more proximal exons are subject to NMD and in effect act as null alleles and demonstrate haploinsufficiency of the SOX10 gene. This results in the Waardenburg–Shah syndrome, which is a more restricted and less severe syndrome than PCWH. CLOSING THOUGHTS The leukodystrophies are diverse genetic disorders illustrating the roles of myelin in nervous system function, and defining the biochemical pathways and molecules important in myelin synthesis and maintenance. Additional genes will be identified as affected in leukodystrophies that currently remain unclassified as to cause. To date, no human diseases are linked to mutations in the genes for myelin basic protein (MBP), 20 ,30 -cyclic nucelotide 30 –phophodiesterase (CNP1) or UDP-galactose: ceramide galactosyltransferase (CGT), which are all major proteins in CNS myelin. Viable null mutations in mice for each of these result in dysmyelination and neurologic syndromes of different degrees and suggest that human diseases linked to these genes are likely (9,536,537). With better understanding of the complex biosynthesis, organization, and maintenance of myelin components, rational approaches to diagnose and treat leukodystrophies should appear. RESOURCES Genetests: www.genetests.org United Leukodystrophy Foundation: www.ulf.org Myelin Project: www.myelin.org PMD Foundation: www.pmdfoundation.org NORD: www.rarediseases.org European Leukodystrophy Association: www.ela-asso.com Human Gene Mutation Database (http://uwcmml1s.uwcm.ac.uk/uwcm/ mg/hgmd/search.html)
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
519
REFERENCES 1. Bielschowsky M, Henneberg R. Uber familiare diffuse Sklerose (Leukodystrophia cerebri progressiva hereditaria). J Psychol Neurol (Lpz) 1928; 36:131–181. 2. Powers JM. The Leukodystrophies: overview and classification. In: Lazzarini RA, ed. Myelin Biology and Disorders. New York: Elsevier Academic Press, 2004: 663–690. 3. Paus T, Collins DL, Evans AC, Leonard G, Pike B, Zijdenbos A. Maturation of white matter in the human brain: a review of magnetic resonance studies. Brain Res Bull 2001; 54(3):255–266. 4. Barkovich AJ, Kjos BO, Jackson DE Jr. Norman D. Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T. Radiology 1988; 166(1 Pt 1): 173–180. 5. Barkovich AJ. Concepts of myelin and myelination in neuroradiology. Am J Neuroradiol 2000; 21(6):1099–1109. 5a. Barkovich AJ. Magnetic resonance techniques in the assessment of myelin and myelinnation. J Inherited Metab Dis 2005; 28:311–343. 6. van der Knaap MS, Valk J. MR imaging of the various stages of normal myelination during the first year of life. Neuroradiology 1990; 31(6):459–470. 7. van der Knaap MS, Valk J. Magnetic resonance of myelin, myelination, and myelin disorders. 3rd ed. Berlin: Springer, 2005. 8. Chirala SS, Chang H, Matzuk M, Abu–Elheiga L, Mao J, Mahon K, Finegold M, Wakil SJ. Fatty acid synthesis is essential in embryonic development: fatty acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad Sci USA 2003; 100(11):6358–6363. 9. Coetzee T, Fujita N, Dupree J, Shi R, Blight A, Suzuki K, Popko B. Myelination in the absence of galactocerebroside and sulfatide: normal structure with abnormal function and regional instability. Cell 1996; 86(2):209–219. 10. Nissl F. Encyklopaedie der mikroscopischen Technik. In: Erlich P, Krause R, Mosse M, Rosin H, Keigert K, eds. Nervernsystem. 2nd ed. Berlin: Urban und Schwarzenberg, 1910:284–342. 11. Alzheimer A. Beitraege zur Kenntnis der pathologischen Neuroglia und ihre Beziehung zu den Abbauvorgangen im Nervengewebe. In: Nissl F, ed. Histologische und Histopathologische Arbeitn ueber die Grosshirnrinde. Jena: Gustav Fischer, 1910:401–562. 12. Witte F. Ueber pathologische Abbauvorgaenge im Zentralnervensystem. Muench Med Wochenschr 1921; 68:69. 13. Jatzkewitz H. [Two types of cerebroside sulfates as so-called prelipids and storage substances in leukodystrophy of type Scholz (metachromatic form of diffuse sclerosis)]. Hoppe Seylers Z Physiol Chem 1958; 311(4–6):279–282. 14. Austin JH. Metachromatic sulfatides in cerebral white matter and kidney. Proc Soc Exp Biol Med 1959; 100(2):361–364. 15. Austin J, McAfee D, Armstrong D, O’Rourke M, Shearer L, Bachhawat B. Low sulfatase activities in metachromatic leukodystrophy (MLD). A controlled study of enzymes in 9 living and 4 autopsied patients with MLD. Trans Am Neurol Assoc 1964; 89:147–150. 16. Mehl E, Jatzkewitz H. Evidence for the genetic block in metachromatic leukodystrophy (MLD). Biochem Biophys Res Commun 1965; 19:407.
Copyright 2006 by Taylor & Francis Group, LLC
520
Garbern
17. Stein C, Gieselmann V, Kreysing J, Schmidt B, Pohlmann R, Waheed A, Meyer HE, O’Brien JS, von Figura K. Cloning and expression of human arylsulfatase A. J Biol Chem 1989; 264(2):1252–1259. 18. Kreysing J, von Figura K, Gieselmann V. Structure of the arylsulfatase A gene. Eur J Biochem 1990; 191(3):627–631. 19. Polten A, Fluharty AL, Fluharty CB, Kappler J, von Figura K, Gieselmann V. Molecular basis of different forms of metachromatic leukodystrophy. N Engl J Med 1991; 324(1):18–22. 20. Eng B, Nakamura LN, O’Reilly N, Schokman N, Nowaczyk MM, Krivit W, Waye JS. Identification of nine novel arylsulfatase a (ARSA) gene mutations in patients with metachromatic leukodystrophy (MLD). Hum Mutat 2003; 22(5):418–419. 21. Hagberg B, Sourander P, Svennerholm L. Sulfatide lipidosis in childhood. Report of a case investigated during life and at autopsy. Am J Dis Child 1962; 104:644–656. 22. Gordon N. The insidious presentation of the juvenile form of metachromatic leucodystrophy. Postgrad Med J 1978; 54(631):335–337. 23. Hyde TM, Ziegler JC, Weinberger DR. Psychiatric disturbances in metachromatic leukodystrophy. Insights into the neurobiology of psychosis. Arch Neurol 1992; 49(4):401–406. 24. Fressinaud C, Vallat JM, Masson M, Jauberteau MO, Baumann N, Hugon J. Adult-onset metachromatic leukodystrophy presenting as isolated peripheral neuropathy. Neurology 1992; 42(7):1396–1398. 25. Balslev T, Cortez MA, Blaser SI, Haslam RH. Recurrent seizures in metachromatic leukodystrophy. Pediatr Neurol 1997; 17(2):150–154. 26. Bostantjopoulou S, Katsarou Z, Michelakaki H, Kazis A. Seizures as a presenting feature of late onset metachromatic leukodystrophy. Acta Neurol Scand 2000; 102(3):192–195. 27. Cappell MS, Marks M, Kirschenbaum H. Massive hemobilia and acalculous cholecystitis due to benign gallbladder polyp. Dig Dis Sci 1993; 38(6):1156–1161. 28. Kim TS, Kim IO, Kim WS, Choi YS, Yeon KM, Hwang YS. Involvement of the gallbladder in childhood metachromatic leukodystrophy: ultrasonographic findings. J Ultrasound Med 1996; 15(12):821–825. 29. Barth ML, Fensom A, Harris A. Missense mutations in the arylsulphatase A genes of metachromatic leukodystrophy patients. Hum Mol Genet 1993; 2(12): 2117–2121. 30. Barth ML, Fensom A, Harris A. The arylsulphatase A gene and molecular genetics of metachromatic leucodystrophy. J Med Genet 1994; 31(9):663–666. 31. Berger J, Loschl B, Bernheimer H, Lugowska A, Tylki-Szymanska A, Gieselmann V, Molzer B. Occurrence, distribution, and phenotype of arylsulfatase A mutations in patients with metachromatic leukodystrophy. Am J Med Genet 1997; 69(3):335–340. 32. Gieselmann V, Polten A, Kreysing J, von Figura K. Arylsulfatase A pseudodeficiency: loss of a polyadenylylation signal and N-glycosylation site. Proc Natl Acad Sci USA 1989; 86(23):9436–9440. 33. Hageman AT, Gabreels FJ, de Jong JG, Gabreels-Festen AA, van den Berg CJ, van Oost BA, Wevers RA. Clinical symptoms of adult metachromatic
Copyright 2006 by Taylor & Francis Group, LLC
Leukodystrophies
34.
35.
36.
37.
38.
39.
40.
41.
42.
43. 44.
45. 46.
47.
521
leukodystrophy and arylsulfatase A pseudodeficiency. Arch Neurol 1995; 52(4):408–413. Ricketts MH, Goldman D, Long JC, Manowitz P. Arylsulfatase A pseudodeficiency-associated mutations: population studies and identification of a novel haplotype. Am J Med Genet 1996; 67(4):387–392. Hohenschutz C, Eich P, Friedl W, Waheed A, Conzelmann E, Propping P. Pseudodeficiency of arylsulfatase A: a common genetic polymorphism with possible disease implications. Hum Genet 1989; 82(1):45–48. Gieselmann V, Fluharty AL, Tonnesen T, Von Figura K. Mutations in the arylsulfatase A pseudodeficiency allele causing metachromatic leukodystrophy. Am J Hum Genet 1991; 49(2):407–413. Barth ML, Fensom A, Harris A. Prevalence of common mutations in the arylsulphatase A gene in metachromatic leukodystrophy patients diagnosed in Britain. Hum Genet 1993; 91(1):73–77. Kappler J, Leinekugel P, Conzelmann E, Kleijer WJ, Kohlschutter A, Tonnesen T, Rochel M, Freycon F, Propping P. Genotype–phenotype relationship in various degrees of arylsulfatase A deficiency. Hum Genet 1991; 86(5):463–470. Kappler J, Potter W, Gieselmann V, Kiessling W, Friedl W, Propping P. Phenotypic consequences of low arylsulfatase A genotypes (ASAp/ASAp and ASA/ASAp): does there exist an association with multiple sclerosis? Dev Neurosci 1991; 13(4–5):228–231 Penzien JM, Kappler J, Herschkowitz N, Schuknecht B, Leinekugel P, Propping P, Tonnesen T, Lou H, Moser H, Zierz S, et al. Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease. Am J Hum Genet 1993; 52(3):557–564. Regis S, Filocamo M, Stroppiano M, Corsolini F, Caroli F, Gatti R. A 9-bp deletion (2320del9) on the background of the arylsulfatase A pseudodeficiency allele in a metachromatic leukodystrophy patient and in a patient with nonprogressive neurological symptoms. Hum Genet 1998; 102(1):50–53. Martin JJ, Ceuterick C, Mercelis R, Joris C. Pathology of peripheral nerves in metachromatic leucodystrophy. A comparative study of ten cases. J Neurol Sci 1982; 53(1):95–112. Rutsaert J, Menu R, Resibois A. Ultrastructure of sulfatide storage in normal and sulfatase-deficient fibroblasts in vitro. Lab Invest 1973; 29(5):527–535. Meier C, Bischoff A. Sequence of morphological alterations in the nervous system of metachromatic leucodystrophy. Light and electronmicroscopic observations in the central and peripheral nervous system in a prenatally diagnosed foetus of 22 weeks. Acta Neuropathol (Berl) 1976; 36(4):369–379. Norton WT, Poduslo SE. Biochemical studies of metachromatic leukodystrophy in three siblings. Acta Neuropathol (Berl) 1982; 57(2–3):188–196. Toda K, Kobayashi T, Goto I, Ohno K, Eto Y, Inui K, Okada S. Lysosulfatide (sulfogalactosylsphingosine) accumulation in tissues from patients with metachromatic leukodystrophy. J Neurochem 1990; 55(5):1585–1591. Hess B, Saftig P, Hartmann D, Coenen R, Lullmann-Rauch R, Goebel HH, Evers M, von Figura K, D’Hooge R, Nagels G, De Deyn P, Peters C, Gieselmann V. Phenotype of arylsulfatase A-deficient mice: relationship to human
Copyright 2006 by Taylor & Francis Group, LLC
522
48.
49. 50.
51.
52. 53.
54.
55. 56. 57. 58. 59.
60.
61.
62.
63. 64.
Garbern metachromatic leukodystrophy. Proc Natl Acad Sci USA 1996; 93(25): 14 821–14 826. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003; 100(4):1902–1907. Gustavson KH, Hagberg B. The incidence and genetics of metachromatic leucodystrophy in northern Sweden. Acta Paediatr Scand 1971; 60(5):585–590. Kolodny E, Fluharty A. Metachromatic leukodystrophy and multiple sulfatase deficiency: sulfatide lipidosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler K, Vogelstein B, eds. Metabolic and molecular bases of inherited disease. 7th ed. New York: McGraw-Hill, 1994:2693–2739. Zlotogora J, Bach G, Barak Y, Elian E. Metachromatic leukodystrophy in the habbanite Jews: high frequency in a genetic isolate and screening for heterozygotes. Am J Hum Genet 1980; 32(5):663–669. Demaerel P, Faubert C, Wilms G, Casaer P, Piepgras U, Baert AL. MR findings in leukodystrophy. Neuroradiology 1991; 33(4):368–371. Kim TS, Kim IO, Kim WS, Choi YS, Lee JY, Kim OW, Yeon KM, Kim KJ, Hwang YS. MR of childhood metachromatic leukodystrophy. Am J Neuroradiol 1997; 18(4):733–738. Zafeiriou DI, Kontopoulos EE, Michelakakis HM, Anastasiou AL, Gombakis NP. Neurophysiology and MRI in late-infantile metachromatic leukodystrophy. Pediatr Neurol 1999; 21(5):843–846. Faerber EN, Melvin J, Smergel EM. MRI appearances of metachromatic leukodystrophy. Pediatr Radiol 1999; 29(9):669–672. Sener RN. Metachromatic leukodystrophy: diffusion MR imaging findings. Am J Neuroradiol 2002; 23(8):1424–1426. Sener RN. Metachromatic leukodystrophy. Diffusion MR imaging and proton MR spectroscopy. Acta Radiol 2003; 44(4):440–443. Black DN, Taber KH, Hurley RA. Metachromatic leukodystrophy: a model for the study of psychosis. J Neuropsychiatry Clin Neurosci 2003; 15(3):289–293. Alves D, Pires MM, Guimaraes A, Miranda MC. Four cases of late onset metachromatic leucodystrophy in a family: clinical, biochemical and neuropathological studies. J Neurol Neurosurg Psychiatry 1986; 49(12):1417–1422. Coulter-Mackie MB, Applegarth DA, Toone J, Vallance H. DNA-based diagnosis of arylsulfatase A deficiencies as a supplement to enzyme assay: a case in point. Clin Biochem 1997; 30(1):57–61. Heukels-Dully MJ, Niermeijer MF. Variation in lysosomal enzyme activity during growth in culture of human fibroblasts and amniotic fluid cells. Exp Cell Res 1976; 97(2):304–312. Tylki-Szymanska AT, Czartoryska B, Lugowska A. Practical suggestions in diagnosing metachromatic leukodystrophy